LETTER OF INVITATION LETTER OF INVITATION

WELCOME WORDS

by the EANM Congress Chair EANM’20 EANM’20 EANM’20 On behalf of the European Association of Nuclear Medicine, it is my great honour to invite you to the 33rd Annual EANM

WORLD LEADING MEETING Congress, which will take place virtually from 22 to 30 WORLD LEADING MEETING October 2020.

Nuclear Medicine keeps on growing in many number of newer features are also being planned clinical areas, from diagnostic imaging to and we will have a new format for the plenary therapy: our procedures are increasingly being sessions, new top-rated oral presentation sessions incorporated into clinical practice, in a variety of and a new ‘Top Trials’ session. settings and diseases. This success is mostly related to a peculiar characteristic of our specialty, namely A further characteristic of our Congress is its the functional approach to medicine. PET imaging multidisciplinarity, and this will be emphasised works so well because of the unique functional in 2020, with a number of sessions bringing information provided to clinicians, and this feature together physicians from many specialties as well is the key to the ongoing rapid diffusion of Nuclear as specialists in radiochemistry and pharmacy, Medicine. physicists and other professionals. In addition, a dedicated track for technologists will be provided. In recent years, the status of the EANM Congress as the world-leading meeting in Nuclear Medicine If all of this still isn’t enough to motivate you to has been firmly established. The number of attend the EANM’20 Congress virtually, we are attendees in 2019 exceeded that in any previous working on providing some extra entertainment to year, with more than 6950 participants, but we make your virtual experience even more fun. This are working to make the 2020 event even bigger, will include a daily nuclear quiz, daily programme more memorable, and virtual. highlights’ announcements, games and social opportunities. EANM cares for its members, participants and patients, with safety being our primary concern as COVID-19 continues to pose a major health threat worldwide. Therefore, it was decided that it is in Stefano Fanti the best interest of the entire NM community to EANM Congress Chair 2020–2022 go virtual only.

Stefano Fanti The Virtual EANM Congress will still have all the CONGRESS CHAIR 2020-2022 features that made the event successful in the past. The usual excellent tracks and sessions, from CME to joint sessions, have already been confirmed. A

4 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 5 EANM EANM

BOARD & ADVISORY SPC & SESSION COUNCIL COORDINATORS

EANM BOARD ADVISORY COUNCIL SCIENTIFIC PROGRAMME SESSION COORDINATORS EANM’20 EANM’20 COUNCIL EANM’20 The EANM Advisory Council is composed of the members of the Board and the Committee Chairs: EANM thanks all Scientific programme Council Members for EANM thanks all Session Coordinators for their huge engagement President 2019 – 2020 their great effort in composing the EANM’20 Virtual Sessions. in organizing the session details and speakers. Oyen, W.J.G (Netherlands)

WORLD LEADING MEETING WORLD LEADING MEETING President Elect 2019 – 2020 Bone & Joint Committee Congress Chair Aarntzen, E. (Netherlands) Loft Jakobsen, A. (Denmark) J. Kunikowska (Poland) T. Van den Wyngaert (Belgium) Fanti, S. (Italy) Aerts, A. (Belgium) Lopci, E. (Italy) Committee Coordinator 2019 – 2020 Cardiovascular Committee Bone & Joint Committee Aide, N. (France) Luurtsema, G. (Netherlands) R. Hustinx (Belgium) H. Verberne (Netherlands) Annunziata , S. (Italy), Paycha, F. (France) Albert, N. (Germany) Lynch, T. (United Kingdom) Congress Chair 2020 – 2022 Dosimetry Committee Cardiovascular Committee S. Fanti (Italy) M.W. Konijnenberg (Netherlands) Attard, M.C. (Netherlands) Mada, M. (United Kingdom) Hyafil, F. (France), Verberne, H. (Netherlands) Education Chair 2020 – 2022 Drug Development Committee Attard, M. (The Netherlands) Mihailovic, J. (Serbia) Dosimetry Committee P. A. Erba (Italy) J. Vercouillie (France) Konijnenberg, M. (Netherlands), Eberlein, U. (Germany) Biassoni, L. (United Kingdom) Minguez Gabiña, P. (Spain) Secretary/Treasurer 2019 – 2020 Ethics Committee Drug Development Committee Camoni, L. (Italy) Morbelli, S. (Italy) W. Wadsak (Austria) W. Knapp (Germany) Vercouillie, J. (France), Smith, G. (United Kingdom) Caobelli, F. (Switzerland) Nanni, C. (Italy) Scientific Liaison Officer 2019 - 2020 Inflammation & Infection Committee Inflammation & Infection Committee M. Lassmann (Germany) A. Glaudemans (Netherlands) Catalano, O. (United States of Olianti, C. (Italy) Treglia, G. (Switzerland), Glaudemans, A. (Netherlands) America) Neuroimaging Committee Palmedo, H. (Germany) Neuroimaging Committee S. Morbelli (Italy) Cerci, J. (Brasil) Paycha, F. (France) Barthel, H. (Germany), Albert, N. (Germany) Oncology & Theranostics Committee Cunha, L. (Portugal) Petranović Ovčariček, P. (Croatia) Oncology & Theranostics Committee K. Herrmann (Germany) De Geus-Oei, L.-F. (Netherlands) Herrmann, K. (Germany), Aide, N. (France) Pietrzak, A. (Poland) Paediatrics Committee Dias, A. (Denmark) Paediatrics Committee Rep, S. (Slovenia) P. Zucchetta (Italy) Zucchetta, P. (Italy), Bar-Sever, Z. (Israel) Dickson, J. (United Kingdom) Santos, A. (Portugal) Physics Committee Physics Committee Eiber, M. (Germany) D. Visvikis (France) Saraste, A. (Finland) Dickson, J. (United Kingdom), Visvikis, D. (France) Fanti, S. (Italy) Radiation Protection Committee Schottelius, M. (Switzerland) Radiation Protection Committee S. Holm (Denmark) Fragoso Costa, P. (Germany) Sciagra, R. (Italy) Cunha, L. (Portugal), Flux, G. (United Kingdom) Radiopharmacy Committee Gabriel, M. (Austria) Semah, F. (France) Radiopharmacy Committee M. Patt (Germany) Gabriel, M. (Germany) Laverman, P. (Netherlands), Patt, M. (Germany) Smith, G. (United Kingdom) Technologist Committee Garibotto, V. (Switzerland) Technologist Committee Strobel, K. (Switzerland) A. Santos (Portugal) Santos, A. (Portugal), Camoni, L. (Italy) Goffin, K. (Belgium) Talbot, J.-N. (France) Thyroid Committee Thyroid Committee Grana, C.M. (Italy) M. Luster (Germany) Terwinghe, C. (Belgium) Hoffmann, M. (Austria), Vrachimis, A. (Cyprus) Grimm, J. (United States of America) Translational Molecular Imaging & Therapy Committee van de Giessen, E. (Netherlands) Translational Molecular Imaging & Therapy Committee F. Van Leeuwen (Netherlands) Hyafil, F. (France) van Leeuwen, F. (Netherlands), Schottelius, M. (Switzerland) Varrone, A. (Sweden) Iakovou, I. (Greece) Vercouillie, J. (France) Kobe, C. (Germany) Vidal-Sicart, S. (Spain) Konijnenberg, M. (Netherlands) Vrachimis, A. (Cyprus) Koole, M. (Belgium) Zuchetta, P. (Italy) Laverman, P. (Netherlands)

6 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 7 EANM REVIEWERS EANM REVIEWERS

EANM’ 20 REVIEWERS

EANM’20 EANM’20 Abbott, B.G. (United States of America) Beer, A. (Germany) Carrio, I. (Spain) de Swart, J. (Netherlands) EANM’20 Abgral, R. (France) Behe, M. (Switzerland) Castell Conesa, J. (Spain) Decristoforo, C. (Austria) Aerts, A. (Belgium) Beheshti, M. (Germany) Castellucci, P. (Italy) Delgado-Bolton, R.C. (Spain) Ahmadzadehfar, H. (Germany) Ben Haim, S. (Israel) Cawthorne, C. (Belgium) Deroose, C. (Belgium)

WORLD LEADING MEETING Aide, N. (France) Bergström, K. (Finland) Cecchin, D. (Italy) Deuther-Conrad, W. (Germany) WORLD LEADING MEETING Ak, I. (Turkey) Bernhardt, P. (Sweden) Ceci, F. (Italy) Dickson, J. (United Kingdom) Akdemir, Ü.Ö. (Turkey) Beyer, T. (Switzerland) Cerci, J. (Brazil) Dierckx, R. (Netherlands) Aloj, L. (United Kingdom) Bilgin, B.E. (Turkey) Cermik, T.F. (Turkey ) Dierickx, L.O. (France) Altini, C. (Italy) Borbely, K. (Hungary) Chakravartty, R. (United Kingdom) Duatti, A. (Italy) Ambrosini, V. (Italy) Borgwardt, L. (Denmark) Chiaravalloti, A. (Italy) Eberlein, U. (Germany) Ametamey, S. (Switzerland) Botelho, M.F.R. (Portugal) Chiesa, C. (Italy) Eiber, M. (Germany) Anagnostopoulos, C. (Greece) Bozkurt, M.F. (Turkey) Chiti, A. (Italy) Ekmekcioglu, O. (Turkey ) Annunziata, S. (Italy) Brandt, M. (Austria) Chouin, N. (France) Elsinga, P.H. (Netherlands) Antunovic, L. (Italy) Brenner, W. (Germany) Ciappuccini, R. (France) Ertay, T. (Turkey) Armstrong, I. (United Kingdom) Brom, M. (Netherlands) Cook, G.J.R. (United Kingdom) Essler, M. (Germany) Asenbaum-Nan, S. (Austria) Brouwers, A.H. (Netherlands) Cornelissen, B. (United Kingdom) Etchebehere, E. (Brazil) Atay Kapucu, L.Ö. (Turkey) Bucerius, J. (Netherlands) Costa, G. (Portugal) Evangelista, L. (Italy) Attard, M.C. (Netherlands) Buchert, R. (Germany) Curran, D. (Ireland) Farolfi, A. (Italy) Bacher, K. (Belgium) Buckle, T. (Netherlands) Czepczyński, R. (Poland) Farsad, M. (Italy) Balkay, L. (Hungary) Burroni, L. (Italy) Da Pieve, C. (United Kingdom) Fendler, W. (Germany) Ballinger, J. (Canada) Buvat, I. (France ) Dalm, S. (Netherlands) Fernandez Lèon, A. (Spain) Balogova, S. (Slovakia) Caldarella, C. (Italy) Daou, D. (France) Ferreira, T.C. (Portugal) Bar-Sever, Z. (Israel) Camoni, L. (Italy) Darcourt, J. (France) Fischer, B.M. (Denmark) Barbet, J. (France) Cantinho-Lopes, M.G. (Portugal) De Bondt, P. (Belgium) Flotats Giralt, A. (Spain) Barthel, H. (Germany) Caobelli, F. (Switzerland) De Geus-Oei, L.-F. (Netherlands) Flux, G. (United Kingdom) Bauckneht, M. (Italy) Capa Kaya, G. (Turkey) de Jong, H. (Netherlands) Forrer, F. (Switzerland) Bax, J.J. (Netherlands) Carrilho Vaz, S. (Portugal) De Palma, D. (Italy) Fragoso Costa, P.A. (Germany)

8 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 9 EANM REVIEWERS EANM REVIEWERS

EANM’20 EANM’20 Franceschi, M. (Croatia) Haberkorn, U. (Germany) Kobe, C. (Germany) Luporsi, M. (France) EANM’20 Frangos, S. (Cyprus) Hacker, M.L. (Austria) Koole, M. (Belgium) Mada, M. (United Kingdom) Fujibayashi, Y. (Japan) Halldin, C. (Sweden) Koranda, P. (Czech Republic) Maes, A. (Belgium) Gabriel, M. (Austria) Hatt, M. (France) Kostadinova, I. (Bulgaria) Maffioli, L. (Italy)

WORLD LEADING MEETING Gafita, A. (Germany) Hendrikse, H. (Netherlands) Kostkiewicz, M. (Poland) Maldonado, A. (Spain) WORLD LEADING MEETING Gallowitsch, H.-J. (Austria) Herholz, K. (United Kingdom) Koutsikos, J. (Greece) Manevska, N. (Macedonia, The Former Yugoslav Garibotto, V. (Switzerland) Herrmann, K. (Germany) Kracmerova, T. (Czech Republic) Republic of) Gear, J. (United Kingdom) Heskamp, S. (Netherlands) Krämer, S. (Switzerland) Mansi, L. (Italy) Georgoulias, P. (Greece) Hicks, R. (Australia) Kraeber-Bodèrè, F. (France) Mapelli, P. (Italy) Gheysens, O. (Belgium) Hindorf, C. (Sweden) Kramer-Marek, G. (United Kingdom) Marcassa, C. (Italy) Giammarile, F. (Austria) Hoffmann, M. (Austria) Krause, B.J. (Germany) Marengo, M. (Italy) Gillings, N. (Denmark) Hofman, M. (Australia) Krolicki, L. (Poland) Marie, P.-Y. (France) Gimelli, A. (Italy) Hubalewska-Dydejczyk, A. (Poland) Kucuk, N.O. (Turkey) Mauxion, T. (United Kingdom) Giovanella, L. (Switzerland) Hutton, B. (United Kingdom) Kurch, L. (Germany) Mihailovic, J. (Serbia) Girotto, N. (Croatia) Hyafil, F. (France ) Kurth, J. (Germany) Minguez Gabiña, P. (Spain) Glatting, G. (Germany) Iagaru, A. (United States of America) Kuwert, T. (Germany) Minn, H.R.I. (Finland) Glaudemans, A. (Netherlands) Iakovou, I. (Greece) Lairez, O. (France) Mitjavila Casanovas, M. (Spain) Gnanasegaran, G. (United Kingdom) Jamar, F. (Belgium) Lammertsma, A. (Netherlands) Monteiro, M. (Switzerland) Goffin, K. (Belgium) Jarzab, B. (Poland) Langbein, T. (Germany) Morbelli, S. (Italy) Gotthardt, M. (Netherlands) Jehanno, N. (France) Lapa, C. (Germany) Mottaghy, F. (Germany) Grana, C.M. (Italy) Karabacak, N. (Turkey) Lasnon, C. (France) Mu, L. (Switzerland) Gratz, S. (Germany) Kinuya, S. (Japan) Laverman, P. (Netherlands) Müller, C. (Switzerland) Grbac-Ivankovic, S. (Croatia) Kirac, S. (Turkey) Lemos Pereira, E.A. (Portugal) Nâgren, K.A. (Denmark) Grimm, J. (United States of America) Kjaer, A. (Denmark) Lewis, J. (United States of America) Nanni, C. (Italy) Guedj, E. (France) Klett, R. (Germany) Ljungberg, M. (Sweden) Neels, O. (Germany) Guillet, B. (France) Kluge, R. (Germany) Lodi, F. (Italy) Nekolla, S. (Germany) Gulliver, N. (United Kingdom) Knuuti, J. (Finland) Lopci, E. (Italy) Nicolini, S. (Italy)

10 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 11 EANM REVIEWERS EANM REVIEWERS

EANM’20 EANM’20 Nobili, F. (Italy) Raavè, R. (Netherlands) Sera, T. (Hungary) van Berckel, B. (Netherlands) EANM’20 Nock, B.A. (Greece) Rac, S. (Croatia) Sgouros, G. (United States of America) van den Wyngaert, T. (Belgium) Nonnekens, J. (Netherlands) Rausch, I. (Austria) Siclari, G. (Italy) van der Meulen, N.P. (Switzerland) Noriega, E. (Spain) Rbah-Vidal, L. (France) Signore, A. (Italy) van Essen, M. (Sweden)

WORLD LEADING MEETING Ocak, E.M. (Turkey) Redondo, F. (Chile) Slart, R. (Netherlands) van Velden, F.H.P. (Netherlands) WORLD LEADING MEETING Olianti, C. (Italy) Resende Geão, A.C. (Portugal) Smith, G. (United Kingdom) van Waarde, A. (Netherlands) Orlhac, F. (France) Rischpler, C. (Germany) Sobic Saranovic, D. (Serbia) Varmenot, N. (France) Orlova, A. (Sweden) Rodrigues Radischat, M. (Austria) Sollini, M. (Italy) Varrone, A. (Sweden) Orru, M.T. (Italy) Rodrìguez-Fraile, M. (Spain) Stefanescu, C. (Romania) Veit-Haibach, P. (Canada) Ozcan, Z. (Turkey) Roelants, V. (Belgium) Stevens, H. (Netherlands) Verberne, H.J. (Netherlands) Ozgen Kiratli, P. (Turkey) Roivainen, A. (Finland) Stokke, C. (Norway) Verburg, F. (Germany) Pagani, M. (Italy) Rominger, A. (Switzerland) Stokkel, M. (Netherlands) Vercouillie, J. (France) Palmedo, H. (Germany) Rossetti, C. (Italy) Strömvall, A.L. (Sweden) Versari, A. (Italy) Panagiotidis, E. (Greece) Rouzet, F. (France) Strand Olsen, R. (Denmark) Verzijlbergen, J.F. (Netherlands) Papathanasiou, N. (Greece) Rubì, S. (Spain) Strigari, L. (Italy) Vidal Sicart, S. (Spain) Pascual, T. (Austria) Santos, A.I. (Portugal) Sundin, A. (Sweden) Virgolini, I. (Austria) Paycha, F. (France) Santos, A. (Portugal) Talbot, J._N. (France) Vrachimis, A. (Cyprus) Payoux, P. (France) Saraste, A. (Finland) Teräs, M. (Finland) Vriens, D. (Netherlands) Peñuelas Sanchez, I. (Spain) Saxtoft, E. (Denmark) Terry, S. (United Kingdom) Weber, W. (Germany) Petranović Ovčariček, P. (Croatia) Schibli, R. (Switzerland) Terwinghe, C. (Belgium) Weiler-Sagie, M. (Israel) Pietrzak, A.K. (Poland) Schindler, T.H. (United States of America) Testanera, G. (United Kingdom) Windhorst, A.D. (Netherlands) Pilkington, P. (Spain) Schmidt, M. (Germany) Todde, S. (Italy) Xavier, C. (Belgium) Pirich, C. (Austria) Schottelius, M. (Germany) Tolmachev, V. (Sweden) Zanoni, L. (Italy) Plachcinska, A. (Poland) Schwarzenböck, S. (Germany) Tosi, G. (Italy) Zerizer, I. (United Kingdom) Poeppel, T. (Germany) Sciagrà, R. (Italy) Treglia, G. (Switzerland) Ziegler, S.I. (Germany) Prassopoulos, V.C. (Greece) Seimbille, Y. (Netherlands) Treves, T. (United States of America) Zimmer, L. (France) Pruim, J. (Netherlands) Semah, F. (France) Ugur, Ü. (Turkey)

12 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 13 CHAIRPERSONS CHAIRPERSONS

EANM’ 20 CHAIRPERSONS

EANM thanks all reviewers for their invaluable commitment.

EANM’20 EANM’20 Acampa, W. (Italy) Chiesa, C. (Italy) Hadaschik, B. (Germany) Mattana, F. (Italy) EANM’20 Adam, J. (Netherlands) Cornelissen, B. (United Kingdom) Hatt, M. (France) McQuaid, S. (United Kingdom) Aerts, A. (Belgium) Cunha, L. (Portugal) Herrmann, K. (Germany) Mihailovic, J. (Serbia) Alessi, A. (Italy) de Palma, D. (Italy) Hindorf, C. (Sweden) Mínguez Gabiña, P. (Spain)

WORLD LEADING MEETING Aloj, L. (United Kingdom) Decristoforo, C. (Austria) Hoffmann, M. (Austria) Morbelli, S. (Italy) WORLD LEADING MEETING Ambrosini, V. (Italy) Deuther-Conrad, W. (Germany) Holm, S. (Denmark) Nanni, C. (Italy) Annunziata, S. (Italy) Dias, A. (Denmark) Hyafil, F. (France) Nekolla, S. (Germany) Arbizu, J. (Spain) Dickson, J. (United Kingdom) Iakovou, I. (Greece) Nonnekens, J. (Netherlands) Armstrong, I. (United Kingdom) Eberlein, U. (Germany) Jehanno, N. (France) Noriega-Alvarez, E. (Spain) Artiko, V. (Serbia) Erba, P.A. (Italy) Kedves, A. (Hungary) Oprea-Lager , D. (Netherlands) Attard, M.C. (Netherlands) Fani, M. (Switzerland) Kobe, C. (Germany) Palmedo, H. (Germany) Balogova, S. (Slovakia) Fanti, S. (Italy) Konijnenberg, M. (Netherlands) Paycha, F. (France) Barthel, H. (Germany) Farolfi, A. (Italy) Koole, M. (Belgium) Petranovic, P. (Croatia) Bashir, H. (Pakistan) Fendler, W. (Germany) Kracmerova, T. (Czech Republic) Pietrzak, A. (Poland) Biassoni, L. (United Kingdom) Fragoso Costa, P. (Germany) Krizsan, A. (Hungary) Pilkington, P. (Spain) Bomanji, J. (United Kingdom) Gabriel, M. (Austria) Kunikowska, J. (Poland) Pirich, C. (Austria) Buckle, T. (Netherlands) Garibotto, V. (Switzerland) Lam, M. (Netherlands) Rep, S. (Slovenia) Burger, I. (Switzerland) Geao, A. (Portugal) Lapa, C. (Germany) Reyes, E. (United Kingdom) Buvat, I. (France) Georgoulias, P. (Greece) Lassmann, M. (Germany) Roca, I. (Spain) Camoni, L. (Italy) Giovanella, L. (Switzerland) Laverman, P. (Netherlands) Rouzet, F. (France) Campenni’, A. (Italy) Glaudemans, A. (Netherlands) Law, I. (Denmark) Santos, A.I. (Portugal) Caobelli, F. (Switzerland) Gnanasegaran, G. (United Kingdom) Loft-Jakobsen, A. (Denmark) Santos, A. (Portugal) Castellucci, P. (Italy) Goffin, K. (Belgium) Lopci, E. (Italy) Saraste, A. (Finland) Catalano, O.A. (United States Of America) Grana, C.M. (Italy) Lynch, T. (United Kingdom) Sattler, B. (Germany) Ceci, F. (Italy) Grimm, J. (United States Of America) Mada, M. (United Kingdom) Schibli, R. (Switzerland) Cerci, J.J. (Brazil) Guedj, E. (France) Marie, P.-Y. (France) Schottelius, M. (Switzerland)

14 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 15 CHAIRPERSONS CHAIRPERSONS

EANM’20 EANM’20 Schwarzenböck, S. (Germany) Treglia, G. (Switzerland) EANM’20 Sciagra, R. (Italy) Unterrainer, M. (Germany) Sheppard, R. (United Kingdom) van de Giessen, E. (Netherlands) Siveke, J. (Germany) van den Wyngaert, T. (Belgium)

WORLD LEADING MEETING Slart, R. (Netherlands) van Weehaeghe, D. (Belgium) WORLD LEADING MEETING Smith, G. (United Kingdom) Vandenberghe, S. (Belgium) Sosabowski, J. (United Kingdom) Varrone, A. (Sweden) Stokke, C. (Norway) Vaz, S. (Portugal) Strand Olsen, R. (Denmark) Verberne, H. (Netherlands) Strigari, L. (Italy) Verburg, F. (Netherlands) Strömvall, A.L. (Sweden) Vidal-Sicart, S. (Spain) Taieb, D. (France) Virgolini, I. (Austria) Talbot, J.-N. (France) Visvikis, D. (France) Telo, S. (Italy) Vrachimis, A. (Cyprus) Terry, S. (United Kingdom) Wadsak, W. (Austria) Terwinghe, C. (Belgium) Zimmer, L. (France) Tran-Gia, J. (Germany) Zucchetta, P. (Italy) Traub-Weidinger, T. (Austria)

These symposia are organized and funded by 16 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | AdvancedVIRTUAL Accelerator Applications,17 a Novartis Company AAA-NP-GL-0107-20 | AAA-NP-UK-0386-20 | October 2020 EANM NATIONAL SOCIETIES EANM NATIONAL SOCIETIES

EANM NATIONAL SOCIETIES: DELEGATES / DEPUTIES

SOCIETY DELEGATE DEPUTY SOCIETY DELEGATE DEPUTY EANM’20 EANM’20 EANM’20

Armenian Society of Nuclear Medicine V. Barsegian M. Grigoryan Irish Nuclear Medicine Association M. O’Connell R. Killeen  Austrian Society of Nuclear Medicine M. Hacker I. Virgolini Israeli Society of Nuclear Medicine Z. Bar-Sever Z. Keidar  

WORLD LEADING MEETING Azerbaijan Society of Nuclear Medicine F. Novruzov A. Aliyev Italian Society of Nuclear Medicine R. Giubbini M. L. DeRimini WORLD LEADING MEETING  Belgian Society of Nuclear Medicine F. Jamar N. Withofs Latvian Society of Nuclear Medicine D. Berzina J. Kedrova

Bosnian Society of Nuclear Medicine Z. Rajkovaca D. Rozic Lithuanian Society of Nuclear Medicine D. Vajauskas I. Kulakiene

British Nuclear Medicine Society S. Vinjamuri R. Graham Luxembourg Society of Nuclear Medicine C. Als C.J. Picard  Bulgarian Society of Nuclear Medicine V. Hadziyska L. Chavdarova Maltese Association of Radiologists and  Nuclear Medicine Physicians M.A. Aquilina A. Samuel Croatian Society of Nuclear Medicine M. Franceschi D. Šnajder  Norwegian Society of Nuclear Medicine T.C. Adamsen R. Sundset Cyprus Society of Nuclear Medicine D. Kyprianou R.K. Demetriadou  Polish Society of Nuclear Medicine R. Czepczynski A. Sowa-Staszczak Czech Society of Nuclear Medicine M. Simanek P. Koranda  Portuguese Society of Nuclear Medicine G. Costa A.P. Moreira Danish Society of Clinical Physiology and Nuclear Medicine L. Jensen P. Hovind

Romanian Society of Nuclear Medicine R. Mititelu V.C. Mazilu Dutch Society of Nuclear Medicine R. Bennink M. Stokkel  Russian Society of Nuclear Medicine P. Rumyantsev V. Sukhov Estonian Nuclear Medicine Society S. Nazarenko K. Ulst  Serbian Nuclear Medicine Society D. Sobic-Saranovic J. Mihailovic Finnish Society of Nuclear Medicine H.Mussalo K. Timonen

Slovak Society of Nuclear Medicine P. Povinec L. Kaliska Macedonian Society of Nuclear Medicine D. Miladinova A. Ugrinska

Slovenian Society of Nuclear Medicine I. Zagar K. Zaletel French Society of Nuclear Medicine F. Cachin J.-P. Vuillez  Spanish Society of Nuclear Medicine M. J. Garcia-Velloso J. A. Vallejo Casas German Society of Nuclear Medicine B. Krause K. Herrmann

Swedish Society of Nuclear Medicine A. Sundin A. Larsson Strömvall George de Hevesy Hungarian Society of NM T. Györke L. Pavics

Swiss Society of Nuclear Medicine T. Krause M. Wissmeyer Georgian Nuclear Medicine Specialists Association N. Shengelia K. Shamatava Turkish Society of Nuclear Medicine Z. Ozcan L.Ö. Atay Hellenic Society of Nuclear Medicine & Biology A. Fotopoulos V.C. Prassopoulos

Ukrainian Society of Nuclear Medicine to be nominated to be nominated Icelandic Society of Nuclear Medicine to be nominated to be nominated 

18 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 19 UEMS/EBNM COMMITTEES UEMS/EBNM COMMITTEES

UEMS/EBNM NATIONAL SOCIETIES: DELEGATES / DEPUTIES

nominated from full UEMS Member Countries

Country Delegate Deputy Country Delegate Deputy EANM’20 EANM’20 EANM’20 AUSTRIA A. Kurtaran R. Lipp NORWAY A.R. Midha M. Revheim  BELGIUM K. Spaepen G. Moulin-Romsee POLAND M. Dziuk B. Birkenfeld 

WORLD LEADING MEETING BULGARIA E. Piperkova A. D. Tzonevska PORTUGAL L. Salgado M. T. Ferreira WORLD LEADING MEETING   CROATIA D. Huic S. Kusacic Kuna ROMANIA G. Andries R. Mititelu  CYPRUS R. K. Demetriadou SLOVAKIA A. Vondrak   CZECH REPUBLIC O. Lang M. Kaminek SLOVENIA M. Grmek D. Hrastnik   DENMARK S. Hess L. T. Jensen SPAIN A. Sorriano F. Pons  ESTONIA E. Kelk A. Poksi SWEDEN E. Trägårdh P. Grybäck  FINLAND H. Mussalo A. Loimaala SWITZERLAND A. Boubaker G. Goerres   FRANCE E. Gremillet J. L. Pelletier UNITED KINGDOM S. Dizdarevic  GERMANY W. Brenner M. Gotthardt

GREECE I. Iakovou S. Tsiouris  HUNGARY L. Pavics I. Szilvasi nominated from UEMS Associate Member Countries  IRELAND S. Skehan R. Mcdermott Country Delegate Deputy  ITALY B. Palumbo A. Ciarmiello TURKEY Y. Yurekli Z. Ozcan  LATVIA I. Vevere A. Berzina  LITHUANIA D. Vajauskas N. Jurkiene

LUXEMBOURG P. Paulus M. Doat nominated from UEMS Observer Countries 

MALTA A. Samuel M. A. Aquilina Country Delegate Deputy 

NETHERLANDS R. J. Bennink L. F. de Geus-Oei ISRAEL A. Steinmetz M. Quastel 

20 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 21 UEMS/EBNM COMMITTEES UEMS/EBNM COMMITTEES

UEMS/EBNM COMMITTEES

EXECUTIVE COMMITTEE CME ACCREDITATION EANM’20 EANM’20 EANM’20

President S. Mirzaei (Austria) Chair M. Farsad (Italy) Secretary & Treasurer R. Hustinx (Belgium) Members E. Lopci (Italy) Member A. Boubaker (Switzerland) A. Haug (Austria) WORLD LEADING MEETING WORLD LEADING MEETING S. Sillanmäki (Finland)

FELLOWSHIP EXAMINATION ACCREDITATION OF NUCLEAR MEDICINE DEPARTMENTS & TRAINING CENTRES Chair Z. Özcan (Turkey) Members I. Kulakiene (Lithuania) Chair J. Prior (Switzerland) S. Frangos (Cyprus) Commitee J. R. Garcia Garzón (Spain) Members A. García-Burillo (Spain) S. Carillho Vaz (Portugal) N. Mutlukoca (Norway) P.. Van Boxem (Belgium) M. L. Hall (United Kingdom) M. Bajc (Sweden) Ex officio: S. Mirzaei (Austria) EDUCATION & SYLLABUS Corresponding Members: F. Giesel (Germany) Chair R. Hustinx (Belgium) A. Jiménez Heffernan (Spain) Members J. Darcourt (France) I. Sippo-Tujunen (Finland) H. B. Sayman (Turkey) N. G. Hartman (United Kingdom) D. Huic (Croatia) S. E. Bouzoucef (Algeria) T. V. Bogsrud (Norway) A. Ciarmiello (Italy) P. Castellucci (Italy) L. Torres (Cuba)

22 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 23 GENERAL INFORMATION GENERAL INFORMATION

GENERAL INFORMATION

CERTIFICATE OF ATTENDANCE CONGRESS APP KEY DATES INDUSTRY EXHIBITION EANM’20 EANM’20 EANM’20 Certificates of Attendance will be available in your No congress app will be provided. All registered October 22, 2020 Inside our fully virtual conference halls, you can myEANM area after the congress. participants have access to the virtual online Virtual Congress Opening & Welcome Happy Hour enter a real-life animated exhibition hall while being platform via their myEANM Area login. October 22, 2020 able to move around and navigate interactively. Plenary 1 – Total Body PET (incl. Marie Curie Lecture) Visitors will be able to communicate with booth CONGRESS CLOSING October 23, 2020 staff via state-of-the-art chat tools, see models of the WORLD LEADING MEETING The Congress Closing incl. the Highlights Lecture CONGRESS E-POSTER AREA Plenary 2 – Cardiac Nuclear Medicine – Present and newest products, participate in raffles and quizzes WORLD LEADING MEETING will be broadcasted on October 30, 2020 at 17:05 The e-Poster Area gives you the possibility to read Future and even find dedicated job offerings. CET. All registered delegates can join online. all uploaded e-Posters of EANM’20 Virtual. You can October 24, 26, 27, 2020 Everyone can participate without closing times search for authors, topics and keywords. Mid-Congress Symposia and EANM Young Daily 24/7 to this active meeting and job-market tool Forums completely free of charge. CME CREDITES & CERTIFICATES October 29, 2020 To acquire CME credits, an evaluation form must CONGRESS LANGUAGE Plenary 3 – What’s Cooking? Next Generation also be completed for each session attended. The congress language is English. No simultaneous Radiopharmaceuticals SQRL’S LEISURE LOUNGE translation will be provided. October 30, 2020 Besides the scientific content there are also different The EANM’20 Virtual has been accredited by the Plenary 4 – Highlights Lecture: Nuclear Medicine as leisure activities available. From interactive features European Accreditation Council for Continuing the Art of Science to different quizzes or city tours – there is a lot to Medical Education (EACCME®) with 31 European EANM OFFICE October 30, 2020 explore in the time in-between or after the sessions: CME credits (ECMEC®s). Each medical specialist The congress office will be available during all Congress Closing • photo booth should claim only those hours of credit that he/she congress days via email and phone. • creative corner actually spent in the educational activity. • gaming area The opening hours are 08:00 to 18:30 CEST/CET EANM EXECUTIVE OFFICE • SQRL hunt The EANM’20 – Mid-Congress Symposia have been (Please keep in mind that on October 25, 2020 the Schmalzhofgasse 26 • Nuclear quiz accredited by the European Accreditation Council times will change from CEST to CET). 1060 Vienna, Austria • 50 Cases Challenge for Continuing Medical Education (EACCME®) with Phone: +43 1 890 44 27 • Live City Tours 2 European CME credits (ECMEC®s). Each medical For any questions, make sure to have a look at the Fax: +43 1 890 44 27-9 • My Nuclear Vienna (nuclear city tours with EANM specialist should claim only those hours of credit FAQs first (can be found in the virtual congress), and Email: [email protected] treasurer Wolfgang Wadsak) that he/she actually spent in the educational activity. then contact us via the info desk in the Lobby of the URL: www.eanm.org Through an agreement between the Union virtual congress. Européenne des Médecins Spécialistes and the American Medical Association, physicians may Contact us via VIRTUAL CONGRESS OPENING & convert EACCME® credits to an equivalent number Email: [email protected] WELCOME HAPPY HOUR of AMA PRA Category 1 CreditsTM. Information on Phone: +43 1 890 44 27 All registered delegates are invited to attend virtually the process to convert EACCME® credit to AMA credit or the direct chat in the congress area. the can be found at www.ama-assn.org/education/ Virtual Congress Opening Welcome Happy Hour earn-credit-participation-international-activities. Thursday, October 22, 2020 – 18:10-20:00

24 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 25 COMMITTEE MEETINGS COMMITTEE MEETINGS EARL RELEASED COMMITEE INTEREST 18F STANDARD 2 ACCREDITATION, Allowing sites to benefit from state-of-the-art MEETINGS PET/CT technology while still ensuring harmonized scanners performance, DURING EANM’20 UNIQUE 89Zr PET/CT ACCREDITATION Based on and derived from the procedures 18

EANM’20 EANM’20 performed for the F-FDG PET/CT EANM’20 accreditation which is a prerequisite for 89Zr accreditation VIRTUAL COMMITTEE INTEREST GROUP MEETINGS WORLD LEADING MEETING WORLD LEADING MEETING Date Time

EANM Bone and Joint Committee Mon. Oct 26 14:00-15:00 Interest Group Meeting EANM Dosimetry Committee Mon. Oct 26 16:00-17:00 Interest Group Meeting EANM Drug Development Committee Interest Group Fri. Oct 30 14:00-15:00 Meeting EANM EANM Inflammation & Infection Committee Interest Tue. Oct 27 12:30-13:30 Group Meeting EANM Neuroimaging Committee Wed. Oct 28 13:30-15:00 RESEARCH Interest Group Meeting EANM Physics Committee Tue. Oct 27 15:00-16:00 Interest Group Meeting LTD (EARL) EANM Radiation Protection Committee Interest Group Fri. Oct 23 09:00-11:00 Meeting EANM Radiopharmacy Committee Tue. Oct 27 13:30-12:00 Interest Group Meeting EANM Technologist Committee Fri. Oct 30 12:30-14:00 Interest Group Meeting EANM Thyroid Committee Mon. Oct 26 10:45-12:45 Interest Group Meeting

EARL is a 100% subsidiary of the EANM, which aims to enhance the quality of nuclear medicine practice for the benefit of public health.

26 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 27 earl.eanm.org SCIENTIFIC PROGRAMME SCIENTIFIC PROGRAMME

INVITED SPEAKER SESSIONS

PLENARY SESSIONS PLENARY SESSIONS EANM’20 EANM’20 EANM’20

1 Thursday, October 22, 15:10 – 16:25 3 Thursday, October 29, 15:10 – 16:25 Total Body PET (incl. Marie Curie Lecture) What’s Cooking? Next Generation Radiopharmaceuticals Chairpersons: Jolanta Kunikowska (PL), Michael Lassmann (DE), Dimitris Visvikis (FR) Chairpersons: Jane Sosabowski (UK), Melpomeni Fani (CH), Wolfgang Wadsak (AT) WORLD LEADING MEETING WORLD LEADING MEETING

» A Game Changer for the Future of PET, Dimitris Visvikis (FR) » What’s New?, Melpomeni Fani (CH) » Marie Curie Lecture: Physics and Development of Total Body PET, Simon Cherry (US) » FAP-Inhibitors are the Future – For Everything?, Uwe Haberkorn (DE) » Is Dynamic PET Imaging Ready for Prime Time?, Irene Buvat (FR) » Brain Tracers – Finally for Clinical Application?, Valentina Garibotto (CH) » Drug Development and Evaluation with Total Body PET, Johannes Czernin (US) » Is Theranostics the Future in Nuclear Medicine?, Michael Hofman (AU) » Challenge for Technologists, Andrea Santos (PT) » Do we need Specific Tracers in the Clinics?, Meltem Ocak (TR) » A Must Have or Another Expensive Luxury Tool?, Ken Herrmann (DE) » Why does it take so long?, Jane Sosabowski (UK) » Discussion, All Speakers » Discussion, All Speakers 2 Friday, October 23, 15:30 – 16:45 4 Friday, October 30, 17:12 – 18:12 Cardiac Nuclear Medicine – Present and Future Highlights Lecture Chairpersons: Paola Anna Erba (IT), Wanda Acampa (IT), Hein Verberne (NL) Moderators: Roland Hustinx (BE), Arturo Chiti (IT)

» Renew or Fade Away, Hein Verberne (NL) » Do we meet the Clinical Demand?, Wanda Acampa (IT) » MBF – Lost in Clinical Translation?, Ronny Büchel (CH) » Imaging Cardiac Amyloidosis, Sharmila Dorbala (US) SPECIAL SESSION » Endocarditis, Paola Anna Erba (IT) » Discussion, All Speakers 1 Thursday, October 29, 16:35 – 18:05 Hot Topic Session Best Clinical Trials

28 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 29 SCIENTIFIC PROGRAMME SCIENTIFIC PROGRAMME

CONTINUING MEDICAL EDUCATION (CME) SESSIONS CONTINUING MEDICAL EDUCATION (CME) SESSIONS EANM’20 EANM’20 EANM’20

1 Thursday, October 22, 13:30 – 15:00 8 Saturday, October 24, 10:40 – 12:10 Radar on Gynaecological Cancers Emergency Conditions in Paediatric Nuclear Medicine Translational Molecular Imaging and Therapy + Oncology & Theranostics Committee Paediatrics Committee WORLD LEADING MEETING WORLD LEADING MEETING 2 Thursday, October 22, 16:35 – 18:05 9 Thursday, October 29, 13:30 – 15:00 Software Tools and Approaches to Measure Nuclear Brain Images New PET Technologies – Digital Revolution or Big Bust? Neuroimaging + Physics Committee Oncology & Theranostics + Physics Committee

3 Friday, October 23, 09:00 – 10:30 10 Thursday, October 29, 16:35 – 18:05 Finding the Right PET Companion for ImmunoOncology Radiomics in Thyroid Imaging Radiopharmacy + Oncology & Theranostics + Translational Molecular Imaging and Therapy Committee Thyroid Committee

4 Friday, October 23, 10:40 – 12:10 11 Friday, October 30, 09:00 – 10:30 Multimodality Imaging-Based Problem Solving for Multiple Bone Lesions SLN – Past and Future Bone & Joint Committee Oncology & Theranostics + Translational Molecular Imaging and Therapy Committee

5 Friday, October 23, 13:50 – 15:20 12 Friday, October 30, 10:40 – 12:10 Imaging Hepatobiliary and Pancreatic Tumours – Pearls, Patterns and Alpha Particle Therapy Without Imaging – Options for Dosimetry, the Pitfalls Alpha and Omega Oncology & Theranostics Committee Dosimetry Committee

6 Friday, October 23, 16:55 – 18:25 13 Friday, October 30, 13:50 – 15:20 Bloody Hell!!! Impact on Quantification of Blood Radiotracer Radiomics in a Preclininical and a Clinical Setting Measurements Translational Molecular Imaging and Therapy + Physics + Oncology & Theranostics + Technologist Committee Drug Development + Radiopharmacy + Neuroimaging Committee 14 Friday, October 30, 15:30 – 17:00 7 Saturday, October 24, 09:00 – 10:30 Molecular Drug Imaging of Solid Tumours Including Nuclear Medicine in Paediatric Infections Microenvironment Inflammation & Infection + Paediatrics Committee Oncology & Theranostics Committee

30 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 31 SCIENTIFIC PROGRAMME SCIENTIFIC PROGRAMME

MID-CONGRESS SYMPOSIA MID-CONGRESS SYMPOSIA EANM’20 EANM’20 EANM’20

1 Monday, October 26, 09:30 – 12:15 Detecting Cardiac Amyloidosis – Increasing Role of Nuclear Medicine 8 Tuesday, October 27, 14:00 – 16:45 Cardiovascular + Inflammation & Infection Committee / EACVI For Youngsters – Essential Oncology for Young Nuclear Medicine WORLD LEADING MEETING Physicians WORLD LEADING MEETING 2 Monday, October 26, 09:30 – 12:15 Artificial Intelligence in Image Acquisition, Reconstruction and 9 Wednesday, October 28, 09:30 – 12:15 Processing Update on Treatment of Hyperthyroidism Physics + Dosimetry Committee Thyroid + Radiation Protection Committee / ETA / ESES 3 Monday, October 26, 14:00 – 16:45 10 Wednesday, October 28, 09:30 – 12:15 Clinical Development of Radioligand Therapy Diagnostic Flowcharts on Musculoskeletal Infections Oncology & Theranostics + Radiopharmacy + Drug Development Committee / ESMO Inflammation & Infection Committee

4 Monday, October 26, 14:00 – 16:45 11 Wednesday, October 28, 14:00 – 16:45 Image Guided Surgery Current State and Future of Tau PET Imaging Translational Molecular Imaging & Therapy + Oncology & Theranostics Committee Neuroimaging + Radiopharmacy Committee 5 Tuesday, October 27, 09:30 – 12:15 How to Read PET/CT – Different Shades of Sugar (FDG) 12 Wednesday, October 28, 14:00 – 16:45 Oncology & Theranostics Committee For Youngsters – Emergency During Nuclear Medicine Procedures – What to Know and What to Do? 6 Tuesday, October 27, 09:30 – 12:15 Improved Insights into Radiobiology – Key for Radionuclide Therapy Wednesday, October 28, 09:00 – 16:00 Dosimetry+Translational Molecular Imaging & Therapy +Oncoloy & Theranostics+Radiation 13 Protection+Inflammation &Infection Committee Mid-Congress Symposium for Technologists – Introduction to Dosimetry Technologist + Dosimetry + Physics Committee 7 Tuesday, October 27, 14:00 – 16:45 Lutetium Therapy Dosimetry + Oncology & Theranostics + Physics Committee

32 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 33 SCIENTIFIC PROGRAMME SCIENTIFIC PROGRAMME

CONTINUING TECHNOLOGIST EDUCATION (CTE) SESSIONS IN ADDITION TO THE CTE SESSIONS THE TECHNOLOGIST’S TRACK INCLUDES 3 MINI COURSES: EANM’20 EANM’20 EANM’20

1 Thursday, October 22, 13:30 – 15:00 1 Friday, October 23, 09:00 – 09:50 Tech Guide Launch New Developments in Cardiac Imaging Instrumentation » 13:30 – 13:40 Opening Technologist Track Technologist Committee WORLD LEADING MEETING WORLD LEADING MEETING » 13:40 – 15:00 Technologist Committee 2 Friday, October 23, 10:00 – 10:50 2 Thursday, October 22, 16:35 – 18:05 Advanced Practice in Hybrid Nuclear Medicine Update in Paediatric Imaging Technologist Committee Technologist + Paediatrics Committee 3 Friday, October 23, 11:00 – 11:50 3 Saturday, October 24, 09:00 – 10:30 Alpha Emitters in Therapy Calibration of Instrumentation for Dosimetry Technologist Committee Technologist + Dosimetry Committee 4 Saturday, October 24, 10:40 – 12:10 NET Imaging and Therapy Technologist Committee 5 Friday, October 30, 09:00 – 10:30 Departmental Organisation Technologist Committee 6 Friday, October 30, 10:40 – 12:10 Advanced Competencies Technologist Committee 7 Friday, October 30, 15:30 – 17:00 Quality Control of Imaging Instrumentation Technologist Committee

34 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 35 SCIENTIFIC PROGRAMME SCIENTIFIC PROGRAMME

JOINT SYMPOSIA JOINT SYMPOSIA

Imaging Neuroinflammation Systemic Therapeutic Options in Advanced Thyroid Cancer EANM’20 EANM’20 1 15 EANM’20 Drug Development Committee / EFMC Thyroid Committee / ETA-CG 2 Nano- and Micro-Particles in Nuclear Medicine (Incl. Radioembolisation) 16 Role of Hybrid Imaging in Jaw and Skull Conditions Translational Molecular Imaging and Therapy + Drug Development + Radiopharmacy + Oncology & Theranostics Bone & Joint Committee / EACMFS Committee / WMIS

WORLD LEADING MEETING 17 Benchside to Bedside and Back – What do we Learn from the Clinic? WORLD LEADING MEETING 3 Primary Staging of Prostate Cancer Reloaded Drug Development Committee / EORTC Oncology & Theranostics Committee / EAU 18 Imaging Tumour Microenvironment 4 Hot Topics in Radiation Protection Oncology & Theranostics + Inflammation & Infection Committee / AIO Radiation Protection Committee / EURADOS 19 Impacting the Outcome of High Grade NET Patients 5 Use of PET in Multiple Myeloma Oncology & Theranostics Committee / ENETS Oncology & Theranostics Committee / EHA 20 Simultaneous PET/MR Imaging of Neuroreceptor Systems 6 Detecting Cardiac Toxicity of Cancer Therapies with Nuclear Imaging Neuroimaging Committee / ECNP Cardiovascular Committee / ASNC 21 Total Body PET Imaging 7 Multiple Sclerosis – Update in Neuroimaging Drug Development + Physics Committee / IEEE Neuroimaging Committee / EAN / ECTRIMS 22 Nuclear Medicine Techniques in the Evaluation of GI Motility in Children 8 The Revival of Radiometals Paediatrics Committee / ESPGHAN Radiopharmacy + Drug Development Committee / SRS 23 New Diagnostic and Therapeutic Frontiers in Digestive Oncology 9 Imaging Pulmonary Fungal Infections Oncology & Theranostics Committee / ESDO Inflammation & Infection Committee / ESMI / ESCMID 24 Technical Advances in Paediatric Dose Reduction 10 Nuclear Cardiology Beyond Perfusion Imaging Physics + Paediatrics Committee / EFOMP Cardiovascular Committee / JSNM 25 Immunotherapy in Brain Tumours 11 How Much PET does Radiation Oncology Require? Neuroimaging Committee / EANO Oncology & Theranostics Committee / ESTRO 26 Quantitative SPECT – An Essential Tool? 12 Selecting the Right Imaging for the Right Patient in CAD Physics + Oncology & Theranostics Committee / AAPM Cardiovascular Committee / EACVI 27 Radar on Immune Cell Imaging 13 Metabolic Tumour Volume (MTV) in Lymphoma Translational Molecular Imaging and Therapy + Oncology & Theranostics + Cardiovascular + Inflammation & Oncology & Theranostics Committee / EHA Infection Committee / ESMI 14 Transporter’s Imaging 28 New Approaches for Cardiovascular Imaging Drug Development Committee / SRS Cardiovascular + Translational Molecular Imaging and Therapy + Drug Development Committee / AHA

36 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 37 SCIENTIFIC PROGRAMME SCIENTIFIC PROGRAMME

PITFALLS & ARTEFACTS SESSIONS TEACHING SESSIONS EANM’20 EANM’20 EANM’20

1 Thursday, October 22, 13:30 – 15:00 1 Friday, October 23, 09:00 – 10:30 Unexpected Findings in Brain Imaging Quantification and Standardisation in Clinical and Preclinical Neuroimaging Committee Molecular Imaging WORLD LEADING MEETING WORLD LEADING MEETING Translational Molecular Imaging and Therapy + Physics Committee / EARL 2 Thursday, October 22, 16:35 – 18:05 Pre- and Post Therapeutic Imaging in Thyroid Cancer 2 Friday, October 23, 10:40 – 11:40 Thyroid Committee The Uncomfortable Truth – Are Nuclear Medicine Physicians Viewed as Second Class Doctors Compared to Radiologists? 3 Friday, October 23, 13:50 – 15:20 Dosimetry as Part of Patient Care 3 Saturday, October 24, 09:00 – 10:30 Dosimetry Committee A Practical Guide to MR when Reading PET/MR Friday, October 23, 16:55 – 18:25 4 Saturday, October 24, 10:40 – 11:40 Interpretation of Response Monitoring During Immune Therapy 4 Oncology & Theranostics + Inflammation & Infection Committee The Intellectual and Emotional Journey to Radiology and Nuclear Equality 5 Thursday, October 29, 13:30 – 15:00 FDG-PET Performed or Suspicious for Infections and Inflammation, 5 Friday, October 30, 09:00 – 10:30 Including COVID-19 PET/CT Guided Biopsy Oncology & Theranostics Committee Inflammation & Infection Committee 6 Thursday, October 29, 16:35 – 18:05 6 Friday, October 30, 10:40 – 12:10 Pitfalls and Artefacts in Paediatric Nuclear Medicine Difficult Cases in Cardiac Imaging Cardiovascular Committee Paediatrics Committee 7 Friday, October 30, 13:50 – 15:20 7 Friday, October 30, 15:30 – 15:20 Bone SPECT/CT Revisited – Learning an Old Fox New Tricks Molecular Imaging in Thyroid Nodules Thyroid Committee Bone & Joint Committee

38 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 39 SCIENTIFIC PROGRAMME SCIENTIFIC PROGRAMME

CUTTING EDGE SCIENCE TRACK CUTTING EDGE SCIENCE TRACK EANM’20 EANM’20 EANM’20

1 Thursday, October 22, 13:30 – 15:00 9 Thursday, October 29, 13:30 – 15:00 Cutting Edge Science Track - TROP Session: Quantification Cutting Edge Science Track - TROP Session: Dosimetry Methods and Models - Part 2 WORLD LEADING MEETING 2 Thursday, October 22, 16:35 – 18:05 WORLD LEADING MEETING Cutting Edge Science Track - TROP Session: Preclinical Dosimetry and 10 Thursday, October 29, 13:30 – 15:00 Radiobiology Cutting Edge Science Track - Featured Session: Radiomics 3 Friday, October 23, 09:00 – 10:30 11 Thursday, October 29, 16:35 – 18:05 Cutting Edge Science Track - Featured Session - Patient Radiation Cutting Edge Science Track - Featured Session: Intra-Operative Nuclear Protection Medicine 4 Friday, October 23, 10:40 – 12:10 12 Friday, October 30, 09:00 – 10:30 Cutting Edge Science Track - TROP Session: New Technologies and Cutting Edge Science Track - TROP Session: Dosimetry for PRRT and Imaging Techniques PSMA 5 Friday, October 23, 13:50 – 15:20 13 Friday, October 30, 10:40 – 12:10 Cutting Edge Science Track - TROP Session: Image Processing - Cutting Edge Science Track - TROP Session: Image Reconstruction and Neurology Corrections 6 Friday, October 23, 16:55 – 18:25 14 Friday, October 30, 13:50 – 15:20 Cutting Edge Science Track - TROP Session: Radiation Protection of Staff, Cutting Edge Science Track - TROP Session: Harmonisation & and Advances in Technology Standardisation 7 Saturday, October 24, 2020 09:00 – 10:30 15 Friday, October 30, 15:30 – 17:00 Cutting Edge Science Track - TROP Session: Dosimetry Methods and Cutting Edge Science Track - TROP Session: AI - Image Processing and Models - Part 1 Data Corrections 8 Saturday, October 24, 2020 10:40 – 12:10 Cutting Edge Science Track - TROP Session: AI - Radiomics and Modelling

40 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 41 SCIENTIFIC PROGRAMME SCIENTIFIC PROGRAMME

M2M TRACK EANM YOUNG DAILY FORUM EANM’20 EANM’20 EANM’20

1 Thursday, October 22, 13:30 – 15:00 YDF 1 Monday, October 26, 12:20 – 13:50 M2M Track - TROP Session: Translational Oncology Imaging Simply the Best – Presentation Skills for Medical Professionals

WORLD LEADING MEETING 2 Thursday, October 22, 16:35 – 18:05 Standing up in front of any audience fills most people with fear and anxiety. That’s quite normal. WORLD LEADING MEETING M2M Track - TROP Session: Cardiology Translational However, an ability to clearly present your ideas and research is possibly the single biggest non- medical skill you can develop to further your career. 3 Friday, October 23, 09:00 – 10:30 Roy has coached tens of thousands of medical professionals to give face-to-face and online presentations that are highly effective, impactful and engaging. He will explain every stage of M2M Track - TROP Session: Pharmacokinetics and Chelators - Best of Both presentation planning and structure. And, based on his 40 years’ presenting experience, will share Worlds priceless tips on how to deliver more relevant and engaging talks that help all your audiences become better informed about your important work. 4 Friday, October 23, 10:40 – 12:10 M2M Track - TROP Session: It Takes Place in the Brain - New Neuro Tracers YDF 2 Tuesday, October 27, 12:20 – 13:50 5 Friday, October 23, 13:50 – 15:20 I will Survive – Managing Work Stress and Building Your Resilience M2M Track - Featured Session: Immune and Microenvironment Imaging How is your mental health? Hundreds of millions of people around the world are suffering. The 6 Friday, October 23, 16:55 – 18:25 pressures within the medical world are intense. And the pressure keeps intensifying. How do you M2M Track - Featured Session: Translational Interventional Nuclear currently cope with work and life stress? In this session, Roy will share tried and tested ways you can improve your resilience and your inner strength to help you cope, and even to thrive, during these Medicine particularly challenging times. This session is broken down into many short easy-to-digest videos and is practical, thought-provoking and inspiring. 7 Saturday, October 24, 2020 09:00 – 10:30 M2M Track - TROP Session: Image Guided Treatment and Biopsy YDF 3 Wednesday, October 28, 12:20 – 13:50 8 Saturday, October 24, 2020 10:40 – 12:10 M2M Track - TROP Session: New Kids on the Block - New Tracers Nothing else Matters – Get your Paper Published in a Top Journal

Thursday, October 29, 2020 16:35 – 18:05 Publish or perish – this is a question of do or die. But how do you get your work published? How do 9 you find the most suitable journal? How much resilience is needed? And is it really worth it? M2M Track - Featured Session: The Revival of Pre-Targeting In this session, we will lift the lid on the secret and mysterious world of journals. Highly experienced editors-in-chief (Arturo Chiti from the EJNMMI and Johannes Czernin from the JNM) will explain how 10 Friday, October 30, 2020 09:00 – 10:30 they evaluate submitted work, how they have experienced the ups and downs of submitting papers M2M Track - TROP Session: New and Established Tracers - Prostate only! and how they see the future of their journals. They will also share examples of the best and worst practices they have encountered in their role as editors. They will be joined by former editor-in-chief 11 Friday, October 30, 2020 10:40 – 12:10 and world-renowned nuclear medicine expert Ignasi Carriò from Spain. Ken Herrmann from Germany will serve as moderator and together they will explore more factors M2M Track - Featured Session: Targeted Radionuclide Therapy - Trick or which researchers need to understand in order to increase the chances of publishing success. Treat? Participants are also invited to shape the session by submitting their related questions online. This will be a unique opportunity to get your burning questions answered by high-level experts. 12 Friday, October 30, 2020 15:30 – 17:00 M2M Track - TROP Session: Hot Stuff - Radionuclide Production

42 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 43 SCIENTIC PROGRAMME EANM’20 WORLD LEADING MEETING

18:10 - 19:00 19:00 - 20:00 16:35 - 18:05 18:05 - 18:10 13:30- 15:00 15:00 - 15:10 15:10 - 16:25 16:25 - 16:35 13:00 - 13:25 13:25 - 13:30 Time (CEST)Time 311 111 e-Poster e-Poster Committee Committee Session 1 Session 2 Channel 11 Channel Presentation Presentation Presentation Special Sessions Oncology & Theranostics Oncology & Theranostics PET - Part Diagnostics 1 PET - Part Diagnostics 2

110 by Terumo Terumo Systems Committee Channel 10 Channel Advances in Advances PET-MPI / CT PET-MPI Cardiovascular Cardiovascular Interventional Interventional Featured Session Featured Satellite Symposia Symposia Satellite e-Poster Presentation Sessions Presentation e-Poster 109 by Thyroid Thyroid Thyroid Thyroid Channel 9 Channel Committee Advanced Advanced and Beyond Accelerator Accelerator TROP SessionTROP Applications, A Applications, Cancer - Radioiodine Cancer Satellite Symposia Symposia Satellite Novartis Company Therapeutic Options in Therapeutic Further TROP/Featured Sessions TROP/Featured Further 108 308 Track Track Track Channel 8 Channel Committee Committee Interventions TROP SessionTROP Medicine - Local Medicine - Local Prostate Beyond Beyond Prostate Featured Session Featured Clinical Oncology Clinical Oncology Clinical Oncology Interventional Nuclear Nuclear Interventional Staging and Restaging Staging Oncology & Theranostics Oncology & Theranostics Mid-Congress-Symposia 107 307 Thyroid Thyroid Channel 7 Channel Pitfalls & Pitfalls & Pitfalls Committee Committee Artefacts1 Artefacts 2 Pre- and Post Pre- and Post Neuroimaging Neuroimaging Brain Imaging Brain Thyroid Cancer Thyroid Clinical Oncology Track Track Clinical Oncology Therapeutic Imaging in Therapeutic Unexpected Findings in Unexpected Findings 106 306 Physics Physics Dosimetry Channel 6 Channel Committee Committee Quantification Cutting Edge Edge Cutting Edge Cutting Track Science Track Science TROP SessionTROP SessionTROP and Radiobiology Preclinical DosimetryPreclinical Pitfalls & Artefacts / Teaching Sessions Teaching & Artefacts Pitfalls / 305 105 Imaging Channel 5 Channel Committee Committee Cardiology Cardiology M2M Track M2M Track Translational TROP TROP Session TROP TROP Session Radiopharmacy + Radiopharmacy + Therapy Imaging & Therapy Therapy Imaging & Therapy Translational Molecular Translational Translational Molecular Translational Translational Oncology Oncology Translational Cutting Edge Science Track Track Science Edge Cutting 304 104 CTE 2 CTE 1 Imaging Channel 4 Channel Opening (13:30-13:40) (13:40-15:00) Technologist + Technologist Technologists‘ Technologists‘ M2M Track Track M2M Tech Guide Launch Tech Update in Paediatric in Paediatric Update Paediatrics Committee Paediatrics Technologist Committee Technologist 303 103 Technologist Track Track Technologist Channel 3 Channel Protection TMI&T + Drug Medicine (Incl. Development + Radiopharmacy + Nano- and Micro- Committee Committee / WMIS Radiation Protection Radiation Protection Particles in Nuclear Radioembolisation) Committee / EURADOS Committee Joint Symposium 4 Symposium Joint Joint Symposium 2 Symposium Joint Oncology & Theranostics Hot Topics in Radiation in Topics Hot 2020 Joint/Special Symposia 302 102 Imaging Reloaded Channel 2 Channel Primary Staging Committee / EAU Committee Committee / EFMC / EFMC Committee Drug Development of Prostate Cancer Cancer of Prostate Neuroinflammation Joint Symposium 3 Symposium Joint Joint Symposium 1 Symposium Joint Oncology & Theranostics October 22, CME Sessions

| 201 301 101 Music CME 2 CME 1 Lecture Opening Radar on Channel 1 Channel Committee Committee Plenary 1 Introduction Info - A Virtual - A Info Total Body PET Total Plenary Sessions Virtual Congress Virtual Congress incl. Marie Curie Marie Curie incl. Software Tools and Software Tools Imaging & Therapy + Therapy Imaging & Welcome Social Hour Welcome Nuclear Brain Images Nuclear Brain Translational Molecular Translational Neuroimaging + Physics + Physics Neuroimaging Welcome and Practical and Practical Welcome Oncology & Theranostics Approaches to Measure Measure to Approaches Gynaecological Cancers Gynaecological THURSDAY

19:00 - 20:00 18:05 - 18:10 18:10 - 19:00 15:00 - 15:10 15:10 - 16:25 16:25 - 16:35 16:35 - 18:05 13:25 - 13:30 13:30- 15:00 13:00 - 13:15 Time Time (CEST)

SCIENTIC PROGRAMME EANM’20 WORLD LEADING MEETING SCIENTIC PROGRAMME EANM’20 WORLD LEADING MEETING

16:55 - 18:25 15:20 - 15:30 15:30 - 16:45 16:45- 16:55 13:50 - 15:20 10:40 - 12:10 12:10- 12:15 12:15- 13:45 09:00 - 10:30 10:30 - 10:40 08:30- 08:45 08:45- 08:55 08:55- 09:00 13:45- 13:50 Time (CEST)Time 811 511 611 411 Thyroid Thyroid in Short Methods Session 2 Dosimetry e-Poster e-Poster e-Poster Committee Committee Committee Session 4 Session 5 Session 3 The Best of The Channel 11 Channel Technologists Presentation Presentation Parathyroids) Cardiovascular Cardiovascular Presentation Presentation Presentation Presentation Presentation Neighbours (The Clinical DosimetryClinical The Thyroid and its Thyroid The Technologist e-Poster e-Poster Technologist Cardiovascular Imaging Cardiovascular 510 610 410 by Knife! Track Isotopen Isotopen Committee Committee Channel 10 Channel Neuroimaging Neuroimaging München Ag ITM Molecular Bone TROP SessionTROP Molecular Brain Molecular Brain Technologien Technologien NET Diagnostics Tumour Imaging Tumour Imaging - Nuclear Featured Session Featured Featured Session Featured Clinical Oncology Clinical Oncology Satellite Symposia Symposia Satellite Medicine‘s Swiss Army Army Swiss Medicine‘s Bone & Joint Committee Oncology & Theranostics 809 509 609 409 Thyroid Thyroid Nuclear League? Paediatrics Paediatrics Channel 9 Channel Committee Committee Committee Committee Parathyroid Parathyroid Neuroimaging Neuroimaging Neuroimaging Neuroimaging Imaging - Who TROP SessionTROP TROP SessionTROP TROP SessionTROP and Adolescents in this Champions in this Champions Featured Session Featured Medicine in Children Medicine in Children Movement Disorders Movement Movement Disorders Movement Playground - Nuclear Playground Scores the Best Goals Scores Molecular Imaging of Molecular Imaging of 808 508 608 408 Track Track Track Track Track Tumours Channel 8 Channel Committee Committee Committee Committee Breast PETBreast PRRT for NETs PRRT for TROP SessionTROP TROP SessionTROP PSMA and Beyond and Beyond PSMA Featured Session Featured Featured Session Featured Clinical Oncology Clinical Oncology Clinical Oncology Clinical Oncology Oncology & Theranostics Oncology & Theranostics Oncology & Theranostics Oncology & Theranostics BCR Detection with Ga- PET for Haematological Haematological PET for 807 507 607 407 Therapy Dosimetry Channel 7 Channel Committee Pitfalls & Pitfalls Pitfalls & Pitfalls Teaching Teaching Teaching Teaching Committee Session 2 Session 1 Patient Care Patient Artefacts 4 Artefacts 3 Radiologists? TMI&T + Physics TMI&T + Physics During Immune Interpretation of Interpretation Committee / EARL Committee Standardisation in Standardisation Truth - Are Nuclear - Are Truth Quantification andQuantification Molecular Imaging The UncomfortableThe Medicine Physicians Medicine Physicians Dosimetry as Part of Doctors Compared to Doctors Compared Response Monitoring Clinical and Preclinical and Preclinical Clinical Inflammation & Infection Viewed as Second Class as Second Viewed Oncology & Theranostics +Theranostics Oncology &

806 506 606 406 Physics Physics Physics Channel 6 Channel Committee Committee Committee Committee Protection Neurology Technology Cutting Edge Edge Cutting Cutting Edge Edge Cutting Edge Cutting Cutting Edge Edge Cutting Science Track Track Science Science Track Track Science Track Science Science Track Track Science TROP SessionTROP TROP SessionTROP TROP TROP Session Patient Radiation Patient Image Processing - Image Processing Radiation Protection Radiation Protection Radiation Protection Radiation Protection Featured Session Featured Imaging Techniques Staff, and Advances in Advances and Staff, Radiation Protection of Radiation Protection New Technologies and Technologies New 805 605 505 405 by Brain - Brain Imaging Medicine Channel 5 Channel Committee Committee Committee Committee Chelators - Chelators M2M Track M2M Track M2M Track M2M Track Translational Translational Immune and

TROP TROP Session TROP TROP Session Ge Healthcare Radiopharmacy + Radiopharmacy + Therapy Imaging & Therapy Therapy Imaging & Therapy Therapy Imaging & Therapy New New Tracers Neuro Microenvironment Microenvironment It Takes Place in the Place Takes It Best of Both Worlds Best of Both Drug Development + Session Featured Featured Session Featured Translational Molecular Translational Translational Molecular Translational Translational Molecular Translational Satellite Symposia Symposia Satellite Pharmacokinetics and Interventional Nuclear Interventional Oncology & Theranostics Radiopharmacy + TMIT + Radiopharmacy + 804 604 by 404c 404a 404b Therapy Medicine Session 1 MATTER - MATTER Siemens Channel 4 Channel (09:00 - 09:50) (10:00 - 10:50) (11:00 - 11:50) Technologists Presentation Presentation Healthineers Mini Course 1 Mini Course 2 Mini Course 3 Mini Course Instrumentation MultidisciplinAry Alpha Emitters in Emitters Alpha in Hybrid Nuclear Advanced Practice Practice Advanced in Cardiac Imaging in Cardiac Presentations 1 - Presentations New Developments Developments New Featured Session Featured Satellite Symposia Symposia Satellite Technologists Oral Oral Technologists Technologist e-Poster e-Poster Technologist TechnologisT rEseaRch TechnologisT Technologist Committee Technologist Committee Technologist Committee Technologist 803 603 503 403 / SRS Imaging Imaging Channel 3 Channel Radiometals Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular The Revival of Revival The Patient in CAD Patient Committee / JSNM Committee Committee / ASNC Committee Toxicity of Cancer of Cancer Toxicity Beyond Perfusion Beyond Committee / EACVI Committee Detecting Cardiac Detecting Cardiac Selecting the Right Nuclear Cardiology Nuclear Cardiology Imaging for the Right Imaging for Radiopharmacy + Drug Joint Symposium 8 Symposium Joint Joint Symposium 6 Symposium Joint Therapies with Nuclear Therapies Joint Symposium 12 Symposium Joint Joint Symposium 10 Symposium Joint Development Committee Development Committee 2020 802 602 502 402 ESCMID Multiple Require? Myeloma Channel 2 Channel Committee / Committee Neuroimaging Neuroimaging EAN / ECTRIMS Neuroimaging Committee / EHA Committee Fungal Infections Fungal Committee / ESMI / Committee Committee / ESTRO Committee Live City Tours 1 Tours City Live Imaging Pulmonary Radiation Oncology Radiation Oncology How Much PETHow does Sclerosis - Update in - Update Sclerosis Use of PET in Multiple Use Joint Symposium 9 Symposium Joint Joint Symposium 7 Symposium Joint Joint Symposium 5 Symposium Joint Oncology & Theranostics Oncology & Theranostics Inflammation & Infection Joint Symposium 11 Symposium Joint October 23,

|

801 701 601 501 401 Music CME 6 CME 5 CME 4 CME 3 Lesions Channel 1 Channel Medicine - Committee Committee Committee Committee Plenary 2 Bone & Joint Nuclear Quiz Lunch Break Lunch and Pancreatic and Pancreatic Measurements + Neuroimaging + Neuroimaging Cardiac Nuclear Cardiac Daily Highlights + Radiopharmacy Radiopharmacy + Tumours - Pearls, - Pearls, Tumours Finding the Right Finding for Multiple Bone for Imaging & Therapy Drug Development Blood Radiotracer Blood Radiotracer ImmunoOncology Present and Future Present PET Companion for for PET Companion Patterns and Pitfalls Patterns on Quantification of on Quantification Bloody Hell!!! Impact Imaging Hepatobiliary Oncology & Theranostics Oncology & Theranostics Based Problem Solving Based Problem + Translational + Translational Molecular My Nuclear Vienna 1 Vienna My Nuclear Multimodality Imaging- FRIDAY

15:30 - 16:45 16:45- 16:55 16:55 - 18:25 15:20 - 15:30 12:10- 12:15 12:15- 13:45 10:30 - 10:40 10:40 - 12:10 08:45- 08:55 08:55- 09:00 09:00 - 10:30 13:50 - 15:20 13:45- 13:50 08:30- 08:45 Time (CEST)Time

SCIENTIC PROGRAMME EANM’20 WORLD LEADING MEETING SCIENTIC PROGRAMME EANM’20 WORLD LEADING MEETING e (CET) e (CET) e (CEST) 12:10 - 12:30 12:30 - 13:00 Tim Tim 09:30 - 12:15 12:15 - 12:20 12:20 - 13:50 13:50 - 14:00 14:00 - 16:45 10:40 - 12:10 10:30 - 10:40 09:00 - 10:30 08:30- 08:45 08:45- 08:55 08:55 - 09:00 Tim 911 1011 Physics e-Poster e-Poster Committee Session 7 Session 6 Committee Channel 11 Channel Channel 11 Channel Channel 11 Channel Optimisation for Infection & for Presentation Presentation Presentation Presentation Story Continues Nuclear Medicine InflammationThe - Inflammation & Infection Physics - Hardware and - Hardware Physics 910 1010 Thyroid Thyroid Therapy Therapy Committee Committee Channel 10 Channel Channel 10 Channel Channel 10 Channel Cardiovascular Cardiovascular TROP SessionTROP in Diagnosis and in Diagnosis Nuclear Imaging in Featured Session Featured Cardiac Arrhythmias Cardiac Nuclear Endocrinology Nuclear Endocrinology

1009 Track Channel 9 Channel Channel 9 Channel Channel 9 Channel Committee Miscellaneous Onco Diagnostics Diagnostics Onco Clinical Oncology Featured Session Oncology & Theranostics 908 1008 Track Track Channel 8 Channel Channel 8 Channel Channel 8 Channel Committee Committee Melanoma Best of Nuclear Medicine Therapy PET in Diagnostics Clinical Oncology Featured Session Featured Session Featured Clinical Oncology Clinical Oncology Oncology & Theranostics Oncology & Theranostics Head Neck Cancers and Head Neck Cancers 907 1007 Equality Channel 7 Channel Channel 7 Channel Channel 7 Channel Teaching Teaching Teaching Teaching Session 4 Session 3 The Intellectual and The Emotional Journey to to Emotional Journey when Reading PET/MR Radiology and Nuclear A Practical Guide to MR MR Guide to A Practical

906 1006 Physics Physics Dosimetry Channel 6 Channel Channel 6 Channel Channel 6 Channel Modelling Committee Committee Cutting Edge Edge Cutting Cutting Edge Edge Cutting Science Track Track Science Science Track Track Science TROP SessionTROP TROP SessionTROP AI - Radiomics and and Models - Part 1 Dosimetry Methods 905 1005 Channel 5 Channel Channel 5 Channel Channel 5 Channel Committee Imaging and New Tracers Tracers New M2M Track M2M Track Image Guided Therapy + Drug Therapy TROP TROP Session TROP TROP Session Radiopharmacy + Translational Molecular Translational Translational Molecular Translational Imaging and Therapy + Therapy Imaging and Treatment and Biopsy Treatment Oncology & Theranostics New KidsNew Block - on the Development Committee 904 1004 CTE 4 CTE 3 Therapy Channel 4 Channel Channel 4 Channel Channel 4 Channel Dosimetry Committee Committee Technologist Technologist Calibration for for Calibration NET Imaging and Instrumentation for for Instrumentation Technologist + Dosimetry Technologist 903 by 1003 / EACMFS Channel 3 Channel Channel 3 Channel Channel 3 Channel Conditions Committee / SRS Committee in Jaw and Skull and Skull in Jaw Drug Development Live City Tours 3 Tours City Live Satellite Symposia Symposia Satellite Transporter‘s Imaging Transporter‘s Bone & Joint Committee Bone & Joint Committee Spectrum Dynamics Role of Hybrid Imaging Joint Symposium 16 Symposium Joint Joint Symposium 14 Symposium Joint 2020 2020 2020 902 by 1002 ETA-CG PHILIPS Channel 2 Channel Channel 2 Channel Channel 2 Channel Committee Committee Processing Lymphoma Thyroid Cancer Thyroid Symposium 4 Symposium Symposium 2 Symposium Committee / EHA Committee Volume (MTV)Volume in Mid-Congress- Mid-Congress- Metabolic Tumour Metabolic Tumour Physics + DosimetryPhysics Live City Tours 2 Tours City Live Imaging & Therapy + Therapy Imaging & Thyroid Committee / Committee Thyroid Reconstruction and Artificial Intelligence Options in Advanced Options in Advanced in Image Acquisition, in Image Acquisition, Translational Molecular Translational Satellite Symposia Symposia Satellite Systemic Therapeutic Therapeutic Systemic Image Guided Surgery Oncology & Theranostics Oncology & Theranostics October24, Joint Symposium 15 Symposium Joint Joint Symposium 13 Symposium Joint

| October26,

October25, |

|

901 1001 Free / ESMO CME 8 CME 7 Forum 1 Forum Medicine Paediatrics Paediatrics Channel 1 Channel Channel 1 Channel Channel 1 Channel Committee Nuclear Quiz Amyloidosis - Amyloidosis Cardiovascular + Cardiovascular Symposium 3 Symposium Symposium 1 Symposium Daily Highlights Mid-Congress- Mid-Congress- Simply the Best – Nuclear Medicine Committee / EACVI Committee Increasing Role of Increasing Detecting Cardiac Detecting Cardiac EANM Young Daily EANM Young Nuclear Medicine in Paediatric Infections Paediatric in Paediatric Nuclear in Paediatric Clinical Development Development Clinical Medical Professionals Presentation Skills for Skills for Presentation Emergency Conditions Emergency Conditions + Paediatrics Committee + Paediatrics Oncology & Theranostics Inflammation & Infection Inflammation & Infection of Radioligand Therapy + Radiopharmacy + Drug My Nuclear Vienna 3 Vienna My Nuclear My Nuclear Vienna 2 Vienna My Nuclear Development Committee Development Committee SATURDAY MONDAY SUNDAY e (CET) e (CET) e (CEST) 12:15 - 12:20 12:20 - 13:50 14:00 - 16:45 13:50 - 14:00 09:30 - 12:15 12:30 - 13:00 12:10 - 12:30 10:40 - 12:10 10:30 - 10:40 08:45- 08:55 08:55 - 09:00 09:00 - 10:30 08:30- 08:45 Tim Tim Tim 48

SCIENTIC PROGRAMME EANM’20 WORLD LEADING MEETING SCIENTIC PROGRAMME EANM’20 WORLD LEADING MEETING e (CET) e (CET) Tim 09:00 - 09:30 09:30 - 12:15 12:15 - 12:20 12:20 - 13:50 13:50 - 14:00 14:00 - 16:45 Tim 12:20 - 13:50 13:50 - 14:00 14:00 - 16:45 09:30 - 12:15 12:15 - 12:20 Channel 11 Channel Channel 11 Channel Channel 10 Channel Channel 10 Channel Channel 9 Channel Channel 9 Channel Channel 8 Channel Channel 8 Channel Channel 7 Channel Channel 7 Channel Channel 6 Channel Channel 6 Channel Channel 5 Channel Channel 5 Channel Channel 4 Channel Channel 4 Channel Live City Tours 5 Tours City Live Channel 3 Channel Channel 3 Channel Dosimetry (09:00 - 16:00) 2020 Introduction to Mid-Congress- Symposium 13 Symposium + Physics Committee + Physics Technologist + Dosimetry Technologist 2020 by Infections Channel 2 Channel Channel 2 Channel Committee Committee October 28, For Youngsters - Youngsters For Symposium 8 Symposium Symposium 6 Symposium Europe GmbH Europe For Youngsters - Youngsters For Sirtex Medical Mid-Congress- Mid-Congress- Symposium 12 Symposium Symposium 10 Symposium Mid-Congress- Mid-Congress- Nuclear Medicine

Dosimetry + TMI&T for Young Nuclear Young for + Onco. & Theran. + Theran. & + Onco. Emergency During Live City Tours 4 Tours City Live on Musculoskeletal on Musculoskeletal Essential Oncology Oncology Essential Rad. Prot. + Infl. & Inf. + Infl. & Inf. Rad. Prot. Medicine Physicians | Procedures - What to to What - Procedures Satellite Symposia Symposia Satellite Diagnostic Flowcharts Flowcharts Diagnostic Radionuclide Therapy Radiobiology - Key for for Radiobiology - Key Know and What to Do? to What and Know Inflammation & Infection Improved Insights into Insights into Improved

October 27,

|

journal Forum 3 Forum Imaging Forum 2 Forum ETA / ESES ETA Channel 1 Channel Resilience Channel 1 Channel Committee Committee Committee Sugar (FDG) I will survive - Radiopharmacy Neuroimaging + Neuroimaging Symposium 9 Symposium Symposium 7 Symposium Symposium 5 Symposium - Get your paper - Get your Mid-Congress- Mid-Congress- Hyperthyroidism Symposium 11 Symposium Future of Tau PET Tau of Future Mid-Congress- Mid-Congress- Current State and State Current published in a top published in a top Thyroid + Radiation Thyroid Lutetium Therapy Lutetium and Building Your and Building Your EANM Young Daily EANM Young EANM Young Daily EANM Young How to Read PET/CT to How - Different Shades of - Different Nothing else matters Nothing else matters Dosimetry + Oncology Protection Committee / Committee Protection Managing Work Stress Managing Work & Theranostics + Physics + Physics Theranostics & Oncology & Theranostics My Nuclear Vienna 5 Vienna My Nuclear Update on Treatment of Treatment on Update My Nuclear Vienna 4 Vienna My Nuclear WEDNESDAY TUESDAY e (CET) e (CET) 09:30 - 12:15 12:15 - 12:20 12:20 - 13:50 14:00 - 16:45 13:50 - 14:00 09:00 - 09:30 14:00 - 16:45 12:15 - 12:20 12:20 - 13:50 13:50 - 14:00 09:30 - 12:15 Tim Tim

SCIENTIC PROGRAMME EANM’20 WORLD LEADING MEETING SCIENTIC PROGRAMME EANM’20 WORLD LEADING MEETING

e (CET) 13:30 - 15:00 16:35 - 18:05 13:15 - 13:25 13:25 - 13:30 15:00 - 15:10 15:10 - 16:25 16:25 - 16:35 13:00 - 13:15 Tim 1111 1311 Beyond Beyond e-Poster Committee Session 8 Channel 11 Channel Presentation Presentation Oncology & Theranostics Special Sessions Staging, Restaging and Restaging Staging, All About the Prostate - the Prostate About All 1110 1309 Physics Physics Radiomics Committee Channel 10 Channel Cutting Edge Edge Cutting Science Track Track Science Featured Session Featured e-Poster Presentation Sessions Presentation e-Poster

1109 1309 Channel 9 Channel Committee SPECT-MPI Advances in Advances Cardiovascular Cardiovascular Best Trials Clinical Featured Session Featured Hot Topic Session Topic Hot Further TROP/Featured Sessions TROP/Featured Further 1308 1108 Track Track Channel 8 Channel Committee Committee Mesothelioma TROP SessionTROP SessionTROP [68Ga]Ga-PSMA Lung Cancer and Cancer Lung PET of Diagnostics Detecting BCR with Clinical Oncology Clinical Oncology Oncology & Theranostics Oncology & Theranostics Mid-Congress-Symposia 1307 1107 Medicine Paediatrics Paediatrics Channel 7 Channel Pitfalls & Pitfalls Pitfalls & Pitfalls Committee Committee Artefacts 6 Artefacts 5 Inflammation, Inflammation, Infections and or Suspicious for or Suspicious for in Paediatric Nuclear in Paediatric Pitfalls and ArtefactsPitfalls Including COVID-19 FDG-PET Performed Inflammation & Infection Clinical Oncology Track Track Clinical Oncology

1106 1306 Physics Physics Medicine Dosimetry Channel 6 Channel Committee Committee Cutting Edge Edge Cutting Cutting Edge Edge Cutting Science Track Track Science Science Track Track Science TROP SessionTROP and Models Part - 2 Featured Session Featured Dosimetry Methods Intra-Operative Nuclear Intra-Operative Pitfalls & Artefacts / Teaching Sessions Teaching & Artefacts Pitfalls / by 1305 Telix Telix Channel 5 Channel Committee M2M Track Pre-Targeting The Revival of Revival The + Radiopharmacy Drug Development Pharmaceuticals Featured Session Featured Satellite Symposia Symposia Satellite Cutting Edge Science Track Track Science Edge Cutting 1304 1104 impact Channel 4 Channel TOP - Technologist TOP - Technologist Presentations 3 - Presentations Presentations 2 - Presentations Featured Session Featured Featured Session Featured Technologists Oral Oral Technologists Technologists Oral Oral Technologists Overview and Practice BOTH ART - The BeautyThe ART - BOTH Of The HeART and mind The Of M2M Track Track M2M 1303 1103 / AIO Channel 3 Channel Technologist Track Track Technologist Neuroimaging Neuroimaging MR Imaging of + Inflammation & Imaging Tumour Imaging Tumour Committee / ECNP Committee Microenvironment Simultaneous PET/ Infection Committee Infection Committee 2020 Oncology & Theranostics Joint Symposium 20 Symposium Joint Joint Symposium 18 Symposium Joint Neuroreceptor Systems Neuroreceptor 1302 1102 Joint/Special Symposia Patients Patients Channel 2 Channel Drug Development Committee / ENETSCommittee of High Grade NETof High Grade Committee / EORTC Committee Live City Tours 6 Tours City Live Benchside to BedsideBenchside to Learn from the Clinic? from Learn October 29, and Back - What do we do we What and Back - Oncology & Theranostics Joint Symposium 19 Symposium Joint Joint Symposium 17 Symposium Joint Impacting the Outcome

|

CME Sessions

1301 1201 1101 Thyroid Thyroid CME 9 Imaging CME 10 New PETNew Channel 1 Channel Committee Plenary 3 Nuclear Quiz Daily Highlights Next Generation Next Generation What‘s Cooking? Cooking? What‘s Physics Committee Physics Radiomics in Thyroid Technologies - Digital - Digital Technologies Plenary Sessions Radiopharmaceuticals Revolution or Big Bust? Revolution Oncology & Theranostics +Theranostics Oncology & My Nuclear Vienna 6 Vienna My Nuclear THURSDAY

e (CET) 15:00 - 15:10 13:25 - 13:30 13:30 - 15:00 15:10 - 16:25 16:25 - 16:35 16:35 - 18:05 13:15 - 13:25 13:00 - 13:15 12:15 - 12:45 Tim

SCIENTIC PROGRAMME EANM’20 WORLD LEADING MEETING SCIENTIC PROGRAMME EANM’20 WORLD LEADING MEETING

e (CET) 15:30 - 17:00 17:00 - 17:05 13:50 - 15:20 15:20 - 15:30 10:40 - 12:10 12:10 - 12:15 12:15 - 13:45 13:45 - 13:50 08:30 - 08:45 08:45 - 08:55 09:00 - 10:30 10:30 - 10:40 Tim 17:05 - 18:25 1711 1511 1611 1411 Physics Physics Imaging e-Poster e-Poster e-Poster e-Poster Committee Committee Committee Committee Mixed Bag Mixed Session 9 Channel 11 Channel Session 12 Session 10 Session 11 Neuroimaging Neuroimaging Presentation Presentation Presentation Presentation Presentation Presentation Molecular Brain Molecular Brain Therapy Beyond Beyond Therapy Special Sessions Nuclear Medicine Image Processing Onco Diagnostics - Diagnostics Onco Physics - Software and Physics Oncology & Theranostics Oncology & Theranostics 1710 1410 1510 1610 Medicine COVID-19 Committee Channel 10 Channel TROP SessionTROP SessionTROP General Nuclear General Our Army at War - War at Our Army Nuclear Medicine and e-Poster Presentation Sessions Presentation e-Poster Inflammation & Infection 1709 1409 1509 1609 Story Thyroid Thyroid Nodules Diseases Channel 9 Channel Committee Committee Committee Committee Malignant? - Malignant? Neuroimaging Neuroimaging Cardiovascular Cardiovascular Is It or Is It Not and Infiltrative and Infiltrative Cardiovascular Cardiovascular TROP SessionTROP TROP SessionTROP SessionTROP in Inflammatory Nuclear Imaging Options in Thyroid Featured Session Featured Imaging Approaches PET for InfectionPET and for Diagnostic/Predictive Diagnostic/Predictive Inflammation - A New - A New Inflammation Novel Molecular Brain Molecular Brain Novel Inflammation & Infection Further TROP/Featured Sessions TROP/Featured Further 1708 1408 1508 1608 Ra and More... Track Track Track Track Track Track 223 Prostate Tumours Lu]Lu-PSMA Lu]Lu-PSMA Channel 8 Channel Committee Committee Committee Committee 177 [ TROP SessionTROP TROP SessionTROP PET Diagnostics of Clinical Oncology Featured Session Featured Session Featured Clinical Oncology Clinical Oncology Clinical Oncology Clinical Oncology Clinical Oncology Radioligand Therapy All About Staging the Staging About All Oncology & Theranostics Oncology & Theranostics Oncology & Theranostics Oncology & Theranostics Gynaecological and GI Gynaecological Prostate Therapy Prostate Cancer - PSMA, - PSMA, Mid-Congress-Symposia 1707 1407 1507 1607 Thyroid Thyroid Biopsy Channel 7 Channel Pitfalls & Pitfalls Teaching Teaching Teaching Teaching Teaching Committee Committee Committee Committee Session 7 Session 5 Session 6 Bone & Joint Artefacts 7 Cardiovascular Cardiovascular Bone SPECT/CT Cardiac Imaging Cardiac Thyroid Nodules Thyroid Difficult Cases in Difficult PET/CT Guided Old Fox New Tricks New Old Fox Molecular Imaging in Revisited - Learning an - Learning Revisited Oncology & Theranostics Clinical Oncology Track Track Clinical Oncology

1706 1406 1506 1606 PSMA PSMA Physics Physics Physics Physics Physics Dosimetry Channel 6 Channel Committee Committee Committee Committee Cutting Edge Edge Cutting Cutting Edge Edge Cutting Edge Cutting Edge Cutting Science Track Science Science Track Track Science Track Science Track Science TROP SessionTROP TROP SessionTROP TROP SessionTROP SessionTROP and Corrections Standardisation Standardisation Harmonisation & Harmonisation and Data Corrections and Data AI - Image Processing AI - Image Processing Image Reconstruction Dosimetry PRRT and for Pitfalls & Artefacts / Teaching Sessions Teaching & Artefacts Pitfalls / 1705 1605 1405 1505 Channel 5 Channel Committee Committee Committee Production M2M Track M2M Track M2M Track TROP TROP Session TROP TROP Session + Radiopharmacy + Radiopharmacy + Radiopharmacy Drug Development Drug Development Imaging and Therapy Featured Session Featured New and Established New Translational Molecular Translational Tracers - Prostate only! - Prostate Tracers Targeted Radionuclide Targeted Therapy - Trick Therapy or Treat? - Trick Hot Stuff - Hot Stuff Radionuclide Cutting Edge Science Track Track Science Edge Cutting by by 1704 1404 1504 CTE 7 CTE 5 CTE 6 Advanced Advanced Channel 4 Channel Committee Committee Committee of Imaging Advanced Advanced Technologist Technologist Technologist Technologist Technologist Organisation Accelerator Accelerator Departmental Competencies Quality Control Quality Control Instrumentation Applications, A Applications, M2M Track Track M2M Boston Scientific Satellite Symposia Symposia Satellite Satellite Symposia Symposia Satellite Novartis Company 1703 1603 1403 1503 Technologist Track Track Technologist / AAPM ESPGHAN Channel 3 Channel Reduction Essential Tool? Essential Cardiovascular + Cardiovascular Evaluation of GI Evaluation Committee / AHA Committee Techniques in the Techniques Nuclear Medicine in Paediatric Dose in Paediatric Physics + Paediatrics + Paediatrics Physics Committee / EFOMP Committee Motility in Children Technical Advances Advances Technical Imaging and Therapy + Drug Development Physics + Oncology & Physics New Approaches for for Approaches New Translational Molecular Translational Paediatrics Committee / Committee Paediatrics Theranostics Committee Committee Theranostics Joint Symposium 28 Symposium Joint Joint Symposium 26 Symposium Joint Joint Symposium 22 Symposium Joint 24 Symposium Joint Cardiovascular Imaging Cardiovascular Quantitative SPECT - An Quantitative 2020 Joint/Special Symposia 1702 1602 1402 1502 Imaging Channel 2 Channel Total Body Total PET Imaging Neuroimaging Neuroimaging Brain Tumours Brain & Theranostics & Theranostics + Cardiovascular + Cardiovascular Committee / ESMI Committee TMI&T + Oncology Committee / ESDO Committee Committee / EANO Committee Live City Tours 7 Tours City Live Immunotherapy in Immunotherapy Digestive Oncology Digestive Drug Development+ New Diagnostic and and Diagnostic New Radar on Immune Cell Radar on Immune Cell Oncology & Theranostics Inflammation & Infection Physics Committee / IEEE Committee Physics Joint Symposium 27 Symposium Joint Joint Symposium 25 Symposium Joint Joint Symposium 23 Symposium Joint Joint Symposium 21 Symposium Joint Therapeutic Frontiers in Frontiers Therapeutic CME Sessions October 30,

|

1801 1701 1601 1401 1501 Award Closing Lecture CME 14 CME 13 CME 12 CME 11 Dosimetry Channel 1 Channel Committee Committee Committee Nuclear Quiz Lunch Break Lunch Radiomics in a Clinical SettingClinical & Theranostics & Theranostics + Molecular Drug Plenary Sessions Daily Highlights Imaging of Solid Imaging & Therapy Physics + Oncology Physics Preclininical and a Preclininical Without Imaging - Without Marie Curie Award Marie Curie Honorary Member Microenvironment Tumours Including Tumours Imaging & Therapy + Therapy Imaging & SLN - Past and Future SLN - Past Translational Molecular Translational Plenary 4 - Highlights the Alpha and Omega the Alpha Alpha Alpha Particle Therapy Options for Dosimetry, Dosimetry, Options for Technologist Committee Technologist Oncology & Theranostics Oncology & Theranostics + Translational + Translational Molecular My Nuclear Vienna 7 Vienna My Nuclear FRIDAY

e (CET) 17:00 - 17:05 15:20 - 15:30 15:30 - 17:00 12:10 - 12:15 12:15 - 13:45 13:45 - 13:50 13:50 - 15:20 09:00 - 10:30 08:45 - 08:55 08:55 - 09:00 10:30 - 10:40 10:40 - 12:10 08:30 - 08:45 17:05 - 18:25 Tim

SCIENTIC PROGRAMME EANM’20 WORLD LEADING MEETING Vereos Digital PET/CT 101 OP-006 CME 1: Radar on Gynaecological Cancers Target Identification and Tracer Design and Development A. Windhorst; Amsterdam UMC/VUMC, Department of Radiology Thursday, October 22, 2020, 13:30 - 15:00 and Nuclear Medicine, Amsterdam, NETHERLANDS. Channel 1 OP-007

Clinical Directions for Neuroinflammation Imaging OP-001 A. Jacobs; European Institute for Molecular Imaging, University Hospital Muenster, Muenster, GERMANY . PET/CT Guided Response Assessment in Gynaecological Tumours C. Nanni; Nuclear Medicine Unit, Policlinico Sant’Orsola Malpighi, OP-008

EANM’20 EANM’20 Bologna, ITALY. EANM’20 OP-002 Clinical Trials of P2X7 Targeted Radiotracers K. van Laere; Division of Nuclear Medicine and Molecular PET/CT in Radiotherapy Treatment Planning Imaging, University Hospitals of Leuven and KU Leuven, Leuven, BELGIUM. J. Adam; Department of Radiology and Nuclear Medicine, WORLD LEADING MEETING Amsterdam University Medical Center, Amsterdam, WORLD LEADING MEETING NETHERLANDS. 103 Joint Symposium 2 (EANM/WMIS): Nano- and OP-003 Micro-Particles in Nuclear Medicine (Incl. Radioembolisation) Interventional Nuclear Medicine Techniques for Gynaecological Tumours Thursday, October 22, 2020, 13:30 - 15:00 S. Vidal Sicart; Nuclear Medicine Hospital Clinic de Barcelona, Channel 3 Barcelona, SPAIN. OP-004

New Radiopharmaceuticals for Improved Diagnosis in OP-009 Gynaecological Tumours - What is the Future? S. Kossatz; Technical University of Munich, Department of Introduction to Nanoparticles in Medicine Nuclear Medicine, Munich, GERMANY. T. Lammers; RWTH Aachen, Experimental Molecular Imaging, Aachen, GERMANY.

102 OP-010 Joint Symposium 1 (EANM/EFMC): Imaging Neuroinflammation Nanocolloids in Theranostics T. Buckle; Leiden University Hospital, Radiology, Leiden, Proven accuracy NETHERLANDS. Thursday, October 22, 2020, 13:30 - 15:00 Channel 2 OP-011 inspires confidence Radioembolization with Microparticles M. Wildgruber; University Hospital Muenster, Radiology, In the transition from volume- to value-based care, accurate treatment OP-005 Muenster, GERMANY. pathways are essential. Philips Vereos Digital PET/CT is the world’s first and only fully digital PET/CT solution—and its accuracy is supported by Introduction Talk rigorous clinical evidence measured in years, not months. There is always D. van Weehaeghe; Division of Nuclear Medicine and Molecular a way to make life better. Imaging, University Hospitals of Leuven and KU Leuven, Leuven, BELGIUM. Join us at EANM 2020. Visit philips.to/EANM2020

56 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 57 Research Medical Center Russian Academy of Sciences, Tomsk, 104 RUSSIAN FEDERATION, 3KTH Royal Institute of Technology, 1Research Centrum for Oncotheranostics, Tomsk Polytechnic CTE 1: Tech Guide Launch Stockholm, SWEDEN, 4Uppsala University, Uppsala, SWEDEN. 104 University, Tomsk, RUSSIAN FEDERATION, 2Tomsk National Research CTE 1: Tech Guide Launch Medical Center Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION, 3KTH Royal Institute of Technology, Stockholm, Thursday, October 22, 2020, 13:30 - 15:00 OP-017 4 Channel 4 SWEDEN, Uppsala University, Uppsala, SWEDEN. Thursday, October 22, 2020, 13:30 - 15:00 Channel 4 Radiolabelling and Preliminary in vivo Study of a Small OP-017 Molecule-based Ligand for CCK2 Receptors Targeting M. Asti1, M. Verona2, S. Rubagotti1, F. Mastrotto2, G. Marzaro2, V. Di Radiolabelling and Preliminary in vivo Study of a Small OP-012 Marco2, S. Corradetti3, N. Realdon2, A. Andrighetto3; Molecule-based Ligand for CCK2 Receptors Targeting 1AUSL-IRCCS, Reggio Emilia, ITALY, 2University of Padua, Padua, OP-012 M. Asti1, M. Verona2, S. Rubagotti1, F. Mastrotto2, G. Marzaro2, V. Di Technologists’ Opening ITALY, 3National Institute of Nuclear Physics, Legnaro (PD), ITALY. Marco2, S. Corradetti3, N. Realdon2, A. Andrighetto3; A. Santos; Hospital CUF Descobertas, Medicina Nuclear Technologists’ Opening 1AUSL-IRCCS, Reggio Emilia, ITALY, 2University of Padua, Padua, Department, Lisbon, PORTUGAL. OP-018 A. Santos; Hospital CUF Descobertas, Medicina Nuclear ITALY, 3National Institute of Nuclear Physics, Legnaro (PD), ITALY. Department, Lisbon, PORTUGAL. EANM’20 EANM’20 EANM’20 OP-013 Evaluation of Molecular Design of HER2-targeting OP-018 Affibody-drug Conjugates for Drug Delivery to Ovarian OP-013 QC of Hybrid Systems Cancer Evaluation of Molecular Design of HER2-targeting QC of Hybrid Systems S. Rep; University Medical Centre, Department of Nuclera T. Xu1, H. Ding2, A. Vorobyeva1,3, M. Oroujeni1, T. Gräslund2, A. Affibody-drug Conjugates for Drug Delivery to Ovarian Medicine, Ljubljana, SLOVENIA. Orlova4,3,5, V. Tolmachev1,3; S. Rep; University Medical Centre, Department of Nuclera Medicine, Cancer WORLD LEADING MEETING WORLD LEADING MEETING 1Department of Immunology, Genetics and Pathology, Uppsala Ljubljana, SLOVENIA. T. Xu1, H. Ding2, A. Vorobyeva1,3, M. Oroujeni1, T. Gräslund2, A. OP-014 University, Uppsala, SWEDEN, 2Department of Protein Science, Orlova4,3,5, V. Tolmachev1,3; KTH Royal Institute of Technology, Stockholm, SWEDEN, 3Research OP-014 1Department of Immunology, Genetics and Pathology, Uppsala The Contribution of Hybrid Imaging to Radionuclide Centrum for Oncotheranostics, Research School of Chemistry University, Uppsala, SWEDEN, 2Department of Protein Science, Therapy and Applied Biomedical Sciences, Tomsk Polytechnic University, The Contribution of Hybrid Imaging to Radionuclide KTH Royal Institute of Technology, Stockholm, SWEDEN, 3Research C. Abreu; The Royal Marsden Hospital, Sutton, UNITED KINGDOM. Tomsk, RUSSIAN FEDERATION, 4Department of Medicinal Therapy Centrum for Oncotheranostics, Research School of Chemistry and Chemistry, Uppsala University, Uppsala, SWEDEN, 5Science for Life C. Abreu; The Royal Marsden Hospital, Sutton, UNITED KINGDOM. Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Laboratory, Uppsala University, Uppsala, SWEDEN. RUSSIAN FEDERATION, 4Department of Medicinal Chemistry, OP-015 Uppsala University, Uppsala, SWEDEN, 5Science for Life Laboratory, OP-019 OP-015 Uppsala University, Uppsala, SWEDEN. Quantitative Methods in SPECT/CT A. L. Strömvall; Umeå University Hospital, Dept. of Radiation Optimization of the biodistribution of 1C1m-Fc anti Quantitative Methods in SPECT/CT OP-019 Physics, Umeå, SWEDEN. TEM-1 antibody fusion protein in soft tissue sarcoma A. L. Strömvall; Umeå University Hospital, Dept. of Radiation model in mice Physics, Umeå, SWEDEN. Optimization of the biodistribution of 1C1m-Fc anti TEM-1 J. Delage1, A. Faivre-Chauvet2, J. K. Fierle3, N. Schaefer4, G. Coukos5, antibody fusion protein in soft tissue sarcoma model in S. M. Dunn3, D. Viertl4, J. O. Prior4; mice 105 1Radiopharmacy Unit, Pharmacy Department, Lausanne J. Delage1, A. Faivre-Chauvet2, J. K. Fierle3, N. Schaefer4, G. Coukos5, M2M Track - TROP Session: Translational University Hospital, Lausanne, SWITZERLAND, 2CRCINA, INSERM 105 S. M. Dunn3, D. Viertl4, J. O. Prior4; Oncology Imaging 1232-CNRS ERL 6001, University of Angers, University of Nantes, M2M Track - TROP Session: Translational 1Radiopharmacy Unit, Pharmacy Department, Lausanne University Nantes, FRANCE, 3LAbCore, Ludwig Institute for Cancer Research, Oncology Imaging Hospital, Lausanne, SWITZERLAND, 2CRCINA, INSERM 1232-CNRS Lausanne University Hospital and University of Lausanne, ERL 6001, University of Angers, University of Nantes, Nantes, Thursday, October 22, 2020, 13:30 - 15:00 Lausanne, SWITZERLAND, 4Department of Nuclear Medicine and 3 Channel 5 FRANCE, LAbCore, Ludwig Institute for Cancer Research, Lausanne Molecular Imaging, Lausanne University Hospital and University Thursday, October 22, 2020, 13:30 - 15:00 Channel 5 University Hospital and University of Lausanne, Lausanne, of Lausanne, Lausanne, SWITZERLAND, 5Ludwig Institute for SWITZERLAND, 4Department of Nuclear Medicine and Molecular Cancer Research and Department of Oncology, Lausanne Imaging, Lausanne University Hospital and University of Lausanne, University Hospital and University of Lausanne, Lausanne, Lausanne, SWITZERLAND, 5Ludwig Institute for Cancer Research OP-016 SWITZERLAND. and Department of Oncology, Lausanne University Hospital and OP-016 University of Lausanne, Lausanne, SWITZERLAND. Phase I study of 99mTc-ADAPT6, a scaffold protein-based OP-020 probe for visualization of HER2 expression in breast Phase I study of 99mTc-ADAPT6, a scaffold protein-based OP-020 cancer 68Ga-NT-20.3 for imaging of neurotensin receptor: first probe for visualization of HER2 expression in breast cancer 1,2 3 4 1,2 68Ga-NT-20.3 for imaging of neurotensin receptor: first O. Bragina1,2, E. von Witting3, J. Garousi4, R. Zelchan1,2, M. human study O. Bragina , E. von Witting , J. Garousi , R. Zelchan , M. Sandström4, A. Orlova1,4, A. Medvedeva2, A. Doroshenko2, F. Wang1, W. Wu1, I. Virgolini2, M. Hodlic3; Sandström4, A. Orlova1,4, A. Medvedeva2, A. Doroshenko2, A. human study A. Vorobyeva1,4, S. Lindbo3, J. Borin3, N. Tarabanovskaya2, J. 1Nanjing Medical University, Nanjing, CHINA, 2Medical University Vorobyeva1,4, S. Lindbo3, J. Borin3, N. Tarabanovskaya2, J. Sörensen4, F. Wang1, W. Wu1, I. Virgolini2, M. Hodlic3; Sörensen4, S. Hober3, V. Chernov1,2, V. Tolmachev1,4; Innsbruck, Innsbruck, AUSTRIA, 3Palacký University Olomouc, S. Hober3, V. Chernov1,2, V. Tolmachev1,4; 1Nanjing Medical University, Nanjing, CHINA, 2Medical University 1Research Centrum for Oncotheranostics, Tomsk Polytechnic Olomouc, CZECH REPUBLIC. University, Tomsk, RUSSIAN FEDERATION, 2Tomsk National

58 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 59 Innsbruck, Innsbruck, AUSTRIA, 3Palacký University Olomouc, OP-024 106 K. Baete, M. Sevenois, E. Pauwels, C. M. Deroose; Olomouc, CZECH REPUBLIC. Nuclear Medicine, University Hospitals Leuven; Nuclear Medicine Cutting Edge Science Track - TROP Session: Affibody-based Theranostics for HER3-expressing cancers: and Molecular Imaging, Department of Imaging and Pathology, Quantification Leuven, BELGIUM. tumor growth inhibition, and PET-imaging of HER3 for OP-021 therapy monitoring in a preclinical model Thursday, October 22, 2020, 13:30 - 15:00 OP-032 1 1 1 2 2 Channel 6 Molecular imaging of monocarboxylate transporters with A. Orlova , S. S. Rinne , M. Altai , C. Dahlsson Leitao , S. Ståhl , J. 2 1 Löfblom , V. Tolmachev ; Experimental validation of absolute SPECT/CT PET - development and biological evaluation of novel 1Uppsala University, Uppsala, SWEDEN, 2Royal Institute of 2-fluoropyridinyl analogs of FACH Technology, Stockholm, SWEDEN. quantification for response monitoring in patients with M. Sadeghzadeh1, W. Deuther-Conrad1, B. Wenzel1, D. Gündel1, M. coronary artery disease Toussaint1, R. P. Moldovan1, S. Fischer1, F. A. Ludwig1, R. Teodoro1, S. OP-028 A. van de Burgt1, P. Dibbets-Schneider1, C. H. Slump2, A. J. H. A. Jonnalagadda2, S. K. Jonnalagadda2, V. R. Mereddy2, L. R. Drewes3, OP-025 Scholte1, D. E. Atsma1, L. F. de Geus-Oei1,2, F. H. P. van Velden1; P. Brust1; An international quantitative SPECT/CT imaging exercise 1Leiden University Medical Center, Leiden, NETHERLANDS, 1Department of Neuroradiopharmaceuticals, Institute of In vitro receptor autoradiography utilising a for Lu-177 2University of Twente, Enschede, NETHERLANDS. 111 1 2 3 2

EANM’20 EANM’20 Radiopharmaceutical Cancer Research, Helmholtz-Zentrum novel In-labeled GIP receptor antagonist J. Tran-Gia , A. P. Robinson , N. Calvert , A. M. Denis-Bacelar , A. J. EANM’20 Dresden-Rossendorf, Leipzig, GERMANY, 2Department of 2,4 2 5,6 5 5 reveal high signals in neuroendocrine tumours: A Fenwick , K. M. Ferreira , D. Finocchiaro , F. Fioroni , E. Grassi , W. Chemistry and Biochemistry, Department of Pharmacy Practice Heetun2, S. J. Jewitt7, T. Kalathas8, M. Kotzasarlidou8, M. Ljungberg9, OP-033 111 & Pharmaceutical Sciences, University of Minnesota, Duluth, MN, comparative study to 111In-DOTATATE and In-JR11 D. R. McGowan7,10, J. Scuffham11, K. Sjögreen Gleisner9, J. Tipping3, J. UNITED STATES OF AMERICA, 3Department of Biomedical Sciences, A. Schumann1, C. Haase1, U. Reineke1, C. Smerling1, J. Wevrett11, M. Lassmann1; Effect of Respiratory Motion on Dosimetric Measurements University of Minnesota Medical School Duluth, Duluth, MN, C. Reubi2, I. Eichhorn3, B. Wiedenmann3, C. Roderburg3; 1Department of Nuclear Medicine, University of Würzburg, for 99mTc-MAA SPECT/CT

WORLD LEADING MEETING 2 WORLD LEADING MEETING UNITED STATES OF AMERICA. 13B Pharmaceuticals GmbH, Berlin, GERMANY, 2Institute of Würzburg, GERMANY, National Physical Laboratory, Teddington, Z. Lu, G. Mok; 3 Pathology, University of Berne, Berne, SWITZERLAND, 3Charité- UNITED KINGDOM, The Christie NHS FT, Manchester, UNITED Biomedical Imaging Laboratory (BIG), Department of Electrical 4 5 OP-022 Universitätsmedizin, Berlin, GERMANY. KINGDOM, Cardiff University, Cardiff, UNITED KINGDOM, Azienda and Computer Engineering, Faculty of Science and Technology, Unità Sanitaria Locale di Reggio Emilia - IRCCS, Medical Physics University of Macau, Taipa, MACAO. 2-[18F]FDG metabolism: The role of alternative metabolic Unit, Reggio Emilia, ITALY, 6Department of Physics and Astronomy, 7 pathways OP-026 University of Bologna, Bologna, ITALY, Oxford University Hospitals OP-034 NHS FT, Oxford, UNITED KINGDOM, 8”THEAGENIO” Anticancer E. Klebermass1,2, M. Mahmudi1, A. Miller3, V. Pichler1, C. Vraka1, T. Hospital, Thessaloniki, GREECE, 9Department of Medical Radiation Balber4, A. Haschemi3, W. Wadsak1,5, M. Hacker1, H. Viernstein2, M. Multimodal In Ovo Imaging: The chicken embyro as an Quantitation of small lesions by routine PET imaging Physics, Lund, SWEDEN, 10University of Oxford, Oxford, UNITED Mitterhauser1,4; alternative model in preclinical research protocols in Finland KINGDOM, 11Royal Surrey NHS FT, Guildford, UNITED KINGDOM. 1Department of Biomedical Imaging and Image-guided Therapy, T. Balber1,2, J. Christl1, J. Friske3, S. M. Bugayong2, V. Fröhlich3, J. Liukkonen1, O. Sipilä2, T. Tolvanen3,4, H. Halme2, M. Hakulinen5,6, Division of Nuclear Medicine, Medical University of Vienna, A. S. Zacher2, L. Nics2, W. Wadsak2,4, M. Hacker2, T. Helbich3, M. T. Kangasmaa7, A. Kangasmäki8, A. Manninen9, T. Ollikainen10, A. Vienna, AUSTRIA, 2Department of Pharmaceutical Technology Mitterhauser1,2; OP-029 Sohlberg11, K. Tahvanainen12, V. Tunninen13, J. Vuorela14; and Biopharmaceutics, University of Vienna, Vienna, AUSTRIA, 1Ludwig Boltzmann Institute Applied Diagnostics, Vienna, AUSTRIA, 1Radiation and Nuclear Safety Authority (STUK), Helsinki, FINLAND, 3Department of Laboratory Medicine, Medical University of Vienna, 2Division of Nuclear Medicine, Department of Biomedical Imaging An in silico study on the influence of radiosensitivity and 2HUS Medical Imaging Center, Clinical Physiology and Nuclear 4 Vienna, AUSTRIA, Ludwig Boltzmann Institute Applied Diagnostics, and Image-guided Therapy, Medical University of Vienna, Vienna, tumor growth on the total tumor volume in 177Lu-PSMA Medicine, University of Helsinki and Helsinki University Hospital, Vienna, AUSTRIA, 5CBmed GmbH - Center for Biomarker Research in 3 3 AUSTRIA, Division of General Radiology, Department of Biomedical therapy Helsinki, FINLAND, Turku PET Centre, Turku University Hospital, Medicine, Graz, AUSTRIA. Imaging and Image-guided Therapy, Medical University of Vienna, Turku, FINLAND, 4Department of Medical Physics, Turku University P. Kletting1, A. Gafita2, H. Wang2, A. Beer1, W. Weber2, M. Eiber2, G. Vienna, AUSTRIA, 4Center for biomarker research in medicine, Hospital, Turku, FINLAND, 5Dept. of Clinical Physiology and Nuclear Glatting1; CBmed GmbH, Graz, AUSTRIA. Medicine, Diagnostic Imaging Center, Kuopio University Hospital, 1Universität Ulm, Ulm, GERMANY, 2Technische Universität München, Kuopio, FINLAND, 6Dept. of Applied Physics, University of Eastern OP-023 München, GERMANY. OP-027 Finland, Kuopio, FINLAND, 7Department of Clinical physiology High-Contrast Radionuclide Imaging of EpCAM Expression and nuclear medicine, Vaasa Central Hospital, Vaasa, FINLAND, 8Departments of Imaging and Radiotherapy, Docrates Cancer in Ovarian Cancer Using DARPin Labeled With a Non- Reducing abdominal background in 4FMFES-PET using OP-030 Center, Helsinki, FINLAND, 9OYS Department of Nuclear Medicine Residualizing Label intestinal peristalsis inhibitors: a translational study 10 Impact of gamma camera uniformity calibration methods and Radiology, Oulu University Hospital, Oulu, FINLAND, Clinical A. Vorobyeva1,2, E. Konovalova3, T. Xu1, A. Schulga3, M. Altai1, J. M. Paquette, E. Espinosa-Bentancourt, É. Lavallée, S. Phoenix, B. physiology and Neurophysiology North Karelia Central Hospital, Garousi1, S. S. Rinne1, A. Orlova1,2, S. M. Deyev3,2,4, V. Tolmachev1,2; Guérin, É. E. Turcotte; in SPECT Imaging Joensuu, FINLAND, 11Laboratory of Clinical Physiology and Nuclear 1Uppsala University, Uppsala, SWEDEN, 2National Research Tomsk Université de Sherbrooke, Sherbrooke, QC, CANADA. K. Ferreira, W. Heetun, A. P. Robinson; Medicine, Päijät-Häme Central Hospital, Lahti, FINLAND, 12HUS Polytechnic University, Tomsk, RUSSIAN FEDERATION, 3Shemyakin National Physical Laboratory, Teddington, UNITED KINGDOM. Diagnostic Center, South Karelia Central Hospital, Department of & Ovchinnikov Institute of Bioorganic Chemistry, Moscow, RUSSIAN Clinical Physiology and Nuclear Medicine, Lappeenranta, FINLAND, FEDERATION, 4Sechenov University, Moscow, RUSSIAN FEDERATION. 13Department of Clinical Physiology and Nuclear Medicine, OP-031 Satakunta Central Hospital, Pori, FINLAND, 14Clinical physiology and nuclear medicine, Central Finland Health Care District, 123 Verification of xSPECT Quant for Quantitative I-mIBG Jyväskylä, FINLAND. SPECT/CT Imaging

60 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 61 OP-035 Pitfalls & Artefacts 1: Unexpected Findings in Brain Imaging Application of a novel image-based partial volume Thursday, October 22, 2020, 13:30 - 15:00 correction method on a multi-reconstructed phantom Channel 7 N. Cole, S. Lindler, K. Krawiec, P. Wilson, D. Nelson, J. Sunderland, A. S. Nelson; MIM Software, Cleveland, OH, UNITED STATES OF AMERICA. OP-037 OP-040

Effect of temporal sampling on myocardial blood flow Unexpected Findings on Coregistered MRI or CT in Hybrid measurements using Rubidium-82 PET PET and SPECT Imaging S. Koenders1,2, J. D. van Dijk1, P. L. Jager1, M. Mouden3, C. H. Slump2, E. van de Giessen; Department of Nuclear Medicine, Academic A. G. Tegelaar1, J. A. van Dalen4; Medical Center, University of Amsterdam, Amsterdam, 1Isala Hospital, Department of Nuclear Medicine, Zwolle, NETHERLANDS. EANM’20 EANM’20 EANM’20 NETHERLANDS, 2Technical Medical Center, University of Twente, Enschede, NETHERLANDS, 3Isala Hospital, Department of OP-041 Cardiology, Zwolle, NETHERLANDS, 4Isala Hospital, Department of Medical Physics, Zwolle, NETHERLANDS. Unexpected Findings of PET Imaging in Brain Tumours J. Arbizu; University of Navarra, Clinica Universidad de Navarra, WORLD LEADING MEETING OP-038 Department of Nuclear Medicine, Pamplona, SPAIN. WORLD LEADING MEETING

Estimating Input Function with Incomplete Blood Samples OP-042 for Quantification of Nonhuman Primate Dynamic F-18- FDG PET/CT Using a Patlak Plot-based Optimization Unexpected Findings of PET and SPECT Imaging in Method Neurodegenerative Diseases R. Wang1,2, S. Zhang1, X. Chen1, J. Zhang1, L. Chen1, Y. Zhou3; D. Cecchin; University of Padua, Department of Medicine, Padova, 1Peking University First Hospital, Beijing, CHINA, 2Peking University ITALY. International Hospital, Beijing, CHINA, 3Washington University School of Medicine, St Louis, MO, UNITED STATES OF AMERICA. 108 Clinical Oncology Track - Featured Session: OP-039 Prostate Beyond Staging and Restaging Investigation of Optimal Beta Value with Frame Duration Thursday, October 22, 2020, 13:30 - 15:00 for PET Bayesian Penalized-Likelihood Reconstructions Channel 8 S. Jewitt1, M. D. Walker1, D. R. McGowan1,2; 1Oxford University Hospitals NHS FT, Oxford, UNITED KINGDOM, 2University of Oxford, Oxford, UNITED KINGDOM.

OP-043

Prostate PET Applications Beyond Staging and Restaging W. Fendler; Universitätsklinikum Essen, Nuclear Medicine, Essen, GERMANY.

OP-044

Impact of PSMA PET/CT on SRT planning: Preliminary

results from a randomized phaseIII trial

J. Calais, W. R. Armstrong, A. U. Kishan, K. M. Booker, J. Czernin, N. G. Nickols; UCLA, Los Angeles, CA, UNITED STATES OF AMERICA.

62 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 63 Added Value of Early Dynamic Imaging After Radical M. Gómez17, C. López18, B. Castelo19, M. Puig20, J. Galofré21, M. OP-045 109 Prostatectomy Villanueva22, I. Argüelles23, F. Araujo24, L. Orcajo24; 1 M. Monteiro1, R. Silva1,2, T. Saraiva1, G. Costa1,3, J. Pedroso de TROP Session: Therapeutic Options in Thyroid Hospital Universitario Reina Sofía, IMIBIC, Córdoba, SPAIN, Urokinase Plasminogen Activator Receptor (uPAR) PET/ 2 Lima1,2,3; Cancer - Radioiodine and Beyond Complejo Hospitalari Universitario de Santiago, Santiago de MRI of Prostate Cancer for Non-invasive Evaluation 3 1Centro Hospitalar e Universitário de Coimbra, Coimbra, Compostela, A Coruña, SPAIN, Intitudo Português de Oncologia de 4 of Aggressiveness: a Prospective Phase II Clinical Trial PORTUGAL, 2Instituto de Ciências Nucleares Aplicadas à Saúde Lisboa Francisco Gentil, Lisbon, PORTUGAL, Hospital Universitario Thursday, October 22, 2020, 13:30 - 15:00 5 Comparing with Gleason Score (ICNAS), Coimbra, PORTUGAL, 3Faculdade de Medicina da Channel 9 de Canarias, Santa Cruz de Tenerife, SPAIN, Hospital Virgen del Rocio, Sevilla, SPAIN, 6Hospital Puerta de Hierro, Madrid, SPAIN, M. Fosbøl, S. Kurbegovic, H. H. Johannesen, M. A. Røder, A. E. Universidade de Coimbra, Coimbra, PORTUGAL. 7Hospital Gregorio Marañón, Madrid, SPAIN, 8Hospital 12 de Hansen, J. Mortensen, A. Loft, P. M. Petersen, J. Madsen, K. Brasso, A. Octubre, Madrid, SPAIN, 9Complejo Asistencial de Burgos, Burgos, Kjaer; OP-050 SPAIN, 10Hospital Vall d’Hebrón, Barcelona, SPAIN, 11Hospital de la Rigshospitalet, Copenhagen, DENMARK. OP-054 Santa Creu i Sant Pau, Barcelona, SPAIN, 12Hospital La Fé, Valencia, Bone marrow expansion in patients with prostate cancer SPAIN, 13Hospital Universitario de Salamanca, Salamanca, SPAIN, 14 15 OP-046 bone metastases: prognostic role and correlation with The effectiveness of 177Lu-DOTATATE in patients with Hospital Universitario de Cruces, Vizcaya, SPAIN, Hospital Ramón y Cajal, Madrid, SPAIN, 16Hospital Virgen de las Nieves, Granada, tumour load, based on 18F-FDG PET/CT segmentation metastatic medullary thyroid cancer Prospective study on PSMA flare phenomenon SPAIN, 17Hospital Universitario Doctor Peset, Valencia, SPAIN,

EANM’20 EANM’20 S. Bilgic, M. S. Sağer, M. F. Beytur, A. Nazari, R. L. Uslu Beşli, S. Asa, L. EANM’20 analysis 18Hospital Universitario Marqués de Valdecilla, Santander, SPAIN, after androgen deprivation therapy evaluated with Kabasakal, H. B. Sayman, K. Sönmezoğlu; F. Fiz1, M. Bauckneht2, S. Morbelli2, A. Miceli3, I. Donegani3, C. 19Hospital La Paz, Madrid, SPAIN, 20Hospital Universitari Germans 18 4 5 2 Istanbul University - Cerrahpasa, Istanbul, TURKEY. F-PSMA-1007 PET/CT in treatment naïve metastatic Campi , M. Piana , G. Sambuceti ; Trias i Pujol, Barcelona, SPAIN, 21Clínica Universidad de Navarra, 1 22 prostate cancer: any link to glucose metabolism? Humanitas Clinical and Research Center - IRCCS, Milan, ITALY, OP-055 Navarra, SPAIN, Complejo Hospitalario Universitario de Vigo, Vigo, S. Malaspina1, O. Ettala2, T. Tolvanen3, S. Forsback1, P. J. Boström2, J. 2IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, 3University SPAIN, 23Hospital Son Espases, Palma de Mallorca, SPAIN, 24EISAI, 1 of Genoa, Genoa, ITALY, 4Dipartimento di Matematica “Tullio

WORLD LEADING MEETING Kemppainen ; WORLD LEADING MEETING The Effectiveness of 177Lu-DOTA TATE in Radioiodine- Madrid, SPAIN. 1Turku PET Centre, University of Turku and Turku University Hospital, Levi-Civita”, Università di Padova, Padua, ITALY, 5Department of Turku, FINLAND, 2Department of Urology, University of Turku Mathematics, University of Genoa, Genoa, ITALY. Refractory Differentiated Thyroid Cancer and Turku University Hospital, Turku, FINLAND, 3Department of A. Nazari, M. S. Sağer, S. Bilgiç, F. Beytur, R. L. Uslu Beşli, S. Asa, L. OP-058 Medical Physics and Turku PET Centre, University of Turku and Turku Kabasakal, H. B. Sayman, K. Sönmezoğlu; University Hospital, Turku, FINLAND. OP-051 Department of Medicine, Istanbul University Cerrahpasa, Istanbul, Radioiodine therapy (RAIT) guided by 124I-PET/CT TURKEY. imaging in metastatic differentiated thyroid cancer (DTC): Clinical significance of 68Ga-DOTATOC prostatic uptake on long-term follow-up of patients recruited in a prospective OP-047 OP-056 PET/CT: A ten-year review trial 1 1 1,2 1,2 F. Gossili , C. E. Almasi , H. D. Zacho , L. J. Petersen ; E. Lodi Rizzini1, C. Pettinato2, L. Zanoni1, V. Allegri1, E. Tabacchi1, A. Predictors of Intertumoral Heterogeneity of 18F-FDG and 1 PRRT with the CCK-2 receptor Agonist 177Lu-PP-F11N - First Department of Nuclear Medicine, Aalborg University Hospital, Repaci3, A. G. Morganti4, S. Fanti1, F. Monari4; 68 2 Ga-PSMA Uptake in Patients with Prostate Cancer Aalborg, DENMARK, Department of Clinical Medicine, Aalborg results of a Phase 1 “LUMED” Study 1Nuclear Medicine Unit, S.Orsola-Malpighi Hospital, Bologna, ITALY, T. Telli, M. Tuncel, M. Caglar; University, Aalborg, DENMARK. C. Rottenburger1, G. Nicolas1, L. McDougall1, M. Fürstner2, M. 2Medical Physics Unit, S.Orsola-Malpighi Hospital, Bologna, ITALY, Hacettepe University Faculty of Medicine, Ankara, TURKEY. Hentschel2, F. Kaul1, E. R. Christ3, M. Cachovan4, H. A. Vija5, R. Schibli6, 3Endocrinology Unit, S.Orsola-Malpighi Hospital, Bologna, ITALY, OP-052 S. Geistlich6, M. Béhé6, D. Wild1; 4Radiation Oncology Center, S.Orsola-Malpighi Hospital, Bologna, 1 University Hospital Basel, Division of Nuclear Medicine, Basel, ITALY. OP-048 Radiolabeled PSMA And Choline PET/MRI In Prostate SWITZERLAND, 2Department of Nuclear Medicine, Inselspital, Cancer: A Systematic Review And Meta-Analysis Bern University Hospital, University of Bern, Bern, SWITZERLAND, 3 The prognostic power of 18F-FDG PET/CT extends to the L. Evangelista1, F. Zattoni2, G. Cassarino1, P. Artioli1, D. Cecchin1, P. Division of Endocrinology, Diabetology and Metabolism, OP-059 4 estimation of systemic treatment response duration in Zucchetta1; University Hospital Basel, Basel, SWITZERLAND, Siemens 5 1 2 Healthcare GmbH, Forchheim, GERMANY, Molecular Imaging, metastatic castration-resistant prostate cancer (mCRPC) University of Padua, Padua, ITALY, Hospital of Udine, Udine, ITALY. Variations in Radioiodine Therapy in Europe- Decision Siemens Medical Solutions USA, Inc., Hoffman Estates, IL, UNITED Making after total Thyroidectomy patients 6 OP-053 STATES OF AMERICA, Center for Radiopharmaceutical Sciences, 1 1 1 2 3 M. Bauckneht1, F. Bertagna2, M. Donegani1, R. Durmo3, A. Miceli1, F. Forrer , G. Fischer , M. Putora , L. Giovnella , M. Hoffmann , I. Paul Scherrer Institute, Villigen, SWITZERLAND. 4 5 6 7 8 V. De Biasi3, R. Laudicella4, S. Baldari4, A. Versari3, R. Giubbini2, G. Iakovou , M. Luster , J. Mihailovic , P. Petranović , A. Vrachimis , S. Evaluation of 68Ga-PSMA PET/CT Images Acquired with a 9 1 Sambuceti1, S. Morbelli1, D. Albano2; Zerdoud , O. Maas ; 1 2 1IRCCS Ospedale Policlinico San Martino, Genova, ITALY, 2Spedali Reduced Scan Time Duration in Prostate Cancer Patients Kantonsspital St. Gallen, St. Gallen, SWITZERLAND, Ospedale 3 Civili of Brescia and University of Brescia, Brescia, ITALY, 3Nuclear using a Digital PET/CT Scanner Regionale di Lugano, Lugano, SWITZERLAND, University Viennna, 4 Medicine, AUSL-IRCCS of Reggio Emilia, Reggio Emilia, ITALY, M. Weber1, R. Hofferber1, K. Herrmann1, W. P. Fendler1, M. Conti2, A. OP-057 Vienna, AUSTRIA, Aristotle University AHEPA Academic Hospital, 5 4Department of Biomedical and Dental Sciences and of Morpho- Wetter3, D. Kersting1, C. Rischpler1, W. Jentzen1, P. Costa1; Thessaloniki, GREECE, Universitätsklinikum Marburg, Marburg, 6 functional Imaging, University of Messina, Messina, ITALY. 1Department of Nuclear Medicine, University of Duisburg-Essen Use Of Iodine-131 (RAI) For The Initial Diagnosis And GERMANY, Oncology Institute of Vojvodina, Novi Sad, SERBIA, 7 8 and German Cancer Consortium (DKTK)-University Hospital Essen, Treatment Of Differentiated Thyroid Cancer (DTC) In Spain University Hospital Center, Zagreb, CROATIA, German Oncology Center, Limassol, CYPRUS, 9Institut Universitaire du Cancer Essen, GERMANY, 2Siemens Medical Solutions USA, INC, Essen, And Portugal (ERUDIT Study) Toulouse, Toulouse, FRANCE. OP-049 GERMANY, 3Institute for Diagnostic and Interventional Radiology J. Vallejo Casas1, V. Pubul2, R. Santos3, M. Llanos4, E. Navarro5, J. and Neuroradiology University Hospital Essen, Essen, GERMANY. Aller6, M. Sambo7, S. Guadalix8, G. Crespo9, C. Zafón10, C. González11, 68 Ga- PSMA PET/CT on Local Disease Detection: The A. Segura12, M. Navarro13, J. Santamaría14, P. Gajate15, J. Valdivia16,

64 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 65 110 C. Nappi1, R. Megna2, V. Gaudieri1,2, T. Mannarino1, R. Assante1, E. OP-060 OP-071 Zampella1, R. Green1, V. Cantoni1, A. D’Antonio1, P. Arumugam3, W. Featured Session: Advances in PET-MPI / CT Acampa1, M. Petretta4, A. Cuocolo1; Prognostic Factors and Disease-Specific Survival of Identification of predictors for myocardial blood flow 1Department of Advanced Biomedical Sciences, University Federico Recurrent Differentiated Thyroid Carcinoma Patients using Rubidium-82 PET II, Naples, ITALY, 2Institute of Biostructure and Bioimaging, National Thursday, October 22, 2020, 13:30 - 15:00 1,2 3 1 4 3 J. Mihailovic, V. Cimbaljevic, J. Roganovic, N. Prvulovic Bunovic; Channel 10 R. Metselaar , J. A. van Dalen , B. N. Vendel , J. R. Timmer , M. Council of Research, Naples, ITALY, Department of Nuclear Institute of Oncology, Sremska Kamenica, SERBIA. Mouden4, J. D. van Dijk1; Medicine, Central Manchester Foundation Trust, Manchester, 1Isala Hospital, department of Nuclear Medicine, Zwolle, UNITED KINGDOM, 4Department of Translational Medical Sciences, NETHERLANDS, 2University of Twente, Enschede, NETHERLANDS, University Federico II, Naples, ITALY. OP-062 3Isala Hospital, department of Medical Physics, Zwolle, OP-066 NETHERLANDS, 4Isala Hospital, department of Cardiology, Zwolle, OP-076 Dosimetric study for refractory metastatic differentiated NETHERLANDS. thyroid with RAS or BRAFV600 mutation treated with Quantification of MBF with PET - How Can Technology Ultra-low-dose coronary artery calcium scoring yields MEK +/- BRAF inhibitors followed by radioactive iodine Improve Accuracy? OP-072 equivalent results compared to standard protocol: a study treatment M. Lubberink; Uppsala University Hospital, PET Center, Uppsala, on 919 consecutive patients Myocardial flow reserve could predict major adverse 1 1 2 1 EANM’20 EANM’20 N. Anizan1, G. Lion2, Y. Godbert3, C. Bournaud4, D. Taieb5, S. Bardet6, SWEDEN. F. Caobelli , I. Allio , C. E. Popescu , M. Zellweger ; EANM’20 7 8 9 9 cardio and cerebrovascular event in the dialysis dependent 1Universitätsspital Basel, Basel, SWITZERLAND, 2Kantonsspital D. Benisvy , S. Zerdoud , I. Borget , S. Leboulleux ; OP-067 1Gustave Roussy, Villejuif, FRANCE, 2CHRU de Lille - Hôpital Claude end stage renal disease patients even without myocardial Baden, Baden, SWITZERLAND. Huriez, Lille, FRANCE, 3CLCC Institut Bergonié, Bordeaux, FRANCE, perfusion abnormality Patient motion influence on the quantitative accuracyof 4CHU Lyon - Groupement Hospitalier Est, Lyon, FRANCE, 5CHU de S. Ohshima; Marseille - Hôpital de la Timone, Marseille, FRANCE, 6CLCC François cardiac 15O-water PET 111

WORLD LEADING MEETING Nagoya Kyoritsu Hospital, Nagoya, JAPAN. WORLD LEADING MEETING Baclesse, Caen, FRANCE, 7CLCC Antoine Lacassagne, Nice, FRANCE, J. Nordström1, H. J. Harms2, T. Kero1, J. Sörensen1, M. Lubberink1; e-Poster Presentation Session 1: PET Diagnostics 8IUCT Oncopole - CLCC Institut Claudius Regaud, Toulouse, FRANCE, 1PET Center Uppsala Akademiska sjukhuset, Uppsala, SWEDEN, - Part 1 9Gustave Roussy, Villejuif, FRANCE. 2Medtrace Pharma A/S, Lyngby, DENMARK. OP-073

OP-068 Coronary microvascular dysfunction as early marker of Thursday, October 22, 2020, 13:30 - 15:00 Channel 11 OP-063 cardiac involvement in patients with Anderson-Fabry Clinical use of a Rb-82 simplified myocardial flow reserve Disease Value of interim F-18 FDG PET/CT imaging in patients model using myocardial activity ratio: Comparison to full- T. Mannarino1, R. Assante1, C. Nappi1, V. Gaudieri1, A. Ponsiglione1, with metastatic radioiodine-refractory thyroid carcinoma kinetics myocardial flow reserve quantitation E. Zampella1, A. D’Antonio1, A. Giordano1, P. Buongiorno1, A. Pisani2, undergoing tyrosine-kinase inhibition therapy C. Kamani, M. Jreige, M. Pappon, P. Genoud, G. Allenbach, J. Prior; M. Imbriaco1, W. Acampa1, A. Cuocolo1; EPS-001 G. Rendl1, B. Sipos1, L. Hehenwarter1, G. Schweighofer-Zwink1, H. University Hospital Lausanne, Lausanne, SWITZERLAND.e 1Department of Advanced Biomedical Sciences, University Federico Gallowitsch2, C. Pirich1; II, Naples, ITALY, 2Department of Public Health, University Federico II, Role of FDG-PET/CT in patients with Non-Hodgkin 1Department of Nuclear Medicine and Endocrinology, University Naples, ITALY. Lymphoma treated with Chimeric Antigen Receptor T Cells Hospital Salzburg, Paracelsus Medical University Salzburg, OP-069 C. Bailly, B. Tessoulin, T. Eugene, T. Gastinne, F. Kraeber-Bodere, S. Le Salzburg, AUSTRIA, 2Department of Nuclear Medicine and OP-074 Gouill, C. Bodet-Milin; Endocrinology, PET/CT Centre, Klinikum Klagenfurt am Wörthersee, 13N-ammonia Regadenoson Stress PET/CT MPI: The Impact CHU Nantes, Nantes, FRANCE. Klagenfurt, AUSTRIA. Of Persistent Caffeine Blood Levels On Myocardial Blood Prognostic value of peri-coronary adipose tissue and Flow Metrics Utilizing A Low-Dose Rest/High-Dose Stress coronary vascular function by cardiac82Rb PET/CT imaging EPS-002 OP-065 Protocol in patients with suspected coronary artery disease and Chimeric Antigen Receptors T Cell Therapy in the U. Mahmood, W. Yap, J. Donald, A. Diliberto, B. Press, M. Feldkamp, normal perfusion imaging 18F-FDG PET/CT whole body volumetric evaluation Treatment of Non-Hogdkin Lymphoma. Assessment of T. Rosamond; V. Gaudieri1, E. Zampella1, C. Nappi1, R. Assante1, T. Mannarino1, in iodine-refractory differentiated thyroid cancer as The University of Kansas Health System, Kansas City, KS, UNITED A. D’Antonio1, A. Giordano1, P. Buongiorno1, M. Petretta2, P. Response and Side Effects using18F-FDG-PET / CT predictors of Lenvatinib response STATES OF AMERICA. Arumugam3, W. Acampa1, A. Cuocolo1; J. Ardila Mantilla, I. Gómez Fernández, A. Rotger Regí, M. Kwon, E. Califaretti1, P. Thuillier1,2, V. Liberini1, A. Ragni3, A. Nervo3, M. 1Department of Advanced Biomedical Sciences, University Federico J. Orcajo Rincón, M. Baquero Oliveros, C. Durán Barquero, D. Gallo3, A. Piovesan3, E. Arvat3, S. Grimaldi1, D. Deandreis1; II, Naples, ITALY, 2Department of Translational Medical Sciences, Zamudio Rodríguez, A. Marí Hualde, Y. Henao Celada, J. Atance 1Division of Nuclear Medicine, Department of Medical Sciences, OP-070 University Federico II, Naples, ITALY, 3Department of Nuclear García de la Santa, J. C. Alonso Farto; University of Turin, Turin, ITALY, 2Department of Endocrinology, Medicine, Central Manchester University Hospitals, Manchester, Hospital General Univeristario Gregorio Marañón, Madrid, SPAIN. University Hospital of Brest, Brest, FRANCE, 3Oncological Effect of PET CT misalignment on the quantitative accuracy UNITED KINGDOM. Endocrinology Unit, Department of Medical Sciences, University of of cardiac 15O-water PET Turin, Turin, ITALY.e J. Nordström1, H. J. Harms2, T. Kero1, M. Ebrahimi1, J. Sörensen1, M. EPS-003 Lubberink1; OP-075 1PET Center Uppsala Academic Hospital, Uppsala, SWEDEN, Possibility of 18F-FDG activity reduction for Hodgkin 2Medtrace, Lynby, DENMARK. Does a Clinical Risk Score Improve the Negative Diagnostic lymphoma patients performed on high sensitivity PET/CT Utility of a Zero Calcium Score? camera

66 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 67 M. Dziuk1,2, E. Witkowska-Patena2, A. Gizewska1, A. Mazurek2, M. Tahseen5; Koza1, A. Pieczonka3, M. Chojnowska2, Z. Podgajny3; 1AKUH, Karachi, PAKISTAN, 2Dept of Medicine Suny Downstate, 1Affidea, PET-CT, Warsaw, POLAND,2 Military Institute of Medicine, Hospital, New York, NY, UNITED STATES OF AMERICA, 3Department 201 3 4 301 Warsaw, POLAND, Affidea, PET-CT, Wroclaw, POLAND. of Medicine, Dr Ruth Hospital, Karachi, PAKISTAN, Dow Medical Plenary 1 (incl. Marie Curie Lecture): Total Body College, Dow University of Health Sciences (DUHS), Karachi, PET CME 2: Software Tools and Approaches to PAKISTAN, 5Department of Radiation Oncology, Aga Khan Measure Nuclear Brain Images EPS-005 University Hospital (AKUH), Karachi, PAKISTAN. Thursday, October 22, 2020, 15:10 - 16:25 Channel 1 Is visual residual lymphoma on FDG PET concordant with EPS-012 Thursday, October 22, 2020, 16:35 - 18:05 Channel 1 it’s quantitative assessment? 18 A. Al-Busaidi1,2, Z. Al-Bimani1,2, A. Miglietta1, W. Zeng1; Image quality and interpretation of [ F]-FES-PET: is there 1Division of Nuclear Medicine, Department of Medicine, University any effect of food intake? of Ottawa, Ottawa, ON, CANADA, 2Ministry of Health, Muscat, J. Boers1, K. Giatagana1, G. A. P. Hospers1, C. P. Schröder1, E. F. J. de OP-077 OMAN. Vries2, A. W. J. M. Glaudemans2; OP-084 1Department of Medical Oncology, University Medical Center A Game Changer for the Future of PET EPS-006 Groningen, Groningen, NETHERLANDS, 2Department of Nuclear D. Visvikis; INSERM UMR1101, LaTIM, CHRU Morvan, Bat 1, et 1, Software Tools and Approaches to Measure FDG PET Brain EANM’20 EANM’20 EANM’20 Medicine and Molecular Imaging, University Medical Center Brest, FRANCE. Images 68 18 Comparison of Ga-PSMA and F-FDG PET/CT Uptake in Groningen, Groningen, NETHERLANDS. V. Berti; Careggi, University of Florence, Departement of Clinical Different Lymphoma Subtypes: Preliminary Results OP-078 and Experimental Biomedical Sciences, Florence, ITALY. C. Ramos1, S. Souza1, N. Tobar1, V. Castro1, F. Frasson1, B. Amorim1, E. EPS-015 Etchebehere1, M. Lima1, J. Mengatti2, E. Araujo2, E. Perini2, C. Souza1, Marie Curie Lecture:Physics and Development of Total OP-085 WORLD LEADING MEETING I. Lorand-Metze1, A. Santos1, M. Delamain1; Multiple bone scintigraphy metastatic lesions in Body PET WORLD LEADING MEETING 1University of Campinas, Campinas, BRAZIL, 2Nuclear and Energy correlation with breast carcinoma human epidermal S. Cherry; University of California, Biomedical Engineering, Davis, Software Tools and Approaches to Measure Amyloid PET Research Institute (IPEN), Sao Paulo, BRAZIL.. growth factor receptor 2 neu and hormone receptor UNITED STATES OF AMERICA. Brain Images J. Gispert; Barcelonabeta Brain Research Center, Department of EPS-007 expression OP-079 S. Stojanoski1,2, A. Jankulovska1, E. Lazareva1, T. Makazlieva1, M. Neuroimaging, Barcelona, SPAIN. Iljovska1, N. Manevska1, M. Jovanovski Srceva1, S. Smichkoska1, D. Artificial intelligence can warn for focal skeleton/bone Is Dynamic PET Imaging Ready for Prime Time? OP-086 Miladinova1; marrow uptake in Hodgkin lymphoma patients staged 1Medical Faculty, Skopje, NORTH MACEDONIA, 2Medical Faculty, I. Buvat; Unité Imagerie Moléculaire In Vivo, CEA/DRF/Service, Hospitalier Frédéric Joliot, Orsay, FRANCE. Software Tools and Approaches to Measure Dopaminergic with FDG-PET/CT Lazarski University, Warsaw, POLAND. M. Sadik1, J. Lopes-Urdaneta1, J. Ullén2, O. Enqvist3, A. Krupic1, R. Brain Imaging Kumar4, P. Andersson5, E. Trägårdh6, L. Edenbrandt7; OP-080 J. Darcourt; Centre Antoine Lacassagne/Université Cote d’Azur, 1Nuclear Medicine, Gothenburg, SWEDEN, 2Eigenvision AB, Malmö, EPS-016 Nice, FRANCE. SWEDEN, 3Image Analysis and Computer Vision, Gothenburg, Drug Development and Evaluation with Total Body PET 18 SWEDEN, 4Nuclear Medicine, Chandigarh, INDIA, 5Hematology and F-FDG PET/CT Volume-based Metabolic Parameters in J. Czernin; University of California Los Angeles, Molecular and Medicine, Borås and Gothenburg, SWEDEN, 6Nuclear Medicine, Advanced Non-Small-Cell Lung Cancer Patients Treated Medical Pharmacology, Los Angeles, UNITED STATES OF AMERICA 302 Malmö, SWEDEN, 7Nuclear Medicine, Malmö and Gothenburg, with anti PD-1 Immunotherapy: A Potential Biomarker for .sa Joint Symposium 3 (EANM/EAU): Primary SWEDEN. Predicting Prognosis Staging of Prostate Cancer Reloaded 1 1 2 OP-082 EPS-008 M. Rashki , E. Triviño-Ibañez , V. Amezcua Hernández , J. Valdivia Bautista2, T. Rudolphi Solero1, J. Fernández Fernández1, J. Llamas- Challenge for Technologists Thursday, October 22, 2020, 16:35 - 18:05 Elvira1, A. Rodríguez-Fernández1; Channel 2 Bone Marrow 18F-FDG Uptake Patterns to Evaluate 1Servicio de Medicina Nuclear, Hospital Virgen de las Nieves, A. Santos; Hospital CUF Descobertas, Medicina Nuclear Infiltration in Mantle Cell Lymphoma Granada, SPAIN, 2Servicio de Oncología Médica, Hospital Virgen de Department, Lisbon, PORTUGAL. A. Sabaté-Llobera1, M. Cortés-Romera1, A. Palomar-Muñoz1, E. las Nieves, Granada, SPAIN.e Llinares-Tello1, C. Soldevila-Lozano1, L. Rodríguez-Bel1, M. Martínez OP-083 de Bourio-Allona1, F. Climent-Esteller2, E. M. González-Barca3; OP-087 1IDI - Hospital Universitari de Bellvitge - IDIBELL, L’Hospitalet de EPS-017 A Must Have or Another Expensive Luxury Tool? Llobregat, SPAIN, 2Hospital Universitari de Bellvitge - IDIBELL, K. Herrmann; Universitätsklinikum Essen, Nuclear Medicine, Essen, Clinical Challenges in Primary Staging of Prostate Cancer L’Hospitalet de Llobregat, SPAIN, 3ICO - Hospital Duran i Reynals - Low-activity digital PET emulation from decimated GERMANY. J. Walz; Institut Paoli-Calmettes Cancer Centre, Department of IDIBELL, L’Hospitalet de Llobregat, SPAIN. statistics applied to lung nodules detection Urology, Marseille, FRANCE. M. Jreige1, S. Gnesin1, P. Schleyer2, M. Conti3, J. O. Prior1; OP-083a EPS-011 1Lausanne University Hospital, Lausanne, SWITZERLAND, 2Siemens Healthineers UK, Frimley, Camberley, UNITED KINGDOM, 3Siemens Discussion Impact of Gender on Metabolic Response in Patients with Healthineers, Knoxville, TN, UNITED STATES OF AMERICA. Head and Neck Cancers using End of Treatment 18FDG PET/ CT M. Zaman1, N. Fatima1, U. Zaman2, A. Zaman3, S. Zaman4, R.

68 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 69 Astellas Pharma Inc., Tsukuba, JAPAN. H. Fushiki, Y. Murakami; OP-088 OP-094 Astellas Pharma Inc., Tsukuba, Ibaraki, JAPAN. mpMRI: Only PC Detection or also for Staging? Selecting Biokinetic Models for TAC Calculations and Issues OP-099 A. Wetter; University Essen, Department of Radiology, Essen, with MIRD Compartmental Model of 18F-FDG OP-104 18 GERMANY . W. Li; Helmholtz Zentrum München, Deutsches Production of [ F]AS3504073-00 for Investigational PET Forschungszentrum für Gesundheit und Umwelt (GmbH), Institute Imaging of Fatty Acid Beta-Oxidation in Human Subjects Multitracer PET imaging for characterization of the IDH OP-089 of Radiation Medicine, Neuherberg, GERMANY. Y. Murakami, H. Fushiki; mutation in glioma: a translational in vitro and in vivo Astellas Pharma Inc., Tsukuba, JAPAN. study Can PSMA PET Contribute for Primary Loco-Regional A. Clement1, T. Zaragori1, M. Doyen1, R. Filosa1, O. Ovdiichuk1, G. Staging? 304 OP-100 Hossu2, C. Collet1, F. Maskali1, J. Pierson3, E. Roeder1, G. Karcher4, A. M. Eiber; Technical University Munich, Department of Nuclear CTE 2: Update in Paediatric Imaging Verger4; Medicine, Munich, GERMANY. Longitudinal evaluation of myocardial fatty acid 1Nancyclotep, Vandoeuvre-Les-Nancy, FRANCE, 2IADI UMR 1254, metabolism post-myocardial ischemia/reperfusion injury Vandoeuvre-Les-Nancy, FRANCE, 3CRAN UMR 7039, Vandoeuvre- OP-090 Thursday, October 22, 2020, 16:35 - 18:05 18 4 Channel 4 in the border and remote myocardium using F-fluoro-6- Les-Nancy, FRANCE, Nuclear Medicine, Vandoeuvre-Les-Nancy, FRANCE. EANM’20 EANM’20 thia-heptadecanoic acid PET imaging in swine model EANM’20 Influence of PSMA PET for Treatment Decision in Primary 1,2 1,2 F. Zhang , Y. Wang ; OP-105 Prostate Cancer 1The Third Affiliated Hospital of Soochow University, Changzhou, I. Burger; University of Zurich, Deparment of Nuclear Medicine, CHINA, 2Changzhou Key Laboratory of Molecular Imaging, OP-095 Towards simultaneous extracorporeal recordings of PET Zurich, SWITZERLAND. Changzhou, Jiangsu Province, CHINA. and MRI arterial input functions in mice WORLD LEADING MEETING Technical Perspective and Challenges in Paediatric P. Backhaus1,2,3, F. Büther1,2, L. Wachsmuth3, S. Hermann2, K. WORLD LEADING MEETING 303 Imaging OP-101 Schäfers2, C. Faber3, M. Schäfers1,2; Joint Symposium 4 (EANM/EURADOS): Hot A. Santos; Hospital CUF Descobertas, Medicina Nuclear 1University Hospital Münster, Department of Nuclear Medicine, Topics in Radiation Protection Department, Lisbon, PORTUGAL. Predicting post-ischemic angiogenesis with an APJ-specific Münster, GERMANY, 2University of Münster, European Institute PET radiotracer for Molecular Imaging (EIMI), Münster, GERMANY, 3University of OP-096 B. Louis1, A. Moyon2, A. Bouhlel1, L. Balasse1, S. Fernandez1, S. Münster, Translational Research Imaging Center (TRIC), Münster, Thursday, October 22, 2020, 16:35 - 18:05 3 2 4 2 2 GERMANY. Channel 3 Simoncini , G. Hache , F. Dignat-George , P. Garrigue , B. Guillet ; Nuclear Medicine in Paediatric Tumours - Past, Present and 1C2VN INSERM 1263 INRA 1260 CERIMED Aix-Marseille Université, the Future Marseille, FRANCE, 2C2VN INSERM 1263 INRA 1260 CERIMED, 306 P. Ozgen Kiratli; Hacettepe University Medical Center, Ankara, APHM, Aix-Marseille Université, Marseille, FRANCE, 3C2VN INSERM Cutting Edge Science Track - TROP Session: TURKEY. 1263 INRA 1260 Aix-Marseille Université, Marseille, FRANCE, 4C2VN Preclinical Dosimetry and Radiobiology OP-091 INSERM 1263 INRA 1260, APHM, Aix-Marseille Université, Marseille, OP-097 FRANCE. LNT Model - Understanding, Applications and Limitations Thursday, October 22, 2020, 16:35 – 17:45 Channel 6 N. Varmenot; Institut de Cancérologie de l’Ouest, Nantes, FRANCE. PET/MR in Paediatric Imaging OP-102 C. Nappi; University Federico II, Department of Advanced OP-092 Biomedical Sciences, Naples, ITALY. Dynamic evaluation of diastolic dyssynchrony by SPECT gated myocardial perfusion imaging early after Breastfeeding - The Confusing Status of Rules and acute myocardial infarction and the relationship with OP-107 305 Guidelines - The Need for Harmonization progression of left ventricular remodeling in swine model Modeling DNA damage induced by targeted radionuclide S. Leide-Svegborn; Lund University, Department of Radiation M2M Track - TROP Session: Cardiovascular F. Zhang1,2, J. Wang3, X. Shao3, Y. Wang1,2; Physics, Malmö, SWEDEN. Imaging Translational 1The Third Affiliated Hospital of Soochow University, Changzhou, therapy 1,2 1 1 2,3 CHINA, 2Changzhou Key Laboratory of Molecular Imaging, G. Tamborino , M. De Saint-Hubert , L. Struelens , J. Nonnekens , OP-093 2 2 4 4 Changzhou, Jiangsu Province, CHINA, 3The Third Affiliated Hospital M. W. Konijnenberg , M. De Jong , Y. Perrot , C. Villagrasa ; Thursday, October 22, 2020, 16:35 - 17:40 1 Channel 5 of Soochow University, Changzhou, China Changzhou Key Research in Dosimetric Applications, Belgian Nuclear Research 2 External Dose Rates from Nuclear Medicine Patients to Laboratory of Molecular Imaging, Changzhou, Jiangsu Province, Centre (SCK•CEN), Mol, BELGIUM, Department of Radiology Specific Patient-Carers Geometries - A Computational CHINA. & Nuclear Medicine, Erasmus MC, University Medical Center 3 Approach Rotterdam, Rotterdam, NETHERLANDS, Department of Molecular Genetics, Erasmus MC, University Medical Center Rotterdam, L. Struelens; Belgian Nuclear Research Centre, Institute for Rotterdam, NETHERLANDS, 4Institut de Radioprotection et de Sûreté Environment, Health and Safety, Mol, BELGIUM. OP-098 OP-103 Nucléaire (IRSN), Fontenay aux Roses, FRANCE. Synthesis and Characterization of 18F-Lableled 4-Thia-oleic [18F]AS3504073-00, Reflects Mitochondrial Fatty-Acid Acid Derivatives for Fatty Acid Beta-Oxidation Imaging Oxidation in Physiological Alterations and Cardiac Y. Murakami, Y. Fujita, H. Fushiki; Disfunctions

70 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 71 E. Seregni1, V. Mazzaferro2; OP-110 OP-115 308 1Nuclear Medicine, Foundation IRCCS Istituto Nazionale Tumori, Clinical Oncology Track - TROP Session: Milan, ITALY, 2HPB Surgery, Hepatology and Liver Transplantation, Radiobiology of Auger Electron-emitter Technetium-99m: Biodistribution and dosimetry studies for the optimization Interventional Nuclear Medicine - Local Foundation IRCCS Istituto Nazionale Tumori, Milan, ITALY, In Vitro Toxicity in Triple Negative Breast Cancer Cells of pre-targeted radionuclide therapy using 211At-labeled Interventions 3Interventional Radiology, Foundation IRCCS Istituto Nazionale Expressing Human Sodium Iodide Symporter modified biotin Tumori, Milan, ITALY, 4Medical Physics, Foundation IRCCS Istituto 5 I. Costa1, N. Siksek1, K. Osytek1, A. Volpe1, F. Man1, E. Verger1, G. N. Ukon1, K. Washiyama1, A. Sugiyama2, S. Zhao1, T. Tatsumi2, M. Nazionale Tumori, Milan, ITALY, Tumour Registry, Foundation 2,3 1 1 1 2 1 1 1 1 Thursday, October 22, 2020, 16:35 - 18:05 Schettino , G. O. Fruhwirth , S. Y. A. Terry ; Aoki , K. Yamatsugu , K. Nishijima , S. Shimoyama , C. Tan , T. Joho , Channel 8 IRCCS Istituto Nazionale Tumori, Milan, ITALY. 1King’s College London, London, UNITED KINGDOM, 2National N. Oriuchi1, M. Kanai2, K. Takahashi1, T. Kodama2; Physical Laboratory, Teddington, UNITED KINGDOM, 3University of 1Fukushima Medical University, Fukushima, JAPAN, 2The University OP-125 Surrey, Guilford, UNITED KINGDOM. of Tokyo, Tokyo, JAPAN. The response and survival rates of Y-90 radioembolization OP-116 OP-120 in patients with unresectable liver tumors; a single-centre 1,2 2 2 2 OP-111 C. Saldarriaga Vargas , P. Covens , M. D’Huyvetter , V. Caveliers , B. experience 3,4 1 W. Miller , L. Struelens ; Transarterial radioembolization versus drug-eluting beads 1 2 1 1 2 O. Ekmekcioglu , O. Tabakci , D. Has Simsek , A. Hasanefendioglu Ratiometric relationship between γH2AX imaging Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM, Vrije chemoembolization for treatment of inoperable early and 2 3 1 1 4 5 EANM’20 EANM’20 3 Bayrak , S. Bilgic , G. Berk , C. Simsek , N. Kaplan , M. Battal ; EANM’20 and Lutetium-177 is predictive of survival following Universiteit Brussel, Jette, BELGIUM, University of Colorado School 1 4 intermediate hepatocellular carcinoma: interim results of Nuclear Medicine Dept, Sisli Etfal Education and Research of Medicine, Aurora, CO, UNITED STATES OF AMERICA, University of 2 radionuclide therapy in vivo the randomized controlled TRACE trial Hospital, Istanbul, TURKEY, Interventional Radiology Dept, Sisli Arizona, Tucson, AZ, UNITED STATES OF AMERICA. 3 E. O’Neill, G. M. Dias, B. Cornelissen; B. Lambert1, E. Dhondt2, L. Hermie2, X. Verhelst2, L. Defreyne2; Etfal Education and Research Hospital, Istanbul, TURKEY, Nuclear University of Oxford, Oxford, UNITED KINGDOM. 1Ghent University, Gent, BELGIUM, 2Ghent University Hospital, Gent, Medicine Dept, Cerrahpasa Medical Faculty, Istanbul, TURKEY, 307 4Medical Oncology Dept, Sisli Etfal Education and Research

WORLD LEADING MEETING BELGIUM. WORLD LEADING MEETING Pitfalls & Artefacts 2: Pre- and Post Therapeutic Hospital, Istanbul, TURKEY, 5General and Hepatobiliary Surgery OP-112 Imaging in Thyroid Cancer Dept, Sisli Etfal Education and Research Hospital, Istanbul, TURKEY. OP-121 Differences of ex vivo and in vivo DSB induction and repair OP-127 Thursday, October 22, 2020, 16:35 - 18:05 Clinical and Dosimetric Parameters Associated with after internal irradiation in PMBCs during radioiodine Channel 7 therapy Contralateral Liver Hypertrophy after Lobar SIRT Boosting 90Y SIRT with SBRT: a planning study with 90Y S. Schumann1, H. Scherthan2, P. E. Hartrampf1, A. K. Buck1, M. Port2, F. Grisanti, P. Rodrigo, J. F. Bastidas, J. J. Rosales, A. Bronte, E. Prieto, PET and TCP/NTCP models M. Lassmann1, U. Eberlein1; C. Beorlegui, M. Iñarrairaegui, B. Sangro, M. Rodríguez-Fraile; J. Mikell, K. Cuneo, Y. K. Dewaraja; 1Department of Nuclear Medicine, University of Würzburg, Clinica Universidad de Navarra, Pamplona, SPAIN. University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA. Würzburg, GERMANY, 2Bundeswehr Institute of Radiobiology OP-117 affiliated to the University of Ulm, Munich, GERMANY. OP-122 OP-128 Molecular Imaging before Radioiodine Therapy L. Giovanella; Imaging Institute of Southern Switzerland, Clinic for Predictive value of99mTc-MAA SPECT-CT based dosimetry in Evaluation of PRRT after Selective Catheterization of the OP-113 Nuclear Medicine, Bellinzona, SWITZERLAND. liver radioembolization with resin microspheres Hepatic Artery as Established Technique (‘Aretaieion’ P. D’Abadie, N. Amini, P. Goffette, S. Walrand, M. Hesse, I. Borbath, Protocol) using 111In-DTPA-Phe1 Octreotide in Inoperable A whole-body physiologically-based pharmacokinetic OP-118 M. Van den Eynde, R. Lhommel, F. Jamar; Liver Metastases Due to Neuroendocrine Tumors model of [212Pb]Pb-DOTAMTATE in neuroendocrine-tumour Cliniques universitaires Saint Luc, Brussels, BELGIUM. G. Limouris1, I. Kyriazanos2, A. Zafeirakis3; Cross-Sectional Imaging Possibilities bearing mice 1Nuclear Medicine, Medical School, National and Kapodistrian M. Radzina; Pauls Stradins Clinical University Hospital, Institute of OP-123 N. Zaid, P. Kletting, A. Beer, G. Glatting; University of Athens, Athens, GREECE, 2I Surgery Clinic, Army Naval Diagnostic Radiology, Riga, LATVIA . Ulm University, Ulm, GERMANY. and Veterans Hospital of Athens, Athens, GREECE, 3Army Share Antireflux catheter improves tumor targeting in liver Fund Hospital of Athens, Athens, GREECE. OP-119 radioembolization OP-114 P. D’Abadie, N. Amini, P. Goffette, I. Borbath, M. Van Den Eynde, R. Molecular Imaging after Radioiodine Therapy Lhommel, A. Van Maanen, F. Jamar; OP-129 Modelling Show Alpha-emitter Astatine-211 is an Apposite Cliniques universitaires Saint Luc- Institut Roi Albert II, Brussels, Candidate for Intra-thecal Radioimmunotherapy of BELGIUM. Sequential PRRT and SIRT. Evaluation of safety and best Neuroblastoma Metastasized to the Central Nervous sequence treatment in liver dominant GEPNETs OP-124 System F. Scalorbi, A. Lorenzoni, S. Mazzaglia, E. Garanzini, C. Chiesa, G. S. Palm1, T. Bäck1, E. Leidermark1, S. Lindegren1, E. Aneheim1, H. Aliberti, V. Fuoco, G. Argiroffi, S. Pusceddu, N. Prinzi, C. Spreafico, Radioembolization of hepatocarcinoma with 90Y glass Jensen2, R. Hultborn1, P. Albertsson1, L. Jacobsson1; G. Centonze, J. Coppa, A. Marchiano’, M. Milione, V. Mazzaferro, E. 1University of Gothenburg, Gothenburg, SWEDEN, 2Rigshospitalet, microspheres: impact of the basal bilirubin level on Seregni, M. Maccauro; Copenhagen, DENMARK. treatment planning Istituto Nazionale Tumori Milano, Milan, ITALY. C. Chiesa1, M. Mira1, M. Maccauro1, S. Bhoori2, G. Bormolini2, C. Spreafico3, A. Cavallo4, S. Mazzaglia1, G. Tagliabue5, A. Marchiano’3,

72 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 73 R. Wang1,2, X. Liao1, S. Chen3, M. Liu1, X. Chen1, L. Yin1, D. Chen3; BULGARIA. OP-130 1Peking University First Hospital, Beijing, CHINA, 2Peking University EPS-025 International Hospital, Beijing, CHINA, 3Peking University, Beijing, 188 High dose brachytherapy with not-sealed Re (Rhenium) CHINA. Metabolic Characteristics of Non-Small Cell Lung Cancer EPS-032 resin in patients with non melanoma skin cancers (NMSC): Lesions as Potential Predictor of Immunotherapy Response 18 single center preliminary results A. Tabain, S. A. Rogan, S. Divošević; The Relationship Between Ca-125 Level and F FDG PET/ P. Castellucci1, F. Savoia2, A. Farina3, G. Lima3, A. Patrizi2, F. Zagni4, C. EPS-020 Polyclinic Medikol, Zagreb, CROATIA. CT Findings in The Assessment of Progressive Disease in Baraldi2, S. Vichi4, C. Pettinato4, L. Strigari4, A. Morganti5, S. Fanti3; Epithelial Ovarian Carcinoma 1 18F-FDG PET Parameters and Radiomics Features Analysis Nuclear Medicine Department, Sant’Orsola-Malpighi Hospital, EPS-026 S. Tatlidil, B. Karasah, H. Sariyildiz, Z. Burak, Z. Ozcan; University of Bologna, Bologna, ITALY, 2Dermatology Unit, in Advanced NSCLC treated with Immunotherapy as Ege University, Izmir, TURKEY. Sant’Orsola-Malpighi Hospital, Bologna, ITALY, 3Nuclear Medicine Predictors of Therapy Response and Survival The value of hybrid 18F-FDG PET / MR in lung cancer and Department, Sant’Orsola-Malpighi Hospital, Bologna, ITALY, G. Polverari1, F. Ceci2, V. Bertaglia3, M. Reale3, O. Rampado4, E. comparing with PET / CT 4Medical Physics Department, Sant’Orsola-Malpighi Hospital, Gallio4, R. Passera2, V. Liberini2, P. Scapoli5, V. Arena1, M. Racca5, A. Y. Xu; EPS-033 Bologna, ITALY, 5Radiation Oncology Department, Sant’Orsola- Veltri6, S. Novello3, D. Deandreis2; Hangzhou Universal Imaging Diagnostic Center, Hangzhou, 18 Malpighi Hospital, Bologna, ITALY. 1Affidea Irmet PET/CT Center, Turin, ITALY,2 Nuclear Medicine CHINA. F-FDG PET/CT and Ca-125 in the evaluation of ovarian cancer relapse or persistence: is there any correlation? EANM’20 EANM’20 Unit, Department of Medical Sciences, University of Turin, Turin, EANM’20 OP-131 ITALY, 3Department of Oncology, University of Turin, San Luigi EPS-028 F. Dondi1, D. Albano1, A. Calabrò2, M. Gregorelli2, A. Mazzoletti2, P. Gonzaga Hospital, Orbassano, ITALY, 4Medical Physics Unit, S.C. Bellini2, M. Gazzilli3, E. Cerudelli3, F. Bertagna1, R. Giubbini1; Rhenium-188 Epidermal treatment for Non-melanoma Fisica Sanitaria, A.O.U. Città della Salute e della Scienza, Turin, Predictive value of 18F-FDG PET/CT in treatment response 1Università degli Studi di Brescia, Brescia, ITALY, 2Università degli Skin Cancers ITALY, 5Nuclear Medicine, Istituto per la Ricerca e la Cura del Cancro of Head and Neck squamous cell carcinoma using studi di Brescia, Brescia, ITALY, 3Spedali Civili di Brescia, Brescia, ITALY. 6 K. Mokoala, M. Vorster, L. Nonjola, N. P. Mokgoro, T. M. G. (IRCC), Candiolo, ITALY, Radiology Unit, Department of Oncology, Deauville criteria WORLD LEADING MEETING University of Turin, San Luigi Gonzaga Hospital, Orbassano, ITALY. WORLD LEADING MEETING Boshomane, I. O. Lawal, M. M. Sathekge; C. Ferrari, G. Santo, A. Nappi, A. Branca, C. Altini, A. Gaudiano, A. Di University of Pretoria & Steve Biko Academic Hospital, Pretoria, Palo, A. Pisani, V. Lavelli, G. Rubini; 401 SOUTH AFRICA. EPS-022 Nuclear Medicine Department, University of Bari “Aldo Moro”, Bari, CME 3: Finding the Right PET Companion for ITALY. ImmunoOncology Sensitivity and characterization of Lung Nodules (LNs) by 311 using Fast-Recovery Fast Spin-Echo (FRFSE-XL) on PET/MR EPS-029 Friday, October 23, 2020, 09:00- 10:30 e-Poster Presentation Session 2: PET hybrid system Channel 1 Diagnostics - Part 2 G. Salvatierra Apala1,2,3, E. Marino1,4, G. Peña1; 1Fundación Escuela de Medicina Nuclear (FUESMEN), Mendoza, Correlation between Apparent Diffusion Coefficients, ARGENTINA, 2Agencia Boliviana de Energía Nuclear (ABEN), La Paz, Standardised uptake values and histological Thursday, October 22, 2020, 16:35 - 18:05 3 Channel 11 BOLIVIA, PLURINATIONAL STATE OF, Investigación Aplicada (INVAP), differentiation : preliminary results in anal cancer Bariloche, ARGENTINA, 4Comisión Nacional de Energía Atómica A. Parsai1, I. Zerizer2, H. Jan3, E. Nowosinska3, S. Subhan4, A. OP-133 (CNEA), Bariloche, ARGENTINA. Haroon3, Y. Bouchareb5, M. E. Miquel1; 1Queen Mary University London, London, UNITED KINGDOM, 2Royal Why Do we Need PET Companion Tracers in EPS-023 Marsden Hospital, London, UNITED KINGDOM, 3BartsHealth NHS Immunooncology? EPS-018 Trust, London, UNITED KINGDOM, 4The Queen Elizabeth Hospital, N. Aide; Centre Hospitalier Universitaire de Caen (CHU Caen), Relationships of semiquantitative parameters assessed on London, UNITED KINGDOM, 5Sultan Qaboos University, Oman, Nuclear Medicine and Medical Biophysics, Caen, FRANCE. 18F-FDG PET/CT interpretation Criteria for the Assessment F-18-FDG PET/CT for predicting EGFR mutation subtypes QATAR. of Therapeutic Response in Patients with Advanced Stage in Lung Adenocarcinoma OP-134 of Lung Cancer: inter-reader reliability, accuracy and R. Wang1,2, X. Liao1, M. Liu1, X. Chen1, Y. Cui1, L. Di1, L. Yin1, Z. Tong1, EPS-030 H. Sun1, C. Wu1; Going Beyond FDG - Development of Tailored PET survival outcomes 18 1 2 2-[ F]FDG PET/CT in Colorectal Cancer Liver Metastases Companion Tracers M. Gazzilli1, D. Albano2, E. Cerudelli1, F. Dondi3, A. Mazzoletti3, P. Peking University First Hospital, Beijing, CHINA, Peking University P. Soeiro, P. Lapa, R. Silva, G. Costa, J. Pedroso de Lima; Bellini3, F. Bertagna2, R. Giubbini2; International Hospital, Beijing, CHINA. S. Heskamp; Radboud University Medical Centre (Radboudumc), Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL. 1Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Department of Radiology and Nuclear Medicine, Nijmegen, Brescia, ITALY, 2Università di Brescia e Azienda Socio Sanitaria NETHERLANDS. Territoriale degli Spedali Civili di Brescia, Brescia, ITALY, 3Università di EPS-024 EPS-031 Brescia, Brescia, ITALY. OP-135 Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Correlation of CEA levels with metabolic tumor volume, Inhibitors assessed by FDG PET and RECIST complient size The Next Step - From Companion Diagnostics Towards EPS-019 A. Castello, S. Rossi, L. Toschi, E. Lopci; measurement in patients with recurrent and/or metastatic Immunotheranostics Humanitas Clinical and Research Hospital, Rozzano (MI), ITALY. colorectal cancer N. Schaefer; Centre Hospitalier Universitaire Vaudois (CHUV), SUV-derived Parameters Assessed on F-18-FDG PET/CT P. Bochev1, Y. Bocheva2, G. Mateva1; Department of Nuclear Medicine, Lausanne, SWITZERLAND. Predict EGFR Mutation in Lung Adenocarcinoma Patients: 1Acibadem Cityclinic UMBAL Mladost Oncology hospital, Sofia, the Construction of CART Predictive Model BULGARIA, 2Medical University “Prof.d-r Paraskev Stoyanov”, Varna,

74 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 75 and Chelators - Best of Both Worlds Maas2, B. von Ungern-Sternberg1, L. Gold1, M. A. Kirchner1, M. J. 402 OP-141 Riemenschneider3, P. Bartenstein1, K. Lauber2, N. L. Albert1; Joint Symposium 5 (EANM/EHA): Use of PET in 1Department of Nuclear Medicine, University Hospital, LMU Assessing LV Dysfunction Friday, October 23, 2020, 09:00 - 10:30 2 Multiple Myeloma Channel 5 Munich, Munich, GERMANY, Department of Radiation Oncology, R. Russell; Cardiovascular Institute of Lifespan, Warren Alpert University Hospital, LMU Munich, Munich, GERMANY, 3Department Medical School of Brown University, Providence , R.I., UNITED of Neuropathology, Regensburg University Hospital, Regensburg, Friday, October 23, 2020, 09:00- 10:30 STATES OF AMERICA. Channel 2 GERMANY. OP-142 OP-147 OP-151

Detecting Myocardial Injury SPECT imaging of SST2-expressing tumors with 99mTc- Low temperature radiolabelling of human serum albumin OP-136 C. Rischpler; University Hospital Essen, Essen, GERMANY. labelled somatostatin receptor antagonists is feasible constructs with terbium-161 and ex vivo biodistribution to depending on the chelator and the spacer assess in vivo stability Multiple Myeloma – MRD OP-143 R. Gaonkar1, F. Wiesmann1, E. Gourni2, R. Mikołajczak3, L. I. Cassells1,2, M. Ooms2, J. Cornelis1, A. R. Burgoyne2, S. Ahenkorah1,2, E. Zamagni; Hematology Department, Seragnoli Institut, University McDougall1, L. Del Pozzo1, H. R. Maecke2, R. Mansi1, M. Fani1; M. Van de Voorde2, T. Cardinaels2,3, C. M. Deroose4, G. Bormans1, F. of Bologna, Bologna, ITALY. Perspectives for CV Imaging in Cardio-Oncology 1 1 EANM’20 EANM’20 Division of Radiopharmaceutical Chemistry, University Hospital Cleeren ; EANM’20 S. Dorbala; Department of Nuclear Cardiology, Brigham and Basel, Basel, SWITZERLAND, 2Department of Nuclear Medicine, 1Radiopharmaceutical Research, Department of Pharmaceutical OP-137 Women’s Hospital, Boston, UNITED STATES OF AMERICA. University Hospital Freiburg, Freiburg, GERMANY, 3National Centre and Pharmacological Science, University of Leuven, Leuven, for Nuclear Research, Radioisotope Centre POLATOM, Otwock, BELGIUM, 2Nuclear Materials Science Institute, Belgian Nuclear Evaluation of Minimal Residual Disease with FDG PET/CT OP-144 POLAND. Research Centre (SCK CEN), Mol, BELGIUM, 3Department of C. Nanni; Nuclear Medicine department, AOU S.Orsola-Malpighi, Chemistry, University of Leuven, Leuven, BELGIUM, 4Nuclear WORLD LEADING MEETING Bologna, ITALY. 404a OP-148 Medicine, University Hospitals Leuven: Nuclear Medicine and WORLD LEADING MEETING Molecular Imaging, Department of Imaging and Pathology, Mini Course 1: New Developments in Cardiac 99m OP-138 Imaging Instrumentation Preclinical characterization of two Tc-labelled Leuven, BELGIUM. SSTR2 antagonists: Selection of a candidate for clinical Where are we now with Non-FDG translation OP-153 Friday, October 23, 2020, 09:00 - 09:50 N. Withofs; 1- Division of Nuclear Medicine and Oncological C. Decristoforo1, R. Mansi2, V. Weingärtner1, P. Kolenc-Peitl3, Channel 4 11 11 Imaging, Department of Medical Physics, CHU of Liege; 2- GIGA- P. Garnuszek4, M. Kroselj3, R. Mikolajczak4, C. Rangger1, A. Optimized Radiosynthesis of [3- C]Alanine and [3- C] CRC in vivo imaging, University of Liège, Liege, BELGIUM. Hubalewska-Dydejczyk5, M. Fani2; Pyruvate for Imaging Central Carbon Metabolism In Vivo 1Department of Nuclear Medicine, Medical University Innsbruck, J. Kelly, T. M. Jeitner, N. Waterhouse, N. Karakatsanis, S. Nehmeh, J. OP-139 Innsbruck, AUSTRIA, 2Division of Radiopharmaceutical Chemistry, W. Babich; OP-145 University Hospital Basel, Basel, SWITZERLAND, 3Department of Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA. Theranostics in MM Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, C. Lapa; University Hospital Augsburg, Department of Nuclear Difference in Myocardial Perfusion Imaging Between SLOVENIA, 4Radioisotope Centre POLATOM, National Centre OP-154 Medicine, Augsburg, GERMANY. Conventional SPECT Imaging and Imaging with Dedicated for Nuclear Research, Otwock, POLAND, 55Department of Cardiac Cameras Endocrinology, Jagiellonian University Medical College, Cracow, Synthesis and in vitro comparison of squaric acid coupled POLAND. S. Rep; University Medical Centre, Department of Nuclera Medicine, lysine-urea-glutamate and glutamate-urea-glutamate 403 Ljubljana, SLOVENIA. based PSMA-inhibitors OP-149 Joint Symposium 6 (EANM/ASNC): Detecting T. Grus, H. Lahnif, M. Omralinov, F. Roesch; Cardiac Toxicity of Cancer Therapies with Department of Chemistry, Johannes Gutenberg-University Mainz, Nuclear Imaging OP-146 PET-MRI imaging of neurotensin receptor-positive tumors Mainz, GERMANY. with 68Ga-labeled antagonists : “the chelate makes again Diagnostic Performance of Dedicated Cardiac Cameras the difference” Friday, October 23, 2020, 09:00 - 10:30 J. Jamsek; University Medical Centre, Department of Nuclera 1 1 1 2 2 OP-155 Channel 3 V. Goncalves , E. Renard , M. Moreau , P. S. Bellaye , M. Guillemin , Medicine, Ljubljana, SLOVENIA F. Denat1; 1 2 Evaluation and Specific Targets of a Novel Tc-99m-MAG - Université Bourgogne Franche-Comté, Dijon, FRANCE, Georges- 3 RRL Probe for Tumor Imaging in Hepatoma Xenografts François Leclerc Cancer Center, Dijon, FRANCE. Model: A Pilot Study

OP-140 R. Wang1,2, Y. Du1, Z. Chen1, P. Yan1, X. Duan1, Q. Jiang1, J. Zhang1; OP-150 1Peking University First Hospital, Beijing, CHINA, 2Peking University Cardiac Complications of Cancer Therapy -A Clinical 404b International Hospital, Beijing, CHINA. Perspective M2M Track - TROP Session: Pharmacokinetics Longitudinal PET Imaging Allows for Non-Invasive J. Bergler-Klein; Department of Cardiology, Vienna, AUSTRIA. Assessment of TSPO Expression in a Glioblastoma Mouse Model A. Holzgreve1, D. Pötter1, M. Brendel1, M. Orth2, L. Weidner3, J.

76 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 77 Simple daily algorithm to reduce biological detriment by 1Guy’s and St Thomas Foundation Trust, London, UNITED OP-156 408 PET/CT on the basis of the patient age KINGDOM, 2King’s College London, London, UNITED KINGDOM. 1 1 2 1 Clinical Oncology Track - Featured Session: PRRT Auger Electron Emitter Radionuclide Therapy: In vitro P. Sannino , M. Sicignano , L. Evangelista , E. Di Giorgio , S. Fiordoro1, S. Imbimbo1, V. Rizzo3, C. Del Vasto1, C. Lanotte1, D. for NETs Study of Thallium-201 Kinetics and Toxicity in Breast and OP-168 Palma1, G. Pecchia1, C. Mainolfi4, M. Spadafora1; Prostate Cancer Cells 1Nuclear Medicine Unit Ospedale del Mare, Naples, ITALY, 2Nuclear Comparative Dosimetry for 68Ga-PSMA with Updated Friday, October 23, 2020, 09:00 - 10:30 K. Osytek, I. Costa, E. Verger, F. Al-Salemee, J. Cheng, S. Terry, V. Medicine Unit, Department of Medicine (DIMED), University of Channel 8 Abbate, P. Blower; Padua, Padua, ITALY, 3Nuclear Medicine Unit Moscati Hospital, Reference Data and Impact for Patient Specific Dose King’s College London, London, UNITED KINGDOM. Avellino, ITALY, 4Department of Advanced Biomedical Sciences, Calculations University of Naples Federico II, Naples, ITALY. P. Gape, D. Rushforth, C. Abreu, I. Murray, J. Gear, G. Flux; The Royal Marsden Hosptial NHS Foundation Trust, London, OP-157 UNITED KINGDOM. OP-173 OP-163 Exploring the limits of intranuclear PET/SPECT imaging The Future of PRRT with IgG-TAT: how low can you go? Low dose computed tomography protocol optimization OP-169 L. Bodei; Memorial Sloan-Kettering Cancer Center, Department of and its influence in radiation dose to the patient Radiology, New York, UNITED STATES OF AMERICA. EANM’20 EANM’20 M. Veal, G. M. Dias, V. Kersemans, D. Sneddon, S. Faulkner, B. EANM’20 225 Cornelissen; V. de Sousa, G. Cardoso, B. Bento, S. Carmona, A. I. Santos; Solid-Phase Extraction of Ac for Internal Dosimetry and University of Oxford, Oxford, UNITED KINGDOM. Hospital Garcia de Orta, E.P.E., Almada, PORTUGAL. Incorporation Measurements OP-174 R. Cusnir1,2, P. Froidevaux1, L. Pfefferlé1, M. Straub1,2; OP-164 1Institute of Radiation Physics, Lausanne University Hospital and First-in-human dose escalation of AlphaMedix for targeted 406 University of Lausanne, Lausanne, SWITZERLAND, 2European alpha-emitter therapy of neuroendocrine tumors WORLD LEADING MEETING Cutting Edge Science Track - Featured Session - Radiation Dose Optimization of a Dual Tracer PET/CT Organization for Nuclear Research (CERN), Geneva, SWITZERLAND. I. Tworowska1, E. S. Delpassand1, R. Esfandiari2, J. Torgue3, J. D. Hurt3, WORLD LEADING MEETING Patient Radiation Protection Protocol for Multiple Myeloma: a Whole Body Ultra-Low R. Nunez2; Dose CT 1RadioMedix Inc., Houston, TX, UNITED STATES OF AMERICA, 2Excel Friday, October 23, 2020, 09:00 - 10:30 Diagnostics and Nuclear Oncology Center, Houston, TX, UNITED Channel 6 E. Prieto, J. M. Martí-Climent, J. D. Aquerreta, V. Morán, L. Irazola, 407 3 J. F. Bastidas, I. Soriano, J. J. Rosales, P. Rodríguez-Otero, M. J. García- Teaching Session 1 (EANM/EARL): Quantification STATES OF AMERICA, Orano Med LLC, Plano, TX, UNITED STATES OF Velloso; and Standardisation in Clinical and Preclinical AMERICA. Clínica Universidad de Navarra, Pamplona, SPAIN. Molecular Imaging OP-176 OP-159 Friday, October 23, 2020, 09:00 - 10:30 Channel 7 OP-165 Tolerability and Efficacy of Peptide Receptor Radionuclide Introduction Therapy in Elderly Neuroendocrine Tumour Patients: S. Holm; Rigshospitalet, Clinical Physiology, Nuclear Medicine & PET, Optimising CT scan range and dose levels for diagnosis of Results of a Case-Control Single Centre Study 18 Copenhagen, DENMARK. bone metastases for F-NaF PET-CT D. Theiler1, M. Cattaneo2, L. O. Dierickx3, P. Igaz4, S. Grozinsky- P. Holdgaard1, N. A. Bebbington2; OP-170 Glasberg5, C. Bournaud6, T. O’Dorisio7, D. Wild1,8, E. Christ9,8, G. P. OP-160 1Lillebælt Hospital, Vejle, DENMARK, 2Siemens Healthcare A/S, Nicolas1,8; Aarhus, DENMARK. Molecular Imaging With Small Animal Architectures - 1Division of Nuclear Medicine, University Hospital of Basel, Basel, European Diagnostic Reference Levels for Computed Challenges and Chances SWITZERLAND, 2Department of Clinical Research, University of Tomography applications in nuclear medicine: results from OP-166 J. Mannheim; University of Tübingen, Department of Preclinical Basel, Basel, SWITZERLAND, 3Department of Nuclear Medicine, the MEDIRAD project Imaging and Radiopharmacy, Tübingen, GERMANY. ENETS CoE, Institut Universitaire du Cancer Toulouse - Oncopole, 131Iodine Concentration in mother’s milk after treatment of 4 G. Verfaillie1, Y. D’Asseler2, K. Bacher1; Toulouse, FRANCE, Second Department of Internal Medicine, 5 1Ghent University, Ghent, BELGIUM, 2Ghent University Hospital, a papillary thyroid cancer with 3700 MBq of Na131I under OP-171 Semmelweis University, Budapest, HUNGARY, Neuroendocrine Ghent, BELGIUM. rhTSH Tumor Unit, ENETS Center of Excellence, Department of EARL and the Road to PET/CT Imaging Harmonisation Endocrinology, Hadassah-Hebrew University Medical Center, G. Le Rouzic, H. Besse, M. Bailly; Jerusalem, ISRAEL, 6Department of Nuclear Medicine, Hospices Centre Hospitalier Régional d’Orléans, Orléans, FRANCE. I. Hristova; Programme Director EARL, Vratsa, BULGARIA. OP-161 Civils de Lyon, Lyon, FRANCE, 7University of Iowa, Iowa City, IA, 8 N. Eftychiou1, R. Fernandez1, S. Allen1, V. Lewington1,2; OP-172 UNITED STATES OF AMERICA, Endocrine and Neuroendocrine Automatic Exposure Control techniques in low dose CT - 1Guy’s and St Thomas Foundation Trust, London, UNITED Tumour Centre, ENETS CoE, University Hospital of Basel, Basel, 9 what benefit in PET/CT studies? KINGDOM, 2King’s College London, London, UNITED KINGDOM. Standardization and Harmonisation for Radiomics Analysis SWITZERLAND, Department of Endocrinology, University Hospital of Basel, Basel, SWITZERLAND. R. Ferreira, V. Sousa, M. R. Victor, S. Carmona, G. Cardoso, A. I. Santos; OP-167 Hospital Garcia de Orta, Almada, PORTUGAL. Preventive measures and management of OP-177 radiopharmaceutical extravasation with[177Lu]Lu-DOTA- OP-162 TATE Survey of Challenges in Access to Diagnostics and N. Eftychiou1, R. Fernandez1, S. Allen1, V. Lewington1,2; Treatment for Neuroendocrine Tumor (NET) Patients

78 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 79 (SCAN) - Usage & Affordability of Nuclear Medicine Tools, a Amadori1, E. Scarpi1, A. Bongiovanni1, C. Cittanti2, L. Urso2, S. Severi1; Shanghai, CHINA. comparative perspective 1IRST, Meldola (FC), ITALY, 2Nuclear Medicine Unit, University of 1 2 3 4 Ferrara, Ferrara, ITALY. S. Dureja , M. McDonnell , D. Van Genechten , C. Bouvier , S. OP-190 Leyden5, T. Kolarova6, D. O’Toole7, H. Singh8, J. Chen9, J. Howe10, S. 11, R. Hicks12, C. Rodien-Louw13; Singh OP-180 409 Brain metabolic correlates of gait initiation in Progressive 1SMH Cancer Centre, New Delhi, INDIA, 2NET Patient Network, TROP Session: Molecular Imaging of Movement 3 Supranuclear Palsy Dublin, IRELAND, vzw NET & MEN Kanker Belgium, Kortrijk, 177 Disorders Initial experience with lutetium peptide receptor 1 2 3 2 3 BELGIUM, 4Neuroendocrine Cancer UK, Leamington Spa, UNITED G. Marotta , C. Palmisano , M. Todisco , J. Volkmann , C. Pacchetti , 4 1 1 1 1 5 KINGDOM, 5NeuroEndocrine Cancer Australia, Victoria, AUSTRALIA, radionuclide therapy for pediatric patients with C. Frigo , R. Leo , C. Sdraiati , D. Capolongo , E. Orunesu , G. Pezzoli , 2 6 Friday, October 23, 2020, 09:00 - 10:30 International Neuroendocrine Cancer Alliance, Boston, MA, somatostatin-receptor-positive tumors Channel 9 I. U. Isaias ; 1 UNITED STATES OF AMERICA, 7National Centre for Neuroendocrine M. Pizzoferro1, B. Cassano2, C. Altini1, A. Serra3, M. Cefalo3, A. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 2 Tumours, St. Vincent’s University and Department of Clinical Cacchione3, M. Villani1, A. Castellano3, V. Cannatà2, M. Garganese1; Milan, ITALY, Department of Neurology, University Hospital and Medicine, St. James Hospital and Trinity College, Dublin, IRELAND, 1IRCCS Bambino Gesù Children’s Hospital, Nuclear Medicine Unit/ Julius Maximilian University of Würzburg, Würzburg, GERMANY, 3 8Prince Court Medical Centre, Kuala Lumpur, MALAYSIA, 9The First Imaging Department, Rome, ITALY, 2IRCCS Bambino Gesù Children’s Parkinson’s Disease and Movement Disorders Unit, IRCCS Mondino 4 Affiliated Hospital, Sun Yat-sen University, Guangdong, CHINA, Hospital, Medical Physics Unit, Rome, ITALY, 3IRCCS Bambino Gesù OP-184 Foundation, Pavia, ITALY, MBMC Lab, Department of Electronics, 10University of Iowa Carver College of Medicine, Iowa City, IA, Information and Bioengineering, Politecnico di Milano, Milan, ITALY, EANM’20 EANM’20 Children’s Hospital, Oncoemathology Unit, Rome, ITALY. EANM’20 5 UNITED STATES OF AMERICA, 11Sunnybrook Odette Cancer Centre, Metabolic and Dopaminergic Correlates of intellectual Centro Parkinson ASST G. Pini-CTO, Milan, ITALY. University of Toronto, Toronto, ON, CANADA, 12Peter MacCallum OP-181 enrichment in De novo PD patients 13 Cancer Centre, Melbourne, AUSTRALIA, APTED Association de S. Raffa1, M. Donegani1, M. Bauckneht2, M. Balma2, D. Arnaldi3, OP-191 Patients porteurs de Tumeurs Endocrines Diverses, Lyon, FRANCE. PRRT/PRCRT in 18F-FDG-avid G3 NET-Patients N. Girtler3, M. Pardini3, A. Miceli1, F. Biagini1, F. Massa3, L. Filippi3, G. H. Svirydenka1, L. Scarpa1, B. Nilica1, M. Rodrigues1, S. Buxbaum1, G. Sambuceti1, M. Pagani4, F. Nobili3, S. Morbelli1; Progressive supranuclear palsy and its variants: pattern WORLD LEADING MEETING OP-178 Di Santo1, C. Uprimny1, S. Bayerschmidt1, B. Neururer1, E. Gamper2, I. 1Nuclear Medicine Unit, Department of Health Sciences, University similarities and differences in 18F-FDG-PET WORLD LEADING MEETING 1 Virgolini ; of Genoa, Genoa, ITALY, 2IRCCS Policlinico San Martino, Genoa, G. Martí-Andrés1, J. J. Rosales1, E. Prieto1, L. van Bommel2, F. 1 PRRT of 200 patients from the SEPTRALU registry: real- Universitätsklinik für Nuklearmedizin, Innsbruck, AUSTRIA, ITALY, 3Clinical Neurology, Department of Neuroscience (DINOGMI, Grisanti1, S. K. Meles2, R. V. Kogan2, V. Gurvits2, R. Valentí1, M. Riverol1, 2 world data 2Division of Psychiatry II,Department of Psychiatry, Psychotherapy Dept. of Excellence of the Italian Ministry for University and M. R. Luquin1, K. Leenders2, J. Arbizu1; 4 M. Mitjavila Casanovas1, A. Carmona Bayonas2, P. Belló3, V. Pubul4, and Psychosomatics, Innsbruck, AUSTRIA. Research- MIUR), University of Genoa., Genoa, ITALY, Institute of 1Clínica Universidad de Navarra, Pamplona, SPAIN, 2University L. García-Cañamaque5, J. Arbizu6, A. Rotger7, B. Llana8, T. Navarro9, Cognitive Sciences and Technologies, Consiglio Nazionale delle Medical Center Groningen, Groningen, NETHERLANDS. M. Castellón10, C. Field5, M. Estorch11, C. Riesco12, A. Teule13, M. OP-182 Ricerche (CNR), Rome, ITALY. Muro14, P. García-Alonso15, A. Repetto16, M. Miguel17, E. Caballero18, OP-192 M. Navarro19, J. Aller1, M. del Olmo3, C. Blanco20, P. Jimenez-Fonseca8; Peptide Receptor Radionuclide Therapy In OP-185 1Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Broncopulmonary Neuroendocrine Tumours - Results Of A [18F]PI-2620 Tau PET to Improve Imaging-Based Diagnosis 2 SPAIN, Hospital Universitario Morales Meseguer, UMU, IMIB, Single Centre Experience Striatal Dopamine Transporter SPECT Quantification: of PSP 3 Murcia, SPAIN, Hospital Universitario La Fe, Valencia, SPAIN, Head-To-Head Comparison Between Two Tridimensional K. Messerschmidt1, H. Barthel1, M. Brendel2, T. Van Eimeren3, 4 G. Ferreira, S. Castro, C. Costa, L. Violante, J. Teixeira, H. Duarte, I. L. Hospital Universitario de Santiago Compostela, Santiago de K. Marek4, V. Villemagne5, J. Rumpf1, D. Saur1, M. Schroeter1, M. 5 Sampaio; Automatic Tools Compostela, SPAIN, Hospital Universitario HM Sanchinarro, 1 1 1 2 1 1 1 2,3 3 Rullmann , K. Hoffmann , C. Scherlach , B. Rauchmann , A. 6 Instituto Português de Oncologia do Porto Francisco Gentil, Porto, S. Raffa , E. Cella , M. Donegani , D. Arnaldi , F. Massa , S. Madrid, SPAIN, Clínica Universidad de Navarra, Pamplona, 1 1 2 2 2 2 2 2 1 1,2 2,3 Schildan , M. Patt , L. Beyer , M. Song , C. Palleis , M. Gehmeyr , U. 7 PORTUGAL. Capitanio , M. Bauckneht , A. Miceli , S. Morbelli , F. Nobili ; SPAIN, Hospital Universitario Gregorio Marañón, Madrid, SPAIN, 2 6 2 2 2 1 Fietzek , G. Respondek , J. Sauerbeck , A. Nitschmann , C. Zach , J. 8 9 Dept of Health Science (DISSAL), University of Genoa, Genoa, ITALY, Hospital Universitario Central de Asturias, Oviedo, SPAIN, Hospital 7 4 4 7 3 4 2 3 Hammes , M. Barbe , Ö. Onur , F. Jessen , B. Neumaier , O. Barret , J. 10 IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, Dept of Universitario Ramón y Cajal, Madrid, SPAIN, Hospital Universitario OP-183 Madonia4, D. Russell4, A. Stephens8, S. Roeber2, J. Herms2, K. Bötzel2, 11 Neuroscience (DINOGMI), University of Genoa, Genoa, ITALY. Virgen de la Arrixaca, Murcia, SPAIN, Hospital de la Santa Creu P. Bartenstein2, J. Levin2, A. Drzezga7, J. Seibyl4, G. Hoeglinger9, J. 12 i Sant Pau, Barcelona, SPAIN, Hospital Universitario Doce de 111 1 Classen1, O. Sabri1; 13 14 Comparison and Evaluation of n.c.a. In-DTPA-Phe - Octubre, Madrid, SPAIN, ICO-Bellvitge, Barcelona, SPAIN, Hospital 1University Hospital Leipzig, Leipzig, GERMANY, 2LMU Hospital 15 Octreotide vs. n.c.a. 177Lu-[DOTA0, Tyr3] TATE / n.c.a. OP-186 Universitario Virgen de las Nieves, Granada, SPAIN, Hospital Munich, Munich, GERMANY, 3Research Center Juelich, Juelich, 16 177Lu-[DOTA0, Tyr3] TOC in (GEP-NENs) Treated Patients Universitario Getafe, Madrid, SPAIN, Hospital Universitario Son GERMANY, 4InviCRO, Boston, MA, UNITED STATES OF AMERICA, 17 1 2 3 4 Machine Learning Assisted DAT PET in the Discrimination Espases, Palma de Mallorca, SPAIN, Hospital Universitario Burgos, G. Limouris , V. Krylov , M. B. Dolgushin , M. Paphiti , R. V. 5Austin Health, Heidelberg, AUSTRALIA, 6DZNE, Bonn, GERMANY, 18 5 6 of Parkinsonism Disorders Burgos, SPAIN, Hospital Universitario Dr Peset, Valencia, SPAIN, McCready , A. Zafeirakis ; 7University Hospital Cologne, Cologne, GERMANY, 8Life Molecular 19 20 1 Q. Xu; Hospital Universitario Salamanca, Salamanca, SPAIN, Hospital Nuclear Medicine, Medical School, National and Kapodistrian Imaging, Berlin, GERMANY, 9Hannover Medical School, Hannover, 2 North Huashan Hospital, Shanghai, CHINA. Universitario Príncipe de Asturias, Madrid, SPAIN. University of Athens, Athens, GREECE, Nuclear Medicine GERMANY. Department, “A Tsyb Research Center”, Obninsk, RUSSIAN FEDERATION, 3N.N. Blokhin Russian Oncological Research Center, OP-187 OP-179 Moscow, RUSSIAN FEDERATION, 4Nuclear Medicine Dept, National Cerebral glucose metabolism abnormalities and OP-193 Health System, Athens, GREECE, 5Institute Cancer Research, Sutton dopaminergic dysfunction in patients with Parkinson’s 177Lu-PRRT in advanced gastrointestinal neuroendocrine Surrey and Royal Sussex County Hospital, Brighton, UNITED disease with bilateral onset Graph theoretical analysis of the structural connectivity in tumors: ten-year follow up of the IRST-Phase II prospective KINGDOM, 6Army Share Fund Hospital of Athens, Athens, GREECE. P. Wu 1, L. Li1, J. Song1, X. Li1, J. Lu1, J. Ge1, J. Wu2, J. Wang2, C. Zuo1; progressive supranuclear palsyin relation to tau burden: A 1PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA, study [18F]PI-2620 PET/MRI study 2Department of Neurology, Huashan Hospital, Fudan University, M. Sansovini1, G. Paganelli1, S. Nicolini1, I. Grassi1, V. Di Iorio1, E. G. Aghakhanyan1,2, M. Rullmann2, J. Rumpf3, M. L. Schroeter4, M.

80 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 81 Patt2, J. Classen3, O. Sabri2, H. Barthel2; Turnover Markers (BTMs) M. Jreige, F. Becce, B. Rozier Aubry, N. Schaefer, J. O. Prior, M. Nicod- Ngoc, F. Grünwald, A. Sabet; 1Regional Center of Nuclear Medicine, University Hospital of Pisa G. Papadakis1,2,3, G. C. Manikis2, A. H. Karantanas1, K. Marias2, M. T. Lalonde; University Medical Center Frankfurt, Department of Nuclear and Department of Translational Research on New Technologies Collins3, A. M. Boyce3; Lausanne University Hospital, Lausanne, SWITZERLAND. Medicine, Frankfurt, GERMANY. in Medicine and Surgery, University of Pisa, Pisa, ITALY, 2Department 1Department of Medical Imaging, Medical School, University of of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY, Crete, Heraklion, GREECE, 2Computational Biomedicine Laboratory 3Department of Neurology, University of Leipzig, Leipzig, GERMANY, (CBML), Foundation for Research and Technology Hellas (FORTH), OP-202 EPS-037 4Max Planck Institute for Human Cognitive and Brain Sciences, Heraklion, GREECE, 3National Institute of Dental & Craniofacial 99m Leipzig, GERMANY. Research (NIDCR), Bethesda, MD, UNITED STATES OF AMERICA. SPECT/CT with Tc-Tektrotyd in imaging tumors secreting Performance comparison of different dosimetry methods fibroblast growth factor 23 (tumor-induced osteomalacia) with respect to complexity and accuracy OP-194 K. Slashchuk, M. Degtyarev, P. Rumyantsev, S. Serzhenko, O. J. Brosch1, C. Uribe2, A. Gosewisch1, L. Kaiser1, P. Bartenstein1, A. OP-198 Baranova, A. Trukhin; Todica1, H. Ilhan1, A. Rahmim3, A. Celler3, S. Ziegler1, G. Böning1; Aberrant functional connectivity in progressive Endocrinology Research Center, Moscow, RUSSIAN FEDERATION. 1University Hospital, LMU Munich, Munich, GERMANY, 2PET supranuclear palsy is associated with tau load in the Lesional uptake decreases on [18F]NaF PET-CT in patients Functional Imaging, BC Cancer, Vancouver, BC, CANADA, 3 dentate nucleus: A [18F]PI-2620 PET/MRI study with Fibrous Dysplasia/McCune Albright syndrome treated Bone scintigraphy in oncological patients: The added value Department of Radiology, University of British Columbia, G. Aghakhanyan1,2, M. Rullmann2, J. Rumpf3, M. L. Schroeter4, M. with Denosumab of SPECT-CT Vancouver, BC, CANADA. 2 3 2 2 1,2 3,4 1,5 3,4 EANM’20 EANM’20 Patt , J. Classen , O. Sabri , H. Barthel ; W. van der Bruggen , M. E. Meier , F. Smit , P. D. S. Dijkstra , L. E. D. Vega, M. J. Tabuenca Mateo, V. Godigna Guilloteau, A. Galiana EANM’20 1Regional Center of Nuclear Medicine, University Hospital of Pisa M. Winter3, L. F. de Geus-Oei1,6, N. M. Appelman-Dijkstra3, D. Vriens1; Moron, S. Ruiz Solis, M. Martin Ferrer, E. Martinez Albero, P. EPS-038 and Department of Translational Research on New Technologies 1Section of Nuclear Medicine, dept. of Radiology, Leiden University Pilkington Woll, P. Sarandeses Fernandez, A. Gomez Grande, J. M. in Medicine and Surgery, University of Pisa, Pisa, ITALY, 2Department Medical Center (LUMC), Leiden, NETHERLANDS, 2Dept. of Nuclear Estenoz Alfaro; Determination of tumour control probability curves for of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY, Medicine, Slingeland Hospital, Doetinchem, NETHERLANDS, Hospital 12 de Octubre, Madrid, SPAIN. treatments with 225Ac-PSMA of metastatic castration 3Department of Neurology, University of Leipzig, Leipzig, GERMANY, 3Center for Bone Quality, dept. of Internal Medicine, division of resistant prostate cancer by means of microdosimetry WORLD LEADING MEETING 4 WORLD LEADING MEETING Max Planck Institute for Human Cognitive and Brain Sciences, Endocrinology, Leiden University Medical Center (LUMC), Leiden, calculations Leipzig, GERMANY. NETHERLANDS, 4Dept. of Orthopaedic surgery, Leiden University OP-206 P. Minguez Gabiña, A. Esteban Figueruelo, M. Nevares Herrero, R. Medical Center (LUMC), Leiden, NETHERLANDS, 5Dept. of Nuclear Valverde Jorge, R. Nuñez Muñoz, Y. Carreres Ortega, I. Fernandez OP-195 Medicine, Alrijne Hospital, Leiderdorp, NETHERLANDS, 6Biomedical SCOREp of clinical and FDG-PET/CT features at staging as Tercero, E. Rodeño Ortiz de Zarate; Photonic Imaging Group, University of Twente, Enschede, risk index of poor response and relapse in Ewing Sarcoma Osakidetza, Barakaldo, SPAIN. HDAC6 distribution in amyotrophic laterals sclerosis NETHERLANDS. A. Martini1, M. Allocca1, R. Di Dato1, M. Di Paolantonio1, I. D. Van Weehaeghe1, M. Koole1, J. De Vocht1, T. M. Gilbert2, F. A. Paglianiti2, E. Spinelli2, D. Volterrani2, R. Sciagrà1, C. Olianti1; Schroeder2, J. E. Kranz2, J. M. Hooker3, P. Van Damme1, K. Van Laere1; OP-199 1University of Florence, Florence, ITALY, 2University of Pisa, Pisa, ITALY. EPS-039 1UZ/KU Leuven, Leuven, BELGIUM, 2Eikonizo, Cambridge, MA, UNITED STATES OF AMERICA, 3Athinoula A. Martinos Center Ultrafast 10x whole-body Na18F digital photon counting Towards in-silico dosimetry studies for (novel) for Biomedical Imaging, Charlestown, MA, UNITED STATES OF PET/CT for assessing osteoblastic metastases: A Phase 1a 411 radiopharmaceuticals based on physiology based AMERICA. intra-individual comparison trial e-Poster Presentation Session 3: Clinical pharmacokinetic models C. Wright, K. Binzel, Y. Hsieh, E. Folefac, D. A. Diaz Pardo, D. G. Stover, Dosimetry Methods R. Bouwman, G. de With; 410 M. V. Knopp; NRG, Arnhem, NETHERLANDS. Featured Session: Molecular Bone Imaging - The Ohio State University, Columbus, OH, UNITED STATES OF Friday, October 23, 2020, 09:00 - 10:30 Nuclear Medicine’s Swiss Army Knife! AMERICA. Channel 11 EPS-040

Friday, October 23, 2020, 09:00 - 10:30 OP-200 Gamma Camera Calibration to Perform SPECT/CT-based Channel 10 Dosimetry in 177Lu-DOTATATE Treatments Hybrid bone SPECT/CT with diagnostic-quality CT for EPS-035 T. Monserrat Fuertes1, N. Montenegro Iglesias1, D. Álvarez Llorente1, recurrent pain following spinal fusion surgery: accuracy M. Peinado Montes1, D. San José Olmedo1, P. Mínguez Gabiña2; and impact on clinical management Salivary gland dosimetry in therapy of metastatic castrate- 1Hospital Universitario Central de Asturias, Oviedo, SPAIN, 2Hospital 177 OP-196 B. Lambert1, B. Van Den Bossche2, J. Bleyen2, J. Mertens2, T. Matton2, resistant prostate cancer with Lu-PSMA-617 Universitario Cruces/Gurutzeta, Bilbao, SPAIN. T. Vandekerckhove2, T. Van den Wyngaert3; C. Happel, L. Völler, W. T. Kranert, J. Baumgarten, D. Gröner, F. Molecular Bone Imaging - Nuclear Medicine’s Swiss Army 1Maria Middelares Hospital and Ghent University, Gent, BELGIUM, Grünwald, A. Sabet; EPS-041 Knife! 2Maria Middelares Hospital, Gent, BELGIUM, 3UZA, Antwerp, University Medical Center Frankfurt, Department of Nuclear D. Morland; Institut Godinot, Médecine Nucléaire, Reims, FRANCE BELGIUM. Medicine, Frankfurt, GERMANY. Patient Specific Peri- and Post-Treatment Analysis of 177Lu-DOTATATE Injected NET Patients EPS-036 O. Yaylali1, S. Beykan2, D. Yüksel3, G. Ergiyen Buldu4, B. Nacar4, A. OP-197 OP-201 Gültekin3, T. Şengöz3, M. Lassmann2, I. Karaaslan4; Dosimetric evaluation of the lacrimal glands in patients 1Pamukkale University Medical Faculty Departement of Nuclear 18F-NaF Activity Related with Fibrous Dysplasia of Bone Tc-99m-diphosphonate bone scan quantification: Fibrous undergoing therapy with 177Lu-PSMA Medicine, Denizli, TURKEY, 2Department of Nuclear Medicine, Lesions is Positively Associated with Established Bone dysplasia versus metastasis of prostate cancer C. Happel, L. Völler, W. T. Kranert, D. Gröner, B. Bockisch, C. Nguyen University of Würzburg, Würzburg, GERMANY, 3Pamukkale

82 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 83 University Medical Faculty Department of Nuclear Medicine, TN, UNITED STATES OF AMERICA, 9Emory University School of Radioembolization Using Tc-99m, Ho-166 and Y-90 OP-210 Denizli, TURKEY, 4Graduate School of Health Sciences, Yeditepe Medicine, Atlanta, GA, UNITED STATES OF AMERICA, 10Vancouver J. Wielaard1,2, B. Kunnen1, G. C. Krijger1, R. van Rooij1, H. W. A. M. de University, İstanbul, TURKEY. General Hospital, University of British Columbia, Vancouver, BC, Jong1; 11 Multiple Osteolytic/Osteoclastic Lesions in the Peripheral CANADA, Yale School of Medicine, New Haven, CT, UNITED 1University Medical Center Utrecht, Utrecht, NETHERLANDS, 2St. STATES OF AMERICA, 12Clinica Universidad de Navarra-IDISNA Antonius hospital, Nieuwegein, NETHERLANDS. Skeleton - Multimodality Imaging-Based Problem Solving EPS-043 and CIBEREHD, Pamplona, SPAIN, 13Singapore General Hospital, S. Carrilho Vaz; Nuclear Medicine-Radiopharmacology, Singapore, SINGAPORE, 14Technical University of Munich, Munich, Champalimaud Centre for the Unknown, Lisbon, PORTUGAL. Comparison of the 24h-uptake value obtained from planar GERMANY, 15S. Orsola Malpighi University Hospital, Bologna, EPS-051 images with a gamma camera and from measurements ITALY, 16Northwestern University, Chicago, IL, UNITED STATES OF OP-211 17 with a thyroid uptake probe in patients with benign AMERICA, Stanford University School of Medicine, Palo Alto, CA, Comparison of Different Time-Activity Curve-Fitting UNITED STATES OF AMERICA, 18The Netherlands Cancer Institute, Multiple Osteosclerotic/Osteoblastic Lesions in the Axial thyroid disease Methods for Voxel-based In-111 Zevalin SPECT Targeted Amsterdam, NETHERLANDS. Skeleton - Multimodality Imaging-Based Problem Solving P. Minguez Gabiña, A. Esteban Figueruelo, M. Nevares Herrero, Radionuclide Therapy Dosimetry Y. Lyu, G. Chen, G. Mok; F. Paycha; Department of Nuclear Medicine, Lariboisière Hospital, R. Valverde Jorge, R. Nuñez Muñoz, Y. Carreres Ortega, J. Genolla EPS-047 Subirats, E. Rodeño Ortiz de Zarate; Biomedical Imaging Laboratory (BIG), Department of Electrical Assistance Publique-Hôpitaux de Paris, Paris, FRANCE. Osakidetza, Barakaldo, SPAIN. and Computer Engineering, Faculty of Science and Technology, Combined Quality and Dose Volume Histograms OP-212

EANM’20 EANM’20 University of Macau, Taipa, MACAO. EANM’20 demonstrates the predictive value of99mTc-MAA SPECT/CT EPS-044 simulation for personalizing radioembolization treatment Mini Course 2: Advanced Practice in Hybrid Multiple Osteosclerotic/Osteoblastic Lesions in the Nuclear Medicine in liver metastatic colorectal cancer Peripheral Skeleton - Multimodality Imaging-Based Improved patient dosimetry for radioactive iodide H. Levillain1,2, M. Burghelea1, I. Duran Derijckere2, T. Guiot1, A. Problem Solving Friday, October 23, 2020, 10:00 - 10:50 by adjusting the ICRP iodide compartment model to 1 1 3 2 1 Channel 4 B. Jonca; Department of Nuclear Medicine, Bichat Hospital,

WORLD LEADING MEETING Gulyban , B. Vanderlinden , M. Vouche , P. Flamen , N. Reynaert ; WORLD LEADING MEETING individual thyroid uptake 1Medical Physics Department, Jules Bordet Institute, Brussels, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE. M. Andersson, S. Mattsson; BELGIUM, 2Nuclear Medicine Department, Jules Bordet Institute, Medical Radiation Physics, Malmö, SWEDEN. Brussels, BELGIUM, 3Radiology Department, Jules Bordet Institute, Brussels, BELGIUM. 502 OP-207 Joint Symposium 7 (EANM/EAN/ECTRIMS): EPS-045 Multiple Sclerosis - Update in Neuroimaging EPS-048 Clinical Applications of PET/CT The tribulations of multi-centre clinical trials dosimetry L. Lezaic; University Medical Center, Ljubljana, SLOVENIA. N. Clayton1, J. Ocampo-Ramos1, G. Flux2,3, J. Taprogge2,3, M. Radioembolization of hepatocarcinoma with 90Y glass Friday, October 23, 2020, 10:40 - 12:10 Channel 2 Bardiès1; microspheres: voxel dosimetry or mean dose approach to OP-208 1 CRCT, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, predict clinical outcomes? Toulouse, FRANCE, 2Royal Marsden NHSFT, London, UNITED Hybrid Imaging in Nuclear Cardiology C. Romanò1, S. Mazzaglia1, M. C. De Nile2, S. Bhoori3, A. Gabutti4, G. KINGDOM, 3The Institute of Cancer Research, London, UNITED Maffi4, C. Spreafico4, A. Marchianò4, V. Mazzaferro3, M. Maccauro1, E. W. Noordzij; University Medical Centre Groningen, Groningen, KINGDOM. Seregni1, C. Chiesa1; NETHERLANDS. OP-213 1Nuclear Medicine Division, Foundation IRCCS Istituto Nazionale EPS-046 Tumori, Milan, ITALY, 2Postgraduate Specialization School in MRI - What is Conventional and What is New? Medical Physics, University of Milan, Milan, ITALY, 3HPB Surgery, 501 M. Assunta Rocca; San Raffaele Hospital/ Università Vita-Salute International recommendations for personalised Hepatology and Liver Transplantation, Foundation IRCCS Istituto CME 4: Multimodality Imaging-Based Problem San Raffaele, Division of Neuroscience, Milan, ITALY. selective internal radiation therapy with yttrium-90 resin Nazionale Tumori, Milan, ITALY, 4Radiology 2, Foundation IRCCS Solving for Multiple Bone Lesions microspheres Istituto Nazionale Tumori, Milan, ITALY. OP-214 H. Levillain1, O. Bagni2, C. M. Deroose3, A. Dieudonne4, S. Gnesin5, 6 7 8 9 10 EPS-049 Friday, October 23, 2020, 10:40 - 12:10 Imaging Neuroinflammation with PET - Added Value of O. S. Grosser , S. Kappadath , A. Kennedy , N. Kokabi , D. Liu , D. Channel 1 Madoff11, A. Mahvash7, A. Martinez de la Cuesta12, D. Ng13, P. M. Studying the White Matter Involvement 90 Paprottka14, C. Pettinato15, M. Rodriguez Fraile12, R. Salem16, B. Absorbed dose assessment in Y radioembolization L. Airas; University of Turku, Turku, FINLAND. Sangro12, L. Strigari15, D. Y. Sze17, L. de Wit Van der Veen18, P. Flamen1; patients with GATE: a comparison between total-body PET 1Jules Bordet Institute, Brussels, BELGIUM, 2Santa Maria Goretti and conventional PET imaging 3 Hospital, Latina, ITALY, University Hospitals Leuven and Nuclear G. Costa, B. Spencer, M. Rusnak, D. T. Caudle, C. Foster, C. T. Vu, E. OP-209 OP-215 Medicine and Molecular Imaging KU Leuven, Leuven, BELGIUM, Roncali; 4 Hôpital Beaujon, AP-HP.Nord, DMU DREAM and Inserm U1149, University of California, Davis, CA, UNITED STATES OF AMERICA. Multiple Osteolytic/Osteoclastic Lesions in the Axial Amyloid PET - A Potential Biomarker of De- and Clichy, FRANCE, 5Institute of Radiation Physics, Lausanne University Skeleton - Multimodality Imaging-Based Problem Solving Re-Myelinization in MS Hospital and University of Lausanne, Lausanne, SWITZERLAND, A. Bazzocchi; Diagnostic and Interventional Radiology, IRCCS B. Stankoff; Saint-Antoine Hospital / Pierre and Marie Curie 6 7 University Hospital Magdeburg, Magdeburg, GERMANY, University EPS-050 Istituto Ortopedico Rizzoli, Bologna, ITALY . University, Department, Paris, FRANCE. of Texas MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA, 8Sarah Cannon Research Institute, Nashville, Comparison of Pre-Treatment Imaging for

84 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 85 a Promising Candidate for Selective Tau PET Tracer in Medicine, Oncology R&D, AstraZeneca, Stockholm, SWEDEN. 503 OP-220 Alzheimer’s disease Joint Symposium 8 (EANM/SRS): The Revival of 1,2 3,4 2,5 3 2 In vivo comparison of the sensitivity of PET radioligands P. Lerdsirisuk , R. Harada , Y. Shimizu , Y. Du , Y. Ishikawa , R. OP-229 Radiometals Iwata2, K. Yanai3, Y. Kudo4, N. Okamura2,6, S. Furumoto2; to detect moderate changes in P-gp function at the blood- 1Radiopharmaceutical chemistry, Graduate School of Amyloid beta (Aβ) imaging in transgenic mice - brain barrier Pharmaceutical Science, Tohoku University, Sendai, JAPAN, Friday, October 23, 2020, 10:40 - 12:10 comparison of [11C]PiB and an antibody-based ligand Channel 3 L. Breuil, F. Caillé, S. Marie, S. Goutal, S. Auvity, M. Goislard, C. 2Cyclotron and Radioisotope Center (CYRIC), Tohoku University, 1 2 2 1 3 Coulon, T. Lekieffre, W. Saba, N. Tournier; Sendai, JAPAN, 3Department of Pharmacology, Graduate School S. Meier , J. Rokka , J. Eriksson , S. Roshabin , U. Neumann , D. 1 1 Laboratoire d’Imagerie Biomédicale Multimodale (BIOMAPS), of Medicine, Tohoku University, Sendai, JAPAN, 4Department Sehlin , S. Syvänen ; 1 Université Paris-Saclay, CEA, CNRS UMR9011, Inserm UMR1281, of Gerontology and Geriatrics, Division of Brain Science, Department of Public Health and Caring Sciences, Uppsala, 2 Service Hospitalier Frédéric Joliot, Orsay, FRANCE. Institute of Development Aging and Cancer (IDAC), Tohoku SWEDEN, Department of Medicinal Chemistry, Uppsala, SWEDEN, 3 OP-216 University, Sendai, JAPAN, 5Department of Pharmacy, Faculty Neuroscience Research, Novartis Institutes for BioMedical of Pharmaceutical Science, Tohoku University, Sendai, JAPAN, Research, Uppsala, SWITZERLAND. Production of New Radiometals OP-221 6Division of Pharmacology, Faculty of Medicine, Tohoku Medical U. Köster; Institut Laue-Langevin (ILL),Grenoble,FRANCEInstitut and Pharmaceutical University, Sendai, JAPAN. Laue-Langevin (ILL), Grenoble, FRANCE. Evaluation of a Novel P-glycoprotein Inducer Using [18F] 506 EANM’20 EANM’20 EANM’20 MC225 and PET OP-225 Cutting Edge Science Track - TROP Session: New OP-217 L. Garcia Varela1, D. Vállez García1, M. Perez Rodriguez2, R. Moraga- Technologies and Imaging Techniques Amaro1, N. A. Colabufo3, P. Aguiar4, T. Sobrino2, R. A. J. O. Dierckx1, A. [18F]FEPPA PET/CT Imaging to Assess STAT Inhibitor Effect Chelators for New Radiometals van Waarde1, P. H. Elsinga1, G. Luurtsema1; in LPS-induced Neuroinflammation Mouse Models F. Rösch; Johannes Gutenberg-University Mainz, Institute of 1University of Groningen, University Medical Center of Groningen, 1,2 1,3 2 2 2,4 Friday, October 23, 2020, 10:40 - 12:10 C. San , P. Millot , M. Brault , F. Hontonnou , L. Sarda-Mantel , N. Channel 6 WORLD LEADING MEETING Nuclear Chemistry, Mainz, GERMANY. Department of Nuclear Medicine and Molecular Imaging, Vignal1,2,4, F. Mouton-Liger1,3, B. Hosten1,2; WORLD LEADING MEETING Groningen, NETHERLANDS, 2IDIS Health Research Institute, Clinical 1INSERM UMR-S 1144, Université de Paris, Paris, FRANCE, 2Unité OP-218 Neurosciences Research Laboratory, Santiago de Compostela, Claude Kellershohn, Institut de Recherche Saint-Louis, Hôpital SPAIN, 3University of Bari Aldo Moro, Department of Pharmacy, Bari, Saint-Louis, APHP, Paris, FRANCE, 3Centre de Neurologie Cognitive/ Strenghts and Limitations of New Radiometals ITALY, 4Clinical University Hospital, IDIS Health Research Institute, CMRR Paris Nord Ile de France, Hôpital Lariboisière, APHP, Paris, OP-230 C. Cutler; Brookhaven National Laboratory, NY, New York, UNITED Department of Nuclear Medicine and Molecular Imaging, Santiago FRANCE, 4Service de Médecine Nucléaire, Hôpital Lariboisière, APHP, STATES OF AMERICA. de Compostela, SPAIN. Paris, FRANCE. Simulation and first measurements of a prototype ultra- long FOV PET/CT scanner OP-222 OP-226 M. Conti, M. Aykac, H. Bal, B. Bendriem, D. Bharkhada, J. Cabello, L. 505 Eriksson, V. Panin, H. Rothfuss, S. Siegel; 89 111 M2M Track - TROP Session: It Takes Place in the Binding of the experimental dual-action antiparkinsonian Brain distribution and retention of Zr and In labeled Siemens Medical Solutions, Knoxville, TN, UNITED STATES OF Brain - New Neuro Tracers drug AG-0029 to dopamine D2 and histamine H3 bispecific antibody in an amyloid beta mouse model AMERICA. receptors: a PET study in healthy rats T. Gustavsson1, T. Tran2, S. Syvänen1, D. Sehlin1; A. Van Waarde1, N. Ghazanfari1, J. W. A. Sijbesma1, D. Vállez 1Department of Public Health and Caring Sciences, Uppsala OP-232 Friday, October 23, 2020, 10:40 - 12:10 1 2 2 1 2 2 2 Channel 5 García , M. Kominia , M. Koelewijn , K. Attia , T. J. Visser , A. Heeres , University, Uppsala, SWEDEN, Department of Radiopharmacy, A. T. M. Willemsen1, R. A. J. O. Dierckx1, P. H. Elsinga1; Karolinska University Hospital, Stockholm, SWEDEN. Clinical impact of fully automated multiparametric PET 1University Medical Center Groningen, Groningen, NETHERLANDS, imaging using direct Patlak reconstruction: Evaluation of 2Syncom, Groningen, NETHERLANDS. OP-228 100 dynamic whole-body 18F-FDG PET/CT scans A. H. Dias, M. F. Pedersen, H. Danielsen, O. L. Munk, L. C. Gormsen; OP-219 Identification and in vitrocharacterization of C05-01, a Aarhus Universitetshospital, Aarhus, DENMARK. OP-223 PPB3 derivative with improved affinity for α-synuclein 1 1 2 2 3 Changes in D2R and SERT Availability in the Rat Brain After P. Miranda Azpiazu , M. Svedberg , M. Higuchi , M. Ono , Z. Jia , D. 4,5 6 1,7 1 Depressive-like Behavior Recovery in the Repeated Social Impact of A2AR agonist and antagonist on binding of the Sunnemark , C. Elmore , M. Schou , A. Varrone ; OP-233 11 1 Defeat Model dopamine D2receptor ligand [ C]raclopride in the rodent Centre for Psychiatry Research, Department of Clinical Use of population input functions for FDG whole-body R. Moraga-Amaro1, D. A. Vazquez-Matias1, L. Reali Nazario1, J. striatum Neuroscience, Karolinska Institutet, & Stockholm Health Care 2 Stehberg2, R. A. J. O. Dierckx1, J. Doorduin1, E. F. J. de Vries1; K. Prasad, E. F. J. de Vries, J. W. A. Sijbesma, K. A. Attia, C. Kwizera, L. Services, Region Stockholm, Stockholm, SWEDEN, Department Patlak imaging 1Department of Nuclear Medicine and Molecular Imaging, Garcia-Varela, D. A. Vazquez-Matias, R. Moraga-Amaro, D. Vallez- of Functional Brain Imaging Research, National Institute of J. van Sluis1, M. Yaqub2, A. H. Brouwers1, W. Noordzij1, R. Boellaard2; University of Groningen, University Medical Center Groningen, Garcia, A. T. Willemsen, R. A. J. O. Dierckx, A. van Waarde; Radiological Sciences, National Institutes for Quantum and 1University Medical Center Groningen, Groningen, NETHERLANDS, 3 Groningen, NETHERLANDS, 2Laboratorio de Neurobiología, University Medical Center Groningen (UMCG), Groningen, Radiological Science and Technology, Chiba, JAPAN, Karolinska 2Amsterdam University Medical Center, Amsterdam, 4 Instituto de Ciencias Biomédicas, Facultad de Medicina y Facultad NETHERLANDS. Institutet, Solna, SWEDEN, Applied Immunology, Department of NETHERLANDS. de Ciencias de la vida, Universidad Andres Bello, Santiago, CHILE. Clinical Neuroscience, Karolinska Institutet, Stockholm, SWEDEN, 5Offspring Biosciences, Offspring Biosciences, Sweden AB, SWEDEN, OP-224 6Early Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, SWEDEN, 7PET Science Centre, Precision Development and Identification of 18[ F]SNFT-1 (THK-5562),

86 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 87 R. Durmo, B. Donati, S. Luminari, M. Casali, A. Ruffini, M. Zanelli, A. OP-234 OP-238 507 Ciarrocchi, F. Merli, A. Versari; AUSL-IRCCS of Reggio Emilia, Reggio Emilia, ITALY. 18 Teaching Session 2: The Uncomfortable Two short F-FDG PET/CT dynamic acquisitions to Optimizing energy window width for digital SPECT-CT in Truth – Are Nuclear Medicine Physicians evaluate with accuracy the influx constant with Patlak myocardial perfusion imaging Viewed as Second Class Doctors Compared to method in patients with lung cancer R. Hirvilammi1, M. Seppänen1,2, M. Hakulinen3, J. Knuuti2, T. Radiologists? OP-249 V. Scolozzi1, A. Capotosti2, L. Indovina2, S. Taralli1, M. Lorusso1, C. Noponen1,4; Caldarella1, M. L. Calcagni1,3; 1Department of Clinical Physiology and Nuclear Medicine, Turku Aberrant patterns of PET-CT response for diffuse large 1 University Hospital, Turku, FINLAND, 2Turku PET Centre, Turku Friday, October 23, 2020, 10:40 - 11:40 Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Channel 7 B-cell lymphoma patients with MYC rearrangement Medicina Nucleare, Dipartimento di Diagnostica per Immagini, University Hospital, Turku, FINLAND, 3Department of Clinical J. Eertink1, F. Celik2, J. Huijbregts3, A. I. J. Arens4, S. E. Wiegers1, C. N. Radioterapia Oncologica ed Ematologia, Rome, ITALY, 2Fondazione Physiology and Nuclear Medicine, Kuopio University Hospital, Burggraaff1, O. S. Hoekstra5, S. Stroobants6, R. Boellaard5, H. C. W. de Policlinico Universitario A. Gemelli IRCCS, UOS Dosimetria Clinica Kuopio, FINLAND, 4Department of Medical Physics, Turku University Vet7, M. E. D. Chamuleau1, J. M. Zijlstra1; e Radioprotezione, Dipartimento di Diagnostica per Immagini, Hospital, Turku, FINLAND. 1Amsterdam UMC, Vrije Universiteit Amsterdam, department Radioterapia Oncologica ed Ematologia, Rome, ITALY, 3Università OP-242 of Hematology, Cancer Center Amsterdam, Amsterdam, Cattolica del Sacro Cuore, Istituto di Medicina Nucleare, Rome, OP-239 NETHERLANDS, 2Department of Radiology and Nuclear Medicine, ITALY. TBA Deventer Ziekenhuis, Deventer, NETHERLANDS, 3Department of EANM’20 EANM’20 EANM’20 Bone metabolism may be monitored through the absolute T. Lynch; Belfast, UNITED KINGDOM. Radiology and Nuclear Medicine, Gelre Ziekenhuis, Apeldoorn, 4 OP-235 quantification provided by a whole-body 360° CZT SPECT/ NETHERLANDS, Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, NETHERLANDS, CT camera during the healing period of vertebral fractures Comparing the accuracy of global and blockwise deadtime 5Amsterdam UMC, Vrije Universiteit Amsterdam, department of A. Bahloul, L. Imbert, A. Blum, G. Karcher, A. Verger, P. Marie; 508 Radiology and Nuclear Medicine, Cancer Center Amsterdam, correction for the BrainPET scanner Nancy University Hospital, Vandoeuvre-les-Nancy, FRANCE. 6 WORLD LEADING MEETING Amsterdam, NETHERLANDS, Department of Nuclear Medicine, WORLD LEADING MEETING A. Issa1, J. Scheins1, L. Tellmann1, C. Régio Brambilla1,2, H. Xu1, N. Antwerp University Hospital (UZA), Antwerp, BELGIUM, 7Amsterdam Shah1,2,3, C. Lerche1; Clinical Oncology Track - TROP Session: PET for UMC, Vrije Universiteit Amsterdam, department of Epidemiology 1Institute of Neuroscience and Medicine 4, INM-4, OP-240 Haematological Tumours and Biostatistics, Amsterdam Public Health research institute, Forschungszentrum Jülich, Jülich, GERMANY, 2Institute of Amsterdam, NETHERLANDS. Neuroscience and Medicine 11, INM-11, JARA, Forschungszentrum Compared visual analyses of whole-body planar bone Friday, October 23, 2020, 10:40 - 12:10 Channel 8 Jülich, Jülich, GERMANY, 3JARA - BRAIN - Translational Medicine, scintigraphies obtained from conventional Anger camera Aachen, GERMANY. and from retro-projections after CT-based corrections of a OP-250 high-speed SPECT recording using a 360° CZT-camera OP-236 Baseline 18F-FDG PET/CT Metabolic Parameters Combined A. Bahloul, A. Verger, M. Perrin, M. Claudin, G. Karcher, P. Marie, L. OP-247 Imbert; with Interim PET/CT Improve Risk Stratification in Patients Characteristics and properties of a novel cost-effective Nancy University Hospital, Vandoeuvre Les Nancy, FRANCE. with Hodgkin Lymphoma 18F-FDG PET/CT baseline radiomics features are predictive preclinical PET scanner for high performance molecular M. Rashki1, E. Triviño-Ibáñez1, L. Lamarca Eraso2, E. Gámez imaging of small animal models of outcome in diffuse large B-cell lymphoma patients Jiménez2, F. Hernández Mohedo2, C. Ramos Font1; F. Castro1,2, P. M. M. Correia2,1, P. M. C. C. Encarnação2, A. L. M. OP-241 J. Eertink1, T. van de Brug2, S. E. Wiegers1, G. J. C. Zwezerijnen3, E. 1Servicio de Medicina Nuclear. Hospital Virgen de las Nieves, Silva2,1, F. M. Rodrigues1, A. G. Sá1, A. C. Azevedo1, F. M. Ribeiro2, I. Pfaehler4, P. J. Lugtenburg5, B. van der Holt6, H. C. W. de Vet2, O. S. Granada, SPAIN, 2Servicio de Hematología y Hemoterapia. Hospital Mohammadi2, R. Oliveira2, A. I. Veloso3, A. C. Santos4, N. A. Gomes5, Going quicker for dopamine transporter DaTSCAN Hoekstra3, R. Boellaard3, J. M. Zijlstra1; Virgen de las Nieves, Granada, SPAIN. M. F. L. Loureiro5, P. Mar5, M. Inocêncio5, J. F. C. A. Veloso2,1; imaging using SPECTStep & Shoot Continuous 1Amsterdam UMC, Vrije Universiteit Amsterdam, department 1RI-TE Radiation Imaging Technologies, Lda, Ílhavo, PORTUGAL, M. Bailly1, G. Le Rouzic1, G. Metrard1, M. Ribeiro2; of Hematology, Cancer Center Amsterdam, Amsterdam, 2Institute for Nanostructures, Nanomodelling and Nanofabrication 1CHR Orléans, Orleans, FRANCE, 2CHRU Tours, Tours, FRANCE. NETHERLANDS, 2Amsterdam UMC, Vrije Universiteit Amsterdam, OP-251 (i3N), University of Aveiro, Aveiro, PORTUGAL, 3DigiMedia, department of Epidemiology and Biostatistics, Amsterdam Public University of Aveiro, Aveiro, PORTUGAL, 4Institute for Clinical and Health research institute, Amsterdam, NETHERLANDS, 3Amsterdam Comparison between 18F-FDG PET/CT and endoscopy in Biomedical Research (iCBR), Center for Innovative Biomedicine and UMC, Vrije Universiteit Amsterdam, department of Radiology the staging of gastrointestinal involvement in Mantle Cell 5 and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam, Biotechnology (CIBB), Coimbra, PORTUGAL, Exatronic, Lda, Aveiro, Lymphoma: A multi-centre study NETHERLANDS, 4Department of Nuclear Medicine and Molecular PORTUGAL. 1 2 1 2 3 Imaging, University of Groningen, University Medical Center C. Ferrari , C. Minoia , V. Lavelli , T. Skrypets , L. Nassi , G. Margiotta 3 4 4 4 1 Groningen, Groningen, NETHERLANDS, 5Erasmus MC Cancer Casaluci , B. Puccini , L. Manelli , S. Kovalchuk , M. Frugis , K. OP-237 5 5 2 2 2 Institute, department of Hematology, Rotterdam, NETHERLANDS, Filonenko , I. Kryachok , A. Sciacovelli , M. Vegliante , A. Daniele , G. 6 2 1 6Erasmus MC Cancer Institute, HOVON Data Center, department of Sacchetti , A. Guarini , G. Rubini ; Channel-based Energy Resolution of TOFPET2C-read PET 1 Hematology, Amsterdam, NETHERLANDS. Nuclear Medicine Department, University of Bari “Aldo Moro”, Bari, Detectors ITALY, 2Haematology Unit, IRCCS Istituto Tumori “Giovanni Paolo V. Nadig1, D. Schug1,2, H. Radermacher1, B. Weissler1,2, V. Schulz1,2,3; II”, Bari, ITALY, 3Haematology Department, Azienda Ospedaliero- 1Physics of Molecular Imaging Systems, RWTH Aachen University, OP-248 Universitaria Maggiore della Carità, Novara, ITALY, 4Haematology, Aachen, GERMANY, 2Hyperion Hybrid Imaging Systems GmbH, University of Firenze, Firenze, ITALY, 5Oncohematology department, Aachen, GERMANY, 3Institute of Physics III B, RWTH Aachen Correlation of baseline TMTV/TLG with early metabolic National Cancer Institute, Kiev, UKRAINE, 6Nuclear Medicine, AOU University, Aachen, GERMANY. response in Hodgkin Lymphoma and integration with the Maggiore della Carità, Novara, ITALY. iPET gene-based predictive model

88 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 89 OP-253 OP-258 OP-260 OP-266

PET/CT-based Prognostic Biomarkers in Diffuse Large Prognostic value of FDG-PET/CT derived visual and Parathyroid scintigraphy pre-surgery: comparison Comparison between digital and analog 18F-Fluorocholine B-cell Lymphoma semi-quantitative parameters in Multiple Myeloma (MM) between methods in primary hyperparathyroidism PET/CT detection rate of parathyroid adenomas S. Czibor1, F. Redondo2, R. Carr3, J. Cerci4, D. Paez5, S. Fanti6, T. patients L. Torres, A. Oliveira, J. Pereira; M. Sizova, D. López-Mora, M. Estorch, F. Fuentes- Ocampo, S. Györke1; A. Farina1, E. Zamagni2, S. Strolin3, L. Strigari3, L. Dozza2, M. Cavo2, S. Centro Hospitalar Universitário São João, Porto, PORTUGAL. Abouzian, A. Flotats, V. Camacho, J. Pérez García, I. Carrió; 1Semmelweis University, Budapest, HUNGARY, 2Fundación Arturo Fanti1, C. Nanni1; Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN. Lopez Perez, Santiago, CHILE, 3Guy’s & St. Thomas’ Hospital, King’s 1Nuclear Medicine Department, Sant’Orsola-Malpighi Hospital, OP-261 College London, London, UNITED KINGDOM, 4Quanta Diagnóstico University of Bologna, Bologna, ITALY, 2Hematology Department, OP-267 e Terapia, Curitiba, Sao Paolo, BRAZIL, 5International Atomic Energy Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, The contribution of protocol selection to diagnostic Agency, Vienna, AUSTRIA, 6Policlinico S. Orsola Malpighi, University ITALY, 3Medical Physics Department, Sant’Orsola-Malpighi Hospital, accuracy in MIBI parathyroid scintigraphy: reevaluation 11C-Methionine PET/CT in Patients with Primary of Bologna, Bologna, ITALY. University of Bologna, Bologna, ITALY. with SPECT/CT and histopathologic findings Hyperparathyroidism and Inconclusive Pre-Operative B. Özdemir, Ü. Korkmaz, S. Soyluoğlu, E. Gökdemir, G. Durmuş Work-Up: Diagnostic Accuracy and Role of Semi- OP-255 Altun; 509 quantitative Analysis EANM’20 EANM’20 Department of Nuclear Medicine, Trakya University, Edirne, TURKEY. D. Maccora1, C. Caldarella2, M. L. Calcagni1,2; EANM’20 18F-FDG PET/CT role in detecting Richter’s transformation Featured Session: Parathyroid Imaging - Who 1Istituto di Medicina Nucleare, Università Cattolica del Sacro of Chronic Lymphocytic Leukemia and predicting overall Scores the Best Goals in this Champions 2 OP-263 Cuore, Rome, ITALY, Dipartimento di Diagnostica per Immagini, survival League? Radioterapia Oncologica ed Ematologia, UOC di Medicina D. Albano1, E. Cerudelli2, M. Gazzilli2, F. Dondi1, A. Mazzoletti1, P. Nucleare, Fondazione Policlinico Universitario A. Gemelli IRCCS, Bellini1, L. Camoni2, F. Bertagna1, R. Giubbini1; Early-phase SPECT/CT, as part of a hybrid dual-phase/ Rome, ITALY. WORLD LEADING MEETING WORLD LEADING MEETING 1 Friday, October 23, 2020, 10:40 - 12:10 University of Brescia and Spedali Civili of Brescia, Brescia, ITALY, Channel 9 double-tracer protocol, improves detection of rapid 2Spedali Civili of Brescia, Brescia, ITALY. washout hyperfunctioning parathyroid glands L. Lemos1, P. Soeiro1, R. Ferreira1,2, G. Costa1,3, J. Pedroso de Lima1,2,3; OP-268 1Centro Hospitalar e Universitário de Coimbra, Coimbra, OP-256 PORTUGAL, 2Instituto de Ciências Nucleares Aplicadas à Saúde The value of PET/CT in patients with primary OP-259 (ICNAS), Faculdade de Medicina, Universidade de Coimbra, hyperparathyroidism and negative or inconclusive neck Patients with Erdheim-Chester Disease who Harbor Coimbra, PORTUGAL, 3Faculdade de Medicina, Universidade de ultrasound and MIBI scintigraphy Starters and Backups in Parathyroid Imaging the BRAF V600E Mutation, Exhibit Significantly Higher Coimbra, Coimbra, PORTUGAL. D. Huic1,2, A. Golubić1, E. Pasini Nemir1; Metabolic Activity in the Adrenal glands Assessed by P. Petranovic; University Hospital Center Sestre milosrdnice, 1Department of Nuclear Medicine and Radiation Protection, Oncology and nuclear medicine, Zagreb, CROATIA. OP-264 2 18F-FDG PET/CT, when Compared to Mutation-Negative University Hospital Centre Zagreb, Zagreb, CROATIA, School of Medicine Zagreb, Zagreb, CROATIA. Counterparts Detection of hyperfunctioning parathyroid tissue G. Papadakis1,2, F. Hannah-Shmouni3, G. C. Manikis2, A. H. with F18-fluorocholine PET/CT in patients with Karantanas1, K. Marias2, K. J. O’ Brien4, W. A. Gahl4, J. I. Estrada- 510 Veras5; hyperparathyroidism 1Department of Medical Imaging, Medical School, University of T. Nazerani Hooshmand1, B. Pernthaler1, A. Ntoumanoglou- Clinical Oncology Track - TROP Session: NET Crete, Heraklion, GREECE, 2Computational Biomedicine Laboratory Schuiki2, P. Ofner-Kopeinig3, R. M. Aigner1; Diagnostics (CBML), Foundation for Research and Technology Hellas (FORTH), 1Medical University of Graz, Department of Radiology, Division Heraklion, GREECE, 3Section on Endocrinology and Genetics, of Nuclear Medicine, Graz, AUSTRIA, 2Medical University of Graz, 3 Friday, October 23, 2020, 10:40 - 12:10 Eunice Kennedy Shriver National Institute of Child Health and Department of Obstetrics and Gynecology, Graz, AUSTRIA, Medical Channel 10 Human Development, Bethesda, MD, UNITED STATES OF AMERICA, University of Graz, Institue for Medical Informatics, Statics and 4Office of the Clinical Director, National Human Genome Research Documentation, Graz, AUSTRIA. Institute, National Institutes of Health, Bethesda, Bethesda, MD, UNITED STATES OF AMERICA, 5Medical Genetics Branch, National OP-265 Human Genome Research Institute, National Institutes of Health, OP-269 Bethesda, MD, UNITED STATES OF AMERICA. A Prospective GCP-Controlled Study of 60 Patients 68 Regarding the Location of Hyperfunctioning Parathyroid Optimal Dose of Ga-Satoreotide Trizoxetan as a PET OP-257 Glands in PHPT Using 11C-Choline PET/CT vs. Dual Isotope Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumours: Qualitative Analysis of PET Role of [18F]FDG PET/CT in patients with Monoclonar SPECT/CT J. Christensen1, A. Ismail1, M. Krakauer2, F. N. Bennedbæk3, B. Images Gammopathy of Unknown Significance (MGUS) Zerahn1, B. Kristensen1, S. B. Søndergaard1, L. T. Jensen1; I. Virgolini1, S. Bahri2, H. Grønbæk3, A. Kjær4, J. Czernin2, E. von T. Rudolphi-Solero, R. Sánchez Sánchez, E. Triviño-Ibáñez, M. 1Dept. of Nuclear Medicine, Herlev & Gentofte University Hospital, Guggenberg1, C. Powell5, S. McEwan6, C. G. Miller5; Rashki, J. Fernández Fernández, Á. C. Rebollo Aguirre; Herlev, DENMARK, 2Dept. of Nuclear Medicine, Herlev & Gentofte 1Medical University Innsbruck, Department of Nuclear Medicine, SAS, Granada, SPAIN. University Hospital, Gentofte, DENMARK, 3Dept. of Endocrinology, Innsbruck, AUSTRIA, 2University of California, Los Angeles, CA, Herlev & Gentofte University Hospital, Herlev, DENMARK. UNITED STATES OF AMERICA, 3Aarhus University Hospital, Aarhus,

90 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 91 DENMARK, 4Rigshospitalet and University of Copenhagen, Toulgoat, E. Mirallie, K. Renaudin-Autin, P. Baumgartner, F. Kraeber- L. Pávics; 1Regional Center of Nuclear Medicine, Department of Translational Copenhagen, DENMARK, 5Ipsen, Cambridge, MA, UNITED STATES Bodere, C. Ansquer; University of Szeged, Department of Nuclear Medicine, Szeged, Research and New Technology in Medicine, University of Pisa and OF AMERICA, 6Ipsen, Toronto, ON, CANADA. University Hospital of Nantes, Nantes, FRANCE. HUNGARY. AOUP, Pisa, ITALY, 2Department of Nuclear Medicine and Molecular Imaging, Medical Imaging Center, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, OP-270 OP-275 OP-280 3PET Centre, Turku University Hospital and University of Turku, Turku, FINLAND, 4Department of Nuclear Medicine, Cliniques [18F]AlF-NOTA-octreotide PET imaging: Pharmacokinetics, F-18 DOPA PET imaging in hyperinsulinemic hypoglicemia Normal pancreatic appearances of [68Ga]Ga-DOTA-TATE Universitaires Saint-Luc, Université Catholique de Louvain (UCL), biodistribution, and head-to-head comparison with [68Ga] K. Toplutas, L. Uslu-Besli, S. Asa, S. Sager, E. Karayel, H. Pehlivanoğlu, G. La Torre, S. Hughes; Brussels, BELGIUM, 5Department of Radiology and Nuclear Ga-DOTATATE in neuroendocrine tumour patients K. Sönmezoğlu; University Hospital Birmingham, Birmingham, UNITED KINGDOM. Medicine, Maastricht University Medical Center (MUMC+), Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, 6 E. Pauwels1, F. Cleeren2, T. Tshibangu2, M. Koole1, K. Serdons1, J. Maastricht, NETHERLANDS, BHF Centre for Cardiovascular 3 3 3 1 2 Department of Nuclear Medicine, Istanbul, TURKEY. Science, University of Edinburgh, Edinburgh, UNITED KINGDOM, Dekervel , E. Van Cutsem , C. Verslype , K. Van Laere , G. Bormans , 7 1 511 Department of Nuclear Medicine, Bichat University Hospital, C. M. Deroose ; 8 1Nuclear Medicine, University Hospitals Leuven; Nuclear Medicine OP-276 Paris, FRANCE, Department of Radiology and Nuclear Medicine, e-Poster Presentation Session 4: The Best of Amsterdam University Medical Centers, Location AMC, University and Molecular Imaging, Department of Imaging and Pathology, Cardiovascular Imaging in Short 9 2 Early response assessment and prediction of overall of Amsterdam, Amsterdam, NETHERLANDS, Nuclear Medicine and

EANM’20 EANM’20 KU Leuven, Leuven, BELGIUM, Radiopharmaceutical Research, EANM’20 Department of Pharmacy and Pharmacology, KU Leuven, Leuven, survival after peptide receptor radionuclide therapy PET, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN, 10Heart Clinic Zurich Hirslanden, Zurich, SWITZERLAND, BELGIUM, 3Digestive Oncology, University Hospitals Leuven, Leuven, D. Huizing, E. A. Aalbersberg, M. W. J. Versleijen, M. E. T. Tesselaar, I. Friday, October 23, 2020, 10:40 - 12:10 Channel 11 11Aix-Marseille Université, IRD, APHM, MEPHI, IHU Méditerranée BELGIUM. Walraven, M. J. Lahaye, B. J. de Wit - van der Veen, M. P. M. Stokkel; Infection, Marseille, France; Département de cardiologie, Hôpital Netherlands Cancer Institute, Amsterdam, NETHERLANDS. de la Timone, AP-HM, boulevard Jean-Moulin, Marseille, FRANCE, OP-271 12 WORLD LEADING MEETING OP-277 Fondazione Toscana Gabriele Monasterio, Pisa, ITALY. WORLD LEADING MEETING Improving target volume delineation for 3D image-based EPS-052 dosimetry in Peptide Receptor Radionuclide Therapy The role of 18F-FDG PET/CT in the prediction of overall EPS-056 S. Berenato1,2, E. Grassi3, F. Fioroni3, D. Finocchiaro3,4, M. Iori3, G. survival of patients with GEP-NECs Identifying and quantification of cardiovascular Lewis2, E. Spezi2,1; M. Aly1,2, H. L. Stokmo3,4, S. M. Seraj1, R. Ghorpade1, A. J. Borja1,5, X. calcification by 18F-NaF PET/CT in alkaptonuria patients High Sympathetic Activity in Raynaud’s Disease 1Department of Medical Physics, Velindre Cancer Centre, Cardiff, Miao1, G. O. Hjortland6, E. Malinen7, T. J. Werner1, A. Alavi1, M. E. E. Alawadhi1, S. Vinjamuri2, J. A. Gallagher1, R. Lakshminarayan3, J. L. Lindberg1, B. Kristensen1, T. W. Hansen2, P. Hasbak3, J. F. Thomsen4, UNITED KINGDOM, 2School of Engineering, Cardiff University, Revheim1,3,4; Dillon1; E. Eldrup5, L. T. Jensen1; Cardiff, UNITED KINGDOM,3 Medical Physics Unit, Azienda Unità 1Department of Radiology, University of Pennsylvania, Philadelphia, 1Institute of Ageing & Chronic Disease, William Henry Duncan 1Department of Nuclear Medicine, Copenhagen University Sanitaria Locale - IRCCS, Reggio Emilia, ITALY, 4Department of PA, UNITED STATES OF AMERICA, 2Department of Radiology, Building, the University of Liverpool, Liverpool, UNITED KINGDOM, Hospital, Herlev Hospital, Herlev, DENMARK, 2Steno Diabetes Physics, University of Bologna, Bologna, ITALY. Asyut University Hospital, Asyut, EGYPT, 3Division of Radiology 2Department of Nuclear Medicine Royal Liverpool University Center Copenhagen, Gentofte, DENMARK, 3Department of and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY, Hospital, Liverpool, UNITED KINGDOM, 3Liverpool Clinical Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, OP-272 4Institute of Clinical Medicine, Faculty of Medicine, University of Laboratories, Royal Liverpool & Broadgreen University Hospitals University of Copenhagen, Copenhagen, DENMARK, 4Department Oslo, Oslo, NORWAY, 5Perelman School of Medicine at the University Trust, Liverpool, UNITED KINGDOM. of Occupational and Environmental Medicine, Copenhagen Serum succinate as a marker of tumor metabolic burden of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA, University Hospital, Bispebjerg and Frederiksberg Hospital, 6 Copenhagen, DENMARK, 5Department of Endocrinology, in patients with 18F-FDG-PET positive sporadic or SDHB- Department of Oncology, Oslo University Hospital, Oslo, NORWAY, EPS-054 7Department of Radiotherapy, Oslo University Hospital, Oslo, Copenhagen University Hospital, Herlev Hospital, Herlev, mutated metastatic malignant pheochromocytomas/ NORWAY. V/Q scintigraphy and SPECT for the diagnosis of Chronic DENMARK. paragangliomas 1 2 3,4 5,2 6 1 Thromboembolic Pulmonary Hypertension: Experience H. Tissot , C. Lamy , M. Faron , A. Paci , E. Baudin , S. Leboulleux , OP-278 EPS-057 J. Hadoux6, S. Broutin5,2; from a reference centre 1Nuclear Medecine Department, Gustave Roussy, Villejuif, FRANCE, D. Vega, P. Pilkington Woll, V. Godigna Guilloteau, A. Galiana Investigation of parameters impacting 68Ga-DOTATOC PET The improvement of hibernating myocardium analyzed by 2INSERM, U1030, Villejuif, FRANCE, 3Department of Surgical Moron, S. Ruiz Solis, E. Martinez Albero, M. J. Tabuenca Mateo, M. D. 99m 18 Oncology, Gustave Roussy, Villejuif, FRANCE, 4Department of image quality and quantification: a clinical and phantom Martin Ferrer, M. P. Sarandeses Fernandez, A. Gomez Grande, J. M. gated Tc-sestamibi SPECT/CT and gated F-FDG PET/CT Biostatistics and Epidemiology, INSERM U1018 CESP, Oncostat, study Estenoz Alfaro; in patients with ischemic cardiomyopathy were associated Gustave Roussy, Villejuif, FRANCE, 5Department of Pharmacology, M. Bernardini, C. Smadja, N. Ghazzar; Hospital 12 de Octubre, Madrid, SPAIN. with the reversal of left ventricular remodeling after Gustave Roussy, University Paris-Saclay, Villejuif, FRANCE, European Hospital Georges Pompidou, Paris, FRANCE. revascularization 6Endocrine Oncology, Gustave Roussy, Villejuif, FRANCE. EPS-055 Y. Lu 1, J. Cao2, J. Tian1, Y. Tian1, W. Dong1, M. Hacker3, R. Dong2, X. Li1, OP-279 X. Zhang1; 1 OP-273 Nuclear medicine techniques for the assessment of cardiac Department of Nuclear Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA, 2Department of Cardiac Surgery, Comparison between metastatic neuroendocrine tumours sarcoidosis and cardiac amyloidosis.Preliminary results of Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA, 68Ga-DOTATOC PET/CT in patients with paraganglioma/ 99m and carcinomas somatostatin receptor expression on Tc- a European survey 3Division of Nuclear Medicine, Department of Biomedical Imaging pheochromocytoma. Interest of combination with other EDDA/HYNIC-TOC SPECT/CT with immunohistochemical, P. Erba1, R. Slart2, A. Saraste3, O. Gheysens4, J. Bucerius5, M. Dweck6, F. and Image-guided Therapy. Medical University of Vienna, Vienna, PET/CT methods according to a monocentric experience histopathological and laboratory parameters Hyafil7, A. Glaudemans2, H. Verberne8, M. Lubberink9, O. Gämperli10, AUSTRIA. 11 12 C. Morvant, D. Drui, C. Ferron, M. Le Bras, E. Langlois-Mourrain, F. G. Sipka, Z. Besenyi, I. Farkas, T. Czékus, Z. Mikó, A. Bakos, S. Urbán, G. Habib , A. Gimelli ;

92 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 93 Actinium-225 and Bismuth-213 EPS-058 EPS-063 Imaging Pulmonary Fungal Infections M. Ooms; SCK-CEN Academy, Brussels, BELGIUM. Combining Genetic Evidence with Myocardial Perfusion SPECT Myocardial Blood Flow and Calcium Scoring Friday, October 23, 2020, 13:50 - 15:20 601 Channel 2 Imaging: Correlations Between RAAS-related Gene measurement in patients referred for Coronary Artery Polymorphisms and SPECT Quantitative Parameters Disease screening CME 5: Imaging Hepatobiliary and Pancreatic G. Angelidis1, M. Samara1, M. Papathanassiou1, M. Satra1, V. M. Bailly1, F. Thibault1, M. Courtehoux2, G. Metrard1, D. Tumours - Pearls, Patterns and Pitfalls Valotassiou1, I. Tsougos1, D. Psimadas1, C. Tzavara1, S. Alexiou1, J. Angoulvant2, M. Ribeiro2; Koutsikos2, N. Demakopoulos3, G. Giamouzis1, F. Triposkiadis1, J. 1CHR Orléans, Orleans, FRANCE, 2CHRU Tours, Tours, FRANCE. OP-287 1 4 1 Friday, October 23, 2020, 13:50 - 15:20 Skoularigis , P. Kollia , P. Georgoulias ; Channel 1 1University of Thessaly, Larissa, GREECE, 2401 General Military Current Dilemmas in Fungal Treatment Hospital, Athens, GREECE, 3Army Share Fund Hospital (417 EPS-064 M. Sanguinetti; Universita Cattolica del S.Cuore (UNICATT), Dept. NIMTS), Athens, GREECE, 4National & Kapodistrian University, of Laboratory Sciences and Infectious Diseases,Rome,ITALY. Athens, GREECE. The Dark Side Of Atrial Uptake On 99mTc-3,3- Diphosphono-1,2-Propanodicarboxylic Acid (99mTC- OP-283 OP-288 EPS-059 EANM’20 EANM’20 DPD) Bone Scintigraphy In Patients With Cardiac EANM’20 What Do we Need from Imaging in Hepatobiliary and Preclinical Tools to Study Fungal Infections Amyloidosis Gated myocardial SPECT results in patients with chronic Pancreatic Tumours - A Clinician’s View G. Vande Velde; Katholieke Universiteit (KU) Leuven, Dept. Imaging R. Mei1, I. Diemberger2, R. Bonfiglioli1, A. Paccagnella1, F. Mattana1, and Pathology, Leuven, BELGIUM. heart failure before and after cardiac contractility C. Gagliardi2, G. Caponetti2, S. Longhi2, P. Massa2, G. Saturi2, M. C. Carvalho; Champalimaud Clinical Centre, Digestive Unit, Lisbon, modulator implantation 2 2 1 PORTUGAL. Sguazzotti , N. Galiè , S. Fanti ; OP-289 A. Ansheles, V. Amanatova, T. Uskach, S. Tereschenko, V. 1Nuclear Medicine Policlinico S.Orsola-Malpighi, Bologna, WORLD LEADING MEETING WORLD LEADING MEETING Sergienko; ITALY, 2Cardio-Thoracic and Vascular Building, Department of OP-284 National Medical Research Center of Cardiology, Ministry of Experimental, Diagnostic and Specialty Medicine, Bologna, ITALY. In vivo Imaging of Host Responses Healthcare, Moscow, RUSSIAN FEDERATION. Abdominal 3T MRI and Spectral CT Imaging of Pancreatic L. Carlin; Beatson Institute for Cancer Research, Glasgow, UNITED and Biliary Cancer - Review of Imaging Techniques, KINGDOM. EPS-066 Protocols and Findings EPS-060 R. Braren; Technische Universität München, Klinikum rechts der OP-290 The Importance Of Monoclonal Proteins Determination Isar, Institute of Diagnostic and Interventional Radiology, Munich, Stress gated blood pool SPECT: the prognosis of left For The Correct Diagnosis Of Transthyretin Cardiac GERMANY. Imaging Pulmonary Infections in the Clinic ventricle repeated remodeling in 12 month after surgical Amyloidosis By [99mTc]Tc-diphosphonates M. Gunzer; University Duisburg-Essen, Center for Medical correction of ischemic cardiomyopathy A. Roteta, D. Nogueira Souto, A. Andrés Gracia, L. Tardin Cardoso, Biotechnology, Essen, GERMANY. V. Shipulin, K. Zavadovsky, S. Andreev, A. Pryakhin, V. M. Shipulin; P. Razola Alba, M. Delgado Castro, T. Escalera Temprado, E. Prats OP-285 Cardiology Research Institute, Tomsk National Research Rivera, M. Abós Olivares; Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN Clinic Hospital “Lozano Blesa”, Zaragoza, SPAIN. Hepatic and Biliary System - Pearls, Patterns and Pitfalls of 603 FEDERATION. PET/CT Imaging Joint Symposium 10 (EANM/JSNM): Nuclear S. Carrilho Vaz; Champalimaud Clinical Centre, Nuclear Medicine - Cardiology Beyond Perfusion Imaging 404c Radiopharmacology, Lisbon, PORTUGAL. EPS-061 Mini Course 3: Alpha Emitters in Therapy OP-286 Friday, October 23, 2020, 13:50 - 15:20 Channel 3 Patient Safety in MPI: Role of the Radiopharmacist in a Friday, October 23, 2020, 11:00 - 11:50 Pancreas and Gallbladder- Pearls, Patterns and Pitfalls of Multidisciplinary Team Channel 4 A. Jimenez-Heffernan, C. Salgado-Garcia, T. Aroui-Luquin, E. PET/CT Imaging Sanchez de Mora, A. Amr-Rey, A. Ramirez-Navarro; G. Gnanasegaran; Royal Free London NHS Foundation Trust, Hospital Juan Ramon Jimenez, Huelva, SPAIN. Department of Nuclear Medicine, London, UNITED KINGDOM. OP-291

EPS-062 OP-281 Imaging Innervation with MIBG 602 K. Nakajima; Department of Functional Imaging and Artificial Added value of Myocardial Flow Reserve measurement Radionuclide Therapy with Radium-223 of Metastatic Joint Symposium 9 (EANM/ESMI/ESCMID): Intelligence, Kanazawa University, Kanazawa, JAPAN. during SPECT perfusion: correlation with invasive Castration-Resistant Prostate Cancer OP-292 coronary angiography V. Frantellizzi; Department of Molecular Medicine, Sapienza Diagnostic Application of BMIPP Imaging in Clinical M. Bailly1, F. Thibault1, M. Courtehoux2, G. Metrard1, D. University of Rome, Rome, ITALY. Angoulvant2, M. Ribeiro2; Practice 1CHR Orléans, Orleans, FRANCE, 2CHRU Tours, Tours, FRANCE. OP-282 T. Chikamori; Department of Cardiology, Tokyo Medical University, Tokyo, JAPAN. An Overview of Targeted Alpha Therapy with

94 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 95 authority of South Savo, Mikkeli, FINLAND. 1Department of Translational Medicine, Malmö, SWEDEN, F. Giesel1, S. Adeberg1, M. Syed1, T. Lindner1, L. Jiménez-Franco2, OP-293 2Radiation Physics, Skåne University Hospital and Lund University, F. Staudinger1, E. Tonndorf-Martini1, S. Regnery1, S. Rieken3, R. El Lund, SWEDEN, 3Department of Urology, Skåne University Hospital Shafie1, M. Roehrich1, P. Flechsig1, A. Kluge4, A. Altmann1, J. Debus1, Imaging Cardiac Amyloidosis with Bone Tracers OP-300 and Und University, Malmö, SWEDEN, 4Department of Urology, U. Haberkorn1, C. Kratochwil1; K. Wechalekar; Department of Nuclear Medicine, Royal Brompton Skåne University Hospital and Lund University, Malmö, SWEDEN, 1University Hospital Heidelberg, Heidelberg, GERMANY, 2ABX CRO 18 5 3 Hospital, Imperial College, London, UNITED KINGDOM. Reduction of [ F]-FDG activity applied is feasible in clinical Department of Urology, Sahlgrenska University Hospital, University advanced pharmaceutical services, Dresden, GERMANY, University routine for 3D TOF PET/CT scanner: A retrospective patient of Gothenburg, Gothenburg, SWEDEN, 6Clinical Physiology and Hospital Goettingen, Goettingen, GERMANY, 4ABX advanced OP-294 study Nuclear Medicine, Skåne University Hospital and Wallenberg Center pharmaceutical services, Dresden, GERMANY. J. Pilz, L. Hehenwarter, G. Rendl, G. Schweighofer-Zwink, C. Pirich; for Molecular Medicine, Lund University, Malmö, SWEDEN. Imaging Endocarditis with Radiolabeled WBC Department of Nuclear Medicine and Endocrinology, University OP-309 Hospital Salzburg, Paracelsus Medical University, Salzburg, OP-305 604 AUSTRIA. Reversing cold tumor microenvironment with targeted Technologists Oral Presentations 1 - Featured A PET Technologist’s Role in Imaging Research alpha-therapy Session: MATTER - MultidisciplinAry D. Ribeiro, R. Janisch; J. Perrin, M. Capitao, S. Gouard, C. Maurel, C. Louvet, M. Lancien, F. TechnologisT rEseaRch OP-301 Invicro, A Konica Minolta Company, London, UNITED KINGDOM. Bruchertseifer, A. Morgenstern, M. Cherel, J. Gaschet, Y. Guilloux; INSERM, Nantes, FRANCE. EANM’20 EANM’20 EANM’20 Dose reduction in FDG-PET by reconstruction optimization Friday, October 23, 2020, 13:50 - 15:20 using resolution modelling M2M Track - Featured Session: Immune and OP-310 Channel 4 Microenvironment Imaging A. Tegelaar - Kuiper1, S. Koenders1,2, D. Koopman1, P. G. Sanches3, B. N. Vendel1, H. Arkies1, J. A. van Dalen4; PET Imaging of PD-L1 Expression in NSCLC: 1 Friday, October 23, 2020, 13:50 - 15:20 Department of Nuclear Medicine, Isala Hospital, Zwolle, Channel 5 Pharmacokinetic Comparison of an Antibody and its Fab WORLD LEADING MEETING 2 WORLD LEADING MEETING NETHERLANDS, Technical Medical Centre, University of Twente, Fragment 3 OP-295 Enschede, NETHERLANDS, Health Systems, Philips Benelux, A. Bouleau1, H. Nozach2, M. Richard1, S. Dubois2, G. Torquet1, B. 4 Eindhoven, NETHERLANDS, Department of Medical Physics, Isala Kuhnast1, B. Maillère2, V. Lebon1, C. Truillet1; Introduction Hospital, Zwolle, NETHERLANDS. 1Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Service P. Fragoso-Costa; Clinic for Nuclear Medicine, University Hospital OP-306 Hospitalier Frédéric Joliot, Orsay, FRANCE, 2Département Essen, Essen, GERMANY. Optimal Balance between Patient Comfort, Received Médicaments et technologies pour la santé, SIMoS, Université Paris- Dose and Image Quality for Block Sequential Regularized Immunotherapy and the TME - Expanding the Scope Saclay, CEA-Saclay, Gif-sur-Yvette, FRANCE. OP-296 Expectation Maximization Reconstruction and Digital PET/ M. Schottelius; CHUV, Lausanne, SWITZERLAND OP-311 CT The effect of Artificial Intelligence (AI) on lung perfusion OP-307 D. Klagyvik1, F. Nagy2, A. Ács-Nagy1, P. Szabó1, I. Garai2, A. Forgács2, 90Y-NM600 Combined with Bempegaldesleukin (NKTR-214) SPECT-CT segmentation analysis Á. K. Krizsán2; FAPI PET/CT: Tracer- biodistribution in patients with head A. Willems van Beveren, G. T. Nauta, A. van Erp-Zeilstra, A. Heus, J. 1ScanoMed Nuclear Medicine Centers, Budapest, HUNGARY, Improves Response to Immune Checkpoint Inhibition in a Pruim; 2ScanoMed Nuclear Medicine Centers, Debrecen, HUNGARY. and neck-, lung-, pancreatic- and colorectal- cancer Syngeneic Murine Model of Head and Neck Cancer UMCG NGMB, Groningen, NETHERLANDS. F. Staudinger1, J. Schlittenhardt1, T. Lindner1, H. Rathke1, M. J. Grudzinski1, A. Bates1, R. Hernandez1, G. Sosa1, E. Nystuen1, S. Röhrich1, S. Körber2,3,4, J. Debus2,3,4, C. Kratochwil5,6, U. Haberkorn1,6,7, Emma1, E. G. Sumiec1, A. Pieper1, R. Patel2, E. Aluicio-Sarduy1, J. OP-297 OP-303 F. Giesel1,6,8; Engle1, I. Marsh1, B. Bednarz1, J. Weichert1, Z. Morris1; 1Department of Nuclear Medicine, Heidelberg University Hospital, 1University of Wisconsin, Madison, WI, UNITED STATES OF AMERICA,

The choice of colour scale for reconstruction of Image quality performance of Block Sequential Heidelberg, GERMANY, 2Department of Radiation Oncology, 2University of Pittsburgh, Pittsburgh, PA, UNITED STATES OF 68Ga-PSMA-11 PET/CT images impacts upon diagnostic Regularized Expectation Maximization and digital PET/CT Heidelberg University Hospital, Heidelberg, GERMANY, 3National AMERICA. 4 performance with the Kyoto IB-10 brain phantom Center for Tumor diseases (NCT), Heidelberg, GERMANY, Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, GERMANY, R. Schepers1, C. Sachpekidis1,2, J. Hünermund1, K. P. Bohn1, V. Fech1, A. Ács-Nagy1, D. K. Klagyvik1, F. Nagy2, P. Szabó1, I. Garai2, Á. K. OP-312 5Department of Nuclear Medicine, University Hospital Heidelberg, A. Rominger1, A. Afshar-Oromieh1, I. Alberts1, C. Mingels1; Krizsán2; Heidelberg, GERMANY, 6Clinical Cooperation Unit Nuclear Medicine, 18 1Department of Nuclear Medicine, Inselspital, Bern University 1ScanoMed Kft., Budapest, HUNGARY, 2ScanoMed Kft., Debrecen, F-FDG-PET for the Evaluation of Response to Therapy German Cancer Research Center (DKFZ), Heidelberg, GERMANY, Hospital, University of Bern, Bern, SWITZERLAND, 2Clinical HUNGARY. of Triple-NegativeBreast Cancer Bearing Nude Mice 7Translational Lung Research Center Heidelberg (TLRC), German Cooperation Unit Nuclear Medicine, German Cancer Research to Pembrolizumab(anti-programmed death 1 (PD-1) Center for Lung Research (DZL), Heidelberg, GERMANY, 8Clinical Center, Heidelberg, GERMANY. Cooperation Unit Radiation Oncology, German Cancer Research monoclonal antibody) OP-304 1 2 1 1 OP-298 Center (DKFZ), Heidelberg, GERMANY. L. Shi , S. An , J. Fu , F. Wang ; 1Nanjing First Hospital, Nanjing Medical University, Nanjing, A Comparative Study Between Conventional & Digital CHINA, 2Department of Nuclear Medicine, Ren Ji Hospital, School of Hand-foot contamination monitoring in hospital OP-308 PET-CT For Detection of Lymph Node Metastases Medicine, Shanghai, CHINA. radiopharmacy laboratory: one-year data in Patients with High-Risk Prostate Cancer Using 18 1 1 1 2 2 FAPI-74 PET/CT Using Either F-AlF or Cold-kit K. Levänen , C. Lehtinen , M. Kullberg , N. Hänninen , J. Heikkinen ; 18F-Flourocholine 1 68Ga-labeling: Biodistribution, Radiation Dosimetry and Department of Radiology and Nuclear Medicine, Social and M. Bjöersdorff1, J. Oddstig2, A. Bjartell3, C. Puterman4, H. Kjölhede5, healtcare joint authority of South Savo, Mikkeli, FINLAND, E. Trägårdh6; Tumor Delineation in Lung Cancer Patients 2Department of Medical Physics, Social and healtcare joint

96 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 97 Freiburg, Faculty of Medicine, Freiburg, GERMANY. Leuven, BELGIUM, 4UCB Pharma, Braine-l’Alleud, BELGIUM. OP-313 OP-318

Immune-checkpoint blockade enhances225Ac-PSMA617 Improvement of FDG PETCT and MRI concordance in OP-322 OP-326 efficacy in a mouse model of prostate cancer Temporal Lobe Epilepsy Pre-surgical Assessment using 123 K. Lueckerath, K. Current, C. E. Mona, L. Nyiranshut, F. Hikmat, C. G. Statistical Parametric Mapping Z-scores Quantification of 18F-Florbetaben amyloid PET images in Reliability of occipital reference region in [ I]-FP-CIT Radu, J. Czernin; M. Kershaw1, H. Amada2, L. Yiping3, V. Sawlani4, S. Hughes4; patients with Alzheimer’s disease SPECT University of California Los Angeles, Los Angeles, CA, UNITED STATES 1University of Birmingham, Birmingham, UNITED KINGDOM, N. H. Patel1, L. Perry1, J. Lilja2,3, M. Golemme1, H. McMeekin4, L. Alves1, T. Noponen1,2, E. Jaakkola3, E. Mäkinen3, M. Eklund3, S. Nuuttila3, K. OF AMERICA. 2Sandwell and West Birmingham NHS Trust, Birmingham, UNITED K. S. Nijran1, P. Malhotra1,5, R. J. Perry1,5, Z. Win1; Lindholm3, J. Joutsa3, M. Seppänen1,4, V. Kaasinen3; KINGDOM, 3Fudan University, Fudan, CHINA, 4University Hospitals 1Imperial College Healthcare NHS Trust, London, UNITED KINGDOM, 1Department of Clinical Physiology and Nuclear Medicine, Turku OP-315 Birmingham, Birmingham, UNITED KINGDOM. 2Uppsala University, Uppsala, SWEDEN, 3Hermes Medical Solutions, University Hospital, Turku, FINLAND, 2Department of Medical Stockholm, SWEDEN, 4Hermes Medical Solutions, London, UNITED Physics, Turku University Hospital, Turku, FINLAND, 3Department of Imaging tumour CD8+ T-cell infiltrates following KINGDOM, 5Imperial College London, London, UNITED KINGDOM. Clinical Neurosciences, Turku University Hospital and University of radioimmunotherapy in an immunocompetent mouse OP-319 Turku, Turku, FINLAND, 4Turku PET Centre, Turku, FINLAND. model OP-323 1 1 1 1 2 Clinical impact of digital vs conventional healthy control OP-327 EANM’20 EANM’20 B. Cornelissen , G. Dias , E. O’Neill , C. Bristow , F. Salazar , R. EANM’20 18 Tavare2, N. Sibson1, A. Wu2; databases for semi-quantitative analysis of brain 18F-FDG Correlation assessment between brain F-Florbetaben 1University of Oxford, Oxford, UNITED KINGDOM, 2City of Hope, PET scans PET/CT SUVR late acquisitions and parametric images Multicenter intensity harmonization of dopamine SPECT Duarte, CA, UNITED STATES OF AMERICA. M. Doyen1, E. Mairal2, T. Rivasseau Jonveaux3, C. Malaplate- obtained from dynamic acquisitions compartmental studies without previous in-site scanner calibration 1 2 3 4 Armand4, V. Roch5, G. Karcher5, E. Guedj6, A. Verger1; analysis J. Silva-Rodríguez , A. Moscoso , A. Niñerola-Baizán , J. Cortés , B. 1 4 4 1 Department of Nuclear Medicine & Nancyclotep Molecular 1,2,3 1 1 1 1 1 Aradas-Cabado , Á. Ruibal , P. Aguiar ;

WORLD LEADING MEETING S. Ferreira , F. Oliveira , M. Silva , R. Oliveira , Â. Silva , C. Oliveira , WORLD LEADING MEETING OP-316 1 Imaging platform, CHRU Nancy; IADI, INSERM U1254, University J. Castanheira1, S. Vaz1, N. Matela3, P. Maniawski4, D. C. Costa1; Health Research Institute of Santiago de Compostela, Santiago 2 2 of Lorraine, Nancy, FRANCE, Department of Nuclear Medicine, 1Champalimaud Centre for the Unknown, Champalimaud de Compostela, SPAIN, Wallenberg Centre For Molecular and Development of [18F]AlF-NODA-CTHRSSVVC for imaging 3 3 CHRU Nancy, Nancy, FRANCE, Department of Geriatrics, Université Foundation, Lisbon, PORTUGAL, 2Philips Portuguesa S.A., Lisbon, Translational Medicine, Gothenburg, SWEDEN, Nuclear Medicine 4 M2 macrophages with PET de Lorraine, CHRU Nancy; 2LPN, University of Lorraine, Nancy, PORTUGAL, 3Institute of Biophysics and Biomedical Engineering, Department, Hospital Clinic, Barcelona, SPAIN, Nuclear Medicine 4 B. Fernandes1, I. F. Antunes2, C. M. M. Jeckel3, E. F. J. de Vries2, P. H. FRANCE, Department of Biochemistry, Molecular Biology and Faculty of Sciences of the University of Lisbon, Lisbon, PORTUGAL, Department, University Hospital of Santiago de Compostela, Elsinga2; Nutrition, CHRU Nancy; AFPA laboratory, ENSAIA, University of 4Philips Medical Systems, Cleveland, OH, UNITED STATES OF Santiago de Compostela, SPAIN. 5 1UMCG, Groningen, NETHERLANDS, 2University of Groningen, Lorraine, Nancy, FRANCE, Department of Nuclear Medicine & AMERICA. University Medical Center Groningen (UMCG), Groningen, Nancyclotep Molecular Imaging platform, CHRU Nancy, Nancy, OP-328 NETHERLANDS, 3Graduate Program in Biomedical Gerontology, FRANCE, 6Department of Nuclear Medicine, Timone University School of Medicine, Pontifical Catholic University of Rio Grande do Hospital; CERIMED, Aix-Marseille Université; CNRS, Ecole Centrale de OP-324 Partial volume correction improves the diagnostic capacity Sul (PUCRS), Porto Alegre, BRAZIL. Marseille, UMR 7249, Institut Fresnel, Marseille, FRANCE. of quantitative amyloid PET imaging for both clinical and 18 Dual-time-window dynamic [ F]MK-6240 PET protocols biomarker-assisted criteria for Alzheimer’s disease 606 OP-320 for improved quantification in longitudinal studies and M. Shekari1,2,3, G. Salvadó1,3, A. Sala4,5,6, E. Rodriguez-Vieitez4, J. L. Cutting Edge Science Track - TROP Session: stroke patients Molinuevo1,2,3, J. D. Gispert1,2,3, for the ADNI study; Understanding gender pattern differences in 1 Image Processing - Neurology G. D. Kolinger1, D. Vállez García1, R. Boellaard1,2, T. G. Lohith3, E. D. BarcelonaBeta Brain Research Center, Barcelona, SPAIN, 11C-Methionine PET Glioma patients with radiomics Hostetler3, C. Sur3, A. Struyk3, M. Koole4; 2Universitat Pompeu Fabra, Barcelona, SPAIN, 3Hospital del Mar analysis 1Medical Imaging Center, University Medical Center Groningen, Medical Research Institute (IMIM), Barcelona, SPAIN, 4Department Friday, October 23, 2020, 13:50 - 15:20 2 Channel 6 L. Papp, S. Rasul, M. Weber, M. Grahovac, T. Beyer, M. Hacker, T. University of Groningen, Groningen, NETHERLANDS, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Traub-Weidinger; of Radiology and Nuclear Medicine, Amsterdam University Medical Stockholm, SWEDEN, 5Vita-Salute San Raffaele University, Milan, Medical University of Vienna, Vienna, AUSTRIA. Centers, location VU Medical Center, Amsterdam, NETHERLANDS, ITALY, 6In Vivo Human Molecular and Structural Neuroimaging 3Merck & Co., Inc., Kenilworth, NJ, UNITED STATES OF AMERICA, Unit, Division of Neuroscience, IRCCS San Raffaele Scientific 4Department of Nuclear Medicine and Molecular Imaging, KU Institute, Milan, ITALY. OP-317 OP-321 Leuven, Leuven, BELGIUM.

Multimodal assessment of test-retest reliability using Age correction has only minor impact on the diagnostic OP-325 functional PET, ASL and BOLD imaging in a complex visuo- accuracy of the specific binding ratio in dopamine spatial motor task transporter SPECT in the diagnosis of parkinsonian Optimizing of the white matter reference region for 11 L. Rischka1, G. M. Godbersen1, V. Pichler2, P. Michenthaler1, S. syndromes synaptic density imaging with [ C]UCB-J PET 1 2,3 4 4 4 Klug1, M. Klöbl1, V. Ritter1, W. Wadsak2, M. Hacker2, S. Kasper1, R. I. Apostolova1, H. Schmitz-Steinkrüger1, C. Lange2, L. Frings3, S. N. Mertens , L. Michiels , B. Lacroix , J. Mercier , R. P. Maguire , R. 2,3 1 1 Lanzenberger1, A. Hahn1; Klutmann1, S. Hellwig3, P. T. Meyer3, R. Buchert1; Lemmens , K. Van Laere , M. Koole ; 1 1Department of Psychiatry and Psychotherapy, Medical University 1University Hospital Hamburg Eppendorf, Hamburg, GERMANY, Nuclear Medicine and Molecular Imaging, University Hospital and 2 of Vienna, Vienna, AUSTRIA, 2Department of Biomedical Imaging 2Charité - Universitätsmedizin Berlin, Corporate Member of Freie KU Leuven, Leuven, BELGIUM, UZ Leuven/KU Leuven, Neurology, 3 and Image-guided Therapy, Division of Nuclear Medicine, Medical Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Neurosciences, Experimental Neurology, Leuven, BELGIUM, VIB, University of Vienna, Vienna, AUSTRIA. Institute of Health, Berlin, GERMANY, 3Medical Center - University of Center for Brain & Disease Research, Laboratory of Neurobiology,

98 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 99 607 OP-335 OP-340 OP-347 Pitfalls & Artefacts 3: Dosimetry as Part of Patient Care In-vivo D’Amico score for predicting low-vs-high risk and Management impact and detection rate of 18F- Prostate- Do SUV values reflect completely accurate results biochemical recurrence in prostate patients from PET/MRI Specific Membrane Antigen (18F-PSMA) PET/CT imaging especially in pediatric cases? with machine learning for biochemically recurrent prostate cancer O. Ozmen1, S. Beykan2, E. Tatcı1; Friday, October 23, 2020, 13:50 - 15:20 1 Channel 7 L. Papp, C. P. Spielvogel, D. Krajnc, M. Grahovac, T. Beyer, M. E. Panagiotidis, A. Paschali, A. Klampatsas, A. Pipintakou, A. University of Health Sciences Atatürk Chest Diseases and Thoracic Hartenbach, M. Hacker; Makridou, V. Chatzipavlidou; Surgery Training and Research Hospital, Ankara, TURKEY, 2Klinik Medical University of Vienna, Vienna, AUSTRIA. Theageneio Cancer Center, Thessaloniki, GREECE. fuer Nuklearmedizin Universitaetsklinikum Wuerzburg, Wuerzburg, GERMANY.

OP-329 OP-336 609 OP-348

TROP Session: Nuclear Playground - Nuclear 18 Patient Specific Therapy in PRRT - The Bright Future The impact of 18F-Choline (FCH) PET/MRI on PSA response Medicine in Children and Adolescents F-FDG-PET/MR Semiquantitative Response Assessment M. Cremonesi; Istituto Europeo di Oncologia (IEO), Radiation in patients with oligometastatic prostate cancer (PCa) Methods in Paediatric Hodgkin Lymphoma Patients Research Unit, Milan, ITALY. 1 1 2 2 1 2 3 3 4,5

EANM’20 EANM’20 L. Evangelista , G. Cassarino , C. Lacognata , S. Da Pozzo , D. S. Gusella , A. Spimpolo , S. Berti , F. Menegatti , C. Campi , M. EANM’20 1 1 Friday, October 23, 2020, 13:50 - 15:20 6 7 3 3 Cecchin , P. Zucchetta ; Channel 9 Pillon , C. Giraudo , D. Cecchin , P. Zucchetta ; OP-330 1University of Padua, Padua, ITALY, 2Hospital of Padua, Padua, ITALY. 1Nuclear Medicine Unit, Ospedale di Bolzano, Bolzano, ITALY, 2Nuclear Medicine Unit, Department of Medicine, PhD Student Patient Specific Therapy with 177Lu PSMA OP-337 International PhD Program in Arterial Hypertension and Vascular Biology, University of Padova, Padua, ITALY, 3Nuclear Medicine WORLD LEADING MEETING 608 Clinical utility of PET/CT with 18F-FSU880 in patients OP-342 Unit, Department of Medicine, University of Padova, Padua, ITALY, WORLD LEADING MEETING 4 Clinical Oncology Track - Featured Session: BCR with biochemical recurrence after curative treatment of Department of Mathematics “Tullio Levi-Civita”, University of Padova, Padua, ITALY, 5Padova Neuroscience Center, University of Detection with Ga-PSMA and Beyond prostate cancer PET metabolic tumor volume as a prognostic factor in Padova, Padua, ITALY, 6Clinic of Paediatric Haematology-Oncology, Y. Nakamoto, Y. Shimizu, T. Ishimori, T. Otani, T. Saga; childhood rhabdomyosarcoma: a cohort study Department of Women’s and Children’s Health, University of Kyoto University, Kyoto, JAPAN. H. Fayolle1, N. Jehanno2, V. Cances-Lauwers3, M. Castex4, D. Padova, Padua, ITALY, 7Institute of Radiology, Department of Friday, October 23, 2020, 13:50 - 15:20 Orbach5, P. Payoux6, A. Hitzel1; Channel 8 Medicine, University of Padova, Padua, ITALY. 1Nuclear Medicine Department, CHU Purpan, Toulouse, FRANCE, OP-338 2Nuclear Medicine Department, Institut Curie, Paris, FRANCE, 3Epidemiology and Public Health department, Toulouse, FRANCE, OP-349 Impact of Targeted Molecular Imaging with 18F-PSMA-1007 4Pediatric Hemato-oncology Department, Toulouse, FRANCE, OP-331 and 68Ga-PSMA-11 PET/CT in Multimodal Evaluation of 5IREDO Oncology Center, PSL University, Institut Curie, Paris, Assessment of prognostic value of baseline 18FDG PET/ 6 Local Recurrence of Prostate Cancer FRANCE, ToNIC, INSERM, Toulouse, FRANCE. CT metabolic parameters (SUV max, MTV and TLG) and PET Tracer Landscape in Prostate Cancer 18 L. Dronka1,2, M. Radzina1,2, M. Tirane1,2, L. Zemniece1, M. Kalnina1,3, L. treatment response on FDG PET/CT scan in patients of I. Burger; University of Zurich, Deparment of Nuclear Medicine, 2,3 4 5 5 6 OP-344 Roznere , I. Briede , V. Lietuvietis , A. Freimanis , E. Vjaters ; Langerhan Cell histiocytosis Zurich, SWITZERLAND. 1Institute of Radiology, Pauls Stradins Clinical University Hospital, 18 M. Pereira, S. Shah, A. Puranik, A. Bedmutha, A. Agrawal, N. 2 Comparison of F-FDG PET/CT with Anatomic Imaging Riga, LATVIA, Riga Stradins University Radiology Research Purandare, V. Rangarajan; OP-333 3 Laboratory, Riga, LATVIA, Riga Stradins University Nuclear Methods in Pediatric Neuroblastoma Tata Memorial Hospital, HBNI, Mumbai, INDIA. Medicine Clinic, Riga, LATVIA, 4Center of Patology, Pauls Stradins M. Engin, A. Arcay, Z. G. Kiprak, C. N. Dundar Caglayan, G. G. Bural, Prospective Single Institution Study of F18-DCFPyL PET/CT Clinical University Hospital, Riga, LATVIA, 5Center of Urology, Riga A. Boz; in Biochemically Recurrent Prostate Cancer: An Analysis of East University Hospital, Riga, LATVIA, 6Center of Urology, Pauls Akdeniz university faculty of medicine nuclear medicine OP-350 Lesions Detection and Localization Stradins Clinical University Hospital, Riga, LATVIA. department, Antalya, TURKEY. Correlation between 18F-DOPA PET/CT findings and A. Iagaru, H. Song, H. Duan, C. Harrison, K. Guja, N. Hatami, B. Franc, J. Nguyen, F. Moradi, C. Mari, G. Davidzon; OP-339 OP-346 genetic mutation analysis in patients with persistent Stanford University, Stanford, CA, UNITED STATES OF AMERICA. hyperinsulinemic hypoglycemia Parameters Predicting [18F]PSMA-1007 scan Positivity and SIOPEN SCORING vs 3 Simplified Scoring Systems in S. Sagar, N. Damle, R. Sharma, K. Reddy, T. Subudhi, V. Jain, C. Bal, Type and Number of Detected Lesions in patients with Pediatric Patients with HR-NB-1 and L2-NB M. Tripathi, M. Jana; OP-334 Biochemical Recurrence of Prostate Cancer C. Olianti1, A. Martini1, R. Di Dato1, M. Allocca1, A. Tondo2, H. AIIMS, Delhi, INDIA. N. Ahmadi Bidakhvidi1, A. Laenen2, S. Jentjens1, C. M. Deroose1, K. Gauthier3; 64 The role of Cu-PSMA PET/CT in the early diagnosis of Van Laere1, C. Berghen3, K. Haustermans3, S. Joniau4, W. Everaerts4, 1University Hospital of Florence, Florence, ITALY, 2University Hospital prostate cancer recurrence: preliminary results on a K. Goffin1; Meyer of Florence, Florence, ITALY, 3Oscar Lamberet Center, Lille, OP-351 prospective cohort of 127 patients 1Nuclear Medicine, University Hospitals Leuven, Leuven, FRANCE. 2 Risk of structural persistent disease in pediatric patients S. Annunziata, R. Sciuto, S. Rea, A. Annovazzi, R. Pasqualoni, S. BELGIUM, Interuniversity Institute for Biostatistics and Statistical Bergomi, L. Romano, C. Mazzone, S. Di Traglia, G. Sanguineti; Bioinformatics, Leuven, BELGIUM, 3Radiation Oncology, University with low or intermediate risk differentiated thyroid cancer IRCCS Regina Elena National Cancer Institute, Rome, ITALY. Hospitals Leuven, Leuven, BELGIUM, 4Urology, University Hospitals M. Manganelli1, M. Klain1, E. Zampella1, F. Volpe1, L. Piscopo1, M. De Leuven, Leuven, BELGIUM.

100 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 101 Risi1, M. De Risi1, V. Gaudieri1, C. Nappi1, A. D’ Antonio1, S. Limone1, L. 3Neuroradiology Unit and CERMAC, IRCCS San Raffaele Scientific Medicine, University Hospital Würzburg, Würzburg, GERMANY, Anzalone1,3, L. Gianolli2, M. Picchio1,2; Pace2, A. Cuocolo1; Institute, Milan, ITALY. 5Department of Neuroradiology, University Hospital Würzburg, 1Vita-Salute San Raffaele University, Milan, ITALY,2 Nuclear Medicine 1Department of Advanced Biomedical Sciences, University Federico Würzburg, GERMANY, 6Department of Nuclear Medicine, University Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, II of Naples, Naples, ITALY, 2Department of Medicine, Surgery and Hospital Augsburg, Augsburg, GERMANY. 3Neuroradiology Unit and CERMAC, IRCCS San Raffaele Scientific Dentistry, University of Salerno, Salerno, ITALY. OP-356 Institute, Milan, ITALY.

Photopenic defects in gliomas with amino-acid PET and OP-359 OP-352 relative prognostic value: a multicentric 11C-Methionine 611 18 18 and 18F-FDOPA PET experience Primary diagnosis of low-grade glioma: F-FET or F-FCH e-Poster Presentation Session 5: The Thyroid and Renogram Image Features and the Reproducibility of A. Verger1, T. Zaragori1, A. Castello2, E. Guedj3, A. Girard4, N. Galldiks5, PET? A pilot study its Neighbours (The Parathyroids) Differential Renal Function Measurements N. Albert6, E. Lopci2; M. Hodolic1, A. Golubic2, A. Misir Krpan3, M. Zuvic2, M. Baucic3, G. A. Brink1, M. Levin1, E. Libhaber2, M. D. Mann1; 1Department of Nuclear Medicine and Nancyclotep Imaging Mrak4, J. Nemir4, D. Huic2; 1 2 1 Friday, October 23, 2020, 13:50 - 15:20 Red Cross War Memorial Children’s Hospital, Department of Platform, CHRU Nancy, Nancy, FRANCE, Nuclear Medicine Nuclear Medicine Department, Faculty of Medicine and Dentistry, Channel 11 Paediatrics, University of Cape Town, Cape Town, SOUTH AFRICA, Department, Humanitas Clinical and Research Hospital, Milan, Palacký University Olomouc, Olomouc, CZECH REPUBLIC, 2School of Clinical Medicine and Health Sciences Research Office, ITALY, 3Department of Nuclear Medicine, Assistance Publique 2Department of Nuclear Medicine and Radiation Protection, Faculty of Health Sciences, University of the Witwatersrand, Hôpitaux de Marseille, Timone University Hospital, Marseille, University Hospital Centre Zagreb, Zagreb, CROATIA, 3Department EANM’20 EANM’20 EANM’20 Johannesburg, SOUTH AFRICA. FRANCE, 4Department of Nuclear Medicine, Eugène Marquis Center, of Oncology, University Hospital Centre Zagreb, Zagreb, CROATIA, Rennes 1 University, Rennes, FRANCE, 5Dept. of Neurology, Faculty 4Department of Neurosurgery, University Hospital Centre Zagreb, OP-353 of Medicine and University Hospital Cologne, University of Cologne, Zagreb, CROATIA. EPS-071 Cologne, GERMANY, 6Department of Nuclear Medicine, University DMSA renal investigations performed with a 360° Hospital, LMU Munich, Munich, GERMANY. OP-360 Association between clinical and tumor features with WORLD LEADING MEETING whole-body CZT SPECT camera as compared with the postoperative thyroglobulin in pediatric papillary thyroid WORLD LEADING MEETING conventional method based on planar images from an OP-357 Is there a need for premedication with Carbidopa for static cancer 18 Anger camera and dynamic F-FDOPA PET imaging of brain tumors? T. Tian, B. Liu; 11C-Methionine Positron Emission Tomography/ A. Bahloul, L. Imbert, G. Karcher, P. Marie, A. Verger; M. Bros, T. Zaragori, F. Rech, M. Blonski, L. Taillandier, A. Verger; West China Hospital, Sichuan University, Chengdu, CHINA. Nancy University Hospital, Vandoeuvre Les Nancy, FRANCE. Computed Tomography (PET/CT): a prognostic factor Centre Hospitalier Régional Universitaire de Nancy, Nancy, FRANCE. for disease progression and survival in patients with OP-361 EPS-072 suspected recurrence of glioma M. Mattoli1, V. Scolozzi2, F. Cocciolillo2, I. Marini2, G. Trevisi3, M. 610 Multicentre evaluation of the clinical impact of 18F-FDOPA Radiation dose to family members during hospitalization Featured Session: Molecular Brain Tumour Caulo4, A. Saponiero5, M. Balducci6, M. Calcagni7; Imaging 1Department of Neurosciences, Imaging and Clinical Sciences, “G. brain PET in the management of high grade gliomas of pediatric thyroid cancer patients treated with d’Annunzio” Chieti-Pescara Universit, Chieti, ITALY, 2Fondazione J. Darcourt1, J. Gal1, R. Schiappa1, V. Bourg2, L. Taillandier3, F. Le radioactive iodine Policlinico Universitario A. Gemelli IRCCS, UOC di Medicina Jeune4, L. Collombier5, A. Kas6, A. Verger3; H. Tissot1, T. Henry1, A. Cosse2, L. Lamartina3, M. Terroir1, J. Hadoux3, Friday, October 23, 2020, 13:50 - 15:20 1 2 4 3 5 2 1 Channel 10 Nucleare, Dipartimento di Diagnostica per Immagini, Radioterapia Centre Antoine Lacassagne - UCA, Nice, FRANCE, CHU - UCA, Nice, D. Hartl , E. Baudin , M. Schlumberger , N. Guilabert , S. Leboulleux ; Oncologica ed Ematologia, Rome, ITALY, 3Neurosurgical Unit, FRANCE, 3CHRU, Nancy, FRANCE, 4Centre Eugène Marquis, Rennes, 1Nuclear Medecine Department, Gustave Roussy, Villejuif, Presidio Ospedaliero Santo Spirito, Pescara, ITALY, 4Department FRANCE, 5CHU, Nîmes, FRANCE, 6CHU Hôpital Pitié-Salpêtrière, Paris, FRANCE, 2Service de Radioprotection, Gustave Roussy, Villejuif, of Radiology, University “G. d’Annunzio” of Chieti, Chieti, ITALY, FRANCE. FRANCE, 3Endocrine Oncology, Gustave Roussy, Villejuif, FRANCE, 5UOSD di Oncologia, Dipartimento di Oncologia, Presidio 4Department of Head and Neck Oncology, Thyroid Surgery Unit, OP-354 Cassia - S. Andrea - ASL RM1, Rome, ITALY, 6Fondazione Policlinico OP-363 Gustave Roussy, Villejuif, FRANCE, 5Departments of Nuclear Universitario A. Gemelli IRCCS, UOC Radioterapia Oncologica Medicine and Endocrine Oncology, Gustave Roussy and University Amino Acid PET of Brain Tumours - An Update Dipartimento di Diagnostica per immagini, Radioterapia Imaging of androgen receptor by [18F]-FDHT PET/CT in Paris-Saclay, Villejuif, FRANCE. N. Galldiks; University Hospital Cologne, Department of Neurology, Oncologica ed Ematologia, Rome, ITALY, 7Istituto di Medicina patients with GBM Cologne, GERMANY Nucleare, Università Cattolica del Sacro Cuore, Rome, ITALY. O. Shamni1, N. Zalcman1, A. Mordechai1, S. Moscovici1, C. EPS-073 Alexandre1, Y. Shoshan1, T. Shahar2, H. Charbit1, M. Guterman1, I. OP-355 OP-358 Paldor1, E. Mishani1, A. Lossos1, M. Orevi1, I. Lavon1; Post-therapeutic dosimetry and thyroglobulin 1Hadassah medical center, Jerusalem, ISRAEL, 2Shaare Zedek concentrations are predictors of thyroid remnant tissue 18 Spatial relationship between brain tumor regions assessed Clinical value of F-FET-PET/CT in pediatric patients with medical center, Jerusalem, ISRAEL. after radioiodine therapy by 11C-Methionine and perfusion weighted imaging (PWI) central nervous system tumors M. Herchuelz1, I. Duran Derijckere1, B. Vanderlinden1, G. Costante2, in neuro-oncological lesions assessed by fully hybrid PET/ O. Kertels1, J. Krauß2, C. M. Monoranu3, S. Samnick4, A. Dierks4, A. K. OP-364 R. Moreno-Reyes3, P. Bourgeois1, P. Flamen1; 4 5 6 MRI Buck , B. Bison , C. Lapa ; 1Nuclear medicine department, Institut Jules Bordet, Université 1Institute of Diagnostic and Interventional Radiology, University Hypoxia characterization in high-grade glioma: 2 P. Mapelli1,2, P. Scifo2, M. Barbera3, F. Fallanca2, A. Castellano1,3, V. Libre de Bruxelles (ULB), Brussels, BELGIUM, Endocrinology clinic, Hospital Würzburg, Würzburg, GERMANY, 2Department of Bettinardi2, R. Menichini2, A. Savi2, L. Gianolli2, N. Anzalone1,3, M. complementary role and spatial relationship of 18F-FAZA medicine department, Institut Jules Bordet Université Libre de Neurosurgery, University Hospital Würzburg, Würzburg, GERMANY, 3 Picchio1,2; PET/CT, perfusion and diffusion brain MRI Bruxelles (ULB), Brussels, BELGIUM, Nuclear medicine departement, 3Department of Neuropathology, Institute for Pathology, University 1Vita-Salute San Raffaele University, Milan, ITALY,2 Nuclear Medicine P. Mapelli1,2, P. Scifo2, A. Castellano1,3, F. Fallanca2, G. Conte3, V. Hopital Erasme, Université Libre de Bruxelles (ULB), Brussels, of Würzburg, Würzburg, GERMANY, 4Department of Nuclear Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, Bettinardi2, A. Savi2, E. Incerti2, A. Coliva2, A. Compierchio2, N. BELGIUM.

102 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 103 I. Saura Lopez, M. J. Ribelles Segura, I. Blanco Saiz, L. Paruta Araez, EPS-074 M. I. Morales Lozano, J. García Torres, N. A. Rudic Chipe, F. Gomez EPS-085 OP-377a Sainz, M. Díaz Tobarra, Á. O. Rabines Juarez, E. Anda Apiñaniz, Is endogenous TSH-stimulation associated with more H. Gomez Herrero, A. Echegoyen Silanes, A. Camarero Salazar, P. Evaluation of Primary Hyperparathyroidism in Hormone Discussion violent cell destruction during radioiodine therapy than Salvador Egea, E. Goñi Gironés; Receptor- Positive Breast Cancer Patients Using [99mTc] exogenous TSH? Navarra Hospital Complex, Pamplona/Iruña, SPAIN. Tc-MIBI SPECT/CT and Ultrasound 801 I. Lopo1, P. Lapa1,2, G. Costa1,2, J. Pedroso de Lima1,2,3; M. Punda, P. Petranovic Ovcaricek, V. Gladic Nenadic, I. Sisko CME 6: Bloody Hell!!! Impact on Quantitation of 1Serviço de Medicina Nuclear do Centro Hospitalar e Universitário Markos, M. Franceschi, T. Jukic; Blood Radiotracer Measurements de Coimbra, Coimbra, PORTUGAL, 2Faculdade de Medicina EPS-081 UHC Sestre Milosrdnice, Zagreb, CROATIA. da Universidade de Coimbra, Coimbra, PORTUGAL, 3Instituto 11C-methionine PET/CT for the evaluation of patients with Friday, October 23, 2020, 16:55 - 18:25 de Ciências Nucleares Aplicadas à Saúde (ICNAS), Coimbra, Channel 1 PORTUGAL. recurrent or persistent secondary hyperparathyroidism 701 after surgery and negative or inconclusive 99mTc-MIBI Plenary 2: Cardiac Nuclear Medicine - Present EPS-077 scintigraphy and Future A. Damian1,2, A. Quagliata1, S. San Roman3, E. Silvera2, M. Rodriguez Radioiodine-131 therapy during preimplantation period OP-378 EANM’20 EANM’20 Taroco1, N. Niell1,2, R. Castro1, R. Silvariño3, O. Alonso1,2; EANM’20 of pregnancy: Evaluation of uterus exposition of a patient 1 Friday, October 23, 2020, 15:30 - 16:45 Uruguayan Centre of Molecular Imaging (CUDIM), Montevideo, Channel 1 True Blood - The Story of How to Quantify Plasma Radio- with differentiated thyroid carcinoma URUGUAY, 2Centro de Medicina Nuclear e Imagenología Molecular, C. Happel1, D. Gröner1, M. Borowski2, M. Fiebich3, B. Schulze4, A. Hospital de Clínicas, UdelaR, Montevideo, URUGUAY, 3Centro de Metabolites Sabet1, W. T. Kranert1, F. Grünwald1; Nefrología, Hospital de Clínicas, UdelaR, Montevideo, URUGUAY. C. Vraka; Department of Biomedical Imaging and Image-guided 1University Medical Center Frankfurt, Department of Nuclear Therapy, Medical University of Vienna, Vienna, AUSTRIA. WORLD LEADING MEETING WORLD LEADING MEETING Medicine, Frankfurt, GERMANY, 2Städtisches Klinikum Braunschweig OP-373 GmbH; Institut für Röntgendiagnostik und Nuklearmedizin, EPS-082 OP-379 Braunschweig, GERMANY, 3Technische Hochschule Mittelhessen Renew or Fade Away Gießen; Institut für Medizinische Physik und Strahlenschutz, Gießen, F18-choline PET/CT in primary hyperparathyroidism when H. Verberne; Academic Medical Center, Department of Nuclear Compartmental Modelling for Kinetic Quantification with GERMANY, 4Genetische Beratung und Diagnostik; Kaiserstraße 6; conventional tests are negative or inconclusive Medicine, Amsterdam, NETHERLANDS. Arterial Input Function and Alternatives Frankfurt am Main, Frankfurt, GERMANY. J. Atance García de la Santa, D. Zamudio Rodríguez, R. Pérez N. Costes; CNRS Research Engineer, CERMEP- Imagerie du vivant, Pascual, J. J. Ardila Mantilla, Y. K. Henao Celada, M. Baquero OP-374 PET-MR department,Lyon,FRANCE. EPS-078 Oliveros, M. I. Gómez Fernández, A. Rotger Regí, C. M. Durán Barquero, A. Marí Hualde, J. E. Orcajo Rincón, J. C. Alonso Farto, S. Do we meet the Clinical Demand? OP-380 Variation of serum thyroglobulin during the first Vargas Martín; W. Acampa; Univ. Federico II di Napoli, Scienze Biomorphologiche e radioiodine therapy: a prognostic marker in patients with Hospital Universitario Gregorio Marañón, Madrid, SPAIN. Funzionali, Naples, ITALY. Bloody Hell, Why Do we Need Metabolite Corrections for thyroid carcinoma? Uptake Quantification I. Lopo1, P. Lapa1,2, G. Costa1,2, J. Pedroso de Lima1,2,3; EPS-083 OP-375 R. Boellaard; Amsterdam University Medical Centres, location 1Serviço de Medicina Nuclear do Centro Hospitalar e Universitário VUMC, Radiology and Nuclear Medicine, Amsterdam, de Coimbra, Coimbra, PORTUGAL, 2Faculdade de Medicina Pre-surgical imaging tests in the diagnosis of primary MBF - Lost in Clinical Translation? NETHERLANDS. da Universidade de Coimbra, Coimbra, PORTUGAL, 3Instituto hyperthyroidism in adverse scenarios: low weight R. Buechel; Department of Nuclear Medicine, Cardiac Imaging, de Ciências Nucleares Aplicadas à Saúde (ICNAS), Coimbra, adenomas and concomitant thyroid disease University Hospital Zurich, Zurich, SWITZERLAND. PORTUGAL. L. Paruta Araez, I. Blanco Saiz, M. Ribelles Segura, M. Morales 802 Lozano, J. García Torres, M. Díaz Tobarra, I. Saura López, N. Rudic OP-376 Joint Symposium 11 (EANM/ESTRO): How Much EPS-079 Chipe, A. Rabines Juárez, F. Gomez Sainz, B. Alvarez Galán, P. PET does Radiation Oncology Require? Caballero García, A. Goikoetxea Urdiain, A. Camarero Salazar, E. Imaging Cardiac Amyloidosis Efficacy of a 740 MBq Single Fixed Radioactive Iodine Goñi Gironés, P. Salvador Egea; S. Dorbala; Brigham and Women’s Hospital, Boston, UNITED STATES OF AMERICA. Friday, October 23, 2020, 16:55 - 18:25 Dose for Subclinical Hyperthyroidism Treatment and Complejo Hospitalario de Navarra, Pamplona, SPAIN. Channel 2 Implications of Pretreatment Thyroid Antibodies Levels F. Cañete, P. Garrastachu, X. Boulvard, L. Romero, M. Mangas, A. EPS-084 OP-377 Cabrera, R. Delgado-Bolton, R. Ramírez; Centre for Biomedical Research of La Rioja (CIBIR), Logroño, SPAIN. Brown Tumors Secondary To Tertiary Hyperparathyroidisim Endocarditis Masqeurading As A Lytic Or Sclerotic Skeletal Metastases P. Erba; Nuclear Medicine, Department of Translational Research OP-381 On Preoperative/Postoperative 18F-FDG PET/CT: A Case and New Technology in Medicine, University of Pisa and Azienda EPS-080 Ospedialiero Universitaria Pisana, Pisa, ITALY. FDG-PET for Radiation Target Volume Delineation Report E. Troost; Faculty of Medicine and University Hospital Carl Gustav C. Engur, T. Ones, N. Filizoglu, S. Kesim, S. Ozguven, K. Oksuzoglu, H. Assessment of preoperative imaging techniques in Carus, Department of Radiotherapy and Radiation Oncology, T. Turoglu, S. Inanir, T. Y. Erdil; Dresden, GERMANY. patients with primary hyperparathyroidism treated in an Marmara University Pendik Training and Research Hospital, unique endocrine surgical unit Department of Nuclear Medicine, Istanbul, TURKEY.

104 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 105 Sedimentation of Radioactive-labelled Colloid During Nagoya University Graduate School of Medicine, Nagoya, JAPAN, JAPAN. OP-382 Transport 2Department of Radiological Technology, Nagoya University Hospital, Nagoya, JAPAN, 3Department of Integrated Health PET Beyond FDG M. Rode Pedersen, B. Hoyer Mathiasen; TEPS-16 Hospital Lillebaelt, Vejle, DENMARK. Science, Nagoya University Graduate School of Medicine, Nagoya, S. Carrilho Vaz; Champalimaud Clinical Centre, Nuclear Medicine - JAPAN. Radiopharmacology, Lisbon, PORTUGAL. Simultaneous myocardial Tc-99m/I-123 imaging using a TEPS-05 cadmium-zinc-telluride camera: Validation of triglyceride OP-383 TEPS-10 deposit cardiomyopathy diagnosis Review of the radiosynthesis preparation of 68Ga-labelled T. Niimi1, M. Sugimoto1, K. Unno1, S. Yoshida2; PET & Radiomics - Does it Matter? PSMA in a fully automated system - a routine procedure Improved TEW method estimating primary photons in the 1Nagoya Daini Red Cross Hospital, Nagoya, JAPAN, 2Nagoya B. Fischer; PET Centre, School of Biomedical Engineering and M. Paula, C. Capelo, A. Fonseca, L. Ribeiro, H. Duarte; energy tail in 201Tl SPECT-MPI on CZT camera University, Nagoya, JAPAN. Imaging Sciences KCL, St Thomas’ Hospital, London, UNITED Ipo Porto, Porto, PORTUGAL. K. Yoshimura1, S. Tomiguchi2, S. Shiraishi3, F. Sakamoto2, R. KINGDOM. Kamezaki3; TEPS-06 1Graduate School of Health Sciences, Kumamoto, JAPAN, 2Faculty TEPS-18 803 of Life Sciences, Kumamoto, JAPAN, 3Kumamoto University Contribution of Information Technology systems in the Hospital, Kumamoto, JAPAN. A comparison of the results of myocardial perfusion EANM’20 EANM’20 Joint Symposium 12 (EANM/EACVI): Selecting EANM’20 the Right Imaging for the Right Patient in CAD planning of radiopharmaceuticals purchase: an ongoing analysis software for ischemia diagnosis between each experience TEPS-11 coronary artery branch area M. Maccagnani, A. Farina, R. Bonfiglioli, C. Malizia, S. Fanti; T. Iimori1, H. Miyauchi2, T. Sada1, T. Umezawa1, K. Sawada1, Y. Friday, October 23, 2020, 16:55 - 18:25 Nuclear Medicine Dynamic Cardiac Phantom Implemented 1 2 3 2 Channel 3 Azienda Ospedaliero-Universitaria S.Orsola-Malpighi, Bologna, Masuda , Y. Kuwabara , T. Uno , Y. Kobayashi ; ITALY. by 3D Printing Technique 1Department of Radiology, Chiba University Hospital, Chiba, WORLD LEADING MEETING WORLD LEADING MEETING H. Park1, J. Lee2; JAPAN, 2Department of Cardiovascular Medicine, Chiba University 1Shingu University, Seongnam, KOREA, REPUBLIC OF, 2Songho Graduate School of Medicine, Chiba, JAPAN, 3Department of TEPS-07 University, Hoengseong, KOREA, REPUBLIC OF. Diagnostic Radiology and Radiation Oncology, Chiba University OP-385 Graduate School of Medicine, Chiba, JAPAN. Normal values of 201Tl myocardial uptake at stress using a TEPS-12 Which Patients Should be Evaluated with CCTA? CZT SPECT and IQ-SPECT TEPS-19 I. Danad; Amsterdam University Medical Centers, Department of A. Matsumoto1, S. Yoshimura1, S. Tomiguchi2, S. Shiraishi3, Y. Phantom analysis in hybrid imaging Cardiology, Amsterdam, NETHERLANDS. Nakamura4, H. Sakamoto2; S. Rep, S. Kotar; Immediate adverse effects recorded in patients with 1Graduate School of Health Sciences, Kumamoto University, University Medical Centre Ljubljana, Ljubljana, SLOVENIA. neuroendocrine tumors undergoing treatment with 2 OP-386 Kumamoto, JAPAN, Faculty of Life Sciences, Kumamoto University, 177Lu-oxodoteotridre, using Lysine and Arginine at a slower Kumamoto, JAPAN, 3Kumamoto University, Hospital, Kumamoto, TEPS-13 rate of infusion. Nursing management Which Patients Should be Evaluated with Cardiac MRI? JAPAN, 4Division of medical technology, Kumamoto University, S. Lopez Gandul, E. Albuixech, J. Arcos, S. Garcia, F. Hernando, F. Bandera; San Donato Milanese, Cardiology, Milano, ITALY. Hospital, Kumamoto, JAPAN. Evaluation of the Usefulness of SPECT Brain Phantom M. Iniesta, E. Lopez, L. Lozano, Y. Samadi, C. Sanchez, I. Garlito, D. Based on 3D printing Villasboas, A. Garcia, J. Castell; OP-387 TEPS-08 1 2 1 3 H. Park , Y. Lee , H. Lee , J. Lee ; Hospital Universitari Vall d’Hebrón, Barcelona, SPAIN. 1Shingu University, Seongnam, KOREA, REPUBLIC OF, 2Kismits, Which Patients Should be Evaluated with Cardiac SPECT? Usefulness of CT attenuation correction for 201Tl/123I-BMIPP Seoul, KOREA, REPUBLIC OF, 3Songho University, Hoengseong, R. Assante; University Federico II, Department of Advanced dual-isotope myocardial SPECT on CZT camera KOREA, REPUBLIC OF. TEPS-20 Biomedical Sciences, Naples, ITALY. S. Yoshimura1, S. Tomiguchi2, F. Sakamoto3, T. Matsubara4, S. Shiraishi4; TEPS-14 Incidental suspicious COVID-19 findings in asymptomatic OP-388 1Graduate School of Health Sciences , Kumamoto University, patient during 18F-FDG PET/CT follow-up Kumamoto, JAPAN, 2Faculty of Life Sciences, Kumamoto University, Implementation of an automatically quantification M. Paula, A. Fonseca, C. Marques, L. Ribeiro, S. Sequeira, H. Duarte; Which Patients Should be Evaluated with Cardiac PET? Kumamoto, JAPAN, 3Facility of Life Sciences, Kumamoto University, package (Hone Graph) for phantom-based image Ipo Porto, Porto, PORTUGAL. 4 Kumamoto, JAPAN, Kumamoto University, Hospital, Kumamoto, quality assessment of bone SPECT: computerized self- 804 JAPAN. TEPS-21 classification of detectability using a novel index Technologists e-Poster Presentation Session 1 H. Ichikawa1,2, T. Shibutani2, M. Onoguchi2, K. Kawakami3, K. TEPS-09 The impact of SARS-Cov-2 emergency in the activity of the Nagatake4, T. Ito5, T. Kato1; 1Department of Radiology, Toyohashi Municipal Hospital, Nuclear Medicine Department, a single-center experience Friday, October 23, 2020, 16:55 - 18:25 Studies on Decision of the Cut-off Standardized Uptake Channel 4 Toyohashi, JAPAN, 2Department of Quantum Medical Technology, M. Maccagnani, A. Farina, R. Bonfiglioli, S. Fanti; Values for Normal Bones and Bone Metastases in the Graduate School of Medical Sciences, Kanazawa University, Azienda Ospedaliero-Universitaria S.Orsola-Malpighi, Bologna, Vertebrae in 18F-fluoride PET/CT and 18F-FDG PET/CT Kanazawa, JAPAN, 3Products Marketing Dept., FUJIFILM Toyama ITALY. R. Ono1, N. Fujita1,2, Y. Ito1, T. Tada1, R. Murayama1, H. Ikeda3, Y. Ochi3, Chemical Co., Ltd., Tokyo, JAPAN, 4Quality Assurance Dept., M. Nishio3, Y. Tsutsumi2, T. Odagawa1, M. Tamura1, S. Abe2, K. Kato3; FUJIFILM Toyama Chemical Co., Ltd., Tokyo, JAPAN, 5Department TEPS-04 1Department of Radiological and Medical Laboratory Sciences, of Radiology, Saiseikai Yokohamashi Tobu Hospital, Yokohama,

106 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 107 penile cancer patients National survey and research on actual circumstances 805 806 H. M. de Vries1, M. N. van Oosterom2, D. M. van Willigen2, H. G. van of radiation exposure and reduction of staff members 1 2 1 2 M2M Track - Featured Session: Translational der Poel , F. W. B. van Leeuwen , O. R. Brouwer , T. Buckle ; Cutting Edge Science Track - TROP Session: working in nuclear medicine and other radiological Interventional Nuclear Medicine 1Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Radiation Protection of Staff, and Advances in procedures in Japan Amsterdam, NETHERLANDS, 2Leiden University Medical Center, Technology 1 2 3 1 4 Leiden, NETHERLANDS. M. Hosono , Y. Mikami , H. Watanabe , M. Takenaka , Y. Koba , Friday, October 23, 2020, 16:55 - 18:00 R. Kanda4, K. Akahane4, T. Yamada5, K. Torisu2, H. Sakamoto6, K. Channel 5 Friday, October 23, 2020, 16:55 - 18:05 Yamamoto7; OP-416 Channel 6 1Kindai University Faculty of Medicine, Osaka-Sayama, JAPAN, 2Yokohama Rosai Hospital, Yokohama, JAPAN, 3Gunma Paz Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis University, Takasaki, JAPAN, 4QST National Institute of Radiological Sciences, Chiba, JAPAN, 5Kindai University Atomic Energy Research OP-411 detection prior to radical prostatectomy and pelvic lymph OP-419 Institute, Higashi-Osaka, JAPAN, 6Juntendo University Faculty of node dissection:A multicenter prospective phase III 7 From Lab to Clinic - Moving Forward in Urologic Surgery Health Science, Tokyo, JAPAN, Tokai University Hospital, Isehara, imaging study JAPAN. O. Brouwer; The Netherlands Cancer Institute, Antoni van Extremity dose in nuclear medicine: EURADOS initiative to J. Calais1, W. R. Armstrong1, V. Murthy2, C. L. Heath2, S. Behr2, F. Leeuwenhoek Hospital, Urology, Amsterdam, NETHERLANDS. update the ORAMED results EANM’20 EANM’20 Barbato3, F. Ceci4, A. Farolfi5, S. Schwarzenboeck6, M. Unterrainer7, H. EANM’20 1 2 3 4 5 OP-425 Zacho8, M. R. Cooperberg2, H. G. Nguyen2, R. E. Reiter1, S. Holden1, K. R. Kollaard , A. Zorz , N. Cherbuin , J. Cooke , P. Covens , M. OP-412 6 7 6 8 9 Herrmann1, W. P. Fendler3, M. Eiber9, J. Czernin1, T. A. Hope2; Crabbé , L. Cunha , J. Dabin , A. Dowling , M. Ginjaume , S. Haruz- 10 11 8 12 The current use of multi-modality imaging in nuclear 1University of California, Los Angeles, CA, UNITED STATES OF Waschitz , A. Kyriakidou , A. McCann , L. McNamara ; 1 A Novel Clickable MSAP Agent for Dual Fluorescence/ AMERICA, 2University of California, San Francisco, CA, UNITED Nuclear Research and Consultancy Group (NRG), Arnhem, medicine in Europe: results from the MEDIRAD project 2 Nuclear Labeling of a GRPR-Targeted Peptide STATES OF AMERICA, 3University Hospital Essen, Essen, GERMANY, NETHERLANDS, Istituto Oncologico Veneto IOV - IRCCS, Padua, G. Verfaillie1, Y. D’Asseler2, K. Bacher1; WORLD LEADING MEETING 3 4 WORLD LEADING MEETING K. Chen, J. Nieuwenhuizen, M. Handula, Y. Seimbille; 4University of Turin, Turin, ITALY, 5S.Orsola University Hospital, ITALY, HUG-CHUV, Lausanne, SWITZERLAND, St. James Hospital, 1Ghent University, Ghent, BELGIUM, 2Ghent University Hospital, 5 6 Erasmus MC, Rotterdam, NETHERLANDS. Bologna, ITALY, 6Rostock University Medical Centre, Rostock, Dublin, IRELAND, VUB, Bruxelles, BELGIUM, SCK.CEN, Mol, Ghent, BELGIUM. 7 8 GERMANY, 7Ludwig-Maximilians-University Munich, Munich, BELGIUM, IsoPor-Azores, Angra do Heroismo, PORTUGAL, St. 9 OP-413 GERMANY, 8Aalborg University Hospital, Aalborg, DENMARK, Vincent’s University Hospital, Dublin, IRELAND, UPC, Barcelona, OP-426 10 11 9Technical University Munich, Munich, GERMANY. SPAIN, Shamir Medical Center, Shamir, ISRAEL, EEAE, Athens, Fluorescence-based video tracking of the DROP-IN gamma GREECE, 12University Hospital Limerick, Limerick, IRELAND. Comparative Study of PET injectors in the routine practice probe during robotic surgery - technological evaluation in OP-417 of Nuclear Medicine porcine models OP-421 M. Costa1, M. Silva1, R. Parafita2, A. Canudo1, B. Freitas1, H. Delgado1, Local recurrence after radical prostatectomy and additive 1 1 1 1 1 M. van Oosterom1,2, K. M. Houwing1, P. R. Roos1, T. Buckle1,2, D. M. J. M. Correia , M. Andrade , M. Machado , R. Oliveira , S. Teixeira , F. van Willigen1, E. Mazzone3,4, K. Bauwens4, P. Dell’Oglio1,4, F. W. B. van radiation - can PSMA-radioguided surgery prolong Femur surgery and clinical management of a patient Oliveira1, P. Ferreira1, D. Costa1; 1 2 Leeuwen1,2,4; therapy-free survival? hospitalized after 131 Iodine cancer radiometabolic Champalimaud Foundation, Lisbon, PORTUGAL, Mercurius 1IMI-Lab, Dept. of Radiology, Leiden University Medical Center, S. Knipper1, L. Ascalone1, B. Ziegler1, R. Simon2, C. Berliner3, M. therapy: dosimetry evaluations for healthcare personnel Health, Lisbon, PORTUGAL. Leiden, NETHERLANDS, 2Department of Urology, Netherlands Graefen1, M. Eiber4, M. Heck2, T. Horn2, T. Maurer1; F. Zito1, M. Schiavini1, E. Cristini1, S. Mazzola1, M. Tolentini1, F. La Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, 1Martini-Klinik Prostate Cancer Center, University Hospital Fauci2, A. Gebbia2, L. Solimeno1; OP-427 NETHERLANDS, 3Division of Oncology/Unit of Urology, URI, IRCCS Hamburg-Eppendorf, Hamburg, GERMANY, 2Department of 1Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Ospedale San Raffaele; Vita-Salute San Raffaele University, Milan, Urology, Technical University of Munich, Munich, GERMANY, Milan, ITALY, 2University of Milan Specialization in Medical Physics, Amyloid hybrid membranes for the treatment of ITALY, 4ORSI Academy, Melle, BELGIUM. 3Department of Radiology and Nuclear Medicine, University Milan, ITALY. radioactive wastewater from nuclear medicine and nuclear Hospital Hamburg-Eppendorf, Hamburg, GERMANY, 4Department industry OP-414 of Nuclear Medicine, Technical University of Munich, Munich, G. Prenosil1, S. Bolisetty2, N. M. Coray2, A. Palika2, R. Mezzenga2; GERMANY. OP-422 11Department of Nuclear Medicine, Inselspital, Bern University Tumor-targeting potential and photodynamic therapy Hospital, University of Bern, Bern, SWITZERLAND, 2Department of 68 efficacy of dual-labeled PSMA-N064: An ex vivo incubation OP-418 Preliminary Investigations on Radiation Exposure in [ Ga] Health Science and Technology, ETH Zürich, Zürich, SWITZERLAND. study on human prostate cancer samples Ga-PSMA-11 based Cerenkov Luminescence Imaging Between pathological prostate cancer lymph node Y. Derks1, M. Rijpkema1, M. Schilham1, H. Amatdjais-Groenen2, Procedures A. Kip1, S. van Lith1, M. Sedelaar1, D. Somford3, M. Simons1, P. and sentinel lymph node status : which one is the most P. Fragoso Costa1, W. Sonnenschein1, I. Binse1, W. P. Fendler1, OP-428 Laverman1, M. Gotthardt1, D. Löwik2, S. Lütje4, S. Heskamp1; informative ? K. Herrmann1, M. R. Grootendorst2, U. Krafft3, J. P. Radtke3, B. 1 3 3 Calibration, radioprotection and dosimetry in Lu-177 Radboud university medical center, Nijmegen, NETHERLANDS, A. Morel1, V. Fleury1, M. Le Thiec1, B. Maucherat1, M. Colombié1, D. Hadaschik , C. Darr ; 2Radboud University, Nijmegen, NETHERLANDS, 3Canisius Rusu1, G. Aillet2, F. Kraeber-Bodéré1,3, T. Rousseau4, L. Campion1,3, C. 1University Hospital Essen, Universty of Duisburg-Essen, treatment of Neuro Endocrine tumours Wilhelmina Hospital, Nijmegen, NETHERLANDS, 4University hospital Rousseau1,3; Department of Nuclear Medicine, Essen, GERMANY, 2Lightpoint P. Saletti1, S. Raspanti2, A. D’Agata1, F. Rossi1, M. Papi1, G. Belli1; Bonn, Nijmegen, NETHERLANDS. 1ICO René Gauducheau, Saint-Herblain, FRANCE, 2Histopathology Medical Ltd., Clinical Research, Chesham, UNITED KINGDOM, 1Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY, Institute, Nantes, FRANCE, 3Nantes University, CNRS, Inserm, 3University Hospital Essen, Universty of Duisburg-Essen, 2University of Florence, Florence, ITALY. OP-415 CRCINA, Nantes, FRANCE, 4Urologic Clinic Nantes-Atlantis, Saint- Department of Urology, Essen, GERMANY. Herblain, FRANCE. C-Met receptor-specific fluorescence-guided surgery in OP-423

108 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 109 and data pre-processing Metastatic Breast Cancer Pathology, Istanbul, TURKEY. 807 D. Krajnc, L. Papp, T. S. Nakuz, H. F. Magometschnigg, M. Grahovac, Z. Yang; Pitfalls & Artefacts 4: Interpretation of Response C. P. Spielvogel, Z. Bago-Horvath, A. Haug, G. Karanikas, T. Beyer, M. Fudan University Shanghai Cancer Center, Shanghai, CHINA. Monitoring During Immune Therapy Hacker, T. H. Helbich, K. Pinker; 811 Medical University of Vienna, Vienna, AUSTRIA. Technologists e-Poster Presentation Session Friday, October 23, 2020, 16:55 - 18:25 Technologists 2 Channel 7 OP-435 OP-440 Friday, October 23, 2020, 16:55 - 18:05 Channel 11 Incidental Focal Breast Uptake On 18F-FDG PET-TC. Our Role of18F-FDG PET/CT metabolic/volumetric parameters Center Experience to predict response to neoadjuvant chemotherapy/chemo- OP-429 C. Wakfie Corieh1, C. Rodríguez Rey1, A. Ortega Candil1, R. immunotherapy and risk stratification in patients with 1 1 1 Valhondo-Rama , A. Blanes García , L. García Beláustegui , M. Triple-Negative (TNBC) and HER2+breast cancer (HER2+) 1 1 1 Current Systems for Response Classification Ruiz Tolón , B. Lannegrand , A. Pascual Martín , F. Ferrando- 1 2 1 1 1 TEPS-23 2 1 G. Paone , S. Di Lascio , L. Knappe , T. Ruberto , G. Treglia , L. J. O’Connor; Division of Cancer Sciences, The University of Castagnetto , J. Carreras Delgado ; 1 1 1 2 Ceriani , L. Giovanella ; 99m 18 Manchester, Manchester, UNITED KINGDOM. Hospital Clínico San Carlos, Madrid, SPAIN, Hospital de Clínicas 1 2 Is there a role for Tc-PSMA in times of F-PSMA? EANM’20 EANM’20 IIMSI, Bellinzona, SWITZERLAND, IOSI, Bellinzona, SWITZERLAND. EANM’20 Dr. Manuel Quintela, Facultad de Medicina, Universidad de la T. Oliveira, B. Beier, J. Sailer, P. Peloscheck, M. Hoffmann; OP-430 República, Montevideo, URUGUAY. Radiology Center, Vienna, AUSTRIA. OP-441 The Role of 18F-FDG-PET Monitoring During Immune OP-436 TEPS-24 Therapy Diagnostic performance and impact on management WORLD LEADING MEETING E. Lopci; Humanitas Clinical and Research Hospital – IRCCS, Dual Tracers of 18F-FES and 18F-FDG for Prediction of of 18F-FDG PET/CT for suspected recurrence in Invasive Cardiac Inhibition Protocol For The Diagnosis Of Infective WORLD LEADING MEETING Rozzano (MI), ITALY. Progression-Free Survival After Fulvestrant Therapy in Lobular Breast Carcinoma Endocarditis Wth 18F-FDG PET/CT Patients with HR+/HER2- Metastatic Breast Cancer J. Alberini1, D. Bonnin1, S. Ladoire1, A. Bertaut1, N. Briot1, C. Drouet1, M. Cabanillas Perez, S. Ruiz Solis, P. Pilkington Wol, J. Sánchez OP-431 Z. Yang; Y. E Silva1, G. Nodari1, C. Tabouret-Viaud1, A. Berriolo-Riedinger1, I. Redondo, J. Estenoz Alfaro; Fudan University Shanghai Cancer Center, Shanghai, CHINA. Dygai-Cochet1, H. Boulahdour2, A. Cochet1; Hospital Universitario 12 Octubre, Madrid, SPAIN. Pitfalls in Interpretation of Response to Immune Therapy 1Centre Leclerc - University Hospital, Dijon, FRANCE, 2University Hospital, Besancon, FRANCE. TEPS-26 808 OP-437 Clinical Oncology Track - TROP Session: Breast Comparison of quantitative assessment for cardiac PET Standarisation Of Normalized Workflow For 18F-FDG PET/ OP-442 sarcoidosis inflammation site using18 F-FDG PET / CT MRI Studies In Staging Of Patients With Breast Cancer images 18F-FES PET/CT influences the diagnosis and management J. Garcia, A. Compte, E. Valls, S. Mourelo, M. Buxeda, T. Blanch, P. R. Murayama1, R. Morimoto2, N. Fujita1,3, Y. Ito1, R. Ono1, T. Tada1, H. Friday, October 23, 2020, 16:55 - 18:15 4 4 4 3 1 1 Channel 8 Bassa, M. Soler, E. Riera; of stage IV patients with dual primary malignancies: Ikeda , Y. Ochi , M. Nishio , Y. Tsutsumi , M. Tamura , T. Odagawa , S. CETIR ASCIRES Grupo biomédico, Barcelona, SPAIN. ER-positive breast cancer combined with another primary Abe3, K. Kato4; 1Department of Radiological and Medical Laboratory Sciences, OP-438 tumour Z. Yang; Nagoya University Graduate School of Medicine, Nagoya, JAPAN, 2 Fudan University Shanghai Cancer Center, Shanghai, CHINA. Department of Cardiology, Nagoya University Graduate School OP-433 Radionuclide bone scans can be removed from the of Medicine, Nagoya, JAPAN, 3Department of Radiological pathway for staging breast cancer patients prior to Technology, Nagoya University Hospital, Nagoya, JAPAN, 4 The Predictive Value of Visual Evaluation and Quantitative neoadjuvant chemotherapy after introduction of FDG OP-443 Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, JAPAN. Metabolic Parameters for Axillary Lymph Node Metastasis PET-CT 68-Ga PSMA and 18-F FDG PET/CT Imaging in Triple- on FDG PET/MRI in Breast Cancer 1 2 2 3,4 P. Holdgaard , S. T. Nygaard , E. H. Jakobsen , S. Hess ; TEPS-27 U. Aydos1, L. Atay1, O. Kurukahvecioglu2, U. Akdemir1, P. Uyar 1Department of Nuclear Medicine, Lillebælt Hospital, Vejle, Negative Breast Cancer 1 1 2 3 4 Gocun3, S. Gulbahar Ates1, K. Seker1, C. Cifter2; DENMARK, 2Department of Oncology, Lillebælt Hospital, Vejle, E. Arslan , N. Ergül , F. D. Can Trabulus , Ö. Mermut , S. Akbaş , M. 1 5 1 Patient Non-Compliance Rates in Following Dietary Gazi University Faculty of Medicine, Department of Nuclear DENMARK, 3Department of Radiology and Nuclear Medicine, Cin , T. F. Çermik ; 1 Medicine, Ankara, TURKEY, 2Gazi University Faculty of Medicine, Hospital Southwest Jutland, Esbjerg, DENMARK, 4Department of University of Health and Sciences, Istanbul Training and Research Instructions for Cardiac Inflammation/Infection Imaging 2 Department of General Surgery, Ankara, TURKEY, 3Gazi University Regional Health Research, Faculty of Health Sciences, University of Hospital, Clinic of Nuclear Medicine, Istanbul, TURKEY, University with FDG PET/CT Faculty of Medicine, Department of Medical Pathology, Ankara, Southern Denmark, Odense, DENMARK. of Health and Sciences, Istanbul Training and Research Hospital, N. Martins, F. Alves, K. Wechalekar; 3 TURKEY. Clinic of Surgery, Istanbul, TURKEY, University of Health and Royal Brompton & Harefield NHS Foundation Trust, London, Sciences, Istanbul Training and Research Hospital, Department of UNITED KINGDOM. OP-434 OP-439 Radiation Oncology, Istanbul, TURKEY, 4University of Health and Sciences, Istanbul Training and Research Hospital, Department Identification of aggressive breast cancer lesions with Pretreatment 18F-FDG-PET/CT Parameters Predict of Medical Oncology, Istanbul, TURKEY, 5University of Health and [18F]-FDG-PET/CT in combination with machine learning Treatment Outcome of First-Line Therapy in Patients with Sciences, Istanbul Training and Research Hospital, Department of

110 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 111 1Gifu University, Gifu, JAPAN, 2Gifu University of Medical Science, TEPS-28 901 OP-450 Seki, JAPAN. CME 7: Nuclear Medicine in Paediatric Infections Sweet child of mine: the use of music in dynamic renal How does MTV fit in with Liquid Biopsy, Circulating TEPS-35 Saturday, October 24, 2020, 09:00 - 10:30 scintigraphy in pediatric patients Channel 1 Tumour Cells, etc. M. Maccagnani, A. Farina, R. Bonfiglioli, M. Levorato, S. Fanti; C. Schmitz; West German Cancer Center (WTZ), Faculty of Medicine Nuclear Medicine Department, Sant’Orsola-Malpighi Hospital, Striatum extraction using deep learning in ioflupane brain and University Hospital Essen, Department of Hematology, Essen, University of Bologna, Bologna, ITALY. scintigraphy - Learning using Monte Carlo simulation GERMANY. images - TEPS-29 H. Tsushima1, R. Murakawa1, S. Kurata2,1, R. Ishitsuka3, H. Nosaka4, OP-445 A. Onoma5, S. Koike6,1; Psychosocial characteristics of patients with coronary 1Ibaraki Prefectural University of Health Sciences, Ami-machi, Clinical Perspective From a Paediatrician About Paediatric 903 artery disease during imaging examinations in the Nuclear Ibaraki, JAPAN, 2Ibaraki Prefectural Central Hospital, Kasama, Infections 3 4 Joint Symposium 14 (EANM/SRS): Transporter’s Medicine Department Ibaraki, JAPAN, Chiba University Hospital, Chiba, JAPAN, Clinical G. Milani; Pediatric Unit, University of Milan, Milan, ITALY. Imaging M. Stolidou1, F. Rondoyanni1, I. Datseris1, G. Alexias2; Imaging Center for Healthcare, Nippon Medical School, Bunkyo-ku, 1 2 Tokyo, JAPAN, 5Yokohama City University Hospital, Yokohama, EANM’20 EANM’20 Evaggelismos Hospital, Athens, GREECE, Panteion University, EANM’20 Japan, JAPAN, 6University of Tsukuba Hospital, Tsukuba, Ibaraki, OP-446 Saturday, October 24, 2020, 09:00 - 10:30 Athens, GREECE. Channel 3 JAPAN. Conventional NM in Paediatric Infections TEPS-30 TEPS-36 D. de Palma; Nuclear Medicine Unit, “Circolo” Hospital, Varese, ITALY. WORLD LEADING MEETING Flow motion modality reduce the patient radiation Development of the pulmonary artery region of interest OP-451 WORLD LEADING MEETING exposure of whole-body PET-CT setting program using deep neural networks for the OP-447 G. Pecchia1, E. Palladino2, S. Amabile1, G. Borselleca1, C. Del 123I-MIBG myocardial quantification PET Imaging of P-Glycoprotein Activity at the Blood-Brain 1 1 1 1 1 1 PET and Fever of Unknown Origin in the Child Vasto , C. Lanotte , U. Marra , V. Milone , D. Palma , S. Piccolo , A. S. Itoyama1, Y. Uchiyama2, K. Yamashita1, A. Takaki3, S. Ito2; Barrier D’Acunzo1, M. Spadafora1; 1Graduate school of health sciences, Kumamoto University, M. Parisi; Seattle Childrens Hospital, Seattle, UNITED STATES OF O. Langer; Medical University of Vienna, Department of Clinical 1Nuclear Medicine Unit, Ospedale del Mare, Naples, ITALY, 2Ospedale Kumamoto, JAPAN, 2Faculty of Life Sciences, Kumamoto University, AMERICA. Pharmacology, Vienna, AUSTRIA. Civile Lipari, Messina, ITALY. Kumamoto, JAPAN, 3Faculty of Fukuoka Medical Technology, Teikyo University, Fukuoka, JAPAN. OP-452 TEPS-31 902 Joint Symposium 13 (EANM/EHA): Metabolic Design and Modification of Labeled Antibodies for Active Occupational Radiation Exposure in the Department of TEPS-37 Tumour Volume (MTV) in Lymphoma Transport Across the Blood-Brain Barrier Nuclear Medicine - the Effect of Distance and Shielding D. Sehlin; Uppsala University, Department of Public Health and Material on the Dose Rate Computer-aided detection of cancer on PET/CT images Caring Sciences, Uppsala, SWEDEN. 1 1 1 2 2 Saturday, October 24, 2020, 09:00 - 10:30 T. Saila , S. Hakkarainen , K. Hirsimäki , T. Taatila , H. Vilpas ; based on anomaly detection using GAN-based deep Channel 2 1Tampere University of Applied Sciences, Tampere, FINLAND, learning OP-453 2Tampere University Hospital, Tampere, FINLAND. T. Maeda1, M. Haga1, T. Hara1, T. Katafuchi2, X. Zhou1, M. Matsusako3, S. Ito4, M. Kato4, A. Yamada5, H. Fujita1; PET Imaging of P-gp Function at the Blood-Brain Barrier in 1Gifu University, Gifu, JAPAN, 2Gifu University of Medical Science, CNS Diseases TEPS-32 Seki, JAPAN, 3St. Luke’s International Hospital, Tokyo, JAPAN, OP-448 P. Mossel; University of Groningen, University Medical Center 4Daiyukai General Hospital, Ichinomiya, JAPAN, 5Shinshu University, Groningen, Department of Nuclear Medicine and Molecular Hand exposure in nuclear medicine technologists working Matsumoto, JAPAN. How to Use MTV in Therapy Guiding Lymphoma? Imaging, Groningen, NETHERLANDS. in the radiopharmaceutical laboratory in diagnostic J. Mettler; University Hospital of Cologne, Department for Nuclear nuclear medicine TEPS-38 Medicine, Cologne, GERMANY. C. Sobral, J. O. Prior, E. Perez; Centre hospitalier universitaire vaudois (CHUV), Lausanne, Use of artifical neural network for the diagnosis of OP-449 SWITZERLAND. myocardial ischemia :Comparison of imaging diagnosis between two devices in the clinical conditions How to Calculate MTV? M. Kano1, D. Ogura1, T. Ino2, T. Toyama3, K. Koyama1; R. Boellaard; Dept. of Radiology and Nuclear Medicine, Amsterdam TEPS-34 1Gunma Prefectural Cardiovascular Center, Maebashi-shi, Gumma- University Medical Centres, location VUMC, Amsterdam, ken, JAPAN, 2Gunma Prefectural Phychiatric Medical Center, NETHERLANDS. Image quality improvement method for nuclear medicine Isesaki-shi, Gumma-ken, JAPAN, 3Toyama cardiovasculary Clinic, images based on deep learning Maebashi-shi, Gumma-ken, JAPAN. R. Yamada1, M. Momiuchi1, T. Hara1, T. Katafuchi2, X. Zhou1, H. Fujita1;

112 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 113 Ziekenhuis Leiderdorp, Leiderdorp, NETHERLANDS, 5Alrijne Milan, ITALY, 4Unit of Obstetrics and Gynaecology, IRCCS San S. Koerber1,2,3, J. Ristau1,2,3, F. Staudinger4, J. Schlittenhardt4, M. F. 904 ziekenhuis leiderdorp, Leiderdorp, NETHERLANDS. Raffaele Scientific Institute, Milan, ITALY,5 University Centre of Haefner1,2,3, C. Kratochwil4,5, T. Lindner4, J. Debus1,2,6, U. Haberkorn4,5,6, CTE 3: Calibration of Instrumentation for Statistics in the Biomedical Sciences, Vita-Salute San Raffaele F. L. Giesel4,5,6; Dosimetry University, Milan, ITALY, 6Unit of Pathology, IRCCS San Raffaele 1Department of Radiation Oncology, Heidelberg University OP-458 Scientific Institute, Milan, ITALY. Hospital, Heidelberg, GERMANY, 2Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, GERMANY, 3National Center for Saturday, October 24, 2020, 09:00 - 10:30 Selective sentinel node biopsy in ductal carcinoma in situ Tumor diseases (NCT), Heidelberg, GERMANY, 4Department of of the breast. Is it justified? OP-463 Nuclear Medicine, Heidelberg University Hospital, Heidelberg, GERMANY, 5Clinical Cooperation Unit Nuclear Medicine, German Channel 4 P. Fernández-Rodríguez, Á. De Bonilla Damia, J. De León Carrillo, R. Álvarez Pérez, J. Jiménez-Hoyuela García; Validation Study Of Sentinel Lymph Node Biopsy In The Cancer Research Center (DKFZ), Heidelberg, GERMANY, 6German Virgen del Rocio University Hospital, Seville, SPAIN. Staging And Treatment Of Endometrial Cancer Cancer Consortium (DKTK), partner site Heidelberg, Heidelberg, D. Patrut, J. Alors Ruiz, I. Sanchez Urbaneja, O. Rahmouni, J. Oliva GERMANY. OP-459 Pastor, S. Sanz Viedma; OP-454 University Hospital Virgen de la Victoria, Málaga, SPAIN. 906 Utility Whole Body PET/CT Scan In Malignant Melanoma. Cutting Edge Science Track - TROP Session: Calibration of Instrumentation for Dosimetry - Principles Can The Location Of The Primary Tumor Guide Image OP-464 EANM’20 EANM’20 Dosimetry Methods and Models - Part 1 EANM’20 and Applications Planning? 18F-FDG PET/CT Radiomics Of Cervical Cancer In L. Beels; AZ Groeninge Kortrijk, Nuclear Medicine, Kortrijk, BELGIUM. V. Godigna Guilloteau, J. P. Pilkington Woll, E. Martínez Albero, Saturday, October 24, 2020, 09:00 - 10:30 A. Galiana Morón, D. Vega Pérez, S. Ruiz Solis, A. Gomez Grande, Predicting Lymph Node Metastasis Channel 6 M. Tabuenca Mateo, M. Sarandeses Fernandez, M. Marin Ferrer, J. L. Monaco1, G. Mathoux1, C. Crivellaro2, F. Elisei2, A. Buda3, R. OP-455 Estenoz Alfaro; Fruscio4,3, C. Landoni4,2, L. Guerra4,2, C. Messa5, E. De Bernardi4; WORLD LEADING MEETING Hospital Universitario 12 de Octubre, Madrid, SPAIN. 1University of Milan–Bicocca, Milan, Lombardia, ITALY, 2Nuclear WORLD LEADING MEETING Calibration of the Non-Imaging Instrumentation for Medicine Department, ASST Monza San Gerardo Hospital, Monza, Dosimetry ITALY, 3Gynaecologic Oncology Surgical Unit, Obstetrics and OP-468 K. Baete; University Hospitals Leuven, Nuclear Medicine, Leuven, OP-460 Gynaecology Department, ASST Monza San Gerardo Hospital, BELGIUM. Monza, ITALY, 4School of Medicine and Surgery, University of Milan- Is a single late SPECT/CT-based kidney 177Lu-dosimetry 5 The value of lymph node ultrasound and [18F]FDG PET/CT Bicocca, Milan, Lombardia, ITALY, Tecnomed Foundation,University superior to dosimetry with sequential whole-body scans in of Milan–Bicocca, Milan, Lombardia, ITALY. OP-456 in stage IIB/C melanoma patients prior to sentinel lymph combination with an early SPECT/CT? node biopsy S. Beykan1, J. Tran-Gia1, S. B. Jensen2,3, M. Lassmann1; Calibration of the Imaging Instrumentation for Dosimetry B. van der Hiel, E. Stahlie, A. Bruining, B. van de Wiel, Y. Schrage, M. OP-465 1Department of Nuclear Medicine, University of Würzburg, J. Gear; The Royal Marsden NHS Foundation Trust, Joint Wouters, W. van Houdt, A. van Akkooi; Würzburg, GERMANY, 2Department of Nuclear Medicine, Aalborg Department of Physics, London, UNITED KINGDOM. the Netherlands Cancer Institute - Antoni van Leeuwenhoek Sentinel lymph node detection in oral cancer: a head to University Hospital, Aalborg, DENMARK, 3Department of Chemistry Hospital, Amsterdam, NETHERLANDS. head comparison between [99mTc]Tc-Tilmanocept and and Bioscience, Aalborg University, Aalborg, DENMARK. [99mTc]Tc-Nanocoll 905 R. Mahieu, I. J. den Toom, R. van Rooij, R. J. J. van Es, M. G. OP-461 Hobbelink, G. C. Krijger, B. M. Tijink, B. de Keizer, R. de Bree; OP-469 University Medical Center Utrecht, Utrecht, NETHERLANDS. M2M Track - TROP Session: Image Guided Sentinel node lymphoscintigrapy reproducibility in In pursuit of fully automated dosimetry: evaluation of Treatment and Biopsy melanoma an automatic VOI propagation algorithm using contour P. Soeiro, R. Silva, F. Morgado, A. Albuquerque, G. Costa, J. Pedroso OP-466 intensity-based SPECT alignments Saturday, October 24, 2020, 09:00 - 10:20 de Lima; D. Mirando1, Y. K. Dewaraja2, N. M. Cole1, A. S. Nelson1; Channel 5 99m Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL. Use of Tc-Tilmanocept for selective sentinel lymph node 1MIM Software, Cleveland, OH, UNITED STATES OF AMERICA, biopsy in oral cavity tumours. Our experience at Hospital 2University of Michigan, Ann Arbor, MI, UNITED STATES OF OP-462 Clínic in Barcelona, Spain AMERICA. R. Valhondo-Rama1,2, C. Martí Pagés1, A. Perissinotti1, A. Tapias OP-457 Diagnostic performance and predictive value of fully Mesa1, N. Sánchez Izquierdo1, A. Ferrer Fuertes1, R. Sieira Gil1, M. hybrid 18F-FDG PET/MRI in preoperative endometrial Cámara Vallejo1, E. García Díez1, S. Vidal-Sicart1; OP-470 Clinical impact of Molecular Breast Imaging as adjunct cancer patients 1Hospital Clínic, Barcelona, SPAIN, 2Hospital Clínico San Carlos, 177Lu dosimetry may be obtained on a whole-body scale diagnostic modality in evaluation of indeterminate breast P. Mapelli1,2, F. Fallanca2, G. Ironi3, A. Bergamini1,4, P. Rancoita5, L. Madrid, SPAIN. abnormalities and unresolved diagnostic concerns Bocciolone4, P. Scifo2, V. Bettinardi2, G. Orlandi2, F. Turba4, A. Savi2, through serial high-speed CZT-SPECT recordings C. Corion1, A. Loevezijn2, R. Smithuis3, L. Wijers4, A. Zeillemaker5, R. G. Candotti1,4, F. Vasta1,4, R. Cioffi1,4, G. Taccagni6, G. Mangili4, L. L. Imbert, E. Chevalier, C. Boursier, V. Roch, G. Karcher, P. Marie; Valdes Omos1, L. de Geus-Oei1, J. van der Hage1, L. Pereira Arias- Gianolli2, F. De Cobelli1,3, M. Picchio1,2; OP-467 CHU Nancy Hopital Brabois Adultes, Vandœuvre-lès-Nancy, Bouda1; 1Vita-Salute San Raffaele University, Milan, ITALY,2 Nuclear Medicine FRANCE. 1LUMC, Leiden, NETHERLANDS, 2AVL, Amsterdam, NETHERLANDS, Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, Improved radiooncological management by FAPI-PET/CT 3Alrijne Zieknhuis Leiderdorp, Leiderdorp, NETHERLANDS, 4Alrijne 3Radiology Department, IRCCS San Raffaele Scientific Institute, as primary staging for patients with esophageal cancer

114 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 115 Medicine, Warsaw, POLAND, 3National Centre for Nuclear Research, Correlation Study between PET/MR Radiomics Features, OP-471 Teaching Session 3: A Practical Guide to MR Radioisotope Centre POLATOM, Otwock, POLAND. when Reading PET/MR Metabolic Parameters and Staging of Nasopharyngeal Voxel-wise Prediction of Post-therapy Dosimetry for Carcinoma 177Lu-PSMA I&T Therapyusing Deep Learning OP-476 Saturday, October 24, 2020, 09:00 - 10:30 J. Liang; Channel 7 Hangzhou Universal Medical Imaging Diagnostic Center, S. Xue1, A. Gafita2, Y. Zhao2, A. Afshar-Oromieh1, M. Eiber2, A. Hangzhou, CHINA. Rominger1, K. Shi1,2; Impact of tumour contouring method on prediction of 1University of Bern, Bern, SWITZERLAND, 2Technical University of survival with 99mTc-MAA-based dosimetry in HCC patients Munich, Munich, GERMANY. treated with selective internal radiation therapy OP-487 G. Nodari1, R. Popoff1,2, J. Riedinger1, O. Lopez3, J. Pellegrinelli3, OP-480 OP-472 I. Dygai-Cochet1, C. Tabouret-Viaud1, B. Presles2, O. Chevallier2,3, Application Value of PET/MR Radiomics Analysis in S. Gehin3, M. Gallet1, M. Latournerie4, S. Manfredi4, R. Loffroy2,3, J. Non-Prostate Oncologic Body PET/MR. MR Needs and Evaluating the Clinical Staging of Nasopharyngeal Combined planar and SPECT image method for bone Vrigneaud1,2, A. Cochet1,2; Expectation. The Nuclear Medicine’s Perspective Carcinoma 177 marrow dosimetry during Lu-DOTATATE treatmens using 1Centre Georges-François Leclerc, Dijon, FRANCE, 2ImVIA, EA 7535, C. Field Galán; HM Hospitales/Hospital Universitario Madrid J. Liang; deep learning generated synthesized projections University of Burgundy, Dijon, FRANCE, 3Department of Vascular Sanchinarro, Nuclear Medicine, Madrid, SPAIN. Hangzhou Universal Medical Imaging Diagnostic Center, 1 2 1 3 4 & Interventional Radiology, University hospital, Dijon, FRANCE, EANM’20 EANM’20 L. Hagmarker , J. Svensson , T. Ryden , M. van Essen , A. Sundlöv , K. Hangzhou, CHINA. EANM’20 4 Sjögreen Gleisner5, P. Gjertsson3, P. Bernhardt1; Gastroenterology Department, University hospital, Dijon, FRANCE. OP-481 1Department of Radiation Physics, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, 2Department OP-477 Non-Prostate Oncologic Body PET/MR. MR Needs and OP-488 of Oncology, Sahlgrenska Academy, University of Gothenburg, Expectation. The MR Expert’s Perspective 3 Gothenburg, SWEDEN, Department of Clinical Physiology, Radioembolization of hepatocarcinoma: dose-response O. Catalano; Harvard University, Massachusetts General Hospital, Impact of Primary Tumor Size, SUVmax of Primary Tumor and WORLD LEADING MEETING Sahlgrenska academy, University of Gothenburg, Gothenburg, assessment with mRECIST and with a new densitometric Radiology, WHT 270, Boston MA, UNITED STATES OF AMERICA. the Most Avid Neck Node on Baseline 18FDG PET/CT Upon WORLD LEADING MEETING 4 SWEDEN, Department of Oncology and Pathology, Clinical method Disease Recurrence in Head and Neck Ooropharyngeal 5 Sciences, Lund University, Lund, SWEDEN, Department of 1 1 2 3 4 OP-482 C. Romanò , S. Mazzaglia , M. C. De Nile , S. Bhoori , A. Gabutti , G. SCC using Standardized Imaging Protocol Radiation Physics, University of Lund, Lund, SWEDEN. 4 3 1 4 1 Maffi , V. Mazzaferro , M. Maccauro , C. Spreafico , E. Seregni , C. M. Zaman1, N. Fatima1, A. Zaman2, U. Zaman3, S. Zaman4, R. 1 Prostate PET/MR. MR Needs and Expectation. The Nuclear Chiesa ; Tahseen1; OP-473 1 Nuclear Medicine, Foundation IRCCS Istituto Nazionale Tumori, Medicine’s Perspective 1AKUH, Karachi, PAKISTAN, 2Dow University of Health Sciences Milan, ITALY, 2Postgraduate Specialization School in Medical Physics H. Bernstine; Assuta Medical Center/ Sackler School of Medicine, (DUHS), Karachi, PAKISTAN, 3Dept of Medicine Suny Downstate, Bone Marrow Dosimetry for Peptide Receptor 3 , University of Milan, Milan, ITALY, HPB Surgery, Hepatology and Tel Aviv University, Tel Aviv, ISRAEL. Hospital, New York, NY, UNITED STATES OF AMERICA, 4Dow Medical Radionuclide Therapy using Patient-specific Liver Transplantation, Foundation IRCCS Istituto Nazionale Tumori, College, Dow University of Health Sciences (DUHS), Karachi, 4 Pharmacokinetic Models Milan, ITALY, Radiology 2, Foundation IRCCS Istituto Nazionale OP-483 PAKISTAN. L. Carnegie-Peake, J. Taprogge, J. Gear, G. Flux; Tumori, Milan, ITALY. Royal Marsden Hospital NHS FT, London, UNITED KINGDOM. Prostate PET/MR. MR Needs and Expectation. The MR OP-478 Expert’s Perspective OP-489 L. Domachevsky; Sheba Medical Center, Radiology and Nuclear OP-474 Radioembolization of hepatocarcinoma with 90Y glass Medicine, Radiology, Tel Aviv, ISRAEL. Comparison of 18F-FDG PET / MR and enhanced MR in microspheres: clinical implications of low precision of skull-base bone invasion of nasopharyngeal carcinoma Improved prediction of haematological toxicity during 99mTc-MAA SPECT/CT dosimetry on lungs and lesions Y. Xu, S. Wang; [177Lu]Lu-DOTA-TATE therapy by optimising serial C. Chiesa1, S. Mazzaglia1, M. Maccauro1, M. C. De Nile2, C. Romano’1, 908 Hangzhou Universal Imaging Diagnostic Center, Hangzhou, SPECT-CT red marrow dosimetry M. Mira1, A. Marchiano’3, E. Seregni1, V. Mazzaferro4, C. Spreafico3; Clinical Oncology Track - Featured Session: CHINA. J. Tipping1, E. Page1, N. Calvert1, D. Hamilton1, D. Cullen2, E. Price2, S. 1Nuclear Medicine, Foundation IRCCS Istituto Nazionale Tumori, PET Diagnostics in Head Neck Cancers and Pells2, G. Needham2, P. Manoharan1; Milan, ITALY, 2Post graduate specialization school in Medical Melanoma OP-490 1The Christie NHS Foundation Trust, Manchester, UNITED Physics, Milan, ITALY, 3Interventional Radiology, Foundation IRCCS KINGDOM, 2The University of Manchester, Manchester, UNITED Istituto Nazionale Tumori, Milan, ITALY, 4HPB Surgery, Hepatology 18F-FDG PET/Low Dose CT as unique multimodality Saturday, October 24, 2020, 09:00 - 10:30 KINGDOM. and Liver Transplantation, Foundation IRCCS Istituto Nazionale Channel 8 imaging method to assess bone involvement in Multiple Tumori, Milan, ITALY. Myeloma patients C. Ferrari1, A. Nappi1, C. Minoia2, M. Zappia3, G. Santo1, P. OP-475 OP-479 Mammucci1, N. Merenda1, A. Guarini2, L. Brunese3, N. Maggialetti3, G. Rubini1; Calculation of absorbed dose distribution for Selective Comparison of different voxel-S-value methods for OP-485 1Nuclear Medicine Department, University of Bari “Aldo Moro”, Bari, Internal Radiation Therapy (SIRT) using Monte Carlo quantitative Y-90 TOF PET dosimetry ITALY, 2Haematology Unit, IRCCS Istituto Tumori “Giovanni Paolo Method G. Chen1, Y. Dewaraja2, G. Mok1; An introduction to PET Radiomics and Texture Analysis II”, Bari, ITALY, 3Radiology Department, University of Campobasso, M. Maciak1, P. Piasecki2, E. Iller3; 1University of Macau, Taipa, MACAO, 2University of Michigan, Ann J. Kleesiek; UK Essen, Essen, GERMANY. Campobasso, ITALY. 1National Centre for Nuclear Research, Otwock, POLAND, Arbor, MI, UNITED STATES OF AMERICA. 2Department of Interventional Radiology, Military Institute of OP-486 FDG-PET/CT in early assessment of immune-related

116 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 117 adverse events during first treatment response assessment of Pathology, University of Würzburg, Würzburg, GERMANY, TROP Session: Nuclear Endocrinology in OP-516 in melanoma patients treated with immune checkpoint Diagnosis and Therapy 6Department of Neurosurgery, University Hospital Würzburg, Würzburg, GERMANY. inhibitors Therapeutic 131I dose for the treatment of hyperthyroidism 1,2 2 1,2 1,2 1,2 K. Kudura , L. Nussbaumer , S. Bengs , A. Haider , D. A. Ferraro , Saturday, October 24, 2020, 09:00 - 10:30 due to unifocal autonomy in compliance with the L. Basler3,2, R. Förster3,2, M. Hüllner1,2, L. Husmann1,2, C. Deubelbeiss4,2, Channel 10 OP-511 optimization principle of Council Directive 2013/59/ F. Dimitriou4,2, R. Dummer4, J. Mangana4,2; 1 EURATOM Department of Nuclear Medicine University Hospital Zurich, Radiosynovectomy is effective in patients with knee Zürich, SWITZERLAND, 2University of Zurich, Zurich, SWITZERLAND, C. Canzi, V. Longari, L. Florimonte, F. Buffoni, M. Castellani; 3 replacement and chronic synovitis Department of Radiation Oncology University Hospital Zurich, OP-507 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Zürich, SWITZERLAND, 4Department of Dermatology University K. Liepe, M. Baehr; Milan, ITALY. Hospital Zurich, Zürich, SWITZERLAND. Klinikum Frankfurt, Frankfurt (Oder), GERMANY. Increased cerebral glucose consumption during hypoglycemia in obese patients measured using dynamic OP-512 OP-517 OP-492 bolus-injection 18F-FDG PET/MR during hyperinsulinemic Off the beaten path in oncology: active BAT by virtue of Hyperactive thyroid nodules treated by radiofrequency euglycemic and hypoglycemic clamp Can [18F]FDG PET/CT predict histopathologic response 18F-FDG PET/CT ablation EANM’20 EANM’20 M. Lubberink, S. Kvernby, N. Abrahamsson, K. Almby, M. Fahlström, EANM’20 1 1 1 1 2 or recurrence after complete surgical resection in prior M. Gingnell, S. Haller, J. Wikström, M. Sundbom, A. Karlsson, J. W. Jalloul , I. C. Grierosu , T. Ionescu , C. Stolniceanu , R. Iacob , R. F. Joosten, H. de Boer, P. Veendrick, W. Bom, E. Bom, M. van Borren; 1 1 1 2 1 2 unresectable stage III melanoma patients treated with Eriksson; Tibu , A. Tarca , M. Gutu , D. Chetan , C. Ștefănescu , A. Naum ; Rijnstate Hospital, Arnhem, NETHERLANDS. 1 neoadjuvant targeted therapy? Uppsala University, Uppsala, SWEDEN. Biophysics and Medical Physics-Nuclear Medicine Laboratory, University of Medicine and Pharmacy „Grigore T. Popa”, Iasi, OP-518 B. van der Hiel, S. Blankenstein, E. Aalbersberg, M. Stokkel, B. van de ROMANIA, 2Nuclear Medicine Laboratory, Regional Institute of

WORLD LEADING MEETING Wiel, W. Klop, A. van Akkooi, J. Haanen; WORLD LEADING MEETING OP-508 Oncology, Iasi, ROMANIA. HIFU For Thyroid Nodules An Effective Therapy For The the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS. Volume Reduction Of Thyroid Nodules The Assessment of Intrahepatic Islet Transplantation with The effectiveness predictive model of radioiodine therapy C. Körber, N. Körber-Hafner; Dynamic Exendin PET Imaging for Graves’ disease in children and adolescents Nuclearmedicine, Fulda, GERMANY. OP-493 T. J. P. Jansen1, M. Buitinga1,2, M. Boss1, M. van der Graaf1, E. J. P. de A. Trukhin1, P. Rumyantsev1, V. Saenko2, D. Dzeytova1, M. Koning3, M. A. Engelse3, M. F. Nijhoff3, I. Velikyan4, O. Korsgren4, O. Sheremeta1, V. Degtyarev1, V. Yasuchenya1, K. Slaschuck1, S. e-Poster Presentation Session 6: Physics - The use of [18F]FDG PET/CT to detect early recurrence Eriksson4, M. Brom1, M. Gotthardt1; Serzhenko1, Y. Sirota1, S. Zakharova1; Hardware and Optimisation after resection of high-risk stage III melanoma 1Radboudumc, Nijmegen, NETHERLANDS, 2KU Leuven, Leuven, 1Endocrinology Research Cener, Moscow, RUSSIAN FEDERATION, BELGIUM, 3LUMC, Leiden, NETHERLANDS, 4Uppsala University, 2Nagasaki University, Nagasaki, JAPAN. Saturday, October 24, 2020, 09:00 - 10:30 B. van der Hiel, E. Stahlie, M. Stokkel, Y. Schrage, W. van Houdt, M. Channel 11 Wouters, A. van Akkooi; Uppsala, SWEDEN. the Netherlands Cancer Institute - Antoni van Leeuwenhoek OP-514 Hospital, Amsterdam, NETHERLANDS. OP-509 18F-FDG -PET/MRI in patients with Graves’orbitopathy OP-494 Pancreatic uptake of radiolabeled exendin as a measure of M. Weber1, J. Koenen2, C. Deuschl3, N. Bechrakis2, K. Herrmann1, A. EPS-086 beta cell mass in T2DM before and after bariatric surgery Eckstein2, I. Binse1, M. Oeverhaus2; 1 PET/CT Evaluation and Patterns of Response to Different L. Deden1, M. Boss2, F. Berends3, H. de Boer3, E. Hazebroek1,4, M. Department of Nuclear medicine, University Hospital Essen, Essen, Assessment of high-speed recording lung perfusion 2 Type of Therapies in Patients with Disseminated Melanoma Gotthardt2; GERMANY, Department of Ophthalmology, University Hospital images provided by a high sensitivity 360° whole-body 3 1 2 1 2 Essen, Essen, GERMANY, Institute for Diagnostic and Interventional S. Divosevic , M. Sunjic ; Vitalys, Rijnstate, Arnhem, NETHERLANDS, RadboudUMC, CZT camera in the pre-operative workup of lung cancer 1 2 3 Radiology and Neuroradiology University Hospital Essen, Essen, Medikol Polyclinic, Zagreb, CROATIA, Clinical Hospital Centre Nijmegen, NETHERLANDS, Rijnstate, Arnhem, NETHERLANDS, S. Melki, A. Verger, G. Karcher, P. Marie, L. Imbert; 4 GERMANY. Sisters of Mercy, Zagreb, CROATIA. Wageningen University & Research, Wageningen, NETHERLANDS. CHRU Nancy, Vandoeuvre-lès-Nancy, FRANCE. OP-495 OP-510 OP-515 EPS-087 Clinical significance of FDG-PET/CT for Mucosal Peptide Receptor Radionuclide Therapy in Patients with Level of Thyrotropin Receptor Antibodies after Treatment Melanomas Neurofibromatosis Type 2 - Initial Experience with Radioactive Iodine An Assessment of the Accuracy of Quantitative SPECT/CT K. Kitaguchi, Y. Nakamoto, T. Nomashi, S. Koyasu, K. Miyake, T. O. Kertels1, M. Breun2, H. Hänscheid3, M. Kircher4, P. Hartrampf3, A. S. Gaberscek1,2, D. Šfiligoj Planjšek1, E. Pirnat1, K. Zaletel1, P. Jaki Imaging Using Tc99m and Lu177 Ishimori, T. Saga; Schirbel3, C. M. Monoranu5, R. I. Ernestus2, A. K. Buck3, M. Löhr2, C. Mekjavić3,2; J. Johnson, K. Adamson, T. Alkahtani; Kyoto University Hospital, Kyoto, JAPAN. Matthies6, C. Lapa4; 1Department of Nuclear Medicine, University Medical Centre Guy’s and St Thomas’ Hospitals NHS Foundation Trust, London, 1Institute of Diagnostic Radiology, University Hospital Würzburg, Ljubljana, Ljubljana, SLOVENIA, 2Faculty of Medicine, University of UNITED KINGDOM. Würzburg, GERMANY, 2Department of Neurosurgery, University Ljubljana, Ljubljana, SLOVENIA, 3Department of Ophthalmology, Hospital Würzburg, Würzburg, GERMANY, 3Department of Nuclear University Medical Centre Ljubljana, Ljubljana, SLOVENIA. EPS-088 Medicine, University Hospital Würzburg, Würzburg, GERMANY, 4Department of Nuclear Medicine, University Hospital Augsburg, Can Half-Time Bone SPECT Replace the Standard Bone 5 Augsburg, GERMANY, Department of Neuropathology, Institute SPECT?

118 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 119 M. El-Sayed, J. O’Brien, T. Jones, A. D’Sa, A. Notghi; University of Duisburg-Essen, Essen, GERMANY, 2Siemens Medical Z. Bar-Sever; Schneider Children’s Medical Center in Israel, Nuclear Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, Solutions, Knoxville, TN, UNITED STATES OF AMERICA, 3German Medicine Department, Petah Tikva, ISRAEL. 1003 UNITED KINGDOM. Cancer Consortium (DKTK)-University Hospital Essen, Essen, Joint Symposium 16 (EANM/EACMFS): Role of GERMANY. Hybrid Imaging in Jaw and Skull Conditions Design and implementation of a network-based OP-521 educational platform for simulation of a benchtop PET EPS-096 Nuclear Medicine Techniques in Urgent Paediatric Saturday, October 24, 2020, 10:40 - 12:10 system Channel 3 Conditions - Part 2 1,2 1 1 I. Mohammadi , P. M. M. Correia , I. F. C. Castro , P. M. C. C. Development of an anthropomorphic rodent phantom 1 1 1 I. Roca Bielsa; HU Vall Hebron, Paediatric Nuclear Medicine Unit, Encarnação , A. L. M. Silva , J. F. C. A. Veloso ; W. McDougald1, N. Weir2, R. Collins3, A. Tavares1; 1 Barcelona, SPAIN. i3N-Physics Department, University of Aveiro, 3810-193, Aveiro, 1BHF-Centre for Cardiovascular Science, College of Medicine & PORTUGAL, 2Department of Basic Sciences, Faculty of Medicine, Veterinary Medicine, Edinburgh, UNITED KINGDOM, 2Department 1002 OP-525 Sari Branch, Islamic Azad University, Sari, IRAN, ISLAMIC REPUBLIC of Medical Physics, NHS Lothian, Edinburgh, UNITED KINGDOM, OF. 3University of Edinburgh College of Arts, Edinburgh School of Joint Symposium 15 (EANM/ETA-CG): Systemic Jaw Osteomyelitis / Osteonecrosis - Clinical Presentation, Architecture and Landscape Architecture, Edinburgh, UNITED Therapeutic Options in Advanced Thyroid Diagnosis, Therapy EPS-090 KINGDOM. Cancer

EANM’20 EANM’20 B. Brokstad Herlofson; Department of Oral Surgery and Oral EANM’20 Medicine, Oslo, NORWAY. Emission time optimisation for [68Ga]Ga-PSMA-11 with a EPS-097 Saturday, October 24, 2020, 10:40 - 12:10 Channel 2 SiPM PET/CT based on phantom measurements OP-526 18 P. Fragoso Costa1, W. Jentzen1, F. Süßelbeck1, W. P. Fendler1,2, C. Optimization of Quantitative F-DCFPyL PET using a Rischpler1, K. Herrmann1, M. Conti3, D. Kersting1, M. Weber1; Realistic Anthropomorphic Phantom with Shell-less Jaw Osteomyelitis / Osteonecrosis – Imaging WORLD LEADING MEETING WORLD LEADING MEETING 1Department of Nuclear Medicine, University Hospital Essen, Radioactive Epoxy Lesions K. Strobel; Radiology and Nuclear Medicine, Cantonal Hospital 2 University of Duisburg-Essen, Essen, GERMANY, German Cancer R. Fedrigo1,2, D. Kadrmas3, P. Edem4, L. Fougner4, I. S. Klyuzhin1,2, M. P. OP-522 Lucerne, Lucerne, SWITZERLAND. Consortium (DKTK)-University Hospital Essen, Essen, GERMANY, Petric4, F. Bénard1,2,4, A. Rahmim1,2,4, C. Uribe2,4; 3 Siemens Medical Solutions, Knoxville, TN, UNITED STATES OF 1BC Cancer Research Centre, Vancouver, BC, CANADA, 2University of Personalized Therapy in View of Molecular Signatures OP-527 AMERICA. British Columbia, Vancouver, BC, CANADA, 3University of Utah, Salt C. Spitzweg; Medizinische Klinik und Poliklinik IV, Ludwig- Lake City, UT, UNITED STATES OF AMERICA, 4BC Cancer, Vancouver, Maximilians-University Munich, Munich, GERMANY. Incidental Findings in Jaw and Skull on Bone Scan and EPS-091 BC, CANADA. SPECT/CT OP-523 E. Panagiotidis; Theageneio Cancer Center, Thessaloniki, GREECE. Optimization of 18F-FDG oncological examination on a EPS-098 TOF-PET/CT scanner: results of a multicenter preliminary Update on Tyrosine Kinase Inhibitors 18 study Dose-scan-time optimization for F-PSMA-PET using a D. Handkiewicz-Junak; Department of Nuclear Medicine and 1004 A. Zorz1, E. Richetta2, M. Poli2, M. A. Rossato1, R. E. Pellerito2, G. M. digital PET scanner Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer CTE 4: NET Imaging and Therapy Sacchetti3, M. Burei1, R. Matheoud3; P. Bergwerff1,2, D. Koopman2, B. N. Vendel2, C. H. Slump3, J. A. van Center and Institute of Oncology, Gliwice, POLAND. 1Istituto Oncologico Veneto IOV - IRCCS, Padua, ITALY, 2AO Ordine Dalen4; 3 1 OP-524 Saturday, October 24, 2020, 10:40 - 12:10 Mauriziano di Torino, Turin, ITALY, AOU Maggiore della Carità, Technical Medicine, University of Twente, Enschede, Channel 4 Novara, ITALY. NETHERLANDS, 2Department of Nuclear Medicine, Isala hospital, Zwolle, NETHERLANDS, 3TechMed Centre, University of Twente, News from Redifferentiation Enschede, NETHERLANDS, 4Department of Medical Physics, Isala J. Nagarajah; Radboud University Medical Centre, (Radboudumc), EPS-092 hospital, Zwolle, NETHERLANDS. Department of Radiology and Nuclear Medicine, Nijmegen, NETHERLANDS. OP-529 The impact of patient’s body shape on PET image quality 1001 in digital and analogic PET/CT CME 8: Emergency Conditions in Paediatric NET Imaging in Conventional NM - Is There Still a Role for K. Weyts, E. Quak, I. Licaj, C. Lasnon, R. Ciappuccini, J. Savigny, G. Nuclear Medicine Conventional NM in NET Imaging? Foucras, S. Bardet, C. Jaudet; N. Girotto; Klinički bolnički centar Rijeka, Clinical department of Centre François Baclesse, Caen, FRANCE. nuclear medicine (Head of Department of Diagnostic imaging), Saturday, October 24, 2020, 10:40 - 12:10 Rijeka, CROATIA. EPS-093 Channel 1s OP-530 Emission time reduction for 2-[18F]FDG examinations in lymphoma patients with a PET/CT with SiPM - a feasibility PET/CT in NET Tumours - Applications and Novelties phantom study OP-520 W. Cholewinski; Poznan University of Medical Sciences, P. Fragoso Costa1, A. Bramer1, M. Weber1, D. Kersting1, M. Conti2, W. Electroradiology Department, Poznan, POLAND. P. Fendler1,3, C. Rischpler1, K. Herrmann1, W. Jentzen1; Nuclear Medicine Techniques in Urgent Paediatric 1Department of Nuclear Medicine, University Hospital Essen, Conditions - Part 1 OP-531

120 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 121 NET Therapy – Oncologist’s Point of View OP-536 OP-540 1006 1005 89 Cutting Edge Science Track - TROP Session: AI - M2M Track - TROP Session: New Kids on the Characterization of a new panel of Zr-labeled RON Fluorine-18 isotopic radiolabelling of the MEK inhibitor Radiomics and Modelling Block - New Tracers targeting monoclonal antibodies as a targeting agent for drug Binimetinib as a new PET imaging tool molecular imaging S. Specklin, R. Pelletier, C. Truillet, B. Kuhnast; 1,2 1 3 3,4 1 Saturday, October 24, 2020, 10:40 - 12:10 D. Spiegelberg , P. Jha , X. Y. Koh , D. Lane , M. Nestor ; CEA, Orsay, FRANCE. Channel 6 Saturday, October 24, 2020, 10:40 - 12:10 1 Channel 5 Dep of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN, 2Dep of Surgical Sciences, Uppsala University, OP-541 Uppsala, SWEDEN, 3P53 Laboratory, Agency for Science, Technology and Research (A*STAR), Singapore, SINGAPORE, 4Dep of Development of a new fluorine-18-labelled PET tracer Microbiology, Tumor and Cell Biology, Science for Life Laboratory, targeting norepinephrine transporter and evaluation on OP-544 OP-532 Karolinska Institutet, Stockholm, SWEDEN. rodent and large animal models Application of artificial neural network to preoperative18 F- X. Chen1,2,3, S. Mühlig2,3, Y. Ohshima2,3,4, Y. Yagi5, H. Kimura5, K. 18 [ F]Crizotinib PET imaging to address the impact of the OP-537 Koshino6, N. Nose7, C. Lapa1, A. Buck2, T. Higuchi2,3,7; FDG PET/CT for predicting pathological nodal involvement P-glycoprotein transport function at the blood-brain 1 EANM’20 EANM’20 Department of Nuclear Medicine, University Hospital of Augsburg, in NSCLC patients EANM’20 D-Peptide-based probes for CXCR4-targeted molecular 2 barrier on the brain delivery of the drug Augsburg, GERMANY, Department of Nuclear Medicine, University S. Taralli1, V. Scolozzi1, L. Boldrini2, J. Lenkowicz2, A. Pelliccioni3, M. F. Caillé1, M. Sardana2, M. Goislard1, L. Breuil1, M. Schou3, G. imaging and radionuclide therapy Hospital of Würzburg, Würzburg, GERMANY, 3Comprehensive Lorusso1, O. Attieh4, G. Cardillo5, M. L. Calcagni6; Wrigley4, N. Tournier1, C. Elmore2, B. Kuhnast1; F. Cleeren1, C. Cawthorne2, T. Van Loy3, J. Kleynhans4, K. Leys1, M. M. Heart Failure Center, University Hospital of Würzburg, Würzburg, 1Fondazione Policlinico Universitario A. Gemelli IRCCS; UOC 1CEA, Orsay, FRANCE, 2Astra Zeneca, Gothenburg, SWEDEN, 3Astra Sathekge4, D. Schols3, C. M. Deroose5, G. Bormans1; GERMANY, 4Department of Radiation-Applied Biology Research, Medicina Nucleare, Rome, ITALY, 2Fondazione Policlinico Zeneca, Stockholm, SWEDEN, 4Astra Zeneca, Cambridge, UNITED 1Radiopharmaceutical Research, Department of Pharmacy and Quantum Beam Science Research Directorate, National Institutes Universitario A. Gemelli IRCCS; UOC Radioterapia Oncologica, WORLD LEADING MEETING KINGDOM. Pharmacology, KU Leuven, Leuven, BELGIUM, 2Nuclear Medicine for Quantum and Radiological Science and Technology, Gunma, Rome, ITALY, 3INAIL, Department of Occupational and WORLD LEADING MEETING and Molecular Imaging, Department of Imaging and Pathology, JAPAN, 5Department of Analytical and Bioinorganic Chemistry, Environmental Medicine, Rome, ITALY, 4Nuclear Medicine KU Leuven, Leuven, BELGIUM, 3Rega Institute for Medical Research, Kyoto Pharmaceutical University, Kyoto, JAPAN, 6Department of Department, Jordanian Royal Medical Services, Amman, JORDAN, OP-533 KU Leuven, Leuven, BELGIUM, 4Department of Nuclear Medicine, Systems and Informatics, Hokkaido Information University, Ebetsu, 5Unit of Thoracic Surgery, San Camillo Forlanini Hospital, Rome, University of Pretoria & Steve Biko Academic Hospital, Pretoria, Hokkaido, JAPAN, 7Graduate School of Medicine, Dentistry and ITALY, 6Fondazione Policlinico Universitario A. Gemelli IRCCS; UOC Validation of [11C]glyburide as PET probe for imaging OATP SOUTH AFRICA, 5Nuclear Medicine, University Hospitals Leuven; Pharmaceutical Sciences, Okayama University, Okayama, JAPAN. Medicina Nucleare-Università Cattolica S. Cuore, Rome, ITALY. function in humans Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM. S. Marie1,2, L. Breuil1, Z. Chalampalakis1, L. Becquemont2, M. OP-542 OP-545 Goislard1, F. Caillé1, C. Comtat1, M. Bottlaender1, N. Tournier1; 1Laboratoire d’Imagerie Biomédicale Multimodale (BIOMAPS), OP-538 Preclinical Evaluation of [18F]OF-NB1, a Promising Weakly-supervised deep learning for the exploration of Université Paris-Saclay, CEA, CNRS UMR9011, Inserm UMR1281, Radioligand for Imaging GluN2B Subunits of the NMDA the prognostic value of 18F-FDG PET/CT in extranodal 2 Service Hospitalier Frédéric Joliot, Orsay, FRANCE, Hôpital Bicêtre, Development of a specific PET radiotracer of APJ: in vitro Receptor in Rodents and Human Brain Tissues natural killer/T-cell lymphoma, nasal type Assistance Publique des Hôpitaux de Paris, Le Kremlin Bicêtre, and in vivo evaluation in a colon adenocarcinoma model H. Ahmed1, A. Haider1, V. Hosseini2, R. Wallimann1, I. Iten1, M. B. Li1, R. Guo1, X. Hu2, H. Song2, P. Xu3, H. Xu4, A. Rominger5, C. Sun1, X. FRANCE. B. Louis1, A. Moyon2, A. Bouhlel1, L. Balasse1, S. Fernandez1, S. Robledo1, T. A. N. Nguyen1, A. Herde1, C. Keller1, S. Gruber1, V. Vogel2, Lin1, B. Menze2, K. Shi2,5; Simoncini3, G. Hache2, F. Dignat-George4, P. Garrigue2, B. Guillet2; R. Schibli1,3, L. Mu1,3, B. Wünsch4, S. M. Ametamey1; 1Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao OP-535 1C2VN INSERM 1263 INRA 1260 CERIMED Aix-Marseille Université, 1Institute of Pharmaceutical Sciences, Department of Chemistry Tong University School of Medicine, Shanghai, CHINA, 2Department Marseille, FRANCE, 2C2VN INSERM 1263 INRA 1260 CERIMED, and Applied Biosciences, ETH Zürich, Zürich, SWITZERLAND, of Computer Science, Technical University of Munich, Munich, Preliminary evaluation of a novel PET tracer for fatty acid APHM, Aix-Marseille Université, Marseille, FRANCE, 3C2VN INSERM 2Laboratory of Applied Mechanobiology, Institute of Translational GERMANY, 3State Key Laboratory of Medical Genomics, Shanghai oxidation, 18F-AS3504073-00 1263 INRA 1260 Aix-Marseille Université, Marseille, FRANCE, 4C2VN Medicine, Department of Health Sciences and Technology, ETH Institute of Hematology, Rui Jin Hospital, School of Medicine, Y. Ohshima1,2, Y. Yagi1,2, X. Chen1,2, S. Mühlig1,2, H. Fushiki3, Y. INSERM 1263 INRA 1260, APHM, Aix-Marseille Université, Marseille, Zürich, Zürich, SWITZERLAND, 3Department of Nuclear Medicine, Shanghai Jiao Tong University, Shanghai, CHINA, 4Department Murakami3, T. Higuchi1,2,4; FRANCE. University Hospital Zürich, Zürich, SWITZERLAND, 4Institute of of Radiation, Rui Jin Hospital, School of Medicine, Shanghai Jiao 1Department of Nuclear Medicine, University Hospital, University Pharmaceutical and Medicinal Chemistry, University of Münster, Tong University, Shanghai, CHINA, 5Lab for Artificial Intelligence of Würzburg, Würzburg, GERMANY, 2Comprehensive Heart Failure OP-539 Münster, GERMANY. Translational Theranostics, Department of Nuclear Medicine, Center, University Hospital, University of Würzburg, Würzburg, University of Bern, Bern, SWITZERLAND. GERMANY, 3Bioimaging Research Laboratories, Astellas Pharma Preclinical evaluation of 68Ga-Desferal for bacterial OP-543 Inc., Tsukuba, JAPAN, 4Okayama University, Graduate School of infection imaging OP-546 Medicine, Dentistry and Pharmaceutical Sciences, Okayama, M. Petrik1, E. Umlaufova1, V. Raclavsky2, A. Palyzova3, V. Havlicek3, J. Biodistribution and Pharmacokinetics of Long-acting JAPAN. Pfister4, Z. Novy1, M. Popper1, M. Hajduch1, C. Decristoforo4; Radiolabeled Cyclic RGD Peptide in MDA-MB-231 Breast Performance of 18F-FDG PET/CT based on machine- 1Institute of Molecular and Translational Medicine, Faculty of Cancer Model learning defined diagnostic criteria is not inferior to a Medicine and Dentistry, Palacky University, Olomouc, CZECH Y. Huang, M. Chen, S. Lee, S. Lo, S. Chen, L. Chen, M. Li, C. Chang; consensus review by experts to detect pelvic lymph node REPUBLIC, 2Department of Microbiology, Faculty of Medicine and Institute of Nuclear Energy Research, Taoyuan, TAIWAN. involvement in bladder cancer Dentistry, Palacky University, Olomouc, CZECH REPUBLIC, 3Institute A. Girard1, L. Dercle2, H. Vila Reyes3, E. Le Stanc4, O. Delcroix5, M. of Microbiology of the Czech Academy of Sciences, Prague, CZECH Rouanne6; REPUBLIC, 4Clinical Department of Nuclear Medicine, Medical 1Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, University Innsbruck, Innsbruck, AUSTRIA.

122 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 123 FRANCE, 2Department of Radiology, Columbia University Medical Equality Kunita, S. Watanabe, T. Hiromasa, H. Mori, S. Saito, Y. Ikawa, D. Center, New York, NY, UNITED STATES OF AMERICA, 3Department of OP-551 Kayano, S. Kinuya; Urology, Columbia University Medical Center, New York, NY, UNITED Kanazawa University Hospital, Kanazawa, JAPAN. 4 Influence of delineation modality on overall accuracy Saturday, October 24, 2020, 10:40 - 11:40 STATES OF AMERICA, Department of Nuclear Medicine, Hôpital Channel 7 Foch, Suresnes, FRANCE, 5Department of Nuclear Medicine, CHU of machine learning predictive model on colorectal de Brest, Brest, FRANCE, 6Department of Urology, Hôpital Foch, carcinoma OP-566 Suresnes, FRANCE. M. Grahovac, L. Papp, C. P. Spielvogel, D. Krajnc, A. Leisser, A. Strassl, 111 J. Bozic-Pavletic, T. Beyer, M. Hacker, A. Haug; PRRT Efficacy of In-DTPA-Octreotide Auger and OP-547 Medical University Vienna, Vienna, AUSTRIA. OP-556 Internal Conversion Electron Emission after Intra-arterial Implementation in Liver Metastasized Colorectal NETs A convolutional neural network for fully automated blood TBA G. Limouris1, V. Krylov2, M. B. Dolgushin3, I. Kyriazanos4, A. SUV determination in oncological FDG-PET OP-552 T. Lynch; Belfast, UNITED KINGDOM. Zafeirakis5; P. Nikulin1, F. Hofheinz1, J. Maus1, Y. Li2, R. Bütof3, C. Lange4, C. Furth4, 1Nuclear Medicine, Medical School, National and Kapodistrian S. Zschaeck4, M. Kreißl5, J. Kotzerke3, J. van den Hoff1; Deep learning radiomics for prediction of Alzheimer 1008 University of Athens, Athens, GREECE, 2Nuclear Medicine Dpt. 1Helmholtz-Zentrum Dresden-Rossendorf, Institute of disease by usingamyloid PET images “A. Tsyb Research Center”, Obninsk, RUSSIAN FEDERATION, 3N.N. Radiopharmaceutical Cancer Research, Dresden, GERMANY, 1 1 1 2 Clinical Oncology Track - Featured Session: Best EANM’20 EANM’20 G. Giovacchini , E. Giovannini , M. Riondato , O. Ferrando , F. Blokhin Russian Oncological Research Center, Moscow, RUSSIAN EANM’20 2Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen Foppiano2, M. De Biasi3, C. Passera3, A. Tartaglione3, P. Lazzeri1, A. of Nuclear Medicine Therapy FEDERATION, 4I Surgery Clinic, Army Naval and Veterans Hospital University, Xiamen, CHINA, 3University Hospital Carl Gustav Carus, Ciarmiello1; of Athens, Athens, GREECE, 5Army Share Fund Hospital of Athens, Technische Universität Dresden, Dresden, GERMANY, 4Charité – 1Nuclear Medicine Unit, S. Andrea Hospital, La Spezia, ITALY, Saturday, October 24, 2020, 10:40 - 12:10 Athens, GREECE. Channel 8 Universitätsmedizin Berlin, corporate member of Freie Universität 2Medical Physics Unit, S. Andrea Hospital, La Spezia, ITALY, Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of 3Neurology Unit, S. Andrea Hospital, La Spezia, ITALY. OP-567

WORLD LEADING MEETING Health, Berlin, GERMANY, 5Klinik für Radiologie und Nuklearmedizin, WORLD LEADING MEETING Universitätsklinikum Magdeburg A.ö.R., Magdeburg, GERMANY. OP-553 Feasibility, Biodistribution and Preliminary Dosimetry in OP-561 Peptide-Targeted Radionuclide Therapy (PTRT) of Diverse OP-548 In-vivo survival prediction of glioma patients from Adenocarcinomas using 177Lu-FAP-2286: First-in-Human Future of NM Therapy Beyond PSMA and PRRT [11C]MET-PET using advanced data pre-processing and Results Deep Learning-Enabled Comprehensive Detection and V. Lewington; Kings College London, Guys Hospital, Nuclear machine learning H. Kulkarni1, C. Smerling2, C. Schuchardt1, A. Singh1, F. Robiller1, M. Medicine, London, UNITED KINGDOM. Quantification of 18FDCFPyL (PyL-PSMA) PET/CT D. Krajnc, L. Papp, C. P. Spielvogel, M. Grahovac, T. Beyer, M. Hacker, Chantadisai1,3, A. Eismant1, D. Mueller1, D. Zboralski2, F. Osterkamp2, 1 1 1 1 1 J. Brynolfsson , K. Johnsson , H. Sahlstedt , J. Richter , K. Sjöstrand , T. Traub-Weidinger; A. Hoehne2, U. Reineke2, R. P. Baum1; 2 2 1,3 1 OP-563 N. G. Nickols , M. B. Rettig , L. Edenbrandt , A. Anand ; Medical University of Vienna, Vienna, AUSTRIA. 1Zentralklinik Bad Berka, Bad Berka, GERMANY, 23B Pharmaceuticals 1 2 Exini Diagnostics AB, Lund, SWEDEN, VA Greater Los Angeles, GmbH, Berlin, GERMANY, 3King Chulalongkorn Memorial Hospital, 3 Los Angeles, CA, UNITED STATES OF AMERICA, University of Personalized Thera(g)nostic Approach in Patients with Bangkok, THAILAND. Gothenburg, Gothenburg, SWEDEN. OP-554 Pheochromocytoma and Paraganglioma: 131I-mIBG and / or Peptide Receptor Radionuclide Therapy Data-driven identification of diagnostically useful OP-549 H. Svirydenka, B. Nilica, C. Mair, L. Rossetti, A. Kroiss, G. Di Santo, S. OP-568 extrastriatal signal in dopamine transporter SPECT using Buxbaum, C. Decristoforo, C. Uprimny, M. Gabriel, I. Virgolini; 131 Whole-body lesion detection and prostate cancer staging explainable AI Universitätsklinik für Nuklearmedizin, Innsbruck, AUSTRIA. IPAX-1: Phase 1/2 study of 4-L-[ I]-iodo-phenylalanine 68 131 in Ga-PSMA-11 PET/CT using deep learning M. Nazari1,2, I. Apostolova3, A. Kluge2, S. Kimiaei2, R. Buchert3; ( I-IPA) administered concomitantly to second line N. Capobianco1, A. Gafita2, G. Platsch1, L. Sibille3, B. Spottiswoode3, 1TU-Dresden, Dresden, GERMANY, 2ABX-CRO, Dresden, GERMANY, external radiation therapy (XRT) in patients with recurrent 2 2 4 2 3 OP-564 M. Eiber , W. A. Weber , N. Navab , S. G. Nekolla ; University Medical Center Hamburg- Eppendorf, Hamburg, glioblastoma multiforme (GBM) 1Siemens Healthcare GmbH, Erlangen, GERMANY, 2Department GERMANY. T. Traub-Weidinger1, R. Wilson2, J. Pichler3; of Nuclear Medicine, Klinikum rechts der Isar, Technical University Transarterial radioembolization of unresectable 1Medical University of Vienna, Vienna, AUSTRIA, 2Telix of Munich, Munich, GERMANY, 3Siemens Medical Solutions USA 90 intrahepatic cholangiocarcinoma with Y glass Pharmaceuticals, Melbourne, AUSTRALIA, 3Kepler Inc., Knoxville, TN, UNITED STATES OF AMERICA, 4Computer Aided OP-555 microspheres: results of a single institution study Universitätsklinikum, Linz, AUSTRIA. Medical Procedures (CAMP), Technical University of Munich, A. Lorenzoni, S. Mazzaglia, C. Spreafico, F. Scalorbi, G. Argiroffi, S. Munich, GERMANY. Evaluation of quantum-encoding for machine learning Bhoori, C. Chiesa, V. Fuoco, T. Cascella, E. Seregni, V. Mazzaferro, M. features in neural network-based predictive models Maccauro; OP-569 OP-550 C. Spielvogel, M. Grahovac, D. Krajnc, M. Hacker, T. Beyer, A. R. Fondazione IRCCS Istituto Nazionale Tumori, Milan, ITALY. Haug, L. Papp; Comparison of 99mTc-MAA SPECT/CT predictive Improved 3D Tumour Definition and Quantification of Medical University of Vienna, Vienna, AUSTRIA. dosimetry and 90Y PET/CT posttreatment dosimetry in Radiotracer Uptake Using Deep Learning OP-565 Radioembolization of Hepatic Tumours L. Dal Toso1, Z. Chalampalakis2, I. Buvat2, C. Comtat2, J. A. O. Ferrando1, F. Foppiano2, A. Ciarmiello3; 131 Schnabel1, P. K. Marsden1; 1007 Effectiveness of high-dose I-MIBG as consolidation 1ASL5 Spezzino, La Spezia, ITALY, 2Medical Physics Department 1King’s College London, London, UNITED KINGDOM, 2CEA, Paris, Teaching Session 4: The Intellectual and therapy for the patients with high-risk neuroblastoma - ASL5 Spezzino, La Spezia, ITALY, 3Nuclear Medicine Department - FRANCE. Emotional Journey to Radiology and Nuclear A. Inaki, R. Kuroda, H. Wakabayashi, N. Akatani, T. Yamase, Y. ASL5 Spezzino, La Spezia, ITALY.

124 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 125 Milano, Milan, ITALY, 2IRCCS Istituto Nazionale dei Tumori di Milano, Arrhythmias E. Zampella, V. Gaudieri, T. Mannarino, R. Green, V. Cantoni, P. OP-570 Milan, ITALY, 3Vita-Salute San Raffaele University, Milan, ITALY, Buongiorno, W. Acampa, A. Cuocolo; 4IRCCS San Raffaele Hospital, Milan, ITALY. Department of advanced biomedical sciences, University Federico II Effectiveness and safety of multiple 90Y-radioembolization Saturday, October 24, 2020, 10:40 - 12:10 Channel 10 of Naples, Naples, ITALY. in patients with primary and secondary liver tumors A. Di Palo, C. Ferrari, C. D’Alò, P. Mammucci, M. Frugis, R. Ruta, V. OP-576 Lavelli, G. Rubini; OP-588 Nuclear Medicine Department, University of Bari “Aldo Moro”, Bari, Phosphoenolpyruvate Carboxykinase1Reduces 18F-FDG ITALY. Uptake in Clear Cell Renal CellCarcinoma OP-583 The ability of 123I-mIBG/199Tl SPECT to predict appropriate L. Shi1, S. An2, Y. Liu3, J. Liu2, F. Wang1; ICD therapy in patients with ischemic heart failure OP-571 1Nanjing First Hospital, Nanjing Medical University, Nanjing, Nuclear Imaging in Cardiac Arrhythmias - What do we S. Sazonova, T. A. Atabekov, R. E. Batalov, J. N. Ilushenkova, Y. B. CHINA, 2Department of Nuclear Medicine, Ren Ji Hospital, School have? What do we still need? Lishmanov, S. V. Popov; 90 Role of Y- microspheres PET based tumor to normal (T/N) of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA, F. Rouzet; Hopital Bichat Claude Bernard, Service de Médecine Cardiology Research Institute, Tomsk NRMC, Tomsk, RUSSIAN dosimetry to assess response in HCC selective internal 3Department of Nuclear Medicine, Shanghai Tenth People’s Nucléaire, Paris, FRANCE. FEDERATION. radiation therapy Hospital, Tongji University School of Medicine, Shanghai, CHINA. OP-584 OP-589 EANM’20 EANM’20 R. B. Martinez, S. Gavane, K. Knesaurek; EANM’20 Icahn School of Medicine at Mount Sinai, New York, NY, UNITED OP-577 STATES OF AMERICA. The value of cardiac sympathetic nervous system activity Myocardial 123I-Metaiodobenzylguanidine Scintigraphy Auxiliary Diagnostic Utility of Partial 18F-FDG PETMR on in predicting the effectiveness of radiofrequency ablation in Patient with Heart Failure: a Gender Study Whole-Body 18F-FDG PETCT of atrial fibrillation M. Conte1, A. Di Rocco2, C. De Angelis1, V. Frantellizzi1, A. Farcomeni3, 1009 Y. Xu; Y. Varlamova, K. Zavadovsky, I. Kisteneva, S. Sazonova, R. Batalov; G. De Vincentis1; WORLD LEADING MEETING WORLD LEADING MEETING Clinical Oncology Track - Featured Session: Onco Hangzhou Universal Imaging Diagnostic Center, Hangzhou, Cardiology Research Institute, Tomsk NRMC, Tomsk, RUSSIAN 1Department of Radiological Sciences, Oncology and Anatomical Diagnostics Miscellaneous CHINA. FEDERATION. Patology, “Sapienza” University of Rome, Rome, ITALY, 2Department of Public Health and Infectious Diseases, “Sapienza” University of OP-578 Rome, Rome, ITALY, 3”Tor Vergata” University of Rome, Rome, ITALY. Saturday, October 24, 2020, 10:40 - 12:10 OP-585 Channel 9 Imaging-based score and diagnostic flow-chart for OP-590 malignant adrenal lesions Relationship between heart rate response and cardiac A. Farolfi1, E. Maietti2, F. Piperno1, P. Coppolino3, A. Lambertini4, R. innervation in patients with suspected or known coronary Altered Electromechanical Coupling With Multisite Onset Mei1, L. Calderoni1, C. Balacchi5, R. Golfieri5, U. Pagotto6, S. Fanti1, artery disease of Left Ventricle Mechanical Contraction Associated With 2 7 7 5 6 OP-572 S. Selva , D. Santini , A. De Leo , C. Mosconi , G. Di Dalmazi , V. C. Nappi1, R. Assante1, E. Zampella1, V. Gaudieri1, G. De Simini1, A. Advanced Coronary Heart Disease 6 1 Vicennati , C. Nanni ; Giordano1, A. D’Antonio1, W. Acampa1, M. Petretta2, A. Cuocolo1; F. Ferrando-Castagnetto1, M. Pedrera Canal2, I. Vilacosta3, C. Real3, 1 PET Beyond FDG Nuclear Medicine Unit, S. Orsola Hospital, University of Bologna, 1Department of Advanced Biomedical Sciences, University Federico M. Ollarves Carrero2, L. García Belaustegui2, M. Olivan2, R. Ricca- 2 D. Taïeb; Centre hospitalo-universitaire Timone, Médecine Bologna, ITALY, Department of Medical and Surgical Sciences, II, Naples, ITALY, 2Department of Translational Medical Sciences, Mallada1, M. Pérez Castejón2, J. Carreras Delgado2; 3 Nucléaire, Marseille, FRANCE. University of Bologna, Bologna, ITALY, Radiodiagnostic and University Federico II, Naples, ITALY. 1Departamento de Cardiología - CCVU, Hospital de Clínicas, Radiotherapy Unit, Department of Medical and Surgical Sciences FM, UdelaR, Montevideo, URUGUAY, 2Servicio de Medicina OP-573 and Advanced Technologies, “GF Ingrassia”, Catania, ITALY, Nuclear, Hospital Clínico San Carlos, Madrid, SPAIN, 3Instituto 4 Department of Nuclear Medicine, Würzburg University Hospital, OP-586 Cardiovascular, Hospital Clínico San Carlos, Madrid, SPAIN. Comparison of 68Ga-FAPI and 18F-FDG PET/CT for the Würzburg, GERMANY, 5Radiology Unit, S. Orsola Hospital, University 6 diagnosis of primary and metastatic lesions in patients of Bologna, Bologna, ITALY, Endocrinology Unit, S. Orsola Hospital, A novel method for regional innervation/perfusion OP-592 University of Bologna, Bologna, ITALY, 7Pathology Unit, S. Orsola with various types of cancer mismatch assessed by cardiac 123I-mIBG and rest 99mTc- Hospital, University of Bologna, Bologna, ITALY. The diagnostic accuracy of cardiac I-123-mIBG scintigraphy H. Chen, L. Zhao, Y. Pang, Q. Lin, L. Sun, H. Wu; tetrofosmin SPECT to predict arrhythmic events in The First Affiliated Hospital of Xiamen University, Xiamen, CHINA. as a biomarker for mild cognitive impairment with Lewy OP-579 ischemic heart failure D. Verschure1,2, E. Poel1, A. F. Jacobson3, H. J. Verberne1; bodies 1Amsterdam UMC, Amsterdam, NETHERLANDS, 2Zaans Medical G. Roberts1,2, R. Durcan1, P. C. Donaghy1, S. Barker1, S. Lawley1, C. OP-574 Contribution of open mouth technique in F-18 FDG PET/CT 1 1 2 2 1 Center, Zaandam, NETHERLANDS, 3Diagram Consulting, Kihei, HI, A. Hamilton , J. Ciafone , G. Petrides , K. Howe , N. Barnett , M. imaging of patients with malignant lip neoplasm Firbank1, J. P. Taylor1, J. O’Brien3, A. J. Thomas1; 18 UNITED STATES OF AMERICA. F-FDG PET/CT in muscle-invasive urothelial bladder G. Mutevelizade, C. Sezgin, E. Sayit, G. Gumuser; 1Newcastle University, Newcastle upon Tyne, UNITED KINGDOM, cancer: the role of functional imaging in neoadjuvant Celal Bayar University, Faculty of Medicine, Department of Nuclear 2Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UNITED immunotherapy, an ancillary analysis of PURE-01 protocol Medicine, Manisa, TURKEY. OP-587 KINGDOM, 3University of Cambridge, Cambridge, UNITED A. Capozza1, L. Marandino2, B. Padovano1, G. Serafini1, A. Briganti3, KINGDOM. D. Raggi2, E. Farè2, F. Pederzoli3, A. Gallina4, M. Bandini3, U. Low-dose dual-isotope by CZT camera: single imaging Capitanio3, M. Bianchi4, G. Gandaglia4, N. Fossati3, P. Giannatempo2, 1010 to assess cardiac function, myocardial perfusion and A. Salonia4, F. Montorsi3, A. Necchi2, E. Seregni1, A. Alessi1; Featured Session: Nuclear Imaging in Cardiac adrenergic innervation in heart failure 1Nuclear Medicine Unit, IRCCS Istituto Nazionale dei Tumori di A. Giordano, G. De Simini, R. Assante, C. Nappi, A. D’Antonio,

126 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 127 Benfratelli, Palermo, ITALY, 2Department of Biomedical and Dental A. Forteza-Gil, A. Ramos-Martinez, R. Jimeno-Pernett, A. Sanfiel OP-593 Sciences and of Morpho-functional Imaging, Nuclear Medicine Delgado, M. Mitjavila-Casanovas; EPS-114 Unit, University of Messina, Messina, ITALY, 3Nuclear Medicine Hospital Universitario Puerta De Hierro, Majadahonda, SPAIN. 18 Predictive value of the cardiac sympathetic innervation Unit, Fondazione Istituto G.Giglio, Cefalù, ITALY, 4Rehabilitation Contribution of F-FDG-PET/CT in the diagnosis of and contractile function in cardiac resynchronization Unit, Paolo Giaccone Hospital, Palermo, ITALY, 5Department of patients with fever of unknown origin therapy Orthopaedic Surgery (DICHIRONS), University of Palermo, Palermo, EPS-109 S. Georga1, P. Exadaktylou1, I. Petrou1, D. Katsampoukas1, E. 6 A. Mishkina, K. Zavadovsky, V. Saushkin, D. Lebedev, Y. Lishmanov; ITALY, Department of Orthopaedic Surgery, Ospedale Civico Moralidis1, K. Arvaniti2, G. Giataganas3, G. Arsos1; 18 Cardiology Research Institute, Tomsk National Research ARNAS, Palermo, ITALY. F-FDG-PET/CT in the Diagnosis of Infective Endocarditis 13rd Department of Nuclear Medicine, Aristotle University Medical Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN in Patient with Electronic Cardiac Device and Fever of School, Papageorgiou Hospital, Thessaloniki, GREECE, 2ICU FEDERATION. EPS-105 Unknown Origin and/or Bacteriemia and Antimicrobial Stewardship Unit, Papageorgiou Hospital, 3 S. Guzmán Ortiz, B. Rodríguez Alfonso, A. Ramos-Martinez, M. Thessaloniki, GREECE, Department of Radiology, Papageorgiou White blood cells scintigraphy as an alternative to the Cobo Marcos, S. Pérez Quirós, M. Mitjavila Casanovas; Hospital, Thessaloniki, GREECE. 1011 arthrocentesis in suspected periprosthetic knee infection University Hospital Puerta de Hierro Majadahonda, Madrid, SPAIN. e-Poster Presentation Session 7: Nuclear E. Noriega-Álvarez, A. M. García Vicente, V. M. Poblete García, M. EPS-115 Medicine for Infection & Inflammation - The E. Bellón Guardia, F. J. Pena Pardo, M. P. Talavera Rubio, B. González García, E. Casillas Sagrado, Á. M. Soriano Castrejón; EPS-110 The role of 18FDG-PET/CT in the diagnostic work-up of EANM’20 EANM’20 Story Continues EANM’20 University Hospital of Ciudad Real, Ciudad Real, SPAIN. fever of unknown origin (FUO) and inflammation of 18 Visual Vascular Score with 2-[ F]FDG: validation on a unknown origin (IUO) Saturday, October 24, 2020, 10:40 - 12:10 EPS-106 Channel 11 control sample M. Allocca, T. Tagliente, D. Malandrino, A. Berni, M. Di Paolantonio, R. Ferreira, M. R. Victor, S. Carmona, A. I. Santos; A. Martini, C. Olianti, P. Saletti, L. Poggesi, R. Sciagrà; 18 One-year follow-up with F-FDG PET/CT of large vessel Hospital Garcia de Orta, Almada, PORTUGAL. University of Florence, Florence, ITALY. WORLD LEADING MEETING vasculitis treated with tocilizumab WORLD LEADING MEETING I. Martinez-Rodriguez1, D. Prieto-Peña2, R. Quirce1, J. Jiménez- EPS-111 EPS-103 Bonilla1, M. de Arcocha-Torres1, A. Sánchez-Salmón1, N. Martínez- EPS-117 Amador1, G. Molina-Mendoza1, O. Cuenca-Vera1, J. Andrés- FDG-PET imaging of gastrointestinal Graft-versus-Host The role of nuclear medicine imaging with 18F-FDG PET/CT, Pacheco1, Á. Gutiérrez-González1, S. Ruiz Llama1, F. J. Gómez-de la disease COVID-19 related findings assessed by dual reporting in combined 111In-WBC/99mTc-Nanocoll and 99mTc-HDP SPECT/ Fuente1, M. Calderón-Goerke2, R. Blanco2, M. A. González-Gay2, I. W. Roll1, G. Evers2, R. Strotmann1, J. Albring2, B. Noto1, M. Weckesser1, our series of 18F-FDG PET/CT studies performed over the 1 CT in evaluation of patients with chronic problem after Banzo ; M. Stelljes2, M. Schäfers1; coronavirus pandemic 1Nuclear Medicine Service. Marqués de Valdecilla University 1 TKA or THA in a prospective study Department of Nuclear Medicine, University Hospital Münster, J. Garcia, S. Ortiz, A. Compte, P. Bassa, S. Mourelo, M. Soler, M. Hospital. Molecular Imaging Group (IDIVAL). University of 2 1 2 1 1 3 Münster, GERMANY, Department of Medicine A, Hematology, R. Aleksyniene , V. Iyer , H. C. Bertelsen , M. Frost , V. Khalid , H. C. 2 Buxeda, T. Blanch, E. Valls, E. Riera; Cantabria, Santander, SPAIN, Rheumatology Service. Marqués de Oncology and Pulmonary Medicine, University Hospital Münster, Schønheyder4, L. H. Larsen4, P. T. Nielsen3, A. Kappel3, T. R. Thomsen5, CETIR ASCIRES Grupo biomédico, Barcelona, SPAIN. Valdecilla University Hospital. IDIVAL, Santander, SPAIN. Münster, GERMANY. J. Lorenzen6, I. Ørsted7, O. Simonsen3, P. L. Jordal6, S. Rasmussen3, PRIS Study Group; 1Department of Nuclear Medicine, Aalborg University Hospital, EPS-107 EPS-112 Aalborg, DENMARK, 2Department of Nuclear Medicine, 68 68 Uppsala University Hospital, Uppsala, SWEDEN, 3Department Correlation of clinical and biochemical parameters with Simple radiosynthesis of Ga-desferrioxamine B ( GaDFO) MCS1 of Orthopaedic Surgery, Aalborg University Hospital, Aalborg, 18F-FDG PET/CT in patients with large vessel vasculitis for infection imaging Mid-Congress-Symposium 1 (EANM/EACVI): DENMARK, 4Department of Clinical Microbiology, Aalborg under biological therapy with tocilizumab A. Darwesh, R. Wellman, V. Abbate, M. S. Cooper, R. Hider, M. Detecting Cardiac Amyloidosis - Increasing Role University Hospital, Aalborg, DENMARK, 5Center for Microbial I. Martínez-Rodríguez1, D. Prieto-Peña2, R. Quirce1, J. Jiménez- Morais, S. Y. A. Terry, M. T. M. Ma, P. J. Blower; of Nuclear Medicine Communities, Aalborg University, Aalborg East, Life Science Bonilla1, M. de Arcocha-Torres1, A. Sánchez-Salmón1, N. Martínez- King’s College London, London, UNITED KINGDOM. Division, The Danish Technology Institute, Aarhus, DENMARK, Amador1, G. Molina-Mendoza1, O. Cuenca-Vera1, J. Andrés- 6Life Science Division, The Danish Technology Institute, Aarhus, 1 1 1 EPS-113 Monday, October 26, 2020, 09:30 - 12:15 Pacheco , Á. Gutiérrez-González , S. Ruiz Llama , F. J. Gómez-de la Channel 1 DENMARK, 7Department of Infectious Disease, Aalborg University Fuente1, M. Calderón-Goerke2, R. Blanco2, M. A. González-Gay2, I. Hospital, Aalborg, DENMARK. Banzo1; FDG-PET/CT is clinically valuable in the majority of 1Nuclear Medicine Service. Marqués de Valdecilla University patients referred from Emergency Department with EPS-104 Hospital. Molecular Imaging Group (IDIVAL). University of unclarified systemic inflammation 2 Cantabria, Santander, SPAIN, Rheumatology Service. Marqués de S. Hess1,2, R. Horvat3; MCS-01 The Use of a Novel Semiquantitave Parameter in the Three- Valdecilla University Hospital. IDIVAL, Santander, SPAIN. 1Dept. of Radiology and Nuclear Medicine, Hospital South West phase Bone Scan to Predict the Results of 99mTc-HMPAO- Jutland, University Hospital of Souther, Esbjerg, DENMARK, Introduction Cardiac Amyloidosis and New Treatment labeled Leukocyte Scintigraphy in Patients with Suspected EPS-108 2Department of Regional Health Research, University of Southern Options 3 Septic Loosening of Unilateral Knee Prosthesis Denmark, Odense, DENMARK, Dept. of Radiology and Nuclear H. Nienhuis; University Medical Center Groningen, Groningen, Chasing Infection: Is There An Specific18 F-FDG Pattern To N. Quartuccio1, L. Sturiale1, M. Siracusa2, A. Arnone1, R. Laudicella2, Medicine, Hospital South West Jutland, University Hospital of NETHERLANDS. 1 3 4 5 5 Accurately Differentiate Septic From Aseptic Inflammation Southern Denmark, Esbjerg, DENMARK. M. T. Arnone , P. Alongi , G. L. Mauro , L. Camarda , M. D’Arienzo , R. MCS-02 Sciortino6, S. Baldari2, G. Arnone1; In Aortic Root/Ascending Aorta Graft Replacement? 1Nuclear Medicine Unit, A.R.N.A.S. Ospedali Civico, Di Cristina e B. Rodriguez-Alfonso, D. Martinez-Lopez, L. Canales-Rodriguez,

128 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 129 Echocardiography and Cardiac MRI in Cardiac Amyloidosis AI and Imaging Biomarkers A. Awada; Institut Jules Bordet, Department of Medicine, Brussels, MCS-25 O. Lairez; University Hospital Toulouse, Toulouse, FRANCE. D. Visvikis; INSERM, LaTIM, Brest, FRANCE. BELGIUM. MCS-17 The Next Step in Image-Guided Surgery, Tracer MCS-03 MCS-12 Refinements and Complementary Use of Different Tracers Regulatory Aspects of Radioligand Therapies - Approval T. Buckle; Dept of Radiology, Leiden University Medical Centre, Cardiac Bone Scans -Protocols, Interpretation, AI for Monte Carlo Simulations Pathways and Non-Clinical Requirements Leiden, NETHERLANDS. Quantification D. Sarrut; CNRS, CREATIS, Lyon, FRANCE. G. Waxenecker; Vienna, AUSTRIA. R. Slart; University Medical Center Groningen, University of MCS-26 Groningen, Groningen, NETHERLANDS. MCS-13 MCS-19 Using Navigation and Hybrid Tracer or Radiotracer + ICG in MCS-05 AI for Dosimetry Applications Head and Neck Cancers J. Bert; University Hospital Brest, LaTIM, Brest, FRANCE. Current Status of Radioligand Therapy C. Schilling; Consultant Head & Neck Surgeon, University College Cardiac MIBG - Protocols, Interpretation, Quantification D. Oprea-Lager; Universitair Medische Centra, Department of London Hospitals NHS Foundation Trust, London, UNITED E. Piekarski; Bichat Claude Bernard Hospital, Paris, FRANCE . MCS-14 Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS. KINGDOM. EANM’20 EANM’20 EANM’20 MCS-06 Potential Clinical Applications of AI in NM MCS-20 MCS5 New PET Radiopharmaceuticals in Cardiac Amyloidosis, YDF1 Identification of New Targets and New Ligands Mid-Congress-Symposium 5: How to Read PET/ Perspectives EANM Young Daily Forum 1: Simply the Best - U. Haberkorn; University of Heidelberg, Department of Nuclear CT - Different Shades of Sugar (FDG) J. Sörensen; Department of Nuclear Medicine & PET, Uppsala Presentation Skills for Medical Professionals Medicine, Heidelberg, GERMANY. WORLD LEADING MEETING University Hospital, Uppsala, SWEDEN . WORLD LEADING MEETING Tuesday, October 27, 2020, 09:30 - 12:15 Channel 1 MCS-07 Monday, October 26, 2020, 12:20 - 13:50 MCS4 Channel 1 Mid-Congress-Symposium 4: Image Guided Results EU Questionnaire on Cardiac Amyloidosis and Surgery Cardiac Sarcoidosis & Clinical cases A. Gimelli; Fondazione Toscana-CNR Gabriele Monasterio, Pisa, MCS-27 OP-132 Monday, October 26, 2020, 14:00 - 16:45 ITALY. Channel 2 How to Read PET/CT - Chemotherapy Setting MCS2 Simply the Best - Presentation Skills for Medical N. Aide; Centre Hosptalier Universitaire de Caen, Caen, FRANCE. Professionals Mid-Congress-Symposium 2: Artificial R. Sheppard; London, UNITED KINGDOM MCS-28 Intelligence in Image Acquisition, MCS-21 Reconstruction and Processing How to Read PET/CT - Radiotherapy Setting MCS3 Sentinel Lymph Node – An Overview of the Different A. Loft Jakobsen; Dept of Clinical physiology, Nuclear Medicine & Monday, October 26, 2020, 09:30 - 12:15 PET, Copenhagen, DENMARK. Channel 2 Mid-Congress-Symposium 3 (EANM/ESMO): Tracers/Technologies for SLN. Strengths and Limitations Clinical Development of Radioligand Therapy S. Vidal-Sicart; Consultant in Nuclear Medicine. Staff member of Diagnostic Imaging Institute Hospital Clinic Barcelona, Barcelona, MCS-29 SPAIN. Monday, October 26, 2020, 14:00 - 16:45 How to Read PET/CT - Post-Surgical Setting Channel 1 MCS-08 MCS-22 A. Agrawal; Dept of Nuclear Medicine & Molecular Imaging, Tata Memorial Centre, Mumbai, INDIA. AI in Image Reconstruction Image Guidance Using Common PET Tracers such as 18F- A. Reader; King’s College London, Biomedical Engineering and FDG MCS-31 Imaging Sciences, London, UNITED KINGDOM. MCS-15 J. Grimm; Radiologist and Nuclear Medicine physician, Memorial Sloan-Kettering Cancer Center, New York, UNITED STATES OF How to Read PET/CT - Immumotherapy Setting MCS-09 Overview of Clinical Development (From Phase 0 to 3) AMERICA. E. Lopci; Instituto Clinico Humanitas IRCCS (Humanitas), Milan, A. Stathis; Oncology Institute of Southern Switzerland, Ospedale ITALY. AI for Image Corrections Regionale die Bellinzona e Valli, Bellinzona, SWITZERLAND. MCS-23 J. Lee; Seoul National University College of Medicine, Seoul, MCS-32 REPUBLIC OF KOREA. MCS-16 From PET to SPECT - Optimizing Surgical Guidance in Pelvic Cancers How to Deal with Incidental Findings MCS-10 Early Development of New Therapeutic Approaches - A T. Maurer; Urologist, Martini-Klinik Prostate Cancer Center, K. Strobel; Head of Nuclear Medicine, Kantonsspital Luzern, Break with the Past University of Hamburg-Eppendorf, Hamburg, GERMANY. Lucerne, SWITZERLAND.

130 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 131 Lu-PSMA Therapy MCS-33 Resilience MCS9 A. Gosewisch; University Hospital, Ludwig-Maximilians-University of Munich, Department of Nuclear Medicine, Munich, GERMANY. Mid-Congress-Symposium 9 (EANM/ETA/ESES): How to Read PET/CT - Tumours with Low FDG Uptake Tuesday, October 27, 2020, 12:20 - 13:50 Channel 1 Update on Treatment of Hyperthyroidism T. van den Wyngaert; Dept of Nuclear Medicine and Molecular Imaging University of Antwerp, Antwerp, BELGIUM. MCS-46 Wednesday, October 28, 2020, 09:30 - 12:15 Channel 1 MCS6 Texture Analysis for Quantification of Non-Uniformity OP-444 Mid-Congress-Symposium 6: Improved Insights MCS8 into Radiobiology - Key for Radionuclide I will Survive - Managing Work Stress and Building Your Therapy Mid-Congress-Symposium 8: For Youngsters - Resilience Essential Oncology for Young Nuclear Medicine MCS-54 R. Sheppard; London, UNITED KINGDOM Physicians Tuesday, October 27, 2020, 09:30 - 12:15 Diagnosis of Diseases Leading to Hyperthyroidism Channel 2 L. Giovanella; Imaging Institute of Southern Switzerland, Clinic for MCS7 Tuesday, October 27, 2020, 14:00 - 16:45 Nuclear Medicine, Bellinzona, SWITZERLAND. EANM’20 EANM’20 Channel 2 EANM’20 Mid-Congress-Symposium 7: Lutetium Therapy MCS-55 MCS-34 Tuesday, October 27, 2020, 14:00 - 16:45 Medical Treatment of Hyperthyroidism Channel 1 Five For the Price of One - Alternatives to the Linear-No- MCS-47 K. Boelaert; Queen Elizabeth Hospital, Endocrinology, Birmingham, WORLD LEADING MEETING Threshold Theory UNITED KINGDOM. WORLD LEADING MEETING M. Verslegers; Belgian Nuclear Research Centre, SCK CEN, Essential Oncology - The Young Nuke`s Need Radiobiology Unit, Mol, BELGIUM. S. Telo; Policlinico S.Orsola-Malpighi, Nuclear Medicine, Bologna, MCS-56 MCS-40 ITALY. MCS-35 Surgical Treatment of Hyperthyroidism Differences Between EBRT and MRT Radiobiology Treatments using 177Lu - The Roles of Image Analysis and MCS-48 P. Riss; University Hospital of Wien, Endocrine Surgery, Vienna, J. Pouget; French Institute of Health and Medical Research (Inserm) Dosimetry AUSTRIA. Montpellier Cancer Research Institute (IRCM), Montpellier, FRANCE. C. Kratochwil; Universität Heidelberg, Department of Nuclear Lung Cancer Medicine, Heidelberg, GERMANY. A. Berghoff; Berghoff, Medical University of Vienna, Clinic for MCS-58 MCS-36 Internal Medicine I, Division of Oncology, Vienna, AUSTRIA. MCS-41 Radioiodine Treatment of Hyperthyroidism Why Dosimetry Alone is Not the Answer MCS-49 D. Deandreis; University Hospital Molinette, Nuclear Medicine, A. Sundlöv; Skåne University Hospital, Unit for Endocrine Tumors Dosimetry & Radiobiology for [177Lu]Lu-PSMA- Torino, ITALY. and Radionuclide Therapy, Dept of Hematology, Oncology and Treatments, Whole-Body Tumour Dose Lymphoma Radiation Physics, Lund, SWEDEN. J. Violet; Peter MacCallum Cancer Centre, Radiation Therapy B. Kiesewetter-Wiederkehr; Medical University of Vienna, Clinic for MCS-59 Division, Melbourne, AUSTRALIA. Internal Medicine I, Division of Oncology, Vienna, AUSTRIA. MCS-38 Radioiodine for Benign Disease - Radiation Protection MCS-42 MCS-51 L. Cunha; IsoPor-Azores, Ermesinde, PORTUGAL. How to Combine Dosimetry and Radiobiology Dosimetry & Radiobiology for Tumours in Preclinical U. Eberlein; University of Würzburg, Department of Nuclear [177Lu]Lu-DOTA-TATE Exposures Breast Cancer MCS-60 Medicine, Würzburg, GERMANY . M. Konijnenberg; Erasmus MC, Department of Nuclear Medicine, K. Strasser-Weippl; MBA, Wilheminenspital Vienna, Center for Rotterdam, NETHERLANDS. oncology and hematology, Vienna, AUSTRIA. Risk of Cancer Following Radioiodine Treatment for MCS-39 Hyperthyroidism MCS-52 I. Iakovou; Aristotle University, Nuclear Medicine, Thessaloniki, Biological Aspects of Radionuclide Therapy MCS-44 GREECE. J. Nonnekens; Erasmus MC, Molecular Genetics and Radiology & Prostate Cancer Nuclear Medicine, Rotterdam, NETHERLANDS. Salivary Gland Uptake in [177Lu]Lu-PSMA Therapy - G. Kramer; Medical University of Vienna, Clinic for Urology, Vienna, Current Status and Novel Approaches AUSTRIA. MCS10 A. Eder; University of Freiburg, University Medical Center Freiburg, Mid-Congress-Symposium 10: Diagnostic YDF2 Freiburg, GERMANY. MCS-53 EANM Young Daily Forum 2: I will Survive - Managing Work Stress and Building Your MCS-45 Discussion Image-Based Dosimetry for Bone Marrow in [177Lu]

132 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 133 Flowcharts on Musculoskeletal Infections A. Nordberg; Karolinska University Hospital, Department NVS, B. J. Füger; Medical University of Vienna, Department of Biomedical YDF3 Clinical Geriatrics, Center for Alzheimer Research, Stockholm, Imaging and Image-guided Therapy, Division of General Radiology EANM Young Daily Forum 3: Nothing else SWEDEN. and Pediatric Radiology, Vienna, Austria Wednesday, October 28, 2020, 09:30 - 12:15 Channel 2 matters - Get your paper published in a top journal MCS-74 MCS-82

Wednesday, October 28, 2020, 12:20 - 13:50 Second-Generation Tau PET Tracers Therapy Associated Emergencies Channel 1 MCS-61 J. Seibyl; Institute for Neurodegenerative Disorders, New Haven, E. Kretschmer-Chott; Medical University of Vienna, Department UNITED STATES OF AMERICA. of Biomedical Imaging and Image-guided Therapy, Division of Correct protocols for WBC imaging Nuclear Medicine, Vienna, AUSTRIA . E. Noriega Alvarez; Hospital General Universitario de Ciudad Real, MCS-75 Department of Nuclear Medicine, Ciudad Real, SPAIN. OP-730 MCS-83 Tau and Other Imaging in Alzheimer’s Disease MCS-62 Round Table Discussion G. Bischof; University Hospital Cologne, Department of Nuclear Discussion A. Chiti; Humanitas University, Nuclear Medicine, Milan, ITALY. Medicine, Cologne, GERMANY. T. Traub-Weidinger; Medical University of Vienna, Department EANM’20 EANM’20 EANM’20 Correct protocols for FDG-PET/CT imaging of Biomedical Imaging and Image-guided Therapy, Division of O. Gheysens; University Hospitals Leuven, Department of Nuclear OP-731 MCS-76 Nuclear Medicine, Vienna, AUSTRIA. Medicine, Leuven, BELGIUM. Round Table Discussion Tau Imaging in Non-AD Neurodegeneration MCS13 MCS-63 I. Carrio; Hospital de la Santa Creu i Sant Pau, Department of Mid-Congress-Symposium 13 - Technologists: WORLD LEADING MEETING Nuclear Medicine, Barcelona, SPAIN. MCS12 Introduction to Dosimetry WORLD LEADING MEETING When do we need imaging in PJI? Mid-Congress-Symposium 12: For Youngsters R. Trebse; Medical University Ljubljana, Valdoltra Orthopaedic OP-732 - Emergency During Nuclear Medicine Hospital, Ljubljana, SLOVENIA. Wednesday, October 28, 2020, 09:00 - 16:00 Procedures - What to Know and What to Do? Channel 3 Round Table Discussion MCS-64 J. Czernin; University of California Los Angeles, Molecular and Medical Pharmacology, Los Angeles, UNITED STATES OF AMERICA. Wednesday, October 28, 2020, 14:00 - 16:45 Channel 2 Diagnostic flowcharts in PJI A. Signore; Sapienza University, Department of Medical-Surgical MCS-84 Sciences and Translational Medicine, Rome, ITALY. MCS11 Mid-Congress-Symposium 11: Current State and Welcome by the EANM Technologist Committee Chair MCS-66 Future of Tau PET Imaging MCS-77 A. Santos; Hospital CUF Descobertas, Medicina Nuclear Dep., Lisbon, PORTUGAL. When do we need imaging in spine infections? Emergencies During Nuclear Medicine Applications - The B. Bouyer; Unité de Chirurgie du rachis, Service d’orthopédie- Wednesday, October 28, 2020, 14:00 - 16:45 MCS-85 Channel 1 Young Nuke`s Need traumatologie, University Hospital of Bordeaux, Bordeaux, FRANCE. F. Mattana; Bologna, ITALY. MIRD Scheme MCS-67 J. Gear; The Royal Marsden NHS Foundation Trust, Joint MCS-78 Department of Physics, London, UNITED KINGDOM. Diagnostic flowcharts in spine infections MCS-70 E. Lazzeri; Pisa University Hospital, Regional Center of Nuclear Myocardial Scintigraphy MCS-87 Medicine, Pisa, ITALY. The Clinical Need for Tau PET Tracers S. Graf; Medical University of Vienna, Clinic for Internal Medicine II, V. Garibotto; Nuclear Medicine and Molecular Imaging Division, Division of Cardiology, Vienna, AUSTRIA. Principles of Dosimetry MCS-68 Geneva University Hospitals, Geneva, SWITZERLAND. G. Marin; Institut Jules Bordet, Nuclear Medicine,Brussels,BELGIUM. MCS-79 When do need imaging in FRI? MCS-71 MCS-89 G. Govaert; University Medical Center Utrecht, Department of Lung Scintigraphy Trauma Surgery, Utrecht, NETHERLANDS. Lessons Learnt from the First-Generation Tau PET Tracers H. Domanovits; Medical University of Vienna, Clinic for Emergency Dosimetry in Radionuclide Therapy Planning - R. Ossenkoppele; Alzheimer Center, Amsterdam University Medical Medicine, Vienna, AUSTRIA. Neuroendocrine Tumours (Interactive Cases) MCS-69 Center, Amsterdam, NETHERLANDS. J. Gear; The Royal Marsden NHS Foundation Trust, Joint MCS-81 Department of Physics, London, UNITED KINGDOM. Diagnostic flowcharts in FRI MCS-72 A. Glaudemans; University Medical Center Groningen, Medical Claustrophobia, CT Contrast Agents and Incidental Imaging Center, Groningen, NETHERLANDS. Design Goals for the Ideal Tau PET Tracer Findings

134 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 135 German Cancer Research Center (DKFZ), Heidelberg, GERMANY. MCS-91 1102 1104 Joint Symposium 17 (EANM/EORTC): Benchside Technologists Oral Presentations 2 - Featured Dosimetry in Radionuclide Therapy Planning - Primary and to Bedside and Back - What do we Learn from OP-605 Session: TOP - Technologist Overview and Metastatic Liver Tumours (Interactive Cases) the Clinic? Practice impact G. Marin; Institut Jules Bordet, Nuclear Medicine, Brussels, BELGIUM. Imaging Cellular Components of the Tumour Microenvironment Thursday, October 29, 2020, 13:30 - 15:00 Thursday, October 29, 2020, 13:30 - 15:00 Channel 2 S. Heskamp; Radboud University Medical Center, Radiology and Channel 4 MCS-93 Nuclear Medicine, Nijmegen, NETHERLANDS.

Quantitative Imaging OP-606 I. Armstrong; Manchester University NHS Foundation Trust, Department of Nuclear Medicine, Manchester, UNITED KINGDOM. OP-599 Imaging Metabolic Components of the Tumour OP-608 Microenvironment MCS-95 Immuno-PET to Assess Response to PD-L1 Blockade T. Witney; King’s College London, School of Biomedical Engineering Introduction F. Bensch; Department of Pulmonary Diseases, University Medical M. Attard; UMC Radboud, Radiology and Nuclear Medicine

EANM’20 EANM’20 and Imaging Sciences, London, UNITED KINGDOM. EANM’20 Artificial Intelligence in Nuclear Medicine Center Groningen, Groningen, NETHERLANDS. Department, Nijmegen, NETHERLANDS. D. Visvikis; INSERM UMR 1101 LaTIM UBO, Brest, FRANCE. OP-600 OP-611

1101 Imaging Tumour Metabolism in Response to Two Deep Inspirations - Friend or Foe? WORLD LEADING MEETING CME 9: New PET Technologies - Digital Immunotherapy J. Terzic, M. Rode Pedersen, S. Monrad Laugesen, B. Hoyer WORLD LEADING MEETING Revolution or Big Bust? E. Lopci; Department of Nuclear Medicine, Humanitas Clinical and Mathiasen; Research Center-IRCCS, Milan, ITALY. Department of Nuclear Medicine, Hospital Lillebaelt, Vejle, DENMARK. Thursday, October 29, 2020, 13:30 - 15:00 OP-601 Channel 1 OP-612 Application of Radiolabelled Amino Acids to Brain Tumour Imaging Evaluation of data-driven gating for 68Ga-DOTATOC PET-CT M. Glas; Department of Neurology, University Hospital Essen, in patients with neuroendocrine tumors OP-594 University Duisburg-Essen, Essen, GERMANY. J. Sigfridsson1, H. Romelin1, E. Lindström2,3, S. Kvernby2,3, I. Velikyan1,3, A. Sundin1,3, M. Lubberink1,3; Background on the Recent Developments in PET OP-602 1PET Centre, Uppsala University Hospital, Uppsala, SWEDEN, Technology 2Medical Physics, Uppsala University Hospital, Uppsala, SWEDEN, I. Armstrong; Manchester University NHS Foundation Trust, Development of New Radiolabelled Amino Acids for 3Radiology & Nuclear Medicine, Department of Surgical Sciences, Nuclear Medicine Department, Manchester, UNITED KINGDOM. Neuro-Oncology Applications Uppsala University, Uppsala, SWEDEN. F. de Vos; Ghent University, Department of Radiopharmacy, Ghent, OP-595 BELGIUM. OP-613

Challenges for Heterogeneity Evaluation in the Era of New Predictive value of multiparametric PET/MR in patients PET Technologies 1103 with head and neck squamous cell carcinoma treated with I. Buvat; Paris Diderot University, UMR 8165, Paris, FRANCE. Joint Symposium 18 (EANM/AIO): Imaging chemoradiotherapy Tumour Microenvironment A. Kedves1,2,3, M. Emri2, K. Fabian1, D. Sipos1,2,3, O. Freihat3, J. Tollar1, OP-596 Z. Cselik4, G. Bajzik2, I. Repa2, A. Kovacs1, Z. Toth3,5; New PET Technology - Pushing the Limits 1Department of Medical Imaging, Faculty of Health Sciences, Thursday, October 29, 2020, 13:30 - 15:00 2 N. Aide; University Hospital, Nuclear Medicine Department, Caen, Channel 3 University of Pecs, Kaposvar, HUNGARY, Dr. Jozsef Baka Diagnostic, FRANCE. Radiation Oncology, Research and Teaching Center, Kaposvar, HUNGARY, 3Doctoral School of Health Sciences, University of Pecs, Pecs, HUNGARY, 4Oncoradiology, Csolnoky Ferenc County Hospital, OP-597 Veszprem, HUNGARY, 5MEDICOPUS Healthcare Provider and Public OP-604 Nonprofit Ltd., Somogy County Moritz Kaposi Teaching Hospital, New PET Technology - Clinical Implications Kaposvar, HUNGARY. C. Kobe; University Hospital, Nuclear Medicine Department, The Clinical Relevance of Tumour Microenvironment in Cologne, GERMANY. Solid Tumours M. Trajkovic-Arsic; German Cancer Consortium (DKTK) and

136 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 137 Catania, Messina, ITALY, 4Univ Rennes, Inserm, LTSI UMR 1099, Mora-Ramirez3, K. Newbold1, S. Schlögl4, S. Schumann4, T. Schurrat6, OP-614 1106 Rennes, FRANCE, 5Université de Nantes, CNRS, Inserm, CRCINA, J. Tran-Gia4, D. Vallot5, F. Verburg6, L. Vija5, A. Vergara Gil3, S. Cutting Edge Science Track - TROP Session: F-44000, Nantes, FRANCE, 6ICO René Gauducheau, F-44800, Zerdoud5, G. D. Flux1,2; Comprehensive Review of Zr-89 Immuno-PET in Emerging Dosimetry Methods and Models - Part 2 Saint-Herblain, FRANCE, 7Institute of Radiation Physics, Lausanne 1Royal Marsden Hospital NHSFT, London, UNITED KINGDOM, Clinical Use: What the Technologist Needs to Know University Hospital, Lausanne, SWITZERLAND, 8Department of 2Institute of Cancer Research, London, UNITED KINGDOM, 3Centre A. Scott1, M. Morris2; Mathematics, Computer Science, Physics and Earth Science, de Recherches en Cancérologie de Toulouse INSERM, Toulouse, 1 Thursday, October 29, 2020, 13:30 - 15:00 9 4 Advanced Molecular Imaging and Therapy, LLC, Glen Burnie, MD, Channel 6 University of Messina, Messina, ITALY, SCK​ ​CEN, Belgian Nuclear FRANCE, Department of Nuclear Medicine, University of Würzburg, UNITED STATES OF AMERICA, 2Advanced Molecular Imaging and Research Centre, Boeretang 200, Mol 2400, BELGIUM, 10Radiation Würzburg, GERMANY, 5IUCT Oncopole, Toulouse, FRANCE, Therapy, Glen Burnie, MD, UNITED STATES OF AMERICA. Protection Group, Kantonsspital Aarau, Lausanne, SWITZERLAND, 6Department of Nuclear Medicine, Philipps-University Marburg, 11Institute of Radiology and Nuclear Medicine, Luzerner Marburg, GERMANY. OP-615 Kantonsspital, Lausanne, SWITZERLAND, 12Universidad de Costa OP-619 Rica, Escuela de Física, CICANUM, San Jose, COSTA RICA. OP-626 Clinical Usefulness of 99mTc-DMSA SPECT/CT in Evaluating Focal Defects in Transplanted Kidneys 3D Anthropomorphic Phantom Facilitates Accurate OP-623 Predictive accuracy of pre-therapy 123I-NaI dosimetry for B. Ferreira, A. Parthipun; Dosimetry for Head and Neck Radiopharmaceutical patients treated with 131I-NaI as part of the UK multi-centre An International Multi-Center Investigation on the

EANM’20 EANM’20 Royal Free London, NHS Foundation Trust, London, UNITED Therapy Trials SELIMETRY trial EANM’20 KINGDOM. D. Adam, J. Grudzinski, B. Cox, I. R. Marsh, T. Bradshaw, P. Hill, P. Accuracy of Radionuclide Calibrators for Theranostics in J. Taprogge1,2, S. Yusuf1, J. Gear1,2, I. Murray1,2, F. Leek1, R. A. Gregory3, Harari, B. P. Bednarz; Nuclear Medicine J. Wevrett4, J. Scuffham5,4, J. Tipping6, B. Murby6, S. Jeans6, M. OP-616 University of Wisconsin-Madison, Madison, WI, UNITED STATES OF C. Saldarriaga Vargas1,2, M. Bauwens3, I. N. A. Pooters3, S. Pommé4, Stuffins4, S. Michopoulou7, M. Guy7, D. Morgan8, A. Hallam8, D. Hall9, AMERICA. S. M. B. Peters5, M. Segbers6, W. Jentzen7, A. Vogg8, F. H. P. van H. Polydor9, C. Brown10, G. Gillen10, N. Dickinson11, S. Brown12, G. Serum Creatinine Measurement as a Predictor for Single Velden9, S. L. Meyer Viol10, M. Gotthard5, F. M. Mottaghy3,8, J. E. Ainsworth12, J. Wadsley13, G. D. Flux1,2; WORLD LEADING MEETING WORLD LEADING MEETING Sample GFR using [99mTc]Tc-DTPA Wildberger3, P. Covens2, R. Wierts3; 1Royal Marsden Hospital NHSFT, London, UNITED KINGDOM, A. Matos, C. Findlay, G. Hilland, S. Small; OP-620 1Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM, 2Vrije 2Institute of Cancer Research, London, UNITED KINGDOM, 3Barts Department of Nuclear Medicine, Gartnavel General Hospital, NHS Universiteit Brussel, Jette, BELGIUM, 3Maastricht University Medical Health NHS Trust, London, UNITED KINGDOM, 4Royal Surrey County Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM. Making a copy of conventional anthropomorphic phantom Center, Maastricht, NETHERLANDS, 4European Commission Joint Hospital NHS Foundation Trust, Guildford, UNITED KINGDOM, section by 3D printing Research Centre (JRC), Geel, BELGIUM, 5Radboudumc, Nijmegen, 5National Physical Laboratory, Teddington, UNITED KINGDOM, 6The OP-617 S. Stuchebrov1, A. Bulavskaya1, Y. Cherepennikov1, A. Grigorieva1, I. NETHERLANDS, 6Erasmus MC, Rotterdam, NETHERLANDS, Christie NHS Foundation Trust, Manchester, UNITED KINGDOM, 7 Miloichikova1,2, E. Gargioni3; 7University of Duisburg-Essen, Essen, GERMANY, 8University Hospital University Hospital Southampton NHS Foundation Trust, 8 Improved Comfort and Image Quality When Using 1Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, RWTH Aachen University, Aachen, GERMANY, 9Leiden University Southampton, UNITED KINGDOM, Oxford University Hospitals 10 9 Purpose-Built Support For Hand and Wrist SPECT/CT In 2Cancer research institute of Tomsk national research medical Medical Center, Leiden, NETHERLANDS, University Medical Center NHS Foundation Trust, Oxford, UNITED KINGDOM, University center of the Russian academy of sciences, Tomsk, RUSSIAN Utrecht, Utrecht, NETHERLANDS. Hospitals Bristol NHS Foundation Trust, Bristol, UNITED KINGDOM, Supine Position 10 FEDERATION, 3University Medical Center Hamburg-Eppendorf, NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM, A. Leite, M. Humphrys, B. Walker, M. Jessop; 11 Hamburg, GERMANY. OP-624 Nottingham University Hospitals NHS Trust, Nottingham, UNITED Brighton and Sussex University Hospitals NHS Trust, Brighton, KINGDOM, 12CTRU, University of Leeds, Leeds, UNITED KINGDOM, UNITED KINGDOM. 13 OP-621 A correlation study between clinical outcome and Weston Park Hospital, Sheffield, UNITED KINGDOM. absorbed dose to organs at risk and lesions for patients OP-618 The dosimetric impact of deformable image registration with High-Risk Neuroblastoma administered with high- OP-627 on multi-timepoint internal dosimetry studies activity therapy of 131I-mIBG Somatostatin Receptor-Based Imaging with 99mTc-EDDA/ Absorbed dose estimation of thyroid residues, salivary I. Marsh, J. J. Grudzinski, R. Hernandez, M. M. Turek, D. M. Vail, Z. S. B. Cassano1, M. Pizzoferro2, S. Valeri3, S. Donatiello1, C. Polito1,4, D. 131 HYNIC-TOC: Departmental Protocol Update to Include Morris, J. P. Weichert, B. P. Bednarz; Ciucci1,3, F. Martire1,3, A. Castellano5, C. Altini2, M. C. Garganese2, V. glands and distal metastases after I therapy using Whole Body SPECT-CT University of Wisconsin-Madison, Madison, WI, UNITED STATES OF Cannatà1; SPECT/CT with scatter, dead time and partial volume R. Martins, L. Aloj, I. Harper; AMERICA. 1IRCCS Bambino Gesù Children’s Hospital, Medical Physics Unit, correction Addenbrooke’s Hospital, CUH, Cambridge, UNITED KINGDOM. Rome, ITALY, 2IRCCS Bambino Gesù Children’s Hospital, Nuclear M. Abuqbeitah, M. Demir, S. Sager, N. Yeyin, K. Sonmezoglu; OP-622 3 Medicine Unit/Imaging Department, Rome, ITALY, Tor Vergata Istanbul University, Istanbul, TURKEY. Postgraduate School of Medical Physics, Rome, ITALY, 4Sapienza OpenDose3D: A free, collaborative 3D Slicer module for University of Rome, Postgraduate School of Medical Physics, Rome, patient-specific dosimetry ITALY, 5IRCCS Bambino Gesù Children’s Hospital, Oncoemathology OP-628 A. Vergara Gil1, E. Amato2,3, L. Auditore2, M. Brenet4, M. Chauvin1, N. Unit, Rome, ITALY. Clayton1, L. Ferrer5,6, B. Gibaud4, S. Gnesin7, A. Italiano3,8, G. Kayal1,9, T. Optimization of a dual-energy quantitative computed Lima7,10,11, J. Ocampo1, D. Pistone3,8, G. Quan1, E. Mora Ramirez12, J. OP-625 tomography (DEQCT) method to quantify the mineral 10 1 Ruegger , M. Bardies ; bone volume fraction (MBVF) for bone marrow dosimetry 1CRCT, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, The MEDIRAD imaging network - Standardisation of in molecular radiotherapy Toulouse, FRANCE, 2Department of Biomedical and Dental Sciences quantitative radioiodine imaging M. Salas Ramírez, J. Tran-Gia, M. Lassmann; and of Morphologic and Functional Imaging, University of Messina, J. Taprogge1,2, F. Leek1,2, M. Bardiès3, A. Buck4, N. Clayton3, F. 3 Department of Nuclear Medicine, University of Würzburg, Messina, ITALY, Istituto Nazionale di Fisica Nucleare, Sezione di 5 4 4 4 6 Courbon , U. Eberlein , C. Lapa , M. Lassmann , M. Luster , E. Würzburg, GERMANY.

138 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 139 OP-629 OP-634 OP-637 OP-641

Implementation of SPECT auto-contouring detector Covid-19 Infection Patterns of failure on 68Ga-PSMA-11 PET/CT after radical 68Ga-PSMA PET/CT prospective study in prostate cancer motion in GATE Monte Carlo simulation for177Lu and 131I J. Talbot; Hopital Tenon & Sorbonne Université, Nuclear Medicine, prostatectomy (RP), radiotherapy (RT), and RP with post- occult recurrence patients: diagnostic performance, Molecular Radiotherapy (MRT) dosimetry Paris, FRANCE. operative RT (RP-PORT) impact on therapeutic decision-making and long-term G. Kayal1,2, M. Chauvin1, E. Mora-Ramirez3, L. Struelens2, M. M. Rodnick, M. Abghari-Gerst, J. W. D. Hearn, J. S. Montgomery, A. benefits Bardiès1; Alva, Z. Reichert, D. E. Spratt, T. D. Johnson, P. J. H. Scott, M. Piert; C. Rousseau1, L. Ferrer1, M. Le Thiec2, V. Fleury2, M. Frindel2, D. 1 2 1108 CRCT, INSERM, Toulouse, FRANCE, SCK CEN, Belgian Nuclear The University of Michigan, Ann Arbor, MI, UNITED STATES OF Rusu2, B. Maucherat2, A. Rauscher2, P. Baumgartner2, A. Morel2, N. Research Centre, Mol, BELGIUM, 3Universidad de Costa Rica, Clinical Oncology Track - TROP Session: AMERICA. Varmenot1, L. Campion1, F. Kraeber-Bodéré1; Escuela de Física, CICANUM, San José, COSTA RICA. Detecting BCR with [68Ga]Ga-PSMA 1ICO René Gauducheau, F-44000 Saint-Herblain; Nantes University, CNRS, Inserm, CRCINA, F-44000, Nantes, FRANCE, 2ICO OP-638 René Gauducheau, F-44000, St Herblain, FRANCE. OP-630 Thursday, October 29, 2020, 13:30 - 15:00 Channel 8 Recurrence patterns after radical prostatectomy, Generation of realistic SPECT/CT images for 177Lu definitive radiation therapy and salvage radiation OP-642 EANM’20 EANM’20 EANM’20 dosimetry in Molecular Radiotherapy (MRT) based on therapy with 68Ga-PSMA-11 PET/CT in non-metastatic Forced diuresis with furosemide increases diagnostic Monte Carlo simulation with GATE castrate sensitive prostate cancer patients: a single 1,2 1 1 1 2 OP-635 certainty in the assessment of local recurrence in prostate G. Kayal , M. Chauvin , A. Vergara-Gil , N. Clayton , L. Struelens , center post-hoc retrospective analysis 1 cancer patients with biochemical recurrence referred for M. Bardiès ; W. Armstrong, P. Thin, R. Alano, K. Nguyen, K. Booker, J. 1 2 Multicentre External Validation of a Prediction CRCT, INSERM, Toulouse, FRANCE, SCK CEN, Belgian Nuclear 68 WORLD LEADING MEETING Gartmann, V. Lok, S. Lira, I. Sonnie, N. G. Nickols, A. U. Kishan, J. [ Ga]Ga-PSMA-11-PET/CT compared to patients without WORLD LEADING MEETING Nomogram for 68Ga-PSMA-11 PET/CT in different Clinical Research Centre, Mol, BELGIUM. Czernin, J. Calais; preparation Settings of PSA Failure, after Radical Treatment for University of California, Los Angeles, Los Angeles, CA, UNITED C. Uprimny, S. Bayerschmidt, A. S. Kroiss, H. Svirydenka, G. di 1107 Prostate Cancer STATES OF AMERICA. Santo, B. Nilica, S. Rauch, E. von Guggenberg, C. Decristoforo, I. J. F. Ceci1, L. Bianchi2,3, P. Castellucci4, C. Artigas5, J. Leite6, P. Corona7, Virgolini; Pitfalls & Artefacts 5: FDG-PET Performed or 4 5 6 7 1 A. Farolfi , Q. A. Shagera , R. Moreira , C. González , D. Deandreis , OP-639 Medical University of Innsbruck, Innsbruck, AUSTRIA. Suspicious for Infections and Inflammation, S. Fanti4,3; Including COVID-19 - Fever, Vascular Graft, 1Nuclear Medicine, Department of Medical Sciences, University Performance of 68Ga-PSMA-11 PET/CT in patients with Granulomatosis, Covid-19 of Turin, Turin, ITALY, 2Department of Urology, S.Orsola-Malpighi OP-643 University Hospital, Bologna, ITALY, 3Department of Specialistic, recurrent prostate cancer. A multi-centre evaluation of Diagnostic and Experimental Medicine, University of Bologna, 2533 patients The influence of digital PET/CT on diagnostic certainty 68 Thursday, October 29, 2020, 13:30 - 15:00 4 1 2 2 Channel 7 Bologna, ITALY, Nuclear Medicine, S.Orsola-Malpighi University A. Afshar-Oromieh , M. Livorsi da Cunha , J. Wagner , U. and interrater reliability in Ga-PSMA-11 PET/CT for Hospital, Bologna, ITALY, 5Department of Nuclear Medicine, Haberkorn3, W. Weber4, M. Eiber4, T. Holland-Letz5, I. Rauscher4; recurrent prostate cancer Institut Jules Bordet, Université Libre de Bruxelles, Bruxelles, 1Department of Nuclear Medicine, University Hospital of Bern, I. Alberts, J. Hünermund, C. Sachpekidis, C. Mingels, V. Fech, K. BELGIUM, 6PET/CT Center, DASA - Diagnósticos da Améric, Rio de University of Bern, Bern, SWITZERLAND, 2Department of Nuclear Bohn, A. Rominger, A. Afhsar-Oromieh; Janeiro, BRAZIL, 7Fundación Centro Diagnóstico Nuclear (FCDN), Medicine, Hospital Israelita Albert-Einstein, Sao Paulo, BRAZIL, Institut für Nuklearmedizin, Bern, SWITZERLAND. OP-631 Buenos Aires, ARGENTINA. 3Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, GERMANY, 4Department of Nuclear Medicine, Fever or Inflammatory Syndrome of Unknown Origin OP-636 Technical University of Munich, Munich, GERMANY, 5Department OP-644 S. Balogova; Comenius University and St. Elisabeth Oncology of Biostatistics, German Cancer Research Center, Heidelberg, Institute, Nuclear Medicine, Bratislava, SLOVAKIA. A phase II, open-label single-arm study to assess safety, GERMANY. The value of early dynamic imaging in 68Ga-PSMA PET/CT clinical utility of disease burden assessments with in prostate cancer patients with biochemical recurrence OP-632 68Ga-PSMA-11 PET/CT in localizing recurrent prostate OP-640 S. Castro, G. Ferreira, L. Violante, J. Teixeira, I. Sampaio Lucena, H. cancer Duarte; Vascular Grafts Infections Early BCR: in which patients is it worth performing a Portuguese Institute of Oncology - Porto, Porto, PORTUGAL. M. Piert1, M. Abghari-Gerst2, M. Rodnick2, J. Hearn2, J. S. C. Lauri; Sant’Andrea Hospital of Rome, Nuclear Medicine Unit, Montgomery2, A. Alva2, Z. Reichert2, D. Spratt2, P. J. H. Scott2; further PSMA scan? Rome, ITALY. 1 1 2 1 1 OP-645 1University of Michigan, Ann Arbor, MI, UNITED STATES OF A. Paccagnella , A. Farolfi , G. Ricci , P. Castellucci , F. Mattana , L. 1 1 AMERICA, 2University of Michigan, Ann Arbor, MI, UNITED STATES Muraglia , S. Fanti ; 1 Is there any clinical-pathological variable able to predict OP-633 OF AMERICA. Department of Nuclear Medicine, Policlinico S.Orsola, University of Bologna, Bologna, ITALY, 2Department of Nuclear Medicine, M. a true positive 68Ga- PSMA PET/CT result? Granulomatous Diseases Bufalini Hospital, Cesena, ITALY. J. Bastidas, F. Grisanti, J. J. Rosales, A. Bronte, A. Erhard, B. Miñana, V. Ambrosini; University of Bologna, S.Orsola-Malpighi Hospital, C. Guitierrez, J. Perez Gracia, J. A. Richter, M. Rodriguez; Nuclear Medicine DIMES, Bologna, ITALY . Clinica Universidad de Navarra, Pamplona, SPAIN. OP-646

140 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 141 Pathological lesions are at risk to be missed in linear Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN 1110 OP-662 colour scales in 68Ga-PSMA-11 PET/CT FEDERATION. 1 1,2 1 1 1 Cutting Edge Science Track - Featured Session: C. Mingels , C. Sachpekidis , J. Hünermund , K. P. Bohn , V. Fech , Relationship between histopathological parameters and A. Rominger1, A. Afshar-Oromieh1, I. Alberts1; Radiomics OP-651 18F-FDG PET radiomic features in breast cancer patients 1Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND, 2Clinical F. Görtan, N. Coskun, N. C. M. Gülaldi; Determinants of myocardial perfusion reserve assessed Thursday, October 29, 2020, 13:30 - 15:00 Cooperation Unit Nuclear Medicine, German Cancer Research Channel 10 Turkish Ministry of Heath, Ankara City Hospital, Department of Center, Heidelberg, GERMANY. by dynamic stress 201Tl/rest99mTc-tetrofosmin single Nuclear Medicine, Ankara, TURKEY. photon emission computed tomography in patients with OP-663 1109 diabetes mellitus and stable coronary artery disease J. Choi, E. Shin, M. Oh, S. Chae, C. Lee, D. Moon; OP-658 Preliminary comparative results between FES and FDG in Featured Session: Advances in SPECT-MPI Asan Medical Center, Seoul, KOREA, REPUBLIC OF. ER+ metastatic breast cancer: a radiomic approach Recent Advances in Radiomics and Challenges Left to L. Ferrer1,2, B. Maucherat1, T. Carlier2,3, F. Kraeber-Bodéré1,2,3, C. Thursday, October 29, 2020, 13:30 - 15:00 OP-652 1,2 Channel 9 Overcome Rousseau ; 1ICO René Gauducheau, St Herblain cedex, FRANCE, 2University EANM’20 EANM’20 M. Hatt; LaTIM, INSERM, UMR 1101, Univ Brest, Brest, FRANCE. EANM’20 Comparison of dynamic SPECT Myocardial Blood Flow of Nantes, CNRS, INSERM CRCINA, Nantes, FRANCE, 3University and Flow Reserve with regadenoson and dipyridamole hospital, Nantes, FRANCE. M. Bailly1, Q. Brana1, F. Thibault1, M. Courtehoux2, G. Metrard1, D. OP-647 Angoulvant2, M. Ribeiro2; OP-659 OP-664 1CHR Orléans, Orleans, FRANCE, 2CHRU Tours, Tours, FRANCE. WORLD LEADING MEETING Quantification of MBF with SPECT - Ready for Clinical Complementary diagnostic value of PSMA PET and MR Identifying a reliable radiomic signature from scarce WORLD LEADING MEETING Use? OP-654 radiomics for prostate cancer staging data: illustration for 18F-FDOPA PET images in A. Manrique; Normandie Université - EA 4650, CHU de Caen, E. Solari1, A. Gafita1, D. Visvikis2, W. Weber1, M. Eiber1, M. Hatt2, S. glioblastoma patients The detection of multivessel coronary artery disease: the 1 Caen, FRANCE. G. Nekolla ; F. Orlhac1,2, A. Rollet3, I. Buvat1, J. Darcourt3,4, V. Bourg5, C. Nioche1, value of SPECT CZT myocardial blood flow and coronary 1Nuklearmedizinische Klinik, Klinikum rechts der Isar, München, C. Bouveyron6, N. Ayache2, O. Humbert3,4; 2 OP-648 flow reserve assessment GERMANY, LaTIM, INSERM, Univ. Brest, Brest, FRANCE. 1Institut Curie, Inserm, U1288 LITO, Orsay, FRANCE, 2Université K. Zavadovsky1, A. Mochula1, A. Maltseva1, A. Baev1, S. Andreev1, Côte d’Azur, Inria, Epione, Sophia-Antipolis, FRANCE, 3Université Fully-automatic data-driven motion correction improves R. Liga2, A. Gimelli3; OP-660 Côté d’Azur, Centre Antoine Lacassagne, Service de Médecine the diagnostic performance of myocardial perfusion 1Cardiology Research Institute, Tomsk National Research Nucléaire, Nice, FRANCE, 4Université Côté d’Azur, CEA, TIRO, imaging with CZT cameras Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN Complementarity of PET and MR radiomic features for Nice, FRANCE, 5Université Côté d’Azur, CHU Pasteur 2, Service de 6 C. Ko1,2, K. Ko1, R. Yen1, C. Chen2; FEDERATION, 2Università di Pisa, Pisa, ITALY, 3Fondazione Toscana/ the characterization of lung cancers Neurologie, Nice, FRANCE, Université Côte d’Azur, Inria, MAASAI, 1National Taiwan University Hospital, Taipei, TAIWAN, 2Biomedical CNR Gabriele Monasterio, Pisa, ITALY. F. Orlhac1, M. Lacroix1,2, I. Buvat1, J. Bernaudin3, C. Nioche1, M. Nice, FRANCE. Engineering, National Taiwan University, Taipei, TAIWAN. Soussan1,4, P. Brillet2, F. Frouin1; OP-657 1Institut Curie, Inserm, U1288 LITO, Orsay, FRANCE, 2AP-HP, Hôpital OP-665 Avicenne, Service de radiologie, Bobigny, FRANCE, 3Université OP-649 Long-term prognostic value of gated SPECT after Paris 13, Inserm, UMR 1272 Hypoxie et Poumon, Bobigny, FRANCE, Textural features combined with static and dynamic acute myocardial infarction and primary percutaneous 4AP-HP, Hôpital Avicenne, Service de médecine nucléaire, Bobigny, parameters of 18F-FDopa PET imaging for the non- Evaluation Of Coronary Flow Reserve By A New Method coronary intervention FRANCE. invasive prediction of the IDH mutation status in glioma Using Routine Myocardial SPECT And Comparison A. D’Antonio, E. Zampella, R. Assante, V. Gaudieri, C. Nappi, T. T. Zaragori1,2, J. Oster1, M. B. Chawki2, B. Chen1,3, V. Roch2, L. To Dynamic SPECT With The Same Patients For Both Mannarino, G. De Simini, A. Giordano, V. Cantoni, R. Green, P. OP-661 Taillandier4,5, G. Karcher2, L. Imbert2,1, A. Verger2,1; Methods Buongiorno, W. Acampa, A. Cuocolo; 1Université de Lorraine, IADI, INSERM, UMR 1254, Vandoeuvre- Radiomics and FDG PET/CT in cervical cancer: a single 2 L. Philippe1, M. Bailly2, Y. El Yaagoubi1, C. Prunier-Aesch1; Department of Advanced Biomedical Sciences, University lès-Nancy, FRANCE, CHRU-Nancy, Université de Lorraine, 1Medecine Nucleaire Tourangelle, Chambray-les-Tours, FRANCE, “Federico II” of Naples, Naples, ITALY. centre experience Department of Nuclear Medicine & Nancyclotep Imaging 1 1 1 1 2 3 2Médecine Nucléaire - CHR Orléans, Orléans - La Source, FRANCE. F. Mattana , A. Farina , S. Telo , N. Fraccascia , G. M. Lima , S. platform, Vandoeuvre-lès-Nancy, FRANCE, CIC-IT 1433, INSERM, Strolin3, E. Loi3, E. De Crescenzo4, A. M. Perrone4, P. De Iaco4, L. CHRU de Nancy and Université de Lorraine, Vandoeuvre- Strigari3, C. Nanni1, S. Fanti1; lès-Nancy, FRANCE, 4CHRU-Nancy, Université de Lorraine, OP-650 1Department of Nuclear Medicine, S.Orsola-Malpighi University Department of Neuro-oncology, Vandoeuvre-lès-Nancy, FRANCE, Hospital, Bologna, ITALY, 2Department of Nuclear Medicine, 5Université de Lorraine, Centre de Recherche en Automatique de The evaluation of myocardial blood flow and coronary Modena University Hospital, Modena, ITALY, 3Medical Physics Nancy CRAN, CNRS UMR 7039, Vandoeuvre-lès-Nancy, FRANCE. flow reserve in myocardial infarction with non- Unit, S.Orsola-Malpighi University Hospital, Bologna, ITALY, 4 obstructive coronary arteries patients Department of Obstetrics and Gynecology, S.Orsola-Malpighi OP-666 University Hospital, Bologna, ITALY. K. Zavadovsky, A. Mochula, A. Maltseva, D. Vorobyeva, M. Gulya, V. Shipulin, V. Ryabov; The influence of central necrosis on radiomic analysis 1,2 1 1,3 4 Cardiology Research Institute, Tomsk National Research W. A. Noortman , D. Vriens , C. D. Y. Mooij , E. H. Aarntzen , A.

142 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 143 van Berkel4, H. J. L. M. Timmers4, J. Bussink4, T. W. H. Meijer4, L. F. de Geus-Oei1,2, F. H. P. van Velden1; OP-671 OP-678 1303 1Leiden University Medical Center, Leiden, NETHERLANDS, Joint Symposium 20 (EANM/ECNP): 2University of Twente, Enschede, NETHERLANDS, 3Delft University Brain Tracers - Finally for Clinical Application? Perspectives of Artificial Intelligence and Radiomics in Simultaneous PET/MR Imaging of of Technology, Delft, NETHERLANDS, 4Radboud University Medical V. Garibotto; Nuclear Medicine and Molecular Imaging Division, Thyroid Imaging (Studies with US and MR) Neuroreceptor Systems Center, Nijmegen, NETHERLANDS. Geneva University Hospitals, Geneva, SWITZERLAND. M. Kirienko; Department of Biomedical Sciences, Humanitas University, Milan, ITALY. OP-672 Thursday, October 29, 2020, 16:35 - 18:05 Channel 3 OP-667 1302 Is Theranostics the Future in Nuclear Medicine? A Phantom Study to Evaluate the Stability of PET Images M. Hofman; Peter MacCallum Cancer Centre, Molecular Imaging, Joint Symposium 19 (EANM/ENETS): Impacting Radiomic Features with Time of Acquisition Melbourne, AUSTRALIA. the Outcome of High Grade NET Patients E. Alsyed1, R. Smith2, L. Bartley2, C. Marshall2, E. Spezi1; OP-682 1 2 OP-673 Thursday, October 29, 2020, 16:35 - 18:05 Cardiff University, Cardiff, UNITED KINGDOM, Wales Research & Channel 2 Diagnostic PET Imaging Centre, Cardiff, UNITED KINGDOM. Functional Characterization of Drugs Targeting the 5-HT Do we need Specific Tracers in the Clinics? 1B Receptors EANM’20 EANM’20 EANM’20 OP-668 E. Ocak; Istanbul University, Pharmacy Faculty, Department of H. Hansen; Massachusetts General Hospital, Athinoula A. Pharmaceutical Technology, Istanbul, TURKEY. Martinos Center for Biomedical Imaging, Charlestown, MA, A transfer learning approach to facilitate ComBat-based OP-679 UNITED STATES OF AMERICA. harmonization of multicentre radiomic features in new OP-674 datasets Nuclear Medicine Physicians´ View (PRRT; SIRT) OP-683 WORLD LEADING MEETING Why does it take so long? WORLD LEADING MEETING M. Hatt1, F. Lucia2,1, I. Masson3, A. Mervoyer3, C. Reinhold4, P. H. Ahmadzadehfar; Westfalen Clinic Robin5, J. Alfieri6, C. Rousseau7, O. Pradier2,1, U. Schick2,1, D. Visvikis1, J. Sosabowski; Queen Mary University of London, Barts Cancer (Knappschaftskrankenhaus), Department of Nuclear Medicine, PET and MR Studies of the µ-Opioid and Dopamine R. Da-ano1; Institute, Centre for Molecular Oncology, London, UNITED Dortmund, GERMANY. Receptor Systems 1INSERM, LaTIM, UMR 1101, Brest, FRANCE, 2CHU Brest, KINGDOM. L. Nummenmaa; University of Turku, Turky PET radiotherapy department, Brest, FRANCE, 3Department of OP-680 Center,Turku,FINLAND. Radiation Oncology, Institut de cancérologie de l’Ouest OP-675 René-Gauducheau, Saint-Herblain, FRANCE, 4Department Oncologists´ View OP-684 of Radiology, McGill University Health Centre, Montreal, QC, Discussion N. Fazio; European Institute of oncology, IEO, Division of CANADA, 5CHU Brest, Department of Nuclear Medicine, Brest, Gastrointestinal Medical Oncology and Neuroendocrine Tumors Demonstrating Biased Agonism of Neuroreceptors with FRANCE, 6Department of Radiation Oncology, McGill University 1301 ,Milan, ITALY. Simultaneous PET/MRI 7 Health Centre, Montreal, QC, CANADA, Department of Nuclear CME 10: Radiomics in Thyroid Imaging L. Zimmer; Lyon University Hospital, Lyon Neuroscience Research Medicine, Institut de cancérologie de l’Ouest René-Gauducheau, OP-681 Center, Lyon, FRANCE. Saint-Herblain, FRANCE. Thursday, October 29, 2020, 16:35 - 18:05 Surgeons´ View Channel 1 1201 A. Frilling; Imperial Collage London / Hammersmith Campus, 1304 Plenary 3: What’s Cooking? Next Generation Department of Surgery and Cancer, London, UNITED KINGDOM. Technologists Oral Presentations 3 - Featured Radiopharmaceuticals Session: BOTH ART - The Beauty Of The HeART and mind OP-676 Thursday, October 29, 2020, 15:10 - 16:25 Channel 1 Imaging Biomarkers in Thyroid Nodules and Cancer Thursday, October 29, 2020, 16:35 - 18:05 Channel 4 (General Concept, Omics) M. Sollini; Nuclear Medicine Department, Humanitas Clinical and Research Center - IRCCS; Department of Biomedical Sciences, OP-669 Humanitas University, Milan, ITALY. OP-685 What’s New? OP-677 M. Fani; University Hospital Basel, Nuclear Medicine, Basel, Introduction to Brain Imaging SWITZERLAND. PET Radiomics in the Characterization of Thyroid Nodules A. Pietrzak; Greater Poland Cancer Centre and Poznan University (FDG/PSMA/FDOPA/DOTA) of Medical Sciences, Nuclear Medicine Dep./Electroradiology Dep., OP-670 C. Lapa; Nuclear Medicine Department, University Hospital Poznan, POLAND. Augsburg, Ausburg, GERMANY . FAP-Inhibitors are the Future - For Everything? U. Haberkorn; Heidelberg University Hopsital, Department of Nuclear Medicine, Heidelberg, GERMANY.

144 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 145 Kumamoto, JAPAN, 2Faculty of Life Sciences Kumamoto Search for the optimal bis-iminobiotin for the M. Verhoeven, M. Handula, K. Chen, M. de Jong, Y. Seimbille, S. U. OP-686 Univercity, Kumamoto, JAPAN, 3Kumamoto University Hospital, pretargeting strategy using a mutated low immunogenic Dalm; Kumamoto, JAPAN. Erasmus MC, Rotterdam, NETHERLANDS. Traumatic Brain Injury Induced Amyloid Plaque streptavidin 1 2 1 2 1 Scintigraphy K. Washiyama , T. Tatsumi , S. Zhao , A. Sugiyama , M. Aoki , K. Yamatsugu2, N. Ukon1, K. Nishijima1, S. Shimoyama1, C. Tan1, T. A. Datta1, G. Mann1,2, A. Kaul1, M. Thirumal2, A. Mishra1; OP-694 OP-705 Joho1, N. Oriuchi1, M. Kanai2, K. Takahashi1, T. Kodama2; 1Institute of Nuclear Medicine and Allied Sciences, Delhi, INDIA, 1Fukushima Medical University, Fukushima, JAPAN, 2The University 2University of Delhi, Delhi, INDIA. Evaluation of extent and severity of myocardial perfusion The “click” chemistry approach as in vivo pre-targeting of Tokyo, Tokyo, JAPAN. defects: quantitative [perfusion SCOREs] and qualitative strategy for microspheres and bacteria OP-687 [segments] analysis M. M. Welling1, N. Duszenko1,2, D. M. van Willigen1, T. Buckle1, D. D. A. Ghilardi1, G. Medolago2; OP-701 D. Rietbergen1,3, M. Roestenberg2, F. W. B. van Leeuwen1; Does gadolinium deposition in the brain affect to F18- 1ASST-PG23, Bergamo, ITALY, 2Humanitas Gavazzeni, Bergamo, 1Interventional Molecular Imaging, Department of Radiology, 177 FDG brain uptake? ITALY. Comparative evaluation of novel Lu-labeled Leiden University Medical Center, Leiden, NETHERLANDS, R. Sanchez Jurado1, E. Blanco Perez2; PNA conjugates for affibody mediated PNA-based 2Department of Parasitology and Department of Infectious 1ERESA, Valencia, SPAIN, 2Alzira’s Hospital, Valencia, SPAIN. pretargeting Diseases, Leiden University Medical Center, Leiden, NETHERLANDS, 3 OP-695 1 1,2 1 1 3 Section of Nuclear Medicine, Department of Radiology, Leiden EANM’20 EANM’20 M. Oroujeni , A. Vorobyeva , Y. Liu , T. Xu , H. Tano , L. EANM’20 University Medical Center, Leiden, NETHERLANDS. OP-688 Vasconcelos3, K. Westerlund3, A. Karlström3, A. Orlova4,2, V. Introduction to COVID-19 Pandemic Tolmachev1,2; Preliminary Results of Developing a Planar Camera for L. Camoni; Università & Spedali Civili di Brescia, Brescia, ITALY 1Department of Immunology, Genetics and Pathology, 1306 Building an Open-type Brain-PET scanner Uppsala University, Uppsala, SWEDEN, 2Research Centrum for Cutting Edge Science Track - Featured Session: H. Liang, H. Wu, C. Cheng, C. Lin; OP-696 Oncotheranostics, Research School of Chemistry and Applied Intra-Operative Nuclear Medicine WORLD LEADING MEETING INER (Institute of Nuclear Energy Research), Taoyuan, TAIWAN. Biomedical Sciences, Tomsk Polytechnic University, Tomsk, WORLD LEADING MEETING Ventilation scintigraphy: is it really safe now with COVID- RUSSIAN FEDERATION, 3Department of Protein Science, School OP-689 of Engineering Sciences in Chemistry, Biotechnology and Thursday, October 29, 2020, 16:35 – 17:50 19 pandemic? Channel 6 S. Mendes, I. Ferreira, J. Isidoro, G. Costa, P. Soeiro, J. P. Lima; Health, KTH Royal Institute of Technology, Stockholm, SWEDEN, Introduction to Cardiac Imaging Hospitais da Universidade de Coimbra, Coimbra, PORTUGAL. 4Department of Medicinal Chemistry, Uppsala University, L. Camoni; Università & Spedali Civili di Brescia, Brescia, ITALY Uppsala, SWEDEN. OP-697 OP-690 OP-702 OP-706 Management of COVID-19 pandemic in Nuclear Start of a new Cardiac PET service with Rb-82 in a UK Medicine Departments: a contribute for the Portuguese Tetrazine-functionalized clearing agent to increase Introduction based hospital: operational management of patients community contrast in antibody imaging B. Sattler; University Hospital Leipzig, Department for Nuclear pathway P. Costa, J. Lemos, D. Vieira, N. Arantes; E. Schlein1, J. Rokka1, T. Gustavsson1, J. Eriksson2,3, S. Syvänen1, D. Medicine, Leipzig, GERMANY G. Testanera, L. Menezes, L. Price, M. Burniston, R. Gregory, C. Nuclear Medicine Department, School of Health, Politécnico do Sehlin1; Copland; Porto, Porto, PORTUGAL. 1Department of Public Health and Caring Sciences, Uppsala OP-707 Barts Health NHS Trust, London, UNITED KINGDOM. University, Uppsala, SWEDEN, 2PET Centre, Uppsala University Hospital, Uppsala, SWEDEN, 3Department of Medical Chemistry, First clinical experiences with an innovative Gamma- 1305 Uppsala University, Uppsala, SWEDEN. probe to guide parathyroid radio-guided surgery: OP-691 Navigator and Lock-on-target functions of the M2M Track - Featured Session: The Revival of OP-703 Pre-Targeting Gonioprobe Assessment of the effect of fasting on stomach V. Frantellizzi, M. S. De Feo, S. Sollaku, R. Falconi, R. Pani, M. Evaluation of therapeutic effect of the targeted alpha interference on Rubidium-82 PET-CT MPI Bononi, J. Lazri, A. Matto, G. De Vincentis; Sapienza University of Thursday, October 29, 2020, 16:35 – 17:45 therapy using Cupid-211At-labeled Psyche-B pretargeting G. Testanera, B. Ribeiro, R. Gregory, M. Costa, S. Ferreira, S. Channel 5 Rome, Rome, ITALY. Townrow, A. Simeonova, C. Copland, L. Price, M. Burniston, L. system in a human gastric cancer cell xenograft Menezes; S. Zhao1, A. Sugiyama2, N. Ukon1, S. Shimoyama1, T. Tatsumi2, M. Barts Health NHS Trust, London, UNITED KINGDOM. Aoki1, F. Gao1, K. Yamatsugu2, K. Nishijima1, T. Joho1, N. Oriuchi1, K. OP-708 Takahashi1, M. Kanai2, T. Kodama2, K. Washiyama1; OP-693 OP-698 1Fukushima Medical University, Fukushima, JAPAN, 2The University Towards a drop-in beta probe for robotic radio guided of Tokyo, Tokyo, JAPAN. surgery The investigation of automated region growing method Pretargeting From Past to Present F. Collamati1, C. Mancini-Terracciano1, S. Morganti1, E. Solfaroli- for the detection of heart to streamline calculation of J. Barbet; GIP Arronax, Université de Nantes, Centre de Recherche Camillocci1, R. A. Valdes Olmos2, F. W. B. van Leeuwen2, M. N. van 201Tl-MUI at stress in patients en Cancérologie de Nantes-Angers, U892, Nantes, FRANCE. OP-704 OOsterom2, R. Faccini3; 1 2 K. Nishimoto1, S. Tomiguchi2, F. Sakamoto2, S. Shiraishi3, Y. INFN Rome, Rome, ITALY, 16Interventional Molecular Imaging Kawamata3; OP-699 Successful Pretargeting Approach for Peptide Receptor Laboratory, Department of Radiology, Leiden University Medical 3 1Graduate School of Health Science Kumamoto University, Radionuclide Therapy of GRPR-positive Prostate Cancer Center, Leiden, NETHERLANDS, Università degli studi di Roma

146 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 147 Sapienza, Rome, ITALY. J. Ferdinandus, F. Barbato, M. Chodyla, W. P. Fendler, L. Kessler, M. OP-713 1308 Metzenmacher, F. Krefting, T. Hager, K. Herrmann, D. C. Christoph; Clinical Oncology Track - TROP Session: PET University Hospital Essen, Essen, GERMANY. OP-709 Imaging Cancer Immunology: Magnetic Particle Imaging Diagnostics of Lung Cancer and Mesothelioma of Immunotherapy Development of the intraoperative movable PET imaging J. Mansfield1, G. Ren1, M. Gerosa2, J. Gaudet1, N. Carvou1, Y. OP-724 2 1 2 Thursday, October 29, 2020, 16:35 - 18:05 system for radio guided surgery Zhang , P. Goodwill , M. Wintermark ; Channel 8 O. Kenichiro1,2, M. R. Liyanaarachchi3, K. Shimazoe3, H. 1Magnetic Insight, Alameda, CA, UNITED STATES OF AMERICA, Interobserver reliability in the quantitative assessment of Takahashi4, S. Aiko1, Y. Seto1, M. Takahashi2, T. Momose2; 2Stanford University, Palo Alto, CA, UNITED STATES OF AMERICA. [99mTc]-labeled anti-Programmed Death-Ligand 1 (PD-L1) 1Department of Surgical Science, The University of Tokyo, Tokyo, SPECT/CT in non-small cell lung cancer 2 JAPAN, Department of Nuclear Medicine, International University OP-714 D. Hughes1, G. Chand1, H. Ting2, V. Warbey1, V. Goh1, G. Cook1; 3 of Health and Welfare, Tokyo, JAPAN, Department of Bio- OP-718 1Department of Cancer Imaging, School of Biomedical Sciences engineering and Management, The University of Tokyo, Tokyo, 3D compton Imaging: A new modality for nuclear and Engineering, King’s College London, London, UNITED 4 JAPAN, Department of Nuclear Engineering and Management, medicine at 511 KeV and above Concordance of PD-L1 status between image-guided KINGDOM, 2Department of Research and Development, The University of Tokyo, Tokyo, JAPAN. A. Iltis1, G. Zeufack1, M. Lopez1, H. Snoussi2, L. Zimmer3,4, N. Costes3, percutaneous biopsies and matched surgical specimen in NanoMab Technology Limited, Shanghai, CHINA. 3 1 3 3

EANM’20 EANM’20 C. Bouillot , Z. Hmissi , F. Lavenne , J. Redoute ; non-small cell lung cancer EANM’20 1 2 OP-710 Damavan Imaging, Rosieres pres Troyes, FRANCE, Université de L. Zhao, H. Chen, Y. Zhuang, Q. Lin; 3 Technologie de Troyes (UTT), Troyes, FRANCE, CERMEP-Imagerie the First Affiliated Hospital of Xiamen University, Xiamen, CHINA. OP-727 Preliminary study of the feasibility of Cerenkov du vivant, Bron, FRANCE, 4INSERM, CNRS, Université de Lyon, Lyon, luminescence imaging in metastasectomy FRANCE. 18F fluorodeoxyglucose PET/CT Radiomic signature for E. Ciarrocchi1, S. Saponaro1, F. Bartoli2, A. G. Cataldi2, S. Vitali2, P. A. prediction of lung cancer histology and outcome WORLD LEADING MEETING Erba2, N. Belcari1; OP-719 E. Giovannini1, L. Florimonte2, M. Cuzzocrea2, M. Castellani2, L. WORLD LEADING MEETING 1University of Pisa, Department of Physics, Pisa, ITALY, 2University 1307 Dellavedova3, E. Borsò1, G. Giovacchini1, C. Aschele4, A. Ciarmiello1; of Pisa and Azienda Ospedaliero Universitaria Pisana, Pitfalls & Artefacts 6: Pitfalls and Artefacts in Differentiation of the histopathological types of solitary 1Nuclear Medicine U.O. - Sant’Andrea Hospital, La Spezia, ITALY, Department of Translational Research and of New Surgical and Paediatric Nuclear Medicine pulmonary nodules with 18F-FDG PET/CT radiomic using 2Fondazione IRCCS Ca’ Granda- Ospedale Maggiore Policlinico, 3 4 Medical Technologies, Pisa, ITALY. machine-learning methods Milan, ITALY, ASST Ovest Milanese, Milan, ITALY, Oncology OU- Y. Zhou, R. Tian; Sant’Andrea Hospital, La Spezia, ITALY. OP-711 Thursday, October 29, 2020, 16:35 - 18:05 Channel 7 West China Hospital, Chengdu, CHINA. Cerenkov Luminescence Imaging in prostate cancer: 1309 unraveling of the basal halo OP-720 Hot Topic Session - Best Clinical Trials J. olde Heuvel1, H. G. van der Poel1, E. M. Bekers1, M. P. M. Stokkel1, C. H. Slump2, B. J. de Wit-van der Veen1; OP-715 Comparison of Metabolic and Morphological Response 1 Thursday, October 29, 2020, 16:35 - 18:05 Netherlands Cancer Instititute, Amsterdam, NETHERLANDS, Criteria for Early Prediction of Response and Survival in Channel 9 2 University of Twente, Enschede, NETHERLANDS. Paediatric Nuclear Medicine Specificities and Image NSCLC Patients Treated with Checkpoint Inhibitors Artefacts A. Castello, S. Rossi, L. Toschi, E. Lopci; OP-712 C. Olianti; Florence University Hospital Careggi, Nuclear Medicine Humanitas Clinical and Research Hospital, Rozzano (MI), ITALY. Department, Florence, ITALY. A smart forceps for intraoperative fluorescence tissue OP-496 characterisation during robotic surgery - technical OP-716 OP-722 development and validation in large animal models Introduction Imaging Artefacts in Paediatric Nuclear Medicine - Planar Prediction of mutational status in lung cancer using PET M. van Oosterom1,2, S. I. van Leeuwen1, F. van Beurden1,2, E. I.Burger; University of Zurich, Deparment of Nuclear Medicine, Mazzone3,4, P. Dell’Oglio1,4, T. Buckle1,2, M. Boonekamp5, K. Imaging radiomics Zurich, SWITZERLAND. Bauwens4, H. Simon6, P. J. van Leeuwen2, H. G. van der Poel2, F. W. B. A. Santos; Hospital Garcia de Orta, Nuclear Medicine M. Berraho1, O. Tankyevych1,2, G. Tachon3, M. Hatt2, D. Visvikis2, C. van Leeuwen1,2,4; Department, Almada, PORTUGAL. Cheze le Rest1,2; OP-497 1IMI-Lab, Dept. of Radiology, Leiden University Medical Center, 1Nuclear medicine, CHU de Poitiers, Poitiers, FRANCE, 2LaTIM, Leiden, NETHERLANDS, 2Department of Urology, Netherlands OP-717 INSERM, UMR1101, Brest, FRANCE, 3Cancer biology, CHU Poitiers, ProPSMA study - A prospective randomised multi-centre Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Poitiers, FRANCE. study of Prostate Specific Membrane Antigen (PSMA) 3 NETHERLANDS, Division of Oncology/Unit of Urology, URI, IRCCS Imaging Artefacts in Paediatric Nuclear Medicine – SPET/ PET/CT imaging for staging high-risk prostate cancer Ospedale San Raffaele; Vita-Salute San Raffaele University, Milan, OP-723 CT, PET/CT and PET/MR prior to curative-intent surgery or radiotherapy ITALY, 4ORSI Academy, Melle, BELGIUM, 5Medical Technology P. Zucchetta; Padua University Hospital, Nuclear Medicine M. Hofman; Peter MacCallum Cancer Centre, Molecular Imaging, Center, Leiden University Medical Center, Leiden, NETHERLANDS, Department, Padova, ITALY. PERCIST-derived metabolic volume response predicts 6 Melbourne, AUSTRALIA. Eurorad, Eckbolsheim, FRANCE. overall and progression-free survival in patients with malignant pleural mesothelioma treated with Pembrolizumab

148 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 149 QC, CANADA, 5CHU de Nantes, Nantes, FRANCE, 6University OP-498 OP-501 Hospital Vienna, Vienna, AUSTRIA, 7GenesisCare Theranostics, 1311 Ramsay Hollywood Private Hospital, Perth, AUSTRALIA, 8Royal Free e-Poster Presentation Session 8: All About the 68Ga-RM2 Gastrin-Releasing Peptide Receptors PET Age and cognitive reserve affect the expression of Hospital, London, UNITED KINGDOM, 9Ipsen, Les Ulis, FRANCE, Prostate - Staging, Restaging and Beyond Imaging for Biochemically Recurrent Prostate Cancer in cingulate island sign in patients with DLB: an European- 10Ipsen, Cambridge, MA, UNITED STATES OF AMERICA, 11Ipsen, the Era of PSMA: Results of a Prospective Study DLB (E-DLB) consortium project Hoofddorp, NETHERLANDS, 12Peter McCallum Cancer Centre, 1 2 3 4 Thursday, October 29, 2020, 16:35 - 18:05 A. Iagaru; Stanford University, Stanford, CA, UNITED STATES OF M. Donegani , M. Bauckneht , A. Chincarini , M. Brendel , A. Melbourne, AUSTRALIA. Channel 11 AMERICA. Rominger4, L. Beyer4, R. Bruffaerts5, R. Vandenberghe5, M. G. Kramberger6, M. Trost6, V. Garibotto7, N. Nicastro8, G. B. Frisoni9, A. OP-504 W. Lemstra10, B. N. M. van Berckel11, A. Pilotto12, A. Padovani12, M. OP-499 A. Ochoa-Figueroa13, A. Davidsson13, V. Camacho14, E. Peira3, S. Lymph node staging by FDG-PET/CT and MRI in cervical Raffa1, A. Miceli1, D. Aarsland15, F. Nobili2, S. Morbelli1; uterine cancer: the impact on FIGO stage migration and EPS-120 Characteristics of the relationship between MTV and 1Department of Health Sciences (DISSAL), University of Genoa, prognostic value 2 Diagnostic efficacy of F-18-rhPSMA-7.3 PET imaging for survival in diffuse large B-cell lymphoma - A PETRA Genoa, ITALY, IRCCS Ospedale Policlinico San Martino, Genoa, J. Holm1, A. Thomassen1, O. Gerke1, M. H. Vilstrup1, D. Spasojevic2, 3 consortium study ITALY, National Institute of Nuclear Physics (INFN), Genoa, S. E. Sponholtz3, K. M. Jochumsen3, P. T. Jensen4, M. G. Hildebrandt1; N-staging in Intermediate and High-Risk Prostate Cancer 4 1,2 3 3 4 ITALY, University Hospital (LMU Munich), Munich, GERMANY, 1 EANM’20 EANM’20 N. Mikhaeel , M. W. Heymans , H. C. W. de Vet , J. J. Eertink , R. Department of Nuclear Medicine, Odense University Hospital, patients validated by histopathology EANM’20 5 Boellaard5, U. Dührsen6, A. Hüttmann6, C. Schmitz6, L. Ceriani7, E. Department of Neurosciences, Ku Leuven, Leuven, BELGIUM, Odense C, DENMARK, 2Department of Radiology, Odense 1 1 1 2 6 7 T. Langbein , I. Rauscher , M. Kroenke , A. Wurzer , K. University Medical Centre, Ljubljana, SLOVENIA, Geneva 3 Zucca8, O. S. Hoekstra5, J. M. Zijlstra4, S. Barrington9; University Hospital, Odense C, DENMARK, Department of Schwamborn3, H. Wörther1, C. Franz1, T. Maurer4, T. Horn5, H. 1Guy’s Cancer Centre, London, UNITED KINGDOM, 2King’s University Hospitals and NIMTLab, Geneva University, Geneva, Gynecology and Obstetrics, Odense University Hospital, Odense 2 1 1 8 Wester , W. Weber , M. Eiber ; SWITZERLAND, Department of Clinical Neurosciences, Geneva 4 College London, School of Cancer and Pharmaceutical C, DENMARK, Department of Obstetrics and Gynecology, Aarhus 1Technical University of Munich, School of Medicine, University Hospitals, Geneva, SWITZERLAND, 9LANVIE (Laboratoire Sciences, London, UNITED KINGDOM, 3Amsterdam UMC, Vrije University Hospital, Aarhus, Denmark, Odense C, DENMARK. Klinikum rechts der Isar, Department of Nuclear Medicine, WORLD LEADING MEETING de Neuroimagerie du Vieillissement), Geneva University Hospitals, WORLD LEADING MEETING Universiteit Amsterdam, department of Epidemiology and Munich, GERMANY, 2Technical University of Munich, Chair of Geneva, SWITZERLAND, 10VU Medical Center Alzheimer Center, Biostatistics, Amsterdam Public Health research institute, De OP-505 Radiopharmacy, Garching, GERMANY, 3Technical University of Amsterdam, NETHERLANDS, 11Department of Radiology and Boelelaan 1117, Amsterdam, NETHERLANDS, 4Amsterdam Munich, School of Medicine, Klinikum rechts der Isar, Institute of Nuclear Medicine, Amsterdam University Medical Centres, UMC, Vrije Universiteit Amsterdam, department of Hematology, Diagnostic Performance and Clinical Impact of Ga-68 Pathology, Munich, GERMANY, 4University Hospital Hamburg- Amsterdam, NETHERLANDS, 12Department of Clinical and Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam, PSMA PET/CT Imaging in Early Relapsed Prostate Cancer Eppendorf, Martini-Klinik, Hamburg, GERMANY, 5Technical Experimental Sciences, University of Brescia, Brescia, ITALY, NETHERLANDS, 5Amsterdam UMC, Vrije Universiteit Amsterdam, University of Munich, School of Medicine, Klinikum rechts der Isar, 13 After Radical Therapy: Phase 3, Prospective, Multicenter department of Radiology and Nuclear Medicine, Cancer Center Department of Clinical Physiology, Institution of Medicine and 14 Department of Urology, Munich, GERMANY. Amsterdam, De Boelelaan 1117, Amsterdam, NETHERLANDS, Health Sciences, Linköping, SWEDEN, Hospital de la Santa Creu i Study (IAEA-PSMA Study) 6Department of Hematology, West German Cancer Center, Sant Pau, Universitat Autònoma de Barcelona, Barcelona, SPAIN, E. Estrada-Lobato; International Atomic Energy Agency, Nuclear 15 EPS-121 University Hospital Essen, University of Duisburg-Essen, Essen, Centre for Age-Related Medicine (SESAM), Stavanger University Medicine and Diagnostic Imaging, Vienna, AUSTRIA. 7 Hospital, Stavanger, NORWAY. GERMANY, Department of Nuclear Medicine and PET/CT Centre, Choosing Wisely recommendations compliance in bone IIMSI - Imaging Institute of Southern Switzerland, Bellinzona, OP-506a scan scintigraphies of newly diagnosed prostate cancer Switzerland; SAKK - Swiss Group for Clinical Cancer Research, OP-502 TheraP Study - A randomised phase II trial of Bern, SWITZERLAND, 8Medical Oncology Clinics, IOSI - Oncology 177Lu-PSMA-617 (Lu-PSMA) theranostic versus patients Institute of Southern Switzerland, Bellinzona; Università della I. Saura Lopez, Á. O. Rabines Juárez, N. A. Rudic Chipe, M. J. Progression to overt Coronary artery disease in Patients cabazitaxel in metastatic castration resistant prostate Svizzera Italiana, Bellinzona, Switzerland; SAKK - Swiss Group Ribelles Segura, M. I. Blanco Saiz, L. Paruta Araez, M. I. Morales cancer (mCRPC) progressing after docetaxel for Clinical Cancer Research, Bern, SWITZERLAND, 9King’s with Diabetes Mellitus at High Coronary Risk: 5 year Lozano, A. Camarero Salazar, E. Goñi Gironés; College London and Guy’s and St Thomas’ PET Centre, School follow-up of the prospective multicenter BARDOT Trial M. Hofman; Peter MacCallum Cancer Centre, Molecular Imaging, Navarra Hospital Complex, Pamplona, SPAIN. of Biomedical Engineering and Imaging Sciences, King’s Health F. Caobelli, P. Haaf, G. Haenny, M. Pfisterer, M. Zellweger; Melbourne, AUSTRALIA. Partners, Kings College London, London, UNITED KINGDOM. Universitätsspital Basel, Basel, SWITZERLAND. OP-506b EPS-122

OP-500 OP-503 Summary Standardized Uptake Values are Adequate Measures of J. Bomanji; University College Hospital NHS Trust, Institute of 18F-DCFPyL Uptake in Patients with Low- to Intermediate 99m 177 Hybrid ICG- Tc-nanocolloid, on the road towards Biodistribution and Dosimetry of Lu-satoreotide- Nuclear Medicine, London, UNITED KINGDOM. Tumour Burden: a Comparison to Tumour-to-Blood Ratio, becoming the new standard for sentinel node biopsy in tetraxetan: an Interim Analysis of a Multi-Centre, Open- a Validated Simplified Pharmacokinetic Analysis penile cancer? Results from 740 inguinal basins assessed Label Phase I/II Study in Patients with Neuroendocrine D. Oprea, Y. J. L. Bodar, B. P. F. Koene, D. Meijer, B. H. E. Jansen, M. C. at a single institution Tumours F. Cysouw, M. Yaqub, H. N. Hendrikse, A. N. Vis, R. Boellaard; H. M. de Vries1, P. Dell’Oglio2, E. Mazzone3, G. H. KleinJan3, H. G. D. Wild1, S. Beykan2, H. Grønbæk3, J. Beauregard4, C. Ansquer5, Amsterdam UMC, Amsterdam, NETHERLANDS. van der Poel1, S. Horenblas1, F. W. B. van Leeuwen3, O. R. Brouwer1; A. Haug6, N. Lenzo7, S. Navalkissoor8, G. Nicolas1, L. Durand- 1 9 10 11 12 2 Netherlands Cancer Institute - Antoni van Leeuwenhoek Gasselin , C. Powell , B. Pais , R. Hicks , U. Eberlein , M. EPS-123 hospital, Amsterdam, NETHERLANDS, 2ASST Grande Ospedale Lassmann2; Metropolitano Niguarda, Milan, ITALY, 3Leiden University Medical 1University Hospital Basel, Basel, SWITZERLAND, 2University of Center, Leiden, NETHERLANDS. Würzburg, Würzburg, GERMANY, 3Aarhus University Hospital, Diagnostic accuracy of 68Ga-PSMA PET-CT at initial Aarhus, DENMARK, 4CHU de Quebec, Université Laval, Quebec, diagnosis in a population of prostate cancer patients

150 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 151 submitted to radical prostatectomy as compared to T. Watabe1, M. Uemura1, F. Soeda1, S. Naka2, H. Sasaki2, T. Kamiya2, UNITED STATES OF AMERICA. OP-736 pathology results E. Shimosegawa1, H. Kato1, N. Nonomura1, F. L. Giesel3,1; 1 2 C. Varela Pinto, B. Martins, D. Calado, C. Loewenthal; Osaka University, Suita, JAPAN, Osaka University Hospital, Suita, 3 Current Clinical Status of Sentinel Node Biopsy in Cervical 1403 Hospital da Luz Lisboa, Lisbon, PORTUGAL. JAPAN, University Hospital Heidelberg, Heidelberg, GERMANY. and Endometrial Cancer Joint Symposium 22 (EANM/ESPGHAN): A. Collarino; Fondazione Policlinico Universitario A. Gemelli Nuclear Medicine Techniques in the Evaluation EPS-125 EPS-131 IRCCS, Nuclear Medicine Unit, Rome, ITALY. of GI Motility in Children Pattern of prostate cancer recurrence in patients Assessment of early oxidative stress following the use OP-737 177 Friday, October 30, 2020, 09:00 - 10:30 with biochemical failure following definitive therapy of radiotheranostics agents Lu-PSMA for prostate Channel 3 evaluated with [68Ga]Ga-PSMA-11 PET/CT cancer and 177Lu-DOTATATE for neuroendocrine tumors; SPECT-CT for the Identification of Sentinel Lymph Nodes I. Lawal1,2, T. Lengana1, K. Mokoala1, T. Boshomane1, J. radioprotective effect of vitamin C in Early Stage Oral Cancer Kleynhans1,2, M. Vorster1,2, N. Mokgoro1, M. Sathekge1,2; M. Assadi1, E. Jafari1, H. Ahmadzadehfar2, D. Bagheri3, A. Amini1; S. Wan; Institute of Nuclear Medicine, University College Hospital, 1University of Pretoria, Pretoria, SOUTH AFRICA, 2Nuclear Medicine 1 London, UNITED KINGDOM Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, OP-742 Research Infrastructure (NuMeRI), Pretoria, SOUTH AFRICA. ISLAMIC REPUBLIC OF, 2Klinikum Westfalen, Knappschaft Hospital, 3 OP-738 EANM’20 EANM’20 Dortmund, GERMANY, Persian Gulf University, Bushehr, IRAN, EANM’20 Clinical Scenarios of GI Motility Disorders in Children ISLAMIC REPUBLIC OF. EPS-127 Technological Advances in Robot-Assisted Radioguided M. van Wijk; Amsterdam University Medical Centre, VUmc, Surgery in the Pelvis Paediatric Gastroenterology Department, Amsterdam, Comparison of early imaging and imaging 60 minutes EPS-132 M. van Oosterom; Interventional Molecular Imaging Lab, NETHERLANDS. post injection after forced diuresis with furosemide in Department of Radiology, Leiden University Medical Center,

WORLD LEADING MEETING 68 WORLD LEADING MEETING the assessment of local recurrence in prostate cancer Prostate Primary Tumor Assessment by [ Ga]Ga-PSMA Leiden, NETHERLANDS. OP-743 patients with biochemical recurrence referred for [68Ga] PET/CT P. Soeiro, R. Silva, R. Almeida, V. Sousa, G. Costa, J. Perdoso de Non-Imaging Techniques in the Evaluation of GI Motility Ga-PSMA-11-PET/CT Lima; 1402 in Children S. Bayerschmidt, C. Uprimny, A. S. Kroiss, H. Svirydenka, G. di Centro Hospitalar e Universitário de Coimbra, Coimbra, A. Rybak; Great Ormond Street Hospital for Children, Department Santo, B. Nilica, S. Rauch, E. von Guggenberg, C. Decristoforo, I. Joint Symposium 21 (EANM/IEEE): Total Body PORTUGAL. of Gastroenterology, London, UNITED KINGDOM. Virgolini; PET Imaging Medizinische Universität Innsbruck, Innsbruck, AUSTRIA. EPS-134 OP-744 Friday, October 30, 2020, 09:00 - 10:30 Channel 2 EPS-128 The Role of Interleukin-23 in Prostate Adenocarcinoma; Gastric Emptying Scintigraphy Comparison to Ga-68 PSMA PET/CT Findings Z. Bar-Sever; Schneider Children’s Hospital, Department of Ga68 PSMA PET/CT in the restaging of patients with N. Ergul1, H. Serin2, E. Beyhan1, Ö. Erol1, B. Yılmaz1, C. Gündoğan1, Nuclear Medicine, Tel Aviv, ISRAEL. prostate cancer. Correlation to PSA levels T. F. Çermik1; V. Prassopoulos, T. Pipikos, D. Kechagias, M. Vogiatzis, V. Filippi, F. 1Istanbul Training and Research Hospital, Department of Nuclear OP-739 OP-745 Vlachou, J. Andreou, K. Gogos, R. Efthymiadou; Medicine, Istanbul, TURKEY, 2Istanbul Training and Research PET/CT Department, Hygeia Hospital, Athens, GREECE. Hospital, Department of Biochemistry, Istanbul, TURKEY. Opportunities and Challenges for Dynamic Imaging with Nuclear Medicine Techniques in Intestinal Motility Total Body PET L. Biassoni; Great Ormond Street Hospital for Children, EPS-129 D. Visvikis; INSERM, LaTIM, Brest, FRANCE. Department of Radiology, London, UNITED KINGDOM.

Diagnostic value of Ga-68 PSMA PET/CT in biochemical 1401 progression in prostate cancer (PC) patients after radical CME 11: SLN - Past and Future OP-740 1404 prostatectomy in the low range values of prostate CTE 5: Departmental Organisation New Opportunities and Clinical Investigations That a specific membrane antigen (PSA) Friday, October 30, 2020, 09:00 - 10:30 Total Body PET Can Offer M. Dyankova1,2, Z. Dancheva1, T. Stoeva1, S. Chausheva1, T. Channel 1 Friday, October 30, 2020, 09:00 - 10:30 Yordanova1, B. Chaushev1, A. Klisarova1; R. Boellaard; Amsterdam University Medical Centres, location Channel 4 1St. Marina University Hospital, Varna, BULGARIA, 2Medical VUMC, Radiology and Nuclear Medicine, Amsterdam, University Varna Prof. Dr. Paraskev Stoyanov, Varna, BULGARIA. NETHERLANDS. OP-735 OP-741 EPS-130 OP-747 Sentinel Node Biopsy in Prostate Cancer - Nomogram- Applications for Exploring Serotonergic Receptors and High detection sensitivity in [18F]PSMA-1007 PET: initial Related Patient Selection and Clinical Reliability Drugs in the Periphery and Central Nervous System Management Basics experience focusing on biochemical recurrence in N. Grivas; Department of Urology, G.Hatzikosta General Hospital, H. Hansen; Massachusetts General Hospital, Athinoula A. W. Kemps; University Hospital Brussels, Brussels ,BELGIUM. prostate cancer patients Ioannina, GREECE. Martinos Center for Biomedical Imaging, Charlestown, MA,

152 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 153 Uppsala, SWEDEN, 2Nuclear Medicine, Klinikum rechts der OP-748 Isar der TUM, Munich, GERMANY, 3Science for Life Laboratory, OP-757 1406 Department of Medicinal Chemistry, Uppsala University, Uppsala, Cutting Edge Science Track - TROP Session: Radiopharmacy SWEDEN, 4Department of Immunology, Genetics and Pathology, Characterisation of a cyclohexanediamine-triazole-PSMA Dosimetry for PRRT and PSMA A. Socan; University Medical Centre Ljubljana, Ljubljana, Uppsala University, Uppsala, SWEDEN. conjugate on spheroids of prostate cancer cells SLOVENIA. W. Sihver1, M. Saager1, M. Walther1, R. Wodtke1, F. Reissig1,2, C. 1,2 1,2 1,2 1 Friday, October 30, 2020, 09:00 - 10:20 Mamat , K. Kopka , J. Pietzsch , H. Pietzsch ; Channel 6 OP-749 OP-753 1Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY, 2Technische Universität Dresden, Faculty of Chemistry and Food Radiation Protection Correlation of PSMA-ligand uptake combining Chemistry, Dresden, GERMANY. K. Pathmaraj; Austin Health, Victoria, AUSTRALIA. autoradiography, histopathology and immunohistochemistry in primary prostate cancer OP-758 OP-762 H. Wang1, M. Reiser2, T. Horn3, K. Schwamborn2, K. Steiger2, H. 177 68 1405 Wester4, M. Schottelius4, W. Weber1, M. Eiber1; Development and preclinical evaluation of Lu-AMTG, Estimation of tumor burden from Ga- Dotatate-PET/CT M2M Track - TROP Session: New and 1Department of Nuclear Medicine, Klinikum rechts der Isar, a novel pharmacophore-modified GRPR-targeted and day-7 planar 177Lu images, for patients treated with 2 177 EANM’20 EANM’20 Established Tracers - Prostate only! Munich, GERMANY, Institute of Pathology, School of Medicine, antagonist with improved metabolic stability Lu-Dotatate EANM’20 Technical University Munich, Munich, GERMANY, 3Department T. Günther, R. Beck, V. Felber, S. Deiser, H. Wester; K. Sjögreen Gleisner1, J. Gustafsson1, A. Stenvall1, D. Roth1, C. of Urology, Klinikum rechts der Isar, Technical University Munich, Technical University of Munich, Garching, GERMANY. Hindorf2, L. Jönsson1, E. Larsson2, T. Olsson2, A. Sundlöv3,1; Friday, October 30, 2020, 09:00 - 10:30 4 1 Channel 5 Munich, GERMANY, Pharmaceutical Radiochemistry, Technical Medical Radiation Physics, Clinical Sciences, Lund, SWEDEN, University Munich, Munich, GERMANY. 2Department of Radiation Physics, Skane University Hospital, OP-759 Lund, SWEDEN, 3Oncology and Pathology, Clinical Sciences Lund, WORLD LEADING MEETING OP-754 Skane University Hospital, Lund, SWEDEN. WORLD LEADING MEETING A preclinical evaluation of 89Zr-labeled PSMA ligands for OP-750 Gallium-66 PET: Production and characterization pre-treatment dosimetry for 177Lu-labeled PSMA therapy OP-763 66 of Ga-NOTA-PEG2-RM26 for PET-imaging of GRPR B. Privé, Y. H. W. Derks, G. M. Franssen, S. M. B. Peters, M. W. 18 Kinetic Modelling of F-rhPSMA-7.3 Uptake in PET expression in prostate cancer Konijnenberg, M. Gotthardt, M. J. R. Janssen, P. Laverman, J. Comparison of The Effect of 1L Vs 2L Lysine/Arginine Imaging of Prostate Cancer S. Rinne1, A. Abouzayed1, K. Gagnon2, V. Tolmachev3, A. Orlova1; Nagarajah, S. Heskamp; Solution (25g/L Each) on Kidney Absorbed Doses and S. Malaspina1, V. Oikonen1, A. Kuisma2, O. Ettala3, K. Mattila2, P. J. 1Department of Medicinal Chemistry, Uppsala University, Radboudumc, Nijmegen, NETHERLANDS. Acute Side Effects in Patients Undergoing Lutathera 3 2 1 4 4 Boström , H. Minn , K. Kalliokoski , E. J. Postema , M. P. Miller , M. Uppsala, SWEDEN, 2GEMS PET Systems AB, Uppsala, SWEDEN, Treatment Scheinin5; 3 OP-760 Department of Immunology, Genetics and Pathology, Uppsala D. Gillett1, S. Ballout1, E. Varzakis1, I. Harper1, D. Pitfield2, A. Powell1, 1Turku PET Centre, University of Turku and Turku University University, Uppsala, SWEDEN. R. T. Casey3,2, S. Heard1, L. Aloj4,1; Hospital, Turku, FINLAND, 2Department of Oncology, University Does the Injected Mass influence the Biodistribution of 1Department of Nuclear Medicine, Addenbrooke’s Hospital CUHFT, of Turku and Turku University Hospital, Turku, FINLAND, F-18-rhPSMA-7.3 on Positron Emission Tomography in Cambridge, UNITED KINGDOM, 2Department of Endocrinology, 3Department of Urology, University of Turku and Turku University OP-755 Prostate Cancer Patients? Addenbrooke’s Hospital CUHFT, Cambridge, UNITED KINGDOM, Hospital, Turku, FINLAND, 4Blue Earth Diagnostics Ltd, Oxford, T. Langbein1, A. Wurzer2, A. Gafita1,3, A. Robertson1, H. Wang1, A. 3Department of Genetics, University of Cambridge, Cambridge, UNITED KINGDOM, 5Clinical Research Services Turku - CRST Ltd, 64 Evaluation of Cu-labelled GRPR-antagonist RM26 for Arçay1,4, M. Herz1, H. Wörther1, C. Franz1, W. Weber1, H. Wester2, M. UNITED KINGDOM, 4Department of Radiology, University of Turku, FINLAND. PET-imaging of prostate cancer in a preclinical model Eiber1; Cambridge, Cambridge, UNITED KINGDOM. S. Rinne1, B. Mitran1, C. Baun2, J. H. Dam2, B. B. Olsen2, V. 1Technical University of Munich, School of Medicine, OP-751 Tolmachev3, H. Thisgaard2, A. Orlova1; Klinikum rechts der Isar, Department of Nuclear Medicine, 1Department of Medicinal Chemistry, Uppsala University, Munich, GERMANY, 2Technical University of Munich, Chair OP-764 Pharmacokinetics of PSMA-617 - dynamics of Uppsala, SWEDEN, 2Department of Nuclear Medicine, Odense for Pharmaceutical Radiopharmacy, Garching, GERMANY, radiopharmaceutical uptake in tumours University Hospital, Odense, DENMARK, 3Department of 3Ahmanson Translational Theranostics Division, Department of Absorbed doses to kidneys based two SPECT K. Bohn, M. Fürstner, M. Hentschel, I. Alberts, A. Rominger, A. Immunology, Genetics and Pathology, Uppsala University, Molecular and Medical Pharmacology, University of California measurements versus seven SPECT measurements Afshar-Oromieh; Uppsala, SWEDEN. Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, patients with neuroendocrine tumours receiving 4Department of Nuclear Medicine, Akdeniz University, Antalya, Department of Nuclear Medicine, Inselspital/Bern University 177Lu-DOTATATE therapy Hospital, University of Bern, Bern, SWITZERLAND. OP-756 TURKEY. M. Sandstrom1, A. Sundin2, M. Lubberink1; 1Medical Physics, Uppsala, SWEDEN, 2Nuclear medicine and PET, OP-752 Influence of the Versatile Bifunctional Chelator AAZTA5on OP-761 Uppsala, SWEDEN. the Radiometal Labelling Properties and the in vitro 68 Heterodimeric Radiotracer Targeting PSMA and GRPR for Performance of a GRPr Antagonist Competition (‘steal’ phenomenon) between [ Ga] Imaging of Prostate Cancer: Optimisation of the Affinity M. Hofstetter1, E. Moon2, F. D’Angelo1, L. Geissbühler1, F. Rösch2, A. Ga-PSMA-11 uptake in prostate tumor and healthy tissue OP-765 towards PSMA by Linker Modification Rominger1, E. Gourni1; E. C. A. van der Sar, S. van den Doel, B. de Keizer, M. G. E. H. Lam, 177 90 1 Preliminary results of a Phase II Lu and Y PRRT F. Lundmark1, A. Abouzayed1, B. Mitran1, S. S. Rinne1, Z. Varasteh2, Department of Nuclear Medicine, Inselspital, Bern University A. J. A. T. Braat; M. Larhed3, V. Tolmachev4, U. Rosenström1, A. Orlova1; Hospital, Bern, SWITZERLAND, 2Department of Chemistry – TRIGA UMC Utrecht, Utrecht, NETHERLANDS. study: analysis of OAR dosimetry and dose-response 1Department of Medicinal Chemistry, Uppsala University, site, Johannes Gutenberg - University Mainz, Mainz, GERMANY. relationship for NET liver metastases E. Tonini1, S. Panareo2, M. Longo3, L. Longo4, L. Perrucci5, E. Fortini5,

154 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 155 G. Di Domenico4, L. Uccelli2, C. Cittanti2, A. Turra1, M. Giganti5, M. B. Feuerecker1,2, M. Chantadisai1,3, A. Allmann1, R. Tauber4, J. Bartolomei2; Allmann1, H. Wester5, W. A. Weber1, C. D’Alessandria1, M. Eiber1; OP-774 OP-781 1Sant’Anna Hospital, Medical Physics Unit, Ferrara, ITALY, 1Technical University of Munich, School of Medicine, Department 2Sant’Anna Hospital, Nuclear Medicine Unit, Ferrara, ITALY, of Nuclear Medicine, München, GERMANY, 2German Cancer Review Indications of PET/CT Guided Biopsy Dynamic PET Perfusion Imaging in Esophageal Cancer 3Sapienza University of Rome, Ph.D. Program in Morphogenesis Consortium (DKTK), partnersite München, Heidelberg, C. Nanni; Azienda Ospedaliero-Universitaria di Bologna Patients Receiving Radiation Therapy & Tissue Engineering, Rome, ITALY, 4Department of Physics and GERMANY, 3Division of Nuclear Medicine, Department of Policlinico S.Orsola-Malpighi, Nuclear Medicine Dapartment, K. Binzel, E. D. Miller, C. L. Wright, Y. Hsieh, A. Wollett, E. Ives, M. V. Earth Sciences, Ferrara University, Ferrara, ITALY, 5Section of Radiology, Faculty of Medicine, Chulalongkorn University, King Bologna, ITALY. Knopp; Diagnostic Imaging, Department of Morphology, Surgery and Chulalongkorn Memorial Hospital, The Thai Red Cross Society, The Ohio State University Wexner Medical Center, Columbus, OH, Experimental Medicine, University of Ferrara, Ferrara, ITALY. Bangkok, THAILAND, 4Technical University of Munich, School OP-775 UNITED STATES OF AMERICA. of Medicine, Department of Urology, München, GERMANY, OP-766 5Technical University of Munich, Department of Pharmaceutical Review Techniques of PET/CT Guided Biopsy OP-782 Radiochemistry, München, GERMANY. J. Cerci; Quanta – Diagnostic and Therapy, PET/CT Department, Lesion-wise dosimetry for multiple bone metastases Curitiba, BRAZIL. Utility of 18F-FDG PET/CT in Management of Pancreatic in mCRPC patients undergoing Lu-177-PSMA therapy: OP-771 and Periampullary Masses : Experience of a Tertiary Care comparison of five dosimetric methods Center in South India 1 2 1 1 1 Quantitative SPECT imaging for Ac-225-based 1408 1 2 2 2 EANM’20 EANM’20 J. Brosch , C. Uribe , A. Gosewisch , L. Kaiser , P. Bartenstein , A. C. Singareddy , R. Manthri , T. Kalawat , V. Venkatarami Reddy , EANM’20 Todica1, H. Ilhan1, A. Rahmim3, A. Celler3, S. Ziegler1, G. Böning1; radionuclide therapy: a phantom feasibility study and Clinical Oncology Track - Featured Session: PET H. Narendra2, B. Vijaya Lakshmi Devi2, A. Chowhan2; 1Department of Nuclear Medicine, University Hospital, LMU first patient trial Diagnostics of Gynaecological and GI Tumours 1SVIMS, Tirupati, INDIA, 2Sri Venkateswara Institute Of Medical Munich, Munich, GERMANY, 2PET Functional Imaging, BC Cancer, A. Gosewisch, M. Schleske, F. J. Gildehaus, A. Todica, J. Brosch, L. Sciences, Tirupati, INDIA. Vancouver, BC, CANADA, 3Department of Radiology, University of Kaiser, P. Bartenstein, H. Ilhan, G. Böning; Friday, October 30, 2020, 09:00 - 10:30 British Columbia, Vancouver, BC, CANADA. Department of Nuclear Medicine, University Hospital, LMU Channel 8 WORLD LEADING MEETING WORLD LEADING MEETING Munich, Munich, GERMANY. OP-784 OP-767 4FMFES and FDG-PET imaging in uterine cancer patients: Individualization of 177Lu-PSMA Therapy based on OP-772 preliminary assessment important physiologic parameters using global OP-777 M. Paquette1, E. Espinosa-Bentancourt1, É. Lavallée1, S. Phoenix1, sensitivity analysis and a physiologically-based Patient-specific kidney absorbed doses in mCRPC K. Lapointe-Milot2, P. Bessette2, B. Guérin1, É. E. Turcotte1; 177 New Developments in PET of Gynaecological Tumours 1 2 pharmacokinetic model patients treated with Lu-PSMA-617: a post-hoc analysis Université de Sherbrooke, Sherbrooke, QC, CANADA, CIUSSS de L. de Geus-Oei; Nuclear Medicine Physician, Department of l’Estrie-CHUS, Sherbrooke, QC, CANADA. G. Glatting1,2, P. Kletting1,2, N. J. Begum1, M. Eiber3, A. J. Beer2, S. A. of a prospective phase 2 study Radiology, Leiden University Medical Center (LUMC), Leiden, Pawiro4, D. Hardiansyah4; C. Meyer1, D. Mirando2, T. Adams2, D. Ranganathan3, R. 4 4 1 1 1 NETHERLANDS OP-785 1Medizinische Strahlenphysik, Nuklearmedizin, Universität Ulm, Esfandiari , E. Delpassand , J. Czernin , J. Calais , M. Dahlbom ; 2 1Ahmanson Translational Theranostics Division, UCLA, Los Ulm, GERMANY, Klinik für Nuklearmedizin, Universität Ulm, Ulm, 68 2 Preliminary application of Ga-PSMA PET/CT in detection GERMANY, 3Nuklearmedizin, Klinikum rechts der Isar, Technische Angeles, CA, UNITED STATES OF AMERICA, MIM Software Inc, OP-778 Universität München, München, GERMANY, 4Medical Physics and Cleveland, OH, UNITED STATES OF AMERICA, 3Radiomedix, of ovarian cancer 13 Biophysics, Physics Department, Faculty of Mathematics and Houston, TX, UNITED STATES OF AMERICA, 4Department of The potential role of dynamic PET with N-ammonia M. Xin, L. Xu, Q. Xia, W. Lou, J. Liu; Natural Sciences, Universitas Indonesia, Depok, INDONESIA. Clinical Nuclear Medicine, Excel Diagnostics Imaging Clinic, for evaluating response to Sorafenib in advanced HCC Renji hospital, School of medicine, Shanghai Jiao Tong university, Houston, TX, UNITED STATES OF AMERICA. patients. A preliminary report of a prospective study Shanghai, CHINA. V. Scolozzi1, S. Taralli1, A. Capotosti2, G. Bencivenga3, F. Ponziani4, OP-769 A. Nicoletti4, M. Pompili4, L. Indovina2, M. L. Calcagni1,5; OP-786 1407 1Fondazione Policlinico Universitario A. Gemelli IRCCS; Targeted Alpha PSMA-based Therapy of mCRPC patients: Teaching Session 5: PET/CT Guided Biopsy UOC Medicina Nucleare, Dipartimento di Diagnostica per Assessment of radiomic PET analysis in the evaluation of previsional dosimetry and radiobiological evaluation Immagini, Radioterapia Oncologica ed Ematologia, Rome, cervical cancer treatment A. Sarnelli1, M. Belli1, E. Mezzenga1, F. Cesarini1, P. Caroli1, V. ITALY, 2Fondazione Policlinico Universitario A. Gemelli IRCCS; F. Scalorbi, A. Alessi, G. Centonze, M. Signorelli, G. Calareso, 1 2 3 1 1 Friday, October 30, 2020, 09:00 - 10:30 Di Iorio , M. Cremonesi , L. Strigari , A. Romeo , S. Nicolini , F. Channel 7 UOS Dosimetria Clinica e Radioprotezione, Dipartimento M. Kirienko, A. Lorenzoni, G. Bogani, F. Martinelli, G. Argiroffi, F. Matteucci1, S. Severi1, G. Paganelli1; di Diagnostica per Immagini, Radioterapia Oncologica ed Raspagliesi, E. Seregni; 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Ematologia, Rome, ITALY, 3Fondazione Policlinico Universitario A. Istituto Nazionale Tumori Milano, Milan, ITALY. (IRST) IRCCS, Meldola, ITALY, 2European Institute of Oncology, Gemelli IRCCS; PET-CT centre, Rome, ITALY, 4Fondazione Policlinico IRCCS 20141 Milano, Milan, ITALY, 3Policlinico S. Orsola-Malpighi, Universitario A. Gemelli IRCCS; Division of Internal Medicine, OP-787 40138 Bologna, Bologna, ITALY. OP-773 Gastroenterology and Hepatology – Università Cattolica del Sacro Cuore, Rome, ITALY, 5Università Cattolica del Sacro Cuore; 18F-FDG PET/CT incidental gynecological uptake: a OP-770 Review Limitations of CT and US Guided Biopsy Istituto di Medicina Nucleare, Rome, ITALY. 8-year retrospective analysis F. Waneck; Division of Cardiovascular and Interventional P. Bellini1, D. Albano1, S. Lucchini2, F. Motta2, A. Peli2, M. Bertoli2, Pre-therapeutic dosimetry of 177Lu-rhPSMA7.3 and Radiology, Department of Biomedical Imaging and Image- G. Bosio2, E. Cerudelli2, M. Gazzilli2, F. Dondi1, A. Mazzoletti1, A. 177Lu-PSMA-I&T in patients with metastatic castration guided Therapy, Medical University of Vienna, Vienna, AUSTRIA. Calabrò1, M. Gregorelli1, M. Bonacina3, F. Bertagna1, R. Giubbini1; 1 resistant prostate cancer Nuclear Medicine, University of Brescia, Spedali Civili Brescia,

156 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 157 Brescia, ITALY, 2Nuclear Medicine, Spedali Civili Brescia, Brescia, J. Rodríguez Gomez1, F. Ferrando-Castagnetto2, C. Wakfie Corieh1, Methodological contributions OP-797 ITALY, 3Nuclear Medicine, Fondazione Poliambulanza, Brescia, M. Pedrera Canal1, M. Ollarves Carrero1, M. Meneses Navas1, J. Diz3, A. Bronte, J. Bastidas, J. Rosales, F. Grisanti, J. Zuaznabar, M. ITALY. E. Silvera4, A. Zamarrón1, Y. Santero1, M. Pérez Castejón1, J. Carreras 18 Herraiz, J. Richter; 1 Prognostic role of serial cardiac F-FDG PET-MR imaging Delgado ; University Clinic of Navarra, Pamplona, SPAIN. 1Servicio de Medicina Nuclear, Hospital Clínico San Carlos, in Anderson-Fabry disease: preliminary results 1409 Madrid, SPAIN, 2Departamento de Cardiología-CCVU, Hospital C. Nappi1, A. Ponsiglione1, A. Pisani2, E. Riccio2, E. Nicolai3, W. Featured Session: Nuclear Imaging in de Clínicas, Facultad de Medicina, Universidad de la República., Acampa1, M. Imbriaco1, A. Cuocolo1; OP-802 Inflammatory and Infiltrative Cardiovascular Montevideo, URUGUAY, 3Instituto Cardiovascular, Hospital Clínico 1Department of Advanced Biomedical Sciences, Federico Diseases San Carlos, Madrid, SPAIN, 4Departamento de Medicina Nuclear, II University, Naples, ITALY, 2Department of Public Health, Prevalence of Bile Acid Malabsorption Diagnosed by Hospital de Clínicas, Facultad de Medicina, Universidad de la Nephrology Unit, Federico II University, Naples, ITALY, 3IRCCS SDN, 75SeHCAT Retention Test in the Last Decade at the República, Montevideo, URUGUAY. Naples, ITALY. Bellvitge University Hospital Friday, October 30, 2020, 09:00 - 10:30 Channel 9 M. Pudis, P. C. Notta, A. Sabaté-Llobera, J. Suils, M. T. Bajen, A. OP-792 OP-798 Rodriguez-Gasen, J. Guardiola, M. Cortés; Bellvitge University Hospital, Barcelona, SPAIN. Incidental Disphosphonate cardiac Uptake In Bone Immune checkpoint inhibitor therapy affects Scintigraphy As A Recommendation For Cardiological inflammatory activity in large arteries - a retrospective EANM’20 EANM’20 EANM’20 OP-788 Monitoring analysis using 18[F]-FDG PET/CT imaging OP-803 J. Bonilla, M. Gomez Martinez, L. Rincon, O. Ajuria, P. Azpeitia, I. R. Calabretta, C. Hoeller, V. Pichler, M. Mitterhauser, G. Karanikas, Nuclear Imaging in Inflammatory and Infiltrative Lopez Villar, P. Jane, M. Rioja, M. Orduña Diez; A. Haug, X. Li, M. Hacker; 75SeHCAT scan in chronic diarrhea for bile acid Cardiovascular Diseases - How Far Can we Go? Hospital Ramón y Cajal, Madrid, SPAIN. Medical University of Vienna, Vienna, AUSTRIA. malansorption: update of an Italian single center E. Reyes; PET imaging centre, St Thomas’ Hospital, King’s College experience WORLD LEADING MEETING WORLD LEADING MEETING London, Royal Brompton Hospital, Nuclear Medicine, London, N. Fraccascia1, E. Tabacchi1, L. Zanoni1, G. Barbara2, V. UNITED KINGDOM. OP-793 1410 Stanghellini2, M. Bortolotti2, L. Rotondo2, M. Levorato1, R. TROP Session: General Nuclear Medicine Bonfiglioli1, S. Fanti1; OP-789 Optimising myocardial suppression and diagnostic 1Nuclear Medicine-DIMES University of Bologna, S. Orsola- confidence in cardiac18 F-FDG PET/CT by adding a high- Malpighi Hospital, Bologna, ITALY, 2Department of Digestive Transthyretin gene mutation carriers: can bone Friday, October 30, 2020, 09:00 - 10:30 fat, low-carbohydrate dietary preparation Channel 10 Diseases, University Hospital S. Orsola; DIMEC, University of scintigraphy identify disease markers early? M. Naik, K. L. Wallitt, S. R. Khan, L. Alves, C. Bowen, W. E. Svensson, Bologna, Bologna, ITALY. F. Mattana1, R. Bonfiglioli1, L. Muraglia1, A. Paccagnella1, R. Mei1, N. D. R. Soneji; G. Caponetti2, G. Saturi2, P. Massa2, M. Sguazzotti2, A. Ponziani2, C. Imperial College Healthcare NHS Trust, London, UNITED OP-804 Gagliardi2, S. Longhi2, N. Galiè2, S. Fanti1; KINGDOM. 1Department of Nuclear Medicine, S.Orsola-Malpighi University OP-799 Usage of hepatobiliary scintigraphy imaging in Hospital, Bologna, ITALY, 2Department of Cardiology, S.Orsola- stratification of patients with chronic viral hepatitis Malpighi University Hospital, Bologna, ITALY. OP-794 SPECT-CT Optimimization of Lung Perfusion D. Jocius1, D. Vajauskas2, A. E. Tamosiunas1; Quantification 1Vilnius University Faculty of Medicine, Vilnius, LITHUANIA, 18 OP-790 Dietary compliance and interpretability of F-FDG S. Menendez Sanchez, E. Carrillo Villamizar, A. Cardozo Saavedra, 2Lithuanian University of Health Science Kauno klinikos, Kaunas, PET-CT scans in diabetic population evaluated for cardiac R. Bellviure Meiro, S. Aguade, J. Castell; LITHUANIA. Evaluation Of The Regional Distribution Of Tc99m-DPD In sarcoidosis Hospital Universitario Vall d’Hebron, Barcelona, SPAIN. The Left Ventricle In Patients With Transthyretin Cardiac K. Wechalekar, S. Clark, S. Hatipoglu, S. R. Underwood, G. OP-805 Amyloidosis Keramida, A. Maenhout, R. Sharma, V. Kouranos; OP-800 The effect of protein binding on calculated glomerular N. Martinez Amador1, I. Martínez-Rodríguez1, A. Sánchez- Royal Brompton and Harefield NHS Foundation Trust, London, Salmón1, R. Quirce1, J. Jiménez-Bonilla1, M. de Arcocha-Torres1, UNITED KINGDOM. Pulmonary Ventilation / Perfusion Scintigraphy In filtration rates using 99m[ Tc] Tc-DTPA: identifying, S. Ruiz-Llama1, G. Molina-Mendoza1, O. Cuenca-Vera1, J. Andrés- Patients With Chronic Thromboembolic Disease With And quantifying and resolving the issue Pacheco1, A. Gutiérrez-González1, M. J. Zarauza-Navarro2, I. Without Confirmed Pulmonary Hypertension. A Clinical- S. Townrow, M. Burniston, N. Sizer; 1 OP-795 Banzo ; Radiological Prediction Barts Health NHS Trust, London, UNITED KINGDOM. 1 Nuclear Medicine Service. Marqués de Valdecilla University J. Cañadas Salazar1, F. Gómez-Caminero López1, P. García- Preliminary Results of 18F-FSPG PET/CT in Patients Hospital. Molecular Imaging Group (IDIVAL). University of Talavera San Miguel1, P. Álvarez-Vega2, J. G. Villanueva Curto1, A. 2 OP-806 Cantabria, Santander, SPAIN, Cardiology Service. Marqués de Referred for Exclusion of Active Cardiac Sarcoidosis after C. Peñaherrera Cepeda1, C. Riola Parada1, M. P. Tamayo Alonso1, S. Valdecilla University Hospital, Santander, SPAIN. Non-Contributory 18F-FDG PET/CT Cadenas Menéndez1; Correlation of CT KUB based renal parenchymal A. Iagaru, H. Duan, L. Baratto, S. S. Gambhir, R. Witteles; 1Sacyl, Salamanca, SPAIN, 2SESPA, Gijón, SPAIN. OP-791 Stanford University, Stanford, CA, UNITED STATES OF AMERICA. abnormalities with 99m - Technitium Dimercaptosuccinic Acid SPECT Renal Scinitigraphy: A Specialized Centre Quantifying Right Ventricle Uptake Of 99mTc-DPDIn OP-801 Experience Cardiac Transthyretin Amyloidosis Through SPECT/CT. M. Siddique1, A. Iqbal2, M. K. Nawaz1; 75Se-SeHCAT test in bile acids malabsorption. Preliminary Results In A Single Center 1Pakistan Kidney and Liver Institute & Research Centre, Lahore,

158 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 159 PAKISTAN, 2LINCS Diagnostic & IR Services, Lahore, PAKISTAN. 1411 EPS-141 EPS-146

e-Poster Presentation Session 9: Physics - 18 OP-807 Software and Image Processing Quantification of 18F-Florbetapir amyloid brain PET Impact of [ F]FDG uptake time on non-small cell lung scans using commercial software: a comparison with an cancer PET radiomics and their repeatability Can Dynamic Renal Scintigraphy Predict Renal Outcome experienced and independently reviewed clinical report G. D. Kolinger1, D. Vállez García1, A. S. Dirand2, G. M. Kramer3, V. Friday, October 30, 2020, 09:00 - 10:30 1 1 2,3 1 4 5 3 3 4,5 4,5 in Acute Kidney Injury? Channel 11 L. Perry , N. H. Patel , J. Lilja , S. R. Khan , S. Curry , F. Loreto , M. Frings , O. S. Hoekstra , E. F. Smit , A. J. de Langen , R. A. J. O. M. Nicod Lalonde, M. Altarelli, M. Jreige, G. Allenbach, N. Golemme1, H. McMeekin6, L. Alves1, K. S. Nijran1, P. Malhotra1,5, R. J. Dierckx1, I. Buvat2, R. Boellaard1,3; Schaefer, J. O. Prior, A. Schneider; Perry1,5, Z. Win1; 1Medical Imaging Center, University Medical Center Groningen, University hospital of Lausanne, Lausanne, SWITZERLAND. 1Imperial College Healthcare NHS Trust, London, UNITED University of Groningen, Groningen, NETHERLANDS, 2Laboratoire KINGDOM, 2Uppsala University, Uppsala, SWEDEN, 3Hermes d’Imagerie Translationnelle en Oncologie, INSERM, Institute OP-808 EPS-136 Medical Solutions, Stockholm, SWEDEN, 4King’s College London, Curie, Université Paris-Saclay, Orsay, FRANCE, 3Department of London, UNITED KINGDOM, 5Imperial College London, London, Radiology and Nuclear Medicine, Amsterdam University Medical Is there a relevance of Hystero-Salphingo-Scintigraphy in Digital PET/CT 4D: A Study Phantom On The Effect Of UNITED KINGDOM, 6Hermes Medical Solutions, London, UNITED Centers, location VU Medical Center, Amsterdam, NETHERLANDS, 4 SPECT/CT era? Respiratory Gating In Volumes And SUV Recoveries KINGDOM. Department of Pulmunology, Amsterdam University Medical 1 2 3 4 5 6 1 1 1 2 Centers, location VU Medical Center, Amsterdam, NETHERLANDS,

EANM’20 EANM’20 S. Barna , J. Lőrincz , F. Dinko , I. Mihovk , T. Herman , P. Török , I. A. Belly-Poinsignon , P. Finitzer , M. M. Alabdoaburas , C. Provost , EANM’20 5Department of Thoracic Oncology, Amsterdam University Garai1,4; L. Champion3, L. Ammour1, R. Belshi1; EPS-142 Medical Centers, location VU Medical Center, Amsterdam, 1Scanomed Ltd., Debrecen, HUNGARY, 2University of Debrecen, 1Institut Curie-Saint Cloud, Medical Physics Department, Paris, NETHERLANDS. Kenézy Gyula University Hospital, Department of Obstetrics FRANCE, 2Institut Curie-Saint Cloud, Radiopharmacology Evaluation of myocardial perfusion images in patients and Gynecology, Debrecen, HUNGARY, 3Faculty of Medicine, Department, Paris, FRANCE, 3Institut Curie-Saint Cloud, Medical with left ventricular dilatation using software program University of Debrecen, Debrecen, Hungary, Debrecen, HUNGARY, Imaging Department, Paris, FRANCE. provided Artificial Neural Network (ANN) EPS-147 WORLD LEADING MEETING 4Department of Medical Imaging, Faculty of Medicine, University WORLD LEADING MEETING K. Koyama1, M. Kanou1, T. Ogura1, S. Naito1, T. Higuchi2, T. of Debrecen, Debrecen, HUNGARY, 5Assisted Reproduction Center, 68 18 EPS-137 Toyama3; Optimal Ga-PSMA-11 and F-PSMA-1007 PET window University of Debrecen, Debrecen, HUNGARY, 6Department of 1Gunma prefectural cardiovascular center, Maebashi, JAPAN, levelling for gross tumour volume delineation in primary Obstetrics and Gynecology, Faculty of Medicine, University of Negative oral contrast agents Utilization in PETCT studies 2Gunma Faculity of medicine Graduate School, Maebashi, JAPAN, prostate cancer Debrecen, Debrecen, HUNGARY. 1 1 2 2 N. Bashank , W. Diab , S. Hassanein , M. Abdel Tawab , M. S. 3Toyama cardiovasculary Clinic, Maebashi, JAPAN. K. Goffin1, C. Draulans2, R. De Roover2, U. A. van der Heide3, L. 1 Keshk ; Kerkmeijer4, R. J. Smeenk4, F. Pos3, W. V. Vogel3, J. Nagarajah5, M. 1 OP-809 Assuit university,AUH, clinical oncology and nuclear medicine Janssen5, S. Isebaert2, F. Maes6, C. Mai7, R. Oyen7, S. Joniau8, M. 2 department, Assuit, EGYPT, Assuit university,AUH, Diagnostic EPS-144 Kunze-Busch4, K. Haustermans2; Rest/Stress Intradermal Lymphoscintigraphy in Women Radiology department, Assuit, EGYPT. 1Nuclear Medicine, University Hospitals Leuven, Leuven, BELGIUM, with Lipedema Deep learning image enhancement for short-duration 2Radiation Oncology, University Hospitals Leuven, Leuven, G. Tartaglione, F. P. Ieria; EPS-138 whole-body FDG PET scans BELGIUM, 3Radiation Oncology, The Netherlands Cancer Institute, Cristo Re Hospital, Rome, ITALY. A. Mehranian1, K. Su2, M. D. Walker3, M. Chetan3, D. R. Amsterdam, NETHERLANDS, 4Radiation Oncology, Radboud TOF Resolution Assessment based on Time Alignment McGowan3,4, F. Gleeson5, A. Brown6, R. Johnsen2, S. D. University Medical Centre, Nijmegen, NETHERLANDS, 5Radiology & OP-810 Procedure Wollenweber2; Nuclear Medicine, Radboud University Medical Centre, Nijmegen, 6 V. Panin, D. Bharkhada, H. Rothfuss; Siemens Medical Solutions 1GE Healthcare, Oxford, UNITED KINGDOM, 2GE Healthcare, NETHERLANDS, Electrical Engineering, ESAT/PSI, KU Leuven, 7 Role of 18F-FDG PET/CT in the evaluation of pyrexia of USA, Knoxville, TN, UNITED STATES OF AMERICA. Waukesha, WI, UNITED STATES OF AMERICA, 3Oxford University Leuven, BELGIUM, Radiology, University Hospitals Leuven, Leuven, 8 unknown origin Hospitals NHS FT, Oxford, UNITED KINGDOM, 4University of BELGIUM, Urology, University Hospitals Leuven, Leuven, BELGIUM. 5 D. Khan, S. Sagar, A. Raj ST, S. Kumar, M. Tripathi, M. Sharma, R. EPS-139 Oxford, Oxford, UNITED KINGDOM, National Consortium of Kumar; Intelligent Medical Imaging(NCIMI), University of Oxford, Big Data EPS-148 6 All India Institute of Medical Sciences, New Delhi, INDIA. Development of an automatic calculation method for the Institute, Oxford, UNITED KINGDOM, Oregon Health & Science specific binding ratio in [I-123]ioflupne SPECT University, Portland, OR, UNITED STATES OF AMERICA. Methodological Quality of Guidelines for Positron H. Okazawa1, M. M. Islam1,2, M. G. M. Rahman1, T. Tsujikawa1; Emission Tomography is Suboptimal 1University of Fukui, Fukui, JAPAN, 2Khulna University of EPS-145 Q. Li1,2, W. Hou1, L. Li2, M. Su1, Y. Ren2, W. Wang2, K. Zou2, R. Tian1, X. Engineering & Technology, Khulna, BANGLADESH. Sun2; Deep-learning based urinary bladder segmentation 1Department of Nuclear Medicine, West China Hospital, Sichuan EPS-140 using 18FDCFPyL (PyL-PSMA) PET/CT images University, Chengdu, CHINA, 2Chinese Evidence-based Medicine J. Brynolfsson1, K. Johnsson1, H. Sahlstedt1, J. Richter1, K. Center, West China Hospital, Sichuan University, Chengdu, CHINA. A new automated method for analysis of cerebrovascular Sjöstrand1, L. Edenbrandt1,2, A. Anand1; reserve capacity deficiency by rCBF SPECT with 1Exini Diagnostics AB, Lund, SWEDEN, 2University of Gothenburg, EPS-149 acetazolamide test: Preliminary results Gothenburg, SWEDEN. Reporting Standards for Bland-Altman Agreement S. Urbán1, G. Sipka1, A. Balogh2, Z. Besenyi1, J. Csirik2, L. Pávics1; 1Department of Nuclear Medicine, University of Szeged, Szeged, Analysis: a Systematic Review of Methodological Reviews HUNGARY, 2Institute of Informatics, University of Szeged, Szeged, O. Gerke1,2; HUNGARY. 1Dept. of Nuclear Medicine, Odense University Hospital, Odense

160 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 161 C, DENMARK, 2Dept. of Clinical Research, University of Southern Denmark, Odense C, DENMARK. OP-812 1503 OP-823 Joint Symposium 24 (EANM/EFOMP): Technical Ac-225 Therapy, What Do We See and What Can We Advances in Paediatric Dose Reduction Research in NM - Technologist’s Role and Responsibilities EPS-150 Measure? I. Costa; Kings College, London, UNITED KINGDOM C. Kratochwil; Heidelberg University Hospital, Department of Bone metastasis classification in bone scintigraphy using Friday, October 30, 2020, 10:40 - 12:10 Nuclear Medicine, Heidelberg, GERMANY. Channel 3 densely-connected convolutional neural networks 1505 N. Papandrianos1, E. I. Papageorgiou2, A. Anagnostis3,4, A. Feleki5, OP-813 M2M Track - Featured Session: Targeted K. Papageorgiou6, D. J. Apostolopoulos7; Radionuclide Therapy - Trick or Treat? 1University of Thessaly, Lamia, GREECE, 2Department of Energy Ra-223 and Th-227 Just Dump it in the Body? Systems, Faculty of Technology, University of Thessaly, Geopolis I. Murray; Royal Marsden NHS Foundation Trust, Joint OP-817 Campus, Larissa, GREECE, 3University of Thessaly, Computer Department of Physics, London, UNITED KINGDOM. Friday, October 30, 2020, 10:40 - 11:55 Channel 5 Science and Telecommunications Department, Lamia, GREECE, CT Dose Reduction Techniques 4Institute for Bio-economy and Agri-technology, Center for M. Kachelriess; German Cancer Research Center (DKFZ), Division Research and Technology Hellas, Volos, GREECE, 5Faculty of 1502 of X-Ray Imaging and CT, Heidelberg, GERMANY. EANM’20 EANM’20 EANM’20 Technology, University of Thessaly, Geopolis Campus, 41500, Joint Symposium 23 (EANM/ESDO): New Larissa, GREECE, 6University of Thessaly, Computer Science & OP-818 OP-824 7 Diagnostic and Therapeutic Frontiers in Telecommunications Department, Lamia, GREECE, University Digestive Oncology of Patras, Medical School, Department of Nuclear Medicine, PC Dose Reduction in PET Therapy and Beyond 26504, Rio, Achaia, GREECE. A. Smith; University College London Hospitals, Institute of Nuclear J. Nonnekens; Erasmus MC, Molecular Genetics and Radiology & WORLD LEADING MEETING Friday, October 30, 2020, 10:40 - 12:10 Medicine, London, UNITED KINGDOM . Nuclear Medicine, Rotterdam, NETHERLANDS. WORLD LEADING MEETING EPS-151 Channel 2 OP-819 OP-825 Segmentation Protocols in 99mTc-MAA SPECT/CT for90Y Radioembolization Treatment Planning Dose Reduction Approaches for Conventional Nuclear Disturbing redox balance enhances the biological effect G. Mok, Z. Lu; OP-814 Medicine of PRRT but not EBRT in a panel of cancer cell lines University of Macau, Taipa, MACAO. M. Attard; UMC Radboud, Radiology and Nuclear Medicine W. Delbart, G. E. Ghanem, P. Flamen, Z. Wimana; Therapeutic Combinations in Digestive Oncology Department, Nijmegen, NETHERLANDS. Institut Jules Bordet, Brussels, BELGIUM. EPS-152 E. van Cutsem; Head of the Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, BELGIUM. OP-828 A new mathematical concept omitting fitting procedures 1504 to describe radio tracer processes in kidneys using linear OP-815 CTE 6: Advanced Competencies Comparison of intravenous and intraperitoneal dosing response theory of the Targeted Alpha Therapy Thorium-227-anetumab Predictive Markers of Efficacy B. Geist1, M. Hacker1, H. Neufeld2; corixetan in a model of peritoneal carcinomatosis of 1 2 C. Lepage; Hepato gastroenterology and digestive oncology, Friday, October 30, 2020, 10:40 - 12:10 Medical University Vienna, Vienna, AUSTRIA, University of Channel 4 mesothelioma University Hospital Dijon, Dijon, FRANCE. Vienna, Vienna, AUSTRIA. U. Hagemann1, M. I. Suominen2, I. Moen3, M. Brand1, C. Ellingsen3, 3 1 OP-816 A. S. Cuthbertson , D. Mumberg ; 1Bayer Ag, Berlin, GERMANY, 2Pharmatest Services, Turku, 1501 FINLAND, 3Bayer AS, Oslo, NORWAY. Combined Imaging Approaches - From Bench to Bedside OP-821 CME 12: Alpha Particle Therapy Without Imaging - Options for Dosimetry, the Alpha L. De Geus-Oei; Nuclear Medicine Physician, Department of Targeted alpha-therapy with 211At-anti-mCD138 mAb Radiology, Leiden University Medical Center (LUMC), Leiden, NMT Advanced Competencies - A Decade in Review and Omega in a syngeneic murine Multiple Myeloma model : can NETHERLANDS. G. Testanera; Bartshealth NHS Trust, Nuclear Medicine, London, UNITED KINGDOM. repeated doses or fractionation protocol overpass single Friday, October 30, 2020, 10:40 - 12:10 dose efficiency? Channel 1 OP-822 S. Gouard1, S. Marionneau-Lambot1,2, J. Gaschet1,3, N. Chouin1,4, F. Haddad5, C. Alliot5, J. Gestin1, F. Guérard1, F. Kraeber-Bodéré1,3,2, M. Radionuclide Therapy - Technologist’s Role and Chérel1,5,3; 1 2 Responsibilities CRCINA, Nantes, FRANCE, Nuclear Medicine Department, 3 OP-811 P. Silva; Jules Bordet Institut, Nuclear Medicine, Brussels, BELGIUM. University Hospital, Nantes, FRANCE, Nuclear Medicine Department, ICO-René Gauducheau Cancer Center, Saint 4 Surrogate Imaging and Dosimetry with PET / SPECT Herblain, FRANCE, Oniris, École Nationale Vétérinaire, L. Bodei; Memorial Sloan-Kettering Cancer Center, Department of Agroalimentaire et de l’alimentation de Nantes-Atlantique, 5 Radiology, New York, UNITED STATES OF AMERICA. Nantes, FRANCE, Groupement d’Intérêt Public Arronax, Saint Herblain, FRANCE.

162 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 163 OP-830 OP-838 OP-843

Increased SST2 Expression on Pulmonary Neuroendocrine 1506 Effect of a motion correction algorithm on malignant Evaluation of Monte Carlo based reconstruction Tumor Cells by Epigenetic Drug Treatment with Histone Cutting Edge Science Track - TROP Session: lung nodule uptake: in comparison to ordinary and concerning visual assessment of liver metastases in Deacetylase Inhibitors Image Reconstruction and Corrections breath-hold PET/CT 111In-octreotide SPECT/CT imaging I. Klomp, S. U. Dalm, P. M. van Koetsveld, F. Dogan-Oruç, M. de M. Jreige1, S. Gnesin1, P. Schleyer2, M. Conti3, J. O. Prior1; E. Wikberg1, M. van Essen2, T. Rydén1, J. Svensson3, P. Gjertsson2, P. Jong, L. J. Hofland; 1Lausanne University Hospital, Lausanne, SWITZERLAND, Bernhardt1; Friday, October 30, 2020, 10:40 - 12:10 2 1 2 Erasmus MC, Rotterdam, NETHERLANDS. Channel 6 Siemens Healthineers UK, Frimley, Camberley, UNITED KINGDOM, Institute of Clinical Sciences, Gothenburg, SWEDEN, Department 3Siemens Healthineers, Knoxville, TN, UNITED STATES OF AMERICA. of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, SWEDEN, 3Department of Oncology, Sahlgrenska OP-831 University Hospital, Gothenburg, SWEDEN. OP-839 Preclinical Evaluation of [18F]F-DPA Uptake in Head OP-834 OP-844 and Neck Cancer Under Normal Conditions and After Application of a generic dynamic reconstruction The prevalence and severity of image degradation from algorithm on PET whole-body pharmacokinetic studies Towards a comprehensive validation of a Monte Carlo EANM’20 EANM’20 Radiotherapy EANM’20 S. Tuominen1,2,3, T. Keller1, D. Eichin4, N. Petruk2,3, A. Verhassel2,3, motion in rest-stress rubidium-82 PET on a SiPM PET-CT Z. Chalampalakis1, S. Stute2,3, M. Filipovic1, S. Marie1,4, M. simulation for clinical SPECT acquisition protocol J. Rajander5, F. López-Picón1, E. Löyttyniemi6, J. Sandholm7, J. system Bottlaender1, N. Tournier1, C. Comtat1; optimisation and image correction 1 Tuomela2,3, T. Grönroos1,8; I. Armstrong1, M. Memmott1, C. Hayden2, P. Arumugam1; Service Hospitalier Frédéric Joliot, CEA, Inserm, CNRS, Univ. S. Pells1,2, D. M. Cullen1, A. P. Robinson2,1,3, B. Pietras1, N. Calvert3, 2 1Turku PET Centre, University of Turku, Turku, FINLAND, 2Institute 1Manchester University NHS Foundation Trust, Manchester, Paris Sud, Univ. Paris Saclay, Paris, FRANCE, Nuclear Medicine D. Deidda2, A. Fenwick2,4, K. Ferreira2, D. Hamilton3, W. Heetun2, P. of Biomedicine, University of Turku, Turku, FINLAND, 3FICAN UNITED KINGDOM, 2Siemens Medical Imaging Inc., Knoxville, TN, Department, Nantes University Hospital, Nantes, FRANCE, Julyan3, G. Needham1, E. Page1,3, E. Price1, J. Tipping3; WORLD LEADING MEETING 3 4 WORLD LEADING MEETING West Cancer Research Laboratory, University of Turku, Turku, UNITED STATES OF AMERICA. CRCINA, INSERM, Nantes University, Nantes, FRANCE, Hôpital 1The University of Manchester, Manchester, UNITED KINGDOM, FINLAND, 4MediCity Research Laboratory, University of Turku, Bicêtre, Assistance Publique des Hôpitaux de Paris, Le Kremlin 2The National Physical Laboratory, Teddington, UNITED Turku, FINLAND, 5Turku PET Centre, Åbo Akademi University, Turku, Bicêtre, Paris, FRANCE. KINGDOM, 3The Christie NHS Foundation Trust, Manchester, FINLAND, 6Department of Biostatistics, University of Turku, Turku, OP-835 UNITED KINGDOM, 4Cardiff University, Cardiff, UNITED KINGDOM. FINLAND, 7Turku Bioscience, University of Turku and Åbo Akademi OP-840 University, Turku, FINLAND, 8Department of Oncology and Comparison of respiratory motion estimation methods in OP-845 Radiotherapy, Turku University Hospital, Turku, FINLAND. cardiac PET/MR Voluntary body motion in WB dynamic PET imaging A. Villagran Asiares1, C. Munoz2, T. Kuestner2, T. Vitadello3, C. J. Trinckauf1, C. Weyermann1, F. Kotasidis2, M. Hug1, V. Schober1, V. Data-Driven Respiratory SPECT-Gating for Pre-Radio- OP-832 Rischpler4, T. Ibrahim3, R. Botnar2, C. Prieto2, S. Nekolla3; 1Klinikum Treyer1, D. Ferraro1, M. Huellner1, K. Kudura1, M. Messerli1, I. Burger1; Embolization Determination of Liver-Lung-Shunt 1 2 rechts der Isar, München, GERMANY, 2King’s College London, University Hospital Zürich, Zurich, SWITZERLAND, GE Healthcare, Fraction Ultrasound enhanced brain delivery of 89Zr-Cetuximab, 3 Zurich, SWITZERLAND. London, UNITED KINGDOM, Klinik und Poliklinik für Innere P. Ritt1, K. Seidl1, M. Cachovan2, A. H. Vija3, T. Kuwert1; an anti-EGFR based immunotherapy followed by Medizin I, Klinikum rechts der Isar, School of Medicine, Technical 1Clinic for Nuclear Medicine, Erlangen, GERMANY, 2Siemens 4 immunoPET University of Munich, Munich, GERMANY, Department of Nuclear OP-841 Healthcare GmbH, Molecular Imaging, Forchheim, GERMANY, Medicine, University Hospital Essen, University of Duisburg-Essen, 3 A. Schweitzer-Chaput1, A. Novell1, N. Tournier1, V. Tran1, B. Jego1, Siemens Medical Solutions USA, Inc., Molecular Imaging, Essen, GERMANY. B. Larrat2, C. Truillet1; Impact of Point Spread Function (PSF) reconstruction on Hoffman Estates, MI, UNITED STATES OF AMERICA. 1Université Paris-Saclay, cea, cnrs, inserm, BioMaps, Orsay, 91401, 68Ga-DOTATOC PET/CT Quantitative Imaging Parameters - FRANCE, 2Université Paris-Saclay, cea, cnrs, NeuroSpin/baobab, OP-836 a patient and phantom pilot study Gif sur Yvette, 91191, FRANCE. A. McCann1,2, S. Liddy2, D. Maguire2, E. Loughman2, A. Dowling2, 1507 Clinical impact of trigger attenuation correction L. Harris2, L. L. Vintro3, S. Cournane1,2, J. Lucey2; 1Centre for Physics Teaching Session 6: Difficult Cases in Cardiac combined with MR-gating in the correction of respiratory in Health & Medicine, School of Physics, University College Imaging OP-833 artifacts in thoracic-upper abdominal PET/MR Dublin, Dublin, IRELAND, 2St Vincent’s University Hospital, Dublin, H. Li1, X. Meng1, X. Guan1, H. Liu2, Y. Zhang1, B. Yu1, H. Zhu1, N. Li1, IRELAND, 3School of Physics, University College Dublin, Dublin, Pharmacological inhibition of mTORC1 increases CCKBR- 1 Friday, October 30, 2020, 10:40 - 12:10 Z. Yang ; IRELAND. Channel 7 specific tumor uptake of radiolabeled minigastrin 1Peking University Cancer Hospital & Institute, Beijing, CHINA, analogue [177Lu]Lu-PP-F11N 2United Imaging Healthcare, Shanghai, CHINA. OP-842 M. Grzmil1, Y. Qin1, C. Schleuniger1, S. Frank2, S. Imobersteg1, A. Blanc1, R. Schibli1,3, M. Behe1; LM-MLEM for an Ultra-High VoR density PET 1 1 2 1 1Paul Scherrer Institute, Villigen PSI, SWITZERLAND, 2Institute of OP-837 P. Encarnação , P. M. M. Correia , I. F. Castro , I. Mohammadi , F. OP-846 1 1 1 1 Pathology, University of Basel, SWITZERLAND, 3Department of M. Ribeiro , A. L. M. Silva , J. F. C. A. Veloso ; I3N - Universidade de 2 Chemistry and Applied Biosciences, ETH Zurich, SWITZERLAND. Comparison of data-driven gating and external Aveiro, Aveiro, PORTUGAL, RI-TE, Radiation Imaging Technology, SPECT Myocardial Perfusion Imaging hardware-gating for 18F-FDG PET/MRI in patients with Aveiro, PORTUGAL. R. Calabretta; Division of Nuclear Medicine, Department of esophageal tumors Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA. S. Kvernby, N. Korsavidou Hult, J. Sigfridsson, H. Ahlström, T. Bjerner, M. Lubberink; Akademiska hospital, Uppsala, SWEDEN.

164 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 165 Anatomical Pathology, “Sapienza” University of Rome, Rome, OP-847 OP-855 ITALY, 3Radiation Oncology Center, S.Orsola-Malpighi Hospital, OP-863 Bologna, ITALY, 4Unit of Nuclear Medicine, “Spirito Santo” Hospital, PET Myocardial Perfusion Imaging Multicenter retrospective Study: Validation of the Pescara, ITALY, 5Unit of Nuclear Medicine, Biomedical Department Low-dose 18F-FDG thyroid PET/CT vs. Thyroid J. Sörensen; Radiology, Department of Surgical Sciences, 3-variable prognostic score (3-PS) in a population with of Internal and Specialist Medicine, University of Palermo, scintigraphy in indeterminate high-risk nodules: a pilot University Hospital, Uppsala Unversity, Uppsala, SWEDEN. metastatic castration resistant prostatic cancer treated Palermo, ITALY, 6Unit of Nuclear Medicine. Department of Medical, dosimetric assessment with Radium223-dichloride Surgical and Experimental Sciences, University of Sassari, Sassari, E. Di Giorgio1, M. Sicignano1, L. Evangelista2, L. Mansi3, P. OP-848 ITALY, 7Department of Economics & Finance, University of Rome 1 1 1 1 4 C. De Angelis1, F. Monari2, M. Mascia3, R. Costa4, G. Rubini5, A. Sannino , F. Masone , F. Squame , N. D’Acunzo , V. Nuzzo , S. “Tor Vergata”, Rome, ITALY, 8Nuclear Medicine Unit, S.Orsola- 5 6 1 Spanu6, A. Di Rocco7, E. Lodi Rizzini8, L. Cindolo9, M. Licari4, G. Spiezia , M. Klain , M. Spadafora ; PET in Inflammation/Infection Malpighi Hospital, Bologna, ITALY, 9Department of Urology, “Villa 1 2 Santo5, S. Nuvoli6, V. Frantellizzi1, V. Dionisi2, C. Ferrari5, G. De Nuclear Medicine Unit, Ospedale del Mare, Naples, ITALY, Nuclear Stuart” Private Hospital, Rome, ITALY. B. Mahida; Nuclear Medicine Department, Bichat Claude Bernard Vincentis1; Medicine Unit, Department of Medicine (DIMED), University of Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Paris 1Department of Radiological Sciences, Oncology and Anatomical Padua, Padua, ITALY, 3CIRPS, Rome. Interuniversity, reseach center Diderot University, Paris, FRANCE. Pathology, “Sapienza” University of Rome, Rome, ITALY, 2Radiation OP-858 for sustainability, Rome, ITALY, 4Endocrinology Unit, Ospedale del Oncology Center, S Orsola-Malpighi Hospital, Bologna, ITALY, Mare, Naples, ITALY, 5Endocrino surgery Unit, Ospedale del Mare, 68 OP-849 3Unit of Nuclear Medicine, “Spirito Santo” Hospital, Pescara, ITALY, The effect of tumor burden in GA-PSMA-PET/CT on Naples, ITALY, 6Department of Advanced Biomedical Sciences, 4 tracer uptake into kidneys in 68Ga-PSMA-PET/CT and the University of Naples Federico II, Naples, ITALY. EANM’20 EANM’20 Unit of Nuclear Medicine, Biomedical Department of Internal EANM’20 Cardiovascular Hybrid Imaging and Specialist Medicine, University of Palermo, Palermo, ITALY, absorbed dose per administered GBq 177Lu-PSMA-617 T. Maaniitty; Department of clinical physiology, nuclear medicine 5 OP-864 Nuclear Medicine Department, University of Bari “Aldo Moro”, during a following therapy and PET, Turku University Hospital, Turku, FINLAND. Bari, ITALY, 6Unit of Nuclear Medicine. Department of Medical, J. Wichert, C. Happel, W. T. Kranert, D. Gröner, J. Baumgarten, C. Surgical and Experimental Sciences. University of Sassari, Sassari, Ten-Year Follow-up and Clinical Outcome in Euthyroid Nguyen Ngoc, N. Mader, S. Banek, F. Grünwald, A. Sabet; Goethe 1508 ITALY, 7Department of Public Health and Infectious Diseases, Patients with Thyroid Nodules in an Iodine Sufficient Area

WORLD LEADING MEETING 8 University Hospital Frankfurt, Frankfurt, GERMANY. WORLD LEADING MEETING “Sapienza” University of Rome, Rome, ITALY, Nuclear Medicine K. Bajuk Studen1, K. Zaletel1, S. Gaberscek1,2; 9 Clinical Oncology Track - Featured Session: Unit, S Orsola-Malpighi Hospital, Bologna, ITALY, Department of 1Department of Nuclear Medicine, University Medical Centre Prostate Cancer Therapy - PSMA, 223Ra and Urology, “Villa Stuart” Private Hospital, Rome, ITALY. OP-861 Ljubljana, Ljubljana, SLOVENIA, 2Faculty of Medicine, University of More... Ljubljana, Ljubljana, SLOVENIA. OP-856 Selective Intraarterial Lu-177 PSMA Therapy for Friday, October 30, 2020, 10:40 - 12:10 OP-865 Channel 8 Castration Resistant Prostate Cancer: Preliminary Results Do the number of previous treatments and bone of a Pilot Study 99mTc-3PRGD SPECT/CT for predicting disease metastases impact Radium-223 therapy efficacy in H. Sayman1, F. Gulsen1, S. Sager1, E. Akgun1, N. Yeyin1, S. Bilgic1, K. 2 mCRPC patients? A multicentre study Toplutas1, F. Beytur1, R. Oklu2, O. Aras3; progression after initial therapy in high risk DTC patients V. Lavelli1, V. Frantellizzi2, E. Lodi Rizzini3, M. Licari4, L. Cindolo5, M. 1Istanbul University-Cerrahpasa, Istanbul, TURKEY, 2Mayo Clinic X. Jia, Y. Wang, Y. Liu, X. Wang, X. Yao, A. Yang, R. Gao; OP-851 Stazza6, A. Nappi1, M. Pontico2, V. Dionisi7, C. Ferrari1, A. Spanu6, M. Arizona, Phoenix, AZ, UNITED STATES OF AMERICA, 3Memorial The first affiliated hospital of Xi’an jiaotong university, Xi’an, Mascia8, R. Costa4, F. Monari7, G. De Vincentis2, G. Rubini1; 1Nuclear Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF CHINA. Positioning PSMA-RLT in the Urooncologial Treatment Medicine Department, University of Bari “Aldo Moro”, Bari, ITALY, AMERICA. Pathway 2Department of Radiological Sciences, Oncology and Anatomical OP-866 B. Hadaschik; Universitätsklinikum Essen, Urology, Essen, Pathology, Sapienza, “Sapienza” University of Rome, Rome, ITALY, GERMANY. 3Nuclear Medicine Unit, S.Orsola-Malpighi Hospital, Bologna, 1509 Is BRAFV600E mutation a risk factor for developing ITALY, 4Unit of Nuclear Medicine, Biomedical Department of TROP Session: Is It or Is It Not Malignant? controlateral limph-node metastases in papillary thyroid OP-853 Internal and Specialist Medicine, University of Palermo, Palermo, - Diagnostic/Predictive Options in Thyroid cancer (PTC) patients? 5 ITALY, Department of Urology, “Villa Stuart” Private Hospital, Nodules A. Campenni’1, R. Ruggeri2, M. Siracusa1, A. Alibrandi3, D. Cardile1, 6 Effects of one cycle of Actinium-225-PSMA-617 (AcPSMA) Rome, ITALY, Unit of Nuclear Medicine. Department of Medical, H. Lanzafame1, F. Panasiti1, F. La Torre1, G. Giacoppo1, A. Ieni4, G. on the salivary glands compared to Lu-177-PSMA Surgical and Experimental Sciences. University of Sassari, Sassari, Giuffrè4, G. Tuccari4, S. Baldari1; ITALY, 7Radiation Oncology Center, S.Orsola-Malpighi Hospital, (LuPSMA)-prelimary results Friday, October 30, 2020, 10:40 - 12:10 1Department of Biomedical and Dental Sciences and Morpho- Bologna, ITALY, 8Unit of Nuclear Medicine, “Spirito Santo” Hospital, Channel 9 B. Feuerecker1,2, A. Gafita1, R. Tauber3, C. Seidl1, F. Bruchertseifer4, Functional Imaging, Nuclear Medicine Unit, University of Messina, Pescara, ITALY. M. Retz3, J. E. Gschwend3, W. A. Weber1, C. D’Alessandria1, A. Messina, ITALY, 2Department of Clinical and Experimental Morgenstern4, M. Eiber1; Medicine, Unit of Endocrinology, University of Messina, Messina, 1Technical University of Munich, School of Medicine, Department OP-857 ITALY, 3Department of Economical, Business and Environmental of Nuclear Medicine, München, GERMANY, 2German Cancer OP-862 Sciences and Quantitative Methods, University of Messina, Consortium (DKTK), partnersite München, Heidelberg, GERMANY, Overall survival in elderly mCRPC patients treated with Messina, ITALY, 4Department of Human Pathology in Adult and 3Technical University of Munich, School of Medicine, Department Radium-223: a national multicenter study MIBI SPECT as first line diagnostic of hypofunctioning Developmental age “Gaetano Barresi”, University of Messina, of Urology, München, GERMANY, 4European Commission, Joint V. Lavelli1, L. Cosma2, F. Monari3, M. Mascia4, R. Costa5, G. Rubini1, thyroid nodules - a long term study Messina, ITALY. Research Centre, Directorate for Nuclear Safety and Security, A. Spanu6, A. Farcomeni7, E. Lodi Rizzini8, L. Cindolo9, A. Murabito5, M. Baehr, K. Liepe; Karlsruhe, GERMANY. S. Nuvoli6, V. Frantellizzi2, V. Dionisi3, A. Nappi1, G. De Vincentis2; Klinikum Frankfurt (Oder), Dept. Nuclear Medicine, Frankfurt 1Nuclear Medicine Department, University of Bari “Aldo Moro”, (Oder), GERMANY. Bari, ITALY, 2Department of Radiological Sciences, Oncology and

166 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 167 Romeo1, A. Giordano1, V. Gaudieri1, E. Zampella1, F. Volpe1, M. De Hospital Universitario La Paz, Madrid, SPAIN. University of Padua, ITALY. OP-867 Risi1, L. Pace3, A. Cuocolo1; 1Department of Advanced Biomedical Sciences, University Comparison between PERCIST criteria, Metabolic Tumor Federico II, Napoli, ITALY, 2IRCCS-SDN, Napoli, ITALY, 3Department OP-875 OP-880 Volume (MTV) and Total Lesion Glycolysis (TLG) in the of Medicine, Surgery and Dentistry, University of Salerno, Salerno, evaluation of response to tyrosine kinase inhibitors in ITALY. Incidental Interstitial Pneumonia Suggestive Of COVID- Signs of a diffuse and intense tracheobronchitis are patients with radioactive iodine-refractory metastatic 19 In Asymptomatic Patients Undergoing 18F-FDG PET/ commonly observed on ventilation scans obtained with CT In A High Prevalence Area 99mTc-labelled aerosols during the disease progression of thyroid cancer OP-872 A. Miceli1, A. Borra1, M. Bauckneht2, S. Gay3, S. Raffa1, M. Albertelli3, D. Albano, E. Cerudelli, M. Gazzilli, F. Dondi, A. Mazzoletti, P. Bellini, coronavirus 2019 1 1 2 1 3 L. Camoni, F. Bertagna, R. Giubbini; P. Marie, A. Bahloul, S. Melki, G. Karcher, C. Selton, F. Goehringer, L. M. Donegani , S. Marra , G. Ferrarazzo , G. Sambuceti , D. Ferone , Clinical Impact Of [68Ga]Ga-DOTA-TATE Imaging In M. GIusti3, S. Morbelli1; University of Brescia and Spedali Civili of Brescia, Brescia, ITALY. Imbert, A. Verger; Patients With Medullary Thyroid Cancer 1DISSAL, Genoa, ITALY, 2IRCCS Ospedale Policlinico San Martino, CHRU Nancy, Vandoeuvre (Les Nancy), FRANCE. Genoa, ITALY, 3DIMI, Genoa, ITALY. M. Tuncel, S. Kılıckap, N. Suslu; Hacettepe University, Ankara, TURKEY. OP-876 OP-881 OP-868 OP-873 Estimating the incidence of asymptomatic SARS- EANM’20 EANM’20 EANM’20 CoV-2 infection by frequency of CT findings in patients Impact of the COVID-19 pandemic in Nuclear Medicine Thyroglobulin doubling time independently predicts Long-term Outcome and Prognostic Features of undergoing PET/CT departments: preliminary report of the first international 18 2-[ F]-FDG-PET/CT results in Patients Affected by Differentiated Thyroid Cancer Patients Treated at I. Alberts, B. Vollnberg, C. Sachpekidis, C. Mingels, S. Weidner, A. survey Differentiated Thyroid Carcinoma with Positive Croatian Referral Centre Rominger; S. Annunziata1, M. Bauckneht2, D. Albano3, G. Argiroffi4, D. 131 T. Jukic1,2, M. Franceschi3, I. Blažeković3, M. Punda3, J. Staničić3, Institut für Nuklearmedizin, Bern, SWITZERLAND. Calabrò5, E. Abenavoli6, F. Linguanti6, R. Laudicella7, Young Group

WORLD LEADING MEETING Thyroglobulin Level and Negative I Whole Body Scan WORLD LEADING MEETING D. Albano1, E. Cerudelli2, M. Gazzilli2, F. Dondi1, A. Mazzoletti1, R. Granić3, P. Petranović-Ovčariček3, V. Gladić-Nenadić3, I. of the Italian Association of NuclearMedicine (AIMN); 1 2 P. Bellini1, L. Camoni2, F. Bertagna1, R. Giubbini1; 1University of Šiško-Markoš3, M. Bosak-Butković1, Z. Sonicki4,2, I. Mihaljević5, V. IRCCS Regina Elena National Cancer Institute, Rome, ITALY, IRCCS 6 3 7 OP-877 3 Brescia and Spedali Civili of Brescia, Brescia, ITALY, 2Spedali Civili of Bedeković , A. Fröbe , Z. Kusić ; Ospedale Policlinico San Martino, Genova, ITALY, University 4 Brescia, Brescia, ITALY. 1Sestre milosrdnice University Hospital Centre, Zagreb, CROATIA, and Spedali Civili, Brescia, ITALY, University of Milan, Milan, 2University of Zagreb, School of Medicine, Zagreb, CROATIA, Incidental lung findings suspicious for SARS-CoV-2 ITALY, 5University of Bologna, S. Orsola-Malpighi, Bologna, ITALY, 3Sestre milosrdnice University Hospital Centre, Department of infection in patients undergoing PET/CT during COVID- 6University of Florence, Firenze, ITALY, 7University of Messina, 4 OP-869 Nuclear Medicine and Oncology, Zagreb, CROATIA, School 19 pandemic Messina, ITALY. of Public Health “Dr. Andrija Štampar”, Zagreb, CROATIA, R. Mei1,2, L. Zanoni1, A. Farolfi1, C. Nanni1, V. Ambrosini1, P. 5 Comparison of Lesion Detectability and Image Quality Clinical Institute of Nuclear Medicine and Radiation Protection, Castellucci1, G. Montini1, V. Allegri1, A. Musto3, A. Golemi3, S. Fanti1; OP-882 among Digital and Analog PET Systems for Recurrence in University Hospital Osijek , Faculty of Medicine Osijek, Josip 1Nuclear Medicine Policlinico S.Orsola-Malpighi, Bologna, ITALY, Thyroid Cancer Patients Using I-124 Juraj Strossmayer University of Osijek, Osijek, CROATIA, 2DIMES, University of Bologna, Bologna, ITALY, 3Metropolitan A pandemic’s impact on a Nuclear Medicine Department: 6Sestre milosrdnice University Hospital Centre, Department of D. Kersting1, M. Weber1, M. Sraieb1, P. Fragoso Costa1, L. Umutlu2, Nuclear Medicine, AUSL di Bologna, Ospedale Maggiore, Bologna, Contingency plan implementation and activity Otorhinolaryngology, Head and Neck Surgery, University of C. Rischpler1, W. P. Fendler1, M. Conti3, K. Herrmann1, W. Jentzen1; ITALY. restrictions in a COVID-19 referral hospital Zagreb, School of Medicine, Zagreb, CROATIA, 7Croatian Academy 1Department of Nuclear Medicine, University Hospital Essen, 1 2 1 1 of Sciences and Arts, Zagreb, CROATIA. L. Torres , M. Monteiro , A. Oliveira , J. Pereira ; Essen, GERMANY, 2Department of Diagnostic and Interventional OP-878 1Centro Hospitalar Universitário São João, Porto, PORTUGAL, Radiology and Neuroradiology, University Hospital Essen, Essen, 2Centro Hospitalar Universitário Coimbra, Coimbra, PORTUGAL. GERMANY, 3Siemens Medical Solutions USA, Inc., Knoxville, TN, 1510 Cancer and COVID-19; Report of Cases in Nuclear UNITED STATES OF AMERICA. TROP Session: Our Army at War - Nuclear Medicine Department during the Pandemia in Spain Medicine and COVID-19 J. Ardila Mantilla, A. Rotger Regí, M. Baquero Oliveros, A. Marí OP-883 OP-870 Hualde, J. Orcajo Rincón, I. Gómez Fernández, C. Durán Barquero, D. Zamudio Rodríguez, Y. Henao Celada, J. Atance García de la Usefulness of Triage in a Nuclear Medicine Unit during Do Histological Patterns of Primary Tumor Predict Friday, October 30, 2020, 10:40 - 12:10 Santa, J. C. Alonso Farto; Channel 10 Covid-19 Pandemic Metabolic Patterns detected by FDG PET/CT in Hospital General Univeristario Gregorio Marañón, Madrid, SPAIN. S. Telo, A. Farolfi, L. Muraglia, D. Bezzi, F. Serani, E. Fortunati, S. Differentiated Thyroid Cancer Patients Mattoni, L. Vetrone, P. Castellucci, C. Nanni, S. Fanti; S. Soyluoglu, E. Tastekin, U. Korkmaz, S. Orum, G. Durmus Altun; OP-879 Nuclear Medicine, Policlinico S.Orsola-Malpighi, Bologna, ITALY. Trakya University, Medical School, Edirne, TURKEY. OP-874 The rate of incidental pulmonary ground glass opacities Teaching PET/CT to medical students under the COVID- (pGGOs) at 18F-Choline PET/CT in prostate cancer (PCa) 19 lockout: Implementing a new freeware client server OP-871 Incidental lung findings suggestive of COVID-19 patients PET/CT viewer in the university network pneumonia in oncologic PET/CT studies 1 2 1 1 1 1 D. Donner , M. Burei , S. Agostini , L. Picori , E. Bagatin , M. Erini , M. Biermann1,2, S. Kanoun3, T. Davidsen4, R. Gray5; Comparison of simultaneous 18F-FDG PET/MR and PET/ D. Monachello Araujo, M. Coronado Poggio, S. Rodado Marina, G. Carbone1, A. Palermo1, F. Chierichetti1, L. Evangelista3; 1Nuclear 1Nuclear Medicine/PET centre, Haukeland University Hospital, CT in the follow-up of patients with differentiated thyroid E. López Llobet, S. Rizkallal Monzón, D. Travaglio Morales, C. Medicine, Santa Chiara Hospital APSS - Trento, ITALY, 2Nuclear Bergen, NORWAY, 2Department of Clinical Medicine, University of cancer Lancha Hernández, L. García Zoghby, J. Cordero García, A. Medicine Unit, Veneto Institute of Oncology IOV-IRCSS, Padua, Bergen, Bergen, NORWAY, 3Nuclear Medicine/PET centre, Institut L. Piscopo1, M. Klain1, C. Nappi1, M. Manganelli1, E. Nicolai2, V. Guzmán Cruz, C. Escabias del Pozo, L. Domínguez Gadea; ITALY, 3Nuclear Medicine Unit, Department of Medicine-DIMED, Claudius Regaud, Tolouse, FRANCE, 4IT Department, University of

168 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 169 Bergen, Bergen, NORWAY, 5Department of Education, University of SPAIN, 2Ramón y Cajal University Hospital, Radiology, Madrid, prognostic biomarkers EPS-166 Bergen, Bergen, NORWAY. SPAIN. M. Celli1, G. Ghigi2, P. Caroli1, D. Arpa3, I. Marini1, L. Fantini1, V. Rossetti1, P. Cenni4, E. Amadori5, A. Romeo3, E. Mezzenga6, A. Myelin imaging with [11C]MeDAS PET Sarnelli6, G. Paganelli1, F. Matteucci1; OP-885 EPS-158 1Nuclear Medicine Unit, Istituto Scientifico Romagnolo per C. W. J. van der Weijden, J. F. Meilof, R. A. J. O. Dierckx, E. F. J. de lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, ITALY, Vries; Radiopharmacy activity during SARS-CoV-2 pandemic: Utility of 18F-FDG PET/CT based Metabolic Parameters in 2Radiation Therapy Unit, Istituto Scientifico Romagnolo per UMCG, Groningen, NETHERLANDS. management and production Differentiating Malignant Brain SOLs lo Studio e la Cura dei Tumori (IRST) IRCCS, Ravenna, ITALY, S. Migliari1, A. Sammartano1,2, M. Scarlattei1,2, G. Baldari1,2, S. A. Bedmutha, N. C. Purandare, A. D. Puranik, M. Pereira, A. 3Radiation Therapy Unit, Istituto Scientifico Romagnolo per lo EPS-168 Bola1,2, T. Graziani1,2, L. Ruffini1,2; Agrawal, S. Shah, V. Rangarajan; Tata Memorial Center, Mumbai, Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, ITALY, 4Neuro- 1AZ. Osp. Universitaria di Parma, Parma, ITALY, 2Nuclear Medicine INDIA. Radiology Unit, AUSL Romagna, Ravenna, ITALY, 5Radiology Brain SPECT perfusion and PET metabolism as discordant Department, University Hospital of Parma, Parma, ITALY. Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei biomarkers in major depressive disorder EPS-159 Tumori (IRST) IRCCS, Meldola, ITALY, 6Health Physics Unit, Istituto E. Guedj1, R. Richieri1, L. Boyer1, T. Korchia2, G. Fond2, C. Lançon1, M. Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Tastevin1; 1511 Single-centre investigation on the prognostic role of IRCCS, Meldola, ITALY. 1Aix Marseille Univ, Marseille, FRANCE, 2APHM, Marseille, FRANCE. semiquantitative FET PETparameters in patients with EANM’20 EANM’20 e-Poster Presentation Session 10: Molecular EANM’20 Brain Imaging previously treated primary brain tumours EPS-162 EPS-169 M. Celli1, G. Ghigi2, P. Caroli1, D. Arpa3, I. Marini1, L. Fantini1, V. Rossetti1, P. Cenni4, E. Amadori5, A. Romeo3, M. Belli6, A. Sarnelli6, G. Assessment of Glioma Aggressiveness Using Dynamic Effect of Statins on Brain Perfusion in Major Depression Friday, October 30, 2020, 10:40 - 12:10 1 1 Channel 11 Paganelli , F. Matteucci ; FDOPA PET/CT as an Addition to Standard Therapy. SPM Analysis 1Nuclear Medicine Unit, Istituto Scientifico Romagnolo per A. Girard1, P. Le Reste2, A. Metais3, N. Chaboub4, A. Devillers1, H. of Inflammation, Platelet Activation, Endothelial WORLD LEADING MEETING 4 1 1 WORLD LEADING MEETING lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, ITALY, Saint-Jalmes , F. Le Jeune , X. Palard-Novello ; Dysfunction and Neurocognitive Parameters 2 1Department of Nuclear Medicine, Centre Eugène Marquis, Radiation Therapy Unit, Istituto Scientifico Romagnolo per T. Massardo1, J. Quintana2, J. Pereira2, C. Sáez2, L. Risco1, S. Corral1, Rennes, FRANCE, 2Neurosurgery, University Hospital of Rennes, lo Studio e la Cura dei Tumori (IRST) IRCCS, Ravenna, ITALY, N. Olivares2, J. Spuler1, G. Castro1, D. Vicentini2, B. Riedel1, G. EPS-153 3 Rennes, FRANCE, 3Department of Pathology, University Hospital Radiation Therapy Unit, Istituto Scientifico Romagnolo per Valenzuela2, C. Villa3; of Rennes, Rennes, FRANCE, 4Inserm, LTSI – UMR 1099 research lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, ITALY, 1Hospital Clinico Universidad de Chile, Santiago, CHILE, 2Pontificia Clinical value of FDG-PET and MRI coregistration in Focal 4 unit - University Rennes 1, Rennes, FRANCE. Neuro-Radiology Unit, “Santa Maria delle Croci” General Universidad Católica de Chile, Santiago, CHILE, 3Instituto 5 Cortical dysplasia Hospital AUSL Romagna, Ravenna, ITALY, Radiology Unit, Istituto Psiquiátrico Dr. Horwitz, Santiago, CHILE. D. Khan, A. Raj ST, M. Tripathi, A. Garg, M. Tripathi, R. Bhargavi, P. Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) EPS-163 6 Chandra, R. Doddamani, A. Kumar, C. Bal; IRCCS, Meldola, ITALY, Health Physics Unit, Istituto Scientifico All India Institute of Medical Sciences, New Delhi, INDIA. Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Dopamine release after fear conditioning as measured 1601 Meldola, ITALY. 11 using bolus-infusion C-raclopride PET-MRI CME 13: Radiomics in a Preclininical and a EPS-154 M. Lubberink, A. Frick, J. Björkstrand, F. Åhs, M. Fredriksson; Clinical Setting EPS-160 Uppsala University, Uppsala, SWEDEN. The clinical value of 18F-FDG PET/CT in assessment of Dual Time-Point FET-PET/CT in Glioma Patients: a Single- EPS-164 Friday, October 30, 2020, 13:50 - 15:20 STN-DBS therapy in PD patients Channel 1 Q. Zhao, H. Yang, J. Cao, R. Wang, F. Wang; Centre Preliminary Experience General Hospital of Ningxia Medical University, Yinchuan, CHINA. A. Vento1, R. Laudicella1, F. Minutoli1, D. Romeo1, S. Russo1, D. Clinical significance of 123I-MIBG and 123I-FP-CIT in Cardile1, R. Filice1, A. D. Comis1, A. Mirabile1, B. Pagano1, S. Bisdas2,3, patients with Parkinsonism EPS-155 S. Baldari1; K. Maruyama, K. Utsunomiya, H. Kishishita, Y. Kono, Y. Ueno, N. 1Nuclear Medicine Unit, Department of Biomedical and Dental Tanigawa; OP-886 Glucose metabolic pattern using 18F-FDG PET/CT in Sciences and Morpho-Functional Imaging, Univeristy Of Messina, Kansai Medical University, Osaka, JAPAN. Parkinson’s disease patients Messina, ITALY, 2Department of Neuroradiology, University Radiomics and Nuclear Medicine - The Basis for Q. Zhao, H. Yang, J. Cao, J. Li, F. Wang; College London Hospitals NHS Trust, London, UNITED KINGDOM, EPS-165 Understanding its Value and a Revision of Literature 3 General Hospital of Ningxia Medical University, Yinchuan, CHINA. Department of Brain Repair and Rehabilitation, University M. Hatt; INSERM, LaTIM UMR 1101, Brest, FRANCE. College London, London, UNITED KINGDOM. The homogeneity of beta amyloid PET: different white EPS-157 matter properties of [18F]Florbetaben and [11C]PiB EPS-161 M. Rullmann1, P. L. Flender1, V. L. Villemagne2, O. Sabri1, H. OP-887 Value of 18F-FDG-PET in early and differential diagnosis Barthel1; of Frontotemporal dementia, a prospective study Initial clinical experience on the complementary role 1Department of Nuclear Medicine, University of Leipzig, Leipzig, Radiomics and Nuclear Medicine - Oncologist’s Requests I. López Villar1, P. Paredes Rodríguez1, D. Lourido García2, A. López- of brain FET-PET imaging with respect to Gd-MRI in the GERMANY, 2Department of Molecular Imaging and Therapy, N. Fazio; IRCCS IEO, European Institute of Oncology, Division of Frías López-Jurado2, P. Jane Soler1, J. Bonilla Plaza1, P. Azpeitia differential diagnosis of treatment-induced changes Centre for PET, Austin Health, Heidelberg, AUSTRALIA. Gastrointestinal Medical Oncology and Neuroendocrine Tumours, 1 1 1 1 1 Milan, ITALY. Hernández , A. Martínez Lorca , A. B , A. B , J. Castro Beiras , M. and true disease progression in treated primary brain Orduña Díez1; tumour patients and association with WHO grading and 1Ramón y Cajal University Hospital, Nuclear medicine, Madrid,

170 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 171 for assessment of Ba-133 as surrogate for I-131 1Department of Medical Physics, University of Wisconsin- OP-888 1603 J. Tran-Gia1, A. P. Robinson2, C. Bobin3, N. Calvert4, S. Collins2,5, A. Madison, Madison, WI, UNITED STATES OF AMERICA, 2Department Joint Symposium 26 (EANM/AAPM): M. Denis-Bacelar2, A. Fenwick2,6, K. Ferreira2, D. Finocchiaro7,8, F. of Medical Physics, Fundación Centro Diagnóstico Nuclear, Radiomics and Nuclear Medicine - Nuclear Physician’s 3 Quantitative SPECT - An Essential Tool? Fioroni7, K. Gianopoulou9, E. Grassi7, W. Heetun2, S. J. Jewitt10, M. Buenos Aires, ARGENTINA, Department of Radiology, University Response Kotzasarlidou9, M. Ljungberg11, V. Lourenço3, D. R. McGowan10,12, J. of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA, M. Kirienko; IRCCS Istituto Nazionale dei Tumori, Nuclear Scuffham13, K. Sjögreen Gleisner11, J. Solc14, C. Thiam3, J. Tipping4, J. 4University of Wisconsin Carbone Cancer Center, Madison, WI, Friday, October 30, 2020, 13:50 - 15:20 13 1 5 Medicine Division, Milan, ITALY. Channel 3 Wevrett , M. Lassmann ; UNITED STATES OF AMERICA, Faculty of Mathematics and 1Department of Nuclear Medicine, University of Würzburg, Physics, University of Ljubljana, Ljubljana, SLOVENIA. OP-889 Würzburg, GERMANY, 2National Physical Laboratory, Teddington, UNITED KINGDOM, 3CEA, LIST, Laboratoire national Henri OP-904 Radiomics and the Future - Where are we Going? Becquerel, (LNE-LNHB), Gif-sur-Yvette Cedex, FRANCE, 4The P. Lambin; Maastricht University, Precision Medicine, School OP-894 Christie NHS FT, Manchester, UNITED KINGDOM, 5Department A realistic Phantom of the head for the Validation of for Oncology and Develop Biol, Fac. Health, Medicine and Life of Physics, University of Surrey, Guildford, UNITED KINGDOM, attenuation corrections methods in PET-MRI 6 7 Sciences, Maastricht, NETHERLANDS. How we get from SPECT to Quantitative SPECT Cardiff University, Cardiff, UNITED KINGDOM, Azienda Unità J. Harries1,2, T. H. Jochimsen2, T. Scholz2, T. Schlender2, H. Barthel2, G. Roberts; The Newcastle upon Tyne Hospitals NHS Foundation Sanitaria Locale di Reggio Emilia - IRCCS, Medical Physics Unit, O. Sabri2, B. Sattler2; 8 1602 Trust, Nuclear Medicine Department, Newcastle, UNITED Reggio Emilia, ITALY, Department of Physics and Astronomy, 1Department of Medical Physics and Radiation Protection, EANM’20 EANM’20 9 EANM’20 KINGDOM. University of Bologna, Bologna, ITALY, ”THEAGENIO” Anticancer Hannover Medical School, Hannover, GERMANY, 2Department of Joint Symposium 25 (EANM/EANO): 10 Immunotherapy in Brain Tumours Hospital, Thessaloniki, GREECE, Oxford University Hospitals NHS Nuclear Medicine, Leipzig University Hospital, Leipzig, GERMANY. OP-895 FT, Oxford, UNITED KINGDOM, 11Department of Medical Radiation Physics, Lund, SWEDEN, 12University of Oxford, Oxford, UNITED OP-905 13 Friday, October 30, 2020, 13:50 - 15:20 The Limitations and Pitfalls of Quantitative SPECT KINGDOM, Royal Surrey NHS FT, Guildford, UNITED KINGDOM, Channel 2 14 WORLD LEADING MEETING C. Kappadath; University of Texas MD Anderson Cancer Center, Czech Metrology Institute, Brno, CZECH REPUBLIC. A PET/MRI phantom study using MRI based attenuation WORLD LEADING MEETING Department of Imaging Physics, Houston, TX, UNITED STATES OF correction to account for attenuation of the phantom AMERICA. OP-900 material I. Rausch, A. Valladares, T. Beyer, E. Unger; OP-890 OP-896 Computer Aided Imaging Analysis software for SPECT/CT Medical University of Vienna, Vienna, AUSTRIA. protocol comparisons Immunotherapy of Gliomas A Physicians View of Quantitative SPECT C. Jaudet, E. Quak, K. Weyts, A. Corroyer Dulmont, C. Lasnon, R. M. Weller; Universitay Hospital Zurich, Department of Neurology, S. Vöö; University College London Hospitals, Institute of Nuclear Ciappuccini, J. Saviny, G. Foucras, A. Batalla, S. Bardet; OP-906 Zurich, SWITZERLAND. Medicine, London, UNITED KINGDOM. Centre François Baclesse, Caen, FRANCE. Automated acceptance calibration and quality control for OP-891 OP-901 a compact benchtop SPECT system 1606 P. Mollet, S. Neyt, K. Braeckman, K. Deprez; Molecubes NV, Ghent, Immunotherapeutic Options in Brain Metastases Cutting Edge Science Track - TROP Session: Development and characterisation of a PET “painting” BELGIUM. E. Le Rhun; University Hospital Lille, Department of Neurosurgery, Harmonisation & Standardisation robotic phantom to generate pseudo-anthropomorphic Lille, FRANCE. brain and geometric test objects under digital computer OP-907 control OP-892 Friday, October 30, 2020, 13:50 - 15:20 Performance Evaluation of a compact benchtop SPECT Channel 6 A. Paramithas, A. Britten; 99m 111 177 St. George’s University Hospitals NHS Foundation Trust, London, system for Tc, In and Lu PET Imaging of Response to Immunotherapy in Brain UNITED KINGDOM. K. Deprez, K. Braeckman, S. Neyt; Tumours MOLECUBES, Ghent, BELGIUM. N. Galldiks; University Hospital Cologne, Department of Neurology, Cologne, GERMANY. OP-898 OP-902 OP-908

Standardisation and Validation of 177Lu Quantitative SUV- Printing 3D Heterogeneous Activity Distributions for Performance of a Novel Small-Animal SPECT System with SPECT/CT Quality Control of SPECT and PET Two Stationary Detectors: A Comparison of Multi-Pinhole T. Alkahtani1,2, J. Johnson2, K. Adamson2, V. Lewington1,2, L. J. Gear, G. Flux; Collimators for Mouse Imaging Livieratos1,2; The Royal Marsden NHSFT, Sutton, UNITED KINGDOM. J. Hoffmann1,2, J. Janssen1,2, T. Kanno2,3, T. Higuchi1,2,4; 1King’s College London, London, UNITED KINGDOM, 2Guy’s & 1Department of Nuclear Medicine, University Hospital of St Thomas’ Hospitals NHS Foundation Trust, London, UNITED OP-903 Würzburg, Würzburg, GERMANY, 2Comprehensive Heart Failure KINGDOM. Center, University Hospital of Würzburg, Würzburg, GERMANY, Retrospective Quantitative Harmonization in PET Using 3Department of Quantum Medical Technology, Graduate School OP-899 Deconvolution and Optimal Filtering of Medical Sciences, Kanazawa University, Kanazawa, JAPAN, D. Huff1, M. Namías2, A. J. Weisman1, T. J. Bradshaw3, M. R. 4Graduate School of Medicine, Dentistry and Pharmaceutical An international quantitative SPECT/CT imaging exercise Albertini4, R. Jeraj1,5; Sciences, Okayama University, Okayama, JAPAN.

172 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 173 OP-909 1608 OP-915 OP-919 Clinical Oncology Track - TROP Session: All Multi-pinhole SPECT Imaging of Rat Hearts and Bones: About Staging the Prostate A Prospective Study to Compare the Role of Prospective evaluation of medium and high risk prostate Image Quality under In Vivo Conditions 68Ga-PSMA-11 PET-CT and 68Ga-GUL-NOTA-PSMA PET-CT cancer patients at initial staging with (18F)AlF-PSMA- J. Janssen1,2, J. Hoffmann1,2, T. Kanno2,3, T. Higuchi1,2,4; in the Evaluation of Prostate Cancer HBED-CC: Intraindividual comparison with 68Ga-PSMA- 1 Friday, October 30, 2020, 13:50 - 15:20 Department of Nuclear Medicine, University Hospital of Channel 8 S. Prakash, C. S. Bal, A. Seth, M. Tripathi, S. Ballal, M. P. Yadav; All HBED-CC Würzburg, Würzburg, GERMANY, 2Comprehensive Heart Failure India Institute of Medical Sciences, New Delhi, INDIA. O. Alonso Nunez1,2, G. dos Santos1,2, M. Rodriguez Taroco1; Center, University Hospital of Würzburg, Würzburg, GERMANY, 1Uruguayan Centre of Molecular Imaging (CUDIM), Montevideo, 3Department of Quantum Medical Technology, Graduate School URUGUAY, 2Nuclear Medicine Centre, Clinical Hospital, University of Medical Sciences, Kanazawa University, Kanazawa, JAPAN, OP-916 of Uruguay, Montevideo, URUGUAY. 4Graduate School of Medicine, Dentistry and Pharmaceutical OP-913 Sciences, Okayama University, Okayama, JAPAN. Novel [F18]siPSMA14 biodistribution at 60, 90 and 120 Is PSMA-PET/CT cost-effective for disease staging in min p.i. showing most favourable kinetics at 90 min p.i. OP-920 1607 men with high-risk prostate cancer? An analysis of the for staging and restaging of prostate cancer patients 68 1 1 2 3 3 The clinical value of Ga-PSMA-11 PET/CT in patients EANM’20 EANM’20 Pitfalls & Artefacts 7: Bone SPECT/CT Revisited proPSMA randomised controlled trial J. Miksch , V. Prasad , D. Di Carlo , F. Zengerling , C. Bolenz , C. EANM’20 – Learning an Old Fox New Tricks R. De Abreu Lourenco1, R. de Feria Cardet1, T. Segard2, J. Yim1, Solbach1, M. Beer4, T. Wiegel5, H. J. Wester2, A. J. Beer1; 1Department with newly diagnosed prostate cancer, ISUP grade 5 and S. Williams3, R. Francis2, M. Frydenberg4, N. Lawrentschuk5, D. G. of Nuclear Medicine, University Hospital Ulm, Ulm, GERMANY, no metastases based on standard imaging Murphy5, M. S. Hofman3; 2Pharmaceutical Radiochemistry, Technische Universität H. Zacho1,2, S. Nalliah1, A. Petersen1, L. J. Petersen1,2; 1Aalborg Friday, October 30, 2020, 13:50 - 15:20 1 2 3 2 Channel 7 University of Technology Sydney, Sydney, AUSTRALIA, Sir Charles München, Garching, GERMANY, Department of Urology and University Hospital, Aalborg, DENMARK, Aalborg University, Gairdner Hospital, Perth, AUSTRALIA, 3Peter MacCallum Cancer Pediatric Urology, University Hospital Ulm, Ulm, GERMANY, Aalborg, DENMARK. WORLD LEADING MEETING Centre, Melbourne, AUSTRALIA, 4Monash University, Melbourne, 4Department of Radiology, University Hospital Ulm, Ulm, WORLD LEADING MEETING AUSTRALIA, 5University of Melbourne, Melbourne, AUSTRALIA. GERMANY, 5Department of Radiation Oncology and Therapy, University Hospital Ulm, Ulm, GERMANY. OP-921 OP-910 OP-914 OP-917 Investigation of 68-Ga PSMA PET and Multiparametric The End of Planar - Optimizing SPECT/CT Acquisition, Prospective comparison of 18F-PSMA-1007 PET/CT and MRI imaging Radiomics based models in the prediction 68 Interpretation, and Reporting whole-body MRI/DWI with CT for primary lymph node Temporal accumulation patterns of Ga-PSMA in primary of ISUP score in prostate cancer patients L. Antunovic; Department of Nuclear Medicine, Humanitas staging of unfavorable intermediate and high-risk prostate cancer: stable or steep? G. Feliciani1, A. Savini1, G. Bellomo1, M. Celli1, F. Ferroni1, E. 1 1 1 2 Research Hospital, Rozzano (MI), ITALY. prostate cancer J. olde Heuvel , M. Sinaasappel , M. P. M. Stokkel , C. H. Slump , B. Menghi1, M. Costantini2, D. Barone1, A. Sarnelli1, G. Paganelli1; 1 1 S. Malaspina1, M. Anttinen2, I. Jambor3, M. Sandell4, I. Rinta- J. de Wit-van der Veen ; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori OP-911 1 2 Kiikka5, S. Kajander1, J. Schildt6, E. Saukko7, T. Noponen8, J. Netherlands Cancer Instititute, Amsterdam, NETHERLANDS, (IRST) IRCCS, Meldola, ITALY, Departement of Pathology Azienda 2 Saunavaara4, P. Taimen9, P. B. Dean7, R. B. Sequeiros7, H. J. Aronen7, University of Twente, Enschede, NETHERLANDS. Ospedaliera-Universitaria Policlinico di Modena, Modena, ITALY. Quantification by SPECT/CT J. Kemppainen1, M. Seppänen10, P. J. Boström2, O. Ettala2; 1Turku T. Kuwert; Department of Nuclear Medicine, University Hospital, PET Centre, University of Turku and Turku University Hospital, OP-918 Erlangen, GERMANY. Turku, FINLAND, 2Department of Urology, University of Turku OP-922 82 and Turku University Hospital, Turku, FINLAND, 3Department Is the increased Rubidium uptake in prostate cancer 68 OP-912 of Radiology, Icahn School of Medicine at Mount Sinai, New explained by underlying Na+/K+-ATPase density? Ga-PSMA PET/CT for Primary Staging of High-Risk York, NY, UNITED STATES OF AMERICA, 4Medical Imaging Centre M. Jochumsen1,2, J. Sörensen1,2, J. R. Nyengaard3, S. R. P. Krag4, Prostate Cancer: A High-Volume Center Study Novel Hardware, Algorithms, and Protocols in Bone of Southwest Finland, University of Turku and Turku University B. G. Pedersen5,2, M. Borre6,2, J. Frøkiær1,2, K. Bouchelouche1,2, L. P. S. Klingenberg1,2,3, M. R. Jochumsen1,2, B. P. Ulhøi4, J. Fredsøe2,3, K. Hybrid Imaging Hospital, Turku, FINLAND, 5Department of Radiology, Tampere Tolbod1,2; D. Sørensen2,3, M. Borre2,5, K. Bouchelouche1,2; Z. Keidar; Department of Nuclear Medicine Rambam Health Care University Hospital, Tampere, FINLAND, 6Department of Clinical 1Aarhus University Hospital, Dept. of Nuclear Medicine and PET- 1Department of Nuclear Medicine & PET-Centre, Aarhus Campus, Haifa, ISRAEL. Physiology and Nuclear Medicine, Helsinki University Central Centre, Aarhus, DENMARK, 2Aarhus University, Dept. of Clinical University Hospital, Aarhus N, DENMARK, 2Department of Clinical Hospital, Helsinki, FINLAND, 7Department of Diagnostic Medicine, Aarhus, DENMARK, 3Department of Clinical Medicine, Medicine, Aarhus University, Aarhus C, DENMARK, 3Department Radiology, University of Turku and Turku University Hospital, Core Centre for Molecular Morphology, Section for Stereology of Molecular Medicine, Aarhus University Hospital, Aarhus N, Turku, FINLAND, 8Department of Medical Physics and Nuclear and Microscopy, Centre for Stochastic Geometry and Advanced DENMARK, 4Department of Pathology, Aarhus University Hospital, Medicine, University of Turku and Turku University Hospital, Bioimaging, Aarhus University, Aarhus, DENMARK, 4Aarhus Aarhus N, DENMARK, 5Department of Urology, Aarhus University Turku, FINLAND, 9Institute of Biomedicine, University of Turku University Hospital, Dept. of Pathology, Aarhus N, DENMARK, Hospital, Aarhus N, DENMARK. and Department of Pathology, Turku University Hospital, Turku, 5Aarhus University Hospital, Dept. of Radiology, Aarhus N, FINLAND, 10Department of Clinical Physiology, Nuclear Medicine DENMARK, 6Aarhus University Hospital, Dept. of Urology, Aarhus, OP-923 and Turku PET Centre, University of Turku and Turku University DENMARK. Hospital, Turku, FINLAND. The impact of dual time point 68Ga-PSMA PET/CT imaging on PSMA uptake of primary tumor in prostate cancer D. Has Simsek; Istanbul University, Istanbul Faculty of Medicine, Istanbul, TURKEY.

174 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 175 Brescia, ITALY, 2Università di Brescia e Azienda Socio Sanitaria OP-924 Territoriale degli Spedali Civili di Brescia, Brescia, ITALY, 3Università OP-931 OP-935 di Brescia, Brescia, ITALY. Diagnostic performance of the novel PSMA-specific PET Diagnostic Performance Of 18FDG-PET/CT In Visual 4-point scoring scale improves the yield of FDG radiotracer [F-18]siPSMA-14 in staging and restaging of Discriminating Patients With/Without Cardiac PET/CT in the diagnosis of cyst infection in patients with prostate cancer OP-928 Implantable Electronic Device Infection: A Case-Control autosomal dominant polycystic kidney disease J. Miksch1, V. Prasad1, D. DiCarlo2, F. Zengerling3, C. Bolenz3, C. Study P. Lovinfosse, M. Neuville, A. Jadoul, F. Jouret, R. Hustinx; A Qualitative Assessment System Proposed to Improve Solbach1, M. Beer4, T. Wiegel5, H. J. Wester2, A. J. Beer1; R. Mei1, V. Marinelli2, R. Bonfiglioli1, L. Calderoni1, G. Massaro2, S. CHU of Liege, Liege, BELGIUM. 1Department of Nuclear Medicine, University Hospital Ulm, the Diagnosis of Infective Endocarditis with 18F-FDG Fanti1, I. Diemberger2; Ulm, GERMANY, 2Pharmaceutical Radiochemistry, Technical PET/CT 1Nuclear Medicine Policlinico S.Orsola-Malpighi, Bologna, 3 OP-936 University Munich, Garching, GERMANY, Department of M. Gazzilli1, D. Albano2, E. Cerudelli1, A. Mazzoletti2, F. Dondi2, P. ITALY, 2Cardio-Thoracic and Vascular Building, Department of Urology and Pediatric Urology, University Hospital Ulm, Ulm, Bellini2, F. Bertagna2, R. Giubbini2; Experimental, Diagnostic and Specialty Medicine, Bologna, ITALY. 18 GERMANY, 4Department of Radiology, University Hospital Ulm, 1Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Automated Quantification of Bowel F-FDG PET/CT Ulm, GERMANY, 5Department of Radiation Oncology, University Brescia, ITALY, 2Università di Brescia, Brescia, ITALY. Uptake for Early Detection of Immune-Related Colitis in Hospital Ulm, Ulm, GERMANY. OP-932 Cancer Patients Receiving Immune Checkpoint Inhibitors 1 2 3 1,4 EANM’20 EANM’20 D. Huff , H. Emamekhoo , S. B. Perlman , R. Jeraj ; EANM’20 OP-929 Semiquantitative Analysis Of 18F-FDG PET/CT Results 1Department of Medical Physics, University of Wisconsin- 1609 In Patients With Cardiac Implantable Electronic Device Madison, Madison, WI, UNITED STATES OF AMERICA, 2Department TROP Session: PET for Infection and Identification Of Brain 18F-FDG PET Metabolic Profile Infection of Medicine, University of Wisconsin-Madison, Madison, WI, Inflammation - A New Story Of Encephalitis In Patients With Infective Endocarditis D. Pursanova, I. P. Aslanidis, O. V. Mukhortova, I. V. Shurupova, I. V. UNITED STATES OF AMERICA, 3University of Wisconsin Carbone (IE): Relationships With Clinical/Biological Features And Ekaeva, T. A. Trifonova, D. A. Popov; Cancer Center, Madison, WI, UNITED STATES OF AMERICA, 4Faculty WORLD LEADING MEETING WORLD LEADING MEETING Prognosis A.N. Bakulev Scientific Center for Cardiovascular Surgery of of Mathematics and Physics, University of Ljubljana, Ljubljana, Friday, October 30, 2020, 13:50 - 15:20 SLOVENIA. Channel 9 M. Philip, E. Kaphan, L. Tessonnier, M. Mulatero, S. Cammilleri, F. the Ministry of Health of the Russian F, Moscow, RUSSIAN Gouriet, J. Casalta, S. Hubert, A. Riberi, G. Habib, E. Guedj; FEDERATION. Hôpital La Timone, Marseille, FRANCE. 1611 OP-933 e-Poster Presentation Session 11: Nuclear OP-925 OP-930 Medicine Therapy Beyond Thyroid PET-MRI in acute gastrointestinal graft versus host Role of [18F]FDG-PET/CT in the diagnosis of The detectability of infective endocarditis is significantly disease 1 2 3 1 3 Friday, October 30, 2020, 13:50 - 15:00 spondylodiscitis enhanced when FDG-PET images are recorded in cine W. Roll , G. Evers , P. Schindler , R. Strotmann , B. Noto , M. Channel 11 R. Viglialoro, R. Zanca, A. Marciano, F. Bartoli, P. Erba, E. Lazzeri; mode Masthoff3, M. Stelljes2, M. Schäfers1,4; 1 Regional Center of Nuclear Medicine, Department of C. Boursier1, X. Duval2,3,4, L. Imbert1,5, B. Mahida6, B. Hoen7, F. Department of Nuclear Medicine, University Hospital Münster, 2 Translational Research and New Technology in Med, Pisa, ITALY. Goehringer7, C. Selton-Suty8, E. Chevalier1, M. Claudin1, V. Roch1, Münster, GERMANY, Department of Medicine A, Hematology, Z. Lamiral9, A. Bourdon10, A. Cochet11, F. Rouzet6,12, P. Marie1,13, the Oncology and Pulmonary Medicine, University Hospital Münster, 3 OP-926 AEPEI-TEPvENDO study group; Münster, GERMANY, Institute of Clinical Radiology, University EPS-170 4 1CHRU-Nancy, Université de Lorraine, Department of Nuclear Hospital Münster, Münster, GERMANY, Europeam Institute for 64Cu-DOTA-Ubiquicidin 29-41 PET/CT in patients with Medicine and Nancyclotep molecular imaging platform, Molecular Imaging, Münster, GERMANY. Is It Safe Enough to Follow-up Patients Only with Post- suspected infectious process: Initial experience in a Vandoeuvre-les-Nancy, FRANCE, 2AP-HP, Hôpital de Bichat therapy Whole-body Scan After PRRT? single center in Mexico Claude Bernard, Department of Infectious Diseases, Paris, OP-934 T. Telli, M. Tuncel, P. Ozgen Kiratli; 3 O. Garcia-Perez1,2, P. Munguia1, H. Valdovinos1, J. Vargas- FRANCE, Université Paris Diderot, INSERM, UMR 1137 (IAME), Hacettepe University Faculty of Medicine, Ankara, TURKEY. 4 Ahumada1, F. Lemus1, I. Soldevilla1, N. Becerra1, M. Acuña3; Paris, FRANCE, INSERM, CIC 1425, AP-HP, Hôpital Bichat Claude Association between residual FDG metabolic activity and 5 1Instituto Nacional de Cancerologia, Mexico City, MEXICO, Bernard, Paris, FRANCE, Université de Lorraine, INSERM, UMR CT features of active tuberculosis on end-of-treatment EPS-172 6 2Imagenus - Diagnostics in Healthcare, Mexico City, MEXICO, 1254, Nancy, FRANCE, AP-HP, Hôpital Bichat Claude Bernard, 18 7 [ F]F-FDG PET/CT in patients treated for pulmonary 3Clinica FOSCAL, Bucaramanga, COLOMBIA. Department of Nuclear Medicine, Paris, FRANCE, CHRU-Nancy, The Role of Ga-68 PSMA PET / CT in Predicting Lu-177 Department of Infectious Diseases, Vandoeuvre-les-Nancy, tuberculosis 1,2 3 3 1 3 PSMA Effectiveness: Can We Project the Ga-68 DOTA PET / FRANCE, 8CHRU-Nancy, Department of Cardiology, Vandoeuvre- I. Lawal , M. Mathebula , I. Moagi , T. Lengana , N. Moeketsi , M. 3 4 5 6 6 CT and Lu-177 DOTA Treatment Experience to PSMA? les-Nancy, FRANCE, 9Université de Lorraine, CHRU-Nancy, Nchabeleng , G. Popoola , C. Hikuam , E. Douglass , J. Ellner , M. OP-927 5 1 1 1 INSERM, CIC 1433, Vandoeuvre-les-Nancy, FRANCE, 10CHRU- Hatherill , B. Fourie , M. Sathekge ; University of Pretoria, Pretoria, U. Korkmaz, F. S. Soyluoglu, G. Durmus-Altun; Trakya University, 2 Nancy,Department of Nuclear Medicine, Montpellier University SOUTH AFRICA, Nuclear Medicine Research Infrastructure Edirne, TURKEY. Could Hypermetabolism of the spleen or bone marrow 3 Hospital, Montpellier, FRANCE, 11Department of Nuclear (NuMeRI), Pretoria, SOUTH AFRICA, Sefako Makgatho University improve the FDG-PET/CT diagnosis of Infective 4 Medicine, Georges-François Leclerc Cancer Center, Dijon, FRANCE, of Medical Science, Pretoria, SOUTH AFRICA, University of Ilorin, 5 EPS-173 Endocarditis as indirect signs? 12Université Paris Diderot, INSERM, UMR 1148 (LVTS), Paris, Ilorin, NIGERIA, University of Cape Town, Cape Town, SOUTH 6 M. Gazzilli1, D. Albano2, E. Cerudelli1, A. Mazzoletti3, F. Dondi3, P. FRANCE, 13Université de Lorraine, INSERM, UMR 1116, Nancy, AFRICA, Boston University, Boston, MA, UNITED STATES OF Peptide receptor radionuclide therapy (PRRT) for Bellini3, F. Bertagna2, R. Giubbini2; FRANCE. AMERICA. 1Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, neuroendocrine tumors (NET): A single institution

176 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 177 experience in the USA D. Vega, J. Estenoz; DKFZ, Heidelberg, GERMANY. Approaches for Cardiovascular Imaging H. Duan, V. Ferri, P. L. Kunz, G. A. Fisher, F. Moradi, G. A. Davidzon, Hospital Universitario 12 de Octubre, Madrid, SPAIN. B. L. Franc, A. H. Iagaru, C. Aparici Mari; OP-939 Friday, October 30, 2020, 15:30 - 17:00 Stanford University, Stanford, CA, UNITED STATES OF AMERICA. Channel 3 EPS-179 Immuno-Positron Emission Tomography with Zirconium- EPS-174 Evaluation of toxicity in peptide receptor radionuclide 89-Labeled Monoclonal Antibodies in Oncology - What therapy (PRRT) for neuroendocrine tumors (NET) Can We Learn From Initial Clinical Trials? Early change of 68Ga-HA-DOTATATE uptake during PRRT H. Duan, V. Ferri, P. L. Kunz, G. A. Fisher, F. Moradi, G. A. Davidzon, D. Vugts; VUmc Imaging Center AmsterdamRadiology & Nuclear OP-944 prognosticates duration of response in patients with B. L. Franc, A. H. Iagaru, C. Aparici Mari; Medicine, Amsterdam, NETHERLANDS. metastatic NET Stanford University, Stanford, CA, UNITED STATES OF AMERICA. Cardiologist’s perspective : what do we need? F. Fiz1, H. Dittmann2, G. Centurioni3, C. la Fougère2; 1Humanitas P. Soman; University of Pittsburgh Medical Center, Pittsburgh, Clinical and Research Center - IRCCS, Milan, ITALY, 2Nuclear EPS-180 1702 UNITED STATES OF AMERICA. Medicine Unit, Department of Radiology, University of Tübingen, Joint Symposium 27 (EANM/ESMI): Radar on Tübingen, GERMANY, 3University of Tübingen, Tübingen, Real-time MR imaging of holmium-166 microsphere Immune Cell Imaging OP-945 distribution during SIRT in salvage patients: proof of EANM’20 EANM’20 GERMANY. EANM’20 principle Physicist’s perspective : what comes next ? Friday, October 30, 2020, 15:30 - 17:00 L. Imbert; Nuclear Medicine Department, CHRU Nancy Brabois, J. Roosen, M. A. Arntz, M. Janssen, K. G. Overduin, M. W. Channel 2 EPS-175 Konijnenberg, J. J. Fütterer, F. W. Nijsen; Nancy, FRANCE. Radboud University Medical Center, Nijmegen, NETHERLANDS. Incidence of raised HbA1c and correlation with WORLD LEADING MEETING Somatostatin analogue therapy (SSA) in patients with WORLD LEADING MEETING Neuroendocrine Tumours (NET) receiving peptide EPS-181 OP-940 receptor [177Lu]Lu-DOTA-TATE radionuclide therapy Absorbed Dose in “Black Hole” as a predict of complete Unravelling the Universe of the Immune System by (PRRT) MRI response in HCC patients treated with Y-90 TARE Targeted Molecular Imaging N. Eftychiou1, H. Ilyas1, H. Ahmed1, F. Hassan1, A. Eccles1, V. M. Meyer, S. Boughdad, J. O. Prior, M. Da Mota, N. Schaefer, A. B. Pichler; University Hospital Tübingen, Department of Preclinical Lewington1,2; Hocquelet; Imaging and Radiopharmacy, Tübingen, GERMANY. 1Guy’s and St Thomas Foundation Trust, London, UNITED 2 CHUV, Lausanne, SWITZERLAND. KINGDOM, King’s College London, London, UNITED KINGDOM. OP-941

EPS-176 1701 Clinical Experience in Immune Cell Imaging in Altherosclerosis 177 CME 14: Molecular Drug Imaging of Solid Single-institution real-life experience of Lu-DOTATATE Tumours Including Microenvironment F. Hyafil; Centre Hospitalier Universitaire Bichat, Assistance treatment in progressive, well differentiated GEPNETs Publique - Hôpitaux de Paris, Department of Nuclear Medicine, F. Scalorbi, A. Lorenzoni, E. Seregni, V. Fuoco, G. Argiroffi, N. Prinzi, Paris, FRANCE. Friday, October 30, 2020, 15:30 - 17:00 S. Pusceddu, G. Aliberti, E. Garanzini, J. Coppa, F. De Braud, V. Channel 1 Mazzaferro, M. Maccauro; Istituto Nazionale Tumori Milano, OP-942 Milan, ITALY. Clinical Experience in Immune Cell Imaging in Myocardial EPS-177 Infarction OP-937 F. Bengel; Hannover Medical School, Department of Nuclear Four-years experience in 177Lu-oxodotreotide therapy Medicine, Hannover, GERMANY. for patients with Neuroendocrine Tumors (NETs) Tumor Immunotargeting Using Innovative Radionuclides A. Cardozo Saavedra, A. García-Burillo, D. Villasboas-Rosciolesi, C. Bailly; Nuclear Medicine Department, University Hospital of OP-943 M. Simó-Perdigó, J. Hernando-Cubero, J. Capdevila Castillón, E. Nantes and ICO-Gauducheau Cancer Center, Nantes, FRANCE. M. Carrillo-Villamizar, S. Menendez Sanchez, J. Castell-Conesa; Inflammation and Immunooncology - Same Targets, Hospital Universitari Vall D’Hebron, Barcelona, SPAIN. OP-938 Different Story? I. Grondman; Radboud University Medical Centre, Department EPS-178 Protease Fibroblast Activation Protein (FAP)-Targeted of Internal Medicine and Radboud Center for Infectious Diseases, Radiotracers for New Applications in Non-Invasive Nijmegen, NETHERLANDS. Treatment of Neuroendocrine Tumors with Lutetium-177 Tumour-Characterization, Staging or Radio-Ligand Oxodotretoide: First Results in our Institution Therapy 1703 Á. Galiana, A. Gardellini, M. Marín, E. Martínez, A. La Salvia, R. U. Haberkorn; Department of Nuclear Medicine, Universität García-Carbonero, M. Tabuenca, S. Ruiz, V. Godigna, J. Pilkington, Heidelberg, and Clinical Cooperation Unit Nuclear Medicine, Joint Symposium 28 (EANM/AHA): New

178 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 179 C. Kutyreff1, J. Pettersson2, K. Seeley1, T. Barnhart1, J. Engle1,3, K. A. Goddard1,2, G. Platsch3, C. Gall1, L. Sibille1, B. Spottiswoode1, V. OP-946 Gagnon2; OP-959 Shah1; 1University of Wisconsin-Madison, School of Medicine and Public 1Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED 188 188 Radiopharmacist’s perspective : what comes next ? Health, Department of Medical Physics, Madison, WI, UNITED Development of an in-house W/ Re generator STATES OF AMERICA, 2Illinois Institute of Technology, Chicago, B. Guillet; Radiopharmacy department, University Hospital STATES OF AMERICA, 2GEMS PET (GE Healthcare), Uppsala, M. Van de Voorde1, A. Burgoyne1, B. Ponsard1, E. Dennis1, T. IL, UNITED STATES OF AMERICA, 3Siemens Healthcare GmbH, Marseille, Marseille, FRANCE. SWEDEN, 3University of Wisconsin-Madison, School of Medicine Cardinaels1,2, M. Ooms1; Erlangen, GERMANY. and Public Health, Department of Radiology, Madison, WI, 1SCK CEN, Mol, BELGIUM, 2KU Leuven, Leuven, BELGIUM. OP-947 UNITED STATES OF AMERICA. OP-965 Nuclear physician’s perspective: what comes next ? OP-954 A. Saraste; Turku PET Centre and Heart Center, Turku University OP-961 Effectively Detecting Left Bundle Branch Block Artefacts Hospital and University of Turku, Turku, FINLAND. Cyclotron-based 68Ga production with dual liquid targets With a Convolutional Neural Network (CNN) Using a Very 1 2 1 2 1 K. Gagnon , M. E. Rodnick , C. Parr , M. Clark , S. A. Grosch , P. J. H. Production of Ac-225 for Targeted Alpha Therapy using Small Training Dataset 2 Scott ; an Electron Linear Accelerator M. Abdi1, Q. Naili1, M. Habbache1, B. Said1, A. Boumenir1, T. 1 2 1704 GEMS PET Systems, Uppsala, SWEDEN, University of Michigan, T. Tadokoro1, Y. Ueno1, Y. Kani1, M. Shimada2, T. Sasaki2, T. Douibi1, D. Djermane2, S. Berrani3; Ann Arbor, MI, UNITED STATES OF AMERICA. 2 3 3 4 4 1 2 EANM’20 EANM’20 CTE 7: Quality Control of Imaging Watanabe , H. Kikunaga , S. Kashiwagi , S. Sekimoto , T. Ohtsuki ; Centre d’imagerie scintigraphique, Blida, ALGERIA, Cardio EANM’20 Instrumentation 1Hitachi, Ltd., Research & Development Group, Hitachi-shi, JAPAN, A2, Mustapha Bacha, Algiers, ALGERIA, 3Ecole Nationale OP-955 2Hitachi, Ltd., Healthcare Business Unit, Tokyo, JAPAN, 3Research Polytechnique, Algiers, ALGERIA. Center for Electron Photon Science, Tohoku University, Sendai, Friday, October 30, 2020, 15:30 - 17:00 Selective, stable chelation of radioantimony for Sb-119 JAPAN, 4Institute for Integrated Radiation and Nuclear Science, Channel 4 Targeted Radionuclide Therapy Kyoto University, Kumatori-cho, JAPAN. OP-966 WORLD LEADING MEETING A. Olson1, Y. Feng2, P. A. Ellison1, E. Aluicio-Sarduy1, T. E. Barnhart1, WORLD LEADING MEETING R. J. Nickles1, S. S. Jurisson3, J. W. Engle1; OP-962 Metabolic tumour volume segmentation for oesophageal 1Department of Medical Physics, University of Wisconsin Madison, cancer on hybrid PET/CT using convolutional network 2 OP-949 Madison, WI, UNITED STATES OF AMERICA, Department of Fluorine-18 labelling of biomolecules via disulfide architecture Radiology, Duke University, Durham, NC, UNITED STATES OF rebridging for PET imaging E. Spezi1, C. Parkinson1, S. Berenato2, W. Riviera3, S. Sobhee4, C. 3 Routine QC Tests on SPECT and SPECT/CT AMERICA, Department of Chemistry, University of Missouri, M. Richard, B. Kuhnast; Stylianou5, T. Crosby2, K. Foley2; C. Pestean; Iuliu Hatieganu University of Medicine and Pharmacy, Columbia, MO, UNITED STATES OF AMERICA. Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Service 1Cardiff University, Cardiff, UNITED KINGDOM,2 Velindre Cancer Nuclear Medicine Department, Cluj, ROMANIA. Hospitalier Frédéric Joliot, Orsay, FRANCE. Centre, Cardiff, UNITED KINGDOM,3 Intel Corporation, London, OP-956 UNITED KINGDOM, 4Intel Corporation, Munich, GERMANY, 5Intel OP-950 OP-963 Corporation Limited, London, UNITED KINGDOM. M. Malinconico1, C. Hollis2, K. Kuan2, C. Barkil2, P. Takhar2, A. 1 2 Routine QC Tests on PET and PET/CT Brunetti , W. Tieu ; [89Zr]ZrTrastuzumab preparation based on commercial OP-967 1COMECER S.p.A., Castel Bolognese, ITALY, 2Molecular Imaging G. Testanera; Bartshealth NHS Trust, Nuclear Medicine, London, cassette base synthesis module and Therapy Research Unit, South Australian Health and Medical UNITED KINGDOM. 1 1 2,3 1 2 A tool for AI-driven Organ Segmentation and Research Institute, Adelaide, AUSTRALIA. E. Cazzola , J. Amico , P. Martini , M. Malachini , G. Sciacca , J. Esposito2, G. Gorgoni1; quantification in SSTR- imaging - Development and OP-951 1Radiopharmacy and Cyclotron Dept, IRCCS Sacro Cuore external validation 2 OP-957 Hospital, Negrar, ITALY, INFN- Legnaro National Laboratories P. Jackson1, B. M. Fischer2, S. F. Barrington2, L. McIntosh1, T. 3 Annual QC Tests on SPECT/CT and PET/CT and Annual (LNL), Legnaro, ITALY, Unife - Ferrara University, Ferrara, ITALY. Kotwal2, G. Krokos2, J. Callahan1, J. Korte1, R. Alipour1, M. Hofman1, 51 54 Report Separation of Cyclotron-Produced Mn from Fe with R. J. Hicks1; P. Tomse; University Medical Centre, Department of Nuclera DGA Resin 1Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, 2King’s Medicine, Ljubljana, SLOVENIA. K. Barrett, E. Aluicio-Sarduy, T. E. Barnhart, J. W. Engle; 1706 College London & Guy’s and St Thomas’ PET Centre, London, University of Wisconsin- Madison, Madison, WI, UNITED STATES Cutting Edge Science Track - TROP Session: AI - UNITED KINGDOM. 1705 OF AMERICA. Image Processing and Data Corrections M2M Track - TROP Session: Hot Stuff - OP-968 Radionuclide Production OP-958 Friday, October 30, 2020, 15:30 - 17:00 Automatic Image Subtraction in Parathyroid Scintigraphy Channel 6 Friday, October 30, 2020, 15:30 - 17:00 Re-Establishing of Production of 188W/188Re Generators Channel 5 using Rotated Principal Components 188 188 1 2 3 1 Utilizing W Activity Obtained from Irradiated WO3 I. Marikova , S. Balogova , J. Talbot , M. Samal ; Ampoules and 188W Solution 1Institute of Nuclear Medicine, First Faculty of Medicine, Charles J. Jernstroem, M. Olmeda Palomar, J. Nikula, N. Vetter, I. Kuru, T. University and the General University Hospital in Prague, Prague, 2 Nikula; OP-964 CZECH REPUBLIC, Department of Nuclear Medicine, Comenius OP-953 OncoBeta GmbH, Garching, GERMANY. University, Faculty of Medicine & St. Elisabeth Cancer Institute, An automated method for locating a liver reference Bratislava, SLOVAKIA, 3Department of Nuclear Medicine, Hôpital 61 Automated Production of [ Cu]CuCl2 at UW-Madison region in PET/CT scans Tenon APHP and Sorbonne University, Paris, FRANCE.

180 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 181 McGowan1,3; Characterization of Thyroid Nodules Munich, GERMANY, 4University Clinic Essen, Essen, GERMANY. OP-969 1Oxford University Hospitals NHS FT, Oxford, UNITED KINGDOM, A. Piccardo; Galliera Hospital, Department of Nuclear Medicine, 2GE Healthcare, Milwaukee, WI, UNITED STATES OF AMERICA, Genoa, ITALY. A cross-scanner robustdeep learning method for the 3University of Oxford, Oxford, UNITED KINGDOM. OP-982 recovery of full-dose imaging quality from low-dose PET 1708 177 S. Xue1, R. Guo2, K. P. Bohn1, J. Matzke3, M. Viscione1, M. Viscione1, B. [ Lu]Lu-PSMA-617 in low-volume metastatic hormone Li2, A. Rominger1, K. Shi1; OP-974 Clinical Oncology Track - TROP Session: [177Lu] sensitive prostate cancer: a prospective pilot study 1University of Bern, Bern, SWITZERLAND, 2Ruijin Hospital, Lu-PSMA Radioligand Therapy B. Prive1, S. M. B. Peters1, C. H. J. Muselaers1, P. Zamecnik1, M. J. R. Shanghai Jiaotong University, Shanghai, CHINA, 3Technical The effect of data preparation of small datasets to predict Janssen1, T. W. J. Scheenen1, M. W. Konijnenberg1, J. Verzijlbergen1, University of Munich, Munich, GERMANY. Friday, October 30, 2020, 15:30 - 17:00 1 1 2 2 biochemical recurrence in prostate patients from PET/MR Channel 8 W. R. Gerritsen , N. Mehra , D. M. Somford , J. A. Van Basten , I. M. 1 1 1 1 1 imaging Van Oort , J. Sedelaar , J. O. Barentsz , S. Heskamp , M. Gotthardt , 1 1 OP-970 D. Krajnc, L. Papp, C. P. Spielvogel, M. Grahovac, M. Hartenbach, J. Witjes , J. Nagarajah ; 1 2 M. Hacker, T. Beyer; Radboudumc, Nijmegen, NETHERLANDS, Canisius Wilhelmina Zero-TE MRI-based Attenuation Correction for Chest FDG Medical University of Vienna, Vienna, AUSTRIA. Hospital, Nijmegen, NETHERLANDS. PET/MRI: A Feasibility Study of Deep Learning Approach OP-979 OP-983 EANM’20 EANM’20 Using Unpaired PET/CT Data EANM’20 Prognostic markers for overall survival and outcome M. Nogami1, H. Matsuo1, M. Nishio1, F. Zeng1, J. Inukai1, F. OP-975 Wiesinger2, S. Kaushik2, T. Kurimoto3, K. Kubo1, T. Murakami1; 1Kobe to LuPSMA radionuclide treatment in patients with Extended radioligand therapy with Lu-177-PSMA-617 in University Hospital, Kobe, Hyogo, JAPAN, 2GE Healthcare, Munich, Novel Software for Computer-aided Differential metastatic castration-resistant prostate cancer patients with advanced metastatic castration-resistant GERMANY, 3GE Healthcare, Hino, Tokyo, JAPAN. Diagnosis of Parkinsonism Using Positron Emission A. Gafita1, J. Calais1, H. Wang2, M. Weber3, H. Rathke4, C. prostate cancer Tomography Kratochwil4, R. Esfandiari5, W. R. Armstrong1, S. Sandhu6, R. N. Mader1, J. Baumgarten1, D. Gröner1, C. Nguyen Ngoc1, K. Davis1, WORLD LEADING MEETING WORLD LEADING MEETING E. Lindström1,2, C. Widström2, T. Danfors2, M. Lubberink1,2, M. Tauber2, E. S. Delpassand5, U. Haberkorn4, W. A. Weber2, K. S. Banek2, N. Tselis3, C. Happel1, F. Grünwald1, A. Sabet1; OP-971 Jonasson1,2; Herrmann3, J. Czernin1, M. S. Hofman6, W. P. Fendler3, M. Eiber2; 1Department of Nuclear Medicine, University Hospital Frankfurt, 1Uppsala University, Uppsala, SWEDEN, 2Uppsala University 1UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, 2Technical Frankfurt am Main, GERMANY, 2Department of Urology, University Deep learning based scatter correction for PET imaging Hospital, Uppsala, SWEDEN. University Munich, Munich, GERMANY, 3University of Duisburg- Hospital Frankfurt, Frankfurt am Main, GERMANY, 3Department of D. Visvikis1, T. Merlin2, A. Bousse1, D. Benoit1, B. Laurent1; 1LaTIM, Essen, Essen, GERMANY, 4Heidelberg University, Heidelberg, Radiooncology, University Hospital Frankfurt, Frankfurt am Main, INSERM, UMR 1101, Brest, FRANCE, 2LaTIM, INSERM, UMR 1101, GERMANY, 5Excel Diagnostics and Nuclear Oncology Center, GERMANY. CHRU Brest, Brest, FRANCE. 1707 Houston, TX, UNITED STATES OF AMERICA, 6Peter MacCallum Teaching Session 7: Molecular Imaging in Cancer Center, Melbourne, AUSTRALIA. OP-984 OP-972 Thyroid Nodules OP-980 Early prostate-specific antigen changes and clinical Data-driven motion compensation of [18F]FDG-PET outcome following 177Lu-PSMA radionuclide treatment Friday, October 30, 2020, 15:30 - 17:00 Circulating androgen receptor gene amplification and brain imaging using conditional Generative Adversial Channel 7 in patients with metastatic castration-resistant prostate Networks (cGANs) resistance to 177Lu-PSMA-617 in patients with metastatic cancer D. Iommi1, L. Shiyam Sundar1, O. Muzik2, Z. Chalampalakis3, E. M. castration-resistant prostate cancer: results of a phase 2 A. Gafita1, M. M. Heck2, I. Rauscher1, R. Tauber2, C. Franz1, L. Cala1, Klebermass4, M. Hienert5, L. Rischka5, R. Lanzenberger5, A. Hahn5, E. trial C. D’Alessandria1, M. Retz2, M. Eiber1, W. A. Weber1; 1Department 6 4 1 Pataraia , T. Traub-Weidinger , T. Beyer ; G. Paganelli1, S. Severi1, M. Sansovini1, S. Nicolini1, I. Grassi1, F. von of Nuclear Medicine, Technical University Munich, Munich, 1 OP-976 QIMP Team, Center for Medical Physics and Biomedical Eyben2, V. Conteduca1, M. Monti1, F. Foca1, G. Gurioli1, M. Celli1, F. GERMANY, 2Department of Urology, Technical University Munich, Engineering, Medical University of Vienna, Vienna, AUSTRIA, Matteucci1, U. De Giorgi1; Munich, GERMANY. 2 [99mTc]TcO4- Scintigraphy in the Evaluation of Thyroid Department of Pediatrics, Children’s Hospital of Michigan, 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, The Detroit Medical Center, Wayne State University School of Nodules IRST IRCCS, Meldola (FC), ITALY, 2Center of Tobacco Control 3 Medicine, Detroit, MI, UNITED STATES OF AMERICA, Service T. Jukic; University Hospital Center Sestre milosrdnice, Research, Odense M, DENMARK. OP-985 Hospitalier Frédéric Joliot, CEA, Inserm, CNRS, Univ. Paris Sud, Department of Oncology and Nuclear medicine, Zagreb, Université Paris Saclay, Orsay, FRANCE, 4Division of Nuclear CROATIA. Risk and Concomitant Factors of Renal Insufficiency Medicine, Department of Biomedical Imaging and Image- OP-981 throughout Radioligand Treatment with 177Lu-PSMA-617 guided Therapy, Medical University of Vienna, Vienna, AUSTRIA, OP-977 C. Nguyen Ngoc1, N. Mader1, K. Davis1, D. Groener1, C. Happel1, P. 5 Department of Psychiatry and Psychotherapy, Medical University Overall survival after177Lu-PSMA-617 molecular Mandel2, N. Tselis3, F. Gruenwald1, A. Sabet1; 6 of Vienna, Vienna, AUSTRIA, Department of Neurology, Medical The Importance of [99mTc]Tc-MIBI Scintigraphy in radiotherapy in patients with metastatic castrate- 1Department of Nuclear Medicine, University Hospital Frankfurt, University of Vienna, Vienna, AUSTRIA. 2 Thyroid Nodules Assessment resistant prostate cancer: Post-hoc analysis of a Frankfurt am Main, GERMANY, Department of Uology, University Hospital Frankfurt, Frankfurt am Main, GERMANY, 3Department of S. Schenke; Department of Radiology and Nuclear Medicine, prospective phase II trial OP-973 Radiooncology, University Hospital Frankfurt, Frankfurt am Main, University Hospital Magdeburg, Magdeburg, GERMANY. J. Calais1, W. R. Armstrong1, J. Gartmann1, P. Thin1, K. Nguyen1, V. GERMANY. Lok1, L. Gosa1, R. Slavik1, M. Dalhbom1, K. Herrmann2, M. Eiber3, W. Automatic Classification of Data-Driven Respiratory OP-978 4 1 P. Fendler , J. Czernin ; OP-986 Waveforms Using AI 1UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, 2University 1 2 2 2 The Role of 2-[18F]FDG PET/CT Imaging in the M. D. Walker , K. Su , S. D. Wollenweber , R. Johnsen , D. R. Hospital Essen, Essen, GERMANY, 3Technical University Munich,

182 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 183 Tracer kinetics in the dual time-point 177Lu-PSMA post- Medical Oncology Division, Istanbul, TURKEY, 3Cerrahpasa Faculty and Vascular Research (HI-MAG), Leipzig, GERMANY, 7University Comparison between regional cerebral blood flow therapy SPECT/CT scan predicts treatment outcome in of Medicine, Urology Department, Istanbul, TURKEY. of Leipzig, Department of Internal Medicine, Leipzig, GERMANY, estimates using different MR arterial spin labelling 8University of Leipzig, Department of Psychosomatic Medicine prostate cancer patients approaches and early-phase amyloid PET on a and Psychotherapy, Leipzig, GERMANY. F. Fiz1, H. Dittmann2, M. Straub3, C. la Fougère2; 1Humanitas 1709 simultaneous PET/MR Clinical and Research Center - IRCCS, Milan, ITALY, 2Nuclear 1,2 3 3 4 TROP Session: Novel Molecular Brain Imaging J. Anton Rodriguez , J. C. Matthews , L. Scott , M. Lohezic , K. Medicine Unit, Department of Radiology, University of Tübingen, OP-995 Herholz3, L. M. Parkes3; 3 Approaches Tübingen, GERMANY, University of Tübingen, Tübingen, 1The Christie NHS Foundation Trust, Manchester, UNITED GERMANY. Brain metabolism and related connectivity after EMDR in KINGDOM, 2Division of Informatics, Imaging and Data Friday, October 30, 2020, 15:30 - 17:00 PTSD of military veterans: a 18F-FDG PET study sensitized Sciences, MAHSC, University of Manchester, Manchester, Channel 9 UNITED KINGDOM, 3Division of Neuroscience and Experimental OP-987 by virtual reality exposure to war scenes Psychology, Faculty of Biology, Medicine and Health, University of 1 2 3 1 4 A. Verger , P. Rousseau , E. Malbos , M. Chawki , F. Nicolas , C. 4 177 Manchester, Manchester, UNITED KINGDOM, Applications and Efficacy and safety of Lu-PSMA radionuclide treatment 3 2 5 Lancon , S. Khalfa , E. Guedj ; Workflow, GE Healthcare, Manchester, UNITED KINGDOM. in patients with diffuse bone marrow involvement: a 1Department of Nuclear Medicine and Nancyclotep Imaging multicenter retrospective study OP-991 Platform, CHRU Nancy, Nancy, FRANCE, 2Laboratoire de 1 2 3 4 2 OP-1002 EANM’20 EANM’20 A. Gafita , W. P. Fendler , H. Wang , S. Sandhu , M. Weber , R. Neurosciences Sensorielles et Cognitives, Marseille, FRANCE, EANM’20 Esfandiari5, J. Calais1, I. Rauscher3, H. Rathke6, R. Tauber3, E. S. A Positron Emission Tomography (PET) Study to Examine 3Department of Psychiatry, La Conception University Hospital, 18 Delpassand5, W. Weber3, K. Herrmann2, J. Czernin1, M. Eiber3, M. S. the Brain Binding of[11C]-PXT012253 in Healthy Subjects Marseille, FRANCE, 4Department of Psychiatry, Hôpital Association of Retention of [ F]-APN-1607, a Novel Tau Hofman4, LuPSMA; P. Stenkrona1, R. Arakawa1, H. Holst2, S. Nag1, M. Mahdi Moein1, Z. d’Instruction des Armées Sainte-Anne, Toulon, FRANCE, PET Tracer, with Brain Glucose Metabolism and Cognition 5 1UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, 2University Jia1, C. Halldin1, A. Varrone1; Department of Nuclear Medicine, Assistance Publique Hôpitaux in Patients of Alzheimer’s Disease 1 2 of Duisburg-Essen, Essen, GERMANY, 3Technical University Munich, Karolinska Institutet, Stockholm, SWEDEN, H. Lundbeck A/S, de Marseille, Timone University Hospital, Marseille, FRANCE. J. Lu1, W. Bao1, M. Li1, L. Li1, Z. Zhang1, I. Alberts2, M. Brendel3, P. WORLD LEADING MEETING WORLD LEADING MEETING Munich, GERMANY, 4Peter MacCallum Cancer Center, Melbourne, Valby, DENMARK. Cumming2, C. Zuo1, Y. Guan1, Q. Zhao4, K. Shi2, A. Rominger2; AUSTRALIA, 5Excel Diagnostics, Houston, TX, UNITED STATES OF OP-997 1PET Center, Huashan Hospital, Fudan University, Shanghai, AMERICA, 6University of Heidelberg, Heidelberg, GERMANY. OP-993 CHINA, 2Department of Nuclear Medicine, University Hospital Predictive value of metabolic and perfusion beyond Bern, Bern, SWITZERLAND, 3Department of Nuclear Medicine, OP-988 Functional Dynamics of Dopamine Synthesis During the seizure onset zone as predictors of postoperative University Hospital of Munich, Ludwig-Maximilian-University Reward Processing outcome in patients with refractory focal epilepsy Munich, Munich, GERMANY, 4Department of Neurology, Huashan Intermittent radioligand therapy with Lu-177-PSMA-617 1 1 2 1 1 A. Hahn , M. B. Reed , V. Pichler , P. Michenthaler , L. Rischka , G. M. Haemels1, D. Van Weehaeghe1, E. Cleeren2, P. Dupont3, J. Van Hospital, Fudan University, Shanghai, CHINA. in metastatic castration-resistant prostate cancer M. Godbersen1, W. Wadsak2,3, M. Hacker2, R. Lanzenberger1; Loon4, T. Theys4, K. Van Laere1, W. Van Paesschen2, K. Goffin1; patients with favorable characteristics and early response 1Department of Psychiatry and Psychotherapy, Medical University 1Department of Nuclear Medicine, University Hospitals Leuven, 2 N. Mader1, C. Nguyen Ngoc1, J. Baumgarten1, D. Gröner1, K. Davis1, of Vienna, Vienna, AUSTRIA, Department of Biomedical Imaging Leuven, BELGIUM, 2Department of Neurology, University Hospitals 1711 J. Wichert1, N. Tselis2, P. Mandel3, F. Grünwald1, A. Sabet1; and Image-guided Therapy, Division of Nuclear Medicine, Medical Leuven, Leuven, BELGIUM, 3Department of Neurosciences, 3 e-Poster Presentation Session 12: Onco 1Department of Nuclear Medicine, University Hospital Frankfurt, University of Vienna, Vienna, AUSTRIA, Center for Biomarker Laboratory of cognitive neurology, KU Leuven, Leuven, BELGIUM, Diagnostics - Mixed Bag Frankfurt am Main, GERMANY, 2Department of Radiooncology, Research in Medicine (CBmed), Graz, AUSTRIA. 4Department of Neurosurgery, University Hospitals Leuven, University Hospital Frankfurt, Frankfurt am Main, GERMANY, Leuven, BELGIUM. 3 OP-994 Friday, October 30, 2020, 15:30 - 16:50 Department of Urology, University Hospital Frankfurt, Frankfurt Channel 11 am Main, GERMANY. OP-998 Assessment ofα4(α6)β2* nicotinic acetylcholine receptor OP-989 (nAChR) availability before and after rewarding food- Epileptogenic zone localization on SISCOS in drug cue stimulation in human obesity and normal-weight refractory epilepsy Efficacy of Lu-177-PSMA-617 Therapy in Metastatic EPS-184 controls D. Khan, S. T. Arun Raj, S. Sagar, M. Tripathi, M. Tripathi, R. Castration-resistant Prostate Cancer Patients, A Single- S. Hesse1,2, M. Rullmann1,2, J. Luthardt1, E. Schweickert-de Doddamani, A. Garg, P. Chandra, C. Sarkar, N. Damle, C. S. Bal; 18F-FDG PET/CT in the Preoperative Staging of Center Experience Palma2, T. Günnewig2, G. A. Becker1, F. Zientek1,2, T. Jochimsen1, A. All India Institute of Medical Sciences, New Delhi, INDIA. T. Telli, M. Tuncel, M. Caglar; Landsmann2, S. Martin2, P. M. Meyer1, M. Patt1, J. Neumann2,3,4, P. Endometrial Cancer Hacettepe University Faculty of Medicine, Ankara, TURKEY. Brust5, M. Blüher6,7, A. Hilbert2,8, O. Sabri1; A. Gutta1,2, W. J. Pilloy1, T. Mosehle1,2, P. B. Nemutaduni1,2; 1University of Leipzig, Department of Nuclear Medicine, Leipzig, 1SMU Health Sciences University, Garankuwa, Pretoria, SOUTH GERMANY, 2University of Leipzig, Integrated Research and OP-1000 AFRICA, 2Dr George Mukhari Academic Hospital, Garankuwa, OP-990 Treatment Center (IFB) AdiposityDiseases, Leipzig, GERMANY, Pretoria, SOUTH AFRICA. 3Ernst-Abbe-Hochschule, University of Applied Sciences, Relation Between Amyloid Deposition and Microbleeds The efficacy of Lu177-PSMA treatment at chemotherapy- Department of Medical Engineering and Biotechnology, Jena, in CAA EPS-185 naive metastatic prostate cancer GERMANY, 4Max Planck Institute for Human Cognitive and Y. Chang, J. Liu, B. Xu; F. Beytur1, S. Sager1, S. Bilgic1, A. Nazari1, L. Uslu-Besli1, S. Asa1, H. B. Brain Sciences, Department of Neurology, Leipzig, GERMANY, Chinese PLA General Hospital, Beijing, CHINA. The Relationship Between HER-2 Expression Levels and Sayman1, D. Tural2, C. Demirdağ3, K. Sonmezoglu1; 5Helmholtz-Zentrum Dresden-Rossendorf, Department of 18F-FDG PET/CT Parameters in Gastric Cancer Patients 1Cerrahpasa Faculty of Medicine, Nuclear Medicine Department, Neuroradiopharmaceuticals, Leipzig, GERMANY, 6Helmholtz OP-1001 S. Ertürk, Z. Hasbek, H. Özer, Ö. Ulaş Babacan; Istanbul, TURKEY, 2Bakirköy Sadi Konuk Teaching Hospital, Zentrum München, Helmholtz Institute for Metabolic, Obesity Sivas Cumhuriyet University, Sivas, TURKEY.

184 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 185 Izmir, TURKEY, 2Department of Radiology, Ege University Medical 1Radiation physics, Skåne university hospital, Lund, SWEDEN, Plenary 4: Highlights Lecture, Closing EPS-186 Faculty, Izmir, TURKEY, 3Department of Statistics, Ege University 2Medical radiation physics, Lund university, Lund, SWEDEN, Medical Faculty, Izmir, TURKEY. 3Clinical physiology and nuclear medicine, Skåne university The comparative performances of 18F-FDG PET/MRI and Friday, October 30, 2020, 17:05 - 18:25 hospital, Lund, SWEDEN. Channel 1 18F-FDG PET/CT for the detection of pancreatic neoplasms H. Xing1, B. Hou2, W. Zhu1, H. Ding3, X. Li4, Y. Hu5, H. Xue2, F. Feng2, K. EPS-190 Lv6, X. Wu7, F. Li1, Z. Jin2, D. Li5, L. Huo1, Y. Zhao5; EPS-194 1Department of Nuclear Medicine, Peking Union Medical College FDG-PET/CT versus Conventional Imaging to Distinguish Hospital,Chinese Academy of Medical Science & Peking Union Between Benign and Malignant Pathology of the Integration of PET/MRI Hybrid Imaging into Radiotherapy OP-1003 Medical College, Beijing Key Laboratory of Molecular Targeted Gallbladder Planning of Cervical Cancer Patients: First Results 1 1 1 2 Honorary Member Award Diagnosis and Therapy in Nuclear Medicine, Beijing, CHINA, A. Sabaté-Llobera1, G. Reynés-Llompart2, J. Mestres-Martí1, J. S. Ahangari , N. Liv Hansen , A. Beck Olin , T. Jakobi Nøttrup , 2 Department of Radiology, Peking Union Medical College J. Robles-Barba1, L. M. Gràcia-Sánchez1, P. C. Notta1, I. Sánchez- A. Kiil Berthelsen1, J. Olof Löfgren1, A. Loft Jakobsen1, A. Kjær1,3, F. Hospital, Chinese Academy of Medical Science & Peking Union Rodríguez1, M. Cortés-Romera1; Littrup Andersen1, B. M. Fischer1,4, A. Espe Hansen1; 1Department OP-1005 3 Medical College, Beijing, CHINA, Center for Biomedical Imaging 1IDI - Hospital Universitari de Bellvitge - IDIBELL, L’Hospitalet de of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Research, Department of Biomedical Engineering, School of Llobregat, SPAIN, 2ICO - Hospital Universitari de Bellvitge - IDIBELL, University of Copenhagen, Copenhagen, DENMARK, 2Department Marie Curie Award Medicine, Tsinghua University, Beijing, CHINA, 4Division of of Oncology, Section of Radiotherapy, Rigshospitalet, University

EANM’20 EANM’20 L’Hospitalet de Llobregat, SPAIN. EANM’20 Nuclear Medicine, Department of Biomedical Imaging and of Copenhagen, Copenhagen, DENMARK, 3Cluster for Molecular OP-1006 Image-guided Therapy, Medical University of Vienna, Vienna, EPS-191 Imaging, University of Copenhagen, Copenhagen, DENMARK, 5 AUSTRIA, Department of General Surgery, Peking Union Medical 4The PET Centre, School of Biomedical Engineering and Imaging Plenary 4: Highlights Lecture College Hospital, Chinese Academy of Medical Science & Peking Potential Value of Quantified Metabolic Indices Obtained Sciences, Kings College London, St Thomas’ Hospital, London, A. Chiti; Humanitas University, Nuclear Medicine, Milan, ITALY. Union Medical College, Beijing, CHINA, 6Department of Doppler in68Ga (DOTATOC) PET/CT to Distinguish Between G1 UNITED KINGDOM.

WORLD LEADING MEETING Ultrasonic, Peking Union Medical College Hospital, Chinese WORLD LEADING MEETING and G2 Low-Grade Neuroendocrine Tumors. A Pilot OP-1007 Academy of Medical Science & Peking Union Medical College, EPS-195 Beijing, CHINA, 7Department of Gastroenterology, Peking Union Experience in a Single Center of Spain Plenary 4: Highlights Lecture Medical College Hospital, Chinese Academy of Medical Science & J. Rodríguez Gomez1, M. Ollarves Carrero1, M. Cabrera Martín1, F. Utility of the Sentinel Lymph Node Biopsy in Breast R. Hustinx; Centre hospitalier Universitaire de Liège, Service de Peking Union Medical College, Beijing, CHINA. Ferrando-Castagnetto2, C. Wakfie Corieh1, M. Meneses Navas1, P. Médecine Nucléaire, Liege, BELGIUM. Romero Fernández1, J. Carreras Delgado1; Cancer after Neoadjuvant Chemotherapy with Negative 1Servicio de Medicina Nuclear, Hospital Clínico San Carlos, Axillary Lymph Nodes or Node Involvement EPS-187 Madrid, SPAIN, 2Departamento de Cardiología-CCVU, Hospital N. Álvarez Mena, F. Sebastián Palacid, P. Turbay Eljach, B. Pérez de Clínicas, Facultad de Medicina, Universidad de la República., López, M. Alonso Rodríguez, C. Gamazo Laherrán, A. Sainz Does diffuse gastric FDG uptake infer Helicobactor pylori Montevideo, URUGUAY. Esteban, M. Ruiz Gómez, M. González Soto, R. Ruano Pérez; infection? Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN. Z. Al Bimani1,2, S. Samman3, W. Zeng1; 1University of Ottawa, Ottawa, ON, CANADA, 2Ministry Of Health, EPS-192 Muscat, OMAN, 3University of Miami, Miami, FL, UNITED STATES EPS-196 OF AMERICA. Impact of PET data driven respiratory motion correction of 68Ga-DOTATATE PET/CT for differentiating Impact Of Sentinel Lymph Node Biopsy In Breast Cancer EPS-188 neuroendocrine tumors (NET) and intrapancreatic Patients Treated With Neoadjuvant Chemotherapy accessory spleens (IPAS) A. Roteta, D. Nogueira Souto, E. Galindo Lalana, L. Tardin Impacts of malnutrition on 18F-FDG PET/CT V. Liberini1,2,3, F. Kotasidis4, V. Treyer2, M. Messerli2, E. Orita2, I. Engel- Cardoso, A. Andrés Gracia, P. Razola Alba, M. Delgado Castro, T. measurements on healthy organs in patients with Bicik2, A. Siebenhüner5, M. Huellner2; Escalera Temprado, E. Prats Rivera, M. Abós Olivares; esophageal cancer 1Department of Nuclear Medicine, A.O.U. Città della Salute e della Clinic Hospital “Lozano Blesa”, Zaragoza, SPAIN. E. Deshayes1, S. Thezenas2, I. Berkane1, N. Flori3, P. Senesse3, T. Scienza di Torino, University of Turin, Turin, ITALY, 2Department of Galvez3; Nuclear Medicine, University Hospital Zürich, University of Zürich, EPS-197 1Nuclear Medicine Department, Institut du Cancer de Montpellier, Zürich, SWITZERLAND, 3ENETS CoE Training Fellowship Grant Montpellier Cedex 5, FRANCE, 2Biometrics Unit, Institut du Cancer 2019, Berlin, GERMANY, 4GE Healthcare, Waukesha, WI, UNITED Tumor Recurrence at 5 Years in Patients with Breast de Montpellier, Montpellier Cedex 5, FRANCE, 3Clinical Nutrition STATES OF AMERICA, 5Department of Hematology and Medical Cancer, Previous Surgery Treatment and Sentinel Lymph and Gastroenterology Department, Institut du Cancer de Oncology, University Hospital Zürich, University of Zürich, Zürich, Node Biopsy Montpellier, Montpellier Cedex 5, FRANCE. SWITZERLAND. N. Álvarez Mena, F. Sebastián Palacid, P. Turbay Eljach, B. Pérez López, C. Gamazo Laherrán, M. Alonso Rodríguez, A. Sainz EPS-189 EPS-193 Esteban, M. Ruiz Gómez, M. González Soto, R. Ruano Pérez; Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN. Clinical Value of 18F FDG Bio-distribution in Metabolic Image quality for two administration schedules for PET/ Characterization of Pancreatic Masses on PET/CT CT-imaging of 68Ga-DOTATOC S. Tatlidil1, E. Guler2, B. Karasah1, G. Hakverdi3, Z. Ozcan1; C. Hindorf1, A. Stenvall1,2, L. Jönsson1,2, B. Olsson3, A. Svensson3, U. 1801 1Department of Nuclear Medicine, Ege University Medical Faculty, Bitzén3, F. Hedéer3; Honorary Member Award, Marie Curie Award,

186 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 187 Clinico San Carlos Hospital, Madrid, SPAIN. Heraklion-Crete, GREECE, 2School of Medicine, University of Crete, [11C]Methionine Uptake In Grade II-III Diffuse Gliomas OP-1012 Institute of Computer Science, Foundation for Research and Does Not Allow To Classify Tumors According To IDH1 Technology-Hellas, Heraklion-Crete, GREECE, 3School of Medicine, Mutation Status Closing EP-004 University of Crete, Heraklion-Crete, GREECE. S. Fanti; EANM Congress Chair, Bologna, ITALY. T. Skvortsova, Z. Savintseva, D. Zakhs; Correlation between 18F-sodium fluoride uptake by PET N. P. Bechtereva Institute of the Human Brain of Russian Academy and dual-energy X-ray absorptiometry in the second EP-008 of Sciences, Saint-Petersburg, RUSSIAN FEDERATION. EP-01 lumbar spine vertebra Bone scan indications in patients under 30 years of age EP-013 All about the Prostate R. Piri1,2, P. Hermann3, H. Petersen1, O. Gerke1,2, A. B. Jespersen4,5, M. Ø. Andersen4,5, P. F. Høilund-Carlsen1,2; N. Manevska, N. Bozinovska, T. Makazlieva, S. Stojanoski, V. 1Research Unit of Clinical Physiology and Nuclear Medicine, Majstorov, D. Miladinova; Initial Experience With 18F-DOPA PET/CT For Medical Faculty, Skopje, NORTH MACEDONIA. e-Poster Area Department of Clinical Research, University of Southern Differentiating Radionecrosis From Tumour Progression Denmark, Odense C, DENMARK, 2Department of Nuclear In Brain Metastasis And Malignant Primary Tumors Of The EP-009 Medicine, Odense University Hospital, Odense, DENMARK, Central Nervous System 3Department of Endocrinology, Odense University Hospital, V. Lopez Prior, R. Diaz Expósito, F. Manchón Adsuar; Odense C, DENMARK, 4Center for Spine Surgery and Research, The role of bone scan in the diagnosis of bone EANM’20 EANM’20 Valencian Oncologic Institution (IVO), Valencia, SPAIN. EANM’20 EP-001 Lillebælt Hospital, Middelfart, DENMARK, 5Institute of Regional metastases in Ewing’s sarcoma Health Research, University of Southern Denmark, Odense, D. Travaglio Morales, J. M. Cordero García, L. García, D. Decision impact study on the use of PET-PSMA for the DENMARK. Monachello Araujo, E. López Llobet, S. Rodado Marina, M. EP-014 initial staging of men with high-risk localized prostate Coronado Poggio, C. Lancha Hernandez, C. Escabias del Pozo, E. 18 18 cancer (PCa) EP-005 Ortiz, R. Sebastián, L. Dominguez Gadea; F-FET or F-FLT PET/CT in diagnosis of low-grade WORLD LEADING MEETING WORLD LEADING MEETING A. Viaouet1, C. Verrier2, S. Mengue2, S. Leroux2, G. Desrez2, T. Hospital Universitario La Paz, Madrid, SPAIN. gliomas? A pilot study Haaser1, R. Herve2, O. Couturier2, P. Gustin2; Comparison of thoracic, abdominal and pelvic SPECT/CT J. Vasina1, M. Hodolič2, R. Jančálek3, Z. Mackerle3, M. Hendrych3, R. 1University Hospital of Bordeaux, Bordeaux, FRANCE, 2General with wholebody bone scan in bone metastases. Can we EP-010 Hejnová1, T. Kazda1, Z. Řehák1; Hospital of French Polynesia, Papeete, FRENCH POLYNESIA. avoid planar wholebody bone scan? 1Masaryk Memorial Cancer Institute, Brno, CZECH REPUBLIC, Usefulness of 18 FDG PET/CT in Ewing sarcoma In Morocco 2 3 A. Sainz Esteban, P. Turbay Eljach, N. Álvarez Mena, F. Sebastian University Hospital, Olomouc, CZECH REPUBLIC, St. Anne´s Palacid, M. González Soto, M. Ruíz Gómez, C. Gamazo Laherrán, A. Sallak, E. Iris, G. Amal; University Hospital, Brno, CZECH REPUBLIC. EP-02 B. Pérez López, R. Ruano Pérez; University Hassan II of medicine, Casablanca, MOROCCO. Bone and Soft Tissues Hospital Clinico Universitario, Valladolid, SPAIN. EP-015 EP-03 Molecular imaging 99mTc-CXCR4-L SPECT in brain tumors EP-006 P. Vallejo Armenta1, G. Ferro Flores2, O. Pérez-García1, J. Soto e-Poster Area Brain tumours Andonaegui3, B. Sandoval-Bonilla3, B. Nettel-Rueda3, C. Bautista- Necessity of Whole Body Bone Scintigraphy In Patients Wong3; 1 With Lung Or Breast Cancer Who Underwent Whole Body Instituto Nacional de Cancerología, Mexico City, MEXICO, e-Poster Area 2Instituto Nacional de Investigaciones Nucleares (ININ), Mexico 18F FDG-PET/CT For Initial Staging City, MEXICO, 3UMAE Hospital de Especialidades. Centro Médico EP-002 F. Görtan1, Z. Kaya Döner2, Ö. Vural Topuz3, E. Arslan4, M. Halaç5; Nacional Siglo XXI. IMSS., Mexico City, MEXICO. 1Turkish Ministry of Heath, Ankara City Hospital, Department of 18 F-NaF Uptake by Fibrous Dysplasia Lesions in the Skull Nuclear Medicine, Ankara, TURKEY, 2Health Sciences University is Signficantly Higher in Patients with Optic Neuropathy Bursa Higher Specialization Training And Research Hospital, EP-011 EP-016 G. Papadakis1,2,3, G. Giannakakis2, A. H. Karantanas3, K. Marias2, Department of Nuclear Medicine, Bursa, TURKEY, 3Istanbul M. T. Collins1, A. M. Boyce1; Okmeydani Training and Research Hospital, Department of Differential diagnosis between progression and 99mTc-EDDA/HYNIC-iPSMA SPECT Imaging in 1National Institute of Dental and Craniofacial Research (NIDCR), Nuclear Medicine, Istanbul, TURKEY, 4Istanbul Training and radionecrosis in brain metastases after stereotactic differentiating radiation necrosis from tumor recurrence 2 Bethesda, MD, UNITED STATES OF AMERICA, Computational Research Hospital,Department of Nuclear Medicine, Istanbul, radiosurgery using hybrid FDG-PET and MRI coregistered in gliomas 5 Biomedicine Laboratory (CBML), Foundation for Research and TURKEY, Neo Life Medical Center, Istanbul, TURKEY. P. Vallejo Armenta1, G. Flores Ferro2, J. Soto Andonaegui3, O. 3 images Technology Hellas (FORTH), Heraklion, GREECE, Department of 4 3 3 H. Otman1, J. Deverdin2, N. Menjot de Chamfleur2, F. Molino2, M. García Pérez , B. Sandoval Bonilla , B. Nettel Rueda , K. Contreras Medical Imaging, Medical School, University of Crete, Heraklion, EP-007 3 3 Bilal Chawki3, F. Cachin1, C. Bouvet1, B. Fayçal2, L. Emmanuelle2, D. Contreras , C. Bautista Wong ; GREECE. 1 Mariano Goulard2; Instituto Nacional de Cancerología., Mexico City, MEXICO, Additional clinical impact of single photon emission 2 1Centre Jean Perrin, Clermont Ferrand, FRANCE, 2University Instituto Nacional de Investigaciones Nucleares (ININ)., Mexico EP-003 computed tomography/computed tomography bone Hospital of Montpellier, Montpellier, FRANCE, 3University Hospital City, MEXICO, 3UMAE Hospital de Especialidades. Centro Médico scintigraphy (SPECT/CT) 16 slices to planar whole body of Nancy, Nancy, FRANCE. Nacional Siglo XXI., Mexico City, MEXICO, 4Instituto Nacional de Prognostic value of 18F-FDG PET/CT-based metabolic BS in evaluation of equivocal lesions Cancerología, Mexico City, MEXICO. parameters in patients with bone sarcoma 1 2 1 1 N. Kapsoritakis , P. Simos , O. Bourogianni , M. Stathaki , A. EP-012 L. García Belaústegui, C. Wakfie Corieh, R. Valhondo Rama, A. Tsaroucha1, E. Papadaki1, S. Koukouraki3; Blanes García, M. Cabrera Martin, J. Carreras Delgado; 1Nuclear Medicine Department, University Hospital,

188 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 189 Brain amyloid load assessed by 11C-PIB PET/CT for Athens, GREECE, 5Neurology Dpt, Evrokliniki, Athens, GREECE, 62nd EP-04 (including Sarcoidosis and Amyloidosis) predicting long-term severity of cognitive impairment University Neurological Dpt, Attikon Hospital, Athens, GREECE, 7Memory Disorders Clinic, Medical Center, Athens, GREECE. Cognitive Impairment in patients with amnestic mild cognitive impairment. A e-Poster Area comparison with 18F-FDG PET/CT scan J. Jiménez-Bonilla1, R. Quirce1, M. De Arcocha-Torres1, I. Martínez- EP-05 e-Poster Area 1 2 2 2 2 Rodríguez , S. López-García , C. Lage , M. García , A. Pozueta , E. Endocrine/Parathyroid Rodríguez-Rodríguez2, P. Sánchez-Juan2, A. Sánchez-Salmón1, N. Martínez-Amador1, S. Ruiz-Llama1, G. Molina1, O. Cuenca-Vera1, J. EP-027 Andrés1, A. Gutiérrez-González1, I. Banzo1; e-Poster Area EP-017 1Nuclear Medicine Service. Marqués de Valdecilla University Description of the typical patient with suspected cardiac Hospital. Molecular Imaging Research Group. University of 2 amyloidosis due to transthyretin deposits and a positive 18 Cantabria, Santander, SPAIN, Neurology Service. Marqués de The metabolic amyloid signature of F-FDG PET/CT in 99mTc Valdecilla University Hospital, Santander, SPAIN. result on the DPD scintigraphy in our health area Alzheimer’s disease F. Sebastián Palacid, N. Álvarez Mena, P. Turbay Eljach, B. Pérez S. Pacella1, V. Isella2,3, E. Preza1, V. Polonia4, A. Franchini1, C. EP-025 López, C. Gamazo Laherrán, M. Alonso Rodriguez, A. Sáinz 5 2,5 2,5 2,3 4 EP-022 EANM’20 EANM’20 Crivellaro , C. Landoni , L. Guerra , C. Ferrarese , A. Formenti , Esteban, M. Ruiz Gómez, M. González Soto, R. Ruano Pérez; EANM’20 18 M. Musarra5; Optimization of F-Fluorocholine PET/CT protocol in Hospital Clínico Universitario Valladolid, Valladolid, SPAIN. 1Postgraduate School of Nuclear Medicine, University of Concordance between amyloid PET imaging and CSF parathyroid imaging Milano Bicocca, Milan, ITALY, 2School of Medicine and Surgery, biomarkers in clinical setting I. Bossert1, M. Hodolic2,3, S. Chytiris4, D. D’Ambrosio5, A. Marchetto1, University of Milano Bicocca, Milan, ITALY, 3Neurology Unit, G. Marotta, L. Sacchi, G. G. Fumagalli, A. M. Pietroboni, A. Arighi, C. Vellani1, A. J. Mallia6, M. Boniardi7, L. Chiovato4, G. Trifirò1; EP-028 ASST Monza San Gerardo Hospital, Monza, ITALY, 4Postgraduate L. Ghezzi, A. Colombi, T. Carandini, M. Scarioni, F. Buffoni, M. 1Nuclear Medicine Unit, Istituti Clinici Scientifici Maugeri SpA SB WORLD LEADING MEETING School of Neurology, University of Milano Bicocca, Milan, ITALY, Rognoni, D. Galimberti, E. Scarpini; IRCCS, Pavia, ITALY, 2Nuclear Medicine Department, Faculty of 99mTc PYP planar and SPECT bone scan in the diagnosis of WORLD LEADING MEETING 5 Department of Nuclear Medicine, ASST Monza San Gerardo Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Medicine and Dentistry, Palacký University, Olomouc, CZECH transthyretin cardiac amyloidosis Hospital, Monza, ITALY. Milan, ITALY. REPUBLIC, 3Nuclear Medicine Research Department, Iason, Graz, M. Garcheva-Tsacheva1, M. Gospodinova2, G. Kirova3, A. AUSTRIA, 4Endocrinology Unit, Istituti Clinici Scientifici Maugeri Todorova4; EP-018 EP-023 SpA SB IRCCS, Pavia, ITALY, 5Medical Physics Unit, Istituti Clinici 1Acibadem City clinic, Sofia, BULGARIA,2 Clinic of Cardiology, Scientifici Maugeri SpA SB IRCCS, Pavia, ITALY,6 Division of Nuclear Medical Institute, Ministry of Interior, Sofia, BULGARIA,3 Clinic of Alternatives to static F-18-FDG brain PET using early- Differences of Perfusion Correlates between Apathy and Medicine, Department of Medical Imaging, Mater Dei Hospital, Medical Imaging, Acibadem City clinic Tokuda, Sofia, BULGARIA, 7 phase F-18-FPN brain PET Depression in Patients with Alzheimer’s disease. A Brain Msida, MALTA, Department of Endocrine Surgery, Niguarda 4Department of Medical Chemistry, Biochemistry , Medical Hospital, Milan, ITALY. H. Yoon1, Y. Jeong1,2, J. Jeong1, H. Shin2, D. Kang1,2; SPECT Study with Brodmann Areas Mapping University Sofia, Genetical Medico- Diagnostics Laboratory, 1 Genica, Sofia, BULGARIA. Dong-A University Medical Center, Busan, KOREA, REPUBLIC OF, V. Valotassiou1, N. Sifakis2, C. Tzavara1, E. Lykou3, N. Tsinia4, V. 2Dong-A University, Busan, KOREA, REPUBLIC OF. Kamtsadeli3, D. Sali5, G. Angelidis1, D. Psimadas1, I. Tsougos1, EP-06 A. Ziaka1, E. Theodorou1, C. Tzioumerka1, C. Ziangas1, S. Epilepsy EP-029 EP-019 Papageorgiou6, P. Georgoulias1, J. Papatriantafyllou3,7; 1Dpt of Nuclear Medicine, University Hospital of Larissa, Larissa, Evaluation of technetium-99m DPD uptake in cardiac Severe Obstructive Sleep Apnea and Increased Cortical 2 GREECE, Dpt of Nuclear Medicine, “Alexandra” University e-Poster Area amyloidosis using myocardial perfusion imaging Amyloid-beta Deposition Hospital, Athens, GREECE, 3IASIS Third Age Center, Athens, GREECE, quantification software 4 T. Laitinen1, S. Ylä-Herttuala2, M. Hakulinen1, P. Poutiainen1, T. M. 1st University Psychiatric Department, Aeginition Hospital, M. O’Connell1,2, F. Delaney1, M. Dore3, M. Coyne2, G. Giblin1, D. O 5 6 Laitinen1, A. Koivisto3, A. Remes4, M. Hallikainen3, J. Lehtola3, T. Athens, GREECE, Neurology Dpt, Evrokliniki, Athens, GREECE, 2nd Sullivan1; Saari2, M. Könönen1, R. Vanninen1, H. Mussalo1, E. Mervaala1; University Neurological Dpt, Attikon Hospital, Athens, GREECE, 1Mater Misericordiae University Hospital, Dublin, IRELAND, 7 1Diagnostic Imaging Center, Kuopio University Hospital, Memory Disorders Clinic, Medical Center, Athens, GREECE. EP-026 2University College Dublin, Dublin, IRELAND, 3Mater Private Kuopio, FINLAND, 2Institute of Clinical Medicine, University of Hospital, Dublin, IRELAND. Eastern Finland, Kuopio, FINLAND, 3KUH Neurocenter, Kuopio EP-024 Brain FDG PET/CT in Patients with Epilepsy : Single Center University Hospital, Kuopio, FINLAND, 4Research Unit of Clinical Experience Neuroscience, University of Oulu, Oulu, FINLAND. Brain Perfusion SPECT Imaging with Brodmann Areas A. Arçay, F. Aydın, E. Apaydın Doğan, M. Akyüz, U. Şenol, K. EP-030 Mapping in the Evaluation of Eating Disorders in Karaali; EP-020 Frontotemporal Dementia Akdeniz University, Antalya, TURKEY. Left ventricular ejection fraction improvement predicted V. Valotassiou1, N. Sifakis2, C. Tzavara1, V. Kamtsadeli3, N. by postoperative gated blood pool SPECT performed on 18 F-FDG PET/CT study on the changes of brain FDG Tsinia4, E. Lykou3, D. Sali5, G. Angelidis1, I. Tsougos1, D. Psimadas1, CZT camera metabolism in patients with DLBCL after chemotherapy E. Theodorou1, A. Ziaka1, C. Tzioumerka1, C. Ziangas1, S. EP-07 V. Shipulin, K. Zavadovsky, S. Andreev, A. Pryakhin, V. M. Shipulin; H. Yang1, Q. Zhao2, J. Cao1, J. Tian1, J. Ren1; Papageorgiou6, P. Georgoulias1, J. Papatriantafyllou3,7; Imaging Clinical Studies -> Cardiovascular Cardiology Research Institute, Tomsk National Research 1Ningxia Medical University, Yinchuan, Ningxia, CHINA, 2General 1Dpt of Nuclear Medicine, University Hospital of Larissa, Larissa, Imaging Clinical Study -> Heart Failure Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN Hospital of Ningxia Medical University, Yinchuan, Ningxia, CHINA. GREECE, 2Dpt of Nuclear Medicine, “Alexandra” University FEDERATION. Hospital, Athens, GREECE, 3IASIS Third Age Center, Athens, GREECE, EP-021 41st University Psychiatric Department, Aeginition Hospital,

190 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 191 Patients With Clinical Suspicion Of Parkinson´s Disease EP-031 L. García Zoghby, S. Rizkallal Monzón, C. Lancha Hernández, D. Monachello Araujo, D. Travaglio Morales, E. López Llobet, Diagnostic accuracy of bone scintigraphy in the S. Rodado Marina, C. Escabias del Pozo, J. Cordero García, M. assessment of cardiac amyloidosis: comparison among Coronado Poggio, L. Domínguez Gadea; different methods of evaluation Hospital Universitario La Paz, Madrid, SPAIN. C. Cottignoli, C. Romagnolo, F. Fringuelli, G. Biscontini, A. Palucci, L. Burroni; Nuclear Medicine, Ancona, ITALY. EP-09 Imaging Clinical Studies -> Cardiovascular Imaging Clinical Study -> Other Cardiovascular EP-032 Imaging (including Plaque)

Volumetric Evaluation of 99mTc-pyrophosphate SPECT/CT

in the Diagnosis of Transthyretin Cardiac Amyloidosis e-Poster Area

EANM’20 EANM’20 S. Watanabe, K. Nakajima, H. Yoneyama, H. Wakabayashi, A. Inaki, T. Konishi, J. Komatsu, S. Yoshida, S. Kinuya; Kanazawa University Hospital, Kanazawa, JAPAN. EP-033 EP-036

WORLD LEADING MEETING Conduction disturbances in cardiac amyloidosis patients Significance of epicardial and visceral adipose tissue and 99mTc-HDP bone scintigraphy measurement by 18F-FDG-PET / CT in type 2 diabetes A. Scarale1, C. Dolci1, A. Capozza1, A. Franchini1,2, I. Gotuzzo1,2, E. mellitus Gay1, G. Cabrini1, M. Milella1, C. Rossetti1; D. Dezso1, K. Zámbó1, Z. Ritter1, Z. Bán1, Z. Szabó1, E. Várady1, 1ASST Grande Ospedale Metropolitano Niguarda, Milano, ITALY, B. Bódis2, O. Nemes2, K. Rucz2, S. Szujó2, E. Mezősi2, L. Bajnok2, E. 2Nuclear Medicine School, University of Milan-Bicocca, Milan, Schmidt1; ITALY. 1University of Pécs, Medical School, Department of Diagnostic, Pécs, HUNGARY, 2University of Pécs, Medical School, 1st EP-034 Department of Medicine, Pécs, HUNGARY.

99mTc-DPD SPECT/CT Quantification In Cardiac EP-037 Transthyretin Amyloidosis. A Pilot Descriptive Study C. Wakfie Corieh1, J. Rodríguez Gómez1, F. Ferrando-Castagnetto2, The use of gated blood-pool SPECT for evaluation M. Pérez Castejón1, M. Pedrera Canal1, I. Vilacosta1, P. Romero of cardiac dyssynchrony in patients with ventricular Fernández1, K. Bayardo2, R. Ferrando2, J. Carreras Delgado1; tachycardia 1 2 Hospital Clínico San Carlos, Madrid, SPAIN, Hospital de Clínicas V. Saushkin, D. Lebedev, S. Popov, Y. Lishmanov; Dr. Manuel Quintela, Facultad de Medicina, Universidad de la Tomsk National Research Medical Center of the Russian Academy República, Montevideo, URUGUAY. of Sciences, Cardiology Research Institute, Tomsk, RUSSIAN FEDERATION. EP-08 Imaging Clinical Studies -> Cardiovascular EP-038 Imaging Clinical Study -> Metabolism and Innervation Assessment of vulnerable atherosclerotic plaques in coronary arteries using somatostatin receptor scintigraphy (SRS) and head-to-head comparison with e-Poster Area myocardial perfusion scintigraphy (MPI): A paradigm under construction M. Assadi, A. Amini, E. Jafari, M. Pourbehi, D. Iranpour, R. Nemati; Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, EP-035 ISLAMIC REPUBLIC OF.

123I-Metaiodobenzylguanidine Cardiac Scintigraphy In EP-039

192 OCTOBER 22–30, 2020 | VIRTUAL Prevalence of transthyretin cardiac amyloidosis 1Hospital Universitari Vall d’Hebron, Barcelona, SPAIN, 2Complejo FSBSI «Tomsk National Research Medical Center, Russian Rubidium Myocardial Perfusion PET/CT: Initial Experience (ATTR-CA) in a population of patients with hip and knee Hospitalario Universitario de Vigo, Vigo, SPAIN. Academy of Sciences», Cardiology Research Ins, Tomsk, RUSSIAN In First 200 Patients FEDERATION. arthroplasty: could they be early signs? L. Price, C. Copland, B. Ade-Ojo, M. Burnistion, M. Costa, S. Ferreira, 1 1 1 1 2 R. Gregory, T. Hussain, B. Ribeiro, A. Simeonova, G. Testanera, L. A. Paccagnella , R. Bonfiglioli , F. Mattana , R. Mei , G. Saturi , P. EP-043 EP-048 Massa2, G. Caponetti2, M. Sguazzotti2, A. Ponziani2, C. Gagliardi2, S. Menezes; Longhi2, N. Galiè2, S. Fanti1; Barts Health NHS Trust, London, UNITED KINGDOM. Preliminary Comparison of Myocardial Perfusion Study Safety of Regadenoson MPI in STEMI Patients Treated 1Department of Nuclear Medicine, Policlinico S.Orsola, University 2 Results on a Standard Dual-head Scintillation Camera with Ticagrelor of Bologna, Bologna, ITALY, Department of Cardiology, Policlinico EP-055 S.Orsola, University of Bologna, Bologna, ITALY. and a CZT Semiconductor Camera A. Jimenez-Heffernan, C. Salgado-Garcia, A. Amr-Rey, T. Aroui- M. Blaszczyk1, P. Cichocki2, J. Kuśmierek2, A. Płachcińska1; Luquin, J. Lopez-Martin, E. Sanchez de Mora; 1Department of Quality Control and Radiological Protection, Hospital Juan Ramon Jimenez, Huelva, SPAIN. Myocardial Perfusion Imaging SPECT May Reveal Silent EP-10 Medical University of Lodz, Łódź, POLAND, 2Department of Myocardial Ischemia In Patients With Epilepsy Imaging Clinical Studies -> Cardiovascular Nuclear Medicine, Medical University of Lodz, Łódź, POLAND. EP-050 C. Sioka, A. Tsoumani, C. Votti, M. Beltsiou, L. Lakkas, K. Pappas, D. Imaging Clinical Study -> Perfusion Kiortsis, A. Fotopoulos, A. Kyritsis, S. Markoula; Could music positively influence cardiac perfusion University Hospital of Ioannina, Ioannina, GREECE. EANM’20 EANM’20 EANM’20 EP-044 studies? 1 1 1 EP-056 e-Poster Area M. Guiote Moreno , B. Luque Espejo , F. R. Maza Muret , J. F. Evaluation of the dyssynchrony difference between Labraca1, R. Zurera Pareja2, J. A. Vallejo Casas1; pharmacological stress and rest of gated myocardial 1Hospital Universitario Reina Sofía, Cordoba, SPAIN, 2Instituto Increased Hypotensive Response With Regadenoson In perfusion single photon emission computed tomography Maimonides de Investigación Biomédica, Cordoba, SPAIN. Elderly Patients WORLD LEADING MEETING J. Villena-Salinas, J. Alors Ruiz, S. Ortega Lozano, E. Ramos WORLD LEADING MEETING EP-040 in patients after acute myocardial infarction EP-051 M. Ota1, T. Kato1, S. Matsuo2; Moreno; 1Gifu prefectural general medical center, Gifu, JAPAN, 2Matsuo Hospital Universitario Virgen de la Victoria, Malaga, SPAIN. Intra- and inter-observer repeatability of three Spleen uptake of sestamibi as an unexpected witness of Medical Clinic, Hirakata, JAPAN. myocardial perfusion scintigraphy software packages in sympathetic response to exercise in myocardial perfusion EP-057 quantification of perfusion abnormalities imaging Repeatability of Coronary Flow Reserve Values C. Sachpekidis1, V. Sachpekidis2, A. Kopp-Schneider3, G. Arsos1, E. EP-045 S. Raffa1, M. Pennone2, M. Bauckneht2, A. Borra1, A. Miceli1, I. Moralidis1; Donegani1, S. Marra1, S. Morbelli1, C. Marini3, G. Sambuceti1; Determined with SPECT Technique Using a CZT 1Department of Nuclear Medicine, Aristotle University of Relevance Of Myocardial Perfusion Gated-SPECT(gMPS) 1Dept. of Health Sciences (DISSAL), University of Genoa, Genoa, Semiconductor Camera Thessaloniki, Papageorgiou Hospital, Thessaloniki, GREECE, As A Pre-Trasplant Screening Method To Detect Ischemia ITALY, 2IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, P. Cichocki1, M. Błaszczyk2, K. Cygulska3, K. Filipczak2, J. Kuśmierek1, 2Department of Cardiology, Papageorgiou Hospital, Thessaloniki, B. Pérez López, F. Sebastián Palacid, N. Álvarez Mena, P. J. Turbay 3Istituto di Bioimmagini e Fisiologia Molecolare (IBFM), CNR, P. Lipiec3, J. D. Kasprzak3, A. Płachcińska2; GREECE, 3Department of Biostatistics, German Cancer Research Eljach, C. Gamazo Laherrán, M. Alonso Rodríguez, M. J. González Milan, ITALY. 1Department of Nuclear Medicine, Medical University of Lodz, Center (DKFZ), Heidelberg, GERMANY. Soto, A. Sainz Esteban, M. A. Ruiz Gómez, R. Ruano Pérez; Lodz, POLAND, 2Department of Quality Control and Radiological Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN. EP-052 Protection, Medical University of Lodz, Lodz, POLAND, 3Chair and EP-041 Department of Cardiology, Medical University of Lodz, Bieganski EP-046 Effect of Ischemia Percentage in MPS on Patient Hospital, Lodz, POLAND. Coronary Flow Reserve (CFR) Obtained with SPECT Management and Revascularization Decision in CAD with Discovery NM 530c Camera - Comparison with Coronary Locating The Latest Site Of Left Ventricular Mechanical Solid-State Cardiac Gamma Camera EP-058 Angiography Contraction Through Gated-SPECT Phase Analysis N. Talay1,2, E. Özdemir1,2, N. Coşkun1,2; The evaluation of myocardial blood flow and coronary M. Blaszczyk1, P. Cichocki2, K. Cygulska3, J. Kuśmierek2, P. In Subjects With Normal Perfusion And Functional 1Nuclear medicine, Ankara, TURKEY, 2Ankara şehir hastanesi, Lipiec3, J. D. Kasprzak3, K. Frynas – Jończyk3, P. Wejner – Mik3, A. Parameters Ankara, TURKEY. flow reserve in MINOCA patients: comparison with 1 Płachcińska ; F. Ferrando-Castagnetto1, C. Real2, M. Pedrera Canal3, I. cardiac magnetic resonance 1 Department of Quality Control and Radiological Protection, Vilacosta2, M. Ollarves Carrero3, L. García Belaustegui3, P. Pascual3, A. Mochula, O. Mochula, A. Maltseva, D. Vorobyeva, V. Ryabov, K. 2 EP-053 Medical University of Lodz, Łódź, POLAND, Department of R. Ricca-Mallada1, M. Pérez Castejón3, J. Carreras Delgado3; Zavadovsky; Nuclear Medicine, Medical University of Lodz, Łódź, POLAND, 1Departamento de Cardiología - CCVU, Hospital de Clínicas, Cardiology Research Institute, Tomsk NRMC, Tomsk, RUSSIAN 3 The results of myocardial perfusion SPECT and coronary Chair and Department of Cardiology, Medical University of Lodz, FM, UdelaR, Montevideo, URUGUAY, 2Instituto Cardiovascular, FEDERATION. Bieganski Hospital, Łódź, POLAND. Hospital Clínico San Carlos, Madrid, SPAIN, 3Servicio de Medicina angiography in Russian patients with different pretest Nuclear, Hospital Clínico San Carlos, Madrid, SPAIN. CAD probability EP-042 A. Ansheles1, E. Denisenko-Kankiya2, I. Sergienko1, V. Sergienko1; EP-059 1National Medical Research Center of Cardiology, Ministry of Optimize the calculation of the left ventricular ejection EP-047 Healthcare, Moscow, RUSSIAN FEDERATION, 2Sity Hospital №4, Association of electrocardiographic changes during fraction with myocardial perfusion gated-SPECT in small Moscow, RUSSIAN FEDERATION. adenosine stress with perfusion defect on myocardial hearts The Effect Of Respiration Motion Correction On perfusion SPECT C. Martínez1,2, C. Espinet1, M. N. Pizzi1, A. Cardoso1, S. Aguadé- Myocardial Perfusion Quality O. Ben Hamida, W. El ajmi, A. Sellem, H. Hammami; Bruix1; E. Popov, A. Mochula; EP-054 Military hospital of instruction of tunis, Tunis, TUNISIA.

194 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 195 Department, Iasi, ROMANIA. 1SS.Spirito Hospital, Dept. of Nuclear Medicine, Pescara, ITALY, 2G. 3 EP-13 EP-12 D’annunzio University, Dept. of Urology, Chieti, ITALY, CDC Villa Stuart, Dept. of Urology, Rome, ITALY. Imaging Clinical Studies -> Oncological Imaging Clinical Studies -> Nephro-Urological EP-12 Imaging Study -> Nephro-Urology Imaging Clinical Study -> Breast Imaging Clinical Studies -> Oncological EP-070 Imaging Clinical Study -> Any Other Malignant The Role Of 18F-FDG PET/CT In The Management Of e-Poster Area (including Primary of Unknown Origin) e-Poster Area Merkel Cell Carcinoma: The Experience Of 51 Studies In Our Institution e-Poster Area V. Lopez Prior, B. LLombart Cussac, R. Diaz Expósito, F. Manchón Adsuar; EP-060 Valencian Oncologic Institution (IVO), Valencia, SPAIN. EP-076

Comparison of different simplified methods to Diagnostic Yield of F-18 FDG PET-CT in Staging and determinate Glomerular Filtration Rate with 99mTc-DTPA EP-064 EP-071 Restaging of Breast Cancer: Where Do We Need the EANM’20 EANM’20 EANM’20 M. A Hernandez Fructuoso1, J. E. Romero Herrera2, B. Santos Addition of Metabolic over Conventional Radiological 1 2 2 The Diagnostic Contribution of 18F-FDG PET/CT SCAN in Quantification of 18F-FDG accumulation in the intact Montero , C. G. Franco Monterroso , S. Ruiz Llama , J. Castell Imaging? 2 Conesa ; Cancer of BMUO testes of oncological patients 1 2 1 3 1 M. Siddique , A. Iqbal , M. K. Nawaz , A. B. Rai ; Hospital Universitario Vall d’Hebron. Institut de Diagnòstic per la Y. Liu; G. Arsos, D. Katsampoukas, P. Exadaktylou, A. Kalaitzogloy, V. 1 2 Pakistan Kidney and Liver Institute & Research Centre, Lahore, Imatge., Barcelona, SPAIN, Hospital Universitario Vall d’Hebron., The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Mpalaris, S. Georga, E. Moralidis; 2

WORLD LEADING MEETING PAKISTAN, LINCS Diagnostic & IR Services, Lahore, PAKISTAN, WORLD LEADING MEETING Barcelona, SPAIN. CHINA.< 3rd Dept. of Nuclear Medicine, Aristotle University of Thessaloniki 3Oxford University, Oxford, UNITED KINGDOM. School of Medicine, Papageorgiou Gen. Hospital, Thessaloniki, EP-061 EP-066 GREECE. EP-077 Correlation between the findings in the first post- Performance of digital PET/CT in the assessment of liver EP-072 transplantation Renogram and the allograft renal metastases 18F-FDG digital PET/CT performances for initial axillary function twelve months after surgery F. Fuentes-Ocampo, A. Flotats, D. López-Mora, M. Sizova, S. 18-F-fluorodeoxyglucose positron emission tomography lymph node status in breast cancer G. Guzmán Prudencio, S. Álvarez Ruiz, L. M. Del Barco Diez Abouzian, V. Camacho, A. Fernández, M. Estorch, J. Duch, A. (18FDG PET) as an attractive oncology imaging modality C. Provost1,2, A. Belly-Poinsignon3, O. Madar1, L. Champion2; Canseco, M. Calderón Calvente, L. Nieto Morcillo, L. De la Cueva Domènech, I. Carrió; in patients with brain metastasis of unknown origin - 1Radiopharmacology department, Institut Curie, Saint Cloud, 2 Barrao, M. Falgás Lacueva, M. Sangrós Sahún, P. Navarro Beltrán, Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN. initial experience FRANCE, Nuclear Medicine department, Institut Curie, Saint Cloud, FRANCE, 3Medical Physics department, Institut Curie, Saint D. Abós Olivares; P. Nikolova1, V. Hadzhiyska1, K. Mladenov1, M. Ilcheva1, V. EP-067 Cloud, FRANCE. Hospital Universitario Miguel Servet, Zaragoza, SPAIN. Grudeva2; 1University Hospital Alexandrovska, Sofia, BULGARIA, Diagnosis of Inmunotherapy Adverse Effects with 18Fdg EP-080 2Department of Imaging Diagnostics, University Hospital „Sv. EP-062 Pet-Ct.Our Experience: Ekaterina”, Sofia, BULGARIA. M. Agolti, L. Solari; Prospective comparison of early interim 18F-FDG PET/CT Usefulness of Additional Quantitative Parameters of Centro de Medicina Nuclear Clinica Modelo, Parana, ARGENTINA. and 18F-FLT PET/CT for predicting treatment response Dynamic Renal Scintigraphy (DSN) in the Diagnosis of EP-074 and survival in metastatic breast cancer Obstructive Uro- and Nephropathy EP-068 S. Chan1, T. Su2, P. Chang2; Utility 18F-FDG PET/CT of the detection of unknown P. Cichocki1, K. Filipczak2, A. Płachcińska2, J. Kuśmierek1; 1Hualien Tzu Chi Hospital, Hualien, TAIWAN, 2Keelung Chang 1Department of Nuclear Medicine, Medical University of Lodz, Dual time point PET/CT adds little to standard PET/CT in primary tumors (UPT) Gung Memorial Hospital, Keelung, TAIWAN. Lodz, POLAND, 2Department of Quality Control and Radiological patients with renal cell carcinoma A. Baena-Garcia, M. Cruz-Montijano, S. Garcia-Martinez, M. Protection, Medical University of Lodz, Lodz, POLAND. L. Geertsen1, J. A. Simonsen2, S. Hvidsten2, P. Høilund-Carlsen2,3, L. De Bonilla-Candau, J. Rodriguez-Rubio Corona, Y. Santaella- Lund1,3; Guardiola, M. Pajares-Vinardell; EP-081 1Department of Urology, Odense University Hospital, Odense, Hospital Universitario Puerta del Mar, Cadiz, SPAIN. EP-063 DENMARK, 2Department of Nuclear Medicine, Odense University Prediction of recurrence in locally advanced breast Hospital, Odense, DENMARK, 3Department of Clinical Research, EP-075 cancer using deep learning analysis Who Can We Trust More? A Comparison of Three Methods University of Southern Denmark, Odense, DENMARK. I. Jo1, J. Kim2, S. Jeong1, Y. Chae3, S. Lee1; for GFR Determination It Takes Two to Tango: Detection Efficiency of18 F-FDG 1Department of Nuclear Medicine, School of Medicine and I. Grierosu1,2, M. Starcea3,2, R. Tibu1, A. Tarca1, C. Gavrilovici3,2, C. EP-069 PET-CT and High Resolution Contrast Enhanced CT in the Chilgok Hospital, Kyungpook National University, Daegu, KOREA, 2 Stolniceanu1,2, W. Jalloul1,2, T. Ionescu1,2, A. Statescu1, R. Iacob2, C. evaluation of Hidden Primary Malignancy REPUBLIC OF, School of Computer Science and Engineering, 1,2 64CuCl : New Radiopharmaceutical PET for Urological Stefanescu ; 2 M. Siddique1, A. Iqbal2, A. B. Rai3, M. K. Nawaz1; Kyungpook National University, Daegu, KOREA, REPUBLIC OF, 1 3 Hospital Sf. Spiridon, Nuclear Medicine Laboratory, Iasi, Cancers 1Pakistan Kidney and Liver Institute & Research Centre, Lahore, Department of Hematology/Oncology, Kyungpook National 2 ROMANIA, University of Medicine and Pharmacy Grigore T. M. Mascia1, C. Villano1, V. De Francesco1, M. Marchioni2, L. Schips2, PAKISTAN, 2LINCS Diagnostic & IR Services, Lahore, PAKISTAN, University Hospital, Kyungpook National University School of 3 Popa, Iasi, ROMANIA, Hospital Sf. Maria, Paediatric Nephrology L. Cindolo3; 3Oxford University, Oxford, UNITED KINGDOM. Medicine, Daegu, KOREA, REPUBLIC OF.

196 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 197 We are exhibiting! Visit us at our virtual booth!

EP-082 EP-088

NaF-PET/CT has very limited clinical impact as a routine Is there a correlation between PET and histopathology adjunct to FDG-PET/CT in breast cancer staging findings of the invasive ductal carcinoma of breast with Supplying over 20 critical medical isotopes, Isotope JSC sets a key S. Hess1,2, R. Horvat1, E. H. Jakobsen3, P. C. Holdgaard4; the histopathological features of coexisting DCIS? 1 target to develop modern nuclear medicine technologies and Dept. of Radiology and Nuclear Medicine, Hospital South West I. Sarikaya1, A. Sarikaya2, A. N. Albatineh1, E. Tastekin2, Y. A. Sezer2; Jutland, University Hospital of Southern Denmark, Esbjerg, 1Kuwait University Faculty of Medicine, Kuwait, KUWAIT, 2Trakya 2 improve patients’ quality of life. DENMARK, Department of Regional Health Research, University University Faculty of Medicine, Edirne, TURKEY. of Southern Denmark, Odense, DENMARK, 3Dept. of Oncology, Lillebælt Hospital, University Hospital of Southern Denmark, Vejle, DENMARK, 4Dept. of Nuclear Medicine, Lillebælt Hospital, EP-089 ⁸⁹Sr University Hospital of Southern Denmark, Vejle, DENMARK. The comparative study of the validation for Tc-99m Tin- ¹⁵³Sm EP-083 colloid and Tc-99m Phytate in sentinel node detection in EANM’20 EANM’20 EANM’20 breast cancer patients ¹⁰⁶Ru Bone Scan Index as Overall Survival predictor in Breast J. Seok; cancer patients with bone metastases at diagnosis Chung-Ang University, Colleage of Medicine, Seoul, KOREA, V. Frantellizzi, A. Matto, M. Conte, G. Brunotti, L. Cosma, J. Lazri, REPUBLIC OF. M. S. De Feo, G. De Vincentis; WORLD LEADING MEETING Sapienza University of Rome, Rome, ITALY. ¹⁷⁷Lu WORLD LEADING MEETING EP-090 EP-084 Evaluation of low glucose uptake of lymph nodes in ²²⁵Ac ¹³¹I Comparison of 1 day protocol and 2 day protocol of patients with advanced breast cancer lymphoscintigraphy by subareolar injection in the C. Romagnolo1, G. Biscontini1, C. Cottignoli1, D. Morichetti2, A. ⁹⁹Mo detection of sentinel lymph nodes in breast cancer Savini3, F. Fringuelli1, A. Palucci1, L. Burroni1; 1 2 patients Nuclear Medicine, Ancona, ITALY, Pathological Anatomy department, Ancona, ITALY, 3Oncology Department, Ancona, J. Seok; ITALY. Chung-Ang University, Colleage of Medicine, Seoul, KOREA, REPUBLIC OF. EP-091

EP-085 Usefulness of PET/CT scan in Brest Cancer Patient A. Guensi, I. Essongue, A. Sallak, H. Benider, S. S. Zouine; ¹²⁵I Negative Predictive Value Of 18F-FDG PET/CT In The Hassan II University, Casablanca, MOROCCO. ¹³¹Cs Axillary Response to Neoadjuvant Chemotherapy In ¹⁹²Ir Patients Diagnosed Of Locally Advanced Breast Cancer EP-092 M. Lara Martínez1, M. López Acosta2, A. Díaz Silván2, O. Vilahomat ⁶⁰Co Hernández2, D. Cabello García2, J. Uña Gorospe2, A. Allende Riera2; Paraneoplastic Cerebellar Degeneration: Initial ¹⁰³Pd 1Hospital Universitario de Canarias, Santa Cruz de Tenerife, SPAIN, Presentation of Occult Breast Cancer 2Hospital Universitario Nuestra Señora de La Candelaria, Santa N. Filizoglu, S. Kesim, C. O. Engur, T. Ones, S. Ozguven, T. Y. Erdil; Cruz de Tenerife, SPAIN. Marmara University Pendik Training and Research Hospital, Istanbul, TURKEY. ⁶⁸Ge/⁶⁸Ga EP-086 EP-14 Positron Emission Mammography In The Evaluation Of Imaging Clinical Studies -> Oncological Interim Response To Neoadjuvant Chemotherapy In Patients With Locally Advanced Breast Cancer S. Medina-Ornelas1, I. Soldevilla-Gallardo1, F. García-Perez1, C. Villarreal-Garza1, E. Bargallo-Rocha1, E. Estrada-Lobato2; 1Instituto Nacional de Cancerologia, Mexico City, MEXICO, 2IAEA, Vienna, AUSTRIA. ISOTOPES FOR THERAPY AND DIAGNOSTICS

198 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 199 www.isotop.ru [email protected] 1 1 Imaging Clinical Study -> Colorectal (including Liver and Non-Endocrine Pancreas) Babacan , F. Arslan ; 1Sivas Cumhuriyet University School of Medicine, Sivas, TURKEY, EP-17 2 Sivas Medicana Hospital, Sivas, TURKEY. Imaging Clinical Studies -> Oncological e-Poster Area e-Poster Area Imaging Clinical Study -> Head and Neck EP-16 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Gynaecological e-Poster Area EP-093 EP-097

e-Poster Area Value of Volumetric and Textural Analysis in Predicting Dual-Time Point Imaging (DTPI) in Gastrointestinal the Treatment Response in Patients with Locally Stromal Tumors (GIST) EP-109 Advanced Rectal Cancer M. Aly1,2, E. Kothekar1, T. Seierstad3, C. Rojulpote1, Ø. Bruland4, T. J. 1 1 1,5,6 Detection of Second Primary Tumors in patients with N. Karahan Sen, A. Aksu, G. Capa Kaya; Werner , A. Alavi , M. E. Revheim ; 1Department of Radiology, University of Pennsylvania, EP-105 head and neck cancers using FDG PET/CT as a screening EANM’20 EANM’20 Dokuz Eylül University, Izmir, TURKEY. EANM’20 2 Philadelphia, PA, UNITED STATES OF AMERICA, Department of imaging tool 3 Role of earlyFDG PET/CT at 6 weeks for the Radiology, Asyut University Hospital, Asyut, EGYPT, Department T. Yordanova1, A. Klisarova1, B. Chaushev1, T. Stoewa1, Z. EP-094 of Research and Development, Oslo University Hospital, Oslo, prediction of response in cervical cancer treated with Dancheva1, S. Chausheva1, M. Dyankova1, N. Sapundzhiev2; 4 NORWAY, Department of Oncology, Oslo University Hospital, chemoradiotherapy 1Medical University Prof. dr P.Stoyanov, Department of nuclear 18 5 F-FDG PET/CT Metabolic Tumor Burden in Primary Oslo, NORWAY, Division of Radiology and Nuclear Medicine, Oslo 2 I. Zerizer1, A. Divoli1, S. Chua1, A. Parsai2; medicine, Varna, BULGARIA, Medical University Prof. dr WORLD LEADING MEETING University Hospital, Oslo, NORWAY, 6Institute of Clinical Medicine, WORLD LEADING MEETING Staging of Colorectal Cancers 1Royal Marsden Hospital, London, UNITED KINGDOM, 2Barts P.Stoyanov, Department of neurosurgery and ENT diseases, Varna, Faculty of Medicine, University of Oslo, Oslo, NORWAY. E. Etchebehere, J. S. Fonseca, A. O. Santos, M. C. L. Lima, M. S. Healthcare, London, UNITED KINGDOM. BULGARIA. Mendes, M. N. Silveira, B. J. Amorim, C. R. Martinez, L. P. Cunha, P. Fanti, J. B. Carvalheira; EP-100 EP-110 The University of Campinas, Campinas, BRAZIL. EP-106 DNA synthesis PET imaging with 4DST: A radiomics Usefulness of MTV, TLG and SUVmax as predictive EP-095 approach for predicting prognosis in patients with Correlation between tumor biological parameters at values of the response to definitive chemo-radiotherapy esophageal cancer diagnosis and response to chemo-radiation therapy in treatment in head and neck tumors The role of 18F- FDG PET-CT in the decision making of M. Hotta, R. Minamimoto, K. Yamada; cervical cancer patients A. Santos Bueno1,2, M. Guite Moreno1,2, L. Rodriguez Perez1, A. radiotherapy treatment in patients with anal cancer National Center for Global Health and Medicine, Tokyo, JAPAN. O. Kagna, R. Abdah-Bortnyak, Z. Keidar; Herrero Muñoz3, J. Gutierrez Jodas1, M. Albala Gonzalez1,2; A. Palucci1, M. di Benedetto2, C. Cottignoli1, L. Vicenzi2, C. Rambam Health Care Campus, Haifa, ISRAEL. 1Hospital Universitario Reina Sofía, Córdoba, SPAIN, 2IMIBIC, Romagnolo1, F. Fringuelli1, G. Biscontini1, F. Fenu2, S. Costantini2, L. Córdoba, SPAIN, 3Facultad de Medicina. Universidad de Córdoba, Burroni1, G. Mantello2; EP-101 Córdoba, SPAIN. 1Nuclear Medicine, Ancona, ITALY, 2Radiotherapy Department, EP-107 Ancona, ITALY. Digital vs Analog PET/CT in the detection of liver metastases FDG-PET/CT Leads A Better Target Volume Definition In EP-111 EP-096 F. Fuentes-Ocampo, D. López-Mora, A. Flotats, M. Sizova, S. Radiotherapy Of Locally Advanced Cervical Cancer Abouzian, V. Camacho, A. Fernández, M. Estorch, J. Duch, A. A. Palucci1, L. Vicenzi2, C. Romagnolo1, M. di Benedetto2, G. Comparison between the efficacy of physical Metabolic parameters of primary tumor in preoperative Domènech, I. Carrió; Biscontini1, F. Fringuelli1, C. Cottignoli1, F. Cucciarelli2, G. Mantello2, examination/endoscopy with the efficacy of FDG-PET/ 18F-FDG PET/CT do not accurately predict occult regional Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN. L. Burroni1; CT for the identification of recurrence in head and neck 1 2 lymph node metastasis in patients with clinically N0 Nuclear Medicine, Ancona, ITALY, Radiotherapy Department, squamous cell carcinoma after curative treatment EP-102 Ancona, ITALY. colorectal cancer T. Yordanova1, A. Klisarova1, B. Chaushev1, T. Stoewa1, Z. M. Zhou1,2, X. Wang1,2, Y. Wang1,2; Dancheva1, S. Chausheva1, M. Dyankova1, N. Sapundzhiev2; Usefulness of regionally different cut-off SUVmax of the EP-108 1Department of Nuclear Medicine, the Third Affiliated Hospital 1Medical University Prof. dr. P. Stoyanov, Deparment of nuclear of Soochow University, Changzhou, CHINA, 2Changzhou Key lymph nodes for the N staging of esophageal cancer medicine, Varna, BULGARIA, 2Medical University Prof. dr 1 2 2 1 PET/CT in calcified metastatic ovarian serous papillary Laboratory of Molecular Imaging, Changzhou, CHINA. K. Takahashi , K. Takanami , K. Takase , T. Kamei ; P.Stoyanov, Department of neurosurgery and ENT diseases, Varna, 1Department of surgery, Tohoku University, Sendai, JAPAN, cystadenocarcinoma, mimicking a benign lesion on CT: BULGARIA. 2Department of Diagnostic Radiology, Tohoku University Hospital, two case reports EP-15 Sendai, JAPAN. Z. Dancheva1, A. Konsulova2, P. Bochev3, B. Chaushev1, M. Imaging Clinical Studies -> Oncological Dyankova1, T. Yordanova1, A. Klisarova1; EP-18 Imaging Clinical Study -> Gastro-Intestinal EP-103 1St Marina University Hospital, Varna, BULGARIA, 2Department Imaging Clinical Studies -> Oncological of Oncology, Complex Oncological Centre, Burgas, BULGARIA, Imaging Clinical Study -> Lung (including The Relationship Between Microsattelite Instability and 3Acibadem Cityclinik Oncology center Sofia, Sofia, BULGARIA. 18F-FDG PET / CT Parameters in Colorectal Cancer Patients Z. Hasbek1, N. Demir2, M. Yılmaz1, H. Özer1, S. A. Ertürk1, Ö. Ulaş

200 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 201 Compelling data available Mesothelioma) Value Of [18F]FDG PET/CT In The Diagnosis Of Thoracic Lymph Node Metastasis In Non-Small Cell Lung Cancer M. Calderón Calvente1, S. Álvarez Ruiz1, M. Sangrós Sahún1, for SIRT in HCC. e-Poster Area L. Nieto Morcillo1, G. Guzmán Prudencio1, L. Del Barco Diez Canseco1, P. Navarro Beltrán2, M. Falgás Lacueva1, L. De la Cueva Barrao1, D. Abós Olivares1; 1Hospital Universitario Miguel Servet, Zaragoza, SPAIN, 2hospital universitario miguel servet, Zaragoza, SPAIN. DOSISPHERE-01: Level 1 evidence of improved patient EP-112 Study on the Relationship Between SUVmax in F-18-FDG EP-117 outcomes with TheraSphere Personalised Dosimetry PET/CT and Expression of Ki-67 in Patients with Non- small Cell Lung Cancer Lymphonodular anthracosis in patients undergoing FDG R. Wang1,2, X. Liao1, M. Liu1, Y. Cui1, Y. Fan1, J. Zhang1, X. Zhang1, L. PET/CT for initial lung cancer diagnostics and/or staging 1 1 EANM’20 EANM’20 Di , Q. Jiang ; is a mayor pitfall: a comparison to the histological gold EANM’20 Median overall (ITT population) 1Peking University First Hospital, Beijing, CHINA, 2Peking University standard International Hospital, Beijing, CHINA. H. Hautzel1, T. Plönes2, K. Darwiche3, W. P. Fendler1, C. Rischpler1, D. Theegarten4, C. Aigner2, K. Herrmann1; 1 EP-113 University Hospital Essen, Department of Nuclear Medicine, Essen, GERMANY, 2University Medicine Essen - Ruhrlandklinik, WORLD LEADING MEETING WORLD LEADING MEETING 16 Department of Thoracic Surgery and Thoracic Endoscopy, Evaluation of Different Registration Landmarks for 3 Months Survival Improvement Essen, GERMANY, University Medicine Essen - Ruhrlandklinik, Thoracic MR-PET/CT Fusion Using High-Frequency (personalised vs. standard dosimetry) Department of Pneumology, Division of Interventional Non-Invasive Ventilation (HF-NIV) for Lung Nodule Bronchology, Essen, GERMANY, 4University Hospital Essen, Assessment Department of Pathology, Essen, GERMANY. M. Jreige, M. Neury, M. Nicod Lalonde, N. Schaefer, E. Darçot, C. % Beigelman, J. O. Prior; EP-118 35 Lausanne University Hospital, Lausanne, SWITZERLAND. Of patients in the personalised arm The relationship between the standard uptake value were downstaged to resection, EP-114 and the BMI in the patients with lung cancer:A study of vs. 4% in the standard arm PET-CT scans Diagnostic effect of benign lung changes in initial cancer Z. Zhao1, S. Jia1, J. Zhang2, H. Yang3; staging with F-18 FDG PET/CT. The Kwa-Zulu Natal 1Shenzhen Yunshan Yinghe medical imaging diagnosis center, experience Shenzhen, CHINA, 2Shenzhen shajing people’s hospital, Shenzhen, N. Nyakale1,2, J. Kabunda2, C. Kalinda3,2, L. Harry12, P. Ramdass2, T. CHINA, 3Peking University Shenzhen Hospital, Shenzhen, CHINA. Better outcomes in gold-standard survival, Ebrahim2; 1Sefako Makgatho Health Sciences University, Pretoria, SOUTH and in trying to convert patients to resection. AFRICA, 2University of Kwa-Zulu Natal, Durban, SOUTH AFRICA, EP-119 “ 3University of Namibia, Namibia, SOUTH AFRICA. A win-win-win on all fronts. Comparison of the image quality and precision of fused lung images acquired by FDG PET/MRI with ZTE and PET/ Prof. Riad Salem, Interventional Radiologist, Northwestern University, Chicago/IL USA. EP-115 CT ” 1 1 1 2 1 J. Inukai , M. Nogami , F. Zeng , T. Kurimoto , T. Murakami ; 18 Semi-quantitative analysis of F-FDG PET/CT in single 1Department of Radiology, Kobe University Graduate School of pulmonary lesion: the role of blood glucose level and Medicine, Kobe, JAPAN, 2GE Healthcare, Hino, JAPAN. body mass index normalization A. Capozza1, C. Dolci1, A. Scarale1, A. Franchini2, I. Gotuzzo2, E. 1 1 1 1 EP-120 Plan, Treat and Confirm absorbed dose distribution Gay , G. Cabrini , M. Milella , C. Rossetti ; 1Nuclear Medicine Unit, ASST Grande Ospedale Metropolitano with Simplicit90Y workflow for 90Y SIRT Niguarda, Milan, ITALY, 2Nuclear Medicine, University of Milano- Establishment and Verification of an Bicocca, Milan, ITALY. 18F-fluorodeoxyglucose (FDG) PET/CT Based Prediction Model for Identifying Malignant from Benign Ground- EP-116 Glass Nodules

PDA: Personalized Dosimetry Arm ; SDA: Standard Dosimetry Arm Reference: Garin E, Tselikas L, Guiu B, Chalaye J et al. Lancet Gastroenterol Hepatol 2020, in press

All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information202 for theOCTOBER use only in countries 22–30, with applicable 2020 health | authority VIRTUAL product registrations. OCTOBER 22–30, 2020 | VIRTUAL 203

© 2020 Boston Scientific Corporation or its affiliates. All rights reserved. www.bostonscientific.eu. PI- 879105-AA www.bostonscientific.eu R. Niu, X. Shao, X. Shao, J. Wang, Y. Wang; Navitski, H. Schöder; Imaging Clinical Study -> Melanoma The Third Affiliated Hospital of Soochow University, Changzhou, EP-126 MSKCC, New York, NY, UNITED STATES OF AMERICA. CHINA. Role of 18F-FDG PET/CT in the evaluation of reponse to e-Poster Area EP-121 therapy in non-small-cell lung cancer (NSCLC) patientes EP-130 treated with inmunotherapy ( prelimary results) Value of total metabolic tumor burden as predictor PET/CT for Detecting Bone Marrow Involvement in M. Suarez-Piñera1, A. Taus2, D. Ramal3, L. Pijuan4, A. Mestre- of overall survival in NSCLC patients treated with Fusco5, E. Arriola2; Diffuse Large B-cell Lymphoma Compared with Bone pembrolizumab 1Nuclear Medicine Department, Hospital del Mar, Barcelona, Marrow Biopsy EP-134 D. Calabro’1, F. G. Dall’Olio2, F. Formica2, G. Argalia1, S. Fanti1, A. SPAIN, 2Medical Oncology Department, Hospital del Mar, C. Soldevila1, M. Cortés-Romera1, A. Sabaté-Llobera1, S. Mercadal- Ardizzoni2, V. Ambrosini1; Barcelona, SPAIN, 3Radiology Department, Hospital del Mar, Vílchez2, A. Palomar-Muñoz1, F. Climent-Esteller3, E. Llinares-Tello1, Melanoma patients: is it really necessary a whole-body 1Nuclear Medicine, S.Orsola-Malpighi Hospital, DIMES University Barcelona, SPAIN, 4Pathology Department, Hospital del Mar, M. Pudis1, E. González-Barca2; PET/CT scan? of Bologna, Bologna, ITALY, 2Sant’Orsola-Malpighi Teaching Barcelona, SPAIN, 5Nuclear Medicine Department, Hospital del 1PET/CT Unit (IDI)- Department of Nuclear Medicine. Hospital D. Calabro’1, L. Vetrone1, A. Farina1, F. Serani1, P. Castellucci2, S. Hospital, University of Bologna, Medical Oncology Unit, Bologna, Mar, Barcelona, SPAIN. Universitari de Bellvitge, L’Hospitalet de Llobregat (Barcelona), Fanti1; 2 1Nuclear Medicine, DIMES University of Bologna, S.Orsola- EANM’20 EANM’20 ITALY. SPAIN, Department of Hematology. ICO. Hospital Duran i EANM’20 Reynals-IDIBELL, L’Hospitalet de Llobregat (Barcelona), SPAIN, Malpighi Hospital, Bologna, ITALY, 2Nuclear Medicine, S.Orsola- EP-122 EP-19 3Department of Pathology. Hospital U. de Bellvitge-IDIBELL, Malpighi Hospital, Bologna, ITALY. Imaging Clinical Studies -> Oncological L’Hospitalet de Llobregat (Barcelona), SPAIN. Molecular imaging as a predictive biomarker response to Imaging Clinical Study -> Lymphoma EP-135 Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer EP-131

WORLD LEADING MEETING 18 WORLD LEADING MEETING S. Medina-Ornelas, F. García-Perez, O. Arrieta-Rodriguez, F. Interim F-FDG PET/CT in survival prediction ofanti-PD-1 Disease Free Survival on Follow-up 18FDG PET/CT in NHL Barron-Barron; e-Poster Area immunotherapy in metastatic melanoma Instituto Nacional de Cancerologia, Mexico City, MEXICO. Patients with Complete Metabolic Response on Interim C. Sachpekidis1, J. C. Hassel2, A. Dimitrakopoulou-Strauss1; scans 1Clinical Cooperation Unit Nuclear Medicine, German Cancer 2 EP-123 N. Fatima1, M.U. Zaman1, A. Zaman2, U. Zaman3, S. Zaman4, R. Research Center (DKFZ), Heidelberg, GERMANY, Department of Tahseen1; Dermatology and National Center for Tumor Diseases, University Clinical role of F-18 FDG PET/CT in thymic epithelial EP-127 1Aga Khan University, Karachi, PAKISTAN, 2Department of Hospital Heidelberg, Heidelberg, GERMANY. tumors Medicine, Dr Ruth Hospital, Karachi, PAKISTAN, 3Dept of Medicine K. Hayasaka, T. Saitoh, H. Inoue, Y. Shiraishi, J. Atsumi, T. Tohgoh, Added Value of SPECT/CT in the Monitoring and Long- Suny Downstate, Hospital, New York, NY, UNITED STATES OF EP-136 M. Hiramatsu, K. Shimoda, H. Yoshimori, K. Ohta; Term Follow-up of Malignant Lymphomas AMERICA, 4Dow Medical College, Dow University of Health Fukujuji Hospital, Anti-Tuberculosis Association, Tokyo, JAPAN. L. Chavdarova, E. Piperkova; Sciences (DUHS), Karachi, PAKISTAN. The application of 18F-FDG PET/CT for the assessment University Specialized Hospital for Active Treatment in Oncology, of tumor response to immunotherapy with PD-1/PD-L1 Sofia, BULGARIA. EP-132 blockage in patients with advanced melanoma I. Kostadinova; EP-124 EP-128 Can Metabolic Parameters Obtained From PET/CT Images Clinic of nuclear medicine, University Hospital Acibadem City Be Used As A Prognostic Factor For Hodgkin Lymphoma? Clinic, Mladost, Sofia, BULGARIA. Prediction of overall and free progression survival by Inter reader agreement andvariabilityof FDG PET C. Sezgin, G. Mutevelizade, E. Sayit, I. Aydogdu, G. Gumuser; means of post-induction chemo/chemoradiotherapy 18F- volumetric parameters in a cohort of patients with Celal Bayar University, Manisa, TURKEY. FDG PET/CT in non-small cell lung cancer patients Diffuse Large B-Cell Lymphoma (DLBCL) EP-137 P. García-Talavera San Miguel, F. Gómez-Caminero, J. G. M. Simó1, A. Hernandez Martinez2, M. Cortes Romera3, M. EP-133 18 Villanueva, B. Lucas, C. Riola, A. C. Peñaherrera, J. C. Cañadas, E. Sarandeses Fernández4, A. Rotger Regi5, X. Setoain Perego6, M. FDG PET/CT role in a case of Pembrolizumab associated Martín, P. Tamayo; Coronado Poggio7; Impact of Gender on Metabolic Response in Patients with sarcoidosis mimicking progression in metastatic Nuclear Medicine. University Hospital of Salamanca, Salamanca, 1Hospital Universitari Vall De Hebron, Barcelona, SPAIN, 2Hospital Non-Hodgkin’s Lymphoma using Interim 18FDG PET/CT melanoma patient SPAIN. Santa Lucia, Cartagena, Murcia, SPAIN, 3Hospital Universitario N. Fatima1, M. U. Zaman1, A. Zaman2, U. Zaman3, S. Zaman4, R. Z. Dancheva1, A. Konsulova2, B. Chaushev1, P. Bochev3, M. de Bellvitge. Idibell, Barcelona, SPAIN, 4Hospital Universitario Tahseen1; Dyankova1, T. Yordanova1, A. Klisarova1; 12 de octubre, Madrid, SPAIN, 5Hospital Universitario Gregorio 1Aga Khan University, Karachi, PAKISTAN, 2Department of 1St Marina University Hospital, Varna, BULGARIA, 2Department EP-125 Marañon, Madrid, SPAIN, 6Hospital Universitari Clinic, Barcelona, Medicine, Dr Ruth Hospital, Karachi, PAKISTAN, 3Dept of Medicine of Oncology, Complex Oncological Centre, Burgas, BULGARIA, SPAIN, 7Hospital Universitari La Paz. On Behalf on the imaging Suny Downstate, Hospital, New York, NY, UNITED STATES OF 3Acibadem Cityclinik Oncology center Sofia, Sofia, BULGARIA. Evaluation of regional lymph node involvement in the subcomitte of GELTAMO, Madrid, SPAIN. AMERICA, 4Dow Medical College, Dow University of Health staging of non-small cell lung cancer with 18F FDG PET/ Sciences (DUHS), Karachi, PAKISTAN. CT EP-129 EP-138 M. Keskin; EP-20 18 Mersin City Training and Research Hospital, Mersin, TURKEY. End of therapy F-FDG PET/CT for assessment of Imaging Clinical Studies -> Oncological Significance of FDG PET/CT in the Evaluation of persistent bone involvement in B-cell lymphoma Melanoma Patients L. Michaud, R. Nakajima, E. Joffe, P. Ghione, S. Ahsanuddin, A. J. Stojanovic, I. Grozdic Milojevic;

204 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 205 Centre for Nuclear medicine, Clinical Center of Serbia, Faculty of Strasbourg, FRANCE, 4University of Iowa, Iowa City, IA, UNITED YOUR CHALLENGE Medicine University of Belgrade, Belgrade, SERBIA. STATES OF AMERICA. OUR EXPERIENCE EP-21 EP-147 Imaging Clinical Studies -> Oncological Imaging Clinical Study -> Neuroendocrine Role of [68Ga]68Ga-DOTANOC PET/CT in presurgical (Pancreatic and Others) staging of small intestine neuroendocrine tumour D. Calabro’1,2, S. Telo1,2, G. Argalia1,2, E. Fortunati1,2, E. Tabacchi1,2, L. Zanoni1,2, C. Ricci2,3, R. Casadei2,3, D. Campana2,3, S. Fanti1,2, V. 1,2 e-Poster Area Ambrosini ; 1Nuclear Medicine, S.Orsola-Malpighi Hospital, DIMES University of Bologna, Bologna, ITALY, 2NET team Bologna, ENETS Center Of Excellence, Bologna, ITALY, 3DIMEC University of Bologna, Bologna, ITALY. EP-140 EANM’20 EP-148 Results of a sequential strategy 68Ga (DOTATOC) - 18F-FDG PET/CT in real-life diagnosis and staging of Early post-surgical 68Ga-DOTANOC PET/CT imaging in neuroendocrine tumors GEP NET patients WORLD LEADING MEETING M. Ollarves Carrero1, J. Rodriguez Gomez1, M. Cabrera Martin1, S. Telo1,2, E. Fortunati1,2, G. Argalia1,2, D. Calabrò1,2, E. Tabacchi1, L. F. Ferrando-Castagnetto2, C. Wakfie Corieh1, A. Blanes Garcia1, R. Zanoni1, D. Campana3, S. Fanti1,2, V. Ambrosini1,2; Couto Caro1, J. L. Carreras Delgado1; 1Nuclear Medicine, Policlinico S.Orsola-Malpighi, Bologna, ITALY, 1Hospital Clinico San Carlos, Madrid, SPAIN, 2Universidad de la 2DIMES University of Bologna, Bologna, ITALY, 3DIMEC University GMP SOLUTIONS FOR YOUR RADIOPHARMA PRODUCTION PLANT República Montevideo, Montevideo, URUGUAY. of Bologna, Bologna, ITALY. GMP RADIOPHARMACY EP-149 EP-142 G1/G2 discrimination of pNET with [68Ga]Ga-DOTANOC Are we enough for insulinoma? PET/CT quantitative parameters: is it feasible? P. Soeiro, L. Fadiga, R. Silva, J. Saraiva, A. Moreira, G. Costa, J. D. Calabro’1,2, S. Malavasi3, A. Bevilacqua3, C. Ricci4,2, S. Telo1,2, G. Pedroso de Lima; Argalia1,2, E. Fortunati1,2, E. Tabacchi1,2, L. Zanoni1,2, R. Casadei4,2, D. Centro Hospitalar e Universitário de Coimbra, Coimbra, Campana4,2, S. Fanti1, V. Ambrosini1,2; PORTUGAL. 1Nuclear Medicine, S.Orsola-Malpighi Hospital, DIMES University of Bologna, Bologna, ITALY, 2NET team Bologna, ENETS Center EP-143 Of Excellence, Bologna, ITALY, 3Advanced Research Center for SAFETY FIRST IN YOUR HOSPITAL’S NUCLEAR MEDICINE DEPARTMENT Electronic Systems (ARCES), University of Bologna, Bologna, ITALY, NUCLEAR MEDICINE Are post-therapeutic SPECT/CT acquisitions useful 4DIMEC University of Bologna, Bologna, ITALY. to predict response to PRRT in patients with gastroenteropancreatic neuroendocrine tumors ? EP-150 Preliminary results Role of [18F] FDG-PET/CT in assessment of effectiveness of T. Godefroy, C. Ansquer, Y. Touchefeu, M. Barbaud, T. Matysiak- Budnik, F. Kraeber-Bodéré, T. Carlier; paraganglioma embolization 1 2 1 1 CHU de Nantes, Nantes, FRANCE. J. Maczewska , K. Kulesza , M. Kobylecka , K. Fronczewska , L. Królicki1; 1Nuclear Medicine Department Warsaw Medical University, EP-146 Warsaw, POLAND, 2Department of General, Endocrine and TAILOR-MADE RADIOISOTOPE GMP [email protected] - www.comecer.com PLANT Vascular Surgery Warsaw Medical University, Warsaw, POLAND. INDUSTRIAL PROJECTS T: +39 0546 656375 - F: +39 0546 656353 90Y- or 177Lu-DOTATOC therapy improves symptoms EP-151 COMECER S.P.A. Via Maestri del Lavoro, 90 - 48014 Castel Bolognese (RA) Italy control and impacts on clinical management of metastatic insulinoma [68Ga]-DOTA-TOC PET-TC prospective comparison with M. Freitag1, M. Braun2, E. Christ1, B. Goichot3, T. O’Dorisio4, D. Bushnell4, M. Walter1, D. Wild1, N. Guillaume1; [99mTc]-HYNIC-TOC SPECT-CT and [18F]-FDG PET-CT 1University Hospital of Basel, Basel, SWITZERLAND, 2Claraspital, in patients with low grade gastroenteropancreatic Basel, SWITZERLAND, 3Hôpitaux Universitaires de Strasbourg,

OCTOBER 22–30, 2020 | VIRTUAL 207 neuroendocrine tumors (GEPNETs) Hospital, Krakow, POLAND, 2Endocrinology Clinic of the Valdecilla University Hospital. University of Cantabria, Santander, recurrent PCa patients: a single center experience M. Simó1, A. Garcia2, J. Hernando3, D. Villasboas2, F. Dellepiane2, I. Endocrinology Department , Faculty of Medicine, Jagiellonian SPAIN. S. Telo, A. Farolfi, R. Mei, S. Mattoni, L. Calderoni, P. Castellucci, S. Navales2, M. Barios2, M. Boronat2, J. Capdevila3, J. Castell2; University Medical College, Krakow, POLAND. Fanti; 1Hospital Universitari Vall De Hebron, Barcelona, SPAIN, 2Hospital EP-161 Nuclear Medicine, Policlinico S.Orsola-Malpighi, Bologna, ITALY. Universitari Vall de Hebron, Barcelona, SPAIN, 3Vhio, Barcelona, EP-157 SPAIN. Can 18F-NaF PET/CT Before Autologous Stem Cell EP-169 Prognostic impact of phenotype heterogeneity Transplantation Predict Survival In Multiple Myeloma? 68 EP-152 of grade 1-2 metastatic gastroenteropancreatic C. Sachpekidis1, A. Kopp-Schneider2, M. Merz3, A. Jauch4, M. Raab3, Pharmacokinetic PET/CT studies with Ga-PSMA-11 in neuroendocrine tumors documented by 18FDG PET-CT H. Goldschmidt3, A. Dimitrakopoulou-Strauss1; patients with biochemical recurrence and progression of Utility of suvmax values of PET / TC 68GA-DOTATOC in the 1 and 68Ga-DOTANOC PET-CT Clinical Cooperation Unit Nuclear Medicine, German Cancer a prostatic cancer 2 diagnosis and monitoring of patients with pulmonary Research Center (DKFZ), Heidelberg, GERMANY, Department of 1 1 2 M. Barbaud1, Y. Touchefeu2, M. Le Bras3, V. Fleury4, T. Carlier1,5, C. D. Strauss , C. Sachpekidis , K. Kopka , A. Dimitrakopoulou- neuroendocrine tumors (NPT) 1,5 6 7 1,5 1 Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Strauss1, L. Pan1, U. Haberkorn3; Bailly , E. Frampas , A. Rauscher , F. Kraeber-Bodere , C. Ansquer ; 3 GERMANY, Department of Internal Medicine V, University Hospital 1 T. Moreno-Monsalve, T. Rodríguez -Locarno, D. Cáceres- Silva, M. 1Nuclear Medicine Unit, University Hospital, Nantes, FRANCE, German Cancer Research Center CCU Nuclear Medicine, Heidelberg and National Center for Tumor Diseases (NCT), 2 Castellón -Sánchez, J. Navarro- Fernández, L. Frutos- Esteban, L. 2Digestive Oncology, Institut Des Maladies De l’Appareil Heidelberg, GERMANY, Institute of Radiopharmaceutical Cancer Heidelberg, GERMANY, 4Institute for Human Genetics, University of Mohamed-Salem, J. Contreras- Gutiérrez, M. Claver Valderas; Digestif, University Hospital, Nantes, FRANCE, 3Department of Research at Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Heidelberg, Heidelberg, GERMANY. 3 Hospital Universitario Virgen De La Arrixaca, Murcia, SPAIN. Endocrinology, University Hospital, Nantes, FRANCE, 4Nuclear GERMANY, Department of Nuclear Medicine, University of Heidelberg, Heidelberg, GERMANY. EANM’20 EANM’20 Medicine Unit, Institut de Cancérologie de l’Ouest, Saint- EANM’20 Herblain, FRANCE, 5CRCINA, INSERM, CNRS, Angers University, EP-162 EP-153 Nantes University, Nantes, FRANCE, 6Department of Radiology, EP-170 University Hospital, Nantes, FRANCE, 7Pharmacy Unit, Institut de The role of 18F-FDG PET/CT and beta-2-microglobulin in Characterization and surveillance of cardiac metastasis Cancérologie de l’Ouest, Saint-Herblain, FRANCE. diagnostic assessment of patients with multiple myeloma PET/CT with68Ga-PSMA-11 for detection of rib in well-differentiated gastroenteropancreatic K. Mladenov1, V. Hadzhiyska1, D. Vasileva2, P. Nikolova1, M. Ilcheva1; involvement in a subgroup of prostate cancer patients WORLD LEADING MEETING WORLD LEADING MEETING neuroendocrine tumor using Ga68-DOTATATE PET/CT and 1Clinic of Nuclear medicine, University Hospital “Alexandrovska”, L. Calderoni, A. Farolfi, R. Mei, S. Telo, S. Fanti; EP-22 2 PET/MR Sofia, BULGARIA, Department of Nuclear Medicine, Specialized Nuclear Medicine, Sant’Orsola University Hospital, Bologna, ITALY. Hospital for Active Therapy of Haematological diseases, Sofia, J. Renfrew, R. Shrestha, M. Yang, T. Halfdanarson, R. Arsanjani, M. Imaging Clinical Studies -> Oncological BULGARIA, . EP-171 Sonbol; Imaging Clinical Study -> Other Hemato- Mayo Clinic - Arizona, Phoenix, AZ, UNITED STATES OF AMERICA. Oncology EP-163 18F-Choline PET/CT in Biochemical Recurrence of Prostate Cancer EP-154 18F-Fluorocholinein the staging of Multiple Myeloma e-Poster Area C. Riola-Parada, B. Lucas-Velázquez, F. Gómez-Caminero, J. patients . First impressions Villanueva, P. García-Talavera, L. Díaz, A. Peñaherrera, J. Cañadas Retrospective Analysis of the Indications to 18F-FDG-PET/ P. Garrastachu Zumaran1, X. Boulvard1, M. Albornoz1, P. Salazar, M. Tamayo; CT in NET Patients Hernández Pérez2, F. Cañete Sanchez1, L. Romero Robles1, A. Nuclear Medicine Department. Hospital Clínico Universitario de G. Argalia1, D. Calabrò1, S. Telo1, E. Fortunati1, E. Tabacchi2, L. Cabrera Villegas1, M. Hermosilla Fernández2, R. Ramirez Lasanta1; Salamanca, Salamanca, SPAIN. Zanoni2, D. Campana3, S. Fanti1, V. Ambrosini1; EP-158 1Fundacion Riojasalud. CIBIR, Logroño, Rioja, SPAIN, 2Hospital San 1Nuclear Medicine, S.Orsola-Malpighi Hospital, DIMES University Pedro, Logroño, Rioja, SPAIN. EP-172 of Bologna, Bologna, ITALY, 2Nuclear Medicine, S.Orsola-Malpighi Prognostic value of 18F-FDG PET / CT in patients Hospital, Bologna, ITALY, 3DIMEC University of Bologna, Bologna, with Multiple Myeloma treated with autologous EP-164 Utility of 68Ga-PSMA PET / CT in occult biochemical ITALY. haematopoietic stem-cell transplantation recurrence of prostate carcinoma with negative 18F-FDG PET / CT findings of Rosai Dorfman Disease with L. Brero Sánchez, R. Álvarez Pérez, J. Cuenca Cuenca, E. Carrillo 18F-Choline PET / TC. Our experience EP-155 Cruz, J. Tirado Hospital, J. Jiménez-Hoyuela García; diffuse extranodal involvement P. Plaza López1, E. Puertas1, J. Aguiló1, B. Domenech1, S. Sanjosé1, Virgen del Rocio University Hospital, Seville, SPAIN. N. Filizoglu, S. Kesim, C. O. Engur, K. Oksuzoglu, S. Ozguven, T. M. Suarez-Piñera2, E. Rivera3, J. Casals1, J. Chicharo4; Corticomedullary mixed tumor of the adrenal gland with Ones, H. T. Turoglu, T. Y. Erdil; 1Hospital Quironsalud Barcelona, Barcelona, SPAIN, 2Hospital del apparent 18F-FDG activity but no 68Ga-DOTATATE uptake PET / CT Imaging in Smoldering Multiple Myeloma Marmara University Pendik Training and Research Hospital, Mar Barcelona, Barcelona, SPAIN, 3Hospital Dexeus Barcelona, 4 on PET/CT Patients F 18-Fluorodeoxyglucose and Ga68-Pentixafor: Istanbul, TURKEY. Barcelona, SPAIN, Cimes. Fundación General Universidad de 1 2 1 2 1 Málaga., Málaga, SPAIN. C. Engur , T. Apaydin , T. Ones , H. I. Gozu , T. Y. Erdil ; Preliminary results 1 Marmara University Pendik Training and Research Hospital, U. Korkmaz, E. G. Umit, G. Durmus-Altun; 2 EP-23 EP-173 Istanbul, TURKEY, Marmara University Pendik Training and Trakya University, Edirne, TURKEY. Research Hospital, Endocrinology Department, Istanbul, TURKEY. Imaging Clinical Studies -> Oncological 18 Imaging Clinical Study -> Prostate BC Predictors Of Positivity Of [ F]F-Choline PET-CT In EP-160 Recurrence Prostate Cancer Recurrence. Preliminary Results EP-156 L. Nieto Morcillo, M. Falgás Lacueva, L. de la Cueva Barrao, A. 11C-Methionine and 18F-FDG PET/CT in multiple myeloma: Borque Fernando, A. Méndez Villamón, I. Guerrero Fernández de Influence of somatostatin analogue type for result of Comparative study e-Poster Area Alba, M. Calderón Calvente, G. Guzmán Prudencio, L. del Barco 68Ga-somatostatin analogue PET/CT and its effect on O. Cuenca-Vera1, M. de Arcocha-Torres1, I. Martínez-Rodríguez1, Diez Canseco, D. Abós Olivares; therapeutic decisions in patients with neuroendocrine R. Quirce1, J. Jiménez-Bonilla1, A. Sánchez-Salmón1, N. Martínez- Hospital Universitario Miguel Servet, Zaragoza, SPAIN. 1 1 1 neoplasm - which result to believe? - case study Amador , G. Molina-Mendoza , J. Andrés-Pacheco , Á. Gutiérrez- González1, S. Ruiz Llama1, A. Bermúdez2, I. Banzo1; EP-174 M. Opalinska1, A. Sowa-Staszczak2,1, K. Skórkiewicz1, M. Buziak- 1Nuclear Medicine Service. Marqués de Valdecilla University EP-168 Bereza2,1, A. Stefańska1, A. Hubalewska-Dydejczyk2,1; Hospital. Molecular Imaging Group (IDIVAL). University of Evaluation Of 18F-Fluorocoline PET-CT Findings In Patients 1Nuclear Medicine Unit, Endocrinology Department, University Cantabria, Santander, SPAIN, 2Hematology Service. Marqués de 68Ga-PSMA-11 PET/CT detection rate in very low risk With Suspicion Of Prostate Cancer Tumor Recurrence And

208 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 209 Gleason <7 Or PSA <2ng / mL Prior To PET Andrés-Pacheco, Á. Gutiérrez-González, S. Ruiz Llama, I. Banzo; Primary staging of untreated prostate cancer in two- Clinical Studies -> Other Clinical Studies S. Garcia Martinez, Á. Baena García, M. De Bonilla Candau, M. Nuclear Medicine Service, Marqués de Valdecilla University phase Ga-68-PSMA-11 PET/CT: The clinical impact of semi- Hospital, Molecular Imaging Group (IDIVAL), University of Cruz Montijano, J. Rodríguez-Rubio Corona; quantitative parameters Puerta del Mar University Hospital, Cadiz, SPAIN. Cantabria, Santander, SPAIN. e-Poster Area F. Weitzer1, B. Pernthaler2, R. Riedl3, R. M. Aigner2; 1Medical University of Graz, Graz, AUSTRIA, 2Medical University EP-24 EP-181 of Graz, Department of Radiology, Division of Nuclear Medicine, Imaging Clinical Studies -> Oncological Graz, AUSTRIA, 3Medical University of Graz, Institute for Medical Imaging Clinical Study -> Prostate Other The Relationship Between Four Parameters: 68Ga PSMA Informatics, Statics and Documentation, Graz, AUSTRIA. EP-190 PET/CT, Gleason Score, PSA Levels and Metastasis C. Sezgin, G. Mutevelizade, Y. Parlak, G. Gumuser, E. Sayit; EP-186 Measurement of blood flow of thoracic vertebral body

e-Poster Area Celal Bayar University, Faculty of Medicine, Department of Nuclear using O-15 water PET Medicine, Manisa, TURKEY. The Role Of Fluciclovine 18F-FACBC-PET/CT In The K. Matsunaga, M. Yanagawa, E. Shimosegwa, J. Hatazawa; Characterization Of High Risk Primary Prostate Osaka University, Suita city, JAPAN. EP-182 Cancer: Comparison With 11C-Choline-PET/CT And EP-192 Histopathological Analysis EP-175 Requirements and complexity: interprofessional R. Mei1,2, L. Maltoni2, L. Zanoni1, C. Pultrone3, F. Giunchi4, C. Nanni1, cooperation within a prospective multicenter clinical trial Paget’s Disease on Bone Scintigraphy: the Role of EANM’20 EANM’20 I. Bossert5, A. Matti2, R. Schiavina3, M. Fiorentino4, L. Bianchi3, C. EANM’20 Comparison between 99mTc-MDP bone scintigraphy 68 using [ Ga]Ga-PSMA-11 - The German Cancer Consortium Fonti1, F. Lodi1, E. Brunocilla3, S. Fanti1,2; Scintigraphic Patterns and Bone SPECT/CT in Diagnosis combined with SPECT/CT and 68Ga-PSMA PET/CT in (DKTK) experience 1Nuclear Medicine Policlinico S.Orsola-Malpighi, Bologna, ITALY, H. Turoglu, S. Kesim, C. O. Engur, N. Filizoglu, S. Ozguven, K. evaluation of bone involvement in patients with prostate O. Neels1,2, C. Zippel3,2, S. Biedenstein4, F. L. Giesel4,5,6, K. Kopka1,5,7; 2DIMES, University of Bologna, Bologna, ITALY, 3Urology, AOU di Oksuzoglu, S. Inanir, T. Ones, T. Y. Erdil; cancer. Preliminary results 1Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Bologna Policlinico S.Orsola-Malpighi, Bologna, ITALY, 4Pathology, Marmara University Istanbul Pendik Training and Research AOU di Bologna Policlinico S.Orsola-Malpighi, Bologna, ITALY, Hospital, Istanbul, TURKEY.

WORLD LEADING MEETING G. Mateva, M. Garcheva-Tsacheva; Radiopharmaceutical Cancer Research, Dresden, GERMANY, WORLD LEADING MEETING 5 Acibadem CityClinic Mladost, Sofia, BULGARIA. 2Formerly: German Cancer Research Center (dkfz), Heidelberg, Nuclear Medicine, Istituti Clinici Scientifici Maugeri, Padua, ITALY. GERMANY, 3Witten/Herdecke University, Faculty of Management EP-193 and Economics, Witten, GERMANY, 4University Hospital Heidelberg, EP-177 Department of Nuclear Medicine, Heidelberg, GERMANY, 5German EP-187 Audit Of Reporting Ventilation-Perfusion (V/Q) Lung Cancer Consortium (DKTK), Heidelberg, GERMANY, 6German Scans In Pregnancy Over A Decade Apart And Across Two PET/CT with 11C-Choline, 68Ga-PSMA, 18F-FACBC in Cancer Research Center (dkfz), Clinical Cooperation Unit Nuclear The Value of the Gleason Score and the Initial PSA Different Institutions castration resistant prostate cancer patients: evaluation Medicine, Heidelberg, GERMANY, 7German Cancer Research Center (Prostate Specific Antigen) Level in Predicting the Results G. Shabo; of MTV and TLA (dkfz), Heidelberg, GERMANY. of Bone Scan in Patients with Newly Diagnosed Prostate University Hospital Lewisham, London, UNITED KINGDOM. E. Tabacchi1, G. Argalia1, S. Vichi1, C. Malizia1, C. Fonti1, F. Massari2, Cancer 2 2 2 1 1 EP-183 V. Mollica , V. Di Nunno , E. Nobili , C. Nanni , S. Fanti ; M. Habbache, Q. Naili, M. Abdi, B. Said; 1 EP-194 Nuclear Medicine, S.Orsola-Malpighi Hospital, DIMES University of Nuclear medicine Center or Blida, Algier, ALGERIA. Bologna, Bologna, ITALY, 2Division of Oncology, S.Orsola-Malpighi Meningeal carcinomatosis in patients with a diagnosis of Hospital, Bologna, ITALY. prostate carcinoma visualized in [18F]18F-PSMA, report Incidental Findings on Single-Photon Emission of three cases EP-188 Computerized Tomographic (SPECT) Studies M. Acuña Hernandez1, Q. Pitalua Cortes2; J. Koutsikos1,2, S. Episkopopoulou1, S. Mpakalis1, S. Vasileiou1, K. EP-178 1Universidad Autónoma de Bucaramanga, Bucaramanga, The Relationship Between The SUVmax Value Obtained Athanasiou1, S. Giourgouli2, A. Kokkini-Pashou1; Santander, COLOMBIA, 2Instituto Nacional de Cancerología in Ga-68 PSMA PET / CT Examination and LDH and ALP in 1401 General Army Hospital, Athens, GREECE, 2Henry Dunant Assessment of Bone Metastasis Using Deep Learning (INCan), Ciudad de México, MEXICO. Prostate Cancer Patients Hospital Center, Athens, GREECE. Software in Prostate Cancer Patients: Correlation with Z. Hasbek, I. Salk, S. A. Erturk, B. Yücel, Ö. Ulaş Babacan, G. Gökçe, Evaluation by Experts R. T. Bulut; EP-195 K. Nomura, M. Nakayama, A. Okizaki; EP-25 Sivas Cumhuriyet University School of Medicine, Sivas, TURKEY. Asahikawa Medical University, Asahikawa, JAPAN. Imaging Clinical Studies -> Oncological Exploratory study of the utility of clinical images with half Imaging Clinical Study -> Prostate Staging dose 18F-FDG in a Biograph Vision PET/CT system EP-189 S. Tagawa, A. Ohnishi, A. Ohhashi, K. Hayashi, M. Nobuhara, N. EP-179 Sakamoto, T. Nakamura; Dual-phase 68Ga-PSMA-11 PET/CT may increase rate of e-Poster Area Kakogawa Central City Hospital, Kakogawa, JAPAN. Incidence of lung nodules positive at 68Ga-PSMA-11 PET/ detected Lesions in Low PSA Levels of Prostate Cancer CT- a single center experience M. Assadi1, H. Dadgar2, N. Norouzbeigi2, F. Emami2, H. EP-196 S. Telo, A. Farolfi, R. Mei, S. Mattoni, L. Calderoni, P. Castellucci, S. Ahmadzadehfar3; Fanti; 1Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, Can we really trust bone scan for condylar hyperplasia? Nuclear Medicine, Policlinico S.Orsola-Malpighi, Bologna, ITALY. EP-184 ISLAMIC REPUBLIC OF, 2Razavi Cancer Research Center, Razavi D. Calabro’1, R. Mei1, G. Argalia1, L. Vetrone1, N. Fraccascia1, R. Hospital, Mashhad, IRAN, ISLAMIC REPUBLIC OF, 3Klinikum Bonfiglioli2, E. Tabacchi2, M. Levorato2, S. Fanti1; EP-180 Ga 68 PSMA PET/CT at the initial staging of high risk Westfalen, Knappschaft Hospital, Dortmund, GERMANY. 1Nuclear Medicine, S.Orsola-Malpighi Hospital, DIMES University 2 patients with prostate cancer of Bologna, Bologna, ITALY, Nuclear Medicine, S.Orsola-Malpighi 11 C-Choline PET/CT Performance in Prostate Cancer V. Prassopoulos, T. Pipikos, D. Kechagias, V. Filippi, F. Vlachou, J. Hospital, Bologna, ITALY. Surveillance. Ten Years Evaluation of Effectiveness Andreou, K. Dalianis, R. Efthymiadou; EP-26 F. Gomez-De La Fuente, I. Martínez-Rodríguez, M. de Arcocha- PET/CT department, Hygeia Hospital, Athens, GREECE. Imaging Clinical Studies -> Other Imaging EP-197 Torres, R. Quirce, J. Jiménez-Bonilla, A. Sánchez-Salmón, N. Martínez-Amador, G. Molina-Mendoza, O. Cuenca-Vera, J. EP-185 Whole-body PET/CT recognizes two distinct patterns of

210 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 211 osteolytic lesions in adult Langerhans cell histiocytosis Radioguided Occult Lesion Localization of Pulmonary de Patología Mamaria. Hospital Clínico Universitario Virgen Alydra Index, a Tool for Quantifing the Drainage in the R. Wang, M. Su, R. Tian; Nodules in Video-Assisted Thoracic Surgery: Initial de la Victoria, Málaga, SPAIN, 3Departamento de Radiología. Preoperative Lymphoscintigraphy for Breast Cancer Universidad de Málaga, Málaga, SPAIN. 1 2 1 Sichuan University West China Hospital, Chengdu, CHINA. Experience J. Alors-Ruiz , F. Sendra-Portero , B. D. Patrût , A. Montellano- A. Cánoves-Llombart1, H. Rodríguez-Parra1, I. Casáns-Tormo1, M. Fenoy1, F. Fernández-García3, S. Sanz-Viedma1; EP-198 Redal-Peña1, V. Carrero-Vásquez1, J. Sabater-Sancho1, P. Cárcamo- EP-207 1UGC Medicina Nuclear. Hospital Clínico Universitario Virgen Ibarra1, M. Rengel-Ruiz2, S. Figueroa-Almanzar3, R. Wins-Birabén3, de la Victoria, Málaga, SPAIN, 2Departamento de Radiología. Small steps driving big changes - How we implemented a G. Galán-Gil3; Sentinel lymph node biopsy in oral squamous cell Universidad de Málaga, Málaga, SPAIN, 3UGC Cirugía General new Gastric Emptying Protocol 1Nuclear Medicine, Valencia, SPAIN, 2Radiology, Valencia, SPAIN, carcinoma: SPECT-CT over planar lymphoscintigraphy y Digestiva. Unidad de Patología Mamaria. Hospital Clínico 3 Universitario Virgen de la Victoria, Málaga, SPAIN. M. Botelho Cruz, A. Pereira, A. Nunes, D. Bailey, C. Sibley-Allen, D. Thoracic Surgery, Valencia, SPAIN. B. Luna1, C. Sampol1,2, V. Lasa1, M. Pastor1, A. Repetto1, N. Orta1,2, Dasgupta, F. Ul-Hassan, A. Eccles; C. Peña1,2; Guy’s and St. Thomas’ Hospital, London, UNITED KINGDOM. EP-203 1Hospital Universitari Son Espases, Palma, SPAIN, 2IdISBa, Palma, EP-213 SPAIN. EP-199 Role Of Double-Phase Parathyroid Scintigraphy With Our experience in Sentinel lymph node biopsy after SPECT-TC, Probe And Portable Gamma Camera In The EP-208 neoadjuvant chemotherapy treatment Conceptions of quality of nuclear medicine care services: Detection And Extraction Of Parathyroid Adenomas A. Utrera, M. Agudelo, J. Bernal, J. Cañon, P. Olivan, A. Yepes, P. The Diagnostic Value Of Hybrid SPECT/CT For Sentinel A prospective two-center study P. Turbay Eljach, M. González Soto, B. Pérez López, A. Sainz Bello, V. Vera; 1 2 3 4 Lymph Node Mapping In Patients With Malignant Hospital la Fe, Valencia, SPAIN. EANM’20 EANM’20 E. Giannoula , I. Katsikavelas , N. Papadopoulos , C. Sachpekidis , Esteban, N. Álvarez Mena, F. Sebastián Palacid, M. Alonso EANM’20 A. Doumas1, F. Spyroglou1, V. Chatzipavlidou5, I. Iakovou1; Rodríguez, C. Gamazo Laherrán, M. Ruíz Gómez, R. Ruano Pérez; Melanoma. Comparison To Dynamic Planar Radioisotopic 1 EP-214 Nuclear Medicine dpt of Aristotle University AHEPA Academic hsp, Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN. Lymphoscintigraphy 2 Thessaloniki, GREECE, Faculty of Engineering, Aristotle University 1 1 2 1 3 M. Stathaki , N. Kapsoritakis , D. Michelakis , O. Bourogianni , E. of Thessaloniki, Thessaloniki, GREECE, G.Gennimatas hsp, 1 1 2 1 Sentinel lymph node biopsy in oral cavity squamous cell 4 Papadaki , A. Tsaroucha , E. De Bree , S. Koukouraki ; Thessaloniki, GREECE, Clinical Cooperation Unit Nuclear Medicine, EP-204 1 carcinoma: our experience

WORLD LEADING MEETING Nuclear Medicine Department, University Hospital, Heraklion- WORLD LEADING MEETING German Cancer Research Center, Heidelberg, GERMANY, 5Nuclear Crete, GREECE, 2Department of Surgical Oncology, University D. Monachello Araujo, C. Escabias del Pozo, L. García Zoghby, Medicine dpt of THEAGENEIO Anticancer hsp, Thessaloniki, γ-probe guided minimally invasive parathyroidectomy in Hospital, Heraklion-Crete, GREECE. D. Travaglio Morales, E. López Llobet, J. Cebrian Carretero, P. Losa GREECE. selected cases of solitary parathyroid adenomas Muñoz, A. Guzmán Cruz, L. Domínguez Gadea; I. Iakovou1, T. Papavramidis2, E. Giannoula1, F. Spyroglou1, G. Hospital Universitario La Paz, Madrid, SPAIN. EP-200 Gerasimou1, E. Papanastasiou3, A. Doumas1; EP-209 1Nuclear Medicine dpt of Aristotle University AHEPA Academic EP-215 Relevance of investigation of deep lymphatic vessels hsp, Thessaloniki, GREECE, 21st Propedeutic Surgery dpt of Aristotle Survival Analysis in Patients with cN0 Breast Cancer in lower limbs lymphoscintigraphy: a single Center University AHEPA Academic hsp, Thessaloniki, GREECE, 3Laboratory who underwent Selective Lymph Node Biopsy after Role of selective sentinel node biopsy in T2-3 experience of Medical Physics dpt of Aristotle University AHEPA Academic hsp, Neoadjuvant Chemotherapy breast carcinomas converted to T0-1 after receiving Thessaloniki, GREECE. C. Dolci1, R. Dentici2, A. F. Scarale1, A. Capozza1, A. Franchini3, I. J. Alors-Ruiz1, S. Sanz-Viedma1, A. Montellano-Fenoy1, B. D. neoadjuvant chemotherapy Gotuzzo3, E. Gay1, G. Cabrini1, M. Milella1, C. Rossetti1; Patrût1, R. Gómez-Pérez2, F. Sendra-Portero3; P. Turbay Eljach, A. Sainz Esteban, B. Pérez López, M. González 1Nuclear Medicine Unit, ASST Grande Ospedale Metropolitano EP-205 1UGC Medicina Nuclear. Hospital Clínico Universitario Virgen de la Soto, N. Álvarez Mena, F. Sebastián Palacid, M. Alonso Rodríguez, Niguarda, Milan, ITALY, 2Nuclear Medicine Unit, ASST Rhodense, Victoria, Málaga, SPAIN, 2UGC Cirugía General y Digestiva. Unidad C. Gamazo Laherrán, M. Ruíz Gómez, R. Ruano Pérez; Caduti Bollatesi Hospital, Bollate, ITALY, 3Nuclear Medicine, 18F-FDG PET/CT in staging and delineation of tumoral de Patología Mamaria. Hospital Clínico Universitario Virgen Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN. University Milano-Bicocca, Milan, ITALY. volume in radiotherapy planning de la Victoria, Málaga, SPAIN, 3Departamento de Radiología. F. Manchon Adsuar, V. Lopez Prior, R. Diaz Exposito; Universidad de Málaga, Málaga, SPAIN. EP-201 Fundacion Instituto Valenciano De Oncologia, Valencia, SPAIN. EP-216 EP-210 FDG-PET/CT in neurofibromatosis type 1: the experience In the sites of blinding lights: the role of of a reference center EP-28 Sentinel lymph node detection in breast cancer patients lymphoscintigraphy in melanoma D. Peres e Leiro Gonçalves Ferraz, I. Patrocínio Carvalho, P. Ratão, Imaging Clinical Studies -> Other Oncological depending on the tracer application site A. Farina1, R. Bonfiglioli1, M. Levorato1, M. Maccagnani1, F. J. Passos, M. Rio Carvalho, M. Silvestre, D. Fraga, I. Vitorino, F. Clinical Study -> Sentinel Node M. Rodrigues, F. Schmidt, R. Moncayo, I. Virgolini; Giorgini2, R. Cipriani2, S. Fanti1; Norton Brandão, R. Sousa, T. Cruz Ferreira, L. Salgado; Department of Nuclear Medicine, Innsbruck Medical University, 1Nuclear Medicine Department, Sant’Orsola-Malpighi Hospital, Instituto Português de Oncologia de Lisboa Francisco Gentil, Innsbruck, AUSTRIA. University of Bologna, Bologna, ITALY, 2Plastic and Reconstructive Lisbon, PORTUGAL. Surgery Department, Sant’Orsola-Malpighi Hospital, University of e-Poster Area EP-211 Bologna, Bologna, ITALY.

EP-27 Sentinel Lymph Node Detection In Patients With EP-217 Imaging Clinical Studies -> Other Oncological Breast Cancer And Positive Axillary Lymph Node After Clinical Study -> Radioguided Surgery and EP-206 Neoadjuvant Chemotherapy Application Of The Sentinel Lymph Node Biopsy In Radiation Therapy Planning P. Cárcamo-Ibarra1, H. Rodríguez-Parra1, M. Redal-Peña1, I. Patients With Axillary Lymph Node Metastasis (cN1) Of Women with cN0 Breast Cancer and Negative Hormonal Casáns-Tormo1, V. Carrero-Vásquez1, A. Cánoves-Llombart1, J. Breast Carcinoma After Neoadjuvant Chemotherapy. Receptors: Is It Time to Reconsider the Use of Sentinel Sabater-Sancho1, U. López-González2, M. Soria-Merino1; Triple Marking Protocol 1 e-Poster Area Lymph Node Biopsy After Neoadjuvant Chemotherapy? Nuclear Medicine. Universitary Clinic Hospital, Valencia, SPAIN, C. Sampol1,2, P. Camarasa3, O. Cordoba4, L. Carrillo4, A. Lopez5, G. 2 J. Alors-Ruiz1, B. D. Patrût1, S. Sanz-Viedma1, A. Montellano-Fenoy1, Preventive Medicine. Universitary Dr Peset Hospital, Valencia, Matheu6, A. Pozo3, A. Perello7, A. Repetto1, C. Peña1,8; F. Fernández-García2, F. Sendra-Portero3; SPAIN. 1Nuclear Medicine. Hospital universitario Son Espases, Palma De 1UGC Medicina Nuclear. Hospital Clínico Universitario Virgen de la Mallorca, SPAIN, 2IDISBA, Palma de Mallorca, SPAIN, 3Radiology. Victoria, Málaga, SPAIN, 2UGC Cirugía General y Digestiva. Unidad EP-212 Hospital universitario Son Espases, Palma De Mallorca, SPAIN, EP-202

212 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 213 4Gynecology department. Hospital universitario Son Espases, 1Nuclear Medicine, Ancona, ITALY, 2Pediatric Endocrinology and EP-227 3D Volume Rendering Model and Pixelated Quantitative Palma De Mallorca, SPAIN, 5Plastic Surgery. Hospital universitario Diabetology, Ancona, ITALY. CT for Accurate Assessment of the Extent and Severity of 6 Son Espases, Palma De Mallorca, SPAIN, Anamopathology 99m Usefulness of Tc-Besilesomab in infection after fracture Patients with COVID-19 department. Hospital universitario Son Espases, Palma De EP-223 osteosynthesis: our experience M. Masoomi, L. Alkhandari, I. Alshammeri, H. ELrahman, H. Mallorca, SPAIN, 7Oncology. Hospital universitario Son Espases, Ramsy, S. Almutairi; Palma De Mallorca, SPAIN, 8IDISBA, Palma De Mallorca, SPAIN. P. Guardia Jimena, M. Martínez del Valle Torres, M. Bermúdez The role of split function quantification of kidney Morales, R. Arenas Aguaza, M. Sánchez Torrente, A. Castro López, ADAN Hospital- MOH, Kuwait, KUWAIT. segments using DMSA scan in the choice of appropriate E. Moratalla Aranda, A. Villena García, R. Nieto Serrano, D. Becerra EP-218 treatment in children with ren duplex or duplicated García; EP-234 Hospital Universitario Clínico San Cecilio, Granada, SPAIN. collecting system - a retrospective study Relevance of Lymphoscintigraphy for Detection of the 1 1 2 3 4 Prevalence of incidental pneumonia consistent with D. Chroustova , L. Cerna , J. Trnka , J. Langer , R. Kocvara , D. EP-228 Sentinel Lymph Node in Males with Breast Cancer Zogala1, L. Lambert5; COVID19 infection an 18F-Fcholine (FCH) PET/CT in N. Álvarez Mena, F. Sebastián Palacid, P. Turbay Eljach, B. Pérez 1Institute of Nuclear Medicine, Charles University - 1st Faculty patients referred for prostate cancer Hybrid imaging in muscular sarcoidosis López, M. Alonso Rodríguez, C. Gamazo Laherrán, A. Sainz of Medicine and General University Hospital, Prague, CZECH L. Turpin1, Q. Pouliot1, J. Zhang1, B. Sgard1, M. Glikman2, F. Denise1, 1 2 2 Esteban, M. Ruiz Gómez, M. González Soto, R. Ruano Pérez; REPUBLIC, 2Department of Medical Physics, General University I. Grozdic Milojevic , D. Sobic-Saranovic , V. Artiko ; J. Talbot1, F. Montravers1; 1 2 Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN. Hospital, Prague, CZECH REPUBLIC, 3Clinic of Paediatrics and Clinical Center of Serbia, Belgrade, SERBIA, Clinical center of 1Hôpital Tenon, Paris, FRANCE, 2Medical office, Pantin, FRANCE. Adolescent Medicine, Charles University - 1st Faculty of Medicine Serbia, Belgrade, SERBIA.

EANM’20 EANM’20 and General University Hospital, Prague, CZECH REPUBLIC, EANM’20 EP-29 4Clinic of Urology, Charles University - 1st Faculty of Medicine EP-229 EP-235 Imaging Clinical Studies -> Paediatric Imaging and General University Hospital, Prague, CZECH REPUBLIC, Study -> Paediatric Study 5Radiodiagnostic clinic, Charles University - 1st Faculty of Medicine The diabetes impact on the course of community- Deployment of a Dedicated “Covid-19” CT in Nuclear and General University Hospital, Prague, CZECH REPUBLIC. acquired pneumonia according to ventilation Medicine : Strategic Issues in the Context of an Epidemic scintigraphy Emergency WORLD LEADING MEETING EP-224 WORLD LEADING MEETING e-Poster Area V. Udodov, A. Zaitseva, V. Zavadovskaia, E. Bukreeva, I. Degtyarev, E. Itti, T. Pillon, D. Giacometti, E. Brimboeuf, T. Barbosa, N. Ambiehl, M. Zamyshevskaya, M. Zorkaltsev, T. Saprina; D. Bazas, S. Mekhail, J. Chalaye, M. Milliner, A. Quilichini, C. Simplify scoring System vs SIOPEN in prognosis risk SSMU, Tomsk, RUSSIAN FEDERATION. Lhermite, A. Maraval, H. Kobeiter, A. Luciani, P. Blanc-Durand; assessment in Neuroblastoma CHU Henri Mondor, AP-HP, U-PEC, Creteil, FRANCE. C. Olianti1, M. Allocca2, A. Martini2, A. Tondo3, H. Gauthier4; EP-219 1University Hospital of Florence, Florence, ITALY, 2University of EP-230 Florence, Florence, ITALY, 3University Hospital Meyer, Florence, ITALY, EP-236 Re-staging post therapy with radioactive iodine and 4Oscar Lamberet Center, Lille, FRANCE. Metabolic Features of Patients with COVID-19 Lung follow-up in pediatric patients with thyroid cancer Infection: Contribution of 18 FDG-PET / CT The Novel Coronavirus: Our Experience in Facing an T. Tairo-Cerron1,2, R. Morales-Guzman-Barron1, R. Ledesma- EP-225 J. Ardila Mantilla, A. Rotger Regí, M. Baquero Oliveros, A. Marí Invisible Enemy Vasquez1, P. Saavedra-Sobrados1, L. Araujo-Cachay1, D. Valdivia- Hualde, J. Orcajo Rincón, I. Gómez Fernández, C. Durán Barquero, L. Cunha1, P. Ratão1,2, A. Roda1,3, M. Capoulas1,4, F. Ferreira1, M. Alvarado1; Experience in our center of pediatric thyroid scintigraphy: D. Zamudio Rodríguez, Y. Henao Celada, J. Atance García de la Sousa5, H. Vasconcelos6, A. S. Moreira1, L. F. Metello1,7; 1Department of Nuclear Medicine, National Institute of Neoplastic a useful tool for the etiologic diagnosis of congenital Santa, J. C. Alonso Farto; 1IsoPor-Azores, Angra do Heroismo, PORTUGAL, 2Nuclear 2 3 Diseases, Lima, PERU, Universidad Peruana Cayetano Heredia, hypothyroidism Hospital General Univeristario Gregorio Marañón, Madrid, SPAIN. Medicine Department, IPOFG, Lisbon, PORTUGAL, Medical 4 Lima, PERU. G. Castillo Simón, V. Rodriguez Morales, C. Martínez Ramos, Physics Department, IPOFG, Coimbra, PORTUGAL, Pharmacy 5 B. Núñez Arana, I. Dominguez-Prado, J. Muñoz Iglesias, F. Loira EP-231 Department, HBA, Loures, PORTUGAL, Interdisciplinary Studies 6 EP-220 Bamio; Research Center, ISEP.IPP, Porto, PORTUGAL, Sc. Techn. Fac., Univ. 7 Hospital Meixoeiro, Vigo, SPAIN. Clinical Manifestations of Patients with Pulmonary Azores, Ponta Delgada, PORTUGAL, ESS-IPP, Porto, PORTUGAL. The effect of manual and automatic motion correction on Abnormalities in 18 FDG-PET with COVID-19 Infection the result of radiorenography in infants J. Ardila Mantilla, A. Rotger Regí, M. Baquero Oliveros, A. Marí EP-239 T. Czékus1, S. Urbán1, D. Hirling2, J. Csirik2, L. Pávics1; EP-30 Hualde, J. Orcajo Rincón, I. Gómez Fernández, C. Durán Barquero, 1Department of Nuclear Medicine, University of Szeged, Szeged, Inflammation & Infection D. Zamudio Rodríguez, Y. Henao Celada, J. Atance García de la Casual cases of nuclear medicine examinations in HUNGARY, 2Department of Computer Algorithms and Artificial Santa, J. C. Alonso Farto; Patients with concurrent/subsequent diagnosis of Intelligence, Szeged, HUNGARY. Hospital General Univeristario Gregorio Marañón, Madrid, SPAIN. COVID-19 1 2 2 2 e-Poster Area C. Olianti , D. Malandrino , T. Tagliente , M. Allocca ; EP-221 EP-232 1University Hospital of Florence, Florence, ITALY, 2University of Florence, Florence, ITALY. Added value of SPECT/CT for diagnosing biliary atresia 18F-FDG and 18F-Fluorocholine PET/CT findings in T. Andersen, R. Aleksyniene, L. J. Pedersen; symptomatic and asymptomatic patients with COVID-19, Department of Nuclear Medicine, Aalborg, DENMARK. EP-226 a French case series EP-31 S. Mekhail, J. Chalaye, B. Emsen, L. Lerman, E. Evangelista, Movement Disorders EP-222 The role of three-phase bone scintigraphy in indentifying M. Abulizi, J. M. Israel, S. Bonnot-Lours, M. Marie, M. Borel, M. complications after hip replacement in liquidators of Gueremy, S. Hamel, C. Juin, S. Larrous, N. Latouche, N. Marin, P. Early Diagnosis of Focal Congenital Hyperinsulinism: a accident at the Chernobyl Nuclear Power Plant with septic Blanc-Durand, E. Itti; e-Poster Area (18 Fluorine-18-labeled Ldihydroxyphenylalanine F-DOPA) and aseptic osteoarthrosis Nuclear Medicine Department, Henri Mondor Hospital APHP, PET/CT study P. Korol1, M. Tkachenko2, N. Ponomarenko1; UPEC, Créteil, FRANCE. L. Burroni1, F. Fringuelli1, G. Biscontini1, A. Palucci1, C. Romagnolo1, 1Kiev Clinic City Hospital # 12, Kiev, UKRAINE, 2A.A. Bohomolets C. Cottignoli1, A. Iannilli2, M. Marino2, V. Cherubini2; EP-233 National Medical University, Kiev, UKRAINE. EP-242

214 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 215 Role of Functional Neuroimaging in early onset Different Origin /820 patients/ KOREA, REPUBLIC OF. Other Medical Preclinical Parkinson’s disease, 123I-MIBG - DaTscan, a multicenter M. Szentesi, Z. Nagy, G. Csőre; study Hospital of the Hospitaller Brothers of St. John of Budapest, EP-251 Budapest, HUNGARY. e-Poster Area J. Lazri1, A. Di Rocco1, S. Nuvoli2, M. L. Stazza2, M. Rondini2, M. S. De Feo1, L. Cosma1, V. Frantellizzi1, A. Farcomeni3, G. De Vincentis1, A. Determination of embolic brain distribution caused by Spanu2; EP-247 right to left shunt in people with patent foramen ovale 1Sapienza University of Rome, Rome, ITALY, 2University of Sassari, M. Assadi, R. Nemati, M. Jalali, H. Salimipour, A. Amini, E. Jafari; Sassari, ITALY, 3University of Rome Tor Vergata, Rome, ITALY. Knee radiosynovectomy with Sm-153 hydroxyapatite Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, EP-256 compared to Y-90 hydroxyapatite: initial results of a ISLAMIC REPUBLIC OF. EP-243 prospective trial Targeted pharmacological inhibition and kinetic 99m E. Etchebehere1, M. Lima1, L. Pereira1, R. Pagnano1, E. Bortoletti2, J. EP-252 modeling to improve the performance of [ Tc] Impact of dopamine depletion on gait initiation in Mengatti2, S. Q. Brunetto1, M. Takahashi1, E. Brunetto1, M. Ozelo1, A. mebrofenin as probe to study MRP2 activity at the liver- 1 Association of dizziness and brain perfusion SPECT : Parkinson’s disease Santos ; bile interface 1 2 2 3 2 1 2 voxel-based analysis of a pilot sample G. Marotta , C. Palmisano , G. Brandt , M. Vissani , N. G. Pozzi , A. The University of Campinas, Campinas, BRAZIL, Institute of S. Marie1, I. Hernández-Lozano2, L. Breuil1, W. Saba1, M. Goislard1, 4 2 2 3 5 1 1 1 1 1 2 Canessa , J. Brumberg , J. Volkmann , A. Mazzoni , C. A. Frigo , I. U. Research and Nuclear Energy (IPEN), Sao Paulo, BRAZIL. M. Assadi , R. Nemati , M. Nayeri , N. Chabi , E. Jafari , H. Dadgar ; A. Novell1, J. Gennisson1, O. Langer2, C. Truillet1, N. Tournier1; 2 1 Isaias ; Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, 1Laboratoire d’Imagerie Biomédicale Multimodale (BIOMAPS), 1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, ISLAMIC REPUBLIC OF, 2Razavi Cancer Research Center, Razavi EANM’20 EANM’20 Université Paris-Saclay, CEA, CNRS UMR9011, Inserm UMR1281, EANM’20 2 Milan, ITALY, University Hospital Würzburg and Julius- EP-33 Hospital, Mashhad, IRAN, ISLAMIC REPUBLIC OF. Service Hospitalier Frédéric Joliot, Orsay, FRANCE, 2Department Maximilian-University, Department of Neurology, Würzburg, of Clinical Pharmacology, Medical University of Vienna, Vienna, 3 Other Neurological Imaging GERMANY, Scuola Superiore Sant’Anna, The Biorobotics EP-253 AUSTRIA. Institute, Translational Neural Engineering Area, Pontedera, ITALY, 4Department of Informatics, Bioengineering, Robotics DWI and SPECT findings in patients with acute ischemic e-Poster Area WORLD LEADING MEETING and System Engineering, Università di Genova, Genova, ITALY, stroke EP-257 WORLD LEADING MEETING 5Politecnico di Milano, Department of Electronics, Information M. Assadi, A. Moradi, M. Emami, K. Mirzaei; and Bioengineering, MBMC Lab, Milan, ITALY. Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, PET and MR imaging for in ovo evaluation of nanoparticle ISLAMIC REPUBLIC OF. biodistribution EP-244 EP-248 J. Loeffler1,2, N. Eberhardt2, R. Fiedler3, M. Lau3, M. Raabe4, M. N. Alam4, A. B. Koch2, E. Scheidhauer2, A. Abaei1, H. Herrmann2, C. Brain metabolic alterations herald falls in patients with Disentangling conscious visual processing by a EP-34 Solbach2, T. Weil5, M. Lindén3, F. Jelezko6, A. J. Beer2, V. Rasche7,1, G. Parkinson’s disease multimodal approach in disorders of consciousness Preclinical Studies -> Preclinical Studies -> In Winter2; G. Marotta1, J. Brumberg2, N. Pozzi2, J. Volkmann2, G. Pezzoli3, I. U. G. Marotta1, D. Sattin2, D. Rossi Sebastiano2, L. D’Incerti2, D. Guido2, Vitro Studies 1Ulm University, Core Facility Small Animal Imaging, Ulm, Isaias2; E. Orunesu1, R. Benti1, S. Tirelli2, F. G. Magnani2, A. Bersano2, D. GERMANY, 2Ulm University Medical Center, Department of 1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Duran2, S. Ferrero2, L. Minati2, A. Nigri2, C. Rosazza2, S. B. Marzoli3, Nuclear Medicine, Ulm, GERMANY, 3Ulm University, Department Milan, ITALY, 2University Hospital Würzburg and Julius-Maximilian- M. Leonardi2; of Inorganic Chemistry II, Ulm, GERMANY, 4Max Planck Institute e-Poster Area University, Department of Neurology, Würzburg, GERMANY, 3ASST 1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, for Polymer Research, Synthesis of Macromolecules Department, G.Pini-CTO, Centro Parkinson, Milan, ITALY. Milan, ITALY, 2Fondazione IRCCS Neurologico Carlo Besta, Milan, Mainz, GERMANY, 5Max Planck Institute for Polymer Research, ITALY, 3Istituto Auxologico Italiano, Milan, ITALY. Synthesis of Macromolecules Department, Ulm, GERMANY, 6Ulm University, Institute for Quantum Optics, Ulm, GERMANY, 7Ulm EP-32 EP-249 EP-254 University Medical Center, Department of InternalMedicine II, Experimental Cardiovascular Imaging, Ulm, GERMANY. Non-Oncological Treatments A multimodal assessment of residual language processing Biological Characterization of the 47Sc Labelled PSMA in disorders of consciousness patients Ligand EP-258 1 2 2 2 2 e-Poster Area G. Marotta , S. Ferraro , A. Nigri , L. D’Incerti , C. Rosazza , D. D. Pawlak, W. Wojdowska, M. Żółtowska, M. Wyczółkowska, U. Sattin2, D. Rossi Sebastiano2, E. Visani2, D. Duran2, G. Demichelis2, E. Karczmarczyk, P. Garnuszek, J. L. Parus, R. Mikołajczak; The 5-HT2A receptor antagonist altanserin affects motor Catricala3, S. Kotz4, L. Verga4, M. Leonardi2, S. Cappa3, M. Schiavini1, National Institute for Nuclear Research Radioisotope Centre activity and hippocampal D2 receptor binding in the rat M. F. Bardo1, M. G. Bruzzone2; POLATOM, Otwock, POLAND. S. Nikolaus1, H. Wittsack1, M. Beu1, C. Antke1, H. Hautzel2, Y. Mori1, 1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, E. Mamlins1, G. Antoch1, H. Müller1; EP-245 Milan, ITALY, 2Fondazione IRCCS Neurologico Carlo Besta, Milan, EP-255 1University Hospital Düsseldorf, Düsseldorf, GERMANY, 2University ITALY, 3Scuola Universitaria Superiore, Pavia, ITALY, 4Maastrict Hospital Essen, Essen, GERMANY. Response Assessment At One Year After 131I Treatment In University, Maastricht, NETHERLANDS. Molecular Imaging as a Quantitative Tool to Assess the Patients With Grave’s Disease And Multinodular Goiter in Skin Malaria Parasite Deposition: Mosquito Bites vs. EP-259 V. Carrero-Vásquez, H. Rodríguez-Parra, M. Redal-Peña, I. Casáns- EP-250 Needle Injection Different effects of the 5-HT2A receptor agonist DOI Tormo, A. Cánoves-Llombart, P. Cárcamo-Ibarra, J. Sabater- C. de Korne, B. M. F. Winkel, M. N. van Oosterom, S. C. Chevalley- Sancho, R. Maestre-Cutillas, M. Soria-Merino; Sex difference in Cerebral blood flow and Cerebral Maurel, J. C. Sijtsma, E. Baalbergen, B. M. D. Franke-Fayard, F. W. B. and the 5-HT2A receptor antagonist altanserin on D2 Nuclear Medicine, University Clinical Hospital, Valencia, SPAIN. glucose metabolism: An activation likelihood estimation van Leeuwen, M. Roestenberg; receptor binding in the rat brain Meta-analysis LUMC, Leiden, NETHERLANDS. S. Nikolaus1, H. Wittsack1, M. Beu1, C. Antke1, H. Hautzel2, Y. Mori1, EP-246 K. Pak1, S. Kim2, S. Lee3; E. Mamlins1, G. Antoch1, H. Müller1; 1Pusan National University Hospital, Busan, KOREA, REPUBLIC OF, 1University Hospital Düsseldorf, Düsseldorf, GERMANY, 2University 10-Years Results After 90-Yttrium and 166-Holmium 2Pusan National University Yangsan Hospital, Yangsan, KOREA, EP-35 Hospital Essen, Essen, GERMANY. Radiosynoviorthesis In Chronic Knee Synovitis Of REPUBLIC OF, 3Kyungpook National University Hospital, Daegu, Preclinical Studies -> Preclinical Studies ->

216 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 217 EP-260 preclinical PET study Sugyo1, A. B. Tsuji1, T. Higashi1; L. Peng2, P. Garrigue3, B. Guillet3; F. Ribeiro1, C. Nicolucci2, M. Lapo Pais3,4,5, A. C. Santos4,5,6, P. M. C. 1National Institutes for Quantum and Radiological Science and 1C2VN INSERM 1263 INRA 1260 CERIMED Aix-Marseille Université, 2 2 [89Zr]-labeled mesenchymal stem cells biodistribution in C. Encarnação1, A. L. M. Silva1,7, I. F. Castro7, P. M. M. Correia1,7, V. I. Technology, Chiba, JAPAN, Nihon Medi-Physics Co., Ltd., Tokyo, Marseille, FRANCE, CINaM CNRS, UMR 7325 Aix-Marseille 1 1 2 JAPAN, 3National Cancer Center Hospital East, Kashiwa, JAPAN. Université, Marseille, FRANCE, 3C2VN INSERM 1263 INRA 1260 rats with local radiation injuries Assunção , J. F. C. A. Veloso , D. G. Priolli ; 1Institute for Nanostructures, Nanomedelling and CERIMED, APHM, Aix-Marseille Université, Marseille, FRANCE, O. Klementyeva, K. Luneva, A. Larenkov, V. Bubenschikov, T. 4 Nanofabrication (i3N), University of Aveiro, Aveiro, PORTUGAL, C2VN INSERM 1263 INRA 1260 Aix-Marseille Université, Marseille, Astrelina, V. Brunchukov; EP-273 5 2Multidisciplinary Research Laboratory, São Francisco University, FRANCE, C2VN INSERM 1263 INRA 1260, APHM, Aix-Marseille Federal Medical Biological Agency, Federal State Budget Bragança Paulista, BRAZIL, 3Faculty of Sciences and Technology, Université, Marseille, FRANCE. Institution, State Research Center “Burnasyan”, Moscow, RUSSIAN Relevance of molecular tracer based on Fludarabine for University of Coimbra, Coimbra, PORTUGAL, 4Institute for Clinical FEDERATION. and Biomedical Research (iCBR), Center for Innovative Biomedicine detection and monitoring of primary brain lymphomas 5 evolution EP-278 EP-261 and Biotechnology (CIBB), Coimbra, PORTUGAL, Institute of Biophysics, University of Coimbra, Coimbra, PORTUGAL, 6Faculty of V. Tran1, S. Antoine2,3, M. Mekhfi1, G. Torquet1, F. Assayag2,3, F. The significance of intraperitoneal administration of 18F- Medicine, University of Coimbra, Coimbra, PORTUGAL, 7Radiation Pouzoulet3, F. Caillé1, B. Kuhnast1, A. Kas4, V. Lebon1, C. Soussain2, Time after synthesis does not affect 4FMFES Imaging Technologies Lda (RI-TE), Ílhavo, PORTUGAL. C. Truillet1; FDG in a preclinical mouse model biodistribution and PET imaging 1Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Orsay, Z. Ritter1, K. Zámbó1, P. Balogh2, D. Szöllősi3, J. Xinkai2, D. Dezső1, M. Paquette, S. Phoenix, B. Guérin, É. E. Turcotte; FRANCE, 2Institut Curie, Site de Saint-Cloud, Saint-Cloud, FRANCE, H. Alizadeh4, I. Horváth3, N. Hegedűs3, D. Máthé3, E. Schmidt1; Université de Sherbrooke, Sherbrooke, QC, CANADA. EP-268 3Institut Curie, PSL Research University, Translational Research 1University of Pécs, Department of Diagnostic, Division of Nuclear Department, Experimental Radiotherapy Platform, Orsay, Medicine, Pécs, HUNGARY, 2University of Pécs, Department of EANM’20 EANM’20 EANM’20 EP-262 Social stress-dependent changes on behavior and FRANCE, 4AP-HP Sorbonne Université, Pitié-Salpêtrière hospital, Immunology and Biotechnology, Pécs, HUNGARY, 3Semmelweis inflammatory parameters in animals with HPA-axis Department of Nuclear Medecine, and LIB, Inserm U1146 F-75013, University Faculty of Medicine, Department of Biophysics and 4 Isotonic saline and dimethylsulfoxide differentially affect disruption Paris, FRANCE. Radiation Biology, Budapest, HUNGARY, University of Pécs, 1st Department of Internal Medicine, Pécs, HUNGARY. motor behavior and nigrostriatal and mesolimbic D2 B. Giacobbo1, R. Moraga-Amaro2, L. Reali Nazario2, A. Schildt2, R. A. receptor binding in the rat J. O. Dierckx2, J. Doorduin2, E. F. J. de Vries2; EP-274 WORLD LEADING MEETING WORLD LEADING MEETING S. Nikolaus1, H. Wittsack1, M. Beu1, C. Antke1, H. Hautzel2, Y. Mori1, E. 1Umeå University, Umeå, SWEDEN, 2University Medical Center EP-280 Mamlins1, G. Antoch1, H. Müller1; Groningen, Groningen, NETHERLANDS. Comparative preclinical biodistribution, dosimetry and 1University Hospital Düsseldorf, Düsseldorf, GERMANY, 2University endoradiotherapy in mCRPC of 177Lu-rhPSMA-7.3 and Multi-modal PET and MRI biodistribution studies of Hospital Essen, Essen, GERMANY. 177Lu-PSMA I&T 89Zr-labelled nanodiamonds in mice EP-269 N. Yusufi1, S. Nekolla1, A. Wurzer2, M. Herz1, C. D’Alessandria1, W. N. Eberhardt1, J. Löffler1,2, M. Raabe3, M. N. A. Alam3, H. Li2, A. Weber1, H. J. Wester2, M. Eiber1; Abaei2, H. Herrmann1, C. Solbach1, F. Jelezko4, T. Weil3, A. J. Beer1, V. EP-36 A Single Day of Accelerated rTMS Causes No Cerebral 1Technical University Munich, Klinikum rechts der Isar, Rasche5,2, G. Winter1; Preclinical Studies -> Preclinical Studies -> Glucose Metabolism Change Assessed by FDG-PET in Department of Nuclear Medicine, Munich, GERMANY, 2Technical 1Ulm University Medical Center, Department of Nuclear Medicine, 2 Preclinical Cardiology and Neurology Beagle Dogs University Munich, Chair of Pharmaceutical Radiopharmacy, Ulm, GERMANY, Ulm University, Core Facility Small Animal 3 Y. Xu 1, R. Dockx1, B. J. G. Broeckx2, A. Dobbeleir3, K. Peremans3, J. H. Garching, GERMANY. Imaging, Ulm, GERMANY, Max Planck Institute for Polymer Saunders3, C. Baeken1; Research, Synthesis of Macromolecules Department, Mainz, 4 1Department of Psychiatry and Medical Psychology, Faculty of EP-275 GERMANY, Ulm University, Institute for Quantum Optics, Ulm, e-Poster Area 5 medicine and health sciences, Ghent University, Ghent, BELGIUM, GERMANY, Ulm University Medical Center, Department of 2Department of Nutrition, Genetics and Ethology, Faculty of Preclinical assessment of octreotate-IRDye800CW Internal Medicine II, Experimental Cardiovascular Imaging, Ulm, veterinary medicine, Ghent University, Merelbeke, BELGIUM, for tumor targeting in intracranial meningioma for GERMANY. 3Department of Veterinary Medical Imaging and Small Animal molecular fluorescence guided surgery EP-264 Orthopedics, Faculty of veterinary medicine, Ghent University, B. Dijkstra1, F. A. E. Kruyt2, F. Andreae3, S. E. Dulfer1, M. C. Stroet4, J. EP-281 Merelbeke, BELGIUM. Nonnekens4,5, W. F. A. den Dunnen6, M. de Jong4, R. J. M. Groen1; 64 The heterogeneous effect of chronic hyperglycaemia on 1Department of Neurosurgery, University Medical Center The feasibility of Cu-PSMA I&T for specific PSMA PET brain 18F-FDG uptake: an experimental study Groningen, University of Groningen, Groningen, NETHERLANDS, imagings A. Miceli1, M. Donegani1, S. Raffa1, S. Marra1, V. Cossu1, L. Emionite1, EP-37 2Department of Medical Oncology, University Medical Center I. Lim, S. Woo, C. Lee, K. Song, S. Lim; S. Morbelli1, C. Marini2, G. Sambuceti1, M. Bauckneht3; Preclinical Studies -> Preclinical Studies -> Groningen, University of Groningen, Groningen, NETHERLANDS, Korea Cancer Center Hospital, Seoul, KOREA, REPUBLIC OF. 1DISSAL, Genoa, ITALY, 2CNR Institute of Molecular Bioimaging and Preclinical Oncology 3piCHEM Forschungs und EntwicklungsGmbH, Raaba-Grambach, Physiology (IBFM), Milan, ITALY, 3IRCCS Ospedale Policlinico San AUSTRIA, 4Department of Radiology and Nuclear Medicine, Martino, Genoa, ITALY. Erasmus MC, Rotterdam, NETHERLANDS, 5Department of Molecular Genetics, Erasmus MC, Rotterdam, NETHERLANDS, EP-283 e-Poster Area EP-265 6Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Preclinical tumor imaging with 89Zr-labeled monoclonal Metabolic changes in an animal model of Amyotrophic NETHERLANDS. antibody ramucirumab Lateral Sclerosis by [18F]-Fluorodeoxyglucose Z. Novy1, J. Janousek2, P. Barta2, M. Petrik1, M. Hajduch1, F. Trejtnar2; B. Giacobbo, T. Mediavilla, J. Axelsson, M. Ericsson, D. Marcellino, EP-270 EP-277 1Faculty of Medicine and Dentistry, Olomouc, CZECH REPUBLIC, F. Sultan; 2Charles University in Prague, Hradec Kralove, CZECH REPUBLIC. Umeå University, Umeå, SWEDEN. Feasibility of PET-guided surgery with 64Cu-labeled- Influence of macrocyclic bifunctional chelators on Self- cetuximab for intraoperative resection of residual tumors assembling supramolecular dendrimer nanosystem EP-284 EP-266 in an orthotopic pancreatic tumor mouse model biodistribution and in pancreatic adenocarcinoma Quantification using 2D scintigraphic versus 3D SPECT Y. Yoshii1, C. Igarashi1, H. Tashima1, Y. Iwao1, E. Yoshida1, H. patient derived cells L-IPC Quercetin as a potential psychotherapeutic agent 1 1 1 2 imaging in pre-clinical oncology studies: A Comparative Wakizaka , G. Akamatsu , T. Yamaya , H. Matsumoto , M. B. Louis1, L. Ding2, Z. LYU2, A. Moyon3, A. Bouhlel1, L. Balasse1, S. in a mouse model with acute exposure to cocaine: a Yoshimoto3, F. Hihara1, T. Tachibana1, M. Zhang1, K. Nagatsu1, A. Fernandez1, J. Yifan2, S. Simoncini4, G. Hache3, F. Dignat-George5, Analysis

218 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 219 M. Rouchota1, P. Tsialios2, S. Sarpaki1, M. Georgiou1, L. Feasibility of MR-guided intratumoral treatment with radioembollization absorbed dose monitoring AOU S. Orsola Malpighi - Bologna, Bologna, ITALY. Fysikopoulos1, I. Pilatis3, P. Papadimitroulas1, G. Loudos1; Holmium-166 microspheres in a brain tumor model J. Labour, P. Boissard, F. Khayi, P. Veyrat Durebex, D. Kryza, S. 1 2 BIOEMTECH, Athens, GREECE, Medical School, National and N. Klaassen1, N. Morsink2, M. de Vries3, J. van den Dobbelsteen3, M. Parisse-Dimartino, T. Mognetti, D. Sarrut, J. N. Badel; 3 EP-41 Kapodistrian University of Athens, Athens, GREECE, University of Boswinkel1, S. van Nimwegen2, J. Nijsen1,4; CREATIS; Centre Léon Bérard; CNRS UMR 5220; INSERM U1044; West Attica, Athens, GREECE. 1 Université de Lyon; INSA Lyon; Université Lyon 1, Lyon, FRANCE. Technical Studies -> Dosimetry and Radboud university medical center, Radboud Institute for Radiobiology -> Preclinical Dosimetry and Molecular Life Sciences, Department of Radiology, Nuclear Radiobiology Medicine and Anatomy, Nijmegen, NETHERLANDS, 2Utrecht EP-40 University, Department of Clinical Sciences of Companion Technical Studies -> Dosimetry and EP-38 Animals, Faculty of Veterinary Medicine, Utrecht, NETHERLANDS, 3Delft University of Technology, Department of BioMechanical Radiobiology -> Clinical Dosimetry e-Poster Area Preclinical Studies -> Preclinical Studies -> Engineering, Delft, NETHERLANDS, 4Quirem Medical B.V., Zutphen, Preclinical Therapy NETHERLANDS. e-Poster Area EP-292 EP-302 e-Poster Area Conjugation of GRPR-targeting antagonist RM26 to Use of tumour control probability model for albumin-binding domain extends antagonist’s blood EP-296 determination of treatment efficiency of head-and-neck EANM’20 EANM’20 EANM’20 circulation and residence in tumours cancer Analysis of results of effective dose estimation obtained EP-288 A. Abouzayed1, S. S. Rinne1, F. Wadeea1, H. Tano2, Á. Nagy2, A. E. E. Sukhikh1,2, Y. Sutygina1,3, L. Sukhikh3; Karlström2, V. Tolmachev1, A. Orlova1; from RADAR 2017 dose assessment model for nuclear 1Tomsk Regional Oncology Center, Tomsk, RUSSIAN FEDERATION, 177 Radionuclide Therapy Using Lu-labeled ABD-fused 1Uppsala University, Uppsala, SWEDEN, 2KTH Royal Institute of medicine procedures 2National Research Tomsk Polytechnic University, Toms, RUSSIAN ADAPT6 Scaffold Protein Technology, Stockholm, SWEDEN. L. Del Barco, M. Calderón Calvente, L. de la Cueva Barrao, A. FEDERATION, 3National Research Tomsk Polytechnic University, WORLD LEADING MEETING WORLD LEADING MEETING J. Garousi1, E. Von Witting2, M. Oroujeni1, J. Borin2, A. Vorobyeva1,3, Gandia Martinez, S. Moñux Salvador, G. Guzmán Prudencio, L. Tomsk, RUSSIAN FEDERATION. M. Altai1, O. Vorontsova1, M. W Konijnenberg4, A. Orlova3,5,6, S. Nieto Morcillo, M. Falgás Lacueva, P. Navarro Beltrán, S. Álvarez Hober2, V. Tolmachev1,3; EP-294 Ruíz, M. Sangrós Sahún, D. Abós Olivares; 1Uppsala University, Rudbeck laboratory, Uppsala, SWEDEN, Hospital Universitario Miguel Servet, Zaragoza, SPAIN. EP-42 2Department of Protein Technology, KTH - Royal Institute of A rat preliminary study on medication-related Technical Studies -> Instrumentation -> SPECT Technology, Stockholm, SWEDEN, 3Research Centrum for osteonecrosis of the jaw and SPECT/CT Oncotheranostics, Research School of Chemistry and Applied F. Ribeiro1, M. Laranjo2,3, P. M. C. C. Encarnação1, C. M. Marto3,4, R. Biomedical Sciences, Research Tomsk Polytechnic University, Santos5,3,2, A. Paula3,4, A. C. Santos3,2,4, A. L. M. Silva1,6, R. Oliveira7, 4 Tomsk, RUSSIAN FEDERATION, Department of Radiology and 3 6 5 1,6 5 N. Lima , I. F. Castro , N. Pereira , P. M. M. Correia , M. Piñeiro , G. e-Poster Area Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS, F. S. Figueiredo1, E. Carrilho3,4, T. Pinho e Melo5, M. F. Botelho2,3, M. EP-299 5 Science for Life Laboratory, Uppsala University, Uppsala, SWEDEN, Marques-Ferreira3,8, J. F. C. A. Veloso1; 6 Department of Medicinal Chemistry, Uppsala University, Uppsala, 1Institute for Nanostructures, Nanomodelling and 177Lu-DOTATATE Quantification for Patient Personalised SWEDEN. Nanofabrication (i3N), University of Aveiro, Aveiro, PORTUGAL, Dosimetry in Therapy of Neuroendocrine Tumours 2 Institute of Biophysics, Faculty of Medicine, University of Coimbra, C. Rodrigues1,2, P. Ferreira1, F. P. M. Oliveira1, Â. Silva1, L. Peralta2,3, D. EP-303 3 EP-289 Coimbra, PORTUGAL, Institute for Clinical and Biomedical C. Costa1; Research (iCBR) Area of Environment Genetics and Oncobiology 1Champalimaud Foundation, Champalimaud Centre for the Scatter correction in 99mTc SPECT by energy window Preclinical evaluation of targeted alpha therapy using (CIMAGO), Center for Innovative Biomedicine and Biotechnology Unknown, Lisbon, PORTUGAL, 2Faculdade de Ciências da narrowing and Monte Carlo simulation 4 (CIBB), Coimbra, PORTUGAL, Institute of Integrated Clinical 3 225Ac-DOTA-E[c(RGDfK)] for pancreatic cancer Universidade de Lisboa, Lisbon, PORTUGAL, Laboratório de S. Arvola, M. Seppänen, T. Noponen; 2 Practice, Faculty of Medicine, University of Coimbra, Coimbra, M. Yoshimoto1, K. Washiyama2, Y. Yoshii3, K. Ohnuki1, H. Fujii1; Instrumentação e Física Experimental de Partículas, Lisbon, Turku University Hospital, Turku, FINLAND. PORTUGAL, 5Faculty of Sciences and Technology, University 1Division of Functional Imaging, EPOC, National. Cancer Center, PORTUGAL. of Coimbra, Coimbra, PORTUGAL, 6RI-TE, Radiation Imaging Kashiwa, JAPAN, 2Advanced Clinical Research Center, Fukushima Technologies Lda, Ílhavo, PORTUGAL, 7Pathology Service, Medical University, Fukushima, JAPAN, 3National Institute of EP-300 EP-43 Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Radiological Sciences, National Institutes for Quantum and PORTUGAL, 8Institute of Endodontics, Faculty of Medicine, Technical Studies -> Radiation Protection -> Radiological Science and Technology, Chiba, JAPAN. An Analysis of Post-Therapy Lu177 Uptake Progression University of Coimbra, Coimbra, PORTUGAL. Radiation Exposure and Protection for Individual Volumes of Interest Across a Full Treatment EP-290 Cycle EP-39 S. McGurk, D. R. McGowan, D. Morgan; 224 e-Poster Area Size-controlled Ra-labelled calcium carbonate Technical Studies -> Data Analysis -> Image Oxford University Hospitals NHS Foundation Trust, Oxford, microparticles against peritoneal carcinomatosis Reconstruction UNITED KINGDOM. R. Li1,2,3, T. B. Bønsdorff3, I. S. Jorstad3, K. Lindland3, S. K. Tonstad3, Ø. S. Bruland1,4, S. Westrøm3, R. H. Larsen3; 1 EP-301 EP-304 Institute of Clinical Medicine, University of Oslo, Oslo, NORWAY, e-Poster Area 2Department of Radiation Biology, Institute of Cancer Research, the Norwegian Radium Hospital, Oslo University Hospital, Effect of attenuation and scatter correction of Tc99m Internal Audits: an Ally in the Promotion of a Radiation Oslo, NORWAY, 3Oncoinvent AS, Oslo, NORWAY, 4Department MAA SPECT images on dose evaluations in patients Protection Culture of Oncology, the Norwegian Radium Hospital, Oslo University treated with Y90 resin microspheres L. Cunha1, A. R. Roda2,1, P. Ratão3,1, M. Capoulas4,1, F. Ferreira1, M. Hospital, Oslo, NORWAY. 5 6,7 1 1,8 EP-295 C. Pettinato, C. Mosconi, A. Cappelli, E. Tabacchi, E. Lodi Rizzini, S. Sousa , H. Vasconcelos , A. S. Moreira , L. F. Metello ; Civollani, E. Terzi, L. Strigari, R. Golfieri; 1IsoPor-Azores, Angra do Heroismo, PORTUGAL, 2Medical Physics EP-291 Yttrium-90 PET imaging with digital photon counting for Department, IPOFG, Coimbra, PORTUGAL, 3Nuclear Medicine

220 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 221 Department, IPOFG, Lisbon, PORTUGAL, 4Pharmacy Department, Entre Rios, ARGENTINA. Head to head comparison of [15O]H O and [11C]MMP in HBA, Loures, PORTUGAL, 5Interdisciplinary Studies Research Center, EP-313 2 ISEP.IPP, Porto, PORTUGAL, 6Sc. Techn. Fac., Univ. Azores, Ponta non-human primates; tracers for measuring regional Delgada, PORTUGAL, 7CEFITEC, Physics Dept, Universidade Nova Dosimetric evaluation to medical workers operating in a EP-44 cerebral blood flow de Lisboa, Lisbon, PORTUGAL, 8ESS-IPP, Porto, PORTUGAL. PET/CT department after the use of dynamic techniques Technical Studies -> Radiopharmacy/ J. Toyohara1, T. Kakiuchi2, H. Ohba2, M. Kanazawa2, T. Tago1, M. K. Dalianis1, G. Kollias1, K. Gogos1, T. Pipikos2, F. Vlachou2, J. Radiochemistry -> New Biological Targets and Sakata1, N. Harada2; Andreou2, R. Eftymiadou2, V. Prassopoulos2; Ligands 1Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN, EP-305 1Medical Physics Deparment, Hygeia Hospital, Athens, Marousi, 2Hamamatsu Photonics, Hamamatsu, JAPAN. GREECE, 2PET/CT Department, Hygeia Hospital, Athens, Marousi, Attitude and commitment of Nuclear Medicine staff GREECE. EP-324 e-Poster Area towards Safety Culture working in Nuclear Medicine department EP-314 Novel radiofluorinated silicon rhodamines for bimodal N. Marwat; PET and NIR-optical imaging Nuclear Medicine Oncology and Radiotherapy Institute, Validation of an alternative measurement method T. Kanagasundaram1,2, M. Laube1, S. Stadlbauer1, C. Kramer3, J. Islamabad, PAKISTAN. to verify [131I]-NaI capsules activity by dose rate EP-319 Pietzsch1, K. Kopka1; determination 1Helmholtz Zentrum Dresden Rossendorf, Institute of Evaluation of Iodine-131 Labelled Lawsone (2-Hydroxy- C. Franco Monterroso1, A. Hernández Fructuoso2, B. Santos Radiopharmaceutical Cancer Research, Dresden, GERMANY, 2 EP-306 2 1 1 1,4-Naphthoquinone) Compound’s Transdermal and Heidelberg University, Faculty of Chemistry and Earth Sciences, EANM’20 EANM’20 Montero , J. Romero Herrera , J. Castell Conesa ; EANM’20 3 1Hospital Universitari Vall d’Hebron, Barcelona, SPAIN, 2Hospital Intravenous Biodistribution Heidelberg, GERMANY, German Cancer Research Center, Estimation of Conversion Factors for Quality Reference Heidelberg, GERMANY. Universitari Vall d’Hebron. Institut de Diagnòstic per la Imatge, V. Tekin1, U. Korkmaz2, I. Ince1, I. Kutlubay2, G. Durmus Altun2, F. mAs for Child to Adult Reference Patient in Child Barcelona, SPAIN. Biber Muftuler1; SPECT-CT Protocols 1Ege University, Izmir, TURKEY, 2Trakya University, Edirne, TURKEY. EP-325 S. Hansen1, N. Bebbington2; WORLD LEADING MEETING 18 WORLD LEADING MEETING 1Rigshospitalet, Copenhagen, DENMARK, 2Siemens Healthineers, EP-315 Radiosynthesis and initial evaluation of [ F]FBAT forin Aarhus, DENMARK. EP-45 vivoPET imaging of inducible nitric oxide synthase Radiation Exposure of the Fingers during Preparation Technical Studies -> Radiopharmacy/ H. Yeh1, W. Huang2, C. Chiu3, C. Chen4, K. Ma5, H. Tian6, T. Yu7, P. and Administration of 90Y-Ibritumomab-Tiuxetan for Radiochemistry -> New Radiopharmaceuticals Wang7, Y. Kuo2, C. Chang2; EP-307 Radioimmunotherapy of Non Hodgkin Lymphoma (NHL) - PET 1National Yang-Ming University, Taipei, TAIWAN, 2Department C. Happel, W. T. Kranert, B. Bockisch, D. Gröner, A. Sabet, F. of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, 3 Dose Rate from Patients after Bone and Myocardial Grünwald; TAIWAN, Department of Nuclear Medicine, Tri-Service General Hospital, Taipei, TAIWAN, 4Department of Biomedical Imaging Perfusion Scintigraphies University Medical Center Frankfurt, Department of Nuclear e-Poster Area B. Martins, C. Varela Pinto, D. Calado, R. Jorge, M. Correia, A. Medicine, Frankfurt, GERMANY. and Radiological Sciences, National Yang Ming University, Taipei, 5 Duarte, N. Alves, M. Rézio, C. Loewenthal; TAIWAN, Departments of Nuclear Medicine and Biology and Hospital da Luz, Lisboa, PORTUGAL. Anatomy, National Defense Medical Center, Taipei, TAIWAN, EP-316 6Departments of Biomedical Engineering and Radiology, Case EP-309 EP-320 Western Reserve University, Taipei, OH, UNITED STATES OF 7 Effective dose of for medical workers operating in a PET/ AMERICA, Brain Research Center, National Yang Ming University, 18 Taipei, TAIWAN. Investigation into the excretion rates and contact CT department Influence of the glutamate concentration on [ F] restrictions of Lu177 Dotatate patients K. Dalianis1, G. Kollias1, K. Gogos1, T. Pipikos2, M. Vogiatzis2, F. PEB binding to metabotropic receptor subtype 5 : a L. Hutton1, D. Morgan1, D. McGowan1,2, A. Hallam1; Vlachou2, V. Prassopoulos2; translational study EP-326 1 1Oxford University Hospitals NHS Foundation Trust, Oxford, Medical Physics Deparment, Hygeia Hospital, Athens, Marousi, A. Dupont1,2, S. Serrière2, L. Barantin2, J. Vercouillie2,3, V. Gissot3, S. 2 UNITED KINGDOM, 2University of Oxford, Oxford, UNITED GREECE, PET/CT Department, Hygeia Hospital, Athens, Marousi, Bodard2, G. Chicheri2, S. Chalon2, F. Bonnet-Brihault2,4, M. Santiago Site-directed conjugation chemistry of the hexahistidine KINGDOM. GREECE. Ribeiro5,2,3, N. Arlicot1,2,3; tag 1Radiopharmacie, CHRU Tours, Tours, FRANCE, 2UMR1253, iBrain, T. Tshibangu1, M. Sillen2, F. Cleeren1, N. Geukens2, P. Declerck2, G. EP-310 EP-317 Inserm, Tours, FRANCE, 3CIC 1415, Inserm, CHRU Tours, Tours, Bormans1; FRANCE, 4Centre universitaire de Pédopsychiatrie, CHRU Tours, 1Laboratory for Radiopharmaceutical Research, KULeuven, Optimisation of Lu-177 therapy administration CT radiation dose in whole-body PET/CT in relation to arm Tours, FRANCE, 5Service de Médecine nucléaire, CHRU Tours, Tours, Leuven, BELGIUM, 2Laboratory for Therapeutic and Diagnostic R. Fernandez1, S. Rai1, A. Perry2, J. Johnson1, P. Croasdale1, N. position in patients with different Body Mass index FRANCE. Antibodies, KULeuven, Leuven, BELGIUM. Eftychiou1; G. Marotta, M. F. Bardo, M. Schiavini, F. Buffoni, R. Leo, M. Rognoni, 1Guy’s and St Thomas’ Hospital, London, UNITED KINGDOM, D. Capolongo, R. Pino, N. Basilico, E. Orunesu, E. Galli, R. Casati, I. EP-321 EP-327 2King’s College London, London, UNITED KINGDOM. Martina, C. Fabbri, L. D’Antonio, D. Marchelli, F. Voltini, C. Canzi; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Synthesis and Pre-clinical Evaluation of Novel Piperazine Copper-64 based Radiopharmaceuticals as Potential EP-311 Milano, ITALY. Amide-modified18 F-Rhodamines as Myocardial Perfusion Theranostic Agents Imaging Agents I. Khan1, R. Zahoor1, M. Numair1, A. Shahid1, A. J. Abrunhosa2; Approach “Lean Thinking” to improving performance and 1 EP-318 J. Inkster1,2, J. L. J. Dearling1,2, E. Snay1, A. B. Packard1,2; Institute of Nuclear Medicine and Oncology (INMOL), Lahore, efficiency in a Nuclear Medicine Department: a tool for 1Boston Children’s Hospital, Boston, MA, UNITED STATES OF PAKISTAN, 2Institute of Nuclear Sciences Applied to Health (ICNAS), radioprotection Dose Optimization Of Brain Tomographic Studies Through AMERICA, 2Harvard Medical School, Boston, MA, UNITED STATES University of Coimbra, Coimbra, PORTUGAL. L. Burroni1, F. M. Fringuelli1, G. Biscontini1, A. Palucci1, C. Quantitative Analysis Of The ASIR Reconstruction OF AMERICA. Romagnolo1, C. Cottignoli1, C. Bianciardi2, J. Guercini3; Technique EP-329 1Nuclear Medicine, Ancona, ITALY, 2Health gestional department, J. Bustos, A. Ruiz; 18 Alessandria, ITALY, 3Healthcare Hospital Department, Pisa, ITALY. Nuclear and Molecular Medicine Center Foundation Entre Rios, EP-322 Novel [ F] FBPA synthesis method from pinacol

222 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 223 T. Mohajer Shojai1, P. Jha1, A. Boström2, F. Y Frejd1, P. J Yazaki3, M. Radiochemistry -> Radiopharmaceutical 1 boran precursor and [18F] fluoride ion using automatic M. De Arcocha Torres1, G. Quincoces2, A. L. Martínez-López3, A. Nestor ; Preparation and Quality Control 1 2 Erhard2, M. Collantes4, I. Martínez-Rodríguez1, I. Luis-De Redin3, M. Uppsala University, Uppsala, SWEDEN, Ridgeview Instruments synthesizer 3 4 1 3 2 AB, Uppsala, SWEDEN, Beckman Research Institute, Duarte, CA, Y. Kanai1,2, Y. Ohta3,4, T. Watanabe5, Y. Hottori3, H. Takenaka4, K. Ecay , I. Banzo , J. M. Irache , I. Peñuelas ; 1 UNITED STATES OF AMERICA. e-Poster Area Uehara4, S. Naka6, T. Sakai7, J. Hatazawa6, M. Kirihata3; Nuclear Medicine Service. Marqués de Valdecilla University 1Osaka University of Pharmaceutical Science, Takatsuki, JAPAN, Hospital. Molecular Imaging Group (IDIVAL). University of 2 2Kansai BNCT Medical Center, Osaka Medical College, Takatsuki, Cantabria, Santander, SPAIN, Radiopharmacy Unit, Nuclear EP-339 JAPAN, 3Research Center of Boron Neutron Capture Therapy, Medicine Service, University Clinic of Navarra, IdiSNA, Pamplona, 3 Osaka Prefecture University, Sakai, JAPAN, 4STELLA PHARMA SPAIN, Department of Pharmacy and Pharmaceutical DOTA-conjugation and 177Lu-DOTA-radiolabeling EP-343 4 5 Technology, University of Navarra, Pamplona, SPAIN, Micropet CORPORATION, Sakai, JAPAN, Sumitomo Heavy Industry, LTD., optimizations of IgG4 antibodies 6 7 Unit. Nuclear Medicine Service, University Clinic of Navarra, IdiSNA, Tokyo, JAPAN, Osaka University, Suita, JAPAN, Hanwa Intelligent P. Jha, H. Berglund, T. M. Shojai, A. C. L. Mortensen, M. Nestor; Multifunctional crown-5-calix[4]arene based phase- Pamplona, SPAIN. Medical Center, Sakai, JAPAN. Immunology, Genetics and Pathology, Uppsala University, transfer catalysts for aromatic 18F-fluorination Uppsala, SWEDEN. W. Lee1,2, S. Kang3, D. Kim3, B. Lee2,4, W. Lee2, S. Kim1,2,4; EP-330 EP-334 1Department of Transdisciplinary Studies, Graduate School of EP-340 Convergence Science and Technology, Seoul National University, Synthesis and In Vivo Behavior Study of Target-directed Evaluation of mercaptoacetyl-based amino acid Suwon, KOREA, REPUBLIC OF, 2Department of Nuclear Medicine, Zr-89 Labeled Nanorods containing chelators for labeling of GRPR antagonist Radiolabeling with Tb-161 and Lu-177: defining the Seoul National University Bundang Hospital, Seongnam, KOREA, EANM’20 EANM’20 EANM’20 3 G. Kim, J. Chae, G. Kang, C. Lee, S. Kim; PEG2- RM26 with 99mTc impact of metal impurities REPUBLIC OF, Department of Chemistry, Inha university, Incheon, 4 1 1 1 1 1,2 KOREA, REPUBLIC OF, Center for nanomolecular imaging and Dongguk Univ., Gyeongju, KOREA, REPUBLIC OF. H. Sabahnoo1, A. Abouzayed1, S. Rinne1, V. Tolmachev2, A. Orlova1; M. Ooms , A. R. Burgoyne , B. Ponsard , D. Elema , T. Cardinaels , 1 innovative drug development, Advanced Institutes of Convergence 1Department of Medicinal Chemistry, Uppsala University, Uppsala, M. Van de Voorde ; 1 2 Technology, Suwon, KOREA, REPUBLIC OF. EP-331 SWEDEN, 2Department of Immunology, Genetics and Pathology, SCK CEN, Mol, BELGIUM, KU Leuven, Department of Chemistry, Uppsala University, Uppsala, SWEDEN. Leuven, BELGIUM. WORLD LEADING MEETING Scale-down production of [68Ga]Ga-NODAGA-Exendin-4 EP-344 WORLD LEADING MEETING PET tracer S. Migliari1,2, A. Sammartano1,2, M. Scarlattei1,2, G. Baldari1,2, B. EP-335 EP-57 Evaluation of DOTA-TATE kit formulation for multi isotope Janota3, R. Bonadonna4,5, L. Ruffini1,2; Technical Studies -> Radiopharmacy/ labelling 1 2 A Novel Tc-99m-labeled and MAG -chelated Arginine- AZ. Osp. Universitaria di Parma, Parma, ITALY, Nuclear Medicine 3 Radiochemistry -> Radionuclide Production M. Maurin, P. Garnuszek, M. Radzik, W. Wojdowska, D. Pawlak, R. Department, University Hospital of Parma, Parma, ITALY, 3National Arginine-Leucine containing Peptide for Tumor Imaging Mikołajczak; Centre for Nuclear Research Radioisotope Centre POLATOM, in Hepatoma Xenografts Model National Centre for Nuclear Research, Radioizotope Centre 4 Otwoch, POLAND, AZ. Osp. Universitaria di Parma, PARMA, ITALY, R. Wang1,2, Y. Du1, Z. Chen1, P. Yan1, Q. Jiang1, X. Duan1; POLATOM, Otwock, POLAND. 5 e-Poster Area Division of Endocrinology and Metabolic Diseases, Parma, ITALY. 1Peking University First Hospital, Beijing, CHINA, 2Peking University International Hospital, Beijing, CHINA. EP-345 EP-55 Technical Studies -> Radiopharmacy/ Automated production of a quinoline-based FAP- Radiochemistry -> New Radiopharmaceuticals EP-336 EP-341 inhibitor68Ga-FAPI-46 for clinical use - SPECT F. Lodi1, C. Malizia1, V. Cabitza1, S. Telo2, C. Nanni2, C. Drake3, F. Influence Of Different Factors On Labelling Yield And New Y Solid Target Concept for89Zr Cyclotron-based Valla3, S. Fanti2; Image Quality Of Leukocytes Labelled With 99mTc-HMPAO Production 1PET Radiopharmacy, Nuclear Medicine Dept. S.Orsola-Malpighi 1 1 2 2 3 University Hospital, Bologna, ITALY, 2Nuclear Medicine Dept. e-Poster Area V. Mendi Barcina, E. Martínez Montalbán, E. Dobra, L. Arias S. Cisternino , H. Skliarova , E. Cazzola , G. Gorgoni , A. Baldini , U. Buendía, M. García Ruiz, S. Rizckallal Monzón, B. Martínez de Anselmi-Tamburini3,4, J. Esposito1; S.Orsola-Malpighi University Hospital, Bologna, ITALY, 3SOFIE Co., Miguel; 1Istituto Nazionale di Fisica Nucleare - Laboratori Nazionali di Totowa, NJ, UNITED STATES OF AMERICA. Hospital Universitario La Paz, Madrid, SPAIN. Legnaro, Legnaro (PD), ITALY, 2IRCCS Sacro Cuore Don Calabria Hospital, Negrar (VR), ITALY, 3Department of Chemistry, University EP-346 EP-332 of Pavia, Pavia (PV), ITALY, 4Istituto Nazionale di Fisica Nucleare, EP-56 Sezione di Pavia, Pavia (PV), ITALY. Impact of Synthesis Procedure, Patient and Procedure- Evaluation of Bivalent Fibroblast Activated Protein Technical Studies -> Radiopharmacy/ related Parameters on Image Quality of 68Ga-PSMA-11 99m EP-342 Inhibitor [ Tc-DTPA-(8-OH-quinoline)2] for SPECT Radiochemistry -> New Radiopharmaceuticals PET/CT imaging of tumor - Therapy L. Calderoni1, A. Farolfi1, F. Lodi2, S. Telo1, G. Ricci1, D. Pianori3, E. Cyclotron-Production of 51/52Mn Isotopes: an Update on A. Wadhwa1,2, S. Chaturvedi3,2, A. K. Mishra3, F. Hussain4; Maietti3, V. Cabitza2, M. Fantini3, P. Castellucci1, S. Fanti1; 1Institute of Nuclear Medicine and Allied Science, DRDO, the METRICS Project 1Nuclear Medicine, Sant’Orsola University Hospital, Bologna, 2 3 1,2 2 3 1 2 2 Delhi, INDIA, INMAS,DRDO, Delhi, INDIA, Defence Research e-Poster Area P. Martini , A. Boschi , E. Cazzola , S. Cisternino , A. Duatti , G. ITALY, PET Radiopharmacy Unit, Sant’Orsola Universital Hospital, Development Organization, Delhi, INDIA, 4Department of Gorgoni3, L. Marvelli2, M. Pasquali1,2, L. Mou1, G. Pupillo1, C. Rossi Bologna, ITALY, 3Department of Biomedical and Neuromotor chemistry, University of Delhi, Delhi, INDIA. Alvarez1, H. Skliarova1, G. Sciacca1, J. Amico3, L. Uccelli2, J. Esposito1; Sciences, Unit of Hygiene, Public Health and Biostatistics, Alma 1Legnaro National Laboratories of the National Institute of Mater Studiorum, University of Bologna, Bologna, ITALY. Nuclear Physic (INFN-LNL), Legnaro (PD), ITALY, 2University of EP-333 EP-338 Ferrara, Ferrara, ITALY, 3Sacro Cuore Don Calabria Hospital, Negrar EP-347 (VR), ITALY. Radiolabelling, stability and in vivo biodistribution In vitro characterizations of 177Lu-anti-CEA antibody and Automated radiosynthesis of [18F]LBT999 on two different studies of albumin nanoparticles with gallium-67 and HSP90 inhibition for potentiated radioimmunotherapy of EP-58 platforms technetium-99m gastrointestinal cancer Technical Studies -> Radiopharmacy/ J. Vercouillie1, C. Vala2, C. Mothes3, G. Chicheri1, P. Magadur3, G. Viot3, J. Deloye2, S. Maia4, Y. Bouvet2, N. Arlicot4, D. Guilloteau4, P.

224 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 225 Hokkaido, JAPAN, 7Graduate School of Medicine, Dentistry and Patients With Relapsed-Refractory High Risk Emond1; Production of [18F]PSMA-1007 using different starting Pharmaceutical Sciences, Okayama University, Okayama, JAPAN. Neuroblastoma: A Dosimetry Based Treatment 1INSERM 1253, CERRP, Tours Hospital, Tours, FRANCE, 2Zionexa, activities of 18F-fluoride: yield and stability of the 1 1 2 1 3 Paris, FRANCE, 3Cyclopharma, Tours, FRANCE, 4Tours Hospital, C. Altini , M. Villani , B. Cassano , M. Pizzoferro , A. Serra , A. radioligand 3 2 1 Tours, FRANCE. EP-60 Castellano , V. Cannatà , M. Garganese ; C. Maisto, A. Morisco, E. Squame, L. D’Ambrosio, M. Aurilio, P. 1IRCCS Bambino Gesù Children’s Hospital, Nuclear Medicine Unit, Therapy Clinical Study -> Oncological Therapy 2 EP-348 Gaballo, S. Lastoria; Imaging Department, Rome, ITALY, IRCCS Bambino Gesù Children’s Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Clinical Study -> Local Radionuclide Therapy Hospital, Medical Physics Unit, Rome, ITALY, 3IRCCS Bambino ITALY. (including Spheres) Gesù Children’s Hospital, Paediatric Haematology/Oncology Full quality control of 11C- and 18F-radiobalelled Department, Rome, ITALY. compounds using compact and automated Quality Control device EP-59 e-Poster Area EP-363 B. Kuhnast1, O. Carvalho1, J. Witczak2, R. Grugel2, X. Franci2; Technical Studies -> Radiopharmacy/ 1CEA, BioMaps, Orsay, FRANCE, 2TRASIS, Ans, BELGIUM. Radiochemistry -> Radiopharmacokinetics and Drug Development Quantitative assessment of SUVs obtained in 68Ga-labeled somatostatin analogue PET/CT for estimation of long term EP-349 EP-359 response to PRRT in patients with neuroendocrine tumors 1 2 2 2 e-Poster Area A. Sowa-Staszczak , M. Opalińska , A. Kania-Kuc , I. Al Maraih , M. Fast, reliable and universal spot test for the detection of Can SPECT/CT lung shunt quantification improves dose 1 1 EANM’20 EANM’20 Buziak-Bereza , A. Hubalewska-Dydejczyk ; EANM’20 TBA+ in radiopharmaceutical preparations optimisation with 99mTc-MAA study for 90Ymicrosphere 1Chair and Department of Endocrinology, Jagiellonian University F. Morelle, A. Vas; workup CM, Krakow, POLAND, 2Nuclear Medicine Unit, Endocrinology Trasis, Liège, BELGIUM. A. Poon1,2, J. Dal Santo1, S. T. Lee1,3,4, B. M. Chappell1, K. Pathmaraj1, Department, University Hospital in Krakow, Krakow, POLAND. EP-356 A. M. Scott1; EP-350 1Austin Hospital, Heidelberg, AUSTRALIA, 2University of Melbourne, WORLD LEADING MEETING WORLD LEADING MEETING CYP3A4 inhibitors affect the pharmacokinetics of the Parkville, AUSTRALIA, 3Olivia Newton-John Cancer Research EP-365 18 Automation and High yield production of [ F] MK-6240, TSPO radioligand [18F]DPA-714 in PET imaging studies in Institute, Heidelberg, AUSTRALIA, 4La Trobe University, Heidelberg, 131 a promising PET Tracer for quantification of Human humans AUSTRALIA. I-MIBG treatment in patients with metastatic Neurofibrillary tangles in Alzheimer disease M. Peyronneau1, B. Jego1, C. Letaillandier2, C. Leroy1, S. Lavisse3, F. paraganglioma and pheocrhomocytoma C. Vriamont, C. Warnier, M. Otabashi; Caillé1, B. Kuhnast1, M. Bottlaender4; J. Bernal, S. Prado, M. Agudelo, A. Utrera, J. Cañón, P. Bello; Trasis, Ans, BELGIUM. 1CEA, BioMaps, Orsay, FRANCE, 2APHP, Hôpital Saint-Antoine, EP-61 Hospital Universitario y Politécnico La Fe, Valencia, SPAIN. Paris, FRANCE, 3CEA, MIRCen, Fontenay-aux-Roses, FRANCE, 4CEA , Therapy Clinical Study -> Oncological Therapy Neurospin, UNIAC, Gif-sur-Yvette, FRANCE. Clinical Study -> Neuroendocrine Therapy EP-366 EP-351 Assessment of early cardiotoxicity following the use of A Generic GC Protocol for the Residual Solvent Analysis EP-357 e-Poster Area radiotheranostics agents177Lu-PSMA for prostate cancer of PET Radiopharmaceuticals and177Lu-DOTATATE for neuroendocrine tumors A Physiologically Based Pharmacokinetic Model of C. Marcolan, M. Glaser, F. Twyman, K. Sander, R. Awais, E. Årstad; M. Assadi1, A. Amini1, E. Jafari1, H. Ahmadzadehfar2, D. Bagheri3; University College London, London, UNITED KINGDOM. 68Ga-DOTATATE to Describe Organ Distribution 1Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, H. Siebinga1,2, B. J. de Wit-van der Veen2, J. H. Beijnen1, M. P. M. ISLAMIC REPUBLIC OF, 2Klinikum Westfalen, Knappschaft Hospital, EP-352 Stokkel2, T. P. C. Dorlo1, A. D. R. Huitema1,3, J. J. M. A. Hendrikx1,2; EP-360 Dortmund, GERMANY, 3Persian Gulf University, Bushehr, IRAN, 1Department of Pharmacy & Pharmacology, The Netherlands ISLAMIC REPUBLIC OF. Investigations on formulation of freeze dried kit for Cancer Institute, Amsterdam, NETHERLANDS, 2Department of Neuroendocrine Tumours (NET) Quantitative SUV-SPECT/ preparation of 99mTc-PSMA-peptid (Mepromostat) Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, CT Change during 177Lu-DOTATATE MRT S. Keresztes1, T. Mándoki1, Z. Kiss-Gombos1, E. Szemenyei1, M. NETHERLANDS, 3Department of Clinical Pharmacy, University T. Alkahtani1,2, L. Livieratos1,2, V. Lewington1,2; EP-62 Antalffy1, J. Környei1, G. Trencsényi2, L. Pávics3; Medical Center Utrecht, Utrecht, NETHERLANDS. 1King’s College London, London, UNITED KINGDOM, 2Guy’s & Therapy Clinical Study -> Oncological Therapy 1Institute Of Isotopes Co., Ltd., Budapest, HUNGARY, 2Department St Thomas’ Hospitals NHS Foundation Trust, London, UNITED Clinical Study -> Other Oncological Treatments of Nuclear Medicine, University of Debrecen, Debrecen, HUNGARY, EP-358 KINGDOM. 3Department of Nuclear Medicine, University of Szeged, Szeged, HUNGARY. Investigation of structure-affinity relationship of novel EP-361 e-Poster Area 18F-labeled norepinephrine analogue tracers EP-354 S. Mühlig1,2, X. Chen1,2,3, Y. Ohshima1,2,4, Y. Yagi5, H. Kimura5, K. Peptide Receptor Radionuclide Therapy With Koshino6, N. Nose7, C. Lapa3, A. Buck1, T. Higuchi1,2,7; [177Lu-DOTA0,Tyr3]octreotate. Experience At Our Center Study of Separation and Formulation Using Solid-Phase 1Department of Nuclear Medicine, University Hospital of M. Lara Martínez1, M. De Sequera Rahola2, A. Díaz Silván2, O. Extraction Method to Produce [11C]DPA713 and [18F] Würzburg, Würzburg, GERMANY, 2Comprehensive Heart Vilahomat Hernández2, E. Martínez2, D. Cabello García2, M. López EP-367 DPA714 as a Translocator Protein Ligands Failure Center, University Hospital of Würzburg, Würzburg, Acosta2, A. Allende Riera2; 3 1 Peptide receptor radionuclide therapy for glioma tumors: S. Naka1,2, K. Kurimoto1, K. Matsunaga1, T. Watabe1, M. Tatsumi2, E. GERMANY, Department of Nuclear Medicine, University Hospital Universitario de Canarias, Santa Cruz de Tenerife, SPAIN, 4 2 Shimosegawa1, H. Kato1, J. Hatazawa1; Hospital of Augsburg, Augsburg, GERMANY, Department Hospital Universitario Nuestra Señora de La Candelaria, Santa An extended report on a pilot study 1Osaka University Graduate School of Medicine, Suita, Osaka, of Radiation-Applied Biology Research, Quantum Beam Cruz de Tenerife, SPAIN. M. Assadi1, R. Nemati1, A. Amini1, H. Ahmadzadehfar2, H. Shooli1, S. JAPAN, 2Osaka University Hospital, Suita, Osaka, JAPAN. Science Research Directorate, National Institutes for Quantum Rekabpour1, E. Jafari1; and Radiological Science and Technology, Gunma, JAPAN, EP-362 1Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, 5 Department of Analytical and Bioinorganic Chemistry, Kyoto ISLAMIC REPUBLIC OF, 2Klinikum Westfalen, Knappschaft Hospital, 6 EP-355 Pharmaceutical University, Kyoto, JAPAN, Department of Systems Tandem High-Dose 131I-MIBG Therapy For Paediatric Dortmund, GERMANY. and Informatics, Hokkaido Information University, Ebetsu,

226 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 227 Initial experience with somatostatin receptor (SSTR) Syndrome:a systematic review and meta-analysis Clinical Study -> Prostate Cancer Therapy imaging and peptide receptor radionuclide therapy for E. Etchebehere1, F. Mourato2, A. Maria2, A. Brito2, A. Leal3, P. Almeida EP-368 2 patients with neuroendocrine differentiation (NED) of Filho ; e-Poster Area 1The University of Campinas, Campinas, BRAZIL, 2Real Hospital Initial practice with Gallium-68 DOTATATE PET/CT and prostate cancer Português de Beneficência em Pernambuco, Recife, BRAZIL,3 Real 1 1 2 1 1 peptide receptor radionuclide therapy for pediatric M. Assadi , S. Rekabpour , H. Ahmadzadehfar , E. Jafari , A. Amini ; Hospital Português de Beneficência em Pernambuco, Re, BRAZIL. 1 patients with relapsed or refractory metastatic Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, ISLAMIC REPUBLIC OF, 2Klinikum Westfalen, Knappschaft Hospital, neuroblastoma: A promising point-of-care after failure EP-374 Dortmund, GERMANY. EP-383 131I- MIBG therapy 1 1 1 2 M. Assadi , G. Fathpour , E. Jafari , H. Dadgar ; Myelotoxicity after Treatment with 177Lu-PSMA-617 in EP-379 Comparison between [11C]-acetate and [18F]-FDG positron 1Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, 2 Patients with Metastatic Prostate Cancer emission tomography (PET) in radioactive-iodine- ISLAMIC REPUBLIC OF, Cancer Research Center, Razavi Hospital, 177 1 1 1 1 1 Fractionated Lu-PSMA-617 therapy with 101 GBq in a Mashhad, IRAN, ISLAMIC REPUBLIC OF. D. Gröner , J. Baumgarten , K. Davis , C. Happel , N. Mader , C. refractory (RAIR) differentiated thyroid cancer (DTC) Nguyen Ngoc1, J. Wichert1, P. Mandel2, N. Tselis3, F. Grünwald1, A. patient with metastatic prostate cancer S. Li, E. Kretschmer-Chott, M. Wibbe, E. Rainer, S. Rasul, R. Dudczak, Sabet1; C. Happel, J. Wichert, W. T. Kranert, L. Völler, B. Bockisch, D. Gröner, F. M. Hacker; EP-369 1Nuclear Medicine, University Hospital Frankfurt, Frankfurt, Grünwald, A. Sabet; Medical University of Vienna, Vienna, AUSTRIA. GERMANY, 2Urology, University Hospital Frankfurt, Frankfurt, University Medical Center Frankfurt, Department of Nuclear Technical and procedural aspects of high dose- GERMANY, 3Radiation Oncology, University Hospital Frankfurt, Medicine, Frankfurt, GERMANY. EANM’20 EANM’20 EANM’20 personalized brachytherapy using a not sealed Frankfurt, GERMANY. EP-384 188Rhenium-resin in patients with non-melanoma skin EP-375 EP-64 The diagnostic value of stimulated serum thyroglobulin in cancer the follow-up of low and intermediate-risk patients with A. Farina1, F. Savoia2, G. Lima1, A. Patrizi3, F. Zagni4, S. Vichi4, G. Thyroid Whole-Body Dosimetry in Therapy of Metastatic Prostate 1 3 4 5 1 1 differentiated thyroid cancer

WORLD LEADING MEETING Argalia , E. Dika , L. Strigari , A. Morganti , S. Fanti , P. Castellucci ; WORLD LEADING MEETING 177 1Nuclear Medicine Department, Sant’Orsola-Malpighi Hospital, Cancer with Lu-PSMA-617 I. Mihaljevic1,2,3, V. Wagenhofer1,2, T. Kralj1,2, D. Vrdoljak1, T. Kizivat1,2, 1,2 4,2,3 4,2 University of Bologna, Bologna, ITALY, 2Dermatology Department, C. Happel, L. Völler, W. T. Kranert, D. Gröner, B. Bockisch, N. Mader, e-Poster Area D. Mudri , M. Franceschi , T. Jukic ; Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, F. Grünwald, A. Sabet; 1Clinical Institute of Nuclear Medicine and Radiation Protection, ITALY, 3Dermatology Medicine Department, Sant’Orsola-Malpighi University Medical Center Frankfurt, Department of Nuclear University Hospital Osijek, Osijek, CROATIA, 2Faculty of Medicine Hospital, University of Bologna, Bologna, ITALY, 4Medical Physics Medicine, Frankfurt, GERMANY. Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, CROATIA, Department, Sant’Orsola-Malpighi Hospital, University of 3Academy of Medical Sciences of Croatia, Zagreb, CROATIA, Bologna, Bologna, ITALY, 5Radiation Oncology Department, EP-376 EP-380 4Department of Oncology and Nuclear Medicine, Sestre milosrdnice Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, University Hospital Centre, Zagreb, CROATIA. ITALY. Brazilian Profile of Ra-223 Therapy - a Multicenter Study Gallium-68 DOTATATE PET/CT and peptide receptor E. Etchebehere1, F. P. P. Lopes2, S. A. L. Matedi2, R. Fockink3, D. A. radionuclide therapy for patients with refractory/ EP-385 3 4 4 5 1 EP-370 Anjos , G. V. Gomes , L. R. Silva , A. O. Santos , T. Minekawa , V. M. recurrence metastatic medullary carcinoma of thyroid 6 6 7 7 8 Araújo , A. B. M. J. Teixeira , R. Martins , G. E. Bier , A. Sanches , N. 1 2 1 1 Standardised uptake value (SUV) of iodine-131 at post- 9 2 10 1 10 M. Assadi , H. Dadgar , S. Rekabpour , E. Jafari , H. Initial experience with 177Lu-PSMA therapy for patients Hanaoka , R. M. Tavares , F. Mourato , M. C. L. Lima , P. Almeida , 3 1 treatment SPECT/CT in patients with differentiated thyroid 10 Ahmadzadehfar , A. Amini ; with advanced liver cancer A. E. T. Brito ; 1 1 2 Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, cancer M. Assadi1, S. Rekabpour1, E. Jafari1, N. Shakibazad1, H. The University of Campinas, Campinas, BRAZIL, Clinica de 2 3 ISLAMIC REPUBLIC OF, Razavi Cancer Research Center, Razavi A. Trukhin, P. Rumyantsev, A. Bubnov, E. Kolpakova, K. Slaschuck, Y. Ahmadzadehfar2, Z. Alipour1, A. Amini1; Medicina Nuclear Villela Pedras, Rio de Janeiro, BRAZIL, Hospital 3 4 Hospital, Mashhad, IRAN, ISLAMIC REPUBLIC OF, Klinikum Sirota, M. Degtyarev, S. Serzhenko; 1Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, Santa Paula, São Paulo, BRAZIL, Núcleos, Brasília, BRAZIL, 5 6 Westfalen, Knappschaft Hospital, Dortmund, GERMANY. Endocrinology Research Cener, Moscow, RUSSIAN FEDERATION. ISLAMIC REPUBLIC OF, 2Klinikum Westfalen, Knappschaft Hospital, Medicina Nuclear de Campinas, Campinas, BRAZIL, Centro de 7 Dortmund, GERMANY. Diagnósticos por Imagem de Goiânia, Goiás, BRAZIL, Centro de Tomografia e Medicina Nuclear (CETAC), Curitiba, BRAZIL, 8 9 EP-65 EP-386 EP-371 Santa Casa de Misericórdia da Bahia, Salvador, BRAZIL, Dimen, Campinas, BRAZIL, 10Real Hospital Português, Recife, BRAZIL. Thyroid Cancer Rare sites of metastasis in differentiated thyroid Molecular Imaging in the selection and evaluation of carcinoma:case series study EP-377 1 2 3 3 response in patients treated with Radium-223 in six e-Poster Area N. Bashank , H. Farghally , S. Hassanein , M. Abdeltawab , M. different solid tumors: A single center experience Wahman4; Bone scintigraphy to evaluate response to therapy 1 S. Medina-Ornelas, F. García-Perez, M. Alvarez-Avitia, N. Assuit university,AUH, clinical oncology and nuclear medicine 2 Sobrevilla-Moreno, D. Garcia-Ortega, F. Barron-Barron, M. with Radium-223 for castration-resistant prostate department, Assuit, EGYPT, Assuit university, clinical oncology and 3 Jimenez-Rios, O. Arrieta-Rodriguez; cancer patients with bone metastases: a single-center nuclear medicine department, Assuit, EGYPT, Assuit University EP-381 Hospitals, Diagnostic Radiology department, Assuit, EGYPT, Instituto Nacional de Cancerologia, Mexico City, MEXICO. experience 4South Vally University,Clinical Oncology and Nuclear Medicine E. Martínez Albero, A. Gómez Grande, A. Saviatto Nardi, Á. 131I-SPECT/CT after radioiodine therapy in patients with Department, Qena, EGYPT. Galiana Morón, D. Vega Pérez, V. Godigna Guilloteau, J. Pilkington EP-63 differentiated thyroid carcinoma (DTC) Woll, S. Ruiz Solís, P. Sarandeses Fernández, M. Tabuenca Mateo, J. EP-387 Therapy Clinical Study -> Oncological Therapy Estenoz Alfaro; S. Nuvoli, A. Marongiu, I. Gelo, L. Mele, M. Rondini, M. L. Stazza, G. Hospital Universitario 12 de octubre, Madrid, SPAIN. Madeddu, A. Spanu; University of Sassari, Sassari, ITALY. 18F-FDG PET-CT: impact in the diagnosis and management of a population of thyroid cancer patients EP-378 EP-382 C. Varela Pinto, B. Martins, D. Calado, D. Macedo, A. Martins, F. Sobral do Rosário, C. Loewenthal; FDG PET/CT versus Somatostatin Receptor PET/CT in TENIS Hospital da Luz Lisboa, Lisbon, PORTUGAL.

228 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 229 due topostponed COVID-19

EP-388 EP-66 A critical review of the contact restrictions following Thyroid Therapy radioiodine (I-131) therapy in the UK E. Stamou, D. Morgan, A. Hallam;

Oxford University Hospitals NHS Trust, Oxford, UNITED KINGDOM. e-Poster Area EP-389

The Diagnostic Contribution and Clinical Impact of 131I SPECT/CT in the Evaluation of Extrathyroidal Uptake in EP-395 Patients with Differentiated Thyroid Carcinoma after Impact of 18F-FDG PET/CT on the management of focusmeeting.eanm.org Radioiodine Therapy well differentiated thyroid cancer (DTC) persistence/ T. Bahceci, E. Özdemir; Seville, spain Ankara City Hospital, Ankara, TURKEY. recurrence in the suspect of radio-iodine refractory disease (RAI-R-DTC) NEW DATES: February 3-5, 2022

EANM’20 EANM’20 1 1 1 2 EANM’20 EP-390 E. Lodi Rizzini , L. Zanoni , E. Tabacchi , A. Repaci , A. G. Morganti3, S. Fanti1, F. Monari3; 1Nuclear Medicine Unit, S.Orsola-Malpighi Hospital, Bologna, Six-Year Experience With The ROLL Technique In The ITALY, 2Endocrinology Unit, S.Orsola-Malpighi Hospital, Bologna, Detection And Treatment Of Loco-Regional Recurrence In ITALY, 3Radiation Oncology Center, S.Orsola-Malpighi Hospital, Thyroid Cancer Bologna, ITALY. WORLD LEADING MEETING WORLD LEADING MEETING J. Villena Salinas, E. Ramos Moreno, J. Alors Ruiz, A. Montellano Fenoy, T. Amrani Raissouni, S. Ortega Lozano; Hospital Universitario Virgen de la Victoria, Malaga, SPAIN. EP-397

Dynamic risk stratification to evaluate prognostic EP-391 factors (PrFs) for differentiated thyroid cancer (DTC): A retrospective cohort study The influences of TSH stimulation level, stimulated Tg E. Giannoula1, N. Papadopoulos2, C. Sachpekidis3, A. Doumas1, G. level and Tg/TSH ratio on the prognosis of 131I treatment Gerasimou1, F. Spyroglou1, V. Chatzipavlidou4, I. Iakovou1; in DTC patients 1Nuclear Medicine dpt of Aristotle University AHEPA Academic W. Zheng, Z. Rui, X. Wang, N. Li, Z. Meng, J. Tan, Q. Jia; hsp, Thessaloniki, GREECE, 2G.Gennimatas hsp, Thessaloniki, Department of Nuclear Medicine, Tianjin Medical University GREECE, 3Clinical Cooperation Unit Nuclear Medicine, German General Hospital, Tianjin, CHINA. Cancer Research Center, Heidelberg, GERMANY, 4Nuclear Medicine dpt of THEAGENEIO Anticancer hsp, Thessaloniki, GREECE. EP-392

Outcome related to changes of stimulated and suppressed thyroglobulin C. Hong, S. Lee, J. Lee, S. Jeong, B. Ahn; Kyungpook National University Hospital, Daegu, KOREA, REPUBLIC OF. EP-393

131I Effective Half-life in Children and Adolescents with Thyroid Cancer Patients X. Zhang, B. Liu; Department of Nuclear Medicine, West China Hospital, Sichuan Molecular Imaging University, Chengdu, CHINA. and Therapy in Haematological Tumours

230 OCTOBER 22–30, 2020 | VIRTUAL european association of nuclearOCTOBER medicine 22–30, 2020 | VIRTUAL 231 SATELLITE SYMPOSIA SATELLITE SYMPOSIA

Friday, October 23, 2020 12:15 - 13:45, Channel 4 SATELLITE Symposium by Siemens Healthineers: SYMPOSIA Bigger Perspective 4 Better Answers Chair: Katherina Swystun, Dr. Curtis Howe Siemens Healthineers Molecular Imaging will be making a big announcement in this symposium Thursday, October 22, 2020 16:35 - 18:05, Channel 9 A small group of molecular imaging leaders will share our vision for the next Symposium by Advanced Accelerator generation of healthcare. Applications, a Novartis company: Optimizing Treatment of Friday, October 23, 2020 12:15 - 13:35, Channel 5 EANM’20 EANM’20 Neuroendocrine Tumors Symposium by GE Healthcare: EANM’20 Chair: Dr. Christos Toumpanakis Elevate Molecular Imaging using Welcome and introduction. Dr. Christos Toumpanakis quantitative digital technologies to WORLD LEADING MEETING Management of GEP-NET patients during the COVID-19 pandemic achieve precision diagnostics WORLD LEADING MEETING Dr. Christos Toumpanakis Practical challenges in administering PRRT during the pandemic Chair: Prof. Mathias Goyen Prof. Ken Herrmann Quantitative SPECT for Synucleinopathies Prof. Val Lowe The GEP-NET patient journey: Patient case 1: Small bowel NEN Evaluation of MotionFree Data-Driven Gating for 68Ga-DOTATOC on Digital PET/CT Patient case 2: Pancreatic NET Prof. Mark Lubberink, PhD Dr. Christos Toumpanakis, Prof. Ken Herrmann, Dr. Thor Halfdanarson, Clinical versatility and diagnostic accuracy with digital CZT SPECT/CT Prof. Wouter de Herder, Elizabeth Quaglia Dr. Philippe Declerck Collaboration is key – the path to success The importance of the multidisciplinary team Dr. Christos Toumpanakis Friday, October 23, 2020 16:55 - 18:25, Channel 10 Symposium by ITM Isotopen Technologien Thursday, October 22, 2020 16:35 - 17:35, Channel 10 München AG: Challenges and Innovative Symposium by Terumo Interventional Approaches in the Management of Systems: The Holmium platform: Osteoblastic Metastatic Disease Individualized SIRT dosimetry at Chair: Prof Andrei Iagaru its full potential Welcome & Introduction Prof Andrei Iagaru. Chair: Prof. Derek Manas (Newcastle, United Kingdom) TALK 1: The Holmium platform Pathophysiology of Osteoblastic Metastatic Disease Prof M. Lam Prof Robert E Coleman TALK 2: The platform in daily clinical practice Current and Future Management Paradigms for Metastatic Bone Disease Dr Boni in Castrate-Resistant Prostate Cancer Prof Oliver Sartor TALK 3: Daily practice bac ed by clinical evidence Dr Braat Future Radiopharmaceutical Treatment Options for Primary and Metastatic Bone Cancer TALK 4: Discussion and Conclusion Prof Wolfgang Weber Prof Lam

232 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 233 SATELLITE SYMPOSIA SATELLITE SYMPOSIA

Monday, October 26, 2020 12:20 - 13:50, Channel 2 Wednesday, October 28, 2020 12:20 - 13:50, Channel 2 Symposium by Philips: Symposium by Sirtex Medical Optimization of F-18 FDG dose Europe GmbH: Evolving SIRT with in a Vereos PET-CT system SIR-Spheres® using new tools and insights

By tuning the reconstruction parameters, we were able to reduce the patient dose Chair: Patrick Flamen for F-18-FDG on a Vereos PET-CT system. The image quality remained constant compared to the image quality before the Welcome and Introduction dose reduction Patrick Flamen Using list mode acquisition we were able to generate images from old data with Optimizing SIRT – from empiric models to personalized medicine EANM’20 EANM’20 EANM’20 the old reconstruction and the new reconstruction. Harun Ilhan With the new reconstruction shorter scan times were used to simulated the lower Confidence in delivery for timely patient care administered dose Lars Stegger Old and new images were reviewed by 5 Nuclear medicine physicians in a blind International expert group recommendations for personalised SIRT

WORLD LEADING MEETING clinical assessment with SIR-pheres WORLD LEADING MEETING Hugo Levillain Speakers: Jan-Willem Postema, Dr. (Nuclear Medicine Physician), Reinier de Graaf Gasthuis Vincent Verhoeven, Ph.D. (Medical Physicist), Reinier de Graaf Gasthuis Advantages of a flexible treatment approach (not only in challenging times) Nicola Mulholland Monday, October 26, 2020 14:00 - 15:20, Channel 3 Panel Q&A* all Symposium by Spectrum Dynamics *via Zoom Medical: Digital 3D Imaging in

Nuclear Medicine: Organ Focused and Total Thursday, October 29, 2020 13:30 - 14:15, Channel 5 Body From Clinical Decision, to 3D Workflow Symposium by Telix Pharmaceuticals: Implementation, to Quantitative Analysis Telix – Next Generation Imaging Moderator: Jim Haisler, VP Global Commercial Operations, Spectrum Dynamics with PSMA-PET & More Nuclear Cardiology 2020: Chair: Prof Andrei Iagaru, Palo Alto, CA, U.S. Transitioning to CZT SPECT Perfusion, Function and Metabolic Imaging Dr. Ronald G. Schwartz , MD Realizing the promise of nuclear medicine in oncology theranostics The Transition to 3600 CZT SPECT/CT: Clinical Decision and Early Experience Prof. Alton O. Sartor, MD Dr. Veronica Sanchez Rodriguez, MD, PhD 68 Ga-PSMA-11: The PET/CT imaging tracer that changed the management of Maximizing 3600 CZT Digital SPECT/CT Diagnostic Capabilities: Implementation of prostate cancer Quantitative Analysis in Routine Clinical Applications Dr. Yong Du, MD, PhD, FRCP Dr. Laetitia Imbert, PhD, Pr. Antoine Verger, MD, PhD The diagnostic and therapeutic dilemma in clear cell renal cell carcinoma Presenters will be available for live discussion and Questions & Answers session Prof. Dr. Peter Mulders Immuno-PET using 89Zr-labeled antibodies Prof. Françoise Kraeber-Bodéré Closing remarks Dr. Colin Hayward

234 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 235 SATELLITE SYMPOSIA SATELLITE SYMPOSIA

Friday, October 30, 2020 12:15 - 13:45, Channel 4 Symposium by Boston Scientific: Optimizing SIRT Planning for Superior Patient Outcomes VISIT OUR

Chair: Prof. Ken Herrmann SATELLITE SYMPOSIUM

Efficacy and Standardisation of Glass Microspheres “Challenges and Innovative Prof. Ken Herrmann Approaches in the Dosisphere-01, a 16 month Increase in Overall Survival Management of Osteoblastic EANM’20 EANM’20 Prof. Etienne Garin Metastatic Disease.” EANM’20 Q & A / Discussion Talk 3: Practical Application of Personalised Dosimetry Dr Irene Torres

WORLD LEADING MEETING Talk 4 & Case Discussion: Case Examples of Personalised Dosimetry in Curative and WORLD LEADING MEETING Palliative Settings Dr Rafael Duran Final Q & A/ Discussion & Close PRECISELY FOR ME.

Dedicated to giving cancer patients Friday, October 30, 2020 13:50 - 15:20, Channel 4 better answers than “maybe”. Symposium by Advanced Accelerator Applications, A Novartis Company: Evolution of theragnostics and targeted therapies for advanced prostate cancer: the role of the multidisciplinary team

Chair: Prof. Joe O’Sullivan

Current treatments and unmet needs in advanced prostate cancer Prof. Bertrand Tombal Advanced targeted therapies on the radar Prof. Joe O’Sullivan Role of the nuclear medicine physician in the management of advanced prostate cancer patients Prof. Dr. med. Ken Herrmann Case study: The role of the MDT in treatment decisions and patient follow-up Dr. Daniel Heinrich Developing Targeted Radionuclide Panel discussion Chair: Prof. Joe O’Sullivan Panel: Prof. Bertrand Tombal, Dr. Daniel Heinrich, Therapies in Precision Oncology. and Prof. Dr. med. Ken Herrmann www.itm.ag

236 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 237 October 23, 2020, 16:55 – 18:25 (CET), Channel 10 at Virtual EANM 2020 LIST OF EXHIBITORS LIST OF EXHIBITORS

LIST OF LIST OF EXHIBITORS & SPONSORS SOCIETIES

ABX GmbH MR Solutions Ltd. AIMN - Italian Association of Nuclear Medicine SNMMI - Society of Nuclear Medicine and Molecular

EANM’20 EANM’20 ABX-CRO advanced pharmaceutical services NRG Petten ANZSNM - Australian and New Zealand Society of Imaging EANM’20 Advanced Accelerator Applications, a Novartis Oncobeta GmbH Nuclear Medicine South African Society of Nuclear Medicine company ORA (Optimized Radiochemical Applications) AOFNMB - Asia Oceania Federation of Nuclear The Health Policy Partnership.com Medicine and Biology Avid / Lilly P.B.L Srl. TSNM - Turkish Society of Nuclear Medicine ASNC - American Society of Nuclear Cardiology WORLD LEADING MEETING Bayer HealthCare Pharmaceuticals Inc. Pars Isotope UEMS/EBNM - European Union of Medical WORLD LEADING MEETING BELNUC Specialists/Section and European Board of Nuclear Blue Earth Diagnostics Ltd. Philips BNMS - British Nuclear Medicine Society Medicine Boston Scientific PMB-ALCEN EACVI European Society of Cardiology WFNMB - World Federation of Nuclear Medicine and Bracco Diagnostics Inc. Point BioPharma Biology Bruker BioSpin HSNM&MI - Hellenic Society of Nuclear Medicine Polatom – Radioisotope Centre of National Centre and Molecular Imaging Springer Nature Comecer for Nuclear Research JSNM - Japanese Society of Nuclear Medicine EARL Curium RI-TE Radiation Imaging Technologies MedSTEP - Job Board ESMIT Cyclomedica Europe Ltd. ROTOP Pharmaka GmbH ONCIDIUM SASAI Dosisoft S.A. Scannix SFMN - French Society of Nuclear Medicine and EANM office DSD Pharma GmbH SHINE Medical Technologies, LLC Molecular Imaging NucMed Guide Eckert & Ziegler Strahlen- und Medizintechnik AG Siemens Healthineers Eczacibasi-Monrol Nuclear Products Co. Sirtex Medical Europe GmbH GE Healthcare Spectrum Dynamics Medical Ltd. Hermes Medical Solutions Sumitomo Heavy Industries Ltd. IBA Telix Pharmaceuticals Ltd IRE-ELiT Tema Sinergie S.p.A. Isotopia Molecular Imaging Ltd. Terumo Interventional Systems ITM Isotopen Technologien München AG Transrad JSC Isotope / Rusatom Healthcare Trasis Lemer Pax Triskem International Medi-Radiopharma Ltd. U.S. Department of Energy Isotope Program Mediso Wallonia Export & Investment Agency Medraysintell MiE medical imaging electronics GmbH MILabs B.V. MIM Software Molecubes NV

238 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 239 EXHIBITOR PROFILES EXHIBITOR PROFILES

EANM’20 EANM’20 ABX advanced biochemical ABX-CRO advanced pharmaceutical Advanced Accelerator Applications, Asia Oceania Federation of Nuclear EANM’20 compounds GmbH services a Novartis company Medicine and Biology

Heinrich-Glaeser-Str. 10 - 14 Blasewitzer Strasse 78-80 4, rue de la Tour de l’île, 3-6-303 Mihogaoka 01454 Radeberg 01307 Dresden 1204 Genève 565-0047 Ibaraki

WORLD LEADING MEETING [email protected] [email protected] [email protected] WORLD LEADING MEETING http://www.abx.de http://www.abx-cro.com http://www.adacap.com http://aofnmb.org/

ABX - leading manufacturer of PET precursors, We are an international CRO with a strong focus on Advanced Accelerator Applications, S.A. (AAA), Asia Oceania Federation of Nuclear Medicine and peptides, reagents kits & hardware Our portfolio molecular imaging and internal radiotherapy clinical a Novartis company, is an innovative medicines Biology (AOFNMB) was launched in 1969 and includes: FDG reagents kits & hardware for nearly all trials. In addition to conducting clinical trials, we company developing targeted radioligand therapies has 73 member countries/regions in Oceania, FDG modules Mannose Triflate (DMF US & Europe) provide specialised end-to-end services including and precision imaging radioligands for oncology east Asia, south east Asia, south Asia, central Asia, Cryptand222 FPSMA-1007 precursors, reagents & consultancy for instance in pharmacokinetics and indications. We are committed to transforming and middle east Asia. The AOFNMB is working for hardware for GE MX, GE FX, GE FASTlab, ORA Neptis, radiopharmacology and put our inhouse image core patients’ lives by leading innovation in nuclear better education and training, and promotion of IBA Synthera, Synthra & Trasis AIO Nucleophilic & lab and data management department at the service medicine.
Founded in 2002, AAA has a legacy nuclear medicine in the region. Head Quarter Office electrophilic FDOPA precursors, reagents & hardware of your demands. Whether you represent a clinical as a pioneer in the development and delivery of (Ibaraki/Osaka), Shanghai Office for Asia Oceania FLT, FCholine, FMISO, FET & NAF precursors, reagents trial site or want to find out how your project could radiopharmaceutical drugs for diagnostic imaging. School of Nuclear Medicine, Multan Office for Asia & hardware Comprehensive range of “scientific” benefit from our experience: Chat with us here or More recently, AAA has focused its efforts on Oceania Nuclear Medicine Board, and Mashhad precursors for oncology (e.g. Fluoroestradiol, FAZA) send a message to [email protected]. We’re looking developing targeted radioligand therapies and Office for the publication of Asia Oceania Journal & neurology (e.g. Raclopride, Fallypride, PK11195, forward to your ideas! Presenting QDOSE: The next precision imaging diagnostics that target specific of Nuclear Medicine and Biology are functioning to Flumazenil, beta-CIT, PIB) SPECT precursors, as step in IRT dosimetry Founded on more than 20 years markers or receptors that are over-expressed by achieve the aims of AOFNMB. AOFNMB is working CuMIBI (DMF US & Europe), MIBG, ECD PEPTIDES, as of experience, we proudly introduce QDOSE as the certain types of solid tumors. together with International Atomic Energy Agency, PSMA-11, DOTA-TOC, DOTA-TATE & DOTA-NOC for flexible stand-alone software tool for safe, efficient World Federation of Nuclear Medicine and Biology, and productive internal dosimetry. Providing a one- Gallium68 Gallium68 reagents kits & hardware Lu177 Radioligand therapy combines a precision targeting European Association of Nuclear Medicine, Society of stop solution for multiple workflows, QDOSE is ready reagents kits & hardware O18 WATER Performance compound with a therapeutic radioisotope. Nuclear Medicine and Molecular Imaging, and other for your daily clinical routine use. Come over for a live of stability studies Development of radiotracers, After administration into the bloodstream, the global organizations. The Asia Oceania Congress demo session and explore how QDOSE can enhance labelling, purification strategies We are well radioligand binds to a marker or receptor on the of Nuclear Medicine and Biology (AOCNMB 2021) your workflow. experienced in GMP productions & do offer custom tumor and acts as the delivery agent for treatment will be held in Amman (Dr. Akram Al-Ibraheem), syntheses according to Q7 chapter 19 for clinical PET via the radioisotope, which damages the target cells, following AOCNMB 2019 in Shanghai (Dr. Huang studies (APIs). Our laboratories & clean rooms are disrupting their ability to replicate and/or triggering Gang and Jun Hatazawa), and followed by AOCNMB GMP certified & meet pharmaceutical standards. We cell death. Each dose is individually produced for a 2022 in Kyoto (Drs. Hiroshi Matsuda and Li Yaming). are GMP & ISO13485 certified. single patient.

AAA currently markets one therapeutic drug (in Europe, Canada and the U.S) and several precision diagnostic drugs in Europe and one in the US and Canada. We are currently investigating the potential utility of radioligand therapeutics and diagnostics in a broad range of solid tumors. For more information, please visit our website: www.adacap.com

240 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 241 EXHIBITOR PROFILES EXHIBITOR PROFILES

EANM’20 EANM’20 Associazione Italiana di Medicina Australian and New Zealand Society Bayer HealthCare Pharmaceuticals Blue Earth Diagnostics Ltd EANM’20 Nucleare (AIMN) of Nuclear Medicine Inc. The Magdalen Centre, Robert Robinson Via Farini, 81 PO Box 6178 100 Bayer Boulevard, P.O. Box 915 Avenue, Oxford Science Park 20159 Milano 3133 Vermont South 07981 Whippany, NJ OX4 4GA Oxford

WORLD LEADING MEETING [email protected] [email protected] [email protected] WORLD LEADING MEETING https://www.aimn.it http://www.anzsnm.org.au https://pharma.bayer.com/ http://www.blueearthdiagnostics.com

The official Italian Association of Nuclear Medicine Founded in 1969, the ANZSNM is the major Bayer is committed to delivering SCIENCE FOR A Blue Earth Diagnostics is a leading molecular imaging and Molecular Imaging It is composed by more than professional society for those practising Nuclear BETTER LIFE by advancing a portfolio of innovative diagnostics company focused on the development 900 members, mainly nuclear medicine physician. Medicine in Australia and New Zealand. Our focus is treatments. The oncology franchise at Bayer and commercialization of novel PET imaging agents The scope of the association is to widespread the promoting excellence in Nuclear Medicine through currently includes six marketed products. Several to inform clinical management and guide care for knowledge of nuclear medicine filed and to share all education, research and a commitment to the other compounds are in various stages of clinical cancer patients in areas of unmet medical need. the information about the molecular imaging. highest professional standards. The Society uniquely development, with the focus on potential first-in- Formed in 2014, Blue Earth Diagnostics is led by includes Technologists, Physicists, Radiopharmacists, class approaches across the areas of novel oncogenic recognized experts in the clinical development Physicians, Nurses, Chemists and others interested in signaling in combination with an effective biomarker and commercialization of innovative nuclear the practice of Nuclear Medicine. It has close ties with strategy, antibody drug conjugates including medicine products. The company’s first approved other professional groups in Nuclear Medicine, most a thorium platform and immuno-oncology. An and commercially available product is Axumin® particularly, the Australasian Association of Nuclear Oncology Strategic Business Unit within the (fluciclovine F 18), a novel molecular imaging agent Medicine Specialists (AANMS) which represents Pharmaceuticals Division of Bayer was established approved in the United States and European Union all practicing medical doctors. Radiologists, in 2017 to support the accelerated development for use in PET imaging to detect and localize prostate Cardiologists, and Oncologists may also participate of new treatment options. The company has also cancer in men with a diagnosis of biochemical and be involved in this area of healthcare. established a broad cooperative research network recurrence. Fluciclovine F 18 has also a broad range with healthcare professionals, academic research of other potential applications in cancer imaging and centers, other pharmaceutical companies and Blue Earth Diagnostics is investigating the molecule innovative biotech organizations worldwide. for other cancers including in neuro-oncology. The Together with these partners, we are fostering an company’s pipeline includes innovative Prostate open exchange of ideas to expand Bayer‘s vision of Specific Membrane Antigen (PSMA)-targeted treatment for cancer patients. radiohybrid (“rh”) agents, which are a clinical-stage, investigational class of theranostic compounds, with potential applications in both the imaging and treatment of prostate cancer. Blue Earth Diagnostics is a subsidiary of Bracco Imaging S.p.A., a global leader in diagnostic imaging.

242 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 243 EXHIBITOR PROFILES EXHIBITOR PROFILES

EANM’20 EANM’20 Boston Scientific Bracco Imaging British Nuclear Medicine Society COMECER EANM’20

Rue René Caudron 2, Parc du Val St Quentin Monroe Township Sir Colin Campbell Building, Triumph Rd Via Maestri del Lavoro 90 78961 Saint-Quentin-en-Yvelines 08831 NJ NG7 2TU Nottingham 48014 Castelbolognese [email protected] [email protected]

WORLD LEADING MEETING http://www.bnms.org.uk https://www.comecer.com WORLD LEADING MEETING

Boston Scientific (NYSE: BSX) is a leading global Bracco Imaging offers products and solutions for all The British Nuclear Medicine Society (BNMS) Comecer, an ATS company, is a developer and healthcare company with approximately 32,000 key diagnostic imaging modalities: X-ray (including established in 1966 is the only independent UK manufacturer of high-tech systems in the field employees and revenue of $9.8 billion. Boston Computed Tomography, Interventional Radiology, forum devoted to all aspects of Nuclear Medicine. of Aseptic Processing and Containment for Scientific transforms lives through innovative medical and Cardiac Catheterization), Magnetic Resonance The BNMS represents all craft groups in nuclear Pharmaceutical Industries. It operates in the solutions that improve the health of patients around Imaging, Contrast Enhanced Ultrasound, and Nuclear medicine and provides advice and guidelines for Radiopharmaceutical sector through the production the world. As a global medical technology leader for Medicine through radioactive tracers. This portfolio all those who practice nuclear medicine. The BNMS of shielding systems and equipment for special 40 years, we advance science for life by providing is complimented by a range of medical devices and is concerned with promoting the clinical benefits applications, both for large industrial groups and for a broad range of high performance solutions that advanced administration systems. of nuclear medicine and supporting the clinical research institutions. address unmet patient needs and reduce the cost practice, education, research and development Comecer designs and builds systems and equipment of healthcare. of nuclear medicine within the UK. It is also active for the safe treatment of radioactive substances internationally in supporting our colleagues in all used in Nuclear Medicine, guaranteeing minimum aspects of nuclear medicine practice. Membership is exposure to the operator, total decontamination and open to those who have a substantial interest and inalterability in any working condition. In particular, involvement in the provision of nuclear medicine Comecer excels in the field of radiochemistry where, services in the UK and overseas. The official journal on behalf of large industrial groups or research of the Society is Nuclear Medicine Communications. institutes, it manufactures shielding systems for Officers of the Society: Dr John Buscombe, President, special applications. Mrs Jilly Croasdale, Honorary Treasurer, Dr Richard Comecer products, such as shielded hot cells, Graham, President Elect, Dr Stewart Redman, synthesis and dispensing isolators, solid target Honorary Secretary. At the BNMS booth, delegates systems and radiopharma injectors, are used can find: • Information on BNMS membership in the most advanced and prestigious research - discount to new members signing up at the centres, universities, hospitals and pharmaceutical meeting. • Information about future meetings in the companies worldwide. UK • BNMS Brochures and Publications • Answers to any other questions regarding the BNMS Pass by our stand for a chance to win free attendance at our Spring Meeting 2021 which will be held at the ICC Waterfront, Belfast in May 2021.

244 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 245 EXHIBITOR PROFILES EXHIBITOR PROFILES

DOSIsoft Eckert & Ziegler Medical Eczacibasi Monrol Nuclear Products Elysia-Raytest EANM’20 EANM’20 EANM’20 45/47 Avenue Carnot Robert-Rössle.Str. 10 Ruzgarli Bahçe Mah. Kavak Sok. No:20 Beykoz Rue du Sart-Tilman 375 94230 Cachan 13125 Berlin 34805 Istanbul 4031 Liège [email protected] [email protected] [email protected] [email protected] https://www.dosisoft.com https://www.ezag.com/home/products/ http://www.monrol.com WORLD LEADING MEETING WORLD LEADING MEETING medical/ Founded in 2002, DOSIsoft develops patient-specific Eczacıbaşı Monrol Nuclear Products is a joint venture Raytest was founded in 1980 and joined the Elysia imaging and dosimetry software in Radiation The Eckert & Ziegler Medical segment pools between Eczacıbaşı Pharmaceuticals Manufacturing group in 2015. The core products were detectors Oncology and Nuclear Medicine to improve patient multifaceted expertise from various areas to provide and Bozlu Holding that was established in 2008. of radioactivity for a variety of applications. safety & treatment quality. 18 years of innovation and a comprehensive range of products and services for Eczacıbaşı Monrol is the market leader for the Turkish From metabolism research in pharmaceutical R&D investments have led to world leading software radiotherapy, brachytherapy, nuclear medicine and Nuclear Medicine market thanks to its high-quality and agrochemical research to nuclear medicine solutions used successfully in over 200 hospital molecular imaging. These include medical devices, radiopharmaceuticals production, wide range of and PET, Elysia-raytest supplies state-of-the-art centers in 38 countries. Spin-off between Gustave radiopharmaceuticals, radiochemicals and related products both in diagnosis and therapy and diverse devices and integral GMP solutions. Today, Elysia- Roussy and Institut Curie, DOSIsoft constantly equipment for the processing of radioisotopes. geographical production sites and manufacturing Raytest is a competent and reliable partner for the innovates in partnership with the major cancer By this we are able to provide both, solutions for capacity. Eczacıbaşı Monrol exports to more than global community in nuclear medicine, PET and institutes and research centers in the world. individual projects and customized packages for 40 countries worldwide and also has manufacturing Radiotherapy. The reputation of Elysia-Raytest is PLANET® Software Suite is a Patient-specific & routine and research application. All of these are sites and operational projects in different regions. We based on the supply of high-quality hardware and MultiRadionuclide Platform (90Y, 177Lu & 131I) perfectly complemented by our expertise in contract produce radiopharmaceuticals used for diagnosis services for quality control (QC) laboratories and dedicated to Molecular Imaging (MI) & Molecular manufacturing, commissioned work, services for and treatment in our 7 world-class production PET tracer and radiopharmaceutical production RadioTherapy (MRT) dosimetry. It comprises: engineering and technical support. Furthermore, facilities with totally 12 cyclotrons and 2 SPECT synthesizers. For the development of new products, we offer extensive know-how to contribute to the production lines, 1 SPECT EU Release Site employing Elysia-Raytest has an in-house team of experienced PLANET® Onco: Oncology software for MI & success of CMC and other projects by providing modern and environment-friendly technologies. We physicists, biologists, engineers and technicians. Radiotherapy. It helps clinical team to optimize individual solutions for their realization. Find out also have been operating cyclotrons in Kuwait, Iraq, Development is orientated towards the customer’s disease diagnosis & therapy through registration, more about the GalliaPharm®, Yttriga, Modular-Lab, Libya, Pakistan and we have long term operational needs . The successful development of new contouring, advanced quantification & patient KitLab, FlowCount, MiniScan, AR-2000, Hot Cell agreements with 2 centers in Turkey and 1 center instruments, in cooperation with the customer, response from multimodal imaging. Texture analysis Solutions, SagiNova, ISOSeed & Co. in Dubai. 7 production plants in total with each of has a long tradition in our company. All Elysia- for diagnosis, follow-up & radiomics is provided. them being around 1,000 sqm in Romania, Bulgaria, Raytest products are manufactured in Germany and Deep learning contouring is under development. Egypt, and Turkey (4 sites in different locations in Belgium. PLANET® Dose: Dosimetry software for MRT providing Turkey). All our facilities are GMP certified. Gebze- fully integrated 3D and hybrid 3D-2D 90Y, 177Lu & Turkey, Romania, Bulgaria facilities also have EU GMP 131I dosimetry. It allows medical team to personalize certificate. Other Certificates ISO 9001, ISO 14001, patient therapy through pre/post-implementation ISO27001, OHSAS 18001 dosimetry, automatic structure propagation, calculation of residence time & comparison between treatment planning & validation control dose maps. Consolidation of multi-treatment stages is available. PLANET® Neuro: Neurology software for neurological & dement

246 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 247 EXHIBITOR PROFILES EXHIBITOR PROFILES

European Association of GE HEALTHCARE Hellenic Society for Nuclear Hermes Medical Solutions Cardiovascular Imaging (EACVI) Medicine and Molecular Imaging 283 rue de la MIniere (HSNM&MI) Strandbergsgatan 16 European Heart House , 2035 route des Colles 78530 Buc 112 51 Stockholm 06903 Sophia Antipolis [email protected] 44-46 Ippokratous street [email protected] 10680 Athens [email protected] http://www.gehealthcare.com https://www.hermesmedical.com/

EANM’20 EANM’20 https://www.escardio.org/EACVI [email protected] EANM’20 https://nuclear-medicine.gr/ Recognised for over 40 years for clinical excellence The European Association of Cardiovascular GE Healthcare is elevating molecular imaging and innovation, Hermes Medical Solutions provides Imaging (EACVI), a branch of the European Society through its total MI solution to empower you on Founded in 1968, by the renowned Honoured a comprehensive range of independent, vendor- of Cardiology, is a not-for-profit organisation. the journey to precision health across multiple care Member of the Academy of Athens for Sciences and neutral software solutions for NM and molecular WORLD LEADING MEETING WORLD LEADING MEETING Everything we do is to support our 14,000 members areas, including oncology, orthopedics, cardiology, Philosophy, Professor of Medicine Vassilios Malamos, imaging. Hermes provides the clinical workflow for worldwide and all healthcare professionals - and neurology. We offer total MI solutions to HSNM&MI is one of the oldest European societies integration, visualisation, processing, remote and cardiologists, technicians, nurses, basic scientists and enable tracer development and accurate imaging in Nuclear Medicine. HSNM&MI aims: • Scientific local reporting, and storage of image data from allied professionals – specialising in cardiovascular acquisition for personalized patient care from development of Nuclear Medicine and its biological multiple modalities within NM, molecular imaging imaging so they can deliver the best possible diagnosis to treatment monitoring. Visit our booth applications. • Contributing to research, study and and radiology. At EANM 2020 we are proud to evidence-based care to patients. Our activities are to discover the innovative components of our total optimization of Nuclear Medicine applications in showcase our groundbreaking Affinity Viewer, driven by volunteers who are renowned experts from MI solutions! - Nuclear Medicine, a comprehensive Greece. • Promoting Nuclear Medicine education which accelerates your PET/CT, PET/MR, and SPECT/ across all imaging techniques: echocardiography, family of nuclear medicine systems to help clinicians in the context of continuing medical education • CT reporting with a fast, responsive and intuitive cardiovascular magnetic resonance, nuclear achieve better outcomes - Discovery MI Gen 2*, a Promoting cooperation of other disciplines in the user interface. Hermes offers a leading range of cardiology and cardiac computed tomography. Our new generation of the world’s first digital PET/CT field of Nuclear Medicine. • Formulation, protection radionuclide therapy and dosimetry software to Mission: to promote excellence in clinical diagnosis, platform - PET Radiopharmacy, enabling accessible and compliance with radiation protection help you personalise treatment for your patients, research, technical development, and education in and reliable PET tracer production and development regulations, in accordance with the existing including Voxel Dosimetry with Monte Carlo dose cardiovascular imaging. in search of true discovery - SIGNA™ PET/MR with provisions, regarding handling, use and disposal of simulation and theranostics dose prediction, organ QuantWorks, a new era in personalized imaging with radioisotopes. • Representation and cooperation dosimetry using industry standard OLINDA/EXM, quantitative PET/MR - Pharmaceutical Diagnostics, of the Society’s representatives with the State, the and SUV-SPECT® quantitative SPECT reconstruction ensuring excellence in patient outcomes, you can European Union and international scientific bodies suitable for any radionuclide and camera. Hermes count on a broad portfolio of products and services. in general. HSNM&MI has a total of 328 members, also offers dedicated and automated tools for Lung including Nuclear Medicine physicians and residents, VQ SPECT and for Lung Lobar Quantification using * Not cleared or approved by the U.S. FDA, not yet CE Nuclear physicists, Technologists, Radiobiologists CT-derived anatomical information. Hermes Medical marked, or approved by any other global regulator and Radiopharmacists. HSNM&MI operates and acts Solutions’ leadership within NM and molecular to be commercially available, placed on the market as the main and only consultant for the Greek State, imaging has been built upon continual innovation, or put into service. in any kind of issue including and interfering with strong customer service, and clinical expertise. We Nuclear Medicine. Since the beginning, HSNM&MI offer the most comprehensive molecular NM & has kept on collaborating worldwide with EANM, imaging software suite for diagnosis and treatment WFNMB and IAEA. In addition, HSNM&MI has a planning, making precision personalised medicine leading role concerning the promotion of Nuclear a reality. Welcome to the Hermes virtual EANM Medicine in the Balkan region, by contributing to the booth! organization of BCNM congresses.

248 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 249 EXHIBITOR PROFILES EXHIBITOR PROFILES

EANM’20 EANM’20 IASON GmbH IBA IRE ELiT Isotope JSC / Rusatom Healthcare EANM’20

Feldkirchner Strasse 4 Chemin du cyclotron 3 Avenue de l’Espérance, 1 Pogodinskaya str., 22 8054 Graz-Seiersberg 1348 Louvain-la-Neuve 6220 Fleurus 119435 Moscow [email protected] [email protected] [email protected] [email protected]

WORLD LEADING MEETING http://www.iason.eu/ https://www.iba-radiopharmasolutions.com/ http://www.ire.eu http://www.isotop.ru WORLD LEADING MEETING

IASON, with its head office in Graz, was founded by IRE ELiT is a Belgian innovative radiopharmaceutical Founded in 1958, Isotope JSC (a company managed its Managing Director Mr Christoph Artner in 1994 Based on longstanding expertise, IBA company that develops, produces and by Rusatom Healthcare JSC) is an expert in and has its origins in the trade of innovative medical RadioPharma Solutions supports hospitals and commercializes simple and premium solutions for organizing secure supplies of isotope products for technology products, which is still a business radiopharmaceutical distribution centers with their Nuclear Medicine. IRE ELiT places quality, reliability nuclear medicine. Located in Moscow, Isotope JSC segment today. As a specialist for the production of in-house radioisotopes production by providing and services at the center of its concerns to secure is responsible for the distribution and marketing of radioactive pharmaceuticals, IASON helped to bring them global solutions, from project design to the the supply and easy use for its customers worldwide. isotope products manufactured by the enterprises the method of positron-emission-tomography (PET) operation of their facility. In addition to high-quality Our portfolio of customer-oriented solutions of ROSATOM State Atomic Energy Corporation. Our to Austria in the late 1990ies. technology production equipment (cyclotron includes radioisotopes for diagnosis or treatment portfolio is comprised of isotope-based products for IASON‘s core competences lie in the development, solutions, targetry systems, synthesizers, control purposes, as well as equipment dedicated to their medical purposes including radiopharmaceuticals production and distribution of radiopharmaceuticals systems, …), IBA has developed in-depth experience preparation. The extension of our range is supported and medicinal devices, as well as a wide range of raw for application in Positron-Emission-Tomography. in setting up (c)GMP radiopharmaceuticals by our R&D team and several partners with expertise materials (radioisotopes, stable isotopes). We supply Our USPs are clearly our Marketing Authorizations, production centers. in different complementary sectors. Our teams are over 20 critical medical isotopes to the international which we currently hold for five products in up to 15 resolutely engaged in research programs with several markets, among which are such core products as European countries. Efdege®, IASOcholine®, IASOflu®, universities and research centers, both in Europe Mo-99, I-131, Sm-153, Ge-68/Ga-68 generators, IASOdopa® and IASOglio® are mainly applied for and on other continents. This policy of strengthened etc. One of the world’s largest producers of such imaging in nuclear medicine (cancer patients), but cooperation between industry and academia promising medical isotopes as Lu-177 and Ac-225, there is also a growing number of non-oncological constitutes a key factor for future developments in we set a key target to contribute to the development indications. the field of cutting-edge radiopharmaceuticals. IRE of the modern nuclear medicine treatments and ELiT is delighted to share its quality of service with technologies to improve patients’ quality of life. Further business segments and competences of practitioners in the field for the benefit of patients’ Isotope JSC is a leading supplier of medical isotopes IASON include clinical research programs and clinical health. to Latin America, Asia and the Middle East. Over know-how transfer, the production of O-18 water as a 100 foreign companies in 50 countries across the raw material for production of radiopharmaceuticals world and around 600 Russian companies including (at the site in Graz), measuring the radiation healthcare providing institutions, manufacturing exposure of flight personnel (IASON F.R.E.E., also facilities, and scientific & research organizations in Graz) and consultancy for turnkey projects (BOT are among partners of Isotope JSC. We deliver build-operate-transfer) for radiopharmaceutical our products all over the world by air, sea, and production sites. land.

250 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 251 EXHIBITOR PROFILES EXHIBITOR PROFILES

EANM’20 EANM’20 Isotopia Molecular Imaging Ltd. ITM Isotopen Technologien LA CALHENE Medi-Radiopharma Ltd. EANM’20 München AG 39 Alexander Yanai 1 RUE DU COMTE DE DONEGAL Szamos u. 10-12. 49277 Petach Tikva Lichtenbergstrasse 1 41100 VENDOME 2030 Érd [email protected] 85748 Garching / Munich [email protected] [email protected]

WORLD LEADING MEETING http://www.isotopia.co.il/ [email protected] https://www.lacalhene.com http://www.mediradiopharma.com/ WORLD LEADING MEETING https://itm-radiopharma.com Isotopia is a Radio Pharmaceutical Company Since its founding in the 60’s La Calhène (part of Medi-Radiopharma (MRP) has more than 30 years established in 2006, since than has become an ITM Isotopen Technologien München AG is a privately the Getinge group) has developed innovative of experience in developing, manufacturing essential supplier for the growing field of nuclear owned biotechnology and radiopharmaceutical solutions complying with safety, security, reliability and supplying radiopharmaceutical products to medicine in Israel. Isotopia was founded by a highly group of companies dedicated to the development, and performance constraints. The equipment customers around the globe. During this time MRP trained group of senior professionals, experienced production and global supply of targeted diagnostic designed, manufactured and serviced by the has become one of the well-known and reliable in all aspects of radio-pharmaceutical operations, and therapeutic radiopharmaceuticals and company contributes to the protection of operators Nuclear Medicine Suppliers – not just in Europe but in collaboration with a group of Canadian radioisotopes for use in cancer treatment in the nuclear and pharmaceutical industries and – all over the world. investors. Isotopia operates a PETtrace Cyclotron Since its foundation in 2004, ITM and its subsidiaries safe transport of fissile materials / pharmaceutical (GE Healthcare), supplying both PET and SPECT materials. have established GMP manufacturing and a robust MRP specialised in the production and supply of tracers, manufactured under strict Quality Control global supply network of a novel, first-in-class generic in-vivo kits for Tc-99m labelling used in Procedures. Apart from FDG, there are newly medical radioisotopes and generator platform for La Calhène supplies the nuclear industry and the field of Nuclear Medicine. Today we supply our available 18F-labeled products, including 18-F-DOPA, a new generation of targeted cancer diagnostics nuclear medicine laboratories with a complete range products to more than 70 countries – our goal is to 18-F-PSMA and 18-F-Choline. Being aware of new and therapies. Furthermore, ITM is developing of remote manipulators for standard and specific further expand our global presence. advancements in nuclear therapy, Isotopia is also a proprietary portfolio and growing pipeline of applications, from the small capacity MA30 to the providing 177-Lu treatments for prostate cancer and targeted treatments in various stages of clinical large capacity MT200 (telescopic type), including the MRP holds a wide and diverse portfolio of well-known neuroendocrine tumors. Since 2014, Isotopia supply development, which address a range of cancers MT200 TAO computer-assisted remote manipulator products registered in more than 67 countries world- 68- Ga- PSMA to the local market, being the first such as neuroendocrine tumors, glioblastoma, with robotic function company responding to this emerging technique osteosarcoma and bone metastases, as well as folate wide. We pride ourselves on our ability to deliver a in prostate cancer management. In our pipeline, will receptor α positive tumors such as lung, ovarian or steady supply of quality diagnostics and we support marketing a cold kit for 68-Ga-PSMA-11 synthesis. breast cancer. Shielded transport casks (PADIRAC and AGNES) and the development of therapeutical compounds with Glove Box equipment provide protection to those the highest standards of quality and safety assured Isotopia is taking steps for becoming a major ITM’s main objectives, together with its scientific, manipulating radio-active substances at every stage. worldwide supplier of 177- Lutetium ca and nca to medical and industrial collaboration partners be used in the field of molecular radiotherapy. As part worldwide, are to significantly improve treatment of Isotopia’s vision, we are looking for collaboration outcomes and quality of life for cancer patients Getinge’s DPTE® patented transfer solutions are MRP holds a valid Manufacturer’s Authorization, with companies and academic institutes to develop while at the same time reducing side effects and installed in hot cells, on isolators and pharmaceutical certificate of GMP Compliance, Wholesale new markers, radiopharmaceuticals production and improving health economics through a new production lines throughout the world. Our DPTE® Distribution Authorization, Certificate of GDP international sales. generation of Targeted Radionuclide Therapies in equipment ensures secure transfer of sterile and/ Compliance, Good Laboratory Practice (GLP) Precision Oncology or toxic materials, into and out of contaminated or Certificate, wholesale distribution license for For more information please visit: www.itm.ag. aseptic zones. It is the industry standard for transfer radiopharmaceuticals – besides the animal testing, of toxic / aseptic products in nuclear and biomedical isotopes licence, ISO Certificate and relevant research institutions and the pharmaceutical authorization for the manufacture. industry globally

Besides the production and distribution MRP also Leak-tight bi-directional transfer is assured by has broad experience and capabilities to research our wide range of Beta parts including re-usable and develop different drug formulation and develop containers (PE, stainless steel), tubing and the DPTE- manufacture process of sterile injectable drug BetaBag® for products.

252 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 253 EXHIBITOR PROFILES EXHIBITOR PROFILES

EANM’20 EANM’20 Mediso Medical Imaging Systems MiE GmbH MILabs MIM Software Inc. EANM’20

Laborc str.3. Hauptstrasse 112 Duwboot 7a 25800 Science Park Dr Ste 180 1037 Budapest 23845 Seth 3991 CD Houten 44122 Cleveland [email protected] [email protected] [email protected]

WORLD LEADING MEETING https://mediso.com https://mie-scintron.com/ https://www.milabs.com/?utm_ http://www.mimsoftware.com WORLD LEADING MEETING source=EANM&utm_medium=EANM&utm_ Mediso works in the field of nuclear medicine since We have produced gamma camera and PET systems campaign=2020 MIM Software Inc. offers a comprehensive suite of 1990 with a profile of development, manufacturing, since 1981 for the complete nuclear imaging applications that support Radiology and Nuclear selling and servicing molecular imaging multi- medical market of the nuclear medical diagnostic. MILabs is a leading innovator in preclinical PET, Medicine’s important role in the patient care modality devices. The company offers complete We provide for the discriminating and price sensitive SPECT, Optical, and X-ray CT imaging systems, pathway. MIM Software products emphasize the market. All our systems are produced according to solutions from hardware design to evaluation and available as stand-alone imaging devices or in any importance of quantitation, collaboration, and current medical and technical requirements. The quantification software for clinical patient care and combination in a single integrated scalable platform. data management to provide physicians with the experience and the know-how since 1974 form the preclinical research. With its 30-years expertise, 1 The scientific community recognizes all modalities necessary information needed to generate confident development of our data and image processing clinical guidance and to inform effective treatments. 250+ clinical cameras, Mediso is within the leaders for superior resolution and image quality. MILabs’ unit SCINTRON. This diagnostic prospects are also systems have received many international awards, in clinical patient care. Besides a unique 3-modality available for the veterinary market. Accredited and advanced preclinical imaging applications have clinical SPECT-CT-PET hybrid system, Mediso MIM Encore® provides advanced visualization, service, constantly care of our hard- and software been published by hundreds of satisfied users. By launched its new TRIPLE head SPECT combination and time accordant design show our capacities. image registration, segmentation, and analysis combining PET, SPECT, Optical, and CT on a single tools that are well-equipped to manage the latest system as part of the 3-modality hybrid families. Since 1995 MiE America, Inc. has been in business in-line platform, MILabs has introduced the first Mediso has a leader position in the preclinical to provide a better service to our america customers. advances in theranostics and other fields. MIM commercial system to exploit the many symbiotic SurePlan™ MRT offers tools to support the feasibility nuclear imaging market with 250+ commissioned MiE America, Inc. is located in Elk Grove Village, IL, strengths such as: • Simultaneous Multi-isotope PET- of molecular radiotherapy dosimetry within the busy preclinical cameras around the world. Beyond the USA. The MiE GmbH is in accordance with EN ISO PET and PET-SPECT imaging • Sub-mm theranostic Nuclear Medicine workflow. Quantitative images are market leading nanoScan PET/CT and SPECT/CT, 13485 certified and our gamma camera systems are imaging including alpha- and beta-emitting needed to calculate accurate dosimetry, and MIM Mediso launched the world’s first integrated PET/ with Annex II of Directive 93/42/EWG approved. Also, radiotherapy isotopes • Quantitative CT-guided we are registered at the FDA – our systems are 510(k) SPECTRA Quant™ provides a vendor-neutral SPECT MRI and SPECT/MRI systems. Further on 3T and 7T Optical Tomography. This single-pass in-vivo approved since 1995. This extensive certification is reconstruction method that pairs dynamically with cryogen-free magnets and PET insert have been imaging platform with synergistic multi-modal the basis for the manufacture and distribution of existing SPECT/CT cameras. added to the product line, resulting in the largest capabilities paves the way for rapid translation of medical products on the world market. install base of integrated PET/MRI systems. Products precision medicine from bench to bedside. MIM Assistant® automates traditional clinical tasks are sold directly or through a network of distributors and centralizes images and related data to a single with over 1500 imaging systems for clinical and repository. Flexible deployment options allow easy preclinical imaging operating in 98 countries around access to MIM Software from anywhere. The result is the globe. greater access to critical patient information when in collaborative settings like tumor boards or for use in dictated reports.

254 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 255 EXHIBITOR PROFILES EXHIBITOR PROFILES

EANM’20 EANM’20 MOLECUBES MR SOLUTIONS GROUP NRG Oncidium foundation EANM’20

Ottergemsesteenweg Zuid 808 bus 325 Old Portsmouth Road, Artington Westerduinweg 3 Avenue Hermann Debroux 40 09000 Ghent GU31LR Guildford 1755 LE Petten 1160 Brussels [email protected] [email protected] [email protected] [email protected]

WORLD LEADING MEETING http://www.molecubes.com http://www.mrsolutions.com http://www.advancingnuclearmedicine.com https://www.oncidiumfoundation.org/ WORLD LEADING MEETING

MOLECUBES MR SOLUTIONS GROUP develops and manufactures Advancing Nuclear Medicine The Oncidium foundation is dedicated to promoting innovative MR, CT, PET and SPECT imaging solutions. by NRG Radiotheranostics (RT) for cancer therapy. It strives All scanners are interchangeable between each to connect patients, practitioners and experts in the Based in Ghent, Belgium, MOLECUBES is an other for multi-modality imaging. Nuclear Medicine field by raising awareness and innovative company, developing and manufacturing FIELD-LAB, an innovative joint R&D centre for nuclear improving access to cancer treatments and clinical scanners for preclinical PET, SPECT and CT imaging. medicine The company is the worldwide leader in high-field trials worldwide. Three pillars: ACCESS – Through Combining more than 15 years of experience in NRG meets the need to accelerate the development cryogen-free MR and delivers systems up to 9.4T a platform that will create cohesion between all hardware and software development, our systems of new nuclear therapies, usually hindered by high with a bore size up to 42 cm. This technology has interlocutors. Notably, for patients, to find the costs and the restricted availability of facilities and are designed and built by a young team who have exclusive features such as rotating the system to 90° nearest treatment center, current clinical trials and isotopes. FIELD-LAB has been created together with been end-users themselves. The engineering team and to change the field within few minutes. It doesn’t to facilitate communication with medical experts; renowned Dutch Academic Medical Centres and is completed by an accomplished support team, require pipes and heavy site building therefore the For practitioners to register their therapy centers; dedicated industry partners, and was presented as well as a sales and management team with long installation cost is extremely low. For RT experts to help promote precision medicine track records in the preclinical arena. Developed to the international nuclear medicine society early and its progresses. Thus, bridging the gap between 2019. by end users, our promises are simple: excellent people to advance availability of this innovative and PET/MR imaging is possible up to 9.4T simultaneously. image quality, functional design, intuitive software, Now we take the next step by presenting the life-saving technology. EDUCATION – Education and PET and SPECT scanners are dissociable within a few progress we have made: awareness are essential, as it helps bring a better a high-throughput workflow and unmatched expert minutes from the MR and pluggable onto the CT. It – Lu-177 n.c.a.: the isotope for targeted therapy
– Pt-195m: to increase effectivity of cisplatin of RT, still unknown to some practitioners and the imaging. chemotherapy
– Pb-212: promising alpha general public. HOPE – When other cures are not an THE CUBES therapeutic isotope for targeted therapy
We option. The foundation is evaluating all possibilities Four models of PET/CT’s and CT’s are available: a expect various publication-ready topics by 2021. to support clinical developments of efficient RT and Benchtop, two high resolutions models and finally a Physical construction of FIELD-LAB (financially individual cases to reduce treatment overall costs in Our benchtop imaging systems, the “CUBES”, require very large bore for 12 kg animals. supported by the EU and the Province of North low income countries. Moreover, Oncidium cannot very little available lab space and allow researchers Holland) will start end of 2020 with supply of GMP act alone and be efficient. The solution is to build to achieve high performance SPECT/CT and PET/ batches expected by the beginning of 2023 a worldwide network of Oncidium Ambassadors CT studies without complex system handling. At in each country for awareness and education Please visit us at our booth in Vienna! MOLECUBES, we provide three separate “CUBES”. campaigns, local collaborations and shared The γ-CUBE (SPECT), β-CUBE (PET) and X-CUBE (CT). knowledge. Together, let’s commit to enhance These modular benchtop scanners are perfectly www.advancingnuclearmedicine.com Access, Education and Hope! suited for in vivo multimodal whole body rat and mouse imaging, while their modularity accounts for the evolution of lab needs.

256 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 257 EXHIBITOR PROFILES EXHIBITOR PROFILES

EANM’20 EANM’20 OncoBeta GmbH P.B.L. SRL PARS ISOTOPE Philips EANM’20

Lichtenbergstraße 8 VIA VOLTA N. 8 No.88, west 23 St. Azadegan Blvrd. Amstelplein 2 85748 Garching b. München 43046 RUBBIANO South Sheikh Bahaiee Breitner Center [email protected] [email protected] 1439955416 Tehran P.O. Box 77900 1070 MX Amsterdam WORLD LEADING MEETING http://www.oncobeta.com http://www.pblsrl.it [email protected] WORLD LEADING MEETING http://www.parsisotope.com OncoBeta® GmbH with its headquarters located ACIC Machinery – PBL The partnership between http://www.philips.com in Munich, is a medical device and radiochemical ACIC Machinery and PBL Srl provides clients with Pars Isotope Co. is the leading producer and supplier state-of-the-art equipment for the production of company specialized in the development and of medical radioisotopes in the Middle East. With Philips is a leading health technology company radiopharmaceuticals globally. ACIC Machinery commercialization of state-of-the-art, innovative more than 50 products in the world of nuclear focused on improving people’s lives across the and PBL provide turnkey automation solutions for therapies utilizing epidermal radioisotope medicine, we supply different radiopharmaceuticals health continuum – from healthy living and radiopharmaceutical manufacturing: • Aseptic Filling, applications. Since its foundation, OncoBeta® GmbH and solutions used in the treatment and diagnosis prevention, to diagnosis, treatment and home Capping & Crimping • Particulate Matter, Cosmetic has concentrated its efforts on the development, process. Based on our deep-seated knowledge and care. Applying advanced technologies and deep and Components Inspection • Radiation Inspection experience in radiopharmaceuticals production, clinical and consumer insights, Philips delivers regulatory approval(s) and commercialization • Labeling • Packaging Systems • Custom Projects • we have succeeded to manufacture some unique integrated solutions that address the Quadruple of the Rhenium-SCT® (Skin Cancer Therapy) Washing Systems • Depyrogenation Tunnels You can radiopharmaceuticals and introduce different Aim: improved patient experience, better health targeting Non-Melanoma Skin Cancers. Since then, learn more: https://acicmachinery.com/products/ solutions to the international market. The most outcomes, improved staff experience, and lower OncoBeta® GmbH has successfully perfected the radiopharmaceutical/ highly prized products in this range are PARSTEC cost of care. Partnering with its customers, Philips customized application and device management (II) which is our TC-99m generator brand and seeks to transform how healthcare is delivered and system in conformity with all health, safety, and PARS GalluGEN that is our Ge-68/Ga-68 generator. experienced. The company is a leader in diagnostic environmental protection regulatory standards. To enhance the quality and quantity of medical imaging, image-guided therapy, patient monitoring Since 2019 OncoBeta® GmbH produces tungsten products according to cGMP regulations Pars Isotope and health informatics, as well as in consumer health (wolfram)-188/rhenium-188 (188W/188Re) is involved in a project to implement new modern and home care. Generators for commercial use. facilities for RRP, CKP, and PET in Iran. Additionally, we are focused on the following activities according to our profession and capabilities: – Production of 12 diverse types of Tc-99m cold kits. – Production of 5 different types of Tc-99m peptide kits. – Production of 5 types of radionuclide generators used in PET & SPECT. – Production of 22 various ready-to-use radiopharmaceuticals in diagnostics and therapeutics. – Production of 7 different types of radiochemicals used in the production of radiopharmaceuticals. – Development and optimization of advanced methodologies in the production of radiopharmaceuticals.

258 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 259 EXHIBITOR PROFILES EXHIBITOR PROFILES

EANM’20 EANM’20 POINT Biopharma RI-TE, Lda - Radiation Imaging ROTOP Pharmaka GmbH SHINE Medical Technologies EANM’20 Technologies 22 St. Clair Avenue East Bautzner Landstrasse 400 101 E Milwaukee St, Suite 600 Suite 1202 Universidade de Aveiro Incubator 01328 Dresden 53545 Janesville M4T 2S3 Toronto PCI - Creative Science Park [email protected] [email protected] Via do Conhecimento, Edifício Central WORLD LEADING MEETING [email protected] http://www.rotop-pharmaka.de http://www.shinemed.com WORLD LEADING MEETING 3830-352 - Ílhavo Aveiro https://www.pointbiopharma.com/ [email protected] ROTOP Pharmaka is a leading German Dedicated to being the world’s leading medical POINT Biopharma is a clinical-stage global https://www.ri-te.pt/ pharmaceutical company that produces cGMP isotope producer SHINE Medical Technologies pharmaceutical company focused on the compliant radiopharmaceuticals for diagnostics and is a nuclear technology company dedicated to development and commercialization of radioligand We’re a tech company developing a new generation therapy in Nuclear Medicine and Molecular Imaging producing medical isotopes for the global market. therapies for the treatment of cancer. POINT of benchtop PET scanners combining simplicity and distributes them in more than 30 countries The company is focused initially on the diagnostic is addressing the inaccessibility of radioligand with high performance. Our mission is to WIDEN worldwide. With almost 20 years of experience isotope Mo-99 and therapeutic isotope n.c.a. Lu-177. in the development, production, authorization treatments by investing heavily in production ACCESS TO PET IMAGING, by making it much more SHINE also expects to produce I-131, Xe-133, Y-90, affordable. Discover easyPET.3D, our uniquely and distribution of sterile kits for radiolabeled Sr-89, and other isotopes using its LEU fusion- capacity and logistics, with the goal of making them affordable PET system for preclinical research and pharmaceuticals ROTOP continuously expands its fission process. SHINE’s platform technology does available to any patient that would benefit from professional training. Keep PET simple! product portfolio by developing new products and not require a reactor, making it safer, cleaner, and them. entering new strategic partnerships.
Our more sustainable than other approaches. The portfolio includes: company will deliver Mo-99 with seamless service • A comprehensive range of Tc-99m kits that is compatible with the existing supply chain • GMP-compliant production of agents for Tc-99m and requires no additional operating costs. SHINE kits Therapeutics is focused initially on the production of n.c.a. Lu-177 under GMP. It has the potential to • Quality control sets for Tc-99m radiopharmaceuticals fundamentally change how cancer is treated. SHINE • Distribution of pharmaceuticals that are produced has established a European office and will build by subcontractors for ROTOP second production facility in the region. For more • Pharmaceutical Development information, please visit https://shinemed.com/ and stop by our virtual booth.

260 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 261 EXHIBITOR PROFILES EXHIBITOR PROFILES

EANM’20 EANM’20 Siemens Healthineers Sirtex Medical Europe Spectrum Dynamics Medical SpringerNature EANM’20

Henkestraße 127 Joseph-Schumpeter-Allee 33 rue de Lausanne 31 Tiergartenstrasse 17 91052 Erlangen 53227 Bonn 1110 Morges 69121 Heidelberg [email protected] [email protected] [email protected]

WORLD LEADING MEETING https://www.siemens-healthineers.com/ http://www.sirtex.com/eu https://www.spectrum-dynamics.com/ http://www.springernature.com WORLD LEADING MEETING

At Siemens Healthineers, our purpose is to Sirtex Medical is a global healthcare business with Spectrum Dynamics is spearheading the Springer Nature advances discovery by serving the enable healthcare providers to increase value offices in the US, Australia, Germany and Singapore, transformation of SPECT imaging systems from whole research community. All the research we by empowering them on their journey towards working to improve outcomes in people with cancer. analog to digital detection technology, enabling publish is robust and in the best possible format expanding precision medicine, transforming care hospitals and clinicians to provide superior healthcare to be discovered, accessed, used, re-used and delivery, and improving patient experience, all Learn more about recent announcements about services with improved image quality, efficiency and shared. Springer Nature is home to brands including enabled by digitalizing healthcare. An estimated 5 Sirtex partnerships on our Website:
– A access to advanced clinical applications. Springer. Please visit springernature.com and @ million patients globally everyday benefit from our strategic transaction with OncoSec Medical Spectrum Dynamics launched the world first digital SpringerNature September 29 innovative technologies and services in the areas Incorporated cardiac dedicated SPECT system – the D-SPECT® of diagnostic and therapeutic imaging, laboratory – A collaboration with MIM Software Inc.
For CARDIO system – in 2007. Since then, the D-SPECT has become the system of choice for functional diagnostics and molecular medicine, as well as digital further information please visit www.sirtex.com. cardiac imaging with hundreds of systems sold health and enterprise services. We are a leading worldwide. The D-SPECT employs digital detectors medical technology company with over 120 years of Our current lead product is a targeted radiation made of Cadmium Zinc Telluride (CZT), which experience and 18,500 patents globally. With more therapy for liver cancer called SIR-Spheres® Y-90 resin along with ingenious hardware design, proprietary than 50,000 dedicated colleagues in more than 75 microspheres. More than 100,000 doses have been software and algorithms, enables imaging of cardiac countries, we will continue to innovate and shape supplied to treat patients with liver cancer, at more patients at unprecedented speed, at a low radiation the future of healthcare. than 1,300 medical centres, in over 50 countries. dose, and with superior image quality. The D-SPECT is a platform for next generation imaging enabling SIR-Spheres is a prescription device for the treatment advanced clinical applications such as Dual Isotope of inoperable liver tumours. It is a minimally invasive Imaging, Dynamic Imaging and Emission Map treatment that delivers high doses of high-energy Attenuation Correction beta radiation directly to the tumours. In 2018, Spectrum Dynamics launched its This therapy is called Selective Internal Radiation multipurpose systems: the VERITON® and the Therapy (SIRT) and is performed, using minimally VERITON-CT® SPECT/CT. The systems employ digital invasive surgical techniques, by an interventional CZT swiveling detectors mounted on 12 robotic radiologist. arms arranged at 360° around the patient, enabling general purpose SPECT imaging at high speed, low radiation dose, and with significant improvement SIR-Spheres is approved for the treatment of in image quality. The VERITON-CT system features a inoperable liver tumours in the European Union. high speed, low dose, 16 or 64/128 slice CT

*SIR-Spheres® is a registered trademark of Sirtex SIR- Spheres Pty Ltd

262 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 263 EXHIBITOR PROFILES EXHIBITOR PROFILES

EANM’20 EANM’20 Sumitomo Heavy Industries,Ltd. Telix Pharmaceuticals Tema Sinergie Terumo Interventional Systems EANM’20

ThinkPark Tower,1-1 Osaki Rue de Hermée 255 Via Malpighi, 120 Interleuvenlaan 40 2-chome,Shinagawa-ku 4040 Herstal 48018 Faenza 3001 Leuven 141-6025 Tokyo [email protected]

WORLD LEADING MEETING https://telixpharma.com/ http://www.temasinergie.com https://www.terumo-europe.com/en-EMEA WORLD LEADING MEETING https://www.shi.co.jp/english/ Telix was created to deliver on the promise of Tema Sinergie, a name that stands for highest Terumo is a global leader in medical technology Sumitomo Heavy Industries, Ltd. (“SUMITOMO”) is nuclear medicine. Nuclear medicine has historically professionalism and quality, represents one of and has been committed to “Contributing to one of the largest heavy machinery companies in suffered from a lack of commercial critical mass and the most qualified companies worldwide in the Society through Healthcare” for nearly 100 years. Japan and manufactures various machinery and commitment to late-stage product development. production of systems for manipulation and dosage Terumo Interventional Systems is working in Molecularly-targeted radiation (MTR) potentially equipment, such as VLCC tanker, power boiler, of radiopharmaceuticals used in Nuclear Medicine. partnership with Interventional Radiologists and offers better-informed treatment decisions and truly plastic machinery, power transmission equipment Professionalism, proactivity, passion and business Nuclear Medics within Interventional Oncology personalised therapy. Our product development intelligence are features that have distinguished and accelerator. In the field of accelerator, with to ensure they have access to high quality tools strategy is to closely integrate and add value to us every day since 1985. Being constantly ready for their patients. This partnership is based on long experiences, Sumitomo produces medical standard care, reflective of the modern team- to anticipate customer needs with innovative Terumo’s comprehensive range of technology and related equipment, i.e. proton therapy system based approach to managing cancer. We are an solutions and cutting edge technologies has made services to support healthcare professionals with and PET (“Positron Emission Tomography”) radio- experienced team of drug developers, clinicians and us a competent and reliable reference point. We their patient needs. QuiremSpheres®microspheres, tracer production system. Regarding PET radio- executives, with a passion for radiation biology and are a multidisciplinary organization, a dynamic QuiremScout® microspheres and Q-Suite™ software tracer production system, Sumitomo is the leading oncology. Telix’s pipeline currently focuses on unmet and innovative system working in synergy to make up The Holmium Platform: three integrated manufacture of cyclotrons as well as various needs in cancer care, specifically in prostate, renal satisfy market needs with a wide range of action. products which aims to individualize SIRT at its full synthesizers, hot cell and ancillary equipment with (kidney) and glioblastoma (brain) cancer. We are also Tema Sinergie will be exhibiting a wide range of potential. QuiremSpheres® is the first Holmium-166 majority of market share in Asia. Sumitomo has an keenly interested in partnership and in-licensing solutions, among which you will find some of its microsphere on the market which brings a experience of delivering the PET cyclotron system opportunities to further expand our portfolio. In flagship products such as Karl100, the smallest and wide range of benefits from higher dose rate, to over 30 years and delivered more than 200 PET December 2018, Telix acquired ANMI SA, a leader safest dose administration system; AGLTS, the most optimized imaging capabilities. QuiremSpheres® are in the field of radiopharmaceutical development. systems in Asian countries, i.e. Japan, South Korea, advanced GMP compliant glove integrity testing also the first SIRT microsphere to be designed with The ANMI team brings a wealth of innovation and China, Taiwan, Thailand, Malaysia, India, Philippines system for isolators and RABs; MorGaNA, the fully scout dose technology, QuiremScout®, which for experience in the streamlined development and automated, stand-alone cold kit labelling device and and Iraq. . the first time utilizes the same particle for the work production of novel radiopharmaceuticals. For automatic dispenser for 68Ga and more. You will also up and the therapy, which aims to optimize patient more information about ANMI, visit anmi.be. We are be introduced to our brand new compact laminar selection and advance treatment planning using our focused on the development and commercialisation flow isolator system CLF-IS, a fully compliant, small Q-SuiteTM software. This CE Marked and in-house of clinical-stage oncology programs. Telix scale cGMP Class A/ISO 5 isolator system designed designed treatment planning software is also used Pharmaceuticals is focused on the development and to be the perfect ally for hospital pharmacies. for dose verification following the SIRT treatment to commercialisation of several clinical-stage oncology ensure you have delivered the dose you planned and assets in renal cancer, prostate cancer and brain will help to drive treatment efficacy and improve the cancer. We are also actively exploring indication outcomes for liver cancer patients. expansion opportunities for our programs and platforms.

264 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 265 EXHIBITOR PROFILES EXHIBITOR PROFILES

EANM’20 EANM’20 The South African Society of Nuclear Trasis Turkish Society of Nuclear Medicine U.S. Department of Energy Isotope EANM’20 Medicine (SASNM) Program Rue Gilles Magnée 90 Cinnah Caddesi Pilot Sokak No:10/12, Çankaya P.O.Box 70950 4430 Ans 06690 Ankara 1 Bethel Valley Road Die Wilgers [email protected] [email protected] 37831 Oak Ridge 0041 Pretoria WORLD LEADING MEETING http://www.trasis.com http://www.tsnm.org/ [email protected] WORLD LEADING MEETING [email protected] https://www.isotopes.gov https://www.sasnm.com Trasis is specialized in the development and the Turkish Society of Nuclear Medicine was founded in manufacturing of innovative and high quality 1975 soon after the approval of Nuclear Medicine as The DOE Isotope Program supports the production SASNM is a voluntary association governed by its radiopharmaceutical equipment. By carefully an independent medical specialty by the Ministry and the development of production techniques constitution and bylaws and was established in listening to professional users and markets trends, of Health. TSNM aims to promote clinical practice, of radioactive and stable isotopes that are in short Trasis provides practical and reliably designed 1974 to provide a forum for collaboration between research and education in nuclear medicine for the supply for research and applications. Isotopes are systems for automated synthesis, dispensing and Physicians, Scientists, Radiographers and other benefit of public health. TSNM also holds a unique high-priority commodities of strategic importance packaging of radio-pharmaceuticals. AllinOne is position to provide collaboration between national professional persons with a common interest in for the nation and are essential for energy, medical, a multiple purpose radiochemistry unit featuring health authorities, departments of nuclear medicine the field of nuclear medicine. Members promote and national security applications and for basic synthesizer, HPLC & reformulation in a single in universities and training and research hospitals, research; a goal of the program is to make critical the practice and development of nuclear medicine compact box, able to efficiently produce the industrial suppliers and other medical societies. The isotopes more readily available to meet domestic through the accumulation and dissemination of most complex compounds such as nucleophilic society organizes several scientific activities each U.S. needs. scientific and technical information.Membership FDopa, Thyrosine, FMT as well as FDG in multiple year, national congresses in spring and a symposium is open to all persons who have an interest in the runs. AllinOne’s versatility also helps researchers dedicated on a different topic of interest in winter The program also coordinates and supports isotope production and promotion, as well as diagnostic and address the growing need for new tracers. MiniAIO season and regular educational events called production at numerous universities, national therapeutic use of radionuclides.Control of the affairs is designed for simpler processes and to cost “School of Nuclear Medicine” designed for residents laboratories, and commercial accelerator and reactor of the Society is vested in a Council and Executive efficiently produce compounds such as FDG, Ga68/ and young physicians by the experts of the scientific facilities throughout the nation to promote a reliable Committee whose members hold office for a 2 Lu177-peptide conjugates or NaF and requires task groups involved within TSNM. Currently TSNM supply of domestic isotopes. The NIDC coordinates year term until their successors are elected at the less space in the hot cell. EasyOne is the latest of has 875 members including physicians, physicists, isotope production across these facilities and the AllinOne family. It has been simplified to the pharmacists and technologists. The official journal following biennial SASNM meeting.The South African manages the business operations of the sale and extreme for routine production of most radiometals of TSNM is “Molecular Imaging and Radionuclide Society of Nuclear Medicine (SASNM) is one of the distribution of isotopes. labelled pharmaceuticals. Compatible with all Ga68 Therapy, MIRT” (http://mirt.tsnmjournals.org). MIRT oldest Nuclear Medicine societies (and probably the Generators, its ultra-compact design and ease of is published in English and indexed in PubMed, most active) on the African continent. The SASNM use are its major assets Unidose, a high speed dose PubMed Central, EBSCO and some other scientific The National Isotope Development Center (NIDC) has approximately 200 members, including nuclear dispenser dedicated to hospitals, simplifies the indexes and provides open access to its content. The is funded by the U.S. Department of Energy Isotope medicine physicians, radiographers, physicists, procedures and reduces drastically the exposure to society also publishes an electronic journal, “Nuclear Program (DOE IP). It serves as an interface with the radiopharmacists and scientists from various the technologists. Trasis offers custom development Medicine Seminars” which is in Turkish dedicated to user community and manages the coordination of specialties. Scientific congresses with international services for chemistry, reagents and disposables. educational articles on specific topics by the invited isotope production across the program facilities at participation have been held biennially since editors in each issue. Argonne, Brookhaven, Idaho, Los Alamos, Oak Ridge, 1974.Through the African Regional Co-operative and Pacific Northwest National Laboratories. These Agreement (AFRA) with a membership of 24 African facilities produce stable and radioactive isotopes in countries, South Africa assists the International short supply using reactors, accelerators, and other Atomic Energy Agency (IAEA) by hosting regional methods. training courses. South Africa has a well-established infrastructure for production of radionuclides. The NIDC website offers more than 250 isotopes for purchase. Visit www.isotopes.gov/catalog to view the catalog of isotopes.

266 OCTOBER 22–30, 2020 | VIRTUAL OCTOBER 22–30, 2020 | VIRTUAL 267 EXHIBITOR PROFILES

EANM’20 EANM’20 World Federation of Nuclear Medicine and Biology (WFNMB)

Schmalzhofgasse 26 1060 Vienna

WORLD LEADING MEETING [email protected] https://www.wfnmb.org/

The World Federation of Nuclear Medicine and Biology (WFNMB) was founded in 1970, meaning that new links were now forged between all Americas, Europe and Asia, Oceania, and Africa. The WFNMB consists of groups, societies or associations acknowledged as representatives in each country primarily involved with research, education, training and/or practice in Nuclear Medicine and Biology. One of our principal activities is to support education efforts for nuclear physicians, physicists, radiopharmacists, radiochemists, technologists and other nuclear medicine scientists, especially from the developing world. In achieving its programmatic goals, the WFNMB will work with its member societies, and with international health and scientific bodies like the International Atomic Energy Agency (IAEA) and the World Health Organisation (WHO). This will enable us to enhance nuclear medicine education and improve access to the highest quality nuclear medicine care..

268 OCTOBER 22–30, 2020 | VIRTUAL European School of Multimodality Imaging and Therapy ESMIT Live Webinar series - Course Programme to be continued! 2021

Various ESMIT Live Webinar Series tba - First half of 2021

Vienna, Austria Place: Bone & Joint Post-Operative Skeleton Jun 24-25 Nuclear Ima in Technolo y: Vienna, Austria Where we came from, where we are and Advanced Quantification Advanced Features of Quantification Jul 1-2 where we are headin in Nuclear Imaging Vienna, Austria Speakers: Moderator: Theranostics Prostate Cancer (advanced) Sep 30-Oct 1 Ian Armstron , John Dickson, Michel Koole PHYSICS Vienna, Austria Stephan Nekolla, Dimitris Visvikis Advanced Quantification Quantification in Neurology Nov 18-19 in Nuclear Imaging Vienna, Austria

Theranostics Management of Thyroid Cancer (advanced) Nov 25-26 Vienna, Austria

Place: Oncology Therapy Assessment Dec 2-3 Vienna, Austria PET MPI:

Theranostics Practical Implementation of Clinical Dosimetry Tracers, Equipment, Protocols, in NM Therapy Dec 9-10 Vienna, Austria Flow Quantification, Viability Speakers: Moderator: Please note that the information given above is subject to change. Mark Lubberink, Christoph Rischpler

For regular updates, please visit the EANM website or Roberto Scia ra CARDIOLOGY subscribe to the ESMIT vNewsletter. eanm.org/esmit For more information visit the ESMIT Booth of EANM’20

Acknowledgement The ESMIT leadership likes to thank all contributors of this initiative. Stay tuned for more Special thanks to the EANM Committees and the ESMIT Project Groups for their continuing support. ESMIT Live Webinars comin up in 2021! Special thanks to the EANM Committees and the ESMIT Working Groups for their continuing support. USEFUL CONTACTS

USEFUL CONTACTS

SCIENTIFIC PROGRAMME REGISTRATION EANM Executive Office EANM Executive Office Ms. Susanne Koebe Ms. Petra Neubauer Mr. Andreas Felser (Congress Manager) Schmalzhofgasse 26/5, 1060 Vienna, Austria Schmalzhofgasse 26/5, 1060 Vienna, Austria Phone: +43 1 890 44 27 Phone: +43 1 890 44 27 Fax: +43 1 890 44 27-9 Fax: +43 1 890 44 27-9 Email: [email protected] Email: [email protected] Web: eanm20.eanm.org Web: eanm20.eanm.org

INDUSTRY EXHIBITION OPENING HOURS EANM Executive Office EANM Executive Office Mr. Andreas Felser (Congress Manager) October 22-30, 2020 Mr. Alexander Berger 08:00 to 18:30 CEST/CET Mrs. Silvia Zippelius Schmalzhofgasse 26/5, 1060 Vienna, Austria Phone: +43 1 890 44 27 Fax: +43 1 890 44 27-9 Email: [email protected] Email: [email protected] Web: eanm20.eanm.org

272 OCTOBER 22–30, 2020 | VIRTUAL